pyrazines has been researched along with bortezomib in 3832 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.03) | 18.2507 |
| 2000's | 1538 (40.14) | 29.6817 |
| 2010's | 2278 (59.45) | 24.3611 |
| 2020's | 15 (0.39) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, J; Ara, G; Herbst, R; Palombella, VJ; Teicher, BA | 1 |
| Adams, J; Chau, V; Elliott, PJ; Lightcap, ES; McCormack, TA; Pien, CS | 1 |
| An, WG; Blagosklonny, MV; Hwang, SG; Trepel, JB | 1 |
| Adams, J; Elliott, P; Frankel, A; Kerbel, RS; Man, S | 1 |
| Cheson, BD; Gore-Langton, RE; Hillsamer, VL; Wright, J | 1 |
| Bennink, JR; Chen, W; Crews, CM; Myung, J; Princiotta, MF; Schubert, U; Yewdell, JW | 1 |
| Adams, J; Anderson, KC; Chauhan, D; Elliott, PJ; Hideshima, T; Palombella, VJ; Richardson, P | 1 |
| Adams, J; Baldwin, AS; Cusack, JC; Elliott, P; Liu, R; Russo, SM; Tepper, JE | 1 |
| Abendroth, K; Adams, J; Baldwin, AS; Cusack, JC; Elliott, PJ; Houston, M; Liu, R | 1 |
| Adams, J; Chen, Z; Crowl Bancroft, C; Dong, G; Elliott, P; Sausville, E; Sunwoo, JB; Van Waes, C; Yeh, N | 1 |
| Blagosklonny, MV | 1 |
| Adams, J; Elliott, PJ | 1 |
| Anderson, KC; Chauhan, D; Hideshima, T; Richardson, P; Schlossman, R | 1 |
| Bold, RJ; McConkey, DJ; Virudachalam, S | 1 |
| McBride, WH; Pajonk, F; Pervan, M; Sun, JR; Withers, HR | 1 |
| Elliott, PJ; Ross, JS | 1 |
| Bardag-Gorce, F; French, BA; French, SW; Gaal, K; Lue, YH; Marceau, N; Riley, NE; van Leeuwen, F; Yuan, QX | 1 |
| Adams, J | 8 |
| Berenson, JR; Ma, HM; Vescio, R | 1 |
| Bardag-Gorce, F; French, BA; French, SW; Li, J | 1 |
| Garber, K | 3 |
| Blackman, RK; Bulawa, CE; Fleming, JA; Lightcap, ES; Sadis, S; Thoroddsen, V | 1 |
| L'Allemain, G | 1 |
| Tan, C; Waldmann, TA | 1 |
| Adams, J; Anderson, KC; Castro, A; Chauhan, D; Dang, L; Hayashi, T; Hideshima, T; Mitsiades, C; Mitsiades, N; Munshi, N; Palombella, V; Richardson, P | 1 |
| Hussein, MA | 2 |
| Daud, A; Munster, P; Spriggs, DR | 1 |
| Schenkein, D | 1 |
| Giles, FJ | 1 |
| Cheson, BD | 4 |
| Adams, J; Aghajanian, C; Canales, C; Daud, A; Dizon, DS; Elliott, PJ; Hensley, ML; Miller, V; Pezzulli, S; Pien, CS; Sabbatini, P; Soignet, S; Spriggs, DR | 1 |
| Adams, J; Anderson, KC; Catley, LP; Goloubeva, O; Gupta, D; Hideshima, T; LeBlanc, R; Lentzsch, S; Mitsiades, CS; Mitsiades, N; Munshi, NC; Neuberg, D; Pien, CS; Richardson, PG | 1 |
| Abbruzzese, JL; Chiao, PJ; Dong, QG; Evans, DB; Fujioka, S; McDonnell, TJ; Peng, B; Schmidt, C; Sclabas, GM; Tsao, MS; Wu, T | 1 |
| Anderson, KC; Bailey, C; Chauhan, D; Fanourakis, G; Gu, X; Hideshima, T; Joseph, M; Libermann, TA; Mitsiades, CS; Mitsiades, N; Munshi, NC; Poulaki, V; Richardson, PG; Treon, SP | 1 |
| Akiyama, M; Anderson, KC; Chauhan, D; Hayashi, T; Hideshima, T; Mitsiades, C; Mitsiades, N; Munshi, NC; Podar, K; Richardson, P; Schlossman, R | 1 |
| Roodman, GD | 4 |
| Anderson, KC; Bailey, C; Chauhan, D; Fanourakis, G; Gu, X; Hideshima, T; Joseph, M; Libermann, TA; Mitsiades, CS; Mitsiades, N; Munshi, NC; Poulaki, V; Richardson, PG; Schlossman, R; Tai, YT | 1 |
| Adams, J; Anderson, JK; Baldwin, AS; Bhagat, R; Depcik-Smith, ND; Elliott, PJ; Esseltine, DL; Guerciolini, R; Lehman, MJ; Mitchell, BS; Novick, SC; O'Connor, OA; Orlowski, RZ; Pien, CS; Shea, TC; Soignet, SL; Stahl, S; Stinchcombe, TE | 1 |
| Adams, J; Buckley, M; Elliott, PJ; Jiang, JD; Liebes, L; Ling, YH; Muggia, FM; Ng, B; Perez-Soler, R | 1 |
| Berenson, JR | 2 |
| Anderson, KC | 6 |
| Barlogie, B; Shaughnessy, J; Tricot, G; Zangari, M | 1 |
| Abbruzzese, JL; Baker, C; Chiao, PJ; Dong, QG; Evans, DB; Frederick, WA; Fujioka, S; Schmidt, C; Sclabas, GM | 1 |
| Mundy, GR; Oyajobi, BO | 1 |
| Dees, EC; Orlowski, RZ | 2 |
| Bailly, C; Lansiaux, A | 1 |
| Adams, J; Altamirano, C; Berenson, JR; Borad, MJ; Frantzen, M; Friedman, JM; Ma, MH; Manyak, S; Mikail, A; Neeser, J; Parker, K; Roussos, E; Sjak-Shie, N; Vescio, RA; Wu, ZQ; Yang, HH | 1 |
| Adams, J; Elliott, PJ; Holland, JF; Jiang, JD; Liebes, L; Ling, YH; Muggia, FM; Perez-Soler, R | 1 |
| Blazar, BR; Brooks, AD; Elliott, PJ; Koh, CY; Ma, W; Murphy, WJ; Raziuddin, A; Sayers, TJ; Seki, N; Zhang, X | 1 |
| Boehncke, WH; Elliott, PJ; Zollner, TM | 1 |
| Anderson, KC; Mitsiades, CS; Mitsiades, N; Richardson, PG; Treon, SP | 1 |
| Mehta, J; Singhal, S | 1 |
| Alsina, M; Djulbegovic, B; Durie, BG; Kumar, A; Loughran, T | 1 |
| Cusack, JC | 1 |
| Richardson, P | 4 |
| Lenz, HJ | 1 |
| Schoenfeldt, M; Wright, JJ; Zerivitz, K | 1 |
| Twombly, R | 1 |
| Ford, RJ; Lo, P; Pham, LV; Tamayo, AT; Yoshimura, LC | 1 |
| Luker, GD; Luker, KE; Pica, CM; Piwnica-Worms, D; Song, J | 1 |
| Liebes, L; Ling, YH; Perez-Soler, R; Zou, Y | 1 |
| Hattori, Y | 1 |
| Mitchell, BS | 1 |
| Adams, J; Alexanian, R; Alsina, M; Anderson, KC; Barlogie, B; Berenson, J; Esseltine, DL; Hideshima, T; Irwin, D; Jagannath, S; Kauffman, M; Kuter, D; Lee, S; Limentani, SA; Orlowski, RZ; Rajkumar, SV; Richardson, PG; Schenkein, DP; Siegel, D; Singhal, S; Srkalovic, G | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Mack, PC | 1 |
| Conrad, D; Dent, P; Grant, S; Rahmani, M; Subler, M; Yu, C | 1 |
| Johnson, TR; Kraft, AS; Nesterov, A; Nikrad, M; Stone, K; Thompson, CB; Yeh, T; Zong, WX | 1 |
| Frantz, S; Paramore, A | 1 |
| Ball, G; Beran, M; Cortes-Franco, JE; Divoky, V; Gatto, S; Kantarjian, HM; Keating, MJ; Milella, M; Onida, F; Pham, L; Ricci, C; Scappini, B; Verstovsek, S | 1 |
| Bold, RJ; Fahy, BN; Schlieman, MG; Virudachalam, S | 1 |
| Gisslinger, H; Kees, M | 1 |
| Jäger, U | 1 |
| Faix, JD | 1 |
| Meisler, AI | 1 |
| Dai, Y; Grant, S; Pei, XY | 2 |
| Sussman, HE | 1 |
| Adams, J; An, J; Belldegrun, A; Fisher, M; Rettig, MB; Sun, YP | 1 |
| Andreeff, M; Calvert, LR; Faderl, S; Keating, M; McConkey, DJ; Niemer, I; Pahler, JC; Ruiz, S | 1 |
| Logothetis, C; McConkey, DJ; Papandreou, C; Pettaway, C; Song, R; Williams, S | 1 |
| Berenson, JR; Schenkein, D; Vescio, R; Yang, HH | 1 |
| Anderson, KC; Chauhan, D; Hideshima, T; Li, G; Ohtake, Y; Podar, K; Shringarpure, R | 1 |
| Dai, Y; Grant, S; Rahmani, M | 1 |
| von Mehren, M | 1 |
| McConkey, DJ; Williams, SA | 1 |
| Goldman, B | 1 |
| Akiyama, M; Anderson, KC; Chauhan, D; Hayashi, T; Hideshima, T; Mitsiades, C; Mitsiades, N; Munshi, NC; Podar, K; Richardson, PG | 1 |
| Stanford, BL; Zondor, SD | 1 |
| Shiotsu, Y | 1 |
| Hu, WX; Shi, YW; Tang, LJ | 1 |
| Bross, PF; Farrell, AT; Kane, RC; Pazdur, R | 1 |
| D'Anneo, A; De Blasio, A; Giuliano, M; Tesoriere, G; Vento, R | 1 |
| Dees, EC; O'Neil, B; Orlowski, RZ; Voorhees, PM | 1 |
| Ansari, RH; Davis, NB; George, C; Ryan, CW; Stadler, WM; Taber, DA; Vogelzang, NJ; Vokes, EE | 1 |
| Bardag-Gorce, F; French, BA; French, SW; Li, J; Lue, YH; Montgomery, RO; Nan, L; Riley, NE | 1 |
| McConkey, DJ; Nawrocki, ST; Sweeney-Gotsch, B; Takamori, R | 1 |
| Anderson, KC; Hideshima, T; Richardson, PG | 2 |
| Ikezoe, T; Kobayashi, M; Koeffler, HP; Saito, T; Taguchi, H; Yang, Y | 1 |
| Jákó, J; Mikala, G; Vályi-Nagy, I | 1 |
| Bold, RJ; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Mack, PC; Mortenson, MM | 1 |
| Anderson, KC; Auclair, D; Chauhan, D; Chen, LB; Hideshima, T; Li, G; Mitsiades, C; Mitsiades, N; Munshi, N; Podar, K; Saxena, S | 1 |
| Bardag-Gorce, F; French, SW; Li, J; Nan, L; Riley, N; Vu, J | 1 |
| Barlogie, B | 1 |
| Ikezoe, T; Koeffler, HP; Saito, T; Taguchi, H; Yang, Y | 1 |
| Bar-Eli, M; Davis, DW; Dinney, CP; Kamat, AM; Karashima, T; Lashinger, L; McConkey, DJ; Millikan, R; Shen, Y | 1 |
| Dai, Y; Dent, P; Grant, S; Pei, XY; Rahmani, M | 1 |
| Kikuchi, S; Komatsu, N; Mori, M; Muroi, K; Noborio-Hatano, K; Ozawa, K; Takahashi, S; Takatoku, M | 1 |
| Broad, RM; Denlinger, CE; Jones, DR; Keller, MD; Mayo, MW | 1 |
| Orlowski, RZ | 6 |
| Durrance, A | 1 |
| Chen, SL | 1 |
| Anderson, KC; Catley, L; Chauhan, D; Gribble, GW; Hideshima, T; Honda, T; Li, G; Mitsiades, C; Munshi, N; Podar, K; Richardson, P; Schlossman, R; Shringarpure, R; Sporn, MB; Suh, N; Tai, YT | 1 |
| Reddy, GK | 1 |
| Gilles, F; Goy, A | 1 |
| Harding, JC; Hess, JL; Mitra-Kaushik, S; Ratner, L | 1 |
| Dent, P; Grant, S; Rahmani, M; Yu, C | 1 |
| Anderson, KC; Chauhan, D; Hideshima, T; Li, G; Mitsiades, C; Munshi, N; Podar, K; Shringarpure, R; Yew, PR | 1 |
| Abbruzzese, JL; Chiao, PJ; Evans, DB; Fujioka, S; Huang, P; Li, Z; Niu, J; Pelicano, H; Peng, B; Schmidt, C; Sclabas, GM; Yao, A; Zhang, W | 1 |
| Kaufman, J; Lonial, S | 1 |
| Bonvini, P; Dalla Rosa, H; Rosolen, A; Vignes, N | 1 |
| Aggarwal, BB; Bharti, A; Georgakis, GV; Li, Y; McConkey, D; Younes, A; Zheng, B | 1 |
| Bisht, KS; Gius, D; Isaacs, JS; Mimnaugh, EG; Neckers, L; Vos, M; Xu, W; Yuan, X | 1 |
| Barao, I; Blazar, BR; Liu, H; Murphy, WJ; O'Shaughnessy, MJ; Panoskaltsis-Mortari, A; Riordan, W; Sayers, TJ; Serody, JS; Sitcheran, R; Sun, K; Welniak, LA; Wysocki, C | 1 |
| Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Guerciolini, R; Kantarjian, H; Koller, C; McConkey, D; Patel, G; Ruiz, SL; Thomas, D; Wright, J | 1 |
| Richardson, PG | 3 |
| Adams, J; Daliani, DD; Dieringer, P; Elliott, P; Esseltine, D; Kim, J; Logothetis, CJ; Madden, T; Millikan, RE; Nix, D; Pagliaro, L; Papandreou, CN; Perez, C; Petrusich, A; Pien, CS; Tu, SM; Wang, X; Yang, H | 1 |
| Adachi, M; Hinoda, Y; Imai, K; Kawamura, R; Minami, T; Zhang, Y; Zhao, X | 1 |
| Koya, Y; Matsuoka, M; Nosaka, K; Satou, Y; Toyokuni, S; Yasunaga, JI | 1 |
| Bold, RJ; Mortenson, MM; Schlieman, MG; Virudachalam, S | 1 |
| Adams, J; Kauffman, M | 1 |
| Bold, R | 1 |
| Alkan, S; Hsi, ED; Kelley, TW; Srkalovic, G | 1 |
| An, J; Fisher, M; Rettig, MB; Sun, Y | 2 |
| Anderson, KC; Chauhan, D; Cotter, FE; Hideshima, T; Li, G; Mitsiades, C; Munshi, N; Podar, K; Richardson, P; Schlossman, R | 1 |
| Abraham, S; Benson, K; Bradley, S; Bross, PF; Brower, ME; Farrell, AT; Gobburu, JV; Goheer, A; Kane, R; Lee, SL; Leighton, J; Liang, CY; Lostritto, RT; McGuinn, WD; Morse, DE; Pazdur, R; Rahman, A; Rosario, LA; Verbois, SL; Wang, YC; Williams, G | 1 |
| Bunn, PA | 1 |
| Capriotti, T | 1 |
| Lenz, HJ; Park, DJ | 1 |
| Anderson, K; Hideshima, T; Mitsiades, C; Richardson, PG | 1 |
| Bostrom, B; Brown, RE; Zhang, PL | 1 |
| O'Connor, OA | 3 |
| Cardoso, F; Durbecq, V; Picart, MJ; Ross, JS; Sotiriou, C | 1 |
| Amiri, KI; Horton, LW; LaFleur, BJ; Richmond, A; Sosman, JA | 1 |
| Hatake, K; Mishima, Y; Terui, Y | 1 |
| Matsuoka, M; Satou, Y | 1 |
| Logothetis, CJ; Papandreou, CN | 1 |
| Benbatoul, K; Laing, N; Poss, MA; Purandare, AV; Vaccaro, W; Wan, H | 1 |
| Durrant, D; Lee, RM; Liu, J; Yang, HS | 1 |
| Bacik, J; Drucker, B; Kondagunta, GV; Marion, S; Mazumdar, M; Motzer, RJ; Russo, P; Schwartz, L | 1 |
| Hussar, DA | 1 |
| Grever, M; Kindler, HL; Kleiber, B; Shah, MH; Webb, I; Wright, J; Young, D | 1 |
| Edmund, NA; Moore, DT; Orlowski, RZ; Shi, YY; Small, GW; Somasundaram, S | 1 |
| Politou, M; Rahemtulla, A; Terpos, E | 1 |
| Adams, J; Alexanian, R; Alsina, M; Anderson, KC; Barlogie, B; Berenson, J; Esseltine, DL; Irwin, D; Jagannath, S; Kauffman, M; Limentani, SA; Niesvizky, R; Richardson, PG; Schenkein, DP; Siegel, D | 1 |
| Denlinger, CE; Jones, DR; Keller, MD; Rundall, BK | 1 |
| Anderson, KC; Chauhan, D; Hamasaki, M; Hideshima, H; Hideshima, T; Higgins, LS; Ishitsuka, K; Mitsiades, C; Munshi, NC; Navas, T; Nguyen, AN; Podar, K; Raje, N; Richardson, PG; Schreiner, G; Tai, YT | 1 |
| Farah, M; Webster, JM; Wojcikiewicz, RJ; Xu, Q | 1 |
| Blasick, TM; Brown, RE; Lun, M; Siegelmann-Danieli, N; Zhang, PL | 2 |
| Anderson, KC; Chauhan, D; Hideshima, T; Ishitsuka, K; Podar, K; Richardson, PG; Sattler, M; Shringarpure, R; Simoncini, M; Tai, YT | 1 |
| Fribley, A; Wang, CY; Zeng, Q | 1 |
| Kyle, RA; Rajkumar, SV | 1 |
| Denlinger, CE; Jones, DR; Rundall, BK | 1 |
| Colson, K; Doss, DS; Swift, R; Tariman, J; Thomas, TE | 1 |
| Duff, SB; Gupta, S; Mehta, J | 1 |
| Gudegast, C; Stöckle, M; Tahmatzopoulos, A; Unteregger, G; Wullich, B; Zwergel, T; Zwergel, U | 1 |
| Black, KL; Koeffler, HP; Kumagai, T; Liu, G; Ong, JM; Yin, D; Zhou, H | 1 |
| Arnulf, B; Bazarbachi, A; Bex, F; Dbaibo, G; de Thé, H; El-Sabban, ME; Hermine, O; Karam, JA; Kfoury, Y; Lepelletier, Y; Nasr, R | 1 |
| Reddy, KG | 1 |
| Duechler, M; Hilgarth, M; Hoelbl, A; Hubmann, R; Schwarzmeier, JD; Shehata, M | 1 |
| Demaria, S; Formenti, SC; Liebes, L; Ng, B; Santori, FR; Vukmanovic, S | 1 |
| Adamson, PC; Berg, SL; Bernstein, M; Blaney, SM; Ginsberg, J; Horton, T; Kitchen, B; Krailo, M; Neville, K | 1 |
| Anderson, KC; Burger, R; Catley, L; Chauhan, D; Denis, L; Hideshima, T; Munshi, NC; Podar, K; Richardson, P; Shringarpure, R; Son, MT; Tai, YT; Tassone, P | 1 |
| Klener, P; Spicka, I | 1 |
| Callery, MP; Canete, JJ; Chandler, NM | 1 |
| Korniluk, J; Wcisło, G; Wojtuń, S | 1 |
| Benedict, W; Dinney, CP; Grossman, HB; Lashinger, L; McConkey, DJ; Millikan, R; Papageorgiou, A | 1 |
| An, J; Fisher, M; Rettig, MB | 1 |
| Aguado, B; Alegre, A; Bladé, J; Esparís-Ogando, A; Gutiérrez, N; Mateo, G; Pandiella, A; San Miguel, JF; Schenkein, D | 1 |
| Fisher, RI | 1 |
| Broglio, K; Cabanillas, F; Dang, NH; Fayad, L; Gilles, F; Goy, A; Hagemeister, F; Hart, S; McLaughlin, P; Pro, B; Rodriguez, AM; Romaguera, JE; Samaniego, F; Samuels, B; Sarris, AH; Schenkein, D; Trehu, E; Wang, M; Younes, A | 1 |
| Adams, J; Choi, E; Dumetrescu, O; Esseltine, D; Hamlin, P; MacGregor-Cortelli, B; Moskowitz, C; Muzzy, J; O'Connor, OA; Portlock, C; Schenkein, D; Straus, D; Stubblefield, M; Trehu, E; Wright, J; Zelenetz, AD | 1 |
| Cooper, C; Liu, GY; Murphy, LC; Niu, YL; Santos, S; Watson, PH | 1 |
| Adams, J; Allred, T; Collins, JM; Dees, EC; Esseltine, DL; Gabriel, DA; Garcia, RA; Green, M; Hall, MD; Ivanova, A; Johri, AR; Jones, PE; Kudrik, FJ; Lehman, MJ; Lindley, CM; Mitchell, BS; Natoli, S; Orlowski, RZ; Shea, TC; Trehu, EG; Van Deventer, HW; Voorhees, PM | 1 |
| Dreicer, R; Price, N | 1 |
| Belani, CP | 1 |
| Schenkein, DP | 2 |
| Cardinale, G; Gervasi, F; Pagnucco, G | 1 |
| Anderson, KC; Hideshima, T; Mitsiades, C; Richardson, PG | 3 |
| Davies, FE; Morgan, GJ | 1 |
| Hempstead, BL; Li, Y; Pearse, RN; Rafii, D; Swendeman, SL | 1 |
| Anderson, KC; Hideshima, T; Rajkumar, SV; Richardson, PG | 1 |
| Chaudhary, PM; Matta, H | 1 |
| Dalton, WS; Holle, L; Jung, L | 1 |
| Davidson, T; Schwartz, R | 1 |
| Alexanian, R; Anderson, J; Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Jagannath, S; Nix, D; Orlowski, RZ; Richardson, PG; Singhal, S; Srkalovic, G | 1 |
| Carvajal-Vergara, X; Esparís-Ogando, A; Gutiérrez, N; López-Pérez, R; Mateo, G; Montero, JC; Pandiella, A; Parmo-Cabañas, M; San Miguel, JF; Tabera, S; Teixidó, J | 1 |
| Jung, W; Schroers, R; Zettl, F | 1 |
| Bruno, B; Fanin, R; Patriarca, F; Prosdocimo, S; Tomadini, V; Vasciaveo, A | 1 |
| Kaplow, R | 1 |
| Anderson, KC; Bonham, L; Chauhan, D; Hideshima, H; Hideshima, T; Ishitsuka, K; Kumar, S; Mitsiades, C; Munshi, NC; Podar, K; Raje, N; Richardson, PG; Singer, JW; Yasui, H | 1 |
| Crawford, CL | 1 |
| Bladé, J; Cibeira, MT; Montoto, S; Rosiñol, L | 1 |
| Antonescu, CR; Kraft, AS; Maki, RG; Scheu, K; Schwartz, GK; Wadler, S; Wright, JJ; Yamada, J | 1 |
| Berdel, WE; Bisping, G; Kienast, J; Kropff, MH; Tchinda, J; Volpert, S; Wenning, D | 1 |
| Alberts, SR; Block, M; Burch, P; Foster, N; Jatoi, A; Kugler, J; Morton, R; Nguyen, PL | 1 |
| Carbonell, AL; del Giglio, A; Manhani, AR; Mitteldorf, CA; Weinschenker, P | 1 |
| Baronas, E; Daniels, JS; Gan, LS; Hsieh, F; Labutti, J; Miwa, G; Nix, D; Parsons, I; Pekol, T | 1 |
| Adams, JM; Beaudoin, B; Bouillet, P; Degenhardt, K; Nelson, DA; Nieves-Neira, W; Tan, TT; Villunger, A; White, E | 1 |
| Adams, J; Coultas, L; Johnson, T; Kraft, AS; Nikrad, M; Puthalalath, H | 1 |
| Engelhardt, M; Maier, W; Müller, AM; Wäsch, R | 1 |
| Bai, J; Callery, MP; Demirjian, A; Marasco, W; Sui, J; Vollmer, CM | 1 |
| Bold, RJ; Fahy, BN; Mortenson, MM; Schlieman, MG; Virudachalam, S | 1 |
| Chou, T | 1 |
| Ahsan, MH; Purchio, AF; Sambucetti, LC; West, DB; Zhang, N; Zhu, L | 1 |
| Magnuson, NS; McKenzie, IF; Shay, KP; Wang, Z; Xing, PX | 1 |
| Dalton, WS | 1 |
| Aghajanian, C | 1 |
| Au, AW; Chim, CS; Lie, AK; Loong, F; Ooi, GC | 1 |
| Beretta, GL; Brigliadori, G; Corna, E; De Cesare, M; Fabbri, F; Ricotti, L; Rosetti, M; Supino, R; Tesei, A; Ulivi, P; Zoli, W; Zunino, F | 1 |
| Cebula, B; Duechler, M; Linke, A; Robak, T; Schwarzmeier, JD; Shehata, M; Smolewski, P | 1 |
| Dubey, S; Schiller, JH | 1 |
| Chiao, PJ; Davis, JJ; Dong, F; Fang, B; Guo, W; Teraishi, F; Wu, S; Zhang, L; Zhu, H | 1 |
| Anderson, KC; Chauhan, D; Hideshima, T; Mitsiades, C; Richardson, P | 1 |
| Fuchida, SI; Inaba, T; Nakano, S; Namura, K; Okamoto, M; Okano, A; Shimazaki, C; Uchida, R | 1 |
| Fleissner, C; Jakob, C; Kaiser, M; Krebbel, H; Possinger, K; Rosche, M; Schmid, P; Sezer, O; Zavrski, I | 1 |
| Anderson, KC; Berkers, CR; Fiebiger, E; Galardy, PJ; Kessler, BM; Lichtman, E; Ovaa, H; Ploegh, HL; Verdoes, M | 1 |
| Chng, WJ; Lau, LG; Mow, BM; Yusof, N | 1 |
| Murphy, WJ; Sayers, TJ | 1 |
| Adjei, AA; Alberti, D; Alberts, SR; Binger, K; Bruzek, L; Dy, GK; Erlichman, C; Hanson, LJ; Kaufmann, SH; Mandrekar, S; Marnocha, R; Pitot, HC; Thomas, JP; Tutsch, K; Wilding, G | 1 |
| Dorr, RT; Landowski, TH; Lynch, RM; Megli, CJ; Nullmeyer, KD | 1 |
| Jagannath, S | 3 |
| Böll, B; Borchmann, P; Engert, A; Hansen, H; Heuck, F; Pogge von Strandmann, E; Reiners, K; Rothe, A | 1 |
| Edelman, MJ | 2 |
| Nelson, JB; Smith, MR | 1 |
| Adjei, AA; Albertini, M; Dawkins, F; Erlichman, C; Fitch, T; Fracasso, PM; Geyer, SM; Lorusso, P; Maples, W; Markovic, SN; Sharfman, W | 1 |
| Bradbury, J | 1 |
| Andtbacka, R; McConkey, D; Nawrocki, ST | 1 |
| Mimnaugh, EG; Neckers, LM | 1 |
| Dinney, CP; Lashinger, LM; McConkey, DJ; Shrader, M; Williams, SA; Zhu, K | 1 |
| Ballestrero, A; Belka, C; Boy, D; Brossart, P; Cirmena, G; Dal Bello, G; Nencioni, A; Patrone, F; Wesselborg, S; Wille, L | 1 |
| Anderson, KC; Bradner, JE; Chauhan, D; Hideshima, T; Richardson, P; Schreiber, SL; Wong, J | 1 |
| Ahsan, MH; Purchio, AF; West, DB; Zhang, N | 1 |
| Rajkumar, SV | 5 |
| Bruno, B; Gallamini, A; Mattei, D; Mordini, N; Rapezzi, D; Vigna Taglianti, R | 1 |
| Agrawal, S; Cavenagh, JD; Curry, N; Drake, M; Esseltine, DL; Morris, C; Oakervee, HE; Popat, R; Schenkein, D; Smith, P; Stec, J | 1 |
| Camacho, E; Crowley, J; Durie, BG; Gabayan, E; Irwin, D; Jagannath, S; Lutzky, J; Mazumder, A; McKinley, M; Schenkein, D; Wolf, J | 1 |
| Dimopoulos, MA; Rahemtulla, A; Terpos, E | 1 |
| Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, AL; Cavenagh, J; Dalton, WS; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Irwin, D; Lonial, S; Porter, JB; Reece, D; Richardson, PG; San-Miguel, JF; Schenkein, D; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
| Agterof, MJ; Biesma, DH | 1 |
| Dispenzieri, A | 3 |
| Anver, MR; Blazar, BR; Murphy, WJ; Panoskaltsis-Mortari, A; Sayers, TJ; Sun, K; Welniak, LA; Wilkins, DE | 1 |
| Dispenzieri, A; Goel, A; Greipp, PR; Mesa, RA; Russell, SJ; Witzig, TE | 1 |
| Bankier, A; Drach, J; Kalhs, P; Krauth, MT; Valent, P | 1 |
| Masuda, N; Yanase, N; Yokoba, M | 1 |
| André, P; Chiadmi, F; Cisternino, S; Fain, O; Fontan, JE; Schlatter, J; Toledano, A | 1 |
| Dunn, ST; Garrett, MW; Huang, S; Kaufman, KM; Kem, DC; Metcalf, JP; Patterson, E; Yu, X; Zhu, M | 1 |
| Lokhorst, HM; Sonneveld, P; van Wieringen, W; Vellenga, E; Wu, KL; Zweegman, S | 1 |
| Azizi, L; Bories, D; Coppo, P; Fouillard, L; Garderet, L; Gorin, NC; Paubelle, E | 1 |
| Heinrich, B | 1 |
| Anderson, KC; Hideshima, T; Mitsiades, CS; Mitsiades, N; Richardson, PG | 2 |
| Drach, J; Kaufmann, H; Seidl, S | 1 |
| Adams, J; Camphausen, K; Chang, AA; Chen, Z; Conley, BA; Druzgal, CH; Elsayed, YA; Gius, D; Lebowitz, PF; Mitchell, JB; Morris, JC; Rudy, SF; Sausville, EA; Sunwoo, JB; Van Waes, C | 1 |
| Graeven, U; König, M; Schmiegel, W; Schmielau, J; Teschendorf, C | 1 |
| Chanan-Khan, A; Miller, KC | 1 |
| Anderson, KC; Barlogie, B; Berenson, J; Esseltine, D; Hideshima, T; Irwin, D; Jagannath, S; Rajkumar, SV; Richardson, PG; Schenkein, D; Singhal, S; Xiao, H | 1 |
| Bold, RJ; Davies, AM; Gandara, DG; Lara, PN; Mortenson, MM; Schlieman, MG; Virudachalam, S | 1 |
| Bennett, F; Bodner, B; Bonish, BK; Chaturvedi, V; Hendrix, MJ; Miele, L; Nickoloff, BJ; Pollock, PM; Qin, JZ; Rizzo, P; Stennett, L; Trent, JM; Ziffra, J | 1 |
| Fernández, Y; Lowe, SW; Miller, TP; Opipari, AW; Rush, JL; Soengas, MS; Steiner, P; Verhaegen, M | 1 |
| Adachi, M; Imai, K; Kawamura, R; Minami, T; Shinomura, Y; Zhang, Y | 1 |
| Ganten, TM; Haas, TL; Herzer, K; Koschny, R; Li-Weber, M; Sykora, J; Walczak, H | 1 |
| Delaney, TF; Harmon, DC; Mohiuddin, MM | 1 |
| Biggs, JR; Garcia, M; Kraft, AS; Peterson, LF; Zhang, DE; Zhang, Y | 1 |
| Linder, S; Shoshan, MC | 1 |
| Birle, D; Degendorfer, P; Hedley, D; Mackay, H; Mackenzie, M; Major, P; Moore, M; Nicklee, T; Oza, A; Siu, L; Townsley, C; Tsao, MS; Vincent, M; Wright, J | 1 |
| Apperley, JF; Karadimitris, A; Kotsianidis, I; Politou, M; Rahemtulla, A; Terpos, E | 1 |
| Brown, RE; Kennedy, TL; Law, A; Lun, M; Pellitteri, PK; Zhang, PL | 1 |
| Davis, JJ; Dong, F; Fang, B; Guo, W; Teraishi, F; Wu, S; Zhang, L; Zhu, H | 1 |
| Albanell, J; Gascon, P; Mellado, B; Montagut, C; Ross, JS; Rovira, A | 1 |
| Alberts, SR; Fitch, TR; Foster, NR; Gill, S; Kim, GP; Kugler, J; Morton, RF; Schaefer, P; Steen, P; Wiesenfeld, M | 1 |
| Adimoolam, S; Chen, D; Kampa, K; Lopez, CD; Naumovski, L; Ramos, J; Sirisawad, M; Yu, Z; Zhu, Z | 1 |
| Ahmad, K | 1 |
| Albert, V; Andreeff, M; Carbone, A; Georgakis, GV; Humphreys, R; Li, Y; O'Brien, S; Younes, A; Younes, M | 1 |
| Anderson, J; Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Francis, D; Giusti, S; Giver, CR; Heffner, LT; Jagannath, S; Jaye, DL; Lonial, S; Orlowski, RZ; Richardson, PG; Schenkein, DP; Singhal, S; Torre, C; Waller, EK; Xiao, H | 1 |
| Bang, SM; Kim, BK; Kim, JH; Kim, NK; Lee, JH; Lee, JS; Lee, KW; Lee, ST; Na, II; Park, S; Shin, H; Song, EK; Yoon, SS; Yun, T | 1 |
| Gan, LS; Lu, C; Miwa, G; Uttamsingh, V | 1 |
| Balleari, E; Boccadoro, M; Bodenizza, C; Carella, AM; Cascavilla, N; Catalano, L; Cavallo, F; Dell'Olio, M; Falcone, A; Greco, MM; Guglielmelli, T; La Sala, A; Mantuano, S; Melillo, L; Merla, E; Musto, P; Nobile, M; Palumbo, A; Sanpaolo, G; Scalzulli, PR; Spriano, M; Zambello, R | 1 |
| Alsina, M; Beaupre, DM; Buzzeo, R; Dalton, WS; Enkemann, S; Lichtenheld, MG; Nimmanapalli, R | 1 |
| Bladé, J; Cibeira, MT; Rosiñol, L | 1 |
| Chen, J; David, E; Khuri, FR; Lonial, S; Sun, SY; Waller, EK | 1 |
| Alexandre, J | 1 |
| Gamradt, SC; Gates, JJ; Lieberman, JR; Whang, PG | 1 |
| Aghajanian, C; Dizon, DS; Dupont, J; Raizer, JJ; Sabbatini, P; Spriggs, DR | 1 |
| Adams, J; Boyden, J; Chachoua, A; Clark, JW; Eder, JP; Elliott, P; Farrell, K; Garcia-Carbonero, R; Hamilton, AL; Kinchla, N; Liebes, L; Muggia, FM; Pavlick, AC; Ryan, DP; Soma, V; Wright, J; Yee, H; Zeleniuch-Jacquotte, A | 1 |
| Altun, M; Anderson, KC; Galardy, PJ; Hideshima, T; Kessler, BM; LeBlanc, R; Ploegh, HL; Shringarpure, R | 1 |
| Anderson, KC; Farrell, AT; Pazdur, R | 1 |
| Chaudhry, V; Umapathi, T | 1 |
| Musch, A | 1 |
| Anderson, KC; Carver, B; Chang, Y; Chauhan, D; He, D; Hideshima, T; Li, G; Mitsiades, N; Neri, P; Podar, K; Richardson, P; Schindler, J | 1 |
| Campo, E; Colomer, D; Montserrat, E; Pérez-Galán, P; Roué, G; Villamor, N | 1 |
| Glasmacher, A; von Lilienfeld-Toal, M | 1 |
| Barlogie, B; Burns, MJ; Elice, F; Esseltine, D; Kang, SH; Lee, CK; Najarian, K; Richardson, P; Sonneveld, P; Tricot, G; Yaccoby, S; Zangari, M | 1 |
| Drobyski, WR; Hari, P; Jacobs, P; Komorowski, R; Vodanovic-Jankovic, S | 1 |
| Caccese, E; Cecchi, M; Messori, A | 1 |
| Facon, T; Giaccone, G; Khayat, D; Ludwig, H | 1 |
| Kroep, JR; Vandenbroucke, JP | 1 |
| Adam, Z; Gregora, E; Hájek, R; Klener, P; Maisnar, V; Schutzova, M; Scudla, V; Spicka, I; Straub, J; Vytrasová, M | 1 |
| Ferrant, A; Jacquemain, A; Knoops, L; Tennstedt, D; Theate, I; Van den Neste, E | 1 |
| Joshua, DE | 1 |
| Gullbo, J; Larsson, R; Lövborg, H; Nygren, P; Oberg, F; Rickardson, L | 1 |
| Alexanian, R; Alsina, M; Anderson, K; Barlogie, B; Berenson, JR; Esseltine, DL; Irwin, D; Jagannath, S; Limentani, S; Niesvizky, R; Rajkumar, SV; Richardson, PG; Schenkein, DP; Siegel, DT; Singhal, S; Srkalovic, G; Trehu, E | 1 |
| Brown, HJ; McBride, WH; Sun, R; Zack, JA | 1 |
| Bachelez, H; Courtois, G; Dubertret, L; Jean-Louis, F; Laroche, L; Michel, L; Pellet, C; Sors, A | 1 |
| Frost, P; Gera, J; Lichtenstein, A; Shi, Y; Yan, H | 1 |
| Apperley, JF; Crawley, D; Lampert, I; Naresh, K; Politou, M; Rahemtulla, A; Terpos, E | 1 |
| Aggarwal, BB; Gutierrez, AM; Lotan, R; Shishodia, S | 1 |
| Anderson, K; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, PG; Schlossman, R | 1 |
| Harousseau, JL; Moreau, P | 1 |
| Sonneveld, P; Wu, KL | 1 |
| Akiyama, M; Anderson, KC; Bailey, C; Chauhan, D; Davies, FE; Gu, X; Hideshima, T; Joseph, M; Kung, AL; Libermann, TA; McMullan, CJ; Mitsiades, CS; Mitsiades, NS; Morgan, G; Munshi, NC; Poulaki, V; Richardson, PG; Rosen, NS; Shringarpure, R | 1 |
| Adjei, AA | 1 |
| Bold, RJ; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Mack, PC | 2 |
| Kiselyov, A | 1 |
| Anderson, KC; Richardson, PG | 1 |
| Bengston, AL; Denoyelle, C; Esteban, JA; Fernández, Y; Miller, TP; Soengas, MS; Tang, WH | 1 |
| Zelenetz, A | 1 |
| Alberca, M; Blanco, B; Carvajal-Vergara, X; López-Holgado, N; Maiso, P; Mateos, J; Pandiella, A; Pérez-Simón, JA; San Miguel, J; Sánchez-Abarca, LI; Schenkein, D; Vidriales, B; Villarón, E | 1 |
| Anderson, KC; Berkers, C; Catley, L; Chao, TH; Chauhan, D; Hideshima, T; Letai, A; Li, G; Mitsiades, C; Mitsiades, N; Neuteboom, ST; Nicholson, B; Ovaa, H; Palladino, MA; Podar, K; Richardson, P; Velankar, M; Yasui, H | 1 |
| Berg, SL; Blaney, SM; D'Argenio, DZ; Gannavarapu, A; Horton, TM; Plon, SE | 1 |
| Einsele, H; Jackson, G; Miguel, JS; Moreau, P | 1 |
| Herrington, JD; Jaskiewicz, AD; Wong, L | 1 |
| Daniel, KG; Dou, QP; Kazi, A; Kuhn, DJ | 1 |
| Andreesen, R; Grassinger, J; Hennemann, B; Südhoff, T | 1 |
| Bay, JO; Blay, JY; Rixe, O; Spano, JP | 1 |
| Abboud, CN; Bechelli, J; Lancet, JE; Liesveld, JL; Lu, C; Phillips, G; Rosell, KE | 1 |
| Bosi, A; Ciolli, S; Gigli, F; Leoni, F; Rigacci, L | 1 |
| Bogner, C; Decker, T; Peschel, C | 1 |
| Leblond, V | 1 |
| Anagnostopoulos, A; Bitsaktsis, A; Castritis, E; Dimopoulos, MA; Kyrtsonis, MC; Pangalis, GA | 1 |
| Greipp, P | 1 |
| Abbruzzese, JL; Boise, LH; Carew, JS; Chiao, PJ; Dunner, K; Huang, P; McConkey, DJ; Nawrocki, ST | 1 |
| Abbruzzese, JL; Carew, JS; Dunner, K; Highshaw, RA; Huang, P; McConkey, DJ; Nawrocki, ST; Pino, MS | 1 |
| Bukowski, RM; Chawla-Sarkar, M; Chikamori, K; Ganapathi, MK; Ganapathi, R; Grabowski, DR; Gudkov, AV; Hill, J; Mekhail, T; Rybicki, LR; Takigawa, N; Vaziri, SA | 1 |
| Brooks, AD; Elliott, PJ; Murphy, WJ; Onksen, J; Ramirez, T; Sayers, TJ; Toh, U | 1 |
| Berrebi, A | 1 |
| Buisson, JP; Magdelenat, H; Monneret, C | 1 |
| Govindan, R; Narra, V; Pillot, G; Subramanian, J | 1 |
| Saunders, G | 1 |
| Behrens, D; Cinatl, J; Doerr, HW; Fichtner, I; Haider, W; Mack, A; Michaelis, M; Rothweiler, F | 1 |
| Anderson, KC; Catley, L | 1 |
| He, M; Khuri, FR; Lin, N; Lonial, S; Sun, SY; Wang, B; Yue, P; Zhou, Z; Zou, W | 1 |
| Anderson, KC; Dammacco, F; Hideshima, T; Ishitsuka, K; Kumar, S; Nico, B; Raje, N; Ribatti, D; Richardson, PG; Roccaro, AM; Shiraishi, N; Vacca, A; Yasui, H | 1 |
| Anastasiadis, AG; Argyropoulou, P; Bourikas, G; Kaloutsi, V; Margaritis, D; Pantelidou, D; Prassopoulos, P; Tsatalas, C | 1 |
| Bladé, J; Boccadoro, M; Cavenagh, J; Glasmacher, A; Jagannath, S; Lonial, S; Ludwig, H; Orlowski, RZ; San Miguel, J; Sonneveld, P | 1 |
| Orlowski, RZ; Voorhees, PM | 3 |
| Booser, DJ; Broglio, KR; Cristofanilli, M; Esseltine, D; Gonzalez-Angulo, AM; Hortobagyi, GN; Islam, R; Krishnamurthy, S; Pusztai, L; Reuben, JM; Stec, J; Yang, CH | 1 |
| Brancolini, C; Demarchi, F | 1 |
| Chizzolini, C; Dayer, JM; Fineschi, S; Guerne, PA; Reith, W | 1 |
| Fujii, T; Kami, M; Kawabata, M; Matsumura, T; Miyakoshi, S; Narimatsu, H; Oshimi, K; Ozawa, K; Sasaki, M; Takatoku, M; Taniguchi, S; Yuji, K | 1 |
| Adams, J; Berenson, JR; Jarutirasarn, SG; Lee, SP; Mapes, R; Morrison, B; Purner, M; Sadler, K; Schenkein, D; Swift, R; Vescio, RA; Wilson, J; Yang, HH | 1 |
| Dispenzieri, A; Geyer, SM; Goel, A; Greiner, S; Peng, KW; Russell, SJ | 1 |
| Furukawa, Y; Ishii, H; Kano, Y; Kobayashi, Y; Ozawa, K; Sutheesophon, K; Takatoku, MA | 1 |
| Scagliotti, G | 1 |
| Beaupre, DM; Boulware, D; Buzzeo, RW; Colaco, NM; Dalton, WS; Parquet, NA; Perez, LE; Wright, G; Yanamandra, N | 1 |
| de la Loge, C; Dhawan, R; Dubois, D; Esseltine, D; Gupta, S; van de Velde, H; Viala, M | 1 |
| Orlowski, RZ; Zeger, EL | 1 |
| Jaehde, U; Scheulen, ME; Simons, S | 1 |
| Anan, A; Baskin-Bey, ES; Bronk, SF; Gores, GJ; Shah, VH; Werneburg, NW | 1 |
| Gallegos, R; Gan, LS; Li, P; Lu, C; Miwa, GT; Nix, D; Pusalkar, S; Uttamsingh, V; Xia, CQ | 1 |
| Adachi, M; Hayashi, T; Ikeda, H; Ikeda, Y; Imai, K; Ishida, T; Nojima, M; Yasui, H | 1 |
| Huang, DC; Sinicrope, FA; Yeung, BH | 1 |
| Murakami, H | 1 |
| Cho, CS; Eom, KS; Kim, CC; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS; Park, G | 1 |
| Bonomi, P; Villaflor, V | 1 |
| Fayad, L; Pro, B; Younes, A | 1 |
| Lilenbaum, R; Raez, LE | 1 |
| Chim, CS; Ooi, GC | 1 |
| De Raeve, H; Lambert, J; Rombouts, S; Schroyens, W; Van de Velde, A; Van de Voorde, K; Van Regenmortel, N | 1 |
| Hajek, R; Krejci, M; Krivanova, A; Pour, L; Vorlicek, J; Zdenek, A | 1 |
| Dick, L; Hu, G; Li, H; Lin, G; Nathan, C; Wang, M; Xu, RM | 1 |
| Alsina, M; Anderson, KC; Barlogie, B; Berenson, J; Irwin, DH; Jagannath, S; Rajkumar, SV; Richardson, PG; Singhal, S; Srkalovic, G | 1 |
| Gaczynska, M; Osmulski, PA; Tan, X | 1 |
| Dasmahapatra, G; Dent, P; Grant, S; Nguyen, TK | 1 |
| Almuete, VI; Armstrong, DK; Baker, SD; Carducci, MA; Dinh, K; Donehower, RC; Lassiter, L; Messersmith, WA; Sullivan, RA; Wright, JJ | 1 |
| Bouley, J; Fisher, M; Henninger, N; Sicard, KM; Stagliano, NE | 1 |
| Moskowitz, CH | 1 |
| Braun, T; Carvalho, G; Castedo, M; Coquelle, A; Kroemer, G; Métivier, D; Mouhamad, S; Pequignot, MO; Vivet, S | 1 |
| Anderson, KC; Hideshima, T; Richardson, PG; Schlossman, R | 1 |
| Kaufman, JL; Lonial, S; Sinha, R | 1 |
| Boise, LH; Carlson, LM; Gutman, DM; Harrington, WJ; Lee, KP; Obeng, EA | 1 |
| Beehler, BC; Benmassaoud, L; Grover, GJ; Sleph, PG | 1 |
| Sánchez-Serrano, I | 1 |
| Colland, F | 2 |
| Calvaruso, G; Carlisi, D; D'Anneo, A; Emanuele, S; Lauricella, M; Portanova, P; Tesoriere, G; Vassallo, B; Vento, R | 1 |
| Bladé, J; Cibeira, MT; Laura, R; Montserrat, E; Salamero, O; Uriburu, C; Yantorno, S | 1 |
| Berkers, CR; Groll, M; Ovaa, H; Ploegh, HL | 1 |
| Ballestrero, A; Brauer, KM; Brossart, P; Grünebach, F; Nencioni, A; Schmidt, SM; Schwarzenberg, K | 1 |
| Chopp, M; Hozeska, A; Liu, X; Lu, M; Riordan, W; Stagliano, N; Zhang, L; Zhang, ZG | 1 |
| Ann, DK; Boo, LM; Chen, Y; Chung, V; Liu, X; Nguyen, HV; Song, J; Yen, Y; Zhou, B; Zhu, L | 1 |
| Albanell, J; Bosch, M; Codony-Servat, J; Domingo-Domenech, J; Gascon, P; Mellado, B; Oliva, C; Rolfe, M; Ross, JS; Rovira, A; Tapia, MA | 1 |
| Coiteux, V; Facon, T; Leleu, X | 1 |
| Kondagunta, GV; Motzer, RJ; Ronnen, EA | 1 |
| Doihara, H; Fujita, T; Kawasaki, K; Ogasawara, Y; Shimizu, N; Takabatake, D; Takahashi, H; Tsukuda, K; Washio, K | 1 |
| Badros, A; Gahres, N | 1 |
| Mitsiades, C; Richardson, PG | 1 |
| Coleman, M; Furman, RR; Leonard, JP | 1 |
| O'Connor, OA; Paoluzzi, L | 1 |
| Kyle, RA; Vincent Rajkumar, S | 1 |
| Fei, XM; Li, JY; Lin, RF; Liu, P; Lu, H; Shen, WY; Wu, YJ; Zhang, JF | 1 |
| Bazzaro, M; Lee, MK; Roden, RB; Santillan, A; Shih, IeM; Stirling, WL; Zoso, A | 1 |
| Abbruzzese, JL; Andtbacka, RH; Bornmann, WG; Carew, JS; Chiao, PJ; Dunner, K; Highshaw, RA; Huang, P; McConkey, DJ; Nawrocki, ST; Pal, A; Pino, MS; Xiong, H | 1 |
| Bonavida, B; Comin-Anduix, B; Dissette, VB; Economou, JS; Garban, HJ; Glaspy, JA; McBride, WH; Owens, SK; Ribas, A; Schumacher, LY; Vo, DD | 1 |
| Ferreri, AJ | 1 |
| Ayuk, FA; Corradini, P; Goldschmidt, H; Hegenbart, U; Kröger, N; Lokhorst, HM; Montefusco, V; Nagler, A; Perez-Simon, JA; Raymakers, RA; San Miguel, JF; van de Donk, NW; van Oers, MH; Verdonck, LF; Zijlmans, M | 1 |
| Kaufman, JL; Lonial, S | 1 |
| Balkwill, F; Boral, A; Hoare, S; Joel, SP; Johnson, PW; Lister, TA; Maharaj, L; Millard, L; Radford, JA; Rohatiner, A; Schenkein, D; Strauss, SJ; Trehu, E; Vinnecombe, S | 1 |
| Daniels, JS; Gan, LS; Huang, R; Labutti, J; Miwa, G; Parsons, I | 1 |
| Handa, H; Murakami, H | 1 |
| Baccarani, M; Cangini, D; Cavo, M; Ceccolini, M; Perrone, G; Tacchetti, P; Tosi, P; Zamagni, E | 1 |
| Anderson, KC; Chakravarty, S; Dugar, S; Haghnazari, E; Henson, M; Hideshima, T; Higgins, LS; Kapoun, AM; Kerr, I; Luedtke, G; Ma, JY; Mavunkel, B; Medicherla, S; Navas, TA; Nguyen, AN; O'Young, G; Perumattam, J; Protter, AA; Reddy, M; Schreiner, GF; Stebbins, EG | 1 |
| Bohlius, J; Engert, A; Hülsewede, H; Kober, T | 1 |
| Cebula, B; Duechler, M; Grzybowska-Izydorczyk, O; Linke, A; Robak, T; Shehata, M; Smolewski, P | 1 |
| Arnold, AC; Back, TC; Hixon, JA; Khan, T; Lincoln, E; Lockett, S; Powell, D; Salcedo, R; Sayers, TJ; Stauffer, JK; Wigginton, JM; Williams, R | 1 |
| Chan, KK; Chanan-Khan, A; Frankel, S; Liu, S; Marcucci, G; O'Connor, OA; Rolfe, M; Smith, EA; Teruya-Feldstein, J; Toner, LE; Wei, X | 1 |
| Hess, U | 1 |
| Giaccone, G; Voortman, J | 1 |
| Gibson, SB; Hu, X; Johnston, JB; Kabore, AF; McCrea, K; Sun, J | 1 |
| Farrell, AT; Kane, RC; Pazdur, R; Sridhara, R | 1 |
| Soria, JC | 1 |
| Awada, A; de Castro, G | 1 |
| Atanackovic, D; Ayuk, F; Kröger, N; Renges, H; Schieder, H; Zabelina, T; Zander, A | 1 |
| Anderson, KC; Atadja, P; Catley, L; Chauhan, D; Hideshima, T; Kiziltepe, T; Munshi, NC; Neri, P; Tai, YT; Tassone, P; Weisberg, E | 1 |
| Calvaruso, G; De Blasio, A; Giuliano, M; Portanova, P; Tesoriere, G; Vento, R | 1 |
| Atadja, P; Carvajal-Vergara, X; Gutiérrez, N; López-Pérez, R; Maiso, P; Mateo, G; Ocio, EM; Pandiella, A; San Miguel, JF | 1 |
| Alexanian, R; Alsina, M; Amato, AA; Anderson, KC; Barlogie, B; Berenson, J; Briemberg, H; Esseltine, D; Irwin, D; Jagannath, S; Limentani, S; Najarian, K; Orlowski, RZ; Rajkumar, SV; Richardson, PG; Schuster, M; Siegel, DS; Singhal, S; Srkalovic, G; Wen, PY | 1 |
| Aizu-Yokota, E; Hatake, K; Kasahara, T; Kuniyoshi, R; Mishima, Y; Rokudai, A; Sonoda, Y; Terui, Y | 1 |
| Devereux, S; Gupta, S; Mufti, GJ; Pagliuca, A; Schey, S | 1 |
| Bang, SM; Cho, KS; Jo, DY; Kim, CC; Kim, CS; Kim, K; Lee, JH; Lee, JJ; Lee, KH; Lee, NR; Min, CK; Min, YH; Park, S; Seong, CM; Sohn, SK; Suh, C; Yoon, HJ; Yoon, SS | 1 |
| Albanell, J; Montagut, C; Rovira, A | 1 |
| Agnese, V; Bazan, V; Russo, A; Santini, D; Terrasi, M | 1 |
| Goranov, SE; Goranova-Marinova, VS | 1 |
| Laurie, SA; Licitra, L | 1 |
| Adjei, AA; Alberts, SR; Bruzek, L; Croghan, GA; Erlichman, C; Hanson, LJ; Jatoi, A; Ma, C; Mandrekar, SJ; Pitot, HC; Reid, JM; Tan, AD; Wright, JJ | 1 |
| Boccadoro, M; Bonifazi, F; Bruno, B; Corradini, P; Fanin, R; Giaccone, L; Guidi, S; Mattei, D; Milone, G; Montefusco, V; Patriarca, F; Peccatori, J; Petrucci, MT; Rotta, M; Sorasio, R | 1 |
| Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Díaz-Mediavilla, J; Esseltine, DL; Fuertes, M; García-Laraña, J; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H | 1 |
| Davis, JJ; Dong, F; Fang, B; Guo, W; Liu, J; Sasazuki, T; Shirasawa, S; Teraishi, F; Zhang, L | 1 |
| Anderson, KC; Chauhan, D; Crawford, LJ; Irvine, AE; Morris, TC; Ovaa, H; Walker, B | 1 |
| Cloos, J; Kaspers, GJ; Vink, J | 1 |
| Swieboda-Sadlej, A | 1 |
| De Coster, R; Dyer, MJ; Kohlhaas, SL; Majid, A; Monbaliu, J; Walewska, RJ; Wheat, LM | 1 |
| Ambrosini, MT; Avonto, I; Boccadoro, M; Bringhen, S; Bruno, B; Cavallo, F; Falco, P; Falcone, A; Gay, F; Massaia, M; Musto, P; Palumbo, A; Rus, C; Scalzulli, PR | 1 |
| Albrecht, JH; Anan, A; Baskin-Bey, ES; Bronk, SF; Gores, GJ; Isomoto, H; Mott, JL | 1 |
| Allegue, F; López-Miragaya, MI; Pérez Castro, S; Romo, M | 1 |
| Cavenagh, J; Joel, S; Oakervee, H; Popat, R | 1 |
| Orlowski, RZ; Shi, YY; Small, GW | 1 |
| Hussein, MA; Kalmadi, SR | 1 |
| Cavo, M | 3 |
| Esseltine, D; MacGregor-Cortelli, B; Muzzy, J; O'Connor, OA; Schenkein, D; Scher, H; Slovin, S; Stubblefield, MD; Wright, J | 1 |
| Cavenagh, JD | 1 |
| Bladé, J; San-Miguel, J | 1 |
| Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Irwin, D; Jagannath, S; Richardson, PG; Schenkein, DP; Singhal, S; Srkalovic, G | 1 |
| Banti, A; Kaloutsi, V; Lazaridou, A; Terpos, E; Verrou, E; Zervas, K | 1 |
| Berdel, WE; Bisping, G; Kienast, J; Kropff, M; Wenning, D | 1 |
| Amadori, S; Boccadoro, M; Caravita, T; de Fabritiis, P; Palumbo, A | 1 |
| Colson, K; Jagannath, S; Richardson, P | 1 |
| Nguyen, CA; Romaguera, J; Wang, M; Zhang, L; Zhou, Y | 1 |
| Burtrum, D; Ludwig, DL; Moore, MA; Wu, KD; Zhou, L | 1 |
| Byrd, JC; Esseltine, DL; Faderl, S; Flinn, IW; Gribben, J; Keating, MJ; O'Brien, S; Rai, K; Sheng, S | 1 |
| Colson, K | 2 |
| Anderson, KC; Bhole, D; Burger, R; Catley, L; Chauhan, D; Galardy, P; Hideshima, T; Kessler, B; Mitsiades, C; Munshi, NC; Ploegh, H; Podar, K; Shringarpure, R; Tai, YT; Tassone, P | 1 |
| Kaluz, S; Kaluzová, M; Stanbridge, EJ | 2 |
| Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H | 2 |
| Auberger, J; Hilbe, W; Loeffler-Ragg, J; Wurzer, W | 1 |
| Ain, KB; Fanourakis, G; Kotoula, V; McMillin, D; McMullan, C; Mitsiades, CS; Mitsiades, N; Negri, J; Poulaki, V; Tseleni-Balafouta, S | 1 |
| Abrams, SI; Alvarez, G; Berg, M; Childs, R; Lundqvist, A; Schrump, DS; Suffredini, D | 1 |
| Hess, G; Heussel, CP; Huber, C; Kreft, A; Wagner, V | 1 |
| Armando, S; Nozza, A; Siracusano, L | 1 |
| Ascensao, JL; Batra, RB; Boyer, JE; Schechter, GP | 1 |
| Anderson, KC; Hunter, T; Joazeiro, CA | 1 |
| Fribley, A; Wang, CY | 1 |
| Hönemann, D; Kenealy, MK; Prince, HM | 1 |
| Inaba, T; Kobayashi, Y; Shimazaki, C; Taniwaki, M | 1 |
| Boral, A; Busam, K; Esseltine, D; Gerecitano, J; Gonen, M; Goy, A; MacGregor-Cortelli, B; Neylon, E; O'Connor, OA; Sachs, D; Schenkein, D; Teruya-Feldstein, J; Wright, J | 1 |
| Mack, GS | 1 |
| Arpaci, F; Ataergin, S; Cetin, T; Gunhan, O; Kaya, A; Kaya, T | 1 |
| Alloro, E; Brocca, MC; Coppi, MR; Mele, G; Pinna, S; Quarta, G | 1 |
| Chandra, J; Keating, M; Krupnik, Y; McConkey, D; Palladino, M; Ruiz, S | 1 |
| Hughes, M; Micallef-Eynaud, P | 1 |
| Compton, J; Hrabeta-Robinson, E; Silberstein, GB; Van Horn, K | 1 |
| Bai, J; Callery, MP; Demirjian, A; Marasco, W; Sui, J | 1 |
| Brignole, C; Cilli, M; Cioni, M; Corrias, MV; Di Paolo, D; Marimpietri, D; Nico, B; Pagnan, G; Pastorino, F; Pezzolo, A; Piccardi, F; Pistoia, V; Ponzoni, M; Ribatti, D | 1 |
| Hideshima, T; Yasui, H | 1 |
| Fleissner, C; Hecht, M; Heider, U; Jakob, C; Kaiser, M; Müller, C; Schulz, CO; Sezer, O; Zavrski, I | 1 |
| Davies, MJ | 2 |
| Barrick, M | 1 |
| Chen, LJ; Li, JY; Qian, SX; Zheng, WJ; Zhu, GR | 1 |
| Evenchik, B; Fribley, AM; Guan, JY; Hale, TJ; Kaufman, RJ; Park, BK; Soengas, MS; Wang, CY; Zeng, Q; Zhang, H | 1 |
| Canfield, SE; McConkey, DJ; Williams, SA; Zhu, K | 1 |
| Jin, J; Mai, W; Meng, H; Wang, L | 1 |
| Ali, R; Kurt, M; Ozan, U; Ozcelik, T; Ozkalemkas, F; Ozkan, A; Ozkocaman, V; Tunali, A | 1 |
| Frost, RA; Huber, D; Lang, CH | 1 |
| Alvarez, JV; Frank, DA; Germain, D; Ishii, Y; Keselman, I; Logothetis, D; Mandeli, J; O'Connell, MJ; Pirkmaier, A; Waxman, S | 1 |
| Alexander, HD; Cavanagh, JD; Drake, M; Finnegan, DP; Kettle, P; Matthews, C; Morris, TC; Popat, R; Wachsman, W | 1 |
| Mimnaugh, EG; Neckers, L; Vos, M; Xu, W; Yuan, X | 1 |
| Harousseau, JL | 8 |
| Moreau, P | 1 |
| Belch, A; Crump, M; Eisenhauer, EA; Gascoyne, RD; Klasa, R; Kouroukis, CT; Powers, J; Sehn, L; Wright, J | 1 |
| Bours, V; Olivier, S; Robe, P | 1 |
| Bladé, J; Cibeira, MT; Esteve, J; Ramiro, L; Rosiñol, L; Torrebadell, M | 1 |
| Degendorfer, P; Gomez-Abuin, G; Moore, MJ; Pond, G; Stadler, WM; Winquist, E; Wright, J | 1 |
| Abbruzzese, JL; Andtbacka, R; Arumugam, T; Khanbolooki, S; Kurzrock, R; Logsdon, CD; McConkey, DJ; Nawrocki, ST; Pino, MS | 1 |
| Adjei, AA; Carter, CA; Friday, BB; Kaufmann, SH; Kay, NE; Lai, JP; Roberts, LR; Sarkaria, J; Yang, L; Yu, C | 1 |
| Arai, A; Koyama, T; Kurosu, T; Miki, T; Miura, O; Murakami, N; Oshikawa, G; Tohda, S | 1 |
| Anderson, K; Ghobrial, I; Mitsiades, C; Richardson, PG | 1 |
| Chang, H; Qi, X; Reece, D; Stewart, KA; Trieu, Y; Xu, W | 1 |
| Barti-Juhász, H; Conte, P; Dominici, M; Douglas, L; Houghton, JA; Izeradjene, K; Kopper, L; Luca Cervo, G; Mihalik, R; Nagy, K; Peták, I; Spano, C; Székely-Szüts, K; Tillman, M | 1 |
| Bernstein, SH; Boral, AL; de Vos, S; Djulbegovic, B; Epner, E; Fisher, RI; Goy, A; Kahl, BS; Krishnan, A; Leonard, JP; Lonial, S; O'Connor, OA; Robertson, MJ; Shi, H; Stadtmauer, EA | 1 |
| Arenillas, L; Bladé, J; Cibeira, MT; Mercadal, S; Muntañola, A; Salamero, O | 1 |
| Alacacioglu, I; Ceneli, S; Demirkan, F; Lebe, B; Ozcan, MA; Ozsan, GH; Piskin, O; Turgut, N; Undar, B | 1 |
| Anderson, KC; Brahmandam, M; Chauhan, D; Ghobrial, I; Hideshima, T; Munshi, N; Podar, K; Raje, N; Richardson, P; Schlossman, R; Velankar, M | 1 |
| Denning, MF; Nickoloff, BJ; Qin, JZ; Sitailo, LA; Xin, H | 1 |
| Beck, A; Berkers, CR; Burg, D; Driessen, C; Gogel, J; Kammer, W; Kraus, M; Ovaa, H; Overkleeft, H; Reich, M; Rückrich, T | 1 |
| Cavallo, F; Esseltine, D; Tricot, G; Yaccoby, S; Zangari, M | 1 |
| Abonour, R; Juliar, BE; Smith, GG; Suvannasankha, A | 1 |
| Cabanillas, M; Peteiro, C; Toribio, J | 1 |
| Appleman, LJ; Clark, JW; Cusack, J; Eder, JP; Enzinger, PC; Fidias, P; Fishman, M; Kashala, O; Lynch, T; Ryan, DP; Supko, JG; Zhu, AX | 1 |
| Okamoto, S | 1 |
| Attal, M; Avet-Loiseau, H; Benboubker, L; Fuzibet, JG; Harousseau, JL; Hulin, C; Leleu, X; Moreau, P; Pegourie, B; Renaud, M; Stoppa, AM; Troncy, J | 1 |
| Galimberti, S; Orciuolo, E; Petrini, M | 1 |
| Heule, F; Lam, K; Sonneveld, P; Wu, KL | 1 |
| Morris, AP; Sellin, JH; Umar, S; Wang, Y | 1 |
| Watts, G | 1 |
| Akerley, W; Axelrod, R; Belt, R; Carbone, DP; Crawford, J; Fanucchi, MP; Fidias, P; Fossella, FV; Govindan, R; Kashala, O; Kelly, K; Limentani, SA; Natale, R; Raez, LE; Reimers, HJ; Ribeiro, M; Robert, F; Schiller, JH; Sheng, S | 1 |
| Appleman, LJ; Clark, J; Cusack, JC; Dees, EC; Eder, JP; Fidias, P; Kashala, O; O'Neil, BH; Orlowski, RZ; Rocha Lima, CM; Ryan, DP; Supko, JG | 1 |
| McKenna, KE; Morris, TC; Ramadan, KM | 1 |
| Berges, C; Daniel, V; Fuchs, D; Höh, A; Miltz, M; Naujokat, C; Opelz, G; Ovens, J; Sadeghi, M; Wieczorek, H | 1 |
| Bernasconi, P; Calatroni, S; Crosetto, N; Dikic, I | 1 |
| Ackermann, J; Drach, J; Kaufmann, H; Küenburg, E; Ludwig, H; Odelga, V; Sagaster, V; Wieser, R; Zielinski, C; Zojer, N | 1 |
| Ballestrero, A; Brossart, P; Grünebach, F; Nencioni, A; Patrone, F | 2 |
| Anderson, KC; Cowan, JM; Facon, T; Harousseau, JL; Irwin, D; Jagannath, S; Richardson, PG; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
| Baer, MR; Minderman, H; O'Loughlin, KL; Zhou, Y | 1 |
| Akatsuka, Y; Ito, K; Ito, Y; Iwata, K; Kiyono, T; Kodera, Y; Kondo, E; Kuzushima, K; Morishima, S; Morishima, Y; Nakanishi, T; Nawa, A; Takahashi, T; Torikai, H; Tsujimura, K | 1 |
| Kenealy, M; Prince, HM | 1 |
| Avonto, I; Boccadoro, M; Bringhen, S; Magarotto, V; Palumbo, A | 1 |
| Anagnostopoulos, A; Chantry, A; Croucher, PI; Dimopoulos, MA; Heath, DJ; Katodritou, E; Pouli, A; Rahemtulla, A; Terpos, E; Verrou, E; Vervessou, EC; Zervas, K | 1 |
| Paydas, S | 2 |
| Belloni, D; Caligaris-Cappio, F; Cangi, MG; Ferrarini, M; Ferrero, E; Foglieni, C; Veschini, L | 1 |
| Gupta, V; Malani, AK; Rangineni, R | 1 |
| Chao, TH; Cusack, JC; Liu, R; Neuteboom, ST; Niu, W; Palladino, MA; Palombella, VJ; Pien, C; Xia, L | 1 |
| Borroni, G; Corso, A; Lazzarino, M; Mangiacavalli, S; Rosso, R; Varettoni, M; Vassallo, C; Zappasodi, P | 1 |
| Jin, J; Li, Y; Meng, H; Qian, J; Tong, Y | 1 |
| Altavilla, G; Arrigo, C; Naro, C; Pitini, V | 1 |
| Benet, I; García-Conde, J; Jantus-Lewintre, E; Sarsotti, E; Terol, MJ | 1 |
| Chanan-Khan, AA; Kaufman, JL; Lonial, S; Mehta, J; Miller, KC; Munshi, NC; Richardson, PG; Schlossman, R; Singhal, S; Tariman, J | 1 |
| Biehn, SE; Dees, EC; Garcia, RA; Lehman, MJ; Moore, DT; Orlowski, RZ; Voorhees, PM | 1 |
| Ambrosini, MT; Avonto, I; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Falco, P; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Pregno, P | 1 |
| Badran, B; Bex, F; Burny, A; Cardoso, F; Desmedt, C; Durbecq, V; Laes, JF; Lagneaux, L; Piccart, M; Ross, JS; Sotiriou, C; Willard-Gallo, K | 1 |
| Sanders, PW; Ying, WZ; Zhang, HG | 1 |
| Lonial, S | 5 |
| Fu, YB; Meng, FY; Sun, QX; Xie, J; Zhou, GB | 1 |
| Aggarwal, BB; Bhardwaj, A; Bueso-Ramos, C; Gaur, U; Nair, AS; Sethi, G; Shishodia, S; Takada, Y; Vadhan-Raj, S | 1 |
| Ribatti, D; Vacca, A | 1 |
| Anderson, KC; Dammacco, F; Hideshima, T; Ribatti, D; Richardson, PG; Roccaro, AM; Russo, D; Vacca, A | 1 |
| Anselmino, A; Atzori, C; Cargnel, A; Mazza, F; Piccinini, M; Rinaudo, MT; Tronconi, E; Valerio, A | 1 |
| Benedict, WF; Dinney, C; Kamat, A; McConkey, DJ; Papageorgiou, A | 1 |
| Blank, JL; Bruzzese, FJ; Cao, Y; Daniels, JS; Dick, LR; Labutti, J; Mazzola, AM; Patil, AD; Reimer, CL; Rolfe, M; Solomon, MS; Stirling, M; Tian, Y; Tsu, CA; Weatherhead, GS; Williamson, MJ; Zhang, JX | 1 |
| Aifantis, I; Alegre, ML; Buonamici, S; Ferrando, A; Kee, BL; Macaroun, S; Mandal, M; Mascarenhas, J; Meng, F; Miele, L; Palomero, T; Spaulding, C; Thompson, B; Vilimas, T | 1 |
| Anderson, KC; Hideshima, T; Ikeda, H; Ishitsuka, K; Jin, J; Kiziltepe, T; Moss, N; Ocio, EM; Okawa, Y; Pargellis, C; Podar, K; Raje, N; Richardson, PG; Vallet, S; Yasui, H | 1 |
| Arrue, I; García-Romero, D; Rodríguez-Peralto, JL; Sánchez-Largo, ME; Sanz-Robles, H; Vanaclocha, F | 1 |
| Burton, AW; Cata, JP; Dougherty, PM; Giralt, S; Villareal, H; Weng, HR | 1 |
| Rukavitsyn, OA | 1 |
| Deggerich, A; Haubert, D; Kashkar, H; Krönke, M; Pongratz, C; Seeger, JM; Wiegmann, K; Yazdanpanah, B | 1 |
| Anderson, KC; Bergsagel, PL; Boral, A; Broyl, A; Bryant, B; Chng, WJ; Esseltine, DL; Fergus, A; Huang, Y; Koenig, E; Mitsiades, C; Mulligan, G; Richardson, P; Roels, S; Schenkein, D; Shaughnessy, JD; Sonneveld, P; Trepicchio, WL; Zhan, F | 1 |
| Dan, K; Gotoh, A; Hotta, T; Ikeda, Y; Ohyashiki, K; Oshimi, K; Usui, N | 2 |
| Chan, TH; Chen, D; Dou, QP; Landis-Piwowar, KR; Milacic, V; Yan, B; Yang, H; Zhao, Y | 1 |
| Bo, J; Da, WM; Gao, CJ; Huang, WR; Jing, Y; Li, R; Wang, QS; Wu, XX; Yu, L; Zhang, YZ | 1 |
| Daniels, TR; Feldman, R; Li, W; Lichtenstein, A; Maxwell, CA; Penichet, ML; Pilarski, L; Reiman, T; Sen, S; Shi, Y | 1 |
| Anderson, KC; Antón, IM; Calamito, M; de la Fuente, MA; Elkhal, A; Gallego, MD; Geha, RS; Ochs, HD; Ramesh, N; Rosen, FS; Sasahara, Y; Siminovitch, K; Suresh, K | 1 |
| Bossi, M; Canta, A; Cavaletti, G; Ceresa, C; D'Incalci, M; De Coster, R; Gilardini, A; Marmiroli, P; Oggioni, N; Rigamonti, L; Rodriguez-Menendez, V | 1 |
| Angitapalli, R; Dhodapkar, MV; Hutchinson, A; Jagannath, S; Kukreja, A; Mazumder, A; O'connor, OA; Vesole, D | 1 |
| Cerniglia, GJ; Gupta, AK; Maity, A; Weber, CN | 1 |
| Campo, E; Colomer, D; Pérez-Galán, P; Roué, G; Villamor, N | 1 |
| Akpek, G; Badros, A; Fenton, R; Goloubeva, O; Harris, C; Meisenberg, B; Rapoport, AP; Ruehle, K; Westphal, S | 1 |
| Boral, AL; Esseltine, DL; Jakob, C; Mehta, J; Richardson, P; Sezer, O; Singhal, S; Stadtmauer, E; Vesole, DH | 1 |
| Utsunomya, A | 1 |
| Lorch, JH; Schmoll, HJ; Thomas, TO | 1 |
| Fenk, R; Garcia-Pardillos, G; Haas, R; Kronenwett, R; Meier, A; Neukirchen, J; Rohr, UP; Rohrbeck, A; Steidl, U | 1 |
| Ara, G; Chen, Z; Duan, J; Friedman, J; Nottingham, L; Van Waes, C | 1 |
| An, J; Rettig, MB | 1 |
| Kim, CC; Kim, M; Kim, Y; Lee, DG; Lee, JW; Lee, S; Min, CK; Min, WS; Moon, SJ; Park, G | 1 |
| Cheriyath, V; Hussein, MA; Jacobs, BS | 1 |
| Benedetti-Panici, P; Biffoni, M; Cognetti, F; Ferretti, G; Humphreys, R; Mariani, G; Pasquini, L; Peschle, C; Petronelli, A; Petrucci, E; Saulle, E; Scambia, G; Testa, U | 1 |
| Basso, G; Bonvini, P; Rosolen, A; Zorzi, E | 1 |
| Dreyling, M; Hiddemann, W; Lang, N; Pastore, A; Rieken, M; Weigert, O | 1 |
| Boccadoro, M; Cavenagh, J; Dicato, M; Harousseau, JL; Ludwig, H; San Miguel, J; Sonneveld, P | 1 |
| De Coster, R; Diels, L; Geerts, R; Hassler, S; Hemeryck, A; Janssen, C; Mamidi, RN; Monbaliu, J; van Beijsterveldt, L; Verhaeghe, T; Verluyten, W | 1 |
| Walker, K | 1 |
| Betlloch, I; Botella, C; Lucas, A; Mataix, J; Villarrubia, B | 1 |
| Stadtmauer, EA; Stoopler, ET; Vogl, DT | 1 |
| Brockman, AH; Hatsis, P; Paton, M; Wu, JT | 1 |
| Charalambous, A; Dhodapkar, MV; Jagannath, S; Mazumder, A; Spisek, R; Vesole, DH | 1 |
| Mileshkin, L; Prince, HM; Schenkel, B | 1 |
| Engel, J; Fagbemi, S; Olatosi, B; Onitilo, AA | 1 |
| Berrebi, A; Duek, A; Feldberg, E; Haran, M | 1 |
| Anderson, KC; Barilà, D; Chauhan, D; DePinho, RA; Hideshima, T; Podar, K; Raab, MS; Raje, N; Sattler, M; Tai, YT; Tonon, G; Yasui, H; Zhang, J | 1 |
| Birle, DC; Hedley, DW | 1 |
| Burger, R; Gramatzki, M; Hahn, S; Herrmann, K; Herrmann, M; Jäck, HM; Meister, S; Neubert, K; Schreiber, S; Schubert, U; Voll, RE; Wilhelm, S | 1 |
| Chen, J; Pamarthy, D; Sun, Y; Tan, M; Wang, S; Wu, M; Yang, D; Zhang, H | 1 |
| Agus, D; Dreicer, R; Petrylak, D; Roth, B; Webb, I | 1 |
| Chanan-Khan, AA; Manochakian, R; Miller, KC | 2 |
| Chew, E; Filshie, R; Wei, A | 1 |
| Ganten, TM; Haas, TL; Kolb, A; Koschny, R; Sprick, MR; Stremmel, W; Sykora, J; Walczak, H | 1 |
| Adamo, L; Anastasi, G; Conticello, C; De Maria, R; Eramo, A; Giuffrida, D; Giuffrida, R; Gulisano, M; Iannolo, G; Memeo, L; Vicari, L; Zeuner, A | 1 |
| Low, E | 1 |
| Chu, K; Jung, KH; Kim, BS; Kim, EH; Kim, JM; Kim, M; Lee, ST; Park, DK; Roh, JK; Sinn, DI; Song, EC; Yoon, SS | 1 |
| Ambinder, RF; Chen, J; Chong, JM; Foss, CA; Fox, JJ; Fu, DX; Lemas, V; Pomper, MG; Tanhehco, YC | 1 |
| Adamson, PC; Blaney, SM; Bomgaars, LR; Brockman, AH; Horton, TM; Ingle, AM; Pati, D; Paton, M; Plon, SE; Thompson, PA; Wright, J | 1 |
| Bruserud, Ø; Gjertsen, BT; Kalland, KH; Olsnes, AM; Ryningen, A; Stordrange, L; Øyan, AM | 1 |
| Bruserud, O; Døskeland, AP; Ersvaer, E; Gjertsen, BT; Hatfield, K; Lorens, JB; Ryningen, A; Stapnes, C | 1 |
| Chen, YB; Fu, WJ; Hou, J; Xi, H; Yang, SL; Yuan, ZG; Zhou, F | 1 |
| Gault, RA; Mattingly, LH; Murphy, WJ | 1 |
| Beier, C; Dörken, B; Lietz, A; Mathas, S; Pezzutto, A; Sebelin-Wulf, K; Subklewe, M | 1 |
| Carlisi, D; D'Anneo, A; Di Fazio, P; Emanuele, S; Lauricella, M; Tesoriere, G; Vassallo, B; Vento, R | 1 |
| Chen, CI; Eisenhauer, E; Kouroukis, CT; Powers, J; Stadtmauer, E; Stewart, AK; Voralia, M; Walsh, W; White, D; Wright, JJ | 1 |
| Anderson, KC; Ghobrial, IM; Hatjiharissi, E; Hideshima, T; Leleu, X; Mitsiades, C; Richardson, P; Schlossman, R | 1 |
| Checinska, A; Giaccone, G; Kruyt, FA; Rodriguez, JA; Voortman, J | 1 |
| Chen, X; Ding, WX; Ni, HM; Yin, XM; Yu, J; Zhang, L | 1 |
| Berenson, JR; Mapes, R; Matous, J; Morrison, B; Swift, RA; Yeh, HS | 1 |
| Allen, P; Higginbottom, K; Joel, SP; Jüliger, S; Lister, TA; Maharaj, L; Schenkein, D; Strauss, SJ | 1 |
| Iida, S | 5 |
| Bonomini, S; Crugnola, M; Ferrari, L; Giuliani, N; Lazzaretti, M; Mancini, C; Martella, E; Morandi, F; Rizzoli, V; Tabilio, A; Tagliaferri, S | 1 |
| Scheinfeld, N | 1 |
| Dierlam, L; Lass, A; McConnell, EJ; Nowis, D; Palamarchuk, A; Wójcik, C | 1 |
| Auradé, F; Chaligné, R; Gastinne, T; Giraudier, S; Gonin, P; Lacout, C; Pisani, DF; Tulliez, M; Vainchenker, W; Villeval, JL; Wagner-Ballon, O | 1 |
| Belloc, F; de Verneuil, H; Lacombe, F; Mahon, FX; Milpied, N; Moreau-Gaudry, F; Pigneux, A; Praloran, V; Reiffers, J; Uhalde, M | 1 |
| Caponigro, F; Iaffaioli, RV; Milano, A | 1 |
| Boccadoro, M; Bruno, B; Carnevale-Schianca, F; Corradini, P; Fanin, R; Giaccone, L; Guidi, S; Mattei, D; Milone, G; Montefusco, V; Patriarca, F; Peccatori, J; Petrucci, MT; Rotta, M; Sorasio, R | 1 |
| Jung, CS; Khuri, FR; Sun, SY; Zhou, Z | 1 |
| Banwait, S; Benz, CC; Hann, B; Marx, C; Park, JW; Scott, GK; Yau, C; Zhou, Y | 1 |
| Busemann, C; Dölken, G; Kiefer, T; Krüger, WH; Lotze, C; Schüler, F | 1 |
| Strobeck, M | 1 |
| Armand, JP; Burnett, AK; Drach, J; Harousseau, JL; Löwenberg, B; San Miguel, J | 1 |
| Bergsagel, L; Bryant, B; Chng, WJ; Mulligan, G | 1 |
| Ahmann, G; Bergsagel, PL; Bryant, B; Carpten, J; Chng, WJ; Chung, TH; Dispenzieri, A; Fonseca, R; Gertz, M; Greipp, P; Henderson, K; Kim, S; Kumar, S; Kyle, R; Lacy, M; Mulligan, G; Price-Troska, T; Rajkumar, SV; Vanwier, S | 1 |
| Davies, AM; Doroshow, JH; Gandara, DR; Gumerlock, PH; Kashala, O; Koczywas, M; Lara, PN; Lau, DH; Lenz, HJ; Longmate, J; Quinn, DI; Schenkein, D | 1 |
| Atkins, JN; Chansky, K; Crowley, JJ; Davies, AM; Farneth, N; Franklin, WA; Gandara, DR; Guaglianone, PP; Gumerlock, PH; Lara, PN; Mack, PC | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Bolejack, V; Crowley, J; Epstein, J; Hollmig, K; Mohiuddin, A; Pineda-Roman, M; Shaughnessy, JD; Tricot, G; van Rhee, F; Woods, G; Zangari, M | 1 |
| Carol, H; Houghton, PJ; Keir, ST; Keshelava, N; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA; Wu, J | 1 |
| Jarois, T; Ju, D; Xie, Y; Xu, H | 1 |
| Anderson, KC; Ben-Yehuda, D; Cavenagh, JD; Facon, T; Harousseau, JL; Irwin, D; Lonial, S; Richardson, PG; San Miguel, JF; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
| Capalbo, S; Chiefa, A; Delia, M; Diomede, D; Liso, V | 1 |
| D'Arena, G; Ferrara, F; Filardi, N; Gay, F; Guariglia, R; Guglielmelli, T; Musto, P; Palumbo, A; Pitini, V; Rossini, F | 1 |
| Iida, S; Yano, H | 1 |
| Janssen, JJ; Lokhorst, HM; Zweegman, S | 1 |
| Castagna, L; Mazza, R; Nozza, A; Rahal, D; Santoro, A; Sarina, B; Todisco, E | 1 |
| Anagnostopoulos, A; Bamias, A; Barmparousi, D; Dimopoulos, MA; Gika, D; Grapsa, I; Kastritis, E; Matsouka, C; Psimenou, E; Roussou, M | 1 |
| Borchmann, P; Engert, A; Keller, U; Naumann, R; Rummel, M; Sezer, O; Trelle, S | 1 |
| Fu, YB; Li, L; Meng, FY; Sun, QX | 1 |
| Croucher, P; Dimopoulos, MA; Sezer, O; Terpos, E | 1 |
| Bonuccelli, G; Capozza, F; Gazzerro, E; Lisanti, MP; Minetti, C; Sotgia, F | 1 |
| Chen, GQ; Li, D; Liu, W; Wang, Y; Wang, YC; Wu, YL; Yan, H | 1 |
| Bachmann, M; Bornhäuser, M; Rieber, EP; Schmitz, M; Straube, C; Wehner, R; Wendisch, M | 1 |
| Germain, D; Ishii, Y; Waxman, S | 1 |
| Aggarwal, BB; Bhutani, M; Guha, S; Kunnumakkara, AB; Nair, AS; Pathak, AK; Sethi, G | 1 |
| Fang, B; Ma, J; Song, Y; Zhao, RC | 1 |
| Wilkes, G | 1 |
| Anderson, KC; Burger, P; Chauhan, D; Fulciniti, M; Ghobrial, IM; Hideshima, T; Leiba, M; Li, XF; Morrison, A; Munshi, NC; Podar, K; Richardson, P; Rumizen, M; Song, W; Tai, YT; Tassone, P | 1 |
| Chen, S; Hu, L; Khuri, FR; Liu, X; Lonial, S; Sun, SY; Yue, P | 1 |
| Andreeff, M; Ashihara, E; Kamitsuji, Y; Kawata, E; Kimura, S; Kuroda, J; Maekawa, T; O'Reilly, LA; Strasser, A; Tabe, Y; Takeuchi, M; Tanaka, R; Taniwaki, M; Yokota, A | 1 |
| Berges, C; Daniel, V; Fuchs, D; Naujokat, C; Opelz, G | 2 |
| Bueno, R; Gordon, GJ; Kindler, HL; Mani, M; Maulik, G; Mukhopadhyay, L; Salgia, R; Sugarbaker, DJ; Yeap, BY | 1 |
| Cho, Y; Kim, BS; Kim, J; Kim, SJ; Seo, BK | 1 |
| de la Vega, CM; Fernández, Y; Nikolovska-Coleska, Z; Riblett, M; Soengas, MS; Verhaegen, M; Wang, S; Wolter, KG | 1 |
| Abouladze, M; Baudard, M; Dreano, M; Goldschmidt, H; Hose, D; Jourdan, M; Klein, B; Mahtouk, K; Moreaux, J; Rème, T; Robert, N; Romanelli, A; Rossi, JF; Vos, JD | 1 |
| Advani, R; Badros, A; Branagan, AR; Cook, D; Hill, J; Hunter, ZR; Joyce, RM; Kaden, BR; Leleu, X; Mannion, B; Matous, J; Sharon, D; Songer, J; Steiss, R; Treon, SP | 1 |
| Ahnert, P; Bauer, M; Ganten, TM; Haas, TL; Holland, H; Koschny, R; Krupp, W; Meixensberger, J; Sprick, MR; Sykora, J; Walczak, H | 1 |
| Amiot, M; Bataille, R; Gomez-Bougie, P; Ménoret, E; Philippe, M; Robillard, N; Trichet, V; Wuillème-Toumi, S | 1 |
| Burns, MJ; Cavallo, F; Elice, F; Esseltine, D; Neuwirth, R; Richardson, P; Sonneveld, P; Tricot, G; Yaccoby, S; Zangari, M | 1 |
| Barton, J; Gould, B; Greco, FA; Hainsworth, JD; Meluch, AA; Meng, C; Simons, L; Spigel, DR | 1 |
| Mayor, S | 1 |
| Brugnatelli, S; Brunetti, L; Corazza, GR; Gobbi, PG; Palladini, G; Perfetti, V; Sgarella, A | 1 |
| Alexanian, R; Delasalle, K; Giralt, S; Handy, B; Wang, M | 1 |
| Hulin, C | 1 |
| Banti, A; Gastari, V; Kaloutsi, V; Kartsios, C; Katodritou, E; Lazaraki, G; Lazaridou, A; Mihou, D; Verrou, E; Zervas, K | 1 |
| Antonio, S; Daniele, V; Enrico, O; Gabriele, B; Giulia, C; Mario, P; Nadia, C; Sara, G | 1 |
| Bhandari, M; Jagannath, S | 1 |
| Bocchia, M; Cerase, A; Fabbri, A; Gozzetti, A; Lauria, F; Pirrotta, MT; Tarantino, A | 1 |
| Abou-Merhi, R; Arnoult, D; Bazarbachi, A; Dbouk, H; de Thé, H; El Hajj, H; El-Sabban, ME; Gessain, A; Hermine, O; Khoriaty, R; Mahieux, R; Munier, S | 1 |
| Anderson, KC; Catley, L; Chauhan, D; Hideshima, T; Ikeda, H; Ishitsuka, K; Kiziltepe, T; Ocio, EM; Okawa, Y; Pozzi, S; Raje, N; Shiraishi, N; Vallet, S; Yasui, H | 1 |
| Giaccone, G; Honeywell, R; Kuenen, BC; Peters, GJ; Smit, EF; van de Velde, H; Voortman, J | 1 |
| Au, WY; Guo, T; Kwong, YL; Liang, RH; Shen, L; Srivastava, G; Tsuchiyama, J; Wong, KY; Wong, ML; Yuen, PW | 1 |
| Fleissner, C; Hecht, M; Heider, U; Jakob, C; Kaiser, M; Kleeberg, L; Krebbel, H; Manz, RA; Mieth, M; Sezer, O; Sterz, J; von Metzler, I | 1 |
| Barlogie, B; Crowley, J; van Rhee, F | 1 |
| Baritaki, S; Berenson, JR; Bonavida, B; Campbell, RA; Chen, H; Gordon, M; Pang, S; Said, J; Sanchez, E; Shalitin, D; Steinberg, JA; Wang, C | 1 |
| Bennett, MK; Chanan-Khan, AA; Chen, Q; Demo, SD; Kuhn, DJ; Orlowski, RZ; Shenk, KD; Strader, JS; Sun, CM; van Leeuwen, FW; Voorhees, PM | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Bolejack, V; Cottler-Fox, M; Crowley, J; Epstein, J; Gurley, J; Haessler, J; Hollmig, K; Jenkins, B; Mohiuddin, A; Petty, N; Pineda-Roman, M; Shaughnessy, JD; Steward, D; Sullivan, E; Tricot, G; van Rhee, F; Zangari, M | 1 |
| Cadranel, JL; Garfield, DH | 1 |
| Anderson, K; Mitsiades, C; Munshi, N; Richardson, PG; Schlossman, R | 1 |
| Adena, M; Hertel, J; Prince, HM; Smith, DK | 1 |
| Dimopoulos, MA; Sezer, O; Terpos, E | 1 |
| Calvaruso, G; Giuliano, M; Pellerito, O; Portanova, P; Tesoriere, G; Vento, R | 1 |
| Broglio, L; Buzio, S; Filosto, M; Mancuso, M; Padovani, A; Pelizzari, AM; Rinaldi, M; Rossi, G; Scarpelli, M; Tentorio, M | 1 |
| Bartlett, NL; Blum, KA; Canellos, GP; Cheson, BD; Johnson, JL; Niedzwiecki, D | 1 |
| Ali, R; Beksac, M; Ozcelik, T; Ozkalemkas, F; Ozkan, A; Ozkocaman, V; Tunali, A | 1 |
| Berdel, WE; Bisping, G; Dechow, T; Einsele, H; Engelhardt, M; Heinecke, A; Hentrich, M; Kienast, J; Kröger, N; Kropff, M; Lang, N; Liebisch, P; Metzner, B; Salwender, H; Schuck, E; Sezer, O; Volpert, S; Wolf, HH | 1 |
| Aujay, MA; Bennett, MK; Buchholz, TJ; Dajee, M; Demo, SD; Ho, MN; Jiang, J; Kirk, CJ; Laidig, GJ; Lewis, ER; Molineaux, CJ; Parlati, F; Shenk, KD; Smyth, MS; Sun, CM; Vallone, MK; Woo, TM | 1 |
| Abou El Hassan, MA; Giaccone, G; Kruyt, FA; Resende, TP; Voortman, J | 1 |
| Davies, FE; Kanagasabaphy, P; Morgan, GJ | 1 |
| Cohen, JI; Kawada, J; Pesnicak, L; Zou, P | 1 |
| Battolla, B; Canestraro, M; Capodanno, A; Casini, A; Collecchi, P; Fazzi, R; Galimberti, S; Mattii, L; Orciuolo, E; Pacini, S; Petrini, M; Piaggi, S; Simi, P; Trombi, L; Veroni, F | 1 |
| Calderoni, A; Cornu, P; Freimann, H; Olie, R | 1 |
| Tobinai, K | 2 |
| Alomar, A; Dalmau, J; Fernández-Figueras, MT; Garcia-Navarro, X; Puig, L; Roe, E | 1 |
| Jack, A | 1 |
| Astori, C; Castagnola, C; Corso, A; Lazzarino, M; Mangiacavalli, S; Varettoni, M; Zappasodi, P | 1 |
| Ben Mamoun, C; Witola, WH | 1 |
| Davies, FE; Jenner, M; Morgan, GJ; Saso, R; Srikanth, M; Wu, P | 1 |
| Amiot, M; Anderson, KC; Chauhan, D; Gouill, SL; Harousseau, JL; Hideshima, T; Opferman, JT; Podar, K; Tai, YT; Zhang, J; Zorn, E | 1 |
| Akpek, G; Badros, A; Can, I; Dalal, JS; Fenton, RG; Goloubeva, O; Heyman, M; Rapoport, AP; Thompson, J | 1 |
| Baumann, P; Bumeder, I; Emmerich, B; Meinhardt, G; Schmidmaier, R; Straka, C | 1 |
| Chen, Y; Cheng, T; Di, G; Jin, W; Li, J; Li, W; Shao, Z; Wu, J; Yao, M | 1 |
| Hsi, ED; Kung, J; Peng, X; Qiu, W; Yegappan, M; Yen-Lieberman, B; Zhao, X | 1 |
| Astori, C; Castagnola, C; Corso, A; Dore, R; Lazzarino, M; Mangiacavalli, S; Varettoni, M; Zappasodi, P | 1 |
| Fu, YB; Li, L; Meng, FY; Sun, QX; Tian, S | 1 |
| Davies, AM; Gandara, DR; Lara, PN; Mack, PC | 1 |
| Jacquemont, C; Taniguchi, T | 1 |
| Bladé, J; Dmoszynska, A; Hajek, R; Harousseau, JL; Horvath, N; Nagler, A; Orlowski, RZ; Parekh, T; Rackoff, W; Robak, T; San Miguel, J; Sonneveld, P; Spencer, A; Spicka, I; Sutherland, HJ; Suvorov, AN; Xiu, L; Yuan, Z; Zhuang, SH | 1 |
| Hatake, K | 1 |
| Fassas, AB; Tricot, G | 1 |
| Hatake, K; Terui, Y; Yokoyama, M | 1 |
| Davidoff, AM; Dickson, PV; Hamner, JB; Ng, CY; Sims, TL; Spence, Y; Zhou, J | 1 |
| Alsina, M; Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, A; Cavenagh, J; Dalton, W; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Irwin, D; Jakubowiak, A; Lacy, M; Lonial, S; Miguel, JS; Rajkumar, SV; Reece, D; Richardson, PG; Schenkein, D; Schuster, M; Sonneveld, P; Stadtmauer, E | 1 |
| Ackermann, H; Baghi, M; Gstöttner, W; Hambek, M; Knecht, R; Strebhardt, K; Wagenblast, J | 1 |
| Lü, SQ; Wang, JM; Yang, JM | 1 |
| Alinari, L; Baccarani, M; de Vivo, A; Derenzini, E; Fina, M; Marchi, E; Musuraca, G; Pellegrini, C; Pileri, S; Sabattini, E; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Sayers, T; Shanker, A | 1 |
| Gao, SL; Shen, HW; Tang, ZY; Wu, YL | 1 |
| Dhodapkar, MV; Spisek, R | 1 |
| Bensinger, W | 1 |
| Anderson, KC; Ghobrial, IM; Ghobrial, J; Hatjiharissi, E; Hideshima, T; Leleu, X; Mitsiades, C; Moreau, AS; Richardson, P; Roccaro, A; Schlossman, R | 1 |
| Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D | 1 |
| Buda, G; Canestraro, M; Fazzi, R; Galimberti, S; Guerrini, F; Khan, R; Maffei, R; Marasca, R; Orciuolo, E; Petrini, M | 1 |
| Anderson, KC; Catley, L; Chauhan, D; Hideshima, H; Hideshima, T; Ikeda, H; Kiziltepe, T; Mitsiades, C; Munshi, NC; Ocio, E; Okawa, Y; Podar, K; Raje, N; Richardson, PG; Tai, YT; Vallet, S; Yasui, H | 1 |
| Li, X; Pennisi, A; Sawyer, JR; Shaughnessy, JD; Yaccoby, S; Zhan, F | 1 |
| Ling, YH; Perez-Soler, R; Piperdi, B | 1 |
| Doihara, H; Fujita, T; Ino, H; Murakami, M; Naito, M; Shimizu, N; Washio, K | 1 |
| Drach, J; Graf, H; Lang, A; Ludwig, H; Meran, JG | 1 |
| Etxebarria, J; Hernández, E; Lopez, O; Mateos-Mazon, J; Pérez-Simón, JA; San Miguel, JF | 1 |
| Anderson, KC; Breitkreutz, I; Raab, MS | 1 |
| Alegre, A; Bladé, J; de la Rubia, J; García-Sánchez, P; Gutiérrez, N; Herrero, C; Lahuerta, JJ; Liu, X; Mateos, MV; Oriol, A; Rosiñol, L; San Miguel, J; Sureda, A; Van de Velde, H | 1 |
| Hanada, M; Iwamoto, Y; Matsunobu, T; Nakamura, T; Nakatani, F; Okada, T; Sakimura, R; Tanaka, K | 1 |
| Bialik, TE; Demina, EA; Falaleeva, NA; Gromova, EG; Kochergina, NV; Kupryshina, NA; Osmanov, DSh; Riabukhina, IuE; Timofeeva, OL; Votiakova, OM | 1 |
| Snively, A | 1 |
| Amen, K | 1 |
| McGee, L | 1 |
| Branch, CD; Chada, S; Gopalan, B; Ramesh, R; Scott, A; Shanker, M | 1 |
| Chacko, A; Fennell, DA; Mutti, L | 1 |
| Banu, E; Beuzeboc, P; Guyader, C; Medioni, J; Oudard, S; Scotte, F | 1 |
| Chim, CS | 2 |
| Delmore, JE; Hayden, P; Kotoula, V; McMillin, DW; McMullan, C; Mitsiades, CS; Mitsiades, N; Negri, J; Poulaki, V | 1 |
| Matteson, DS | 1 |
| Chim, CS; Wong, LG | 1 |
| Abe, M; Asano, J; Choraku, M; Fujii, S; Hashimoto, T; Kagawa, K; Kitazoe, K; Matsumoto, T; Miki, H; Ozaki, S; Shigekiyo, Y; Takeuchi, K; Tanaka, O | 1 |
| Dagher, R; Farrell, A; Justice, R; Kane, RC; Ko, CW; Pazdur, R; Sridhara, R | 1 |
| Jin, F; Joshi, I; Smith, MR | 1 |
| Ludwig, A; Meiners, S; Stangl, K; Stangl, V | 1 |
| Abayomi, EA; Jacobs, P; Sissolak, G | 1 |
| Kurtis, B; Lacouture, ME; Mekki, M; Newman, MA; Paiva, CM; Singhal, S | 1 |
| Daguindau, N; Feugier, P; Perrot, A; Tomowiak, C | 1 |
| Hamamura, RS; Kobayashi, C; Kurashina, R; Ohyashiki, JH; Ohyashiki, K; Takaku, T; Zhang, Y | 1 |
| Boe, A; Buffolino, S; Cedrone, M; Diverio, D; Foà, R; Lo-Coco, F; Mariani, G; Peschle, C; Riccioni, R; Riti, V; Senese, M; Testa, U | 1 |
| Kotoula, V; McMillin, D; Miller, JW; Mitsiades, CS; Mitsiades, N; Negri, J; Poulaki, V | 1 |
| Anderson, KC; Hayden, PJ; Mitsiades, CS; Richardson, PG | 1 |
| Han, XH; Kwak, LW; Qian, JF; Romaguera, J; Shi, YK; Wang, M; Yang, J; Yi, Q; Zhang, L | 1 |
| Coleman, RL; Gershenson, DM; Johnston, TA; Landen, CN; Levenback, C; Milam, MR; Ramirez, PT | 1 |
| Barbone, D; Darnowski, JW; Fennell, DA; Galvani, A; Gasparri, F; Gaudino, G; Mutti, L; Nici, L; Porta, C; Sartore-Bianchi, A | 1 |
| Anderson, G; Belani, C; Feng, R; Lentzsch, S; Mapara, MY; Oton, A | 1 |
| Esparza, J; Flores, A; Garrett, IR; Gupta, A; Mundy, GR; Muñoz, S; Oyajobi, BO; Zhao, M | 1 |
| Avcu, F; Cetin, T; Nevruz, O; Ural, AU | 1 |
| Cavenagh, JD; Oakervee, H; Popat, R | 1 |
| Moran, E; Nencioni, A | 1 |
| Eicher, C; Heller, G; Kelly, WK; Morris, MJ; Ryan, C; Scher, HI; Slovin, S | 1 |
| Garber, AM; McClellan, MB | 1 |
| Chagin, AS; Chrysis, D; Dantuma, NP; Eriksson, E; Fadeel, B; Menendez-Benito, V; Sävendahl, L; Takigawa, M; Zaman, F | 1 |
| Barlogie, B; Garg, TK; Kellum, RE; Malaviarachchi, PA; Mulder, A; Shaughnessy, JD; Shi, J; Storrie, B; Szmania, SM; Tricot, GJ; van Rhee, F | 1 |
| Badve, S; Bergan, R; Brown, JA; Engel, RH; Gradishar, WJ; O'Regan, RM; Rademaker, A; Von Roenn, JH | 1 |
| Dytfeld, D; Komarnicki, M; Lewandowski, K; Matuszak, M | 1 |
| Brandenburg, J; El Bissati, K; Günzl, A; Mamoun, CB; Reynolds, JM | 1 |
| Cai, YX; Fu, YB; Li, L; Meng, FY; Sun, QX | 2 |
| Ganser, A; Peest, D | 1 |
| Björkstrand, B; Gahrton, G | 1 |
| Ando, K; Hotta, T; Itoh, K; Kagami, Y; Kobayashi, Y; Maruyama, D; Minami, H; Morishima, Y; Nakata, M; Ogawa, Y; Ogura, M; Taji, H; Tobinai, K; Tsuchiya, T; Watanabe, T | 1 |
| Dammacco, F; Merchionne, F; Perosa, F | 1 |
| Fadeel, B; Sävendahl, L; Zaman, F | 1 |
| Chen, Q; Corringham, RE; Hunsucker, SA; Kuhn, DJ; Nemeth, JA; Orlowski, RZ; Small, GW; Strader, JS; Voorhees, PM; Zaki, MH | 1 |
| Kyritsis, AP; Puduvalli, VK; Rao, JS; Tachmazoglou, F | 1 |
| Iannitto, E; Minardi, V; Tripodo, C | 1 |
| Lin, ZH | 1 |
| Al-Masri, H; Alkan, S; Meyer, P; Ni, H; Ozpuyan, F | 1 |
| Bostan, F; Ozkaynak, C; Timurağaoğlu, A; Tuzuner, S; Undar, L | 1 |
| Dimopoulos, MA; Kastritis, E; Mitsiades, CS; Richardson, PG | 1 |
| Corso, A; Lazzarino, M; Mangiacavalli, S; Pica, GM; Varettoni, M; Zappasodi, P | 1 |
| Fujii, H; Harada, Y; Kotobuki, Y; Nomura, S | 1 |
| Fleissner, C; Heider, U; Jakob, C; Kaiser, M; Kloetzel, PM; Kuckelkorn, U; Rademacher, J; Rosche, M; Rötzer, S; Sezer, O; Sterz, J; von Metzler, I | 1 |
| Anderson, KC; Brahmandam, M; Chauhan, D; Hideshima, T; Munshi, N; Palladino, MA; Podar, K; Richardson, P; Singh, A | 1 |
| Agnese, V; Bazan, V; Cicero, G; Fratto, ME; Russo, A; Santini, D; Schiró, V; Tonini, G; Vincenzi, B | 1 |
| Checińska, A; Giaccone, G; Voortman, J | 1 |
| Fu, YB; Li, CY; Li, L; Meng, FY; Song, LL; Sun, QX; Yi, ZS | 1 |
| Merlini, G; Palladini, G; Sitia, R | 1 |
| Cavaletti, G; Nobile-Orazio, E | 1 |
| Anagnostopoulos, A; Delibasi, S; Dimopoulos, MA; Kastritis, E; Mellou, S; Migkou, M; Nanas, J; Pamboukas, C; Psimenou, E; Roussou, M; Tassidou, A; Terpos, E; Toumanidis, S; Xilouri, I | 1 |
| Anderson, K; Chauhan, D; Ghobrial, I; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, P; Schlossman, R | 1 |
| Acoca, S; Beauparlant, P; Bélec, L; Billot, X; Cluse, L; Goulet, D; Johnstone, RW; Marcellus, RC; Murthy Madiraju, SR; Nguyen, M; Purisima, E; Roulston, A; Serfass, L; Shore, GC; Viallet, J; Watson, M; Wiegmans, A | 1 |
| Chinnaiyan, AM; Fernandez, Y; Gratchouck, V; Jakubowiak, AJ; Nikiforov, MA; Riblett, M; Soengas, MS; Tang, WH; Varambally, S; Verhaegen, M; Zhuang, D | 1 |
| Puthalakath, H; Strasser, A | 1 |
| Chaudhary, U; Dunder, S; Green, M; Hayslip, J; Kraft, A; Meyer, M; Montero, AJ; Salzer, S; Sherman, C | 1 |
| Allievi, C; Berkers, C; Bernareggi, A; Bussolati, B; Camussi, G; Cassin, M; Coscia, M; Costa, G; de Feudis, P; di Giovine, S; Ferracini, R; Ferrero, D; Giai, V; Hunter, K; Inghirami, G; Jones-Bolin, S; Massaia, M; Neri, A; Nicoli, P; Ovaa, H; Palumbo, A; Peola, S; Pescalli, N; Pezzoni, G; Piva, R; Roato, I; Ruggeri, B; Strepponi, I; Tamagno, I; Williams, M; Zhao, H | 1 |
| Barr, P; Fisher, R; Friedberg, J | 1 |
| Congdon, LM; Dorr, RT; Escalante, AM; Landowski, TH; Pourpak, A | 1 |
| Faiman, B | 1 |
| Brodmann, S; Cathomas, R; Girardi, V; Gyr Klaas, E; von Moos, R | 1 |
| Gertz, MA | 4 |
| Bruns, I; Czibere, A; Fenk, B; Fenk, R; Graef, T; Haas, R; Kobbe, G; Michael, M; Neumann, F; Zohren, F | 1 |
| Handa, H; Murakami, H; Saitoh, T | 1 |
| Ishida, T | 3 |
| Gotoh, A; Ohyashiki, K | 1 |
| Shimazaki, C | 1 |
| Takatoku, M | 1 |
| Kizaki, M | 1 |
| Mateos, MV; San Miguel, JF | 1 |
| Fang, BW; Zhang, YJ | 1 |
| Christian, PA; Schwarze, SR; Thorpe, JA | 2 |
| Dagher, R; Farrell, AT; He, K; Justice, R; Ning, YM; Pazdur, R; Sridhara, R | 1 |
| Miwa, A | 2 |
| Gastari, V; Hadjiaggelidou, C; Katodritou, E; Terpos, E; Verrou, E; Zervas, K | 1 |
| Baumann, P; Mandl-Weber, S; Oduncu, F; Schmidmaier, R | 2 |
| Baiocchi, RA; Blum, W; Byrd, JC; Caligiuri, MA; Chan, KK; Garzon, R; Huynh, L; Klisovic, RB; Lehmann, E; Liu, S; Liu, Z; Marcucci, G; Pang, J; Perrotti, D; Porcu, P; Takeki, M; Vukosavljevic, T; Wu, LC; Xie, Z; Yu, J | 1 |
| Dirksen, WP; Fernandez, SA; Lairmore, MD; Nadella, MV; Rosol, TJ; Shu, ST; Thudi, NK; Werbeck, JL | 1 |
| Beckett, LA; Christensen, S; Davies, AM; Gandara, DR; Ho, C; Lara, PN; Lau, DH; Metzger, AS; Tanaka, M | 1 |
| Cai, Y; Chen, LE; Park, JW; Qi, WN; Urbaniak, JR | 1 |
| Davies, FE; Morgan, GJ; Srikanth, M | 1 |
| Ames, E; Barao, I; Hallett, WH; Hudig, D; Motarjemi, M; Murphy, WJ; Sayers, TJ; Shanker, A; Tamang, DL | 1 |
| Friedberg, JW; Hagemeister, FB; Leonard, JP; Levine, AM | 1 |
| Eom, KS; Han, K; Kim, CC; Kim, M; Kim, Y; Lee, JW; Lee, MJ; Lee, S; Lim, J; Min, CK; Min, WS | 1 |
| Agrawal, SG; Du, MQ; Gribben, JG; Jia, L; Liu, FT; Newland, AC; Ye, H | 1 |
| Alvarez-Fernández, S; Colado, E; Garayoa, M; Maiso, P; Martín-Sánchez, J; Montero, JC; Ocio, EM; Pandiella, A; San Miguel, JF; Vidriales, MB | 1 |
| Bold, R; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Lau, DH; Lenz, HJ; Ruel, C; Schenkein, DP; Shibata, S | 1 |
| Ambinder, RF; Barber, JP; Borrello, I; Brennan, S; Huff, CA; Jones, RJ; Lin, L; Matsui, W; McNiece, I; Peacock, C; Smith, BD; Wang, Q; Watkins, DN | 1 |
| Chun, YS; Huang, LE; Lee, DS; Park, JW; Shin, DH | 1 |
| Dolcet, X; Encinas, M; Eritja, N; Llobet, D; Llombart-Cussac, A; Marti, RM; Matias-Guiu, X; Schoenenberger, JA; Sorolla, A; Yeramian, A | 1 |
| Bladé, J; Cibeira, MT; Cid, MC; Filella, X; Lozano, E; Rosiñol, L; Rozman, M; Segarra, M | 1 |
| Blau, IW; Busse, A; Driessen, C; Keilholz, U; Kraus, M; Na, IK; Rietz, A; Scheibenbogen, C; Thiel, E | 1 |
| Barlogie, B; Bryant, B; Mulligan, G; Shaughnessy, JD; Zhan, F | 1 |
| Clay, D; Gauduchon, J; Marsaud, V; Renoir, JM; Seguin, A; Sola, B | 1 |
| DiPersio, JF; Fisher, NM; Peles, S; Tomasson, MH; Trivedi, R; Uy, GL; Vij, R; Zhang, QJ | 1 |
| Herrmann, M; Maseda, D; Meister, S; Neubert, K; Voll, RE | 1 |
| Cavenagh, JD; Davies, FE; Jackson, GH; Morgan, GJ | 1 |
| Canestaro, M; Ciancia, E; Fazzi, R; Galimberti, S; Marasca, R; Petrini, M | 1 |
| De Aos, I; Garrett, MW; Huang, S; Kem, DC; Patterson, E; Yu, X | 1 |
| Corral, J; de Arriba, F; Ferrer, F; González, M; Hernández-Espinosa, D; Martínez, C; Miñano, A; Mota, RA; Ordoñez, A; Pérez-Ceballos, E; Vicente, V | 1 |
| Berges, O; Decaudin, D; Kirova, YM; Servois, V | 1 |
| Adler, AS; Chang, HY; Lin, M; Nuyten, DS; Regev, A; Segal, E; van de Vijver, MJ; Wong, DJ | 1 |
| Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, AL; Cavenagh, JD; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Irwin, D; Lonial, S; Neuwirth, R; Reece, D; Richardson, PG; San-Miguel, JF; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
| Anderson, KC; Carrasco, DR; Dranoff, G; Jinushi, M; Munshi, NC; Neuberg, D; Prabhala, RH; Ritz, J; Tai, YT; Vanneman, M | 1 |
| Casanova, JM; Dolcet, X; Egido, R; Llobet, D; Llombart, A; Marti, RM; Matias-Guiu, X; Pérez de Santos, AM; Schoenenberger, JA; Soria, X; Sorolla, A; Vilella, R; Yeramian, A | 1 |
| Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H | 1 |
| Dietrich, PY; Favet, L; Kerl, K; Piguet, V; Sanchez-Politta, S | 1 |
| Berges, C; Daniel, V; Fuchs, D; Haberstock, H; Miltz, M; Naujokat, C; Opelz, G; Sadeghi, M | 1 |
| Anderson, KC; Aronson, JP; Bouxsein, ML; Chhetri, S; Fulciniti, M; Glimcher, LH; Hideshima, T; Jones, DC; Lian, JB; Liu, JC; Mukherjee, S; Patel, C; Pozzi, S; Purton, LE; Raje, N; Scadden, DT; Schoonmaker, JA; Seo, YD; Stein, G; Vallet, S; Wein, MN | 1 |
| Ribatti, D; Roccaro, AM; Vacca, A | 1 |
| Carbone, R; Lacy, J; Loomis, R; Srimatkandada, P; Srimatkandada, S | 1 |
| Chen, S; Dai, Y; Dent, P; Funk, VL; Grant, S; Kramer, LB | 1 |
| Chaudhary, PM; Lu, G; Punj, V | 1 |
| Chen, SJ; Chen, Z; Garcia, JF; Janin, A; Leboeuf, C; Li, JM; Liu, YY; Ma, J; Shen, ZX; Song, YP; Wang, L; Zhang, QL; Zhang, YW; Zhao, WL | 1 |
| Chen, TC; Golden, EB; Hofman, FM; Kardosh, A; Louie, SG; Petasis, NA; Pyrko, P; Schönthal, AH; Uddin, J | 1 |
| Gillmore, JD; Hawkins, PN; Lachmann, HJ; Offer, M; Wechalekar, AD | 1 |
| Cascio, P; Cenci, S; Cerruti, F; Mariani, E; Oliva, L; Pasqualetto, E; Sitia, R | 1 |
| Bocchia, M; Bucalossi, A; Cerase, A; Defina, M; Gozzetti, A; Lauria, F; Pirrotta, MT | 1 |
| Atkins, JN; Bajorin, DF; Halabi, S; Himelstein, AL; Hohl, RJ; Millard, F; Rosenberg, JE; Sanford, BL; Small, EJ | 1 |
| Betlloch, I; Mataix, J; Palmero, F; Romero, A | 1 |
| Blaise, D; de Lavallade, H; El-Cheikh, J; Faucher, C; Fürst, S; Hardan, I; Michallet, M; Mohty, M; Nagler, A; Nicolini, FE; Revesz, D; Shimoni, A; Sobh, M | 1 |
| Anargyrou, K; Angelopoulou, MK; Christoulas, D; Dimitriadou, EM; Dimopoulos, MA; Kalpadakis, C; Kyrtsonis, MC; Masouridis, S; Panayiotidis, P; Pangalis, GA; Pouli, A; Sachanas, S; Terpos, E; Tsionos, K; Tzenou, T; Vassilakopoulos, TP | 1 |
| Bladé, J; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; Sonneveld, P; Spencer, A; Zhuang, SH | 1 |
| Anaissie, E; Barlogie, B; Crowley, J; Haessler, J; Pineda-Roman, M; Shaughnessy, JD; Tricot, G; van Rhee, F; Zangari, M | 1 |
| Hussein, K; Lasho, T; Mesa, RA; Pardanani, A; Rivera, C; Tefferi, A; Verstovsek, S; Wu, W | 1 |
| Fu, WJ; Hou, J; Wang, DX; Yuan, ZG; Zhou, LL | 2 |
| Amrein, PC; Attar, EC; Ballen, KK; D'Amato, F; De Angelo, DJ; Galinsky, I; Levine, J; McAfee, S; Miller, KB; Neuberg, D; Schenkein, D; Sirulnik, A; Stone, RM; Supko, JG; Trehu, EG; Wadleigh, M; Zahrieh, D | 1 |
| Binder, A; Czuczman, MS; Deans, J; Gowda, A; Hernandez-Ilizaliturri, FJ; Kaur, H; Knight, J; Kotowski, A; Olejniczak, S; Starostik, P | 1 |
| Anderson, KC; Azab, A; Azab, F; Burwick, N; Chauhan, D; Farag, M; Ghobrial, IM; Hideshima, T; Jia, X; Leleu, X; Melhem, M; Moreau, AS; Ngo, HT; Palladino, MA; Roccaro, AM; Runnels, J; Sacco, A; Treon, SP | 1 |
| Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Esseltine, DL; Fuertes, M; García-Laraña, J; Garcia-Sanchez, P; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H | 1 |
| Alberti, D; Binger, K; Eickhoff, J; Geiger, P; Heideman, J; Kolesar, J; LoConte, NK; Marnocha, R; Thomas, JP; Utecht, K; Wilding, G | 1 |
| Irvine, AE; McCloskey, SM; McMullin, MF; Walker, B | 1 |
| Kalachand, R; Kelly, K; Murphy, P | 1 |
| Avonto, I; Boccadoro, M; Bringhen, S; Bruno, B; Callea, V; Caravita, T; Cascavilla, N; Falcone, A; Gay, F; Magarotto, V; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Ruggeri, M | 1 |
| Carey, LA; Collichio, F; Collins, J; Dees, EC; Esseltine, D; Ivanova, A; Lindley, CM; O'Neil, BH; Orlowski, RZ; Riordan, WJ | 1 |
| Anderson, KC; Azab, A; Azab, F; Brown, M; Burwick, N; Carrasco, DR; Eeckhoute, J; Farag, M; Ghobrial, IM; Hatjiharissi, E; Hideshima, T; Hunter, Z; Jia, X; Leleu, X; Melhem, MR; Moreau, AS; Ngo, HT; Roccaro, AM; Runnels, J; Sacco, A; Treon, SP; Witzig, TE | 1 |
| Drize, N; Nifontova, I; Petrova, T; Svinareva, D | 1 |
| Caligaris-Cappio, F; Cozza, S; Ferrarini, M; Nerini-Molteni, S; Sitia, R | 1 |
| Boulanger, E; Meignin, V; Oksenhendler, E | 1 |
| Accornero, P; Bersani, F; Crepaldi, T; Miretti, S; Morotti, A; Ponzetto, C; Taulli, R | 1 |
| Anderson, KC; Ciccarelli, B; Dammacco, F; Ghobrial, IM; Hatjiharissi, E; Jia, X; Leleu, X; Moreau, AS; Ngo, HT; Patterson, CJ; Roccaro, AM; Russo, D; Sacco, A; Treon, SP; Vacca, A; Xu, L | 1 |
| Chrysanthopoulou, H; Dimopoulos, MA; Kastritis, E; Matsouka, C; Michopoulos, S; Petraki, K | 1 |
| Chim, CS; Hwang, YY; Shek, TW | 1 |
| Fuchs, SY | 1 |
| Bae, SH; Hyun, MS; Kim, MK; Lee, KH; Ryoo, HM; Sin, JI | 1 |
| Kami, M; Tsubokura, M | 1 |
| Liang, S; Liao, ZJ; Ma, WL; Meng, FY; Meng, W; Zheng, WL | 1 |
| Caldara, A; Graiff, C; Mandarà, M; Pedersini, R; Sava, T; Vattemi, E | 1 |
| Cavenagh, JD; Curry, N; Drake, M; Esseltine, DL; Foot, N; Hallam, S; Morris, C; Oakervee, HE; Odeh, L; Popat, R | 1 |
| Beard, M; Cohen, SJ; Engstrom, PF; Langer, CJ; Lewis, NL; McLaughlin, S; Meropol, NJ; Weiner, LM | 1 |
| Aguirre Errasti, C; Alonso Alonso, JJ; Barreiro García, JG; Cánovas Fernández, A | 1 |
| Berrino, L; Cascone, T; Ciardiello, F; Heymach, JV; Kim, WY; Lee, HY; Morelli, MP; Morgillo, F; Pepe, S; Rodolico, G; Tortora, G | 1 |
| Banerjee, AK; Chumakov, KM; Dragunsky, EM; Gudkov, AV; Neznanov, N; Neznanova, L; Wek, RC | 1 |
| Kimpe, M; Nuyts, S; Prenen, H | 1 |
| Andersen, TL; Boissy, P; Delaissé, JM; Kupisiewicz, K; Lund, T; Plesner, T | 1 |
| Anderson, KC; Campbell, RM; Chauhan, D; Dios, AD; Hideshima, T; Ishitsuka, K; Kiziltepe, T; Munshi, N; Neri, P; Ocio, EM; Okawa, Y; Raje, N; Shen, Z; Shih, C; Shiraishi, N; Starling, JJ; Tamura, K; Tassone, P; Vallet, S | 1 |
| Roberts, AW; Wei, AH | 1 |
| Daibata, M; Gibellini, F; Lai, R; Lee, E; Mora-Jensen, H; Rizzatti, EG; Weniger, MA; Wiestner, A | 1 |
| Barete, S; Bodemer, C; Dubreuil, P; Georgin-Lavialle, S; Hermine, O; Lepelletier, Y; Lortholary, O; Suarez, F | 1 |
| Goy, A; Suh, KS | 1 |
| Bosi, A; Breschi, C; Casini, C; Ciolli, S; Leoni, F; Santini, V | 1 |
| Annunziata, C; Fojo, T; Poruchynsky, MS; Robey, RW; Sackett, DL; Ward, Y | 1 |
| Ding, Y; Huang, BH; Li, J; Luo, SK; Peng, AH; Su, C; Tong, XZ; Wang, HH; Zhao, Y; Zheng, D | 1 |
| Brun, J | 1 |
| Dekhuijzen, PN; Heunks, LM; Jin, B; Li, YP; Linkels, M; Ottenheijm, CA; Pigmans, CJ; van Hees, HW | 1 |
| Baritaki, S; Berenson, J; Bonavida, B; Daniels, TR; Jazirehi, AR; Palladino, M; Penichet, ML; Spandidos, DA; Suzuki, E; Umezawa, K | 1 |
| Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Hoering, A; Petty, N; Pineda-Roman, M; Shaughnessy, J; Szymonifka, J; van Rhee, F; Zangari, M | 1 |
| Encinas García, S; Izarzugaza Perón, Y; Khosravi Shahi, P; Pérez Manga, G; Sabin Domínguez, P | 1 |
| Li, X; Pennisi, A; Yaccoby, S | 1 |
| López-Pérez, R; Montero, JC; Pandiella, A; San Miguel, JF | 1 |
| Adjei, AA; Atadja, P; Friday, BB; Sarkaria, J; Wigle, D; Yang, L; Yu, C | 1 |
| Brooks, AD; Elliott, PJ; Murphy, WJ; Sayers, TJ; Shanker, A; Smyth, MJ; Takeda, K; Tristan, CA; Wine, JW; Yagita, H | 1 |
| Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, NR; Hauge, MD; Jaslowski, AJ; Jatoi, A; Ma, C; Moore, DF; Rowland, KM; Stella, PJ; Thomas, SP | 1 |
| AbdulJabbar, A; Ahmed, M; Al-Dayel, F; Al-Kuraya, KS; Al-Sanea, N; Alhomoud, S; Ashari, LH; Bavi, P; El-Sayed, R; Hussain, AR; Uddin, S | 1 |
| Hamaki, T; Kami, M; Kodama, Y; Kusumi, E; Matsumura, T; Miyakoshi, S; Narimatsu, H | 1 |
| Albanell, J; Awada, A; Baselga, J; Canney, PA; Cardoso, F; Dirix, LY; Gascon, P; Gil, T; Piccart, MJ | 1 |
| Ghori, N; Hanada, S; Harada, M; Omary, MB; Toivola, DM | 1 |
| Argiroffo, CB; Bongiovanni, M; Chizzolini, C; Dayer, JM; Djaafar, S; Donati, Y; Ferrari-Lacraz, S; Fineschi, S; Goffin, L; Naso, F; Pache, JC | 1 |
| Dicker, AP; Kamer, S; Ren, Q | 1 |
| An, C; Beenen, MA; Ellman, JA | 1 |
| Carew, JS; Giles, FJ; Nawrocki, ST | 1 |
| Berenson, JR; Hilger, J; Lee, SP; Mapes, R; Morrison, B; Nassir, Y; Swift, R; Vescio, RA; Wilson, J; Yang, HH; Yellin, O | 1 |
| Barmparousi, D; Dimopoulos, MA; Grapsa, I; Kastritis, E; Matsouka, C; Migkou, M; Psimenou, E; Roussou, M; Terpos, E | 1 |
| Atiq, OT; Dragovich, T; Hochster, H; Kozuch, PS; Lenz, HJ; O'Neil, BH; Pipas, JM; Rocha-Lima, CM; Ryan, DP | 1 |
| Kandasamy, K; Kraft, AS | 1 |
| Dimopoulos, MA; Roussou, M; Terpos, E | 1 |
| Fu, W; Hou, J; Jiang, H; Wang, D; Yuan, Z; Zhou, L | 1 |
| Kahl, BS; Markovina, S; Miyamoto, S; Yang, DT; Young, KH | 1 |
| Hahne, JC; Heider, U; Lamottke, B; Rademacher, J; Sezer, O; Sterz, J; Terpos, E; von Metzler, I | 1 |
| Gladney, SP; Kaufman, JL; Lonial, S | 1 |
| Bao, X; Chen, P; Gong, S; Guo, L; Lü, S; Song, N; Song, X; Wang, J; Yang, J; Zhou, H | 1 |
| Bernstein, SH; Fisher, RI; Friedberg, JW; Jordan, CT; Kelly, J; Liesveld, J; Marquis, D; Mendler, JH; Rich, L; Rossi, RM; Voci, S | 1 |
| Crawford, LJ; Irvine, AE; Walker, B | 1 |
| Dimopoulos, MA; Kastritis, E; Rajkumar, SV | 1 |
| Garderet, L; Gorin, NC; Isnard, F | 1 |
| Cavallo, F; Esseltine, D; Fink, L; Guerrero, J; Prasad, HK; Zangari, M | 1 |
| Armeanu, S; Baltz, KM; Bitzer, M; Krusch, M; Lauer, UM; Salih, HR; Smirnow, I; Steinle, A; Weiss, TS | 1 |
| Bladé, J; Dimopoulos, MA; Kastritis, E; Ludwig, H; Rosinol, L | 1 |
| Boyault, S; Brejon, S; Combaret, V; Iacono, I; Puisieux, A; Rousseau, R | 1 |
| Belch, AR; Debes Marun, C; Kirshner, J; Martin, LD; Pilarski, LM; Reiman, T; Thulien, KJ | 1 |
| Chen, D; Dou, QP; Landis-Piwowar, KR; Milacic, V; Yang, H | 1 |
| Li, M; Murphy, WJ; Sayers, TJ; Sun, K; Welniak, LA | 1 |
| Amann, K; Kalden, JR; Manz, RA; Maseda, D; Meister, S; Moser, K; Neubert, K; Voll, RE; Weisel, F; Wiethe, C; Winkler, TH | 1 |
| Huang, B; Hung, CF; Monie, A; Tseng, CW; Wang, MC; Wu, CY; Wu, TC | 1 |
| Barton, J; Farley, C; Greco, FA; Hainsworth, JD; Hon, J; Schreeder, M; Spigel, DR | 1 |
| Liu, X; Wang, H; Xu, B | 1 |
| Facon, T; Hulin, C; Moreau, P | 2 |
| Bush, D; Carew, JS; Casero, RA; Cleveland, JL; Goodwin, A; Houghton, JA; Marton, LJ; Nawrocki, ST; Reddy, VK; Rehg, JE | 1 |
| Bertoglio, J; Bréard, J; Mérino, D; Micheau, O; Ndozangue-Touriguine, O; Sebbagh, M | 1 |
| Chen, L; Chen, Z; Gong, S; Guo, L; Lü, S; Wang, J; Yang, J; Zhou, H | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Assaraf, YG; Berkers, CR; Cloos, J; Debipersad, K; Dijkmans, BA; Franke, NE; Jansen, G; Kaspers, GL; Lemos, C; Oerlemans, R; Peters, GJ; Scheffer, GL; Scheper, RJ; van der Heijden, JW; van Zantwijk, I; Vojtekova, K; Ylstra, B | 1 |
| Feng, R; Hager, JH; Hassig, CA; Lentzsch, S; Ma, H; Mapara, MY; Payne, JE; Smith, ND | 1 |
| Grandis, JR; Johnson, DE; Li, C; Li, R | 1 |
| Fujihara, S; Imataki, O; Kirizume, K; Ohnishi, H; Ohue, Y; Shintani, T; Waki, F | 1 |
| Arpaci, F; Ataergin, S; Demiriz, M; Ozet, A | 1 |
| Kolesar, J; Utecht, KN | 1 |
| Argyriou, AA; Iconomou, G; Kalofonos, HP | 1 |
| Allen, CT; Chen, Z; Colunga, A; Frenkel, V; Li, KC; Poff, JA; Traughber, B; Van Waes, C; Wood, BJ; Xie, J | 1 |
| Asaoku, H; Katayama, Y; Kimura, A; Kubo, T; Kuroda, Y; Munemasa, S; Okikawa, Y; Sakai, A; Shimose, S | 1 |
| Cvek, B; Dvorak, Z | 2 |
| Bazarbachi, A; Hatoum, HA; Mahfouz, RA; Otrock, ZK; Salem, ZM; Tawil, A; Zaatari, GS | 1 |
| Anderson, KC; Ghobrial, I; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, PG; Schlossman, R | 1 |
| Bi, YW; Gu, XH; He, XP; Li, XX; Pang, XY; Sun, WY; Yue, WM | 1 |
| Bhagat, G; Furman, RR; Gardner, JR; Gonen, M; Gueorguiev, VD; Heaney, ML; Manova, K; O'Connor, OA; Paoluzzi, L; Scotto, L | 1 |
| Armstrong, JL; Birch-Machin, MA; Brown, AM; Corazzari, M; Hill, D; Lovat, PE; Martin, S; Pagliarini, V; Piacentini, M; Redfern, CP | 1 |
| Allen, C; Arun, P; Chen, Z; Nottingham, L; Saigal, K; Van Waes, C | 1 |
| Han, K; Jung, S; Kim, M; Kim, Y; Lim, J; Min, CK; Min, WS | 1 |
| Cao, W; Namiki, K; Porvasnik, S; Rosser, CJ; Sakai, Y; Shiverick, KT; Urbanek, C | 1 |
| Campo, E; Colomer, D; López-Guerra, M; Montserrat, E; Nguyen, M; Pérez-Galán, P; Roué, G; Shore, GC; Villamor, N | 1 |
| Anderson, KC; Breitkreutz, I; Chauhan, D; Hideshima, T; Mitsiades, C; Munshi, NC; Okawa, Y; Raab, MS; Raje, N; Richardson, PG; Vallet, S | 1 |
| McConkey, DJ | 2 |
| Brandes, G; Buer, J; Carlomagno, T; Frank, R; Geffers, R; Gossler, A; Gütgemann, I; Kalesse, M; Kubicka, S; Malek, NP; Manns, MP; Menche, D; Nickeleit, I; Sasse, F; Sörensen, I; Steinmetz, H; Zender, S | 1 |
| Atkins, H; Belch, AR; Canning, LA; Kovacs, MJ; LeBlanc, R; Leitch, HA; Reece, DE; Voralia, M; White, D | 1 |
| Sayers, T | 1 |
| Terpos, E | 2 |
| Bauer, S; Bode, B; Knuth, A; Liewen, H; Renner, C; Samaras, P; Stenner, F; Tchinda, J; Weber, A; Zweifel, M | 1 |
| Chow, L; Eckhardt, SG; Gore, L; Lieu, C; Morrow, M; O'Bryant, CL; Pierson, AS; Tran, ZV; Wright, JJ | 1 |
| de Jong, S; de Vries, EG; Oldenhuis, CN; Stegehuis, JH; Walenkamp, AM | 1 |
| Chen, I; Chen-Kiang, S; Di Liberto, M; Garcia, J; Huang, X; Menu, E; Toogood, PL; Vanderkerken, K | 1 |
| Agrawal, SG; Gribben, JG; Jia, L; Liu, FT; Movasaghi, Z; Newland, AC; Rehman, IU; Wyatt, PB | 1 |
| Ohashi, K | 1 |
| Gonullu, E; Hacihanefioglu, A; Tarkun, P | 1 |
| Asaka, M; Fujita, N; Hashino, S; Imamura, M; Kahata, K; Kondo, T; Morita, R; Onozawa, M; Shirai, S | 1 |
| Grune, T; Jung, T | 1 |
| Bertoni, F; Capri, G; Catapano, CV; Cresta, S; Gallerani, E; Gianni, L; Maccioni, E; Maur, M; Passalacqua, D; Rinaldi, A; Sessa, C; Tosi, D; Viganò, L | 1 |
| Goldberg, SN | 1 |
| Carew, JS; Cleveland, JL; Courage, JF; Giles, FJ; Houghton, JA; Huang, P; Maclean, KH; McConkey, DJ; Nawrocki, ST | 1 |
| Driessen, C; Gogel, J; Hartmann, JT; Koscielniak, E; Kraus, M; Malenke, E; Müller, H; Ovaa, H; Overkleeft, H; Rückrich, T | 1 |
| Bagain, L; Chen, Z; Lee, TL; Malhotra, PS; Nottingham, L; Ricker, JL; Van Waes, C; Yeh, NT | 1 |
| Chen, C; Kukreti, V; Mikhael, J; Pantoja, M; Reece, DE; Rodriguez, GP; Stewart, AK; Trudel, S; Xu, W | 1 |
| Beveridge, RA; Conner, TM; Doan, QD; LeBlanc, AL; Walters, IB | 1 |
| Auran-Schleinitz, T; Blaise, D; Bouabdallah, R; Coso, D; de Collela, JM; de Lavallade, H; El-Cheikh, J; Gastaut, JA; Mohty, M; Stoppa, AM | 1 |
| Dobra, K; Hjerpe, A | 1 |
| Anderson, KC; Bladé, J; Boral, AL; Coleman, M; Esseltine, DL; Facon, T; Harousseau, JL; Irwin, D; Niesvizky, R; Rajkumar, SV; Richardson, PG; Rosiñol, L; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
| Aydin, NE; Celik, O; Elter, K; Gurates, B; Hascalik, S; Tagluk, ME | 1 |
| Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG | 1 |
| Bao, L; Huang, XJ; Lu, XJ; Zhang, XH; Zhang, Y; Zhu, HH | 1 |
| Bagain, L; Chen, Z; Hager, GL; Karpova, T; McNally, JG; Silvin, C; Sung, MH; Van Waes, C; Voss, TC; Yang, X | 1 |
| Berenson, JR; Yellin, O | 1 |
| Bamia, C; Bamias, A; Christoulas, D; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Gika, D; Kastritis, E; Melakopoulos, I; Migkou, M; Roussou, M; Terpos, E | 1 |
| Eom, HS; Huh, J; Kang, HJ; Kim, K; Kim, WS; Ko, YH; Lee, J; Park, K; Ryoo, BY; Suh, C | 1 |
| Ahn, KS; Bae, EK; Kim, BK; Kim, BS; Lee, YY; Park, J; Yoon, SS | 1 |
| Biron, P; Ghesquières, H; Labidi, SI; Nicolas, EV; Sebban, C | 1 |
| Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L | 1 |
| Broggini, M; Carrassa, L; Crippa, F; Damia, G; Ganzinelli, M; Tavecchio, M | 1 |
| Chen, KF; Cheng, AL; Huang, SY; Lu, YS; Yeh, KH; Yeh, PY | 1 |
| Cochrane, M; Davidoff, AM; Gray, JT; McIntosh, J; Nathwani, AC; Ng, CY; Zhou, J | 1 |
| Callander, NS; Kahl, BS; Kim, J; Kim, K; Leith, CP; Markovina, S; Miyamoto, S; O'Connor, SL; Raschko, M; Werndli, JE | 1 |
| Anderson, KC; Ben-Yehuda, D; Chanan-Khan, A; Facon, T; Goldschmidt, H; Harousseau, JL; Lonial, S; Neuwirth, R; Reece, D; Richardson, PG; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
| Anderson, KC; Bladé, J; Cavenagh, J; Esseltine, DL; Harousseau, JL; Jakubowiak, AJ; Lonial, S; Rajkumar, SV; Richardson, PG; San Miguel, J; Schuster, MW; Sonneveld, P | 1 |
| Adamo, L; Anastasi, G; Caruso, L; Conticello, C; Cupri, A; De Maria, R; Di Raimondo, F; Giuffrida, R; Giustolisi, R; Gulisano, M; Iannolo, G; Moschetti, G; Palumbo, GA; Vicari, L | 1 |
| He, Y; Hu, XX; Lü, SQ; Wang, JM; Yang, JM; Zhou, H | 1 |
| Li, JY; Lu, H; Qian, SX; Qiu, HX; Shen, WY; Wang, LX; Wu, HX; Wu, YJ; Zhang, JF | 1 |
| Al-Nawakil, C; Bardet, V; Bourry, E; Bouscary, D; Chapuis, N; Choquet, S; Dreyfus, F; Park, S; Roux, C; Tamburini, J | 1 |
| Chen, X; Dong, H; Gao, G; Gu, H | 1 |
| Abdulkadyrov, KM; Anderson, KC; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H | 1 |
| Durie, BG | 1 |
| Claxton, D; Fink, L; Talamo, G; Tricot, G; Zangari, M | 1 |
| Calliada, F; Castagnola, C; Corso, A; Lazzarino, M; Mangiacavalli, S; Varettoni, M; Zappasodi, P | 1 |
| Barrientos, J; Elstrom, R; Leonard, JP; Martin, P | 1 |
| Golenkov, AK; Mitina, TA | 1 |
| Do, YR; Joo, YD; Kim, BS; Kim, H; Kim, HJ; Kim, I; Kim, K; Kim, SJ; Kwon, JH; Lee, HJ; Lee, JH; Lee, NR; Lee, WS; Nam, SH; Shin, HJ; Sohn, SK; Suh, C; Won, JH; Yoon, SS | 1 |
| Acharya, M; Coiteux, V; Harousseau, JL; Hulin, C; Leleu, X; Moreau, P; van de Velde, H | 1 |
| Anagnostopoulos, N; Christoulas, D; Croucher, P; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Heath, D; Kastritis, E; Roussou, M; Terpos, E; Tsionos, K | 1 |
| Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP | 1 |
| Armstrong, MB; Castle, VP; Mody, R; Opipari, AW; Schumacher, KR; Yanik, GA | 1 |
| Clarke, PA; Powers, MV; Workman, P | 1 |
| Eder, S; Enrich, J; Hochegger, K; Mayer, B; Mayer, G; Perco, P; Pirklbauer, M; Rosenkranz, AR; Rudnicki, M; Sarközi, R; Schramek, H; Wiesinger, M | 1 |
| Ambinder, RF; Chen, J; Chong, JM; Foss, CA; Fox, JJ; Fu, DX; Fukayama, M; Hobbs, RF; Kowalski, J; Pomper, MG; Sgouros, G; Tanhehco, Y | 1 |
| Hongming, H; Jian, H | 1 |
| Alexanian, R; Alsina, M; Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Irwin, D; Jagannath, S; Limentani, SA; Niesvizky, R; Richardson, PG; Siegel, DS | 1 |
| Almasan, A; Gama, V; Matsuyama, S; Mazumder, S; Plesca, D | 1 |
| Diehl, JA; Herlyn, M; Klein-Szanto, A; Lioni, M; Noma, K; Rustgi, AK; Smalley, KS; Snyder, A | 1 |
| Dimopoulos, MA; Kastritis, E | 1 |
| Ayturan, M; Driessen, C; Fissolo, N; Kraus, M; Overkleeft, H; Reich, M; Weissert, R | 1 |
| Braiteh, F; Giralt, SA; Hymes, SR; Jones, R | 1 |
| Colvin, LA; Fallon, M; Fleetwood-Walker, SM; Johnson, PR; Mitchell, R | 1 |
| Agostinelli, C; Arpinati, M; Chirumbolo, G; Nicolini, B; Rondelli, D | 1 |
| Anthoney, A; Bauer, J; Caponigro, F; Govaerts, AS; Lacombe, D; Marréaud, S; Milano, A; Twelves, C | 1 |
| Berden, JH; van der Vlag, J | 1 |
| Huang, J; Jin, J; Pan, HZ; Yang, M | 1 |
| Czuczman, MS; O'Connor, OA | 1 |
| Liang, YM; Liu, H; Wang, QW; Wang, T; Zhu, XD | 1 |
| Chen, LJ; Li, JY; Lu, H; Lu, SF; Shen, WY; Wang, LX | 1 |
| Alfonsi, E; Corso, A; Costa, A; Lazzarino, M; Lozza, A; Mangiacavalli, S; Moglia, A; Piccolo, G; Ravaglia, S; Varettoni, M; Zappasodi, P | 1 |
| Dick, L; Lin, G; Nathan, C; Tsu, C; Zhou, XK | 1 |
| Ackermann, H; Arnoldner, C; Baghi, M; Bisdas, S; Gstöttner, W; Hambek, M; Knecht, R; May, A; Wagenblast, J | 1 |
| Horiike, S; Inaba, T; Shimazaki, C; Shimura, K; Taniguchi, K; Taniwaki, M | 1 |
| Boccadoro, M; Bringhen, S; Falco, P; Gay, F; Magarotto, V; Palumbo, A | 1 |
| Adachi, D; Hattori, N; Nakamaki, T; Nakashima, H; Saito, B; Tomoyasu, S | 1 |
| Bladé, J; Rosiñol, L | 1 |
| Corso, A; Lazzarino, M; Mangiacavalli, S; Pica, G; Varettoni, M; Zappasodi, P | 1 |
| Batár, P; Kiss, A; Méhes, L; Telek, B; Udvardy, M | 1 |
| Furukawa, Y; Kano, Y; Kikuchi, J; Mori, M; Muroi, K; Nagai, T; Noborio-Hatano, K; Nobuyoshi, M; Oh, I; Ozaki, K; Ozawa, K; Sato, K; Shimizu, R; Suzuki, T; Takatoku, M; Ueda, M; Wada, T | 1 |
| Ahmed, M; Ajarim, D; Al-Dayel, F; Al-Kuraya, KS; Bavi, P; Belgaumi, A; Hussain, A; Uddin, S | 1 |
| Jimenez, SA; Roman-Blas, JA | 1 |
| Bachmann, AS | 1 |
| Joyce, RM; Siddiqi, T | 1 |
| Fonseca, R; Rajkumar, SV | 1 |
| Adams, S; Barrett, AJ; Berg, M; Childs, R; Eniafe, R; Goldman, JM; Hensel, N; Keyvanfar, K; Lundqvist, A; Savani, BN; Sloand, EM; Yong, AS | 1 |
| Bouchard, P; Brown, L; Carson, WE; Chaudhury, AR; Go, MR; Guenterberg, K; Guttridge, DC; Hade, E; Ladner, KJ; Lesinski, GB; Lewis, A; Quimper, M; Raig, ET; Shah, NN; Young, G | 1 |
| Li, JY; Liu, P; Lu, H; Lu, SF; Shen, WY; Wang, LX; Wang, YR; Yang, H; Zhang, JF | 1 |
| Chen, XP; Liang, W; Lou, YR; Lu, Y; Mu, QT; Ouyang, GF; Xu, W; Zhang, Y | 1 |
| Casadonte, F; Focà, D; Macrina, L; Malara, N; Santoro, L; Savino, R; Scaramuzzino, M; Sesto, MF; Terracciano, R | 1 |
| Arnoldner, C; Baghi, M; Bisdas, S; Gstöttner, W; Hambek, M; Knecht, R; May, A; Wagenblast, J | 1 |
| Chastagner, P; Delfortrie, S; Labussiere, M; Pinel, S; Plenat, F | 1 |
| Jin, J; Meng, H; Qian, W; Yang, C; Zhou, Y | 1 |
| Bonavida, B; Huerta-Yepez, S; Jazirehi, AR; Martinez-Maza, O; Martinez-Paniagua, M; Umezawa, K; Vega, MI | 1 |
| Amiot, BP; Burns, JM; Gloor, JM; Gores, GJ; Perry, DK; Pollinger, HS; Stegall, MD | 1 |
| Khan, S; Li, X; Ling, W; Pennisi, A; Yaccoby, S; Zangari, M | 1 |
| Anderson, KC; Crawford, B; Dhawan, R; Gupta, S; Irwin, D; Lee, SJ; Massaro, J; Richardson, PG; San Miguel, JF; Schuster, MW; Sonneveld, P | 1 |
| Aizawa, S; Heike, Y; Kim, SW; Kobayashi, Y; Maruyama, D; Nagase, K; Takahashi, N; Tobinai, K; Waki, F; Watanabe, T; Yamasaki, S; Yokoyama, H | 1 |
| Chang, M; Lee, ML; Whitmore, GA | 1 |
| Dahdaleh, FS; Musallam, KM; Shamseddine, AI; Taher, AT | 1 |
| Battleman, DS; LeBlanc, A; Richardson, PG; Schuster, M; Walters, IB; Wolf, J | 1 |
| Littlehales, C | 1 |
| Hamaki, T; Hori, A; Kami, M; Kishi, Y; Kodama, Y; Komatsu, T; Matsumura, T; Narimatsu, H; Takita, M; Tanaka, Y; Yuji, K | 1 |
| Märten, A; Mehrle, S; Schmidt, J; Serba, S; von Lilienfeld-Toal, M; Zeiss, N | 1 |
| Palumbo, A; Rajkumar, SV | 1 |
| Bazzaro, M; Bradner, J; Bristow, RE; Chan, KC; Lee, MK; Lin, Z; Mazitschek, R; Roden, RB; Santillan, A; Wang, MC | 1 |
| Ayala, G; Ding, Y; Frolov, A; Harper, JW; Hayes, TG; Ittmann, MM; Kadmon, D; Li, R; Lynch, RG; MacDonnell, V; Miles, BJ; Mims, MP; Thompson, TC; Tsai, MJ; Wheeler, TM; Yan, J | 1 |
| Fels, DR; Koong, AC; Koumenis, C; Kridel, SJ; Olson, M; Segan, AT; Spiotto, M; Ye, J | 1 |
| Aleskog, A; Carlson, K; Larsson, R; Lindhagen, E; Nygren, P; Wiberg, K | 1 |
| Plosker, GL | 1 |
| Bladé, J; Cibeira, MT; Fernández de Larrea, C; Lloreta, J; Mascaró, JM; Rovira, M; Serra, N; Solé, M; Torras, A | 1 |
| Asaoku, H; Katayama, Y; Kimura, A; Kuroda, Y; Matsui, H; Mizuno, M; Munemasa, S; Nakaju, N; Nishisaka, T; Ogawa, K; Okikawa, Y; Sakai, A; Tanaka, H; Tsuyama, N | 1 |
| Erin, N; Yerlikaya, A | 1 |
| Chaganti, RS; Houldsworth, J; Olshen, AB; Petlakh, M | 1 |
| Dammacco, F; Mangialardi, G; Ria, R; Vacca, A | 1 |
| Coleman, M; Mark, T; Niesvizky, R | 1 |
| DiPersio, JF; Fisher, NM; Goyal, SD; Oza, AY; Stockerl-Goldstein, K; Tomasson, MH; Uy, GL; Vij, R | 1 |
| Drake, MT; Rajkumar, SV | 1 |
| Deng, SH; Qiu, LG; Wang, Y; Wang, YF; Wu, T; Xu, Y; Zhao, YZ; Zou, DH | 1 |
| Belch, AR; Corso, A; Komarnicki, M; Lucio, MN; Maiolino, A; Mikhael, JR; Musto, P; Petrucci, MT; Prince, HM; Stewart, AK | 1 |
| Brüning, A; Burger, P; Burges, A; Friese, K; Lenhard, M; Rahmeh, M; Vogel, M | 1 |
| Bao, L; Huang, XJ; Lu, XJ; Zhang, XH | 1 |
| Baiz, D; Dapas, B; Farra, R; Giansante, C; Grassi, G; Grassi, M; Guarnieri, G; Pozzato, G; Scaggiante, B; Uxa, L; Zennaro, C | 1 |
| Dimopoulos, MA; Fermand, JP; Garcia-Sanz, R; Gertz, MA; Ghobrial, IM; Kastritis, E; Kimby, EK; Kyle, RA; Leblond, V; Merlini, G; Morel, P; Morra, E; Ocio, EM; Owen, R; Seymour, J; Treon, SP | 1 |
| Chen, Q; Hunsucker, SA; Kuhn, DJ; Orlowski, M; Orlowski, RZ; Voorhees, PM | 1 |
| Furtado, M; Rule, S | 1 |
| Kim, JH; Lee, SK; Lee, SW; Park, YB | 1 |
| Abdalla, S; Hu, M; Karadimitris, A; Kotsianidis, I; Melo, V; Naresh, K; Rahemtulla, A; Reid, A; Spanoudakis, E; Terpos, E | 1 |
| Guerciolini, R; Hsieh, FY; Miwa, G; Pekol, TM; Tengstrand, E | 1 |
| Bladé, J; Cibeira, MT; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; San Miguel, JF; Sonneveld, P; Spencer, A; Sutherland, HJ; Zhuang, SH | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Hadjikonstantinou, V; Kastritis, E; Migkou, M; Zirogiannis, P | 1 |
| Ding, J; Iida, S; Inagaki, A; Ishida, T; Ito, A; Komatsu, H; Kusumoto, S; Ri, M; Ueda, R; Utsunomiya, A; Yano, H | 1 |
| Ambrus, JL; Islam, A | 1 |
| Barbui, T; Barosi, G; Rambaldi, A | 1 |
| Anderson, KC; Azab, AK; Azab, F; Burwick, N; Chen, C; Ghobrial, IM; Jia, X; Leleu, X; Melhem, MR; Ngo, HT; Novina, CD; Roccaro, AM; Rollins, BJ; Runnels, J; Sacco, A; Varticovski, L | 1 |
| Bernstein, SH; Boral, AL; de Vos, S; Djulbegovic, B; Epner, E; Fisher, RI; Goy, A; Kahl, BS; Krishnan, A; Leonard, JP; Lonial, S; Nasta, S; O'Connor, OA; Robertson, MJ; Shi, H | 1 |
| Au, WY; Kwong, YL; Liang, RH; Shen, L; Shimizu, N; Srivastava, G; Tsuchiyama, J; Wong, KY | 1 |
| Cavaletti, G; Gilardini, A; Marmiroli, P | 1 |
| Hu, X; Huang, C; Lü, S; Ni, X; Qiu, H; Wang, J; Xu, X; Yang, J | 1 |
| Conti, AA; Dilaghi, B; Modesti, PA; Nozzoli, C | 1 |
| Andrews, D; Curran, WJ; Dicker, AP; Kubicek, GJ; Machtay, M; Mallon, G; Myers, T; Ramirez, M; Werner-Wasik, M | 1 |
| Fan, LS; Hu, Y; Kong, FF; Li, Y; Ma, D; Song, XH; Wang, SX; Weng, DH; Xing, H | 1 |
| Alexiadis, M; Chu, S; Fuller, PJ | 1 |
| Fladd, C; Huynh, L; Jiang, C; Ly, D; Rotin, D; Trzcinska-Daneluti, AM | 1 |
| Allen, S; Mehta, J; Singhal, S; Vickrey, E | 1 |
| Kami, M; Komatsu, T; Tsubokura, M | 1 |
| Avvisati, G | 1 |
| García-Bustínduy, M; Martín-Herrera, A; Noda-Cabrera, A; Rodríguez-Martín, M; Sáez-Rodríguez, M | 1 |
| Albain, KS; Chansky, K; Crowley, J; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Vogel, SJ | 1 |
| Barbone, D; Broaddus, VC; Fennell, DA; Yang, TM | 1 |
| Anel, A; Balsas, P; Galán-Malo, P; López-Royuela, N; Marzo, I; Naval, J | 1 |
| Alloway, RR; Arend, LJ; Brailey, P; Cardi, M; Everly, JJ; Everly, MJ; Govil, A; Mogilishetty, G; Rike, AH; Roy-Chaudhury, P; Susskind, B; Tevar, A; Wadih, G; Woodle, ES | 1 |
| Kaporskaia, TS; Kiselev, IV | 1 |
| Brossart, P; Fröhlich, E; Wahl, R | 1 |
| Groll, M; Huber, R; Moroder, L | 1 |
| Li, J; Liu, P; Lu, H; Xu, B | 1 |
| Dmoszyńska, A | 1 |
| Voelkel-Johnson, C | 1 |
| Brady, JN; Dohoney, K; Janik, JE; Lee, MJ; Morris, JC; O'Mahony, D; Pise-Masison, CA; Radonovich, M; Trepel, J; Waldmann, TA | 1 |
| Alt, C; Anderson, KC; Azab, AK; Azab, F; Burwick, N; Carlson, AL; Farag, M; Ghobrial, IM; Hideshima, T; Jia, X; Kung, AL; Leleu, X; Lin, CP; Melhem, MR; Moreau, AS; Munshi, NC; Ngo, HT; Ospina, B; Pitsillides, C; Roccaro, AM; Rollins, BJ; Runnels, JM; Sacco, A; Wright, R | 1 |
| Bernardi, P; Brancolini, C; Crivellato, E; Demarchi, F; Fontanini, A; Foti, C; Maestro, R; Potu, H | 1 |
| Berdel, WE; Bisping, G; Gustavus, D; Hilberg, F; Kienast, J; Kropff, M; Mesters, RM; Müller-Tidow, C; Munzert, G; Roth, GJ; Stefanic, M; Stelljes, M; Volpert, S; Wenning, D | 1 |
| Elliott, GI; Farshchi-Heydari, S; Howell, SB; Jandial, DD; Larson, CA; Wrasidlo, WJ | 1 |
| Dawson, MA; Donovan, M; Hertzberg, M; Horvath, N; McLean, CA; Monaghan, K; Opat, SS; Prince, HM; Roberts, AW; Spencer, A; Taouk, Y; Zammit, M | 1 |
| Anderson, KC; Carrasco, R; Chabner, B; Chauhan, D; Chhetri, S; Cirstea, D; Hideshima, T; Ikeda, H; Kiziltepe, T; Mitsiades, C; Mukherjee, S; Munshi, NC; Okawa, Y; Parikh, H; Podar, K; Pozzi, S; Raab, M; Raje, N; Richardson, PG; Rooney, M; Scadden, D; Sharma, S; Vallet, S | 1 |
| Akazawa, H; Komuro, I | 1 |
| Chen, W; Hai, T; Mora-Jensen, H; Perez-Galan, P; Ron, D; Trenkle, W; Wang, Q; Weniger, MA; Wiestner, A; Wolford, C; Ye, Y | 1 |
| Amiot, M; Bataille, R; Descamps, G; Gomez-Bougie, P; Moreau, P; Venot, C | 1 |
| Amato, AA; Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, AL; Cavenagh, JD; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Lonial, S; Reece, D; Richardson, PG; San Miguel, J; Schuster, MW; Sonneveld, P; Stadtmauer, EA; Wen, PY | 1 |
| Prommer, EE | 1 |
| Ales, M; Caravita, T; Cupelli, L; de Fabritiis, P; Dentamaro, T; Fratoni, S; Giovannini, M; Niscola, P; Santeusanio, G; Scaramucci, L; Siniscalchi, A; Tendas, A | 1 |
| Carrell, JA; Humphreys, R; Luster, TA; McCormick, K; Sun, D | 1 |
| Eckhardt, SG; Kaufman, SA; Morrow, M; Pitts, TM; Tentler, JJ | 1 |
| Liu, YP; Ma, YJ; Qu, XJ | 1 |
| Kesarwala, AH; Piwnica-Worms, D; Samrakandi, MM | 1 |
| Chandra, J; Keating, MJ; Miller, CP; Palladino, M; Rudra, S; Wierda, WG | 1 |
| Hunter, P | 1 |
| Basu, S; Cavenagh, J; Cook, M; Craddock, C; Foot, N; Hallam, S; Harding, S; Joel, S; Oakervee, H; Odeh, L; Popat, R; Singer, C; Williams, C | 1 |
| Davies-Hill, T; Jin, L; Miida, T; Miyake, K; Pittaluga, S; Raffeld, M; Rudelius, M; Sebasigari, D; Tabe, Y | 1 |
| Abaya, CD; Berenson, JR; Duvivier, H; Mapes, R; Nassir, Y; Patel, R; Swift, RA; Yellin, O | 1 |
| Cadenas, E; Chen, TC; Gaffney, KJ; Golden, EB; Kardosh, A; Lam, PY; Louie, SG; Petasis, NA; Schönthal, AH | 1 |
| Aguirre-Ghiso, JA; Schewe, DM | 1 |
| Cammarota, S; Cavaletti, G; Frigeni, B; Jann, S; Lanzani, F; Mattavelli, L; Petrò, D; Rossini, F | 1 |
| Borrello, I; Chaudhry, V; Cornblath, DR; Ferguson, A; Polydefkis, M | 1 |
| Higa, GM; Saad, AA; Sharma, M | 1 |
| Barlogie, B; Chen, Y; Hu, B; Qiang, YW; Shaughnessy, JD; Shi, B; Zhong, Y | 1 |
| Berg, M; Childs, R; Lundqvist, A; Smith, A; Yokoyama, H | 1 |
| Eby, C | 1 |
| Arenkiel, BR; Capecchi, MR; Cho, MJ; Guttridge, DC; Hansen, MS; Keller, C; McCleish, AT; Qualman, SJ; Rivera, OJ; Scott, MP; Taniguchi, E | 1 |
| Du, ZX; Guan, Y; Meng, X; Wang, HQ; Zhang, HY | 1 |
| Blumel, S; Butos, J; Cooper, B; Dumitrescu, O; Gonen, M; Gordon, L; Hamelers, R; Hamlin, P; Mac-Gregor Cortelli, B; Moskowitz, C; Neylon, E; O'Connor, OA; Portlock, C; Sarasohn, D; Straus, D; Vose, J; Winter, J; Wright, JJ; Zelenetz, AD | 1 |
| Bose, P; Gandhi, D; Ghabach, B; Ozer, H; Thompson, C | 1 |
| Assaf, C; Heider, U; Lamottke, B; Mieth, M; Moebs, M; Rademacher, J; Sezer, O; von Metzler, I | 1 |
| Ames, E; Hallett, WH; Murphy, WJ | 1 |
| Hiepe, F; Voll, R | 1 |
| Beck, A; Driessen, C; Gogel, J; Kalbacher, H; Kraus, M; Ovaa, H; Overkleeft, HS; Rückrich, T; Verdoes, M | 1 |
| Anagnostopoulos, N; Christoulas, D; Delimbassi, S; Dimopoulos, MA; Economopoulos, T; Gika, D; Kartasis, Z; Kastritis, E; Katodritou, E; Michali, E; Pouli, A; Roussou, M; Symeonidis, A; Terpos, E; Zervas, K; Zomas, A | 1 |
| Bergsagel, PL; Chen, C; Fonseca, R; Hentz, J; Kukreti, V; Leis, JF; Mikhael, JR; Noble, B; Pirooz, NA; Piza, JG; Reece, DE; Reeder, CB; Spong, JE; Stewart, AK; Trudel, S; Zepeda, VH | 1 |
| Abe, M; Fujii, S; Kagami, S; Kagawa, K; Lee, E; Matsumoto, T; Miki, H; Nakamura, S; Ozaki, S; Takeuchi, K; Takimoto, T; Tanaka, O; Watanabe, H; Yata, KI | 1 |
| Abaya, CD; Berenson, JR; Cartmell, A; Duvivier, H; Eades, B; Flam, MS; Hilger, J; Nassir, Y; Patel, R; Swift, RA; Woytowitz, D; Yellin, O | 1 |
| Armstrong, JL; Birch-Machin, MA; Flockhart, R; Hill, DS; Lovat, PE; Martin, S; Redfern, CP; Simpson, DG; Tonison, JJ | 1 |
| Brignole, C; Carosio, R; Cilli, M; Di Paolo, D; Galietta, LJ; Loi, M; Marimpietri, D; Nico, B; Pagnan, G; Pastorino, F; Pezzolo, A; Piccardi, F; Pistoia, V; Ponzoni, M; Ribatti, D | 1 |
| Fadeel, B; Feng, X; Henter, JI; Ji, C; Nordenskjöld, M; Ottosson, A; Wang, X; Zheng, C | 1 |
| Barr, RJ; Cole, GW; Dyson, SW; Murase, JE; Theate, I; Wu, JJ | 1 |
| Chen, XQ; Dong, HJ; Gao, GX; Gao, Y; Gu, HT; Pan, YZ; Zhu, HF | 1 |
| Chen, SL; Hu, Y; Li, X; Zhang, JJ; Zhong, YP | 1 |
| Chan, W; Heymach, J; McConkey, DJ; Wilkinson, M; Zhu, K | 1 |
| Grandis, JR; Johnson, DE; Li, C; Li, R; Patel, NS; Zang, Y | 1 |
| Anargyrou, K; Christoulas, D; Dimopoulos, MA; Kastritis, E; Katodritou, E; Michalis, E; Pouli, A; Terpos, E; Tsiftsakis, E; Tsionos, K; Verrou, E; Zervas, K | 1 |
| Brauer, KM; Bringmann, A; Brossart, P; Held, SA; Schaub, A; von Schwarzenberg, K | 1 |
| Chen, L; Chen, Z; Han, F; Li, J; Lü, S; Wang, J; Xu, X; Yang, J; Zhou, H | 1 |
| Caravita, T; de Fabritiis, P; Del Poeta, G; Fratoni, S; Santeusanio, G; Siniscalchi, A | 1 |
| Chen, KF; Chen, PJ; Cheng, AL; Hsieh, HP; Hsu, C; Hsu, CH; Lu, YS; Yeh, PY | 1 |
| Handa, H; Karasawa, M; Koiso, H; Mawatari, M; Murakami, H; Nojima, Y; Osaki, Y; Saitoh, T; Sekigami, T; Tahara, K; Tsukamoto, N; Uchiumi, H; Yokohama, A | 1 |
| Shiguang, Z; Tianhu, Z; Xinghan, L | 1 |
| Brancolini, C; Demarchi, F; Foti, C | 1 |
| Dasmahapatra, G; Dent, P; Fisher, RI; Friedberg, J; Grant, S; Kramer, L; Lembersky, D; Rahmani, M | 1 |
| Berdel, WE; Einsele, H; Gann, CN; Knop, S; Kropff, M; Liebisch, P; Wand, H; Weisel, K | 1 |
| Fuchs, O; Kuzelova, K; Marinov, I; Provaznikova, D; Spicka, I | 1 |
| Baker, RD; Finkbiner, KL; Henry, DW; Kettle, JK; Klenke, SE; Williams, CB | 1 |
| Jang, HS; Kim, KM; Oh, KJ; Park, JW; Rhyu, IJ | 1 |
| Chen, SJ; Chen, Z; Janin, A; Jiang, XX; Shen, ZX; Wang, L; Wu, WL; Yang, F; Zhang, QL; Zhang, YW; Zhao, WL | 1 |
| Hirakawa, T; Inokuchi, K; Yokose, N | 1 |
| Fujiwara Yamada, M; Harigae, H; Ishikawa, I; Ishizawa, K; Kameoka, J; Ohguchi, H; Okuda, M; Onishi, Y; Sugawara, T; Tomiya, Y; Yamamoto, J | 1 |
| Bates, AL; Edwards, CM; Fowler, JA; Lwin, ST; Mundy, GR; Oyajobi, BO; Zhuang, J | 1 |
| Grünberg, K; Sonneveld, P; Wittgen, BP; Wondergem, MJ; Zweegman, S | 1 |
| Alexandrescu, DT; Dasanu, CA | 2 |
| Berg, M; Childs, R; Fan, Y; Lundqvist, A; McCoy, P; Samsel, L; Tawab, A | 1 |
| Dreyling, M; Hartmann, E; Hiddemann, W; Hutter, G; Pastore, A; Rieken, M; Rosenwald, A; Weinkauf, M; Zimmermann, Y | 1 |
| Guan, M; Hughes, A; Somlo, G; Yen, Y; Zhou, B; Zhu, L | 1 |
| Chim, CS; Hwang, YY; Pang, C; Shek, TW | 1 |
| Asmann, YW; David, CS; Rajagopalan, G; Tilahun, AY | 1 |
| Chott, A; Formanek, M; Hauff, W; Jonak, C; Müllauer, L; Püspök, A; Raderer, M; Troch, M; Zielinski, CC | 1 |
| Armitage, JO | 1 |
| Cavenagh, J; Lonial, S | 1 |
| Chen, Q; Hunsucker, SA; Kuhn, DJ; Nemeth, JA; Orlowski, RZ; Small, GW; Voorhees, PM | 1 |
| Bentz, M; Dreyling, M; Hiddemann, W; Jentsch-Ullrich, K; Mueck, R; Rohrberg, R; von Schilling, C; Weidmann, E; Weigert, O | 1 |
| Geffray, L | 1 |
| Balkaran, S; Gay, J; Ghobrial, I; Leleu, X; Morel, P; Pascal, L; Robu, D; Roccaro, A; Wemeau, M; Willekens, C | 1 |
| Chen, S; Goldenberg, DM; Smith, MR; Stein, R; Zalath, M | 1 |
| Guan, X; Koide, SS; Li, S; Miao, S; Song, W; Wang, L; Wang, Y; Zong, S | 1 |
| Chen, C; Eisenhauer, E; Kouroukis, CT; Powers, J; Stadtmauer, E; Stewart, AK; Voralia, M; Walsh, W; White, D; Wright, JJ | 1 |
| Azab, AK; Azab, F; Ghobrial, IM; Jia, X; Leleu, X; Melhem, M; Moreau, AS; Ngo, HT; Roccaro, AM; Runnels, J; Sacco, A | 1 |
| Kagechika, H; Kurosu, T; Miura, O; Ohki, M; Wu, N | 1 |
| Anderson, KC; Baccarani, M; Calabrese, E; Cavo, M; Chauhan, D; Cirstea, D; Gorgun, G; Hideshima, T; Ikeda, H; Okawa, Y; Perrone, G; Raje, N; Santo, L | 1 |
| Butcher, BE; Cannell, P; Horvath, N; Mikhael, JR; Prince, HM; Quach, H | 1 |
| Aggarwal, BB; Anand, P; Guha, S; Kunnumakkara, AB; Sethi, G; Sung, B | 1 |
| Knauf, WU; Kornacker, M; Otremba, B; Overkamp, F | 1 |
| Everly, MJ; Terasaki, PI | 2 |
| Callahan, LA; Supinski, GS; Vanags, J | 1 |
| Czuczman, MS; Dave, SS; Dunleavy, K; Grant, N; Jaffe, ES; Janik, JE; Pittaluga, S; Shovlin, M; Staudt, LM; Wilson, WH; Wright, G | 1 |
| Ahn, KS; Ayyappan, V; Bae, EK; Kim, BK; Kim, BS; Lee, C; Lee, YY; Park, J; Yoon, SS | 1 |
| Ceresa, C; Giaccone, G; Giovannetti, E; Honeywell, R; Laan, AC; Peters, GJ; Voortman, J | 1 |
| Acharya, M; Britten, CD; Chan, K; Cohen, N; Dudov, A; Fuloria, J; Gabrail, N; Nemunaitis, J; Quinn, DI; Yee, L | 1 |
| Bradner, JE; Cohen, JI; Kawada, J; Mazitschek, R; Zou, P | 1 |
| Anderson, KC; Chauhan, D; Hideshima, T; Klippel, S; Laubach, JP; McMillin, DW; Mitsiades, CS; Munshi, NC; Richardson, PG | 1 |
| Chen, L; Chen, X; Dong, B; Dong, H; Gao, G; Gao, Y; Gu, H | 1 |
| Benninger, K; Carson, WE; Kreiner, M; Lesinski, GB; Quimper, M; Young, G | 1 |
| Tsukamoto, S; Yokosawa, H | 1 |
| Baumann, G; Fechner, M; Grimbo, N; Ludwig, A; Meiners, S; Stangl, K; Stangl, V; Wilck, N | 1 |
| Dun, XY; Hou, J; Li, YH; Yuan, ZG | 1 |
| Dudek, AZ; Franklin, M; Greeno, EW; Kratzke, RA; Kumar, P; Lesniewski-Kmak, K; Pandey, ON; Shehadeh, NJ | 1 |
| Ding, L; Duan, LN; Liu, J; Wang, HX; Wang, ZD; Xue, M; Yan, HM; Zhu, L | 1 |
| Adam, Z; Buchler, T; Buresova, L; Hajek, R; Krejci, M; Krivanova, A; Pour, L; Sandecka, V; Vorlicek, J; Zahradova, L | 1 |
| Heider, U; Jakob, C; Kaiser, M; Lamottke, B; Mieth, M; Sezer, O; von Metzler, I | 1 |
| Delmonte, A; Ghielmini, M; Sessa, C | 1 |
| Haane, C; Nehmann, N; Schumacher, U; Valentiner, U | 1 |
| Balasubramanian, S; Bhalla, S; Buggy, J; David, K; Evens, AM; Gordon, LI; Mauro, L; Miller, R; Prachand, S; Sirisawad, M | 1 |
| Bottini, A; Generali, D; Harris, AL; Mellor, HR; Milani, M; Pike, L; Rzymski, T | 1 |
| Mohamed, AJ; Mohanram, V; Simonson, OE; Smith, CI; Spetz, AL; Yu, L | 1 |
| Chen, Z; Gong, S; Lü, S; Wang, J; Xu, X; Yang, J; Zhou, H | 1 |
| Abe, M | 1 |
| Anderson, KC; Carrasco, RD; Chauhan, D; Hideshima, T; Ikeda, H; Mitsiades, C; Munshi, NC; Okawa, Y; Podar, K; Raje, N; Richardson, PG | 1 |
| Curran, MP; McKeage, K | 1 |
| Billet, A; Chaby, G; Chatelain, D; Christophe, O; Dadban, A; Damaj, G; Lenglet, A; Lok, C; Marolleau, JP; Royer, R; Thuillier, D; Vaida, I; Viseux, V | 1 |
| Andreoli, A; Briere, J; Cavelier Balloy, B; Petit, A; Thomas, M | 1 |
| Avenel-Audran, M; Croué, A; Dib, M; Hunault-Berger, M; Lissandre, S; Moles, MP; Tanguy-Schmidt, A; Zidane-Marinnes, M | 1 |
| Godley, LA; Goodenbour, JM; Pan, T; Wickrema, A; Zhou, Y | 1 |
| Li, J; Li, W; Luo, S; Su, C; Zou, WY | 1 |
| Anderson, KC; Ghobrial, IM; Laubach, JP; Mitsiades, CS; Richardson, PG; Roccaro, AM | 1 |
| Dispenzieri, A; Gertz, MA; Kumar, S; Sadek, I | 1 |
| Eller, K; Heininger, D; Huber, JM; Mayer, G; Rosenkranz, AR; Tagwerker, A | 1 |
| Hertan, LM; Koumenis, C | 1 |
| Dave, SD; Everly, MJ; Feroz, A; Idica, AK; Kaneku, H; Khemchandani, SI; Modi, PR; Shankar, V; Terasaki, PI; Trivedi, HL; Trivedi, VB; Vanikar, AV | 1 |
| Berndt, N; Guida, WC; Kazi, A; Lawrence, H; McLaughlin, ML; Sebti, SM; Springett, GM; Yip, RM | 1 |
| Baltaci, M; Böckle, BC; Sepp, NT; Weyrer, W | 1 |
| Ailawadhi, S; Barcos, M; Bernstein, ZP; Chanan-Khan, A; Czuczman, MS; Iancu, D; Lee, K; Miller, KC; Mohr, A; Musial, L; Padmanabhan, S; Patel, M; Sher, T; Yu, J | 1 |
| Biczó, G; Halm, G; Rakonczay, Z; Szabolcs, A; Takács, T; Tiszlavicz, L; Wittmann, T | 1 |
| Cho, BS; Eom, HS; Kim, CC; Kim, M; Kim, Y; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Cakana, A; Comenzo, RL; Elsayed, YA; Fermand, JP; Hegenbart, U; Liu, X; Merlini, G; Palladini, G; Reece, DE; Sanchorawala, V; Vescio, RA | 1 |
| Cheong, JW; Jeong, TS; Kim, HJ; Kim, TY; Lee, DS; Lee, JH; Min, HJ; Oh, B; Park, J; Park, SB; Suh, C; Yoon, SS | 1 |
| Jin, J; Liu, H; Tong, HY; Wei, JY; Yu, WJ; Zhang, FJ; Zhu, WF | 1 |
| Birner, A; Boral, A; Diener, JG; Esseltine, DL; Ghobrial, IM; Ioakimidis, L; Keogh, GP; Matous, J; Mattern, J; Myers, TJ; Nelson, M; Patterson, CJ; Sheehy, P; Soumerai, JD; Treon, SP; Willen, M | 1 |
| Blanco, B; Caballero-Velazquez, T; Del Cañizo, C; Díez-Campelo, M; Gutierrez-Cossío, S; Hernández-Campo, P; Herrero-Sanchez, C; Pérez-Simón, JA; Rodriguez-Serrano, C; San Miguel, JF; Sánchez-Abarca, LI; Sánchez-Guijo, FM; Santamaría, C | 1 |
| Rolfe, M; Smith, PG; Soucy, TA | 1 |
| Benavides, A; Frost, P; Hoang, B; Lichtenstein, A; Shi, Y | 1 |
| Boise, LH; Gutman, D; Morales, AA | 1 |
| Algarotti, A; Corso, A; Lazzarino, M; Mangiacavalli, S; Pascutto, C; Pica, GM; Varettoni, M; Zappasodi, P | 1 |
| Emadi, A; Ghosh, N | 1 |
| Camacho, FJ; Elrafei, T; Gucalp, R; Ho, L; Li, T; Perez-Soler, R; Piperdi, B; Rigas, JR | 1 |
| Knopf, KB; Moretto, JC; Waller, JM | 1 |
| Powell, CA | 1 |
| Amato, AA; Anderson, KC; Avigan, DE; Briemberg, HR; Chanan-Khan, AA; Doss, D; Esseltine, DL; Hassoun, H; Heffner, LT; Kesari, S; Kuter, DJ; Lonial, S; Mitsiades, C; Munshi, NC; Oaklander, AL; Richardson, PG; Schlossman, RL; Weller, E; Wen, PY; Xie, W | 1 |
| Adachii, M; Ando, K; Hirose, T; Hosaka, T; Inoue, F; Ishida, H; Kadofuku, T; Kanome, T; Kusumoto, S; Ohmori, T; Ohnishi, T; Okuda, K; Saijo, N; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Accorsi, P; Antuzzi, G; Bavaro, P; Carrozza, F; Dell'Isola, M; Di Bartolomeo, P; Gigli, R; Giglio, G; Magri, M; Musacchio, M; Romito, S | 1 |
| Arts, J; Coulton, L; Croucher, P; De Raeve, H; Deleu, S; Lemaire, M; Menu, E; Van Camp, B; Van Valckenborgh, E; Vande Broek, I; Vanderkerken, K | 1 |
| Giralt, S; Krishnan, A; Mccarthy, P; Pasquini, MC; Somlo, G; Stadtmauer, E; Vesole, DH | 1 |
| Bedor, M; Burrows, W; Edelman, MJ; Krasna, MJ; Smith, R; Suntharalingam, M | 1 |
| Choi, EK; Jeong, SY; Kim, TH; Moon, AR; Seo, YW; Woo, HN | 1 |
| Anderson, KC; Breitkreutz, I; Podar, K; Raab, MS; Richardson, PG | 1 |
| Aki, SZ; Erdem, O; Ozkurt, ZN; Sucak, GT; Yağci, M | 1 |
| Testa, U | 1 |
| Chen, YJ; Huang, RX; Huang, XC; Li, XL; Peng, MY; Xie, ZX; Yang, XG | 1 |
| Albanell, J; Belda-Iniesta, C; Cejas, P; Chattopadhyay, S; Cortes-Sempere, M; de Castro-Carpeño, J; Gonzalez-Barón, M; Machado-Pinilla, R; Manguan-García, C; Moratilla, C; Nistal, M; Perona, R; Rodriguez-Fanjul, V; Rovira, A; Sánchez-Pérez, I; Tapia, M | 1 |
| Anderson, KC; Bensinger, W; Bergsagel, L; Blade, J; Cavo, M; Comenzo, RL; Durie, BG; Einsele, H; Giralt, S; Harousseau, JL; Kumar, S; Lentzsch, S; Lonial, S; Ludwig, H; Munshi, N; Niesvizky, R; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Sonneveld, P; Stadtmauer, EA; Tosi, P; Vesole, D | 1 |
| Gajate, C; Mollinedo, F; Reis-Sobreiro, M | 1 |
| Dahlmann, B; Kloss, A; Ludwig, A; Meiners, S | 1 |
| Bryant, J; Clegg, A; Cooper, K; Green, C; Smith, A; Stephens, M; Takeda, A | 1 |
| Alakus, H; Auer, T; Gamerith, G; Hilbe, W; Krugmann, J; Lindner, H; Loeffler-Ragg, J; Martin, HJ; Maser, E; Menzel, J; Mueller, D; Sarg, B; Schmid, KW; Schmitz, KJ; Skvortsov, S; Skvortsova, I; Zwierzina, H | 1 |
| Chou, T; Hasegawa, Y; Hirose, T; Imai, Y; Ishiguro, T; Kawahara, F; Nagai, H | 1 |
| Carew, JS; Esquivel, JA; Giles, FJ; Huang, P; Kelly, K; Mahalingam, D; Medina, EC; Mita, AC; Mita, MM; Nawrocki, ST; Swords, R; Zhang, H | 1 |
| Chen, X; Ding, WX; Gao, W; Kang, JH; Liu, J; Ni, HM; Stolz, DB; Yin, XM | 1 |
| Foley, PW; Hamilton, MS; Leyva, F | 1 |
| Brice, P; Briere, J; Ertault, M; Ferme, C; Gisselbrecht, C; Golfier, JB; Haioun, C; Mounier, N; Ribrag, V; Salles, G | 1 |
| Bocchia, M; Defina, M; Gozzetti, A | 1 |
| Marchi, E; O'Connor, OA; Paoluzzi, L; Scotto, L; Seshan, VE | 1 |
| Lattin, G; Sanders, O; Timpone, V | 1 |
| Ballon, DJ; Chang, CC; Chen, H; Feng, Y; Huang, W; Kamble, RT; Liao, B; Preti, HA; Rice, L; Wen, J; Zu, Y | 1 |
| Berciano, MT; Casafont, I; Lafarga, M | 1 |
| Chen, SL; Zhong, YP | 1 |
| Fang, H; Hu, Z; Zhou, G | 1 |
| Camacho, ES; Crowley, J; Durie, BG; Gabayan, AE; Irwin, D; Jagannath, S; Lutzky, J; Mazumder, A; McKinley, M; Potts, P; Vescio, R; Wolf, JL | 1 |
| Cortelli, BM; Dumitrescu, O; Gerecitano, J; Hamelers, R; Hamlin, P; Lin, D; Moskowitz, C; Neylon, E; O'Connor, OA; Pappanicholaou, J; Portlock, C; Sarasohn, D; Straus, D; Wright, J; Zelenetz, AD; Zhang, Z | 1 |
| Bacovsky, J; Langova, K; Minarik, J; Ordeltova, M; Pika, T; Scudla, V | 1 |
| Littmann, L; Lüftenegger, D; Rössner, S; Schubert, U; Steinkasserer, A; Zinser, E | 1 |
| Bodkin, D; Chiappori, A; Eton, O; Favis, R; Fenton, D; Halmos, B; Hirsh, V; Liu, H; Lynch, TJ; Middleman, EL; Shepherd, FA; Trepicchio, WL | 1 |
| Ahmed, M; Al-Dayel, F; Al-Kuraya, KS; Bavi, P; Hussain, AR; Jehan, Z; Munkarah, A; Uddin, S | 1 |
| Alonso Vence, N; Bello Lopez, JL; Bendaña Lopez, A; Diaz Arias, J; Fraga Rodriguez, M; Sobas, MA | 1 |
| Grandis, JR; Johnson, DE; Leeman-Neill, RJ; Li, C; Man, DS; Sen, M; Zang, Y | 1 |
| Bolen, J | 1 |
| Dewar, MR; Ghaffari, S; Grassian, A; Jagani, Z; Khosravi-Far, R; Kutok, JL; Melet, A; Miller, K; Ren, R; Rodin, HY; Santos, T; Song, K; Wu, C; Yeckes-Rodin, H | 1 |
| Bahlis, NJ; Barr, PM; Cooper, BW; Dowlati, A; Fu, P; Gerson, SL; Horvath, N; Koc, ON; Lazarus, HM; Snell, MR | 1 |
| Brunetti, AE; Cafforio, P; Dammacco, F; De Matteo, M; Maiorano, E; Silvestris, F | 1 |
| Bukowski, RM; Burk, R; Ganapathi, MK; Ganapathi, R; Grabowski, DR; Hill, J; Rybicki, LR; Vaziri, SA | 1 |
| Arkenbout, EK; Deming, CB; Hansen, BS; Hiroi, T; McDevitt, MA; Myers, TJ; Rade, JJ; Zhao, H | 1 |
| Alloway, RR; Everly, JJ; Walsh, RC; Woodle, ES | 1 |
| Dreyling, M; Issels, R; Lorenz, M; Milani, V; Pastore, A; Rieken, M; Weinkauf, M | 1 |
| Badros, A; Baer, MR; Burger, AM; Egorin, MJ; Espinoza-Delgado, I; Goloubeva, O; Grant, S; Harris, C; Holleran, JL; Kolla, SS; Niesvizky, R; Philip, S; Wright, JJ; Zwiebel, J | 1 |
| Gu, B; Liu, Y; Qiu, H; Ruan, C; Shi, X; Sun, A; Tang, X; Wu, D; Xue, S; Zhou, H | 1 |
| Corso, A; Lazzarino, M; Mangiacavalli, S; Pascutto, C; Varettoni, M; Zappasodi, P | 1 |
| Gerecitano, J | 1 |
| Cvek, B | 2 |
| Biesma, B; Bosquée, L; Chan, KC; De Marinis, F; Gans, S; Germonpré, P; Gervais, R; Lee, JS; Makhson, A; Manikhas, G; Morgan, B; Park, K; Planchard, D; Ramlau, R; Reck, M; Scagliotti, GV; Szczesna, A; Vansteenkiste, J; von Pawel, J; Zhu, Y | 1 |
| Fukushima, T; Hirose, Y; Iwao, H; Masaki, Y; Miki, M; Nakajima, A; Sakai, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
| Chou, T; Hirose, T; Igarashi, N; Imai, Y; Ishiguro, T; Nemoto, K | 1 |
| Bult, H; De Meyer, GR; Herman, AG; Martinet, W; Van Herck, JL; Vrints, CJ | 1 |
| De Biasi, M; Rezvani, K; Teng, Y | 1 |
| Avezza, F; Canta, A; Carozzi, VA; Cavaletti, G; Ceresa, C; Chiorazzi, A; Crippa, L; Gilardini, A; Marmiroli, P; Meregalli, C; Oggioni, N | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Haessler, J; Nair, B; Shaughnessy, JD; van Rhee, F; Waheed, S; Zhou, Y | 1 |
| Andersen, RJ; Kennah, M; Krystal, G; Mui, AL; Nodwell, M; Ong, CJ; Yau, TY | 1 |
| Gu, L; Kirshner, J; Lerro, K; Lilenbaum, R; Vokes, E; Wang, X | 1 |
| Schiff, D; van den Bent, MJ; Wen, PY | 1 |
| Dave, SD; Everly, MJ; Feroz, A; Idica, A; Kaneku, H; Khemchandani, SI; Modi, PR; Shankar, V; Terasaki, PI; Trivedi, HL; Trivedi, VB; Vanikar, AV | 2 |
| Baryshnikov, AIu; Golenkov, AK; Klinushkina, EF; Kogarko, IN; Liubimova, NV; Mitina, TA | 1 |
| Aghajanian, C; Blessing, JA; Darcy, KM; DeGeest, K; Mannel, RS; Reid, G; Riordan, W; Rotmensch, J; Rubin, SC; Schilder, RJ | 1 |
| Alyea, EP; Antin, JH; Armand, P; Cutler, C; Garcia, M; Ho, VT; Kim, HT; Koreth, J; Ritz, J; Soiffer, RJ; Stevenson, KE | 1 |
| Gastl, G; Gunsilius, E; Kern, J; Sarg, B; Steurer, M; Untergasser, G; Zenzmaier, C | 1 |
| Focosi, D | 1 |
| Barbarousi, D; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Grapsa, I; Kastritis, E; Matsouka, C; Migkou, M; Primenou, E; Roussou, M; Terpos, E; Zagouri, F | 1 |
| Daroczi, B; Dicker, AP; Kari, G; Ren, Q; Rodeck, U | 1 |
| Afar, DE; Balasa, B; Barlogie, B; Chao, D; Dillon, M; Ganguly, B; Garg, TK; Li, X; Moreno-Bost, AM; Rice, AG; Shaughnessy, JD; Shi, J; Stone, MK; Szmania, SM; van Abbema, AM; van Rhee, F; Yaccoby, S; Yun, R; Zhan, F | 1 |
| Anderson, KC; Boral, A; Facon, T; Harousseau, JL; Irwin, D; Neuwirth, R; Richardson, PG; Schuster, MW; Sonneveld, P; Stadtmauer, EA; Vogl, DT | 1 |
| Endo, T; Fujimoto, K; Goto, H; Kasahara, I; Koike, T; Nishio, M; Sato, N; Takeda, Y; Yamaguchi, K; Yamamoto, S | 1 |
| Dun, X; Fu, W; Hou, J; Yuan, Z; Zhang, C | 1 |
| Buda, G; Cecconi, N; Galimberti, S; Orciuolo, E; Petrini, M | 1 |
| Antognoni, F; Barale, R; Brunori, M; Buda, G; Galimberti, S; Gentile, M; Maggini, V; Martino, A; Morabito, F; Orciuolo, E; Petrini, M; Rossi, AM | 1 |
| Carloss, H; Druck, M; Kerr, R; Lee, M; Lopez, J; Noga, SJ; Sood, R; Walters, IB | 1 |
| Bai, QX; Bai, YN; Chen, XQ; Gu, HT; Liang, R; Shu, MM; Wang, WQ; Wang, YW; Yang, L; Zhang, T; Zhang, YQ; Zhu, HF | 1 |
| Bayik, M; Cetiner, M; Kaygusuz, I; Kocakaya, O; Tezcan, H; Uzay, A | 1 |
| Anderson, RD; Chao, NJ; Chute, JP; Davis, PH; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Horwitz, ME; Keogh, G; Long, GD; Moore, JO; Neuwirth, R; Rizzieri, D; Sullivan, KM; Sutton, LM | 1 |
| Berges, C; Daniel, V; Fuchs, D; Haberstock, H; Naujokat, C; Opelz, G; Sadeghi, M | 1 |
| Ahmed, A; Al-Zoubi, A; Braun, T; Brozo, C; Campagnaro, E; Jakubowiak, AJ; Kaminski, MS; Kendall, T; Khaled, Y; Mineishi, S; Talpaz, M | 1 |
| Orlowski, RZ; Shah, JJ | 1 |
| Anderson, KC; Carreau, N; Ghobrial, IM; Hideshima, T; Laubach, JP; Mahindra, A; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL | 1 |
| Barone, E; Mancuso, C | 1 |
| Bachmann, AS; Clerc, J; Driessen, C; Dudler, R; Florea, BI; Groll, M; Huber, R; Kaiser, M; Kraus, M; Overkleeft, HS | 1 |
| Cippitelli, M; Fionda, C; Iannitto, ML; Malgarini, G; Santoni, A; Soriani, A | 1 |
| Ahnert, P; Bauer, M; Bockmuehl, U; Erdal, H; Ganten, TM; Holland, H; Koschny, R; Krupp, W; Meixensberger, J; Stremmel, W; Sykora, J; Walczak, H | 1 |
| Belt, R; Boral, AL; Dakhil, SR; de Vos, S; Flowers, CR; Glenn, M; Goy, A; Gregory, SA; Hart, L; Holladay, C; Knapp, M; McLaughlin, P; Patel-Donnelly, D; Saleh, MN; Zhang, T | 1 |
| Grant, S | 2 |
| Beguin, Y; Bonnet, C; de Leval, L; Deprijck, B; Fillet, G | 1 |
| Cai, Z; He, J; Huang, H; Huang, W; Li, L; Lin, M; Luo, Y; Shi, J; Wei, G; Wu, W; Xie, W; Xue, X; Ye, X; Zhang, J; Zheng, W | 1 |
| Bekaii-Saab, T; Byrd, JC; Culler, K; Grever, MR; Lesinski, GB; Lucas, DM; Ramaswamy, B; Ruppert, AS; Schaaf, LJ; Shapiro, CL; Wilkins, D; Wright, JJ; Young, DC | 1 |
| Anargyrou, K; Carney, W; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Hamer, P; Kastritis, E; Leitzel, K; Lipton, A; Migkou, M; Shrivastava, V; Terpos, E | 1 |
| San Miguel, JF | 2 |
| Alsina, M; Anderson, KC; Avigan, DE; Dalton, W; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Knight, R; Lunde, LE; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL; Warren, DL; Weller, E | 1 |
| San Miguel, J | 1 |
| DeMartino, GN | 1 |
| Hamlin, P; MacGregor-Cortelli, B; Moskowitz, CH; Muzzy, J; O'Connor, O; Schenkein, DP; Straus, D; Trehu, E; Wright, J; Zelenetz, AD | 1 |
| Stadtmauer, EA | 1 |
| Mitsiades, CS | 2 |
| Anderson, KC; Bandi, M; Bianchi, G; Brahmandam, M; Carrasco, R; Chauhan, D; Hideshima, T; Jaye, DL; Kumar, SK; Mitsiades, C; Munshi, N; Podar, K; Raje, N; Richardson, P; Singh, AV; Tai, YT | 1 |
| Avcu, F; Aydur, E; Baran, Y; Basal, S; Beyzadeoglu, M; Dirican, B; Goktas, S; Pekel, A; Ural, AU; Yazici, S | 1 |
| Bousquet-Dubouch, MP; Burlet-Schiltz, O; Gallay, N; Manenti, S; Matondo, M; Monsarrat, B; Payrastre, B; Recher, C; Uttenweiler-Joseph, S | 1 |
| Ciechanover, A; Navon, A | 1 |
| Dowling, M; Hayat, A; Hayden, P; Meenaghan, T; Murray, M; O'Dwyer, M | 1 |
| Conticello, C; Di Raimondo, F | 1 |
| Agyin, JK; Nair, HB; Roy, SS; Santhamma, B; Tekmal, RR | 1 |
| Hou, J; Jiang, H; Li, YH; Xi, H; Zhu, R; Zou, JF | 1 |
| Chen, ST; Gaffney, KJ; Louie, SG; Petasis, NA; Schönthal, AH; Thomas, S | 1 |
| Decaux, O; Karras, A | 1 |
| Cavero, S; Español, I; Funes, C; García, MC; Ibáñez, J; Iturbe, T; López, MD; Martínez, A; Tejedor, A | 1 |
| Barlogie, B; Chen, L; Entin, I; Epstein, J; Shaughnessy, JD; Wang, S; Wu, X; Xiong, W; Yaccoby, S; Zhan, F; Zhou, Y | 1 |
| Chen, XY; Jiang, XX; Shen, ZX; Wu, WL; Zhang, QL; Zhao, WL | 1 |
| Basler, M; Beck, U; Groettrup, M; Lauer, C | 1 |
| Baritaki, S; Berenson, J; Bonavida, B; Palladino, M; Yeung, K | 1 |
| Aulino, J; Baumann, J; Burkey, B; Chung, CH; Cmelak, AJ; Gilbert, J; Hatakeyama, H; Muldowney, NJ; Murphy, BA; Netterville, J; Parker, J; Shyr, Y; Sinard, R; Slebos, RJ; Yarbrough, WG | 1 |
| Aichberger, KJ; Baumgartner, C; Cerny-Reiterer, S; Ferenc, V; Gleixner, KV; Gruze, A; Kneidinger, M; Mayerhofer, M; Mirkina, I; Peter, B; Pickl, WF; Sillaber, C; Valent, P | 1 |
| Duan, MH; Jiao, L; Li, J; Shen, T; Zhang, W; Zhao, YQ; Zhou, DB | 1 |
| Alexeeva, J; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Kastritis, E; Khuageva, NK; Kropff, M; Liu, K; Masszi, T; Mateos, MV; Petrucci, MT; Richardson, PG; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; van de Velde, H | 1 |
| Bargetzi, M; Heizmann, M; Kotrubczik, N; Moosmann, P; Wernli, M | 1 |
| Akahane, D; Gotoh, M; Kitahara, T; Ohyashiki, K; Sakuta, J | 1 |
| Gozzetti, A | 1 |
| Anderson, KC; Carreau, NA; Chauhan, D; Ghobrial, IM; Hideshima, T; Laubach, JP; Mahindra, A; Mitsiades, CS; Munshi, NC; Raje, N; Richardson, PG; Schlossman, RL | 1 |
| Dunner, K; McConkey, DJ; Zhu, K | 1 |
| Araujo, C; Attal, M; Avet-Loiseau, H; Caillot, D; Danho, C; Dib, M; Dorvaux, V; Fruchart, C; Garderet, L; Harousseau, JL; Hulin, C; Huynh, A; Kolb, B; Lenain, P; Marit, G; Mary, JY; Mathiot, C; Moreau, P; Pégourié, B; Randriamalala, E; Roussel, M; Royer, B; Stoppa, AM | 1 |
| Brancolini, C; Florean, C; Foti, C; Gustincich, S; Pezzutto, A; Roncaglia, P; Tomasella, A | 1 |
| Chang, DZ; Chiang, J; Delasalle, K; Fang, W; Forman, A; Garcia, MK; Guo, Y; Lu, J; Romaguera, J; Wang, M; Yi, Q; Zhou, Y | 1 |
| Bernardeschi, P; Ferreri, MI; Fiorentini, G; Giustarini, G; Montenora, I; Pirrotta, MT; Simi, P | 1 |
| Böll, B; Chalaris, A; Eichenauer, DA; Engert, A; Hansen, HP; Krell, HW; Reiners, KS; Rose-John, S; Simhadri, VL; Simhadri, VR; Vahdat, AM; von Strandmann, EP; Wiegmann, K | 1 |
| Attal, M; Bourin, P; Laroche, M; Lemaire, O | 1 |
| Benavidez, D; Eliseev, RA; Shapovalov, Y; Zuch, D | 1 |
| Bacovsky, J; Langova, K; Minarik, J; Ordeltova, M; Pika, T; Scudla, V; Zemanova, M | 1 |
| Almasan, A; Banerjee, AK; Fairchild, RL; Gasparian, AV; Gorbachev, AV; Gudkov, AV; Gurova, KV; Komarov, AP; Neznanov, N; Neznanova, L | 1 |
| Bitter, M; Brunvand, MW | 1 |
| Downey, HD; Dunn, D; Finn, JD; High, KA; Hui, D; Mingozzi, F; Pien, GC; Zhou, S | 1 |
| Harvey, RD; Lonial, S; Nettles, J; Sun, SY; Wang, B | 1 |
| Dereure, O; Guillot, B; Michot, C | 1 |
| Khong, T; Monaghan, K; Smith, G; Spencer, A | 1 |
| Chen, KF; Chen, PJ; Cheng, AL; Lee, SS; Liu, TH; Yu, HC | 1 |
| D'Auria, F; Dammacco, F; Di Pietro, G; Ditonno, P; Gnoni, A; Guarini, A; Mangialardi, G; Moschetta, M; Musto, P; Ria, R; Ribatti, D; Ricciardi, MR; Vacca, A | 1 |
| Kanda, Y | 1 |
| Ozaki, S | 1 |
| Belloni, D; Caligaris-Cappio, F; Dell'Antonio, G; Ferrarini, M; Ferrero, E; Foglieni, C; Veschini, L | 1 |
| Buda, G; Orciuolo, E; Pelosini, M; Petrini, M | 1 |
| Becker, P; Bensinger, WI; Camacho, E; Capo, G; Crowley, J; Durie, BG; Hilger, J; Irwin, D; Jagannath, S; Mazumder, A; McKinley, M; Potts, P; Vescio, R; Vesole, DH; Wolf, J | 1 |
| Ahn, JS; Kim, HJ; Kim, YK; Lee, JH; Lee, JJ; Moon, JH; Sohn, SK; Yang, DH | 1 |
| Bruserud, O; Hatfield, KJ; Kalland, KH; Kittang, AO; Oyan, AM; Reikvam, H | 1 |
| Anasetti, C; Dalton, W; Meads, M; Parquet, N; Perez, LE | 1 |
| Belardo, G; Piva, R; Santoro, MG | 1 |
| Bhattacharya, N; Döhner, H; Führer, M; Idler, IS; Mertens, D; Sarno, A; Stilgenbauer, S; Zenz, T | 1 |
| Berenson, JR; Campbell, RA; Chen, H; Li, ZW; Sanchez, E; Shalitin, D; Steinberg, J | 1 |
| Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P | 1 |
| Lupfer, C; Pastey, MK; Patton, KM | 1 |
| Babcock, T; Bannerman, B; Cao, Y; Hatsis, P; Kupperman, E; Robertson, R; Silva, MD; Terkelsen, J; Williamson, MJ; Xia, C; Yu, L | 1 |
| Anderson, KC; Buon, L; Charalambous, E; Chauhan, D; Clynes, M; Daskalaki, E; Hayden, PJ; Hideshima, T; Kotoula, V; McMillin, DW; Mitsiades, CS; Mitsiades, N; Munshi, NC; O'Gorman, P; Ooi, MG; Raje, NS; Richardson, PG | 1 |
| Alsina, M; Beg, AA; Boulware, D; Chen, DT; Dalton, WS; Hazlehurst, LA; Mathews, L; Oliveira, V; Shain, KH; Villagra, A; Wang, X; Yarde, DN | 1 |
| Aggarwal, BB; Pandey, MK; Sung, B | 1 |
| Amschler, K; Erpenbeck, L; Pletz, N; Schön, M; Schön, MP; Wallbrecht, K | 1 |
| Dimopoulos, MA; Terpos, E | 1 |
| Alarid, ET; Casa, AJ; Ellison-Zelski, SJ; Lee, AV; Powers, GL | 1 |
| Veselý, K | 1 |
| Adam, Z; Cermáková, Z; Feit, J; Hájek, R; Krejcí, M; Mayer, J; Pour, L; Vasků, V | 1 |
| Bandi, P; Booth, CJ; Chisari, FV; Garcia, ML; Robek, MD | 1 |
| Li, ZY; Lu, QX; Pan, XY; Sun, HY; Wu, SH; Xu, KL | 1 |
| Adam, Z; Buchler, T; Hajek, R; Koza, V; Kralova, D; Krejci, M; Krivanova, A; Mayer, J; Pour, L; Sandecka, V; Schutzova, M; Scudla, V; Tothova, E; Vorlicek, J; Zahradova, L | 1 |
| Atadja, P; Crusoe, E; de Alava, E; Fernández-Lázaro, D; Garayoa, M; Hernández-Iglesias, T; Maiso, P; Ocio, EM; Pandiella, A; San-Miguel, JF; San-Segundo, L; Shao, W; Vilanova, D; Yao, YM | 1 |
| Caravita, T; de Fabritiis, P; Dentamaro, T; Perrotti, A; Siniscalchi, A; Tatangelo, P | 1 |
| Huang, BH; Li, J; Su, C; Zeng, LJ; Zhao, Y | 1 |
| Berenson, JR; Bonavida, B; Chen, H; Li, M; Li, ZW; Sanchez, E; Shen, J; Steinberg, JA; Wang, C | 1 |
| Dou, QP; Lonardo, F; Pass, HI; Puliyappadamba, VT; Rishi, AK; Ruckdeschel, JC; Sharma, S; Tarca, A; Wali, A; Wang, Y; Yang, H | 1 |
| Asmar, L; Barrera, D; Boehm, KA; Boston, J; Boyd, T; Cochran, EW; Di Bella, N; Dien, PY; Kolibaba, K; Lyons, R; Raju, R; Schlegel, PJ; Taetle, R; Vukelja, SJ; Wang, Y | 1 |
| Bölke, E; Bruch-Gerharz, D; Budach, W; Buhren, BA; Fenk, R; Gerber, PA; Haas, R; Homey, B; Reifenberger, J | 1 |
| Alessandrino, EP; Barbarano, L; Bernasconi, P; Cafro, AM; Carella, AM; Corso, A; Grillo, G; Lazzarino, M; Mangiacavalli, S; Montalbetti, L; Morra, E; Pascutto, C; Spriano, M; Varettoni, M | 1 |
| Cherem, L; Kahan, BD; Kaposztas, Z; Katz, SM; Van Buren, CT | 1 |
| Dong, X; Gao, SL; Jiang, RY; Peng, JP; Wang, J; Wu, YL; Xie, QP; Zhan, YC | 1 |
| Chang, CC; Chang, TC; Chen, CH; Golubovskaya, VM; Hsu, C; Ko, BS; Kuo, CC; Liou, JY; Liu, CC; Shen, TL; Shen, YC; Shyue, SK | 1 |
| Mateos, MV; San-Miguel, JF | 1 |
| Gay, F; Palumbo, A | 3 |
| Stewart, AK | 1 |
| Ghobrial, IM; Stewart, AK | 1 |
| AKIYAMA, H; KATO, I; KOBAYASHI, T; MIYAZAWA, M; NAJIMA, Y; NAKANO, M; OHASHI, K; SAKAMAKI, H; SAWADA, T; YAMASHITA, T | 1 |
| Ding, Y; Gu, J; Huang, B; Li, J; Wang, Q; Zeng, L; Zhao, Y; Zheng, D | 1 |
| Chung, JS; Do, YR; Eom, HS; Jin, JY; Kim, CS; Kim, HJ; Kim, HY; Kim, K; Kim, YK; Lee, DS; Lee, JH; Oh, SJ; Seong, CM; Suh, C | 1 |
| Dana, K; Hana, S; Jaroslav, M; Jiri, V; Lucie, K; Ludek, P; Marta, K; Martina, A; Miroslav, P; Roman, H; Tomas, B; Zdenek, A | 1 |
| Chapman, C; Rosser, A; Swallow, G; Swann, RA | 1 |
| Mehta, AB; Shah, AD; Watts, AJ; Wechalekar, AD | 1 |
| Brancolini, C | 1 |
| Armstrong, JL; Flockhart, R; Lovat, PE; Redfern, CP; Veal, GJ | 1 |
| Childs, R; Lundqvist, A; Rao, S; Su, S | 1 |
| Amiri, KI; Ayers, GD; Horton, LW; Kelley, MC; Koehler, E; Puzanov, I; Richmond, A; Sosman, JA; Su, Y; Yu, Y | 1 |
| Bauer, S; Brown, MF; Chatterjee, P; Chin, A; Duensing, A; Duensing, S; Fletcher, JA; Kuan, SF; Mühlenberg, T; Parry, JA; Rubin, BP; Seneviratne, D | 1 |
| Cho, HS; Kim, JS; Kim, KH; Kim, SJ; Kim, SY; Lee, JI; Lim, JH; Park, CG; Shin, JS; Shin, JY; Yoon, IH | 1 |
| Lin, MF; Ouyang, GF | 1 |
| Jing, HM; Ke, XY; Yang, P; Zhang, WJ | 1 |
| Azaïs, I; Brault, R; Debiais, F | 1 |
| Bakan, CE; Benson, DM; Devine, SM; Elder, P; Hamadani, M; Hofmeister, CC; Krugh, D; O'Donnell, L; Panzner, K; Smith, MK | 1 |
| Yaccoby, S | 1 |
| Kumiega, B; Skotnicki, AB; Wolska-Smoleń, T | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Caltagirone, S; Corradini, P; Crippa, C; Falco, P; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Montefusco, V; Musto, P; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Petrucci, MT; Rossi, G; Rossini, F | 1 |
| Bruserud, Ø; Ersvaer, E; Hatfield, KJ; Kittang, AO; Lassalle, P; Reikvam, H | 1 |
| Ausserlechner, MJ; Bodner, M; David, R; Geiger, K; Hagenbuchner, J; Meister, B; Obexer, P; Porto, V; Villunger, A | 1 |
| Bastida, J; Campos-Adsuar, C; Dehesa, L; Gómez-Duaso, J; Limeres-González, M | 1 |
| Gartel, AL; Pandit, B | 4 |
| Al Diab, AR; Al Momen, AK; Aleem, A; Niaz, F; Qayum, A | 1 |
| Bortolotto, A; Camargo, J; Camargo, S; Canabarro, R; Costa, C; Felicetti, J; Fernandes, S; Machuca, T; Michelon, T; Neumann, J; Perin, F; Sanchez, L; Schio, S; Sporleder, H; Tarrasconi, H | 2 |
| Gupta, S; Honig, NH; Kraus, JP; Kruger, WD; Singh, LR | 1 |
| Marchi, E; O'Connor, OA; Paoluzzi, L; Scotto, L; Seshan, VE; Zain, J | 1 |
| Blumel, S; Butos, J; Cooper, B; Dumitrescu, O; Evens, AM; Gerecitano, J; Gonen, M; Hamlin, P; Mac-Gregor Cortelli, B; Moskowitz, C; Neylon, E; O'Connor, OA; Portlock, C; Sarasohn, D; Straus, D; Vose, J; Winter, J; Wright, J; Zelenetz, AD | 1 |
| Brancolini, C; Potu, H; Sgorbissa, A | 1 |
| Allan, EK; Bhatia, R; Chu, S; Crawford, L; Heaney, NB; Holyoake, TL; Irvine, AE; Jorgensen, HG; Kazmi, SM; Pellicano, F; Zhang, B | 1 |
| Handa, H; Higeta, D; Hirato, J; Karasawa, M; Koiso, H; Mawatari, M; Murakami, H; Nojima, Y; Osaki, Y; Saito, T; Sekigami, T; Tahara, K; Tsukamoto, N; Uchiumi, H; Yokohama, A | 1 |
| Pondrom, S | 1 |
| Attal, M; Avet-Loiseau, H; Belhadj, K; Dorvaux, V; Fermand, JP; Garderet, L; Hulin, C; Minvielle, S; Moreau, P; Soulier, J; Yakoub-Agha, I | 1 |
| Arvanitis, A; Caulder, E; Combs, AP; Favata, M; Fridman, JS; Kelley, JA; Li, J; Newton, R; Rogers, JD; Scherle, PA; Solomon, KA; Sparks, RB; Thomas, B; Vaddi, K; Wen, X | 1 |
| Einsele, H | 2 |
| Berkers, CR; Ovaa, H | 1 |
| Li, J; Su, C; Wang, HH; Zeng, LJ; Zhao, Y | 1 |
| Bauer, F; Dasanu, CA; Reale, MA | 1 |
| Dreyling, M; Hartmann, E; Hutter, G; Rosenwald, A; Weinkauf, M; Zimmermann, Y | 1 |
| Huan, C; Zenilman, ME | 1 |
| Dimopoulos, MA; Gillmore, JD; Hawkins, PN; Kastritis, E; Merlini, G; Palladini, G; Perfetti, V; Wechalekar, AD | 1 |
| Beksac, M; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Ketterer, N; Kropff, M; Ludwig, H; Mendeleeva, L; Morgan, G; Palumbo, A; Plesner, T; San Miguel, J; Shpilberg, O; Sondergeld, P; Sonneveld, P; Zweegman, S | 1 |
| Adamo, V; Bronte, G; Cicero, G; Fulfaro, F; Gebbia, N; Rizzo, S; Russo, A | 1 |
| Calinski, D; Chanan-Khan, AA; Li, F; Ling, X; Zhou, M | 1 |
| Campion, L; Charbonnel, C; Clément, M; Decaux, O; Gouraud, W; Loiseau, HA; Magrangeas, F; Minvielle, S | 1 |
| Blaskovits, FM; Carson, WE; Chan, AN; Grignol, VP; Guenterberg, KD; Lesinski, GB; Mundy, BL; Nuovo, GJ; Raig, ET; Young, GS; Zimmerer, JM | 1 |
| Lokhorst, HM; Minnema, MC; van de Donk, NW; van der Spek, E | 1 |
| Duong, TQ; Jung, I; Keller, C; Kilcoyne, A; Lin, AL; Morgan, WW; Nelon, LD; Nowak, BM; Ohshima-Hosoyama, S; Prajapati, SI; Rubin, BP; Samano, AK; Taniguchi, E; Togao, O; Whitney, TG | 1 |
| Chatta, G; Chen, E; Cooper, M; Egorin, M; Karol, M; Neuwirth, R; Rader, M; Ramalingam, S; Ramanathan, RK; Riordan, W; Trepicchio, W; Venkatakrishnan, K; von Moltke, L | 1 |
| Beckwith, LG; Carson, KR; Mehta, J | 1 |
| Barrett, JR; Bhalla, KN; Erickson, B; Ganapathy, V; Gopal, E; Hill, WD; Jackson, WH; Periyasamy-Thandavan, S; Raney, L; Samaddar, JS; Schoenlein, PV | 1 |
| Dick, LR; Fleming, PE | 1 |
| Anglicheau, D; Candon, S; Hermine, O; Legendre, C; Leruez, M; Loupy, A; Martinez, F; Nochy, D; Pallet, N; Rabant, M; Sberro-Soussan, R; Snanoudj, R; Suberbielle-Boissel, C; Thervet, E; Zuber, J | 1 |
| Alden, CL; Cardoza, K; Csizmadia, E; Csizmadia, V; Fedyk, ER; Gallacher, M; Kadambi, VJ; O'Brien, L; Raczynski, A; Silverman, L; Simpson, C | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Hoering, A; Nair, B; Shaughnessy, JD; Szymonifka, J; van Rhee, F; Waheed, S | 1 |
| Benedetti-Panici, P; Cognetti, F; Greggi, S; Mariani, G; Pasquini, L; Petronelli, A; Petrucci, E; Saulle, E; Scambia, G; Testa, U | 1 |
| Chen, C; Eckhardt, SG; Pugh, TJ; Raben, D; Rabinovitch, R; Rusthoven, KE; Swing, R | 1 |
| Czuczman, MS; Reddy, N | 1 |
| Hou, J; Jiang, H; Ma, YL | 1 |
| Kulharya, A; Shah, R; Ustun, C; Yuan, J | 1 |
| El-Cheikh, J; Harousseau, JL; Mohty, B; Mohty, M; Moreau, P; Yakoub-Agha, I | 1 |
| Anderson, K; Laubach, JP; Mitsiades, C; Richardson, PG; Schlossman, RL | 1 |
| Anderson, KC; Badros, A; Chuma, S; Ghobrial, IM; Harris, B; Hong, F; Kunsman, J; Leduc, R; Matous, J; Padmanabhan, S; Richardson, PG; Rourke, M; Sam, A; Treon, SP; Warren, D; Weller, E | 1 |
| Alloway, RR; Arend, LJ; Brailey, P; Everly, JJ; Govil, A; Mogilishetty, G; Rike, AH; Roy-Chaudhury, P; Walsh, RC; Woodle, ES | 1 |
| Chang, H; Hsiao, SC; Pei, SN; Wang, MC | 1 |
| Granberg, D; Hassan, S; Larsson, DE; Oberg, K; Wickström, M | 1 |
| Chow, W; Cristea, M; Doroshow, JH; Frankel, P; Gaur, S; Koczywas, M; Lim, D; Luu, T; Margolin, K; Morgan, RJ; Somlo, G; Yen, Y | 1 |
| Bannerman, B; Berger, A; Blank, J; Bolen, J; Bruzzese, F; Cao, Y; Dick, L; Fitzgerald, M; Fleming, P; Garcia, K; Hales, P; Kupperman, E; Lee, EC; Liu, J; Manfredi, M; Rolfe, M; Tsu, C; Yang, Y; Yu, J; Yu, L | 1 |
| Budinger, GR; Jain, M; Mutlu, GM; Weiss, CH | 1 |
| Abken, H; Brinkmann, K; Coutelle, O; Hombach, AA; Kashkar, H; Krönke, M; Mauch, C; Schmidt, P; Seeger, JM; Wagner-Stippich, D; Zigrino, P | 1 |
| Achatz, G; Luger, EO; Radbruch, A; Renz, H; Wegmann, M; Worm, M | 1 |
| Alé, A; Bruna, J; Monbaliu, J; Navarro, X; Silverman, L; Udina, E; Vilches, JJ; Vynckier, A | 1 |
| Aoki, K; Eda, H; Kato, S; Marumo, K; Ohkawa, K; Okawa, Y; Takada, K; Tanaka, T | 1 |
| Chen, JF; Jin, J | 1 |
| Basak, GW; Bil, J; Bojarczuk, K; Dabrowska-Iwanicka, A; Golab, J; Jakobisiak, M; Nowis, D; Sułek, K; Winiarska, M | 1 |
| Adachi, S; Ashihara, E; Hatake, K; Hirashima, M; Horiike, S; Kobayashi, T; Kuroda, J; Oomizu, S; Sasaki, N; Takagi, T; Taniwaki, M; Taniyama, A; Terui, Y; Yamamoto, M; Yamauchi, A | 1 |
| Alfonsi, E; Corso, A; De Amici, M; Lazzarino, M; Lozza, A; Mangiacavalli, S; Varettoni, M | 1 |
| Buller, B; Chopp, M; Jiang, J; Jiang, Y; Liu, X; Morris, D; Zhang, L; Zhang, ZG; Zhao, D | 1 |
| Celis, E; Lee, S; Sayers, TJ; Yagita, H | 1 |
| Richards, T; Weber, D | 1 |
| Burt Nabors, L; Carson, KA; Desideri, S; Grossman, SA; Lesser, G; Mikkelsen, T; Olson, JJ; Phuphanich, S; Rosenfeld, S; Supko, JG | 1 |
| Chen, CC; D'Andrea, A; Hu, L; Kesari, S; Kung, A; Ng, K; Nitta, M | 1 |
| Blackwell, TS; Kalomenidis, I; Karabela, SP; Kollintza, A; Magkouta, S; Moschos, C; Psallidas, I; Roussos, C; Sherrill, TP; Stathopoulos, GT; Theodoropoulou, P | 1 |
| Beck, JF; Becker, S; Gressmann, S; Schmudde, M; Sonnemann, J; Wittig, S | 1 |
| Bocchia, M; Defina, M; Fabbri, A; Gozzetti, A; Lauria, F; Marchini, E; Oliva, S | 1 |
| Dasmahapatra, G; Dent, P; Fisher, RI; Friedberg, J; Grant, S; Kramer, L; Lembersky, D | 1 |
| Lu, Q; Lu, SF | 1 |
| Assereto, S; Bonetto, A; Bonuccelli, G; Bruno, C; Cilli, M; Gazzerro, E; Lisanti, MP; Minetti, C; Pistorio, A; Scarfì, S; Sotgia, F; Zara, F | 1 |
| Agirre, X; Albero, MP; Andreu, EJ; Franch, L; Ivorra, C; Pérez-Roger, I; Poch, E; Prosper, F; Vaquer, JM; Villanueva, JJ | 1 |
| Hoevenaren, A; Hoevenaren, IA; Levenga, H; Minnema, MC; Raymakers, R; van Vulpen, LF | 1 |
| Acharya, M; Burris, H; Chatta, G; Karol, M; Keith Stewart, A; Lonial, S; Mohrbacher, AF; Neuwirth, R; Reece, DE; Riordan, WJ; Shustik, C; Sullivan, D; Venkatakrishnan, K; von Moltke, LL; Zannikos, P | 1 |
| Boccadoro, M; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Crippa, C; De Rosa, L; Drandi, D; Ferrero, S; Grasso, M; Guglielmelli, T; Ladetto, M; Liberati, AM; Musto, P; Pagliano, G; Palumbo, A; Passera, R; Pisani, F; Pregno, P; Santo, L | 1 |
| Chitambar, CR; Purpi, DP | 1 |
| Chen, S; Deng, X; Khuri, FR; Li, C; Lonial, S; Sun, SY; Yue, P | 1 |
| Chaudhary, R; Ghose, A; Taj, A; Tariq, Z | 1 |
| Böhmig, GA; Drach, J; Geyeregger, R; Haidinger, M; Kikić, Z; Körmöczi, GF; Prikoszovich, T; Säemann, MD; Wahrmann, M; Weichhart, T | 1 |
| Aguayo-Leiva, I; Carrillo-Gijon, R; Jaén-Olasolo, P; Vano-Galvan, S | 1 |
| de Maat, MP; Leebeek, FW; Libourel, EJ; Sonneveld, P; van der Holt, B | 1 |
| Gunsilius, E; Mitterer, M; Spizzo, G | 1 |
| Bang, SM; Chung, J; Do, YR; Jin, JY; Joo, YD; Kang, HJ; Kim, BS; Kim, HY; Kim, K; Lee, DS; Lee, GW; Lee, JH; Lee, JJ; Lee, MH; Lee, SS; Park, J; Ryoo, HM; Shim, H; Suh, C; Yoon, SS | 1 |
| Brocca, CM; Coppi, MR; Giannotta, A; Loseto, G; Mele, G; Melpignano, A; Pinna, S; Quarta, G | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kikuchi, J; Mitsunaga, K; Noborio-Hatano, K; Nobuyoshi, M; Ozawa, K; Shimizu, R; Wada, T | 1 |
| Ludwig, H; Zojer, N | 1 |
| Dingli, D; Rajkumar, SV | 1 |
| Bocchia, M; Chitarrelli, I; Defina, M; Fabbri, A; Gozzetti, A | 1 |
| Balkaran, S; Daudignon, A; Fernandez, J; Hautecoeur, A; Hivert, B; Lai, JL; Leleu, X; Lepelley, P; Morel, P; Poulain, S; Rossignol, J; Roumier, C; Soenen, V; Wemeau, M | 1 |
| Aomatsu, K; Arao, T; Fujita, Y; Kaneda, H; Kotani, Y; Kudo, K; Matsumoto, K; Nishimura, Y; Nishio, K; Saijo, N; Tamura, D; Tanaka, K; Watanabe, T | 1 |
| Abdulkadyrov, KM; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H | 1 |
| Chen, C; Dimopoulos, MA; Gavriatopoulou, M; Kastritis, E; Treon, SP | 1 |
| Heider, U; Kaiser, M; Kleeberg, L; Rademacher, J; Sezer, O; von Metzler, I | 1 |
| Eeltink, CM; Huls, G; Kersten, MJ; Kneppers, E; Koedam, J; Lokhorst, HM; Minnema, MC; Raymakers, RA; Schaafsma, MR; Sonneveld, P; van Oers, MH; Vellenga, E; Wijermans, PW; Wittebol, S; Zweegman, S | 1 |
| Jagannath, S; Mazumder, A; Vesole, DH | 1 |
| Guo, H; Mao, J; Sun, C; Wang, J; Zhou, X | 1 |
| David, CS; Patel, R; Rajagopalan, G; Theuer, JE; Tilahun, AY | 1 |
| Chang, J; Cho, SH; Kang, W; Kim, JS; Kim, SK; Park, MS | 1 |
| Bernard, SA; Calvo, BF; Caskey, LS; Chakravarthy, AB; Chan, E; Goldberg, RM; Ivanova, A; Kim, HJ; Myers, MO; O'Neil, BH; Raftery, L; Sanoff, HK; Tepper, JE; Wise, PE | 1 |
| Baou, M; Butterworth, M; Cohen, GM; Dinsdale, D; Dyer, MJ; Eldering, E; Kohlhaas, SL; Majid, A; Vogler, M; Walewska, R | 1 |
| Adachi, T; Hayakawa, F; Iwasaki, T; Kurahashi, S; Narimatsu, H; Sawamoto, A; Sugimoto, T; Sugiura, I; Suzuki, H; Suzuki, K | 1 |
| Anderson, KC; Bandi, M; Bianchi, G; Calabrese, E; Carrasco, RD; Cirstea, D; Ecsedy, J; Görgün, G; Hideshima, T; Hu, Y; Ikeda, H; Mani, M; Munshi, N; Nahar, S; Perrone, G; Raje, N; Richardson, P; Santo, L; Tai, YT; Zheng, M | 1 |
| He, Q; Lin, M; Luo, P; Shen, J; Wang, Z; Yang, B; Zhu, D | 1 |
| Anderson, KC; Avigan, DE; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, AJ; Joyce, R; Kaster, S; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Mazumder, A; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, DL; Weller, E; Xie, W | 1 |
| Bambi, F; Barti-Juhasz, H; Bussolari, R; Cafarelli, L; Casali, C; Conte, P; De Santis, G; Dominici, M; Frassoldati, A; Grisendi, G; Horwitz, EM; Morandi, U; Paolucci, P; Petak, I; Rasini, V; Rossi, G; Scarabelli, L; Spano, C; Tagliazzucchi, M; Veronesi, E | 1 |
| Goldschmidt, H; Ho, AD; Schmitt, S | 1 |
| Hou, KZ; Liu, J; Liu, YP; Qu, JL; Qu, XJ; Xu, L; Zang, Y | 1 |
| Adam, Z; Germáková, Z; Hájek, R; Kovárová, L; Krejcí, M; Kren, L; Krivanová, A; Mardová, J; Mayer, J; Moulis, M; Nedbálková, M; Pour, L; Stepánková, S; Svobodová, I; Veselý, K; Zahradová, L | 1 |
| Hatzidaki, E; Karagiannaki, A; Papandreou, CN; Patrikidou, A; Stathakis, NE; Tsapakidis, K; Voutsadakis, IA | 1 |
| Dasanu, CA | 2 |
| Benz, CC; Gibson, BW; Held, JM; Marx, C | 1 |
| Jones, DR; Liu, Y; Nagji, AS; Taylor, MD; Theodosakis, N | 1 |
| Bergsagel, PL; Chen, C; Fonseca, R; Hentz, J; Kukreti, V; Laumann, K; Leis, JF; Mikhael, JR; Pirooz, NA; Piza, JG; Reece, DE; Reeder, CB; Stewart, AK; Tiedemann, R; Trudel, S | 1 |
| Kirk, AD | 1 |
| Hara, T; Muroi, E; Ogawa, F; Sato, S; Shimizu, K; Yanaba, K; Yoshizaki, A | 1 |
| Branch, DR; Chang, H; Jayakar, J; Jiang, H; Reece, D; Saha, MN | 1 |
| Alexanian, R; Delasalle, K; Giralt, S; Wang, M | 1 |
| Kumar, S | 3 |
| Kahl, BS | 1 |
| Gleason, C; Kaufman, J; Lonial, S | 1 |
| Baldini, L; Boccadoro, M; Bringhen, S; Di Raimondo, F; Falco, P; Larocca, A; Magarotto, V; Palumbo, A | 1 |
| Caron, C; Debliquis, A; Itzhar-Baikian, N; Ojeda-Uribe, M | 1 |
| Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Caillot, D; Casassus, P; Doyen, C; Facon, T; Harousseau, JL; Hulin, C; Lenain, P; Leyvraz, S; Maisonneuve, H; Marit, G; Mathiot, C; Michallet, M; Moreau, P; Pégourié, B; Stoppa, AM | 1 |
| Chan, EY; Chan, SY; Cheung, SC; Chim, CS; Kwong, YL; Leung, YY; Liang, R; Lie, AK | 1 |
| Alvarez, M; Chizzolini, C; Goffin, L; Reith, W; Seguin-Estévez, Q | 1 |
| Bruna, J; Clapés, V; Navarro, X; Petit, J; Velasco, R; Verdú, E | 1 |
| Brooks, AD; Jacobsen, KM; Li, W; Sayers, TJ; Shanker, A | 1 |
| Ben Salem, C; Biour, M; Bouraoui, K; Elouni, B; Sakhri, J; Zamy, M | 1 |
| Kotani, T; Nakao, S; Okumura, H; Sawazaki, A; Takamatsu, H; Yamashita, T | 1 |
| Bargetzi, M; Betticher, D; Gmür, J; Gregor, M; Heim, D; Hess, U; Ketterer, N; Lerch, E; Matthes, T; Mey, U; Pabst, T; Renner, C; Taverna, C | 1 |
| Blank, JL; Burkhardt, AL; Chen, S; Chen, W; Driscoll, DL; Garcia, K; Gray, J; Hales, P; Leroy, PJ; Lightcap, ES; Lingaraj, T; Liu, XJ; Menon, S; Morgenstern, JP; Peters, T; Pickard, MD; Rabino, C; Rappoli, DM; Ringeling, J; Sappal, DS; Spelman, JJ; Yu, J | 1 |
| Anichini, A; Bolognesi, M; Delia, D; Drago, C; Kashkar, H; Lecis, D; Manzoni, L; Mastrangelo, E; Scolastico, C; Seneci, P; Walczak, H | 1 |
| Aldana-Masankgay, G; Cho, CH; Fan, D; Lee, CW; Milani, M; Sakamoto, KM; Sung, JJ; Wu, K; Wu, WK; Yu, J | 1 |
| Daniel, C; Gückel, E; Hugo, C; Meister, S; Starke, C; Stief, A; Vogelbacher, R; Voll, R; Wittmann, S | 1 |
| Aisa, Y; Iwabuchi, M; Kakimoto, T; Mihara, A; Nakazato, T; Sanada, Y; Suzuki, K | 1 |
| Canestraro, M; Cine, N; Galimberti, S; Guerrini, F; Metelli, MR; Nagy, B; Palumbo, GA; Petrini, M; Piaggi, S; Savli, H; Tibullo, D | 1 |
| Mateos, MV | 4 |
| Dimopoulos, MA; Jagannath, S; Lonial, S | 1 |
| Dhanasekaran, DN; Ha, JH; Jayaraman, M; Kim, SG; Kwak, MK; Lee, CH; Lee, S; Nam, CW; Yang, YM | 1 |
| Cao, X; Cui, Y; Littlejohn, JE; Peddaboina, C; Smythe, WR; Zhang, L | 1 |
| de Haan, CA; Drijfhout, JW; Kikkert, M; Posthuma, CC; Raaben, M; Rottier, PJ; Snijder, EJ; te Lintelo, EG; Verheije, MH | 1 |
| de Haan, CA; Grinwis, GC; Raaben, M; Rottier, PJ | 1 |
| Cavaletti, G; Jakubowiak, AJ | 1 |
| Anargyrou, K; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Kokkoris, P; Migkou, M; Terpos, E; Tsionos, K | 1 |
| Marchi, E; O'Connor, OA; Paoluzzi, L; Scotto, L; Seshan, VE; Zain, JM; Zinzani, PL | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Hoering, A; Nair, B; Petty, N; Shaughnessy, JD; Szymonifka, J; van Rhee, F; Waheed, S | 1 |
| Adomat, H; Batey, RA; Chen, C; Cloos, J; Franke, NE; Guns, E; Jamal, N; Jansen, G; Kay, LE; Li, X; Li, ZH; Mao, X; Messner, H; Navon, A; Religa, TL; Rose, DR; Schimmer, AD; Sprangers, R; Trudel, S; Verbrugge, SE; Wang, X; Wood, TE; Zhang, Y | 1 |
| Bhandari, M; Callander, N; Flinn, I; Gasparetto, C; Glass, J; Grosman, D; Hari, P; Krishnan, A; Kumar, SK; Noga, SJ; Rajkumar, SV; Richardson, PG; Rifkin, R; Sahovic, EA; Shi, H; Webb, IJ; Wolf, JL | 1 |
| Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gika, D; Grapsa, I; Kastritis, E; Migkou, M; Psimenou, E; Roussou, M; Terpos, E | 1 |
| Colby, TV; Fonseca, R; Khan, ML; Viggiano, RW | 1 |
| Destian, S; Hwang, BJ; Jagannath, S; Mazumder, A; Méndez, CE; Vesole, DH | 1 |
| Bergsagel, PL; Buadi, F; Dingli, DD; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Kapoor, P; Ketterling, RP; Kumar, S; Kyle, RA; Lacy, MQ; Rajkumar, SV; Sinha, S; Stewart, AK; Witzig, TE | 1 |
| Buffa, F; Hammond, E; Harris, AL; Mellor, HR; Milani, M; Pike, L; Pires, I; Ragoussis, I; Rzymski, T; Winchester, L | 1 |
| Burnett, AK; Crooks, PA; Fegan, C; Hewamana, S; Pepper, C; Pratt, G; Walsby, EJ | 1 |
| Akagi, Y; Fujii, T; Kage, M; Kusukawa, J; Miyagi, M; Sayers, TJ; Seki, N; Shirouzu, K; Toh, U; Yamana, H | 1 |
| Abramczyk, P; Bil, J; Bugajski, M; Dabrowska-Iwanicka, A; Duszyński, J; Golab, J; Jakóbisiak, M; Kujawa, M; Mackiewicz, U; Maczewski, M; Malinowska, M; Nowis, D; Ratajska, A; Salwa, P; Siński, M; Wieckowski, MR; Wilczyński, GM; Winiarska, M; Wójcik, C | 1 |
| Armstrong, JL; Birch-Machin, M; Fulda, S; Harbottle, A; Hill, DS; Hiscutt, EL; Kerr, R; Lovat, PE; Martin, S; Redfern, CP | 1 |
| Everly, MJ; Jahr, F; Kaneku, H; Terasaki, PI; Trivedi, HL | 1 |
| Everly, MJ | 2 |
| Abdellatif, A; Achkar, K; Dilioglou, S; Gaber, AO; Jeroudi, A; Knight, R; Land, G; Patel, S; Raghavan, R; Suki, W | 1 |
| Pavlakis, M | 1 |
| Everly, MJ; Kittleson, M; Kobashigawa, JA; Patel, JK | 1 |
| Chen, G; Lin, Z; Liu, S; Xiang, Y; Zhu, L | 1 |
| Abbadie, O; Blanchol, G; Brouard, S; Cantarovich, D; Cesbron, A; Dantal, J; Giral, M; Gosselin, M; Hourmant, M; Lino, M; Mai, HL; Meurette, A; Soulillou, JP | 1 |
| Alberú, J; Leyva, S; Marino-Vázquez, LA; Morales-Buenrostro, LE; Reyes-Loaeza, JA; Uribe-Uribe, N; Vega, O | 1 |
| Dagher, NN; Lonze, BE; Montgomery, RA; Segev, DL; Simpkins, CE; Singer, AL; Zachary, AA | 1 |
| Al Meshari, K | 1 |
| Claas, FH; Doxiadis, II; Heidt, S; Mulder, A; Roelen, DL; Vergunst, M | 1 |
| Haddad, T; Lopez-Cepero, M; Rolfe, M; Weston, M | 1 |
| Lee, RA; Saidman, SL; Smith, RN; Wong, W; Zorn, E | 1 |
| Chakkera, HA; Hamawi, K; Heilman, RL; Mazur, MJ; Mekeel, KL; Moss, AA; Mulligan, DC; Reddy, KS | 1 |
| Böhmig, GA; Drach, J; Geyeregger, R; Haidinger, M; Kikić, Z; Raab, R; Säemann, MD; Wahrmann, M | 1 |
| Birkenbach, M; Constantinescu, S; Daller, JA; Gillespie, A; Karachristos, A; Lee, I; Leech, S; Sifontis, NM; Silva, P; Swami, A | 1 |
| Basu, A; Lunz, J; Mapara, M; Morgan, C; Randhawa, P; Shapiro, R; Sharma, V; Tan, HP; Zeevi, A | 1 |
| Legendre, C; Sberro-Soussan, R; Suberbielle-Boissel, C; Zuber, J | 1 |
| Cook, WJ; Elkins, S; Gaston, RS; Kumar, V; Prendergast, MB; Reddy, V; Sanders, PW | 1 |
| Alloway, R; Brailey, P; Girnita, A; Govil, A; Mogilishetty, G; Roy-Chaudhury, P; Tevar, A; Wall, GE; Walsh, RC; Woodle, ES | 1 |
| Chan, L; Cooper, JE; Wiseman, AC | 2 |
| Barth, RN; Cooper, M; Gurk-Turner, C; Hurley, H; KuKuruga, D; Manitpisitkul, W; Philosophe, B; Rasetto, F; Wilson, N | 1 |
| Gonzalez, ML; Gonzalez-Pinto, IM; Island, ER; Rossique, M; Ruiz, P; Selvaggi, G; Smith, LJ; Solano, JP; Tekin, A; Tryphonopoulos, P; Tsai, HL; Tzakis, AG | 1 |
| Bartos, C; Berry, J; Chan, KM; Chang, AC; Kamoun, M; Mahidhara, R; Samaniego, M; Stuckey, LJ; Wadhwa, A | 1 |
| Alloway, RR; Eckman, PM; Kim, Y; Maurer, D; Thorsgard, M; Woodle, ES | 1 |
| Alford, K; Hardinger, KL; Murillo, D | 2 |
| Bloom, D; Djamali, A; Lorentzen, D; Mezrich, JD; Miller, KM; Muth, BL; Pirsch, JD; Sollinger, HW; Torrealba, J | 1 |
| Boothpur, R; Brennan, DC; Torrence, S | 1 |
| Aull, MJ; Dadhania, D; Hartono, C; Kapur, S; Saal, S | 1 |
| Aull, MJ; Dadhania, D; Figueiro, J; Hartono, C; Kapur, S; Lubetzky, M; Saal, S | 1 |
| Budde, K; Lachmann, N; Schönemann, C; Schütz, M; Waiser, J | 1 |
| Abildgaard, N; Delaissé, JM; Garnero, P; Lund, T; Ormstrup, T; Pedersen, PT; Plesner, T; Søe, K | 1 |
| Bolick, SC; Desai, S; Dessureault, S; Maurin, M; Smith, MA; Sotomayor, E; Tao, J; Wright, KL | 1 |
| Bladé, J; Buda, G; Cohen, N; Favis, R; Harousseau, JL; Huang, CC; Orlowski, RZ; Ricci, D; Sonneveld, P; Zhuang, SH | 1 |
| Callandar, N; Dispenzieri, A; Fonseca, R; Greipp, PR; Jacobus, S; Vesole, DH | 1 |
| Hirai, T; Yamaguchi, Y; Yamamura, M | 1 |
| Chang, H; Jiang, NN; Qi, X; Reece, D; Trieu, Y; Xu, W | 1 |
| Barosi, G; Campanelli, R; Facchetti, F; Fisogni, S; Gattoni, E; Goldberg, J; Guglielmelli, P; Hoffman, R; Marchioli, R; Vannucchi, AM | 1 |
| Fadeel, B; Feng, X; Henter, JI; Nordenskjöld, M; Wang, Y; Yan, J; Zheng, C; Zierath, JR | 1 |
| Birch-Machin, MA; Hill, DS; Lovat, PE; Martin, S; Paton, AW; Paton, JC; Redfern, CP | 1 |
| Iida, S; Inagaki, A; Ishida, T; Ito, A; Komatsu, H; Kusumoto, S; Miyazaki, H; Mori, F; Nakashima, T; Ri, M; Shiotsu, Y; Ueda, R | 1 |
| Bertsch, U; Goldschmidt, H; Schmitt, S | 1 |
| Bocchia, M; Chitarrelli, I; Defina, M; Fabbri, A; Gozzetti, A; Lauria, F; Marchini, E | 1 |
| Adam, Z; Büchler, T; Feit, J; Hájek, R; Krejcí, M; Pour, L | 1 |
| D'Rozario, J; Hanrahan, R; Lueck, C; Terwiel, E | 1 |
| Hou, SY; Hu, R; Li, YC; Liu, ZG; Yang, W; Yang, Y; Yao, K; Zhang, R | 1 |
| Jiang, M; Ruan, CG; Xie, LQ; Xue, LX | 1 |
| Albertini, M; Croghan, GA; Eckardt, J; Erlichman, C; Flaherty, L; Linette, G; Ma, C; Maples, WJ; Markovic, SN; Suman, VJ | 1 |
| Gleason, C; Heffner, LT; Kaufman, JL; Lonial, S; Nooka, A; Vrana, M | 1 |
| Kurzrock, R; Subbiah, V; Trent, JC | 1 |
| Brennan, SK; Kowalski, J; Matsui, W; Meade, B; Merchant, AA; Wang, Q | 1 |
| Chang, I; Chen, X; Guan, J; Han, D; Kim, J; Wang, CY | 1 |
| Bernstein, SH; Boral, AL; Bryant, B; Fisher, RI; Fleming, MD; Goy, A; McDonald, A; Mulligan, G; Pickard, MD; Shi, H; Trepicchio, W | 1 |
| Capanu, M; Holen, KD; Ilson, DH; Kelsen, DP; Kemeny, MM; Kindler, HL; Power, DG; Shah, MA; Tang, L; Wright, JJ | 1 |
| Chen, F; Chen, H; Guo, H; Jiang, Y; Lu, M; Mao, J; Qian, X; Shen, Y; Sun, C; Sun, H; Xia, J; Yang, G; Zhou, X; Zhuang, Y | 1 |
| Fujieda, A; Ishibashi, M; Iwamoto, T; Katayama, N; Masuya, M; Okuda, M | 1 |
| Engelhardt, M; Felthaus, J; Follo, M; Hein, M; Ihorst, G; Ngo, BT; Wäsch, R; Wider, D | 1 |
| Gertz, MA; Tadmor, T | 1 |
| Gonzalez, E; Joeris, T; Kaufmann, SH; Kühl, AA; Loddenkemper, C; Mollenkopf, H; Schmidt, N; Steinhoff, U; Visekruna, A | 1 |
| Bostrom, BC; Dubois, S; Eckroth, E; Gaynon, P; Glade-Bender, J; Hutchinson, R; Messinger, Y; Raetz, E; Sposto, R; van der Giessen, J | 1 |
| Hu, HY; Lu, L; Shen, Y | 1 |
| Brodoefel, H; Claussen, CD; Fenchel, M; Horger, M; Konaktchieva, M; Kraus, S; Weisel, K | 1 |
| Dudek, SE; Ludwig, S; Luig, C; Pauli, EK; Schubert, U | 1 |
| Horak, KM; Huang, W; Li, J; Liang, Q; Molkentin, JD; Su, H; Tang, M; Tian, Z; Wang, X | 1 |
| Callander, NS; Hematti, P; Kim, J; Kim, K; Leith, CP; Markovina, S; Miyamoto, S; O'Connor, SL; Shi, Y; Trivedi, P; Xu, G | 1 |
| Bornmann, W; Ford, RJ; Li, C; Pham, LV; Priebe, W; Tamayo, AT | 1 |
| Cho, GJ; Choi, YJ; Chung, JS; Joo, YD; Kim, SG; Kim, SH; Lee, GW; Lee, HS; Lee, SM; Seol, YM; Shin, HJ; Song, MK; Yun, EY | 1 |
| Isayama, R; Mizutani, R; Nakagawa, M; Shiga, K; Shimazaki, C; Tokuda, T | 1 |
| Bhatt, S; Blasini, W; Cavallin, LE; Gentles, AJ; Lossos, IS; Mesri, EA; Natkunam, Y; Ramos, JC; Sarosiek, KA; Toomey, NL | 1 |
| Blackman, BA; Brady, MM; Duong, T; Giles, FJ; Green, DP; Keller, C; Kilcoyne, A; McCarthy, SD; Michalek, JE; Ohshima-Hosoyama, S; Prajapati, SI; Rubin, BP; Samano, AK; Sledz, TJ; Tatiparthi, AK; Zarzabal, LA | 1 |
| Chen, SJ; Janin, A; Jiang, XX; Leboeuf, C; Shi, WY; Wang, L; Xiao, D; Yang, F; Yao, Y; Zhao, WL | 1 |
| Albitar, M; Anderson, KC; Badros, AZ; Berman, D; Jagannath, S; Messina, M; Richardson, PG; Tarantolo, S; Wolf, JL | 1 |
| Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; De Vita, F; Martinelli, E; Morgillo, F; Orditura, M; Troiani, T | 1 |
| Chang, I; Chen, Z; Kang, M; Song, J; Wang, CY | 1 |
| Cakana, A; Cavo, M; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Golenkov, A; Harousseau, JL; Kentos, A; Komarnicki, M; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; van de Velde, H | 1 |
| Barrett, C; Blackburn, C; Blank, JL; Bruzzese, FJ; Bump, N; Dick, LR; Fleming, P; Garcia, K; Gigstad, KM; Hales, P; Jones, M; Liu, JX; Olhava, EJ; Sappal, DS; Sintchak, MD; Soucy, TA; Tsu, C | 1 |
| Fielding, K; Neeson, P; Quach, H; Ritchie, DS | 1 |
| Dagher, NN; Locke, JE; Lonze, BE; Montgomery, RA; Segev, DL; Simpkins, CE; Singer, AL; Zachary, AA | 1 |
| Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Campion, L; Facon, T; Guerin-Charbonnel, C; Harousseau, JL; Hulin, C; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Minvielle, S; Moreau, P; Roussel, M; Stoppa, AM; Voillat, L; Wetterwald, M | 1 |
| Atadja, P; Balusu, R; Bhalla, KN; Buckley, KM; Coothankandaswamy, V; Fiskus, W; Ha, K; Joshi, A; Nalluri, S; Rao, R; Savoie, A; Sotomayor, E; Tao, J | 1 |
| Chen, J; Chopp, M; Jiang, H; Mahmood, A; Ning, R; Qu, C; Xiong, Y; Zhang, L | 1 |
| Cai, Z; Chung, V; Guan, M; Huang, H; Yen, Y; Zheng, W; Zhu, L | 1 |
| Badowska, W; Czyzewski, K; Juraszewska, E; Konatkowska, B; Kuzmicz, M; Malinowska, I; Olejnik, I; Pogorzala, M; Sobol, G; Stanczak, E; Stefaniak, J; Styczynski, J; Szczepanek, J; Szczepanski, T; Wysocki, M | 1 |
| Frey, B; Gaipl, US; Lang, VR; Meister, S; Schett, G; Schlötzer-Schrehardt, U; Voll, RE | 1 |
| Anderson, KC; Badros, A; Chuma, S; Ghobrial, IM; Harris, B; Kunsman, J; Leduc, R; Matous, J; Padmanabhan, S; Poon, T; Richardson, PG; Rourke, M; Sam, A; Treon, SP; Warren, D; Weller, E; Xie, W | 1 |
| Ajchenbaum-Cymbalista, F; Baran-Marszak, F; Boukhiar, M; Fagard, R; Gressin, R; Harel, S; Laguillier, C; Ledoux, D; Martin, A; Roger, C; Varin-Blank, N | 1 |
| Cheung, YK; Coleman, M; Elstrom, R; Furman, RR; LaCasce, AS; Leonard, JP; Martin, P; Ruan, J; Vose, JM | 1 |
| Abdul-Jaleel, M; Candelaria-Quintana, D; Libby, E; Moualla, H; Rabinowitz, I | 1 |
| Adamo, L; Amato, G; Anastasi, G; Colarossi, C; Conticello, C; De Maria, R; Di Raimondo, F; Giuffrida, R; Giustolisi, R; Gorgone, A; Gulisano, M; Iannolo, G; Martinetti, D; Romano, A; Salomone, E | 1 |
| Cos Arregui, E; González Asanza, C; Huerta Madrigal, A; Menchén Fernández-Pacheco, P; Merino Rodriguez, B; Nogales Rincón, O | 1 |
| Boozari, B; Gürlevik, E; Kloos, A; Knocke, S; Kubicka, S; Kühnel, F; Manns, MP; Mundt, B; Schache, P; Strüver, N; Wirth, TC; Woller, N | 1 |
| Burbury, K; Harrison, SJ; Joyce, T; Peinert, S; Prince, HM; Ritchie, D; Seymour, JF; Stokes, K; Thompson, PA; Wolf, M | 1 |
| Wright, JJ | 1 |
| Abildgaard, N; Andersen, NF; Gimsing, P; Gregersen, H; Klausen, TW; Rasmussen, HB; Søeby, K; Vangsted, AJ; Vogel, U; Werge, T | 1 |
| Mele, G; Melpignano, A; Pinna, S; Quarta, G | 1 |
| Belanger, E; Benavides, A; Cappia, S; Frost, P; Gera, J; Guglielmelli, T; Hoang, B; Lichtenstein, A; Pezeshkpour, G; Shi, Y | 1 |
| Elia, JR; Hirsch, ML; Kafri, T; Kantor, B; Lothrop, CD; Monahan, PE; Samulski, RJ; Sarkar, R; Sun, J; Tillson, DM | 1 |
| Chanan-Khan, A; Deeb, G; Lee, K; Miller, KC; Sher, T | 1 |
| Luo, J; Ma, C; Niu, X; Shao, Z; Shen, K | 1 |
| Du, Z; Fan, M; Gu, W; Jiao, Y; Kim, JG; Nosrat, CA; Pavicevic, Z; Pfeffer, LM; Rao, SK; Rosebush, M; Samant, S | 1 |
| Cho, YJ; Chung, EJ; Jung, SA; Kim, SW; Lee, JH; Moon, SW | 1 |
| Bhende, PM; Damania, B; Dittmer, DP; Lim, MS; Park, SI | 1 |
| Cho, SH; Jones, DR; Lee, JK; Liu, Y; Nagji, AS | 1 |
| Aggarwal, BB; Kannappan, R; Yadav, VR | 1 |
| Choo, C; Goh, YT; Hwang, W; Lao, ZT; Lau, LC; Lee, LH; Lee, YS; Lim, A; Lim, TH; Premalatha, P; Su, S; Tan, D; Teoh, G; Wee, HC; Wee, N; Yap, KC | 1 |
| Anagnostopoulos, A; Athanasiou, E; Bougiouklis, D; Kaloyannidis, P; Palladas, P; Papadopoulou, A; Paraskeva, A; Yannaki, E; Yiangou, M | 1 |
| Huang, HB; Wu, SQ; Zhan, R | 1 |
| Bo, J; Dou, LP; Gao, CJ; Han, XP; Huang, WR; Jing, Y; Li, F; Li, HH; Wang, FF; Wang, QS; Wang, SH; Yu, L; Zhao, Y; Zhu, HY | 1 |
| Carbone, A; Gloghini, A; Spina, M; Tirelli, U | 1 |
| Chen, KF; Chen, PJ; Cheng, AL; Hou, DR; Lin, YC; Liu, CY; Liu, TH; Yu, HC | 1 |
| Chen, SL; Gao, W; Jiang, B; Qiu, LG; Yu, L; Zhong, YP | 2 |
| Fayad, LE; Feldman, T; Ford, P; Goldberg, S; Goy, A; Hartig, K; Kwak, LW; McLaughlin, P; Pecora, A; Pro, B; Rodriguez, A; Romaguera, JE; Smith, J; Wang, M; Weaver, P | 1 |
| Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; Cibeira, MT; de Arriba, F; de Paz, R; García-Laraña, J; García-Sanz, R; González, Y; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; Martín, A; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Mediavilla, JD; Miguel, JF; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Ramos, ML; Ribera, JM; Sureda, A; Teruel, AI; Vidriales, MB | 1 |
| Flowers, CR; Harvey, RD; Heffner, LT; Kaufman, J; Khoury, HJ; Langston, AA; Lechowicz, MJ; Lonial, S; McMillan, S; Nooka, A; Renfroe, H; Tighiouart, M; Torre, C; Waller, EK | 1 |
| Christoulas, D; Dimopoulos, MA; Efstathiou, E; Gavriatopoulou, M; Gkotzamanidou, M; Iakovaki, M; Kastritis, E; Matsouka, C; Migkou, M; Mparmparoussi, D; Roussou, M; Terpos, E | 1 |
| Abe, M; Fujii, S; Harada, T; Jinno, T; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Ozaki, S; Takeuchi, K; Yata, K | 1 |
| Vokurka, S | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D | 1 |
| Ackerman, E; Berenson, JR; Eades, B; Mapes, R; Swift, RA; Waterman, GN; Yellin, O | 1 |
| Cavalli, F; Conconi, A; Devizzi, L; Ferreri, AJM; Lopez-Guillermo, A; Luminari, S; Martinelli, G; Rigacci, L; Vitolo, U; Zinzani, PL; Zucca, E | 1 |
| Liang, Y; Seymour, RE; Sundberg, JP | 1 |
| Coyne, PJ; Dodson, P; Parker, GL; Ramakrishnan, V; Smith, TJ | 1 |
| Chen, Z; Ge, F; Jia, H; Li, L; Lu, C; Lu, X; Zeng, H | 1 |
| He, Q; He, Y; Tan, D; Zhao, X | 1 |
| Drach, J; Lamm, W; Lang, A; Ludwig, H; Müldür, E; Schauer-Stalzer, B; Willenbacher, W; Zielinski, CC; Zojer, N | 1 |
| Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Casassus, P; Facon, T; Harousseau, JL; Hulin, C; Lenain, P; Maisonneuve, H; Maloisel, F; Marit, G; Mathiot, C; Michallet, M; Mohty, M; Moreau, P; Petillon, MO; Webb, I | 1 |
| Alba, L; Antinori, A; Bibas, M; Del Nonno, F; Grisetti, S; Picchi, G | 1 |
| Adam, Z; Autzinger, EM; Egyed, M; Gisslinger, H; Greil, R; Hajek, R; Keil, F; Lang, A; Ludwig, H; Thaler, J; Tóthová, E; Womastek, I; Zojer, N | 1 |
| Choi, I; Hata, H; Higuchi, M; Masaki, Y; Nagafuji, K; Sunami, K; Takamatsu, Y; Tamura, K; Uozumi, K | 1 |
| Berno, T; Briani, C; Campagnolo, M; Zambello, R | 1 |
| Bocchia, M; Crupi, R; Defina, M; Gozzetti, A | 1 |
| Abramowicz, D; Lemy, A; Toungouz, M | 1 |
| Jang, SY; Jung, J; Lee, HK; Park, HT; Seo, SY; Shin, YK; Suh, DJ | 1 |
| Bossi, M; Canta, A; Carozzi, VA; Cavaletti, G; Chiorazzi, A; Marmiroli, P; Meregalli, C; Oggioni, N; Sala, B | 1 |
| Guo, H; Jiang, Y; Shen, Y; Sun, C; Tong, Y; Wang, J; Wang, Z; Yang, G; Zhou, X | 1 |
| Boyer, M; Erlichman, C; Holen, K; Kim, GP; Mahoney, MR; Marshke, R; Mok, TS; Nowak, A; Philip, PA; Picus, J; Pitot, HC; Rubin, J; Szydlo, D; Wright, JJ | 1 |
| Cohen, LJ; Humphreys, BD; Laubach, JP; Rennke, HG | 1 |
| Ayers, DC; Barthel, TK; Bouxsein, ML; Cheng, D; Hussain, S; Jones, MD; Lian, JB; Liu, JC; Lovria, E; Mukherjee, S; Mulay, S; Schoonmaker, JA; Stein, GS | 1 |
| Boise, LH; Chen, J; David, E; Flowers, CR; Kaufman, JL; Lonial, S; Marcus, AI; Schafer-Hales, K; Sun, SY; Torre, C | 1 |
| Aschan, J; Dhawan, R; Hornberger, J; Liwing, J; Löthgren, M; Rickert, J | 1 |
| Jin, L; Kojima, K; Konopleva, M; Miida, T; Pittaluga, S; Raffeld, M; Tabe, Y; Zhou, Y | 1 |
| Bui, TN; Efuet, ET; Keyomarsi, K | 1 |
| Golenkov, AK; Kataeva, EV; Klinushkina, EF; Lutskaia, TD; Mitina, TA; Trifonova, EV | 1 |
| Bartczak, A; Chen, L; Edwards, A; Khattar, R; Levy, G; Liu, MF; Ma, XZ; McGilvray, ID; Zhang, J | 1 |
| Bertsch, U; Broyl, A; Corthals, SL; de Knegt, Y; Durie, BG; el Jarari, L; Goldschmidt, H; Jongen, JL; Kuiper, R; Lokhorst, HM; Sonneveld, P; van der Holt, B; van Duin, M | 1 |
| Adini, I; Bischoff, J; Boscolo, E; Greenberger, S; Mulliken, JB | 1 |
| Beysel, S; Yağci, M; Yeğın, ZA | 1 |
| Cakana, A; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Van De Velde, H; Wu, KL | 1 |
| Rummel, M | 1 |
| Cheng, B; Cheung, YK; Lee, SM | 1 |
| Besterman, J; Brady, H; Buglio, D; Heise, C; Khaskhely, NM; MacBeth, K; Mamidipudi, V; Martell, RE; Younes, A | 1 |
| Agathocleous, A; Hunter, H; Johnson, P; Kerr, JP; Lister, A; Matthews, J; Montoto, S; Neeson, SM; Radford, J; Rohatiner, A; Rule, S; Strauss, S | 1 |
| Li, F; Rajendran, P; Sethi, G | 1 |
| Chou, T; Hirose, T; Igarashi, N; Imai, Y; Ishiguro, T | 1 |
| Mey, UJ | 1 |
| Carrier, L | 1 |
| Adami, F; Cabrelle, A; Colpo, A; Gnoato, M; Gurrieri, C; Manni, S; Montini, B; Pavan, L; Piazza, F; Semenzato, G; Trentin, L; Tubi, LQ; Zambello, R | 1 |
| Böhm, C; Jäck, HM; Lang, VR; Meister, S; Mielenz, D; Neubert, K; Schett, G; Voll, RE | 1 |
| Akaogi, T; Hatsuse, M; Horiike, S; Iwai, T; Kamitsuji, Y; Kaneko, H; Kawata, E; Kiyota, M; Kobayashi, T; Kobayashi, Y; Koshida, M; Kuroda, J; Matsumoto, Y; Murakami, S; Okano, A; Shimazaki, C; Shimura, K; Tanaka, T; Taniwaki, M; Uchiyama, H; Ueda, S; Ueda, Y; Uoshima, N | 1 |
| Kolesar, JM; Pomplun, ML; Vanderloo, JP; Vermeulen, LC | 1 |
| Bi, LJ; Ge, F; He, QY; Jia, HT; Li, LP; Lu, CH; Tao, SC; Xiao, CL; Xiong, S; Yin, XF | 1 |
| Hagedorna-Tronina, R; Kraj, M; Kruk, B; Pogłód, R; Warzocha, K; Łetowska, M | 1 |
| Ding, N; Harrison, SJ; Howman, R; Khot, A; Pitman, M; Thakerer, A; Thompson, PA | 1 |
| Bangia, N; Belicha-Villanueva, A; Blickwedehl, J; Clements, JL; Czuczman, MS; Gibbs, J; Hernandez-Ilizaliturri, FJ; Mavis, C; Olejniczak, SH; Riaz, W | 1 |
| Tsukamoto, S | 1 |
| Cao, TM; Li, G; Liu, Y; Salama, M; Shi, L; Tricot, G; Wang, S; Wu, Y; Xiao, F; Xu, C; Xu, H; Yang, Y; Zangari, M; Zhan, F | 1 |
| Cohen, N; Klein, S; Kravchenko-Balasha, N; Levitzki, A; Mizrachy-Schwartz, S | 1 |
| Bladé, J; Delforge, M; Dimopoulos, MA; Facon, T; Kropff, M; Ludwig, H; Palumbo, A; San-Miguel, JF; Sonneveld, P; Van Damme, P | 1 |
| Asmar, L; Beveridge, R; Boehm, KA; Greenspan, A; Kannarkat, GT; Mandanas, RA; Rifkin, RM; Schwerkoske, JF; Stephenson, JJ; Zhan, F | 1 |
| Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cavalli, M; Ciccone, G; Falcone, AP; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Leonardi, G; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rizzo, M; Rossi, D | 1 |
| Gong, Y; Liu, T; Meng, W; Xing, H | 1 |
| Fujita, Y; Fukushima, T; Hirose, Y; Iwao, H; Masaki, Y; Miki, M; Nakajima, A; Nakamura, T; Sakai, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Yahng, SA | 1 |
| Bae, SH; Do, YR; Kim, K; Kim, SJ; Lee, JJ; Yang, DH | 1 |
| Connolly, G | 1 |
| Cavallo, F; Esseltine, D; Gruenwald, JM; Kern, S; Kumar, NS; Pappas, L; Ranganathan, S; Suva, LJ; Tricot, G; Yaccoby, S; Zangari, M; Zhan, F | 1 |
| Bendall, LJ; Bradstock, KF; Cisterne, A; Saunders, P; Weiss, J | 1 |
| Giubellino, A; Linehan, WM; Neckers, L; Sourbier, C; Sudarshan, S; Valera-Romero, V; Yang, Y | 1 |
| Fukunaga, K; Saeki, Y; Tanaka, K | 1 |
| Anderson, KC; Barlogie, B; Bladé, J; Cavo, M; Chanan-Khan, A; Comenzo, RL; Dimopoulos, MA; Durie, BG; Fermand, JP; Giralt, S; Harousseau, JL; Jagannath, S; Leung, N; Ludwig, H; Niesvizky, R; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Sonneveld, P; Terpos, E; Tosi, P | 1 |
| Chapman, CM; Dunleavy, KM; Liu, P; Maric, I; Mo, CC; Mora-Jensen, H; Pérez-Galán, P; Pittaluga, S; Rader, C; Raghavachari, N; Rizzatti, EG; Shaffer, AL; Staudt, LM; Stennett, LS; Stetler-Stevenson, M; Weniger, MA; Wiestner, A; Wilson, WH; Yuan, C | 1 |
| Fujita, H; Fukui, R; Hirai, M; Kadowaki, N; Kamihira, S; Kitawaki, T; Maeda, T; Miyachi, Y; Miyake, K; Takaori-Kondo, A; Uchiyama, T | 1 |
| Chosa, M; Nagase, K; Tobinai, K; Watanabe, T | 1 |
| He, XX; Huang, JJ; Huang, Y; Li, ZM; Lin, TY; Tian, Y; Xiao, J | 1 |
| Palumbo, A | 2 |
| Alimena, G; Breccia, M; Cilloni, D; D'Auria, F; Gottardi, E; Latagliata, R; Mandelli, F; Musto, P; Saglio, G; Sanpaolo, G | 1 |
| Hao, H; Hasegawa, S; Hirota, S; Lee-Kawabata, M; Masuyama, T; Naito, Y; Ogawa, H; Tamaki, H; Taniguchi, Y | 1 |
| Abeltino, M; Agnelli, L; Bolzoni, M; Bonomini, S; Colla, S; Giuliani, N; Neri, A; Rizzoli, V; Storti, P; Todoerti, K | 1 |
| Horiike, S; Kiyota, M; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Nakayama, R; Ohshiro, M; Sasaki, N; Shimazaki, C; Shimura, Y; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Yamamoto, M | 1 |
| Guo, HF; Mao, JJ; Su, HL; Sun, C; Wang, J; Zhou, X | 1 |
| Fan, LS; Hu, Y; Kong, FF; Li, Y; Ma, D; Song, XH; Wang, SX; Wang, W; Weng, DH; Xing, H | 1 |
| Ballanti, S; Corvatta, L; Gentili, S; Gozzetti, A; Leoni, P; Liberati, AM; Nozzoli, C; Offidani, M; Palumbo, A; Polloni, C; Pulini, S | 1 |
| Bardag-Gorce, F; French, BA; French, SW; Li, J; Lin, A; Oliva, J | 1 |
| Barbarat, A; Houlgatte, R; Raharijaona, M; Rolland, D; Thieblemont, C | 1 |
| Everly, MJ; Hopfield, J; Kaneku, H; Terasaki, PI; Trivedi, HL | 1 |
| Askar, M; Banning, S; Chiesa-Vottero, A; Fatica, R; Flechner, SM; Koo, A; Poggio, E; Srinivas, T; Stephany, BR | 1 |
| Resmi, H | 1 |
| Auwerda, JJ; Bertina, RM; de Maat, MP; Leebeek, FW; Osanto, S; Sonneveld, P; Yuana, Y | 1 |
| Lei, M; Li, Y; Ma, Y; Shao, F; Wu, G; Yang, J; Yu, S; Yuan, Y; Zhao, X; Zhu, X; Zhu, Y | 1 |
| Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Schmidt-Hieber, M; Thiel, E; Weimann, A | 1 |
| Bouley, DM; Denko, NC; Koong, AC; Lust, S; Niwa, M; Offner, F; Olson, M; Papandreou, I; Solow-Cordero, DE; Tam, A; Van Melckebeke, H | 1 |
| Liedtke, M; Medeiros, BC | 1 |
| Freiberg, AN; Holbrook, MR; Lake, M; Lee, B; Park, A; Pentecost, M; Torres, B; Wang, YE; Wolf, MC; Yun, TE | 1 |
| Anderson, K; Laubach, J; Richardson, P | 1 |
| Cavalli, F; Johnston, PB; Witzig, TE; Yuan, R | 1 |
| Bo, J; Dou, LP; Gao, CJ; Han, XP; Huang, WR; Jing, Y; Li, HH; Wang, QS; Wang, SH; Yu, L; Zhao, Y; Zhu, HY | 1 |
| Aaron, KJ; Basnayake, K; Sanders, PW; Wang, PX; Ying, WZ | 1 |
| Campo, E; Colomer, D; López-Guerra, M; Mozos, A; Normant, E; Pérez-Galán, P; Rosich, L; Roué, G; Saborit-Villarroya, I; Xargay-Torrent, S | 1 |
| Sargent, DJ | 1 |
| Djulbegovic, B; Hozo, I; Kumar, A; Wheatley, K | 1 |
| Ahn, KS; Jang, HJ; Kim, HJ; Kim, SH; Kim, SM; Na, YS; Park, KR | 1 |
| Khosroshahi, A; Stone, JH | 1 |
| Morgan, G | 2 |
| Bommakanti, SV; Dudek, AZ; Gada, PD; Khatri, A; Kirstein, MN | 1 |
| Chen, XQ; Dong, HJ; Gao, GX; Gu, HT; Shu, MM; Wang, YW; Yang, Y; Zhu, HF | 1 |
| Bai, QX; Fan, LN; Huang, GS; Wang, L; Yang, LJ; Yue, P; Zhang, XY; Zhao, H; Zhu, J | 1 |
| Barnett, MJ; Broady, R; Connors, JM; Forrest, DL; Hamata, L; Hogge, DE; Mourad, YA; Nantel, SH; Narayanan, S; Nevill, TJ; Nitta, J; Power, MM; Shepherd, JD; Smith, CA; Song, KW; Sutherland, HJ; Toze, CL; Venner, CP | 1 |
| Andreeff, M; Asou, H; Inaba, T; Jin, L; Kimura, S; Konopleva, M; Kuroda, J; Miida, T; Tabe, Y; Zhou, Y | 1 |
| Baccarani, M; Caravita, T; Cavo, M; Cellini, C; Corradini, P; Crippa, C; Deliliers, GL; Di Raimondo, F; Galli, M; Ledda, A; Narni, F; Offidani, M; Palumbo, A; Pantani, L; Patriarca, F; Pescosta, N; Petrucci, MT; Spadano, A; Tacchetti, P; Tosi, P; Zamagni, E | 1 |
| Bernard, PS; Carey, LA; Chiu, WK; Collichio, FA; Dees, EC; Irvin, WJ; Ivanova, A; Orlowski, RZ; Perou, C; Stijleman, IJ | 1 |
| Fukuhara, N; Harigae, H; Ichinohasama, R; Ishizawa, K; Ohba, R; Ohguchi, H; Okitsu, Y; Onishi, Y; Yamamoto, J | 1 |
| Jeon, SH; Kim, DH; Kwan, J; Lee, WS; Park, KS; Park, SD; Shin, SH; Woo, SI; Yi, HG | 1 |
| Gerlach, UA; Koch, M; Lachmann, N; Pascher, A; Schoenemann, C | 1 |
| Alici, E; Gahrton, G; Jansson, M; Nahi, H; Sutlu, T | 1 |
| Chen, WM; Yang, GZ | 1 |
| Hanzawa, K; Kizaki, M; Mori, S; Nemoto, T; Sagawa, M; Tokuhira, M; Tomikawa, T; Watanabe, R | 1 |
| Chastagner, P; Labussière, M; Pinel, S; Plénat, F; Vandamme, M | 1 |
| Fujiwara, S; Gotoh, K; Isobe, Y; Ito, Y; Iwata, S; Kawada, J; Kimura, H; Nishiyama, Y; Sugimoto, K; Ushijima, Y; Yano, S | 1 |
| Ahn, KS; Chen, CY; Han, I; Jeong, SJ; Jung, JH; Kang, M; Kim, DK; Kim, SH; Kwon, TR; Lee, JW; Lee, SG; Yun, SM | 1 |
| Aries, PM; Fröhlich, K; Gross, WL; Holle, JU; Moosig, F | 1 |
| Che, XF; Itoh, M; Kawaguchi, T; Miyazawa, K; Moriya, S; Naito, M; Ohtomo, T; Tomoda, A | 1 |
| Einsele, H; Knop, S; Kortüm, M | 1 |
| Arai, J; Emi, N; Hasegawa, M; Hiki, Y; Ishii, J; Kato, M; Kondo, F; Murakami, K; Nabeshima, K; Nakai, S; Ohashi, A; Sugiyama, S; Tomita, M; Yamamoto, K; Yuzawa, Y | 1 |
| Fu, BB; Li, YC; Liao, AJ; Liu, ZG; Wang, HH; Yang, W; Yao, K; Zhang, R | 1 |
| Chen, LJ; Li, CM; Li, JY; Lu, H; Qian, SX; Qiu, HX; Wu, HX; Xu, W | 1 |
| Laubach, J; Richardson, P | 1 |
| Buda, G; Galimberti, S; Orciuolo, E; Pelosini, M; Petrini, M | 1 |
| Cesarman, E; Chadburn, A; Cheung, K; Coleman, M; Elstrom, R; Ely, S; Furman, RR; Lacasce, A; Lee, SM; Leonard, JP; Martin, P; Morrison, J; Ruan, J; Vose, JM | 1 |
| Farquhar-Smith, P | 1 |
| Li, QF; Wang, H; Wang, LS; Wu, CT; Xiao, FJ; Yan, J; Yang, YF; Zhang, K | 1 |
| Armoiry, X; Aulagner, G; Benboubker, L; Facon, T; Fagnani, F; Fermand, JP; Hulin, C; Moreau, P | 1 |
| Blake, J; Brandner, S; D'Sa, S; Elliott, KJ; Lunn, MP; Rabin, N; Reilly, MM; Saifee, TA; Yong, KL | 1 |
| Bowles, KM; MacEwan, DJ; Rushworth, SA | 1 |
| Fujisawa, M; Miyake, H; Sakai, I; Terakawa, T | 1 |
| Ebert, B; Kisiela, M; Maser, E; Wsól, V | 1 |
| Jane, EP; Pollack, IF; Premkumar, DR | 1 |
| Anderson, KC; Buon, L; Delmore, J; Hayden, P; Jacobs, HM; Jakubikova, J; Laubach, J; Lengauer, C; McMillin, DW; Mitsiades, CS; Munshi, NC; Negri, J; Ooi, M; Richardson, PG; Schlossman, R | 1 |
| Celiker, MY; Chang, TP; Ghosh, CC; Juvekar, A; Manna, S; Ramaswami, S; Vancurova, I; Vu, HY | 1 |
| Farid, M; Koo, GC; Lim, ST; Loong, S; Quek, R; Tao, M; Tay, K; Yau, YW | 1 |
| Du, J; Fu, W; Hou, J; Huo, J; Jiang, H; Shi, J; Yi, Q; Yuan, Z; Zhang, C | 1 |
| Broderick, E; Favis, R; Harousseau, JL; Levey, L; Meyers, M; Mulligan, G; Ricci, DS; Richardson, PG; Sun, Y; van de Velde, H | 1 |
| Blaskovich, MA; Burton, M; Cubitt, C; Duong, VH; Lancet, JE; Sebti, S; Stuart, RK; Sullivan, DM; Winton, EF; Wright, JJ; Zhang, S | 1 |
| Bontscho, J; Kettritz, R; Luft, FC; Manz, RA; Schneider, W; Schreiber, A | 1 |
| Armitage, JO; Bernstein, SH; Blumel, S; Fisher, RI; Friedberg, JW; Grant, S; Kelly, JL; Leonard, JP; Liesveld, J; Peterson, D; Proia, NK; Rich, L; Vose, JM; Young, F | 1 |
| De Baets, MH; Duimel, H; Gomez, AM; Losen, M; Manz, RA; Martínez-Martínez, P; Molenaar, PC; Phernambucq, M; van der Esch, E; Verheyen, F; Voll, RE; Vrolix, K | 1 |
| Borrello, I; Ferguson, A; Ghosh, N; Huff, CA; Ye, X | 1 |
| Boise, LH; Lonial, S | 2 |
| Argiris, A; Axelrod, RS; Burtness, B; Deconti, RC; Forastiere, AA; Ghebremichael, M | 1 |
| Chen, D; Dou, QP; Frezza, M; Kanwar, J; Schmitt, S | 1 |
| Annunziata, CM; Burris, J; Driscoll, JJ | 1 |
| André, S; Bayry, J; Delignat, S; Dimitrov, JD; Kaveri, SV; Lacroix-Desmazes, S; Meslier, Y | 1 |
| Candoni, A; De Muro, M; De Stefano, V; Ferrara, F; Fianchi, L; Galieni, P; Gozzetti, A; Leone, G; Musto, P; Pagano, L; Petrucci, MT; Pogliani, EM; Pulsoni, A; Specchia, G; Valentini, CG; Venditti, A; Visani, G; Visco, C | 1 |
| Arnulf, B; Asli, B; Belhadj, K; Bories, JC; Bouscary, D; Brouet, JC; Chandesris, O; Choquet, S; Fermand, JP; Ghez, D; Hermine, O; Karlin, L; Macro, M; Malphettes, M; Porcher, R; Soulier, J | 1 |
| Chang, TC; Ko, BS; Liou, JY | 1 |
| Al Sabah, S; Armstrong, JL; Corazzari, M; Ellis, N; Falasca, L; Fimia, GM; Hill, DS; Lovat, PE; Martin, S; Pagliarini, V; Piacentini, M; Redfern, CP | 1 |
| Danchaivijitr, P; Rapoport, AP; Yared, J | 1 |
| Argiris, A; Belani, CP; Gandara, DR; Gitlitz, B; Koczywas, M; Lara, PN; Lau, DH; Leighl, N; Longmate, J; Mack, PC; Ramalingam, S; Reckamp, K; Shepherd, FA; Wright, JJ | 1 |
| Fujita, J; Kanakura, Y; Kang, S; Mizuki, M; Otsuka, M | 1 |
| Ashcroft, J; Cavenagh, J; Cavet, J; Conn, J; Cook, G; Cook, M; Drake, M; Kazmi, M; Kettle, P; Marshall, S; Morris, C; Oakervee, H; Olujohungbe, A; Popat, R; Quinn, M; Snowden, J; Streetly, M; Tighe, J | 1 |
| Ashcroft, J; Cook, G; Cromack, J; Feyler, S; Owen, R; Parrish, C | 1 |
| Cavaletti, G | 1 |
| Chen, ST; Dewar, R; Khosravi-Far, R; Miller, K; Yeckes-Rodin, H | 1 |
| Burns, JM; Diwan, TS; Gloor, JM; Kremers, WK; Raghavaiah, S; Stegall, MD | 1 |
| Braggio, E; Bruins, LA; Keats, JJ; Mousses, S; Schmidt, JE; Sereduk, C; Shi, CX; Stewart, AK; Tiedemann, R; Yin, H; Zhu, YX | 1 |
| Borsini, W; Di Stasi, V; Donadio, V; Giannoccaro, MP; Gomis Pèrez, C; Liguori, R | 1 |
| Aguirre-Ghiso, J; Bahadur, U; Germain, D; Ishii, Y; Papa, L; Shioda, T; Waxman, S; Yue, Z | 1 |
| Duensing, A; Duensing, S | 1 |
| Co, JP; Dosani, I; Lucas, JG; Nwaogwugwu, UT; Sureshkumar, KK | 1 |
| Cleary, MA; Laver, T; McMahon, S; Mellert, H; Schelter, JM; Sotillo, E; Thomas-Tikhonenko, A | 1 |
| Gong, YP; Yang, X; Zheng, BH; Zhou, RQ | 1 |
| Chang, H; Gong, YP; Xing, HY; Yang, L; Yang, X; Zheng, BH; Zhou, RQ | 1 |
| Ando, K; Kojima, M; Moriuchi, M; Nakamura, N; Ogawa, Y; Ohmachi, K; Tsuboi, K | 1 |
| Amiot, M; Boccadoro, M; Cavallo, F; Descamps, G; Facon, T; Harousseau, JL; Hulin, C; Leleu, X; Mignard, D; Moreau, P | 1 |
| Breen, M; Chen, CS; Keller, ET; Kisseberth, WC; Lanigan, LG; Martin, CK; McCauley, LK; Murahari, S; Nadella, MV; Rosol, TJ; Shu, ST; Simmons, JK; Thudi, NK; Van Bokhoven, A; Werbeck, JL; Williams, C | 1 |
| Anderson, KC; Laubach, JP; Mitsiades, CS; Richardson, PG; Schlossman, RL | 1 |
| Assouline, S; Buckstein, R; Chua, NS; Crump, M; Eisenhauer, E; Fernandez, LA; Gascoyne, RD; Klasa, RJ; Kouroukis, CT; Powers, J; Turner, R; Walsh, W | 1 |
| Dokos, C; Hatzitolios, A; Kaiafa, G; Savopoulos, C | 1 |
| Bladé, J; Harousseau, JL; Lantz, K; Londhe, A; Lowery, C; Orlowski, RZ; Shah, J; Sonneveld, P | 1 |
| Chan, KM; Chen, TC; Lee, CF; Lee, CS; Lee, WC; Wu, TJ | 1 |
| Lacy, MQ; Tefferi, A | 1 |
| Chen, L; Li, JM; Shen, ZX; Wang, AH; Wei, L; Wu, WL; Zhao, SQ | 1 |
| Baldisserotto, A; Destro, F; Gallerani, E; Gavioli, R; Marastoni, M; Marescotti, D; Sforza, F; Sicurella, M | 1 |
| Cornell, LD; Fidler, ME; Nasr, SH; Qian, Q; Sethi, S | 1 |
| Ahn, KS; Chen, CY; Jeong, SJ; Jung, JH; Kim, SH; Kim, SY; Kwon, TR; Lee, JC; Rhee, YH; Yoon, HJ; Zhu, S | 1 |
| Chen, T; Fang, Y; Hu, Y; Jiang, X; Ma, D; Ma, Q; Meng, L; Tian, Y; Wang, B; Wang, S; Wu, P; Xia, X; Xu, G; Zhang, Q; Zhou, J | 1 |
| Anderson, KC; Armand, P; Bagshaw, M; Banwait, R; Chuma, S; Dollard, A; Ghobrial, IM; Harris, B; Jakubowiak, AJ; Kunsman, J; Laubach, J; Leduc, R; Maiso, P; Munshi, NC; Poon, T; Richardson, PG; Roccaro, A; Rodig, S; Sam, A; Schlossman, R; Vij, R; Warren, D; Weller, E | 1 |
| Du, ZX; Gao, YY; Liu, BQ; Meng, X; Niu, XF; Wang, HQ; Yan, Y; Zhang, HY | 1 |
| Dumitrescu, O; Gerecitano, J; Hamlin, P; Horanlli, E; Iasonos, A; Mo, Q; Moskowitz, CH; Noy, A; O'Connor, OA; Pappanicholaou, J; Portlock, C; Rojas, CN; Sarasohn, D; Schulman, P; Straus, D; Zelenetz, AD; Zhang, Z | 1 |
| Bota, DA; Gong, X; Linskey, ME; Schwartz, PH | 1 |
| Barbetti, V; Dello Sbarba, P; Giuntoli, S; Rovida, E; Tanturli, M | 1 |
| Mateos, MV; San-Miguel, J | 1 |
| Abildgaard, N; Andersen, NF; Gimsing, P; Gregersen, H; Klausen, TW; Nexø, BA; Vangsted, AJ; Vogel, U | 1 |
| Schots, R | 1 |
| Li, J; Wu, XM; Zhang, DY | 1 |
| Aujay, M; Azab, AK; Azab, F; Ghobrial, IM; Issa, GC; Liu, Y; Maiso, P; Morgan, B; Ngo, HT; Quang, P; Roccaro, AM; Sacco, A; Zhang, Y | 1 |
| Amm, HM; Buchsbaum, DJ; Kuo, H; Li, Y; Steg, AD; Zhou, T | 1 |
| Claxton, DF | 1 |
| Abraham, J; Awan, FT; Craig, M; Gibson, L; Hamadani, M; Jillella, A; Kochuparambil, ST; Osman, S; Remick, SC | 1 |
| Baum, W; Distler, JH; Frey, B; Gückel, E; Meister, S; Neubert, K; Polzer, K; Schett, G; Voll, RE; Zwerina, J | 1 |
| Chen, XY; Jin, J; Li, WP; Rao, SM; Yan, FZ; Yan, JS; Yang, Y; Zhao, J | 1 |
| Anderl, JL; Arastu-Kapur, S; Ball, AJ; Bennett, MK; Driessen, C; Kirk, CJ; Kraus, M; Lee, SJ; Muchamuel, T; Parlati, F; Shenk, KD | 1 |
| Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Goldschmidt, H; Khuageva, NK; Kropff, M; Liu, K; Magen-Nativ, H; Mateos, MV; Petrucci, MT; Ricci, DS; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Terpos, E; van de Velde, H | 1 |
| Fujisaki, T; Kan, S; Murakami, H; Muta, T; Nakanishi, H; Senba, S; Ueda, Y; Yasunaga, M | 1 |
| Nishi, S | 1 |
| Emmerich, B; Frohn, C; Hess, G; Hrusovsky, I; Olie, RA; Pliskat, H; Taverna, C; Voegeli, J; von Rohr, A | 1 |
| Anderson, K; Cakana, A; Deraedt, W; Dimopoulos, M; Esseltine, DL; Hou, J; Khuageva, N; Kropff, M; Liu, K; Mateos, MV; Petrucci, MT; Richardson, P; Robak, T; Rossiev, V; San Miguel, JF; Schlag, R; Shpilberg, O; van de Velde, H; Vekemans, MC | 1 |
| Chen, S; Dai, Y; Dent, P; Grant, S; Kramer, LB; Pei, XY; Wang, L | 1 |
| Adam, Z; Buchler, T; Gregora, E; Hajek, R; Krejci, M; Krivanova, A; Mayer, J; Minarik, J; Pour, L; Scudla, V; Straub, J; Zahradova, L | 1 |
| Bolaman, Z; Dayanir, V; Dayanir, Y; Kadikoylu, G; Kocaturk, T; Yavasoglu, I | 1 |
| Fukami, K; Koike, K; Morishige, S; Okamura, T; Okuda, S; Taguchi, K; Yakushiji, K | 1 |
| Fang, Y; Tao, Y; Wang, J; Wang, L; Yang, D; Zhang, W; Zhou, H | 1 |
| Chen, HJ; Chen, KF; Chen, PJ; Chen, YC; Cheng, AL; Hou, DR; Liu, CY; Yu, HC | 1 |
| Bosi, A; Maratea, D; Messori, A; Nozzoli, C | 1 |
| Bannerman, B; Berger, A; Bolen, J; Claiborne, C; Dick, L; Fleming, P; Hales, P; Jones, M; Kupperman, E; Manfredi, M; Monbaliu, J; Tsu, C; Xu, L; Yu, J | 1 |
| Haga, M; Miwa, A; Nagata, A; Noto, S; Sekiguchi, N; Takezako, N | 1 |
| Adachi, K; Endoh, A; Nakamura, R; Oda, Y; Ooi, S; Urushidani, Y | 1 |
| Attal, M; Palumbo, A; Roussel, M | 1 |
| Lonial, S; Mitsiades, CS; Richardson, PG | 1 |
| Cheung, YK; Lee, SM | 1 |
| Bagshaw, M; Banwait, R; Ghobrial, IM; Leduc, R; Leleu, X; Roper, N; Weller, E; Xie, W | 1 |
| Cahu, X; Dauriac, C; Houot, R; Lamy, T; Marchand, T; Tas, P | 1 |
| Li, YC; Liao, AJ; Liu, ZG; Wang, HH; Wang, HT; Wu, B; Yang, W; Yao, K; Zhang, R | 1 |
| Fu, K; Hao, XS; Ma, YL; Qian, ZZ; Wang, HQ | 1 |
| Akimoto, T; Hamano, Y; Hanawa, S; Imai, T; Inoue, M; Kotoda, A; Kusano, E; Matsuyama, T; Muto, S; Ozawa, K; Saito, O; Ueda, M; Uehara, E; Yoshizawa, H; Yumura, W | 1 |
| Blasi, N; Brunori, M; Caraffa, P; Catarini, M; Corvatta, L; Ferranti, M; Gentili, S; Leoni, P; Malerba, L; Mele, A; Offidani, M; Polloni, C; Rizzi, R; Samori, A | 1 |
| Rule, S | 1 |
| Arfons, LM; Ataergin, SA; Barr, PM; Cooper, BW; Creger, RJ; Fu, P; Gerson, SL; Kaplan, D; Kaye, NM; Kindwall-Keller, TL; Laughlin, MJ; Lazarus, HM; Liu, F; Sommers, SR | 1 |
| Brodie, C; Brodie, S; Cazacu, S; Finniss, S; Goldstein, RS; Kahana, S; Lee, HK; Mikkelsen, T; Roitman, V; Slavin, S; Xiang, C | 1 |
| Anand, M; Armanious, H; Belch, A; Gelebart, P; Lai, R | 1 |
| Beksac, M; Bladé, J; Cavenagh, J; Cavo, M; Delforge, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Kropff, M; Leal da Costa, F; Louw, V; Ludwig, H; Magen-Nativ, H; Mendeleeva, L; Nahi, H; Palumbo, A; Plesner, T; San-Miguel, J; Sondergeld, P; Sonneveld, P; Udvardy, M | 1 |
| Antoch, G; Buchbender, C; Nawatny, J | 1 |
| Gudkov, AV; Komarov, AP; Neznanov, N; Neznanova, L; Stanhope-Baker, P | 1 |
| Abal, L; Casanova, JM; Dolcet, X; Egido, R; Llombart-Cussac, A; Martí, RM; Matias-Guiu, X; Moreno, S; Puig, S; Santacana, M; Sorolla, A; Valls, J; Velasco, A; Vilella, R; Yeramian, A | 1 |
| Coppola, D; Dawson, J; Doyle, A; Figg, WD; Grant, S; Hogan, KT; Holkova, B; Kang, L; Kolla, S; Peer, C; Perkins, EB; Ramakrishnan, V; Roberts, JD; Roodman, GD; Shrader, E; Stuart, RK; Sullivan, DM; Talreja, N; Tombes, MB; Wellons, MD; Wright, J | 1 |
| Ambinder, RF; Chen, J; Hayward, SD; Li, H; Shamay, M; Shirley, CM; Zahnow, CA | 1 |
| Dreyling, M | 1 |
| Dou, QP; Frezza, M; Yang, H | 1 |
| Ding, T; Huang, J; Jin, J; Liu, H; Sun, X; Yang, M | 1 |
| Bladé, J; Hajek, R; Harousseau, JL; Lantz, KC; Nagler, A; Orlowski, RZ; Robak, T; San Miguel, JF; Sonneveld, P; Spencer, A; Sutherland, HJ; Zhuang, SH | 1 |
| Foli, A; Lavatelli, F; Merlini, G; Milani, P; Obici, L; Palladini, G; Russo, P | 1 |
| Ciccarelli, B; Fulciniti, M; Gong, P; Hatjiharissi, E; Hunter, ZR; Ioakimidis, L; Liu, X; Maghsoudi, K; Munshi, NC; O'Connor, OA; Patterson, CJ; Sheehy, P; Sun, JY; Treon, SP; Tseng, H; Xu, L; Yang, G; Zhou, Y; Zhu, B | 1 |
| Chen, J; Chen, L; Cheng, Q; Cross, B; Li, B; Yuan, ZM | 1 |
| Correia, C; Dai, H; Kaufmann, SH; Lee, SH; Schmitz, I; Smith, AJ; Takahashi, R | 1 |
| Delgado, ME; Devocelle, M; Düssmann, H; Laussmann, MA; Passante, E; Prehn, JH; Rauen, JA; Rehm, M; Würstle, ML | 1 |
| Byrn, SR; Milton, MJ; Tishmack, PA; van de Velde, H | 1 |
| Brioli, A; Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E; Zannetti, B | 1 |
| Debatin, KM; Fulda, S; Kappler, R; Naumann, I; von Schweinitz, D | 1 |
| Dekhuijzen, R; Ennen, L; Heunks, L; Linkels, M; Ottenheijm, C; van Hees, H | 1 |
| Alvarez Fernández, GM; de Alarcón Jiménez, RM; García Hernández, MA; Jimeno Griñó, C; Molina Núñez, M; Navarro Parreño, MJ; Roca Meroño, S; Zarco Pedrinaci, E | 1 |
| Farrell, K; Soutar, R; Stobo, DB | 1 |
| Bergsagel, PL; Chesi, M; Chng, WJ; Chung, TH; Fonseca, R; Gonzalez-Paz, N; Huang, GF; Mulligan, G; Ng, SB; Troska-Price, T | 1 |
| Hayashi, T; Ikeda, H; Imai, K; Ishida, T; Kawakami, K; Kobayashi, T; Nishimura, S; Shinomura, Y; Takahashi, F; Yasui, H | 1 |
| Azab, AK; Bahlis, NJ; Boise, LH; Brentnall, M; Duggan, P; Ghobrial, IM; Gratton, K; Klimowicz, AC; Lin, C; Mansoor, A; Neri, P; Ren, L; Stewart, DA; Tassone, P | 1 |
| Aujay, M; Bahlis, N; Belch, A; Berno, T; Hetherington, KL; Jagannath, S; Jakubowiak, A; Keith Stewart, A; Kukreti, V; Lonial, S; Orlowski, RZ; Siegel, D; Singhal, S; Somlo, G; Tricot, G; Trudel, S; Vij, R; Wang, L; Zangari, M; Zhan, F | 1 |
| Davies, A; Egorin, MJ; Hamilton, A; Ivy, SP; Leal, TB; Lenz, HJ; LoRusso, PA; Mani, S; Mier, J; Mulkerin, D; Neuwirth, R; Ramanathan, RK; Remick, SC; Sarantopoulos, J; Shibata, S; Takimoto, CH; Venkatakrishnan, K; von Moltke, L; Wright, JJ | 1 |
| Gharwan, H; Truica, CI | 1 |
| Chott, A; Drach, J; Hoffmann, M; Kaufmann, H; Lamm, W; Raderer, M; Zielinski, C | 1 |
| Jeong, KS; Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Woo, SM; Yang, KY; Yoon, WJ; Yoon, YB | 1 |
| Deckard, LA; Logsdon, NJ; Sontheimer, H; Spiller, SE | 1 |
| Abraham, J; Bridoux, F; Delbès, S; Desport, E; Fermand, JP; Jaccard, A; Lacotte-Thierry, L; Moumas, E; Touchard, G | 1 |
| Bringhen, S; Mateos, MV; Palumbo, A; San Miguel, JF | 1 |
| Akiba, T; Aotsuka, N; Matsuura, Y; Oguro, R; Satoh, M; Takada, K; Tani, Y; Wakita, H; Yamanaka, C | 1 |
| Moore, H; Romeril, K | 1 |
| Arnulf, B; Cavet, J; Deraedt, W; Esseltine, DL; Feng, H; Girgis, S; Grishunina, M; Grosicki, S; Harousseau, JL; Karamanesht, I; Kropff, M; Leleu, X; Masliak, Z; Moreau, P; Pylypenko, H; Rekhtman, G; Robak, T; Shubina, A; van de Velde, H | 1 |
| Eckhardt, SG; Kulikowski, GN; Morelli, MP; Pitts, TM; Serkova, NJ; Spratlin, JL; Tentler, JJ | 1 |
| Kyle, RA; Steensma, DP | 1 |
| Boyd, KD; Davies, FE; Morgan, GJ | 1 |
| Attal, M; Facon, T; Harousseau, JL; Moreau, P; Roussel, M | 1 |
| Goldschmidt, H; Moehler, T | 1 |
| Gahrton, G | 1 |
| Benevolo, G; Boccadoro, M; Botto, B; Evangelista, A; Frairia, C; Gay, F; Gentile, M; Larocca, A; Morabito, F; Palumbo, A; Pregno, P; Vitolo, U | 1 |
| Abduljabbar, A; Abubaker, J; Ahmed, M; Al-Dayel, F; Al-Kuraya, KS; Al-Sanea, N; Alhomoud, S; Ashari, LH; Bavi, P; Bu, R; Hussain, AR; Jehan, Z; Prabhakaran, S; Sultana, M; Uddin, S | 1 |
| Abraham, J; Bridoux, F; Debiais, C; Delbès, S; Desport, E; Fermand, JP; Hanf, W; Jaccard, A; Lacotte-Thierry, L; Moumas, E; Touchard, G | 1 |
| Anderlini, P; Fanale, M; Fayad, L; Horowitz, S; Ji, Y; Kwak, LW; Liboon, MJ; Nunez, C; Popat, U; Pro, B; Samaniego, F; Younes, A | 1 |
| Chen, XW; Xia, HL; Xia, RX | 2 |
| Everly, JJ; Everly, MJ; Terasaki, PI | 1 |
| Cristofanon, S; Debatin, KM; Fulda, S; Karpel-Massler, G; Nonnenmacher, L; Unterkircher, T; Vellanki, SH; Wirtz, CR | 1 |
| Abe, M; Amou, H; Fujii, S; Harada, T; Hiasa, M; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Oda, A; Ozaki, S; Takeuchi, K; Watanabe, T | 1 |
| Bearden, J; Butler, W; Chen, CS; Garrett-Mayer, E; Golshayan, A; Kraft, AS; Lilly, M; Wahlquist, AE | 1 |
| Brugnatelli, S; Foli, A; Invernizzi, R; Lavatelli, F; Merlini, G; Milani, P; Nuvolone, M; Obici, L; Palladini, G; Russo, P | 1 |
| An, G; Chang, H; Han, Y; Hao, M; Li, C; Meng, H; Qiu, L; Xie, Z; Xu, Y; Yu, Z; Zhang, L | 1 |
| Albitar, M; Alsina, M; Anderson, KC; Berman, D; Carroll, MP; Chanan-Khan, AA; Krishnan, AY; Lonial, S; Messina, M; Richardson, PG | 1 |
| Chen, SM; Cui, XY; Han, XF; Ling, Z; Shao, M; Sun, L; Wang, F; Zhang, H | 1 |
| Kupisiewicz, K | 1 |
| Meerang, M; Ramadan, K | 1 |
| Cheung, YK; Hershman, DL; Lee, SM; Leonard, JP; Martin, P | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Goh, YT; Han, ST; Hwang, WY; Linn, YC; Mya, DH; Tan, DC | 1 |
| Fingerle-Rowson, G; Goldschmidt, H; Ho, AD; Neben, K; Pham, M; Schmitt, S; Storch-Hagenlocher, B | 1 |
| Ailawadhi, S; Chanan-Khan, A; Czuczman, MS; Hernandez-Ilizaliturri, FJ; Hong, F; Iancu, D; Jamshed, S; Lawrence, W; Lee, K; Manfredi, D; Masood, A; Miller, KC; Sher, T; Soniwala, S; Sood, R; Tan, W; Wilding, G; Wood, M | 1 |
| Bladé, J; Cakana, A; Comenzo, RL; Enny, C; Esseltine, DL; Fermand, JP; Hassoun, H; Heffner, L; Hegenbart, U; Liu, K; Merlini, G; Palladini, G; Reece, DE; Sanchorawala, V; van de Velde, H; Vescio, RA | 1 |
| Khan, ML; Stewart, AK | 1 |
| An, G; Deng, SH; Li, CW; Li, Q; Liu, XP; Qi, JY; Qiu, LG; Wang, YF; Xu, Y; Zhao, YZ; Zou, DH | 1 |
| Bao, L; Huang, XJ; Lai, YY; Lu, J; Lu, XJ; Zhang, XH; Zhu, HH | 1 |
| Chen, C; Hou, M; Zhao, CL | 1 |
| Fink, L; Tricot, G; Zangari, M; Zhan, F | 1 |
| Anderson, KC; Anderson, T; Barrickman, JC; Campagnaro, EL; Esseltine, DL; Griffith, KA; Harvey, CK; Hofmeister, CC; Jakubowiak, AJ; Kaminski, MS; Kelley, SL; Laubach, JP; Lonial, S; Mietzel, MA; Raje, NS; Reece, DE; Richardson, PG; Schlossman, RL; Tendler, CL; Wear, SM; Zimmerman, TM | 1 |
| Bahram, S; Béné, MC; Davi, F; Gribben, JG; Herbrecht, R; Jacob, F; Leblond, V; Merle-Béral, H; Nadaud, S; Perrot, A; Pionneau, C; Vallat, L | 1 |
| Kay, LE; Ruschak, AM; Schimmer, AD; Slassi, M | 1 |
| Britton, M; Downey, SL; Filippov, DV; Florea, BI; Kisselev, AF; Mirabella, AC; Overkleeft, HS; Pletnev, AA; Shabaneh, TB; Verdoes, M | 1 |
| Aoki, T; Imahashi, N; Kitamura, K; Nishiyama, T | 1 |
| Djamali, A; Kim, J; Lorentzen, D; Mohamed, MA | 1 |
| Czyz, M; Duechler, M; Wilczynski, J | 1 |
| Sayers, TJ | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Hanamura, I; Heuck, CJ; Nair, B; Qu, P; Shaughnessy, JD; Stephens, O; Tian, E; Usmani, S; van Rhee, F; Waheed, S; Williams, R; Zhang, Q; Zhou, Y | 1 |
| Abonour, R; Anderson, KC; Desaiah, D; Ghobrial, IM; Harris, BN; Laubach, JP; Munshi, NC; Myrand, SP; Porter, NM; Richardson, PG; Schlossman, RL; Shi, P; Wooldridge, JE | 1 |
| Brunson, CY; Costa, LJ; Milligan, L; Rivell, GL; Stuart, RK | 1 |
| Bardag-Gorce, F | 1 |
| Davare, MA; Hosoyama, T; Keller, C; Nelon, LD; Ohshima-Hosoyama, S | 1 |
| Sherman, MY | 1 |
| Coudert, L; Filion, C; Fournier, MJ; Gareau, C; Labelle, Y; Martel, D; Mazroui, R | 1 |
| Andersson, BS; Champlin, RE; Decker, WK; Giralt, SA; Gocke, CD; Jones, RB; Jones, RJ; Lu, J; McMannis, JD; Ng, J; Nieto, Y; Parmar, S; Robinson, SN; Shah, N; Shpall, EJ; Steiner, D; Thomas, MW; Xing, D; Yang, H | 1 |
| Graw, J; Lee, M; Pellegata, NS; Roncaroli, F; Theodoropoulou, M; Zatelli, MC | 1 |
| Ciccarelli, B; Fulciniti, M; Gong, P; Hunter, Z; Liu, X; Maghsoudi, K; Munshi, NC; Patterson, CJ; Sun, JY; Treon, SP; Tseng, H; Xu, L; Yang, G; Zhou, Y; Zhu, B | 1 |
| Balleisen, S; Bruns, I; Fenk, R; Haas, R; Kobbe, G; Kondakci, M; Liese, V; Neubauer, F; Saure, C; Schröder, T | 1 |
| Blanco, B; Caballero-Velázquez, T; Inogés, S; Pérez-Simón, JA; Sánchez-Abarca, LI; Santamaría, C | 1 |
| Basak, GW; Jaksic, O; Koristek, Z; Labar, B; Masszi, T; Mayer, J; Mikala, G; Wiktor-Jedrzejczak, W | 1 |
| Burnette, BL; Leung, N; Rajkumar, SV | 1 |
| Gounder, M; Kane, M; Karantza, V; Levinson, K; Lin, H; Lin, Y; Mehnert, JM; Moss, R; Poplin, E; Rubin, EH; Shih, WJ; Sovak, M; Stein, MN; Tan, AR; White, E | 1 |
| Bagshaw, M; Banwait, R; Campigotto, F; Ghobrial, IM; Harris, B; Leduc, R; Leleu, X; O'Regan, K; Ramaiya, N; Weller, E; Yarar, D | 1 |
| Curtit, E; Mansi, L; Viel, E; Vignot, S | 1 |
| Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Reeder, C; Roy, V; Russell, SJ; Short, KD; Stewart, AK; Zeldenrust, S | 1 |
| Ishak, J; Rodrigues, F | 1 |
| Alexanian, R; Delasalle, K; Fu, W; Hou, J; Song, S; Wang, J; Wang, M | 1 |
| Alberú, J; Leyva, S; Marino-Vázquez, LA; Morales-Buenrostro, LE | 1 |
| Al Meshari, K; Altalhi, M; Alzayer, F; Elgamal, H; Pall, A | 1 |
| Böhmig, GA; Haidbauer, B; Regele, H; Schmidt, A; Schwaiger, E; Wahrmann, M; Werzowa, J | 1 |
| Birkenbach, M; Constantinescu, S; Daller, JA; Gillespie, A; Karachristos, A; Lee, I; Leech, S; Rao, S; Sifontis, NM; Silva, P | 1 |
| Basu, A; Humar, A; Lunz, J; Mapara, M; Randhawa, P; Shapiro, R; Sharma, V; Tan, HP; Zeevi, A | 1 |
| Legendre, C; Sberro-Soussan, R; Suberbielle-Boissel, C; Zuberl, J | 1 |
| Auli, MJ; Dadhania, D; Hartono, C; Kapur, S; Leeser, D; Lubetzky, M; Walker, J | 1 |
| Alberú, J; Leyva, S; Marino, LA; Morales-Buenrostro, LE | 1 |
| Cooper, M; Drachenberg, C; Haririan, A; Kukuruga, D; Manitpisitkul, W; Nogueira, J; Philosophe, B; Wilson, NS | 1 |
| Dytfeld, D; Friedman, J; Griffith, KA; Harvey, C; Jakubowiak, AJ; Kaminski, MS; Lebovic, D | 1 |
| Boyette-Davis, JA; Cata, JP; Dougherty, PM; Driver, LC; Kennedy, WR; Wendelschafer-Crabb, G; Zhang, H | 1 |
| Dunleavy, K; Liu, D; Munson, PJ; Pérez-Galán, P; Raghavachari, N; Rizzatti, EG; Tweito, MM; Wang, Q; Weniger, MA; White, T; Wiestner, A; Wilson, WH; Ye, Y | 1 |
| Belani, CP; Davies, AM; Edelman, MJ; Gandara, DR; Gitlitz, B; Lara, PN; Longmate, J; Ramalingam, SS; Reckamp, K; Salgia, R; Villalona-Calero, M; Vokes, EE; Wright, JJ | 1 |
| Adam, Z; Hájek, R; Jakubcová, R; Klincová, M; Krejcí, M; Mayer, J; Pour, L; Szturz, P; Zahradová, L | 1 |
| Ju, S; Li, C; Wang, H; Wang, X; Wang, Y; Zhong, R | 1 |
| Colado, E; de Queiroz Crusoe, E; Delgado, M; Fernandez-Lazaro, D; Garayoa, M; Garcia-Gomez, A; Gutierrez, NC; Lee, FY; Maiso, P; Martin-Sanchez, J; Ocio, EM; San-Segundo, L | 1 |
| Tomás, JF | 1 |
| Coiffier, B; Crump, M; de Vos, S; Elsayed, YA; Enny, C; Esseltine, DL; Hong, X; Mayer, J; Offner, F; Osmanov, EA; Rule, S; Scheliga, A; Shpilberg, O; Teixeira, A; Theocharous, P; van de Velde, H; Walewski, J; Zhu, E; Zinzani, PL | 1 |
| Anderson, KC; Chauhan, D; Kuhn, D; Orlowski, R; Raje, N; Richardson, P; Tian, Z; Zhou, B | 1 |
| Fan, Y; Fu, BB; Hao, LC; Liao, AJ; Liu, ZG | 1 |
| Bai, QX; Chen, JJ; Huang, GS; Yang, LJ; Zhang, XY; Zhao, H | 1 |
| Chen, YB; Hu, J; Shen, ZX; Tang, W; Wang, L; Wang, Y; Wu, W; Xu, L; Zhao, WL | 1 |
| Hawley, RG; Hawley, TS; Riz, I; Toma, I; Zweier-Renn, LA | 1 |
| Han, D; Liu, H; Liu, Y; Wang, C; Wang, Y; Wu, J; Xu, D; Yang, H; Ye, Y; Zhang, G; Zhao, S; Zhen, Y; Zheng, T | 1 |
| Fujita, Y; Fukushima, T; Iwao, H; Masaki, Y; Miki, M; Motoo, Y; Nakajima, A; Nakajima, H; Nakamura, T; Sakai, T; Sato, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
| Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE | 1 |
| Balakrishnan, K; Gandhi, V | 1 |
| Henderson, RA; McGhee, CN; Patel, D; Pradhan, MA; Vincent, AL | 1 |
| Guo, F; He, G; Hu, X; Shen, Y; Sun, A; Xu, J | 1 |
| Ahsan, A; Arai, Y; Argiris, A; Chen, Z; Cooley-Zgela, T; Duffy, AG; Jang, M; Kannabiran, VR; Kim, SW; Kummar, S; Nyati, MK; Ramanand, SG; Rudy, SF; Simone, NL; Suksta, N; Van Waes, C; Wright, JJ; Yang, X | 1 |
| Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Reufi, B; Schmidt-Hieber, M; Thiel, E; Tietze-Buerger, C | 1 |
| Chen, F; Cryns, VL; Messersmith, PB; Su, J | 1 |
| Dalal, N; Kozolff, M; Nabhan, C; Starr, A; Tolzien, K; Villines, D | 1 |
| Bladé, J; Cakana, A; Comenzo, RL; Dubrey, SW; Elsayed, Y; Enny, C; Fermand, JP; Hassoun, H; Heffner, LT; Hegenbart, U; Liu, X; Merlini, G; Mortimer, S; Palladini, G; Ramaswami, P; Reece, DE; Sanchorawala, V; Van De Velde, H; Vescio, RA | 1 |
| Alloway, RR; Girnita, A; Woodle, ES | 1 |
| Chen, XQ; Chen, YL; Cheng, YX; Jin, J; Liang, HX; Liu, Y; Zhang, B; Zhang, FX; Zhou, GB | 1 |
| Aydin, F; Bayik, M; Firatli-Tuglular, T; Kaygusuz, I; Toptas, T; Uzay, A | 1 |
| Mori, A; Takeda, K; Yanagida, M | 1 |
| Bruning, A; Burges, A; Friese, K; Mylonas, I; Vogel, M | 1 |
| Chiriva-Internati, M; Chui, K; Cobos, E; Jenkins, MR; John, CM; Mirandola, L; Yu, Y | 1 |
| Bollard, CM; Buglio, D; Derenzini, E; Illés, A; Ji, Y; Jóna, A; Khaskhely, N; Medeiros, LJ; Shafer, JA; Younes, A | 1 |
| Harper, JW; Lim, HJ; Tan, MK | 1 |
| Molica, S; Piro, E | 1 |
| Li, XY; Ma, LM; Niu, YY; Ren, RR; Wang, T; Zhang, HP; Zhou, Y | 1 |
| Hayakawa, Y; Hirata, Y; Kinoshita, H; Koike, K; Maeda, S; Nakagawa, H; Nakata, W; Sakamoto, K; Takahashi, R | 1 |
| Reid, EG | 1 |
| Burns, CJ; Khong, T; Monaghan, KA; Spencer, A | 1 |
| Chung, JS; Eom, HS; Kang, HJ; Kim, CS; Kim, HJ; Kim, JS; Kim, K; Lee, DS; Lee, JH; Lee, JL; Lee, SJ; Park, JS; Seong, CM; Sohn, SK; Suh, C; Won, JH; Yoon, SS | 1 |
| Fulda, S | 1 |
| Avet-Loiseau, H; Corthals, SL; Goldschmidt, H; Hajek, R; Johnson, DC; Kuiper, R; Magrangeas, F; Morgan, GJ; Sonneveld, P; van der Holt, B | 1 |
| de la Rubia, J; Roig, M | 1 |
| Balyasnikova, IV; Ferguson, SD; Han, Y; Lesniak, MS; Liu, F | 1 |
| Liu, L; Ran, X; Sheng, Z; Wang, B; Wang, L | 1 |
| Basi, S; Cantin, G; Chen, BE; Couban, S; Crump, M; Djurfeldt, M; Gascoyne, RD; Imrie, K; Lemieux, B; MacDonald, D; Rubin, S; Rubinger, M; Sehn, LH; Shepherd, L; Sussman, J | 1 |
| Amin, B; Cashen, AF; Cheson, BD; Fowler, N; Jacobs, SA; Kahl, BS; Lee, P; Letzer, J; Matous, JV; Parasuraman, S; Rosen, P; Saleh, A; Shi, H; Smith, S; Williams, ME | 1 |
| Fox, BA; Hu, HM; Jensen, SM; Twitty, CG | 1 |
| Beaven, AW; Feldman, T; Ferraro, M; Ford, P; Goy, A; Ivanova, A; Moore, DT; Shea, TC; Smith, J | 1 |
| O'Connell, C; Schroyens, W; Sykes, DB | 2 |
| Ambinder, RF; Baechler, S; Esaias, C; Fu, DX; Hobbs, RF; Pomper, MG; Sgouros, G | 1 |
| Borthakur, G; Cortes, J; Faderl, S; Ferrajoli, A; Kantarjian, H; McConkey, D; O'Brien, S; Santos, FP; Wright, J | 1 |
| Ayaori, M; Hisada, T; Iizuka, M; Ikewaki, K; Komatsu, T; Nakaya, K; Ogura, M; Ohsuzu, F; Ozasa, H; Sasaki, M; Takiguchi, S; Terao, Y; Uto-Kondo, H; Yakushiji, E | 1 |
| Bosi, A; Bruno, B; Corradini, P; Einsele, H; Fanin, R; Festuccia, M; Isola, M; Morabito, F; Nozza, A; Nozzoli, C; Patriarca, F; Sperotto, A; Spina, F; Stuhler, G | 1 |
| Chang, H; Jiang, A; Reece, D | 1 |
| Bello, C; Cohen, A; Comenzo, RL; Drullinsky, P; Hassoun, H; Hoover, E; Jhanwar, S; Landau, H; Lendvai, N; Lesokhin, A; Nimer, SD; Pandit-Taskar, N; Riedel, E; Schulman, P | 1 |
| Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Migkou, M; Terpos, E | 1 |
| Bello, C; Comenzo, RL; Hassoun, H; Hoover, E; Landau, H; Nimer, SD; Riedel, ER | 1 |
| Badelita, S; Coriu, D; Crisan, M; Dobrea, C; Dogaru, M; Ostroveanu, D; Talmaci, R | 1 |
| Abonour, R; Benson, MD; Kramer, G; Suvannasankha, A | 1 |
| Antolino, G; Bianchi, MP; De Biase, L; La Verde, G; Monarca, B; Moscetti, A; Porrini, R; Saltarelli, F | 1 |
| Burr, DA; Cai, P; Callaghan, MU; Cruz, PG; Fribley, AM; Jacobs, RR; Kaufman, RJ; Kirchhoff, PD; Larsen, MJ; Larsen, SD; Miller, JR; Narula, N; Neubig, RR; Ron, D; Schultz, PJ; Sherman, DH; Showalter, HD; Tamayo-Castillo, G | 1 |
| Blank, J; Callander, NS; Chang, JE; Choi, S; Eickhoff, JC; Gilbert, LA; Huie, MS; Kahl, BS; Kim, K; Longo, WL; McFarland, TA; Peterson, C; Rogers, ES; Volk, M; Werndli, JE; Yang, DT | 1 |
| Araujo, C; Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Caillot, D; Chaleteix, C; Decaux, O; Dib, M; Doyen, C; Escoffre, M; Facon, T; Fontan, J; Fuzibet, JG; Garderet, L; Harousseau, JL; Hulin, C; Kolb, B; Lenain, P; Lepeu, G; Lioure, B; Marit, G; Mathiot, C; Moreau, P; Pégourié, B; Randriamalala, E; Sebban, C; Stoppa, AM; Tiab, M; Traullé, C; Wetterwald, M | 1 |
| Chow, W; Chung, V; Cristea, M; Frankel, P; Koehler, S; Leong, L; Lim, D; Martel, C; Morgan, R; Portnow, J; Reckamp, K; Shibata, S; Synold, TW; Twardowski, P | 1 |
| Budde, K; Lachmann, N; Liefeldt, L; Neumayer, HH; Rudolph, B; Schönemann, C; Schütz, M; Waiser, J | 1 |
| Adam, Z; Feit, J; Hájek, R; Klincová, M; Krejčí, M; Mayer, J; Pour, L; Szturz, P; Vašků, V; Zahradová, L | 1 |
| Bhagat, G; Bongero, D; Lipstein, M; Montanari, F; O'Connor, O; Paoluzzi, L | 1 |
| Andrea, NT; Quillen, K; Sanchorawala, V; Seldin, DC; Sloan, JM | 1 |
| Khong, T; Spencer, A | 1 |
| Bergsagel, PL; Bjorklund, CC; Braggio, E; Bruins, LA; Chang, XB; Fonseca, R; Orlowski, RZ; Schmidt, JE; Shi, CX; Stewart, AK; Van Wier, S; Zhu, YX | 1 |
| Hino, N; Omura, H; Tanaka, T; Yamasaki, R | 1 |
| Begus-Nahrmann, Y; Beissbarth, T; Eick, D; Gorsler, T; Hennion, M; Hintermair, C; Hsu, C; Johnsen, SA; Kramer, F; Kremmer, E; Prenzel, T; Simons, M | 1 |
| Cheung, PH; Foreman, O; Hain, HS; Kaur, P; Kavirayani, A; Saha, S; Tung, D | 1 |
| Huang, CM; Lü, SQ; Song, NX; Wang, JM; Xu, XQ; Yang, JM; Zhou, H | 1 |
| Fei, XM; Lu, H; Wang, CY; Wang, LX; Zhu, Y | 1 |
| Sun, ZQ; Tan, DW | 1 |
| An, N; Chen, SL; Hu, Y; Li, X; Zhang, JJ; Zhong, YP | 1 |
| Al-Eisawi, Z; Beale, P; Chan, C; Huq, F; Yu, JQ | 1 |
| Koh, LP; Poon, LM | 1 |
| Bronson, R; Feldser, DM; Jacks, T; Meylan, E; Oliver, TG; Winslow, MM; Xue, W | 1 |
| Falk, RH | 1 |
| Dagli, F; Isik, A; Koca, SS; Ozercan, IH; Ozgen, M; Sahin, K; Tuzcu, M | 1 |
| Kale, AJ; Lechner, A; McGlinchey, RP; Moore, BS | 1 |
| Bacovsky, J; Lochman, P; Minarik, J; Pika, T; Scudla, V; Tichy, T; Zadrazil, J | 1 |
| Alloway, RR; Brailey, P; Girnita, A; Walsh, RC; Woodle, ES | 1 |
| Bashir, Q; Bassett, RL; Champlin, RE; Giralt, SA; Hosing, CM; Khan, H; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Shah, JJ; Shah, N; Sharma, M; Thall, PF; Wang, M | 1 |
| Gao, J; Wang, X; Xiao, C; Xing, X; Xiong, C; Ye, S | 1 |
| Möller, J; Murthy, A; Nicklasson, L | 1 |
| Asano, T; Ito, K; Sato, A; Sumitomo, M | 1 |
| Tokuhira, M | 1 |
| Ohmachi, K | 1 |
| Bargay, J; Bengoechea, E; Bladé, J; de Arriba, F; Díaz-Mediavilla, J; Fernández, M; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Lahuerta, JJ; Martín, A; Martín-Mateos, ML; Martín-Ramos, ML; Martínez-López, J; Mateos, MV; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Ribera, JM; San Miguel, JF; Sureda, A; Teruel, AI; Vidriales, MB | 1 |
| Bannerman, B; Bano, K; Berger, AJ; Bolen, JB; Bradley, DP; Carsillo, M; Donelan, J; Fitzgerald, M; Hales, P; Janz, S; Kupperman, E; Lee, EC; Li, P; Li, Z; Liu, R; Manfredi, M; Neppalli, VT; Pickard, M; Silva, MD; Subakan, O; Tayber, O; Terkelsen, J; Van Ness, B | 1 |
| Anolik, JH; Barnard, J; Conley, T; Goldman, BI; Ichikawa, HT; Jiang, J; Kirk, CJ; Lee, S; Looney, RJ; Muchamuel, T; Nevarez, S; Owen, T | 1 |
| Campo, E; Colomer, D; Jares, P; López-Guillermo, A; Martinez, A; Mozos, A; Roué, G | 1 |
| Arnold, LA; Atkinson, JM; Boulos, N; Carcaboso, AM; Eden, C; Ellison, DW; Féau, C; Gajjar, A; Gibson, P; Gilbertson, RJ; Guy, RK; Johnson, RA; Koul, D; Kranenburg, TA; Mohankumar, KM; Phoenix, T; Poppleton, H; Priebe, W; Shelat, AA; Stewart, CF; Tong, Y; Wright, K; Yung, WK; Zhu, L | 1 |
| Bousquet, A; Join-Lambert, O; Malfuson, JV; Martinaud, C; Soler, C | 1 |
| Befani, CD; Bonanou, S; Hatzidaki, E; Liakos, P; Papandreou, CN; Patrikidou, A; Simos, G; Vlachostergios, PJ | 1 |
| Jia, L; Joel, SP; Juliger, S; Kassam, S | 1 |
| Bellovich, K; El-Ghoroury, M; Goel, SK; Granger, D; Marin, M; Qu, H | 1 |
| Dean, J; Dickinson, M; Harrison, SJ; Januszewicz, H; Johnstone, R; Link, E; Neeson, P; Nichols, J; Prince, HM; Quach, H; Ritchie, DS; Ruell, S; Seymour, JF | 1 |
| Dimopoulos, MA; Mateos, MV; Redman, K; Richardson, PG; Spicka, I | 1 |
| Albrecht, P; Braun, SA; Hanneken, S; Methner, A | 1 |
| Cserti-Gazdewich, C; Dzik, WH; Haspel, RL | 1 |
| Bridoux, F; Fermand, JP; Hutchison, C | 1 |
| Alloway, RR; Sadaka, B; Woodle, ES | 2 |
| Bahlis, NJ; Boise, LH; Duggan, P; Gratton, K; Johnson, J; Klimowicz, A; Lonial, S; Mansoor, A; Neri, P; Ren, L; Stebner, E; Stewart, DA; Tassone, P | 1 |
| Dimeski, G; Wood, P | 1 |
| Chongmei, H; Hui, C; Jianmin, Y; Shuqing, L; Wang, J | 1 |
| Budinger, GR; Chandel, NS; Chiarella, SE; Ghosh, AK; Go, LH; Jain, M; Kamp, DW; Lam, AP; Mutlu, GM; Pardo, A; Rivera, S; Selman, M; Sznajder, JI; Urich, D; Varga, J; Wu, M; Zirk, A | 1 |
| Kuwabara, S | 1 |
| Sun, S; Tong, H; Tu, Y; Wang, G; Wei, W; Yao, F | 1 |
| Della Donna, L; Lagadec, C; Pajonk, F | 1 |
| Ghobrial, IM; Roccaro, AM; Sacco, A | 1 |
| Grant, S; Holkova, B | 2 |
| Assaraf, YG; Chan, ET; Cloos, J; Franke, NE; Geerke, DP; Jansen, G; Kaspers, GJ; Kirk, CJ; Niewerth, D; Schimmer, AD; van Meerloo, J; van Zantwijk, CH; Vojtekova, K; Zweegman, S | 1 |
| Delforge, M | 1 |
| Alexander, MP; Méndez, GP; Nasr, SH; Rennke, HG; Watson, DC | 1 |
| Berenson, JR; Bessudo, A; Boccia, RV; Chen, CS; Eades, B; Hilger, J; Hilger, JD; Mapes, R; Nassir, Y; Patel, R; Swift, RA; Vescio, R; Wirtschafter, E; Yang, HH; Yellin, O; Yung, E | 1 |
| Anderson, KC; Bandi, M; Chauhan, D; Raje, N; Ray, A; Richardson, P; Singh, AV | 1 |
| Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Cascavilla, N; Cavo, M; Di Raimondo, F; Gentile, M; Grasso, M; Guglielmelli, T; Majolino, I; Marasca, R; Mazzone, C; Montefusco, V; Morabito, F; Musolino, C; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, I | 1 |
| Gupta, A; Pandey, A; Sethi, S | 1 |
| Griskevicius, L; Janiulioniene, A; Matuzeviciene, R; Peceliunas, V; Zvirblis, T | 1 |
| Blosser, W; de Maria, R; Dowless, M; Low, J; Pallini, R; Ricci-Vitiani, L; Stancato, L | 1 |
| Goel, A; Spitz, DR; Weiner, GJ | 1 |
| Cheng, T; Mao, X; Pan, X; Zhang, X | 1 |
| Baz, R; Chen, F; Li, M; Nefedova, Y; Pisklakova, A; Sullivan, DM | 1 |
| Chang, D; Everly, M; Kittleson, M; Kobashigawa, J; Patel, J; Reed, E | 1 |
| Alsina, M; Nishihori, T | 1 |
| Balsas, P; Galán-Malo, P; Marzo, I; Naval, J | 1 |
| Cuzzoni, E; De Iudicibus, S; Decorti, G; Piscianz, E; Tommasini, A; Valencic, E | 1 |
| Doss, S; Hay, N; Sutcliffe, F | 1 |
| Baráth, S; Bíró, T; Griger, Z; Gyetvai, Á; Kovács, I; Sipka, S; Tarr, T; Tóth, BI; Zeher, M | 1 |
| Allerton, J; Anderson, KC; Bar, M; Colson, K; Densmore, J; Gardner, L; Ghobrial, IM; Hideshima, T; Irwin, D; Jakubowiak, A; Krishnan, A; Laubach, J; Lonial, S; Martin, T; Munshi, N; Poradosu, E; Raje, N; Richardson, PG; Schlossman, R; Sportelli, P; Wolf, J; Zonder, J | 1 |
| Johnson, DE; Li, C | 2 |
| Al-Shabeeb, A; Allen, JD; Catalano, A; Fleming, S; Harrison, S; Ho, PJ; Horvath, N; Iland, H; Joshua, DE; Lau, EK; Ling, SC; Nikolic, A | 1 |
| Chang, HC; De La Rosa, M; Han, L; Lupov, IP; Oza, K; Pelloso, D; Robertson, MJ; Sahu, RP; Schwartz, A; Travers, JB; Voiles, L | 1 |
| Dong, W; Qian, J; Sun, L; Wang, M; Yang, J; Yi, Q; Zhang, L | 1 |
| Cao, R; He, H; Huang, KK; Jiang, XJ; Liao, LB; Lin, R; Meng, FY; Wang, Q; Wu, FQ; Xu, D; Yang, M; Yi, ZS; Yin, CX; Zheng, ZX; Zhou, HS | 1 |
| Carew, JS; Coffey, M; Espitia, CM; Giles, FJ; Kelly, KR; Mahalingam, D; Nawrocki, ST; Oyajobi, BO | 1 |
| Alé, A; Bruna, J; Jaramillo, J; Navarro, X; Udina, E; Velasco, R | 1 |
| Chen, J; Curran, S; Dick, LR; Hjerpe, R; Kurz, T; Shpiro, N; Thomas, Y; Zemla, A | 1 |
| Arndt, T; Bartsch, DK; Brendel, C; Fischer, M; Greene, BH; Hinterseher, U; Hoffmann, S; Ramaswamy, A; Roth, S; Wunderlich, A | 1 |
| Fang, Y; He, Q; Jing, H; Luo, P; Song, H; Yang, B; Zhong, L; Zhou, X | 1 |
| Chan, TH; Dou, QP; Kanwar, J; Mujtaba, T; Wan, SB | 1 |
| Alexis Vigier, M; Arakelyan, N; Assouline, D; Bouabdallah, K; Caulet-Maugendre, S; Courby, S; Dartigeas, C; El Yamani, A; Fornecker, L; Gressin, R; Harousseau, JL; Houot, R; Le Gouill, S; Maisonneuve, H; Moles, MP; Mounier, C; Ojeda Uribe, M; Rodon, P; Sutton, L; Tournilhac, O | 1 |
| Gotoh, K; Ito, Y; Iwata, S; Kamakura, M; Kawada, J; Kimura, H; Nishiyama, Y; Saito, T | 1 |
| Molineaux, SM | 1 |
| Arai, S; Ichikawa, M; Imai, Y; Kataoka, K; Kumano, K; Kurokawa, M; Nakagawa, M; Nannya, Y; Nishimoto, N; Sato, T; Shimabe, M; Shinohara, A; Watanabe-Okochi, N; Yoshimi, A | 1 |
| Chen, Z; Fayad, L; Jung, HJ; Kwak, LW; McCarty, N; Romaguera, J; Wang, M | 2 |
| Dalmau, J; Fett, NM; Shinohara, MM; Toporcer, MB; Vogl, DT | 1 |
| Eto, Y; Higuchi, T; Ida, H; Kobayashi, H; Nishida, H; Nishiyama, Y; Ohashi, T; Shimada, Y | 1 |
| Assaraf, YG; Chan, ET; Cloos, J; de Wilt, LH; Jansen, G; Kirk, CJ; Kruyt, FA; Peters, GJ; Schimmer, AD; van Meerloo, J | 1 |
| Benson, DM; Crawford, BS; Efebera, Y; Elder, P; Hofmeister, CC; Mori, S; Phillips, G; Roddy, JV | 1 |
| D'Arena, G; Di Renzo, N; Falcone, A; Ferrara, F; Guariglia, R; Mansueto, G; Martorelli, MC; Mastrullo, L; Musto, P; Onofrillo, D; Pagano, L; Palumbo, A; Pietrantuono, G; Semenzato, G; Specchia, G; Valentini, CG; Venditti, A; Villani, O | 1 |
| Gräwert, MA; Groll, M | 1 |
| Chen, WM; Chen, XQ; Hou, J; Huang, XJ; Jin, J; Li, Y; Liu, ZG; Shen, ZX; Yuan, ZG | 1 |
| Fei, XM; Hu, HJ; Li, JX; Li, JY; Lu, H | 1 |
| Bai, H; Ling, YQ; Wang, CB; Wang, ML; Wu, B; Zhang, Q | 1 |
| Miwa, A; Nagata, A; Noto, S; Sekiguchi, N; Takezako, N; Wagatsuma, M; Yamada, K | 1 |
| Cipok, M; Deutsch, VR; Farnoushi, Y; Goldstein, RS; Jan, H; Kay, S; Naparstek, E; Ohana, A | 1 |
| Chang, H; Chen, MH; Qi, C; Reece, D | 1 |
| Kaiser, M; Krahn, D; Ottmann, C | 1 |
| Bratengeier, C; Christoulas, D; Delimpasi, S; Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Katodritou, E; Meletis, J; Michalis, E; Pouli, A; Terpos, E; Zervas, K | 1 |
| Ailawadhi, S; Bryant, B; Chanan-Khan, A; Gaile, DP; Lee, KP; Mashtare, T; Masood, A; Miecznikowski, J; Mulligan, G; Neuwirth, R; Sher, T; Stein, L; Wang, D; Wilding, GE | 1 |
| Brnjic, S; D'Arcy, P; De Cesare, M; Fryknäs, M; Hassan, M; Larsson, R; Linder, S; Lindsten, K; Olofsson, MH; Perego, P; Sadeghi, B | 1 |
| Berkers, CR; de Jong, A; Ovaa, H; Rodenko, B; Schuurman, KG | 1 |
| Kakpakova, ES; Panischeva, LA; Rybalkina, EY; Stavrovskaya, AA | 1 |
| Chen, HJ; Chen, KC; Chen, KF; Cheng, AL; Huang, CY; Wei, CC | 1 |
| Agostino, NR; DiDomenico, JD; Jane, EP; Pollack, IF; Premkumar, DR | 1 |
| He, Q; Li, L; Lin, M; Luo, P; Yang, B | 1 |
| Guo, H; Mao, J; Qian, X; Sun, C; Sun, H | 1 |
| Feng, H; Girgis, S; Hellmann, A; Louw, VJ; Patel, H; Rule, S; Shpilberg, O; Skee, DM; van de Velde, H; Walewski, J | 1 |
| Benjamin, M; Gibbs, S | 1 |
| Gong, X; Zhou, Y | 1 |
| Anderson, SK; Buckner, J; Friday, BB; Galanis, E; Geoffroy, F; Giannini, C; Gross, H; Jaeckle, K; Mazurczak, M; Pajon, E; Schwerkoske, J; Yu, C | 1 |
| Hou, K; Liu, J; Liu, Y; Qu, J; Qu, X; Teng, Y; Xu, L; Zhang, L; Zhang, Y | 1 |
| Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, P; Hayman, S; Keith Stewart, A; Khan, ML; Kumar, SK; Lacy, MQ; Laumann, KM; Leif Bergsagel, P; Lust, J; Mikhael, JR; Reece, DE; Reeder, CB; Russell, S; Vincent Rajkumar, S; Zeldenhurst, S | 1 |
| Andrade, VC; Atanackovic, D; Caballero, OL; Camargo, AA; Colleoni, GW; Costa, ET; de Carvalho, F; Gregorio, JC; Masotti, C; Strauss, BE | 1 |
| Budunova, IV; Kirsanov, KI; Lesovaya, EA; Yakubovskaya, MG; Yemelyanov, AY | 1 |
| Cao, Y; Chen, RA; Liang, Y; Liu, L; Tu, Y | 1 |
| Seol, DW | 1 |
| Dang, N; De Bruyne, E; De Bryune, E; Hu, J; Menu, E; Van Camp, B; Van Valckenborgh, E; Vanderkerken, K; Xu, D | 1 |
| Churchill, E; Ma, Y; Mahaffey, CM; Martin, SM; McKnight, H; O'Donnell, RT; Tuscano, JM | 1 |
| De Mesmaeker, P; Deleu, I; Dirix, LY; Prové, A; Rasschaert, M; Sas, L; Tjalma, WA; Trinh, XB; Van Dam, PA; Van de Velde, H; Van Laere, SJ; Vermeulen, PB; Vinken, P; Wojtasik, A | 1 |
| Dimopoulos, MA; Eleftherakis-Papapiakovou, E; Gkotzamanidou, M; Grapsa, I; Kastritis, E; Nikitas, N; Psimenou, E; Roussou, M; Terpos, E | 1 |
| Carney, DA; Gangatharan, SA; Harrison, SJ; Januszewicz, EH; Prince, HM; Ritchie, DS; Wolf, MM | 1 |
| Bansal, R; Boise, LH; Fink, EE; Hu, Q; Lee, KP; Liu, S; Mannava, S; Moparthy, KC; Nair, JR; Nikiforov, MA; Wawrzyniak, JA; Zhuang, D; Zucker, SN | 1 |
| Gong, Y; Shan, Q; Yang, X; Zheng, B; Zhou, R | 1 |
| Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J | 1 |
| Bryant, J; Clegg, AJ; Cooper, K; Picot, J | 1 |
| Liu, H; Song, CC; Song, CZ; Wang, QW | 1 |
| Reece, D; Scott, E | 1 |
| Bertsch, U; Blau, IW; Derigs, HG; Dührsen, U; Goldschmidt, H; Haenel, M; Hielscher, T; Ho, AD; Hose, D; Jauch, A; Lindemann, W; Lokhorst, HM; Martin, H; Neben, K; Peter, N; Pfreundschuh, M; Raab, MS; Salwender, H; Scheid, C; Schmidt-Wolf, IG; Sonneveld, P; Teschendorf, C; van de Velde, H; van der Holt, B; Weisel, K | 1 |
| Knop, S | 2 |
| Fonseca, R | 2 |
| Brown, RE; Buryanek, J; Pfister, S; Rytting, ME; Vats, TS; Wolff, JE | 1 |
| Agadjanian, H; Guo, X; Karlan, BY; Kwon, S; Miller, C; Nassanian, H; Orsulic, S; Taylor-Harding, B; Walsh, CS | 1 |
| Li, LS; Shen, JK; Zhang, GS | 1 |
| Huang, HB; Lin, J; Wu, SQ; Xu, ZZ; Zhan, R | 1 |
| Appel, A | 1 |
| Berglund, J | 1 |
| Frazier, EA; Garcia, X; Harville, TO; Howard, EL; Jaquiss, RD; Knecht, KR; Mahle, WT; Morrow, WR; Pye, SE; Saylors, RL; Smith, RN; Woodle, ES | 1 |
| Besse, B; Ducourtieux, M; Khayat, D; Lafontaine, C; Lumbroso, J; Mathiot, C; Pignon, JP; Planchard, D; Soria, JC; Taillade, L; Veillard, AS | 1 |
| Ayub, B; Mangalmurti, S; Matsumura, ME | 1 |
| Anderson, KC; Avet-Loiseau, H; Beksac, M; Bladé, J; Cavo, M; Chng, WJ; Comenzo, R; Delforge, M; Dimopoulos, M; Durie, BG; Einsele, H; Harousseau, JL; Jagannath, S; Jongen, JL; Lahuerta, JJ; Lee, JH; Lonial, S; Mateos, MV; Mazumder, A; Merlini, G; Miguel, JS; Moreau, P; Morgan, G; Munshi, N; Niesvizky, R; Orlowski, R; Palumbo, A; Rajkumar, SV; Richardson, PG; Sezer, O; Siegel, D; Sonneveld, P; Terpos, E; Usmani, S; Vesole, D; Voorhees, P; Wen, P | 1 |
| Bachmann, AS; Ibarra-Rivera, TR; Opoku-Ansah, J; Pirrung, MC | 1 |
| Cai, JL; Duarte, L; Farol, L; Forman, SJ; Frankel, PH; Htut, M; Karanes, C; Kogut, NM; Krishnan, AY; Murata-Collins, JL; Parker, PM; Popplewell, LL; Reburiano, E; Ruel, C; Sahebi, F; Somlo, G; Spielberger, RT; Thomas, SH | 1 |
| Inazu, M; Itoh, M; Kohno, N; Komatsu, S; Miyazawa, K; Moriya, S; Naito, M; Takase, A; Tomoda, A | 1 |
| Chan, KM; Kamoun, M; Stuckey, LJ | 1 |
| Dou, QP; Mujtaba, T | 1 |
| Duvic, M; Falchook, GS; Hong, DS; Kurzrock, R; Lim, J; Naing, A; Wheler, J | 1 |
| Baumann, P; Junghanns, C; Mandl-Weber, S; Oduncu, F; Schmidmaier, R; Strobl, S | 1 |
| Fehrenbach, H; Lunding, L; Manz, RA; Orinska, Z; Wegmann, M; Wong, DM | 1 |
| Arastu-Kapur, S; Bennett, MK; Bergsagel, PL; Demo, S; Deu, E; Keats, J; Kirk, CJ; Suzuki, E | 1 |
| Bhalla, P; Budunova, I; Iwadate, K; Karseladze, A; Ugolkov, A; Yang, X; Yemelyanov, A | 1 |
| de Lima, M; Koreth, J; Reddy, P | 1 |
| Terpos, E; Tricot, G; Zangari, M; Zhan, F | 1 |
| Dreyling, M; Hiddemann, W; Hutter, G; Pastore, A; Rieken, M; Weigert, O; Weinkauf, M; Zimmermann, Y | 1 |
| Al, M; Assaraf, YG; Chan, ET; de Gruijl, TD; den Uyl, D; Dijkmans, BA; Jansen, G; Kirk, CJ; Oerlemans, R; Peters, GJ; Scheffer, GL; Scheper, RJ; van der Heijden, JW; Verbrugge, SE | 1 |
| Gil, L; Komarnicki, M; Rupa-Matysek, J | 1 |
| Fukuda, Y; Gemma, A; Hatake, K; Katoh, T; Kudoh, S; Kusumoto, M; Mukai, H; Ohyashiki, K; Sakai, H; Sugiyama, Y | 1 |
| Bridoux, F; Delbes, S; Desport, E; Fermand, JP; Jaccard, A; Pourreau, F; Puyade, M; Sirac, C; Touchard, G | 1 |
| Ahn, PH; Anne, PR; Axelrod, RS; Cognetti, D; Curran, WJ; Dicker, AP; Fogh, S; Kubicek, GJ; Machtay, M; Myers, TJ | 1 |
| Banner, NR; Hodges, AM; Lyster, H; McDermott, A; Rice, AJ; Rose, ML; Smith, JD | 1 |
| Anderson, KC; Buon, L; Delmore, JE; Hunter, ZR; Jacobs, HM; Kung, AL; McMillin, DW; Mitsiades, CS; Monrose, V; Richardson, PG; Smith, PG; Treon, SP; Yu, J | 1 |
| Everly, MJ; Terasaki, PI; Trivedi, HL | 1 |
| Anderson, KC; Bradner, J; Canavese, M; Cirstea, D; Eda, H; Hideshima, T; Jarpe, M; Jones, SS; Kung, AL; Mazitschek, R; Ogier, WC; Raje, N; Rodig, S; Santo, L; Scullen, T; Tamang, D; Tseng, JC; van Duzer, JH; Yang, M | 1 |
| Beebe, DJ; Callander, NS; Kahl, BS; Miyamoto, S; Pak, C; Yang, DT; Young, EW | 1 |
| Andemariam, B; Coleman, M; Elstrom, RL; Furman, RR; Leonard, JP; Martin, P; Ruan, J; Shore, TB | 1 |
| Hahn, EG; Kalden, JR; Meister, S; Ocker, M; Voll, R; Wissniowski, TT | 1 |
| Brandt, S; Chinratanalab, W; Englehardt, B; Goodman, S; Greer, JP; Jagasia, MH; Kassim, A; Morgan, DS; Oluwole, O; Reddy, N; Savani, BN | 1 |
| Ahmed, M; Al-Dayel, F; Al-Kuraya, KS; Bavi, P; Hussain, AR; Siddiqui, K; Uddin, S | 1 |
| Apcher, S; Arnulf, B; Bono, C; Bories, JC; Fermand, JP; Galicier, L; Harel, S; Karlin, L; Labaume, S; Mouly, E; Sauvageon, H | 1 |
| Anderson, KC; Gaballa, MR; Ghobrial, IM; Laubach, JP; Mitsiades, CS; Munshi, N; Noonan, K; Redman, K; Richardson, PG; Schlossman, RL | 1 |
| Airia, P; Cockwell, P; Cook, M; Grima, D; Heyne, N; Hutchison, CA; Schindler, R; Zickler, D | 1 |
| Andreesen, R; Grube, M; Hafner, C; Hart, C; Wurm, S | 1 |
| Feliu, J; García-Muñoz, R; Olavarría, E; Zabalza, A | 1 |
| Kisselev, AF; Overkleeft, HS; van der Linden, WA | 1 |
| Amann, K; Benz, K; Daniel, C; Hainz, N; Meister, S; Neubert, K; Rauh, M; Thomas, S; Voll, RE; Wiesener, M | 1 |
| Chapman, WC; Csontos, K; Glasgow, SC; Jia, J; Liaw, JM; Liu, W; Mohanakumar, T; Ramachandran, S; Upadhya, GA | 1 |
| Besa, E; Bray, P; Caro, J; Dulau Florea, A; Mahipal, A; Sbenghe, MM | 1 |
| Blackwell, TS; Cheng, DS; Gleaves, LA; Han, W; Kairi, CA; Kalomenidis, I; Karabela, SP; McMahon, F; Psallidas, I; Roussos, C; Sherrill, TP; Stathopoulos, GT; Stathopoulos, I; Vassiliou, S; Yull, FE; Zakynthinos, SG; Zaynagetdinov, R | 1 |
| Abonour, R; Anderson, KC; Bengoudifa, BR; Bourquelot, PM; de Magalhaes-Silverman, M; Goldschmidt, H; Hazell, K; Lonial, S; Matous, J; Siegel, D; Vij, R; Wolf, JL | 1 |
| Bladé, J; de Larrea, CF; Rosiñol, L | 1 |
| Afar, DE; Anderson, KC; Bensinger, W; Benson, DM; Jakubowiak, AJ; Mohrbacher, A; Richardson, PG; Siegel, DS; Singhal, AK; Zimmerman, TM | 1 |
| Bocchia, M; D'Arena, G; D'Auria, F; Defina, M; Gozzetti, A; Musto, P; Papini, G; Statuto, T; Steduto, T | 1 |
| Asano, T; Ito, K; Sato, A | 2 |
| Berkowitz, A; Walker, S | 1 |
| Anderson, KC; Colson, K; Doss, D; Ghobrial, IM; Hideshima, T; Laubach, JP; Lunde, L; McKenney, M; Mitsiades, C; Munshi, NC; Noonan, K; Redman, KC; Richardson, PG; Schlossman, RL; Warren, D | 1 |
| Attal, M; Avet-Loiseau, H; Bourin, P; Cordelier, P; Corre, J; Espagnolle, N; Facon, T; Fournié, JJ; Gadelorge, M; Hébraud, B; Huynh, A; Klein, B; Labat, E; Moreau, P; Roussel, M | 1 |
| Chen, SJ; Chen, YL; Chen, Z; Cheng, X; Fang, HT; Feng, TT; Gao, L; Hu, ZG; Liu, Z; Ma, L; Pan, XF; Sheng, GQ; Xie, J; Yang, Y; Yu, XJ; Zhang, B; Zhang, FX; Zhao, HX; Zhen, T; Zhou, GB | 1 |
| Gumber, MR; Kute, VB; Patel, HV; Shah, PR; Trivedi, HL; Vanikar, AV | 1 |
| Buettner, R; Chang, S; Hedvat, M; Jove, R; Jove, V; Liu, L; Scuto, A; Tian, Y; Van Meter, T; Wen, W; Yang, F; Yen, Y; Yip, ML | 1 |
| Ahn, JS; Bae, SY; Jung, SH; Kim, HJ; Kim, YK; Lee, JJ; Moon, JH; Park, HC; Sohn, SK; Yang, DH | 1 |
| Digumarthi, R; Gundeti, S; Linga, VG; Mallavarapu, KM; Rajappa, S; Uppin, SG | 1 |
| Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ | 1 |
| Azakir, BA; Di Fulvio, S; Kinter, J; Sinnreich, M | 1 |
| Fang, FM; Huang, CK; Huang, HY; Kang, HY; Lan, J; Lee, JC; Li, CF; Li, SH; Shiue, YL; Wang, JM; Wang, JW; Wang, YH; Wu, LC; Wu, WR; Yu, SC | 1 |
| Befani, CD; Daliani, DD; Hatzidaki, E; Liakos, P; Moutzouris, G; Papandreou, CN; Patrikidou, A; Tsapakidis, K; Vlachostergios, PJ; Voutsadakis, IA | 1 |
| Guthoff, M; Häring, HU; Heyne, N; Königsrainer, A; Schmid-Horch, B; Weisel, KC | 1 |
| Bai, L; Du, BY; Miao, SY; Shen, Y; Song, W; Wang, LF | 1 |
| Elemento, O; Houghtaling, BR; Kapoor, TM; Wacker, SA | 1 |
| Chanan-Khan, AA; Dimopoulos, MA; Jagannath, S; Ludwig, H; San Miguel, JF | 1 |
| Foard, D; Gibbs, SD; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Lane, T; Pinney, JH; Rannigan, L; Venner, CP; Wechalekar, AD; Whelan, CJ | 1 |
| Bello, N; Bergsagel, PL; Fonseca, R; Jimenez-Zepeda, VH; Mikhael, JR; Reeder, CB; Schuster, SR; Spong, J; Stewart, AK | 1 |
| Gao, Y; Long, XX; Ping, BH | 1 |
| Chen, WW; Huang, KK; Huang, M; Jiang, XJ; Meng, FY; Wang, Q; Wang, ZX; Wu, FQ; Zhou, HS | 1 |
| Chen, J; Chuang, M; Jiang, D; Que, W | 1 |
| Hu, XH; Shen, YY; Xu, JJ | 1 |
| Li, LH; Tang, XW; Zhang, R | 1 |
| Chen, CC; Chen, KC; Chen, KF; Cheng, AL; Lin, YC | 1 |
| Cumová, J; Hájek, R; Jedličková, L; Potáčová, A; Potěšil, D; Sedo, O; Stejskal, K; Zdráhal, Z | 1 |
| Anderson, K; Laubach, J; Mahindra, A; Munshi, N; Raje, N; Richardson, PG | 1 |
| Gallastegui, N; Groll, M | 1 |
| Bertsch, U; Goldschmidt, H; Hose, D; Schmitt, S | 1 |
| Gartel, AL; Wang, M | 1 |
| Berenson, JR; Bravin, E; Cartmell, A; Chen, CS; Flam, M; Hilger, JD; Kazamel, T; Nassir, Y; Swift, RA; Vescio, R; Woliver, T; Yellin, O | 1 |
| Bassell, GJ; Gross, C; Muddashetty, RS; Nalavadi, VC | 1 |
| Auricchio, N; Kwiatkowski, DJ; Malinowska, I; Manning, BD; Shaw, R | 1 |
| Choi, Y; Kang, YA; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Seol, M | 1 |
| Imagawa, J; Kimura, A; Kinoshita, M; Mihara, K; Mino, T; Sakai, A; Yoshida, T | 1 |
| Hussain, SM; Jasnosz, KM; Khan, AS; Ko, TY; Marcus, RJ; Parris, G; Sureshkumar, KK; Thai, NL; Tom, K; Vivas, CA | 1 |
| Steiger, J; Zecher, D | 1 |
| Iwama, K; Matsue, K; Nishida, Y; Takeuchi, M; Yamakura, M | 1 |
| Ramchandren, R | 1 |
| Chen, Y; Ge, QF; Lu, Y; Mu, QT; Ouyang, GF; Zhang, Y | 1 |
| Cheng, T; Mao, X; Pan, X; Peng, X; Zhang, X; Zhao, S | 1 |
| Agostino, NR; DiDomenico, JD; Jane, EP; Pollack, IF; Premkumar, DR; Vukmer, NA | 1 |
| Al-Husein, B; Al-Shabrawey, M; Bollag, WB; Choudhary, V; Davis, M; Dong, Z; El Gaish, M; Kaddour-Djebbar, I; Kumar, MV; Lakshmikanthan, V; Shirley, R; Zhong, R | 1 |
| Gopinathan, G; Gribben, JG; Jia, L; Sukumar, JT | 1 |
| Fehr, T; Gaspert, A | 1 |
| Dowlati, A; Esseltine, DL; Hamilton, A; Ivy, P; LoRusso, PM; Mani, S; Mulkerin, D; Neuwirth, R; Ramanathan, RK; Rudek, MA; Sarantopoulos, J; Shibata, SI; Takimoto, CH; Venkatakrishnan, K | 1 |
| Filipczak, PT; Glowala-Kosinska, M; Krawczyk, Z; Piglowski, W; Scieglinska, D | 1 |
| Cao, Q; Dudek, AZ; Wang, H | 1 |
| Cañueto, J; Contreras, T; García-Sanz, R; Gutiérrez, NC; Labrador, J; Román, C; Santos-Briz, A | 1 |
| Andersen, NF; Andréasson, B; Billström, R; Carlson, K; Carlsson, MS; Flogegård, M; Forsberg, K; Gimsing, P; Gulbrandsen, N; Hjertner, Ø; Hjorth, M; Holmberg, E; Karlsson, T; Knudsen, LM; Linder, O; Nahi, H; Othzén, A; Pedersen, PT; Swedin, A | 1 |
| Flanagan, L; Hellwig, CT; Huber, HJ; Laussmann, MA; Passante, E; Prehn, JH; Rehm, M; Tomiczek, B | 1 |
| Chan, KM; Chou, HS; Eldeen, FZ; Lee, CF; Lee, WC; Soong, RS; Wu, TH; Wu, TJ | 1 |
| Cirone, M; Conte, V; Di Renzo, L; Faggioni, A; Frati, L; Gonnella, R; Lotti, LV; Santarelli, R; Trivedi, P | 1 |
| Boenisch, O; Denecke, C; Khalpey, Z; Pratschke, J; Reutzel-Selke, A; Sawitzki, B; Seifert, M; Tullius, SG; Volk, HD | 1 |
| Dispenzieri, A; Kohut, IE; Warsame, R | 1 |
| Brunetti, O; Ciavarella, S; Dammacco, F; Dominici, M; Grisendi, G; Silvestris, F; Tucci, M | 1 |
| Callander, N; Estevam, J; Flinn, I; Hari, P; Kumar, S; Mulligan, G; Noga, SJ; Rajkumar, SV; Richardson, PG; Rifkin, R; Shi, H; Stewart, AK; Turturro, F; Webb, IJ; Wolf, J | 1 |
| Baugé, C; Boumédiene, K; Galéra, P; Girard, N; Leclercq, S | 1 |
| Chinen, Y; Fuchida, S; Horiike, S; Kiyota, M; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Nakayama, R; Ohshiro, M; Sakamoto, N; Sasaki, N; Shimazaki, C; Shimura, Y; Taniwaki, M; Uchiyama, H; Yamamoto-Sugitani, M | 1 |
| Cheng, T; Mao, X; Pan, X; Peng, X; Zhang, X | 1 |
| D'Souza, J; Khandros, E; Thom, CS; Weiss, MJ | 1 |
| Kwong, YL; Loong, F; Yeung, CK | 1 |
| Miyata, Y; Mizuno, H; Nakao, N; Nakayama, T; Naoe, T; Nishiwaki, S; Saito, S; Takeshita, K | 1 |
| Berkers, CR; Jones-Bolin, S; Leestemaker, Y; Ovaa, H; Ruggeri, B; Schuurman, KG; Williams, M | 1 |
| Badgett, TC; Chen, QR; Cheuk, AT; Khan, J; Song, YK; Tsang, PS; Wei, JS | 1 |
| Ang, AL; Goh, YT; Mok, SJ; Phipps, C; Tan, D | 1 |
| Bardag-Gorce, F; French, SW; Li, J; Oliva, J | 1 |
| Alekshun, TJ; Alsina, M; Anasetti, C; Baz, R; Chen, DT; Dalton, W; Fernandez, HF; Fulp, W; Han, G; Kharfan-Dabaja, MA; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Oliveira, V; Perez, L; Pidala, J; Raychaudhuri, J; Shain, K; Sullivan, DM; Yarde, DN | 1 |
| Gu, JL; Huang, BH; Li, J; Liu, JR; Su, C; Zheng, D; Zhou, ZH | 1 |
| Bergsagel, PL; Chesi, M; Garbitt, VM; Johnstone, RW; Lefebure, M; Matthews, GM; Palmer, SE; Shortt, J; Stewart, AK | 1 |
| Beckers, EA; Cornelis, T; Driessen, AL; Koek, GH; van der Sande, FM | 1 |
| Barresi, MJ; Benaich, N; Bernardos, RL; Downes, GB; Hutson, LD; Khan, TM; Malone, CF; Russell, AR | 1 |
| Cakana, A; Delforge, M; Dhawan, R; Esseltine, DL; Meunier, J; Regnault, A; Richardson, PG; Robinson, D; San Miguel, JF; van de Velde, H | 1 |
| Jimenez-Zepeda, VH | 1 |
| Domján, G; Gadó, K | 1 |
| Silvennoinen, R; Sinisalo, M; Wirta, O | 1 |
| Bardag-Gorce, F; Bartrons, R; Bonaccorsi-Riani, E; Boncompagni, E; Carbonell, T; French, SW; Oliva, J; Padrissa-Altés, S; Roselló-Catafau, J; Zaouali, MA | 1 |
| Barosi, G; Billio, A; Boccadoro, M; Cavo, M; Corradini, P; Marchetti, M; Massaia, M; Merlini, G; Palumbo, A; Tosi, P; Tura, S | 1 |
| Bartsch, DK; Brendel, C; Greene, BH; Hinterseher, U; Hoffmann, S; Ramaswamy, A; Roth, S; Wunderlich, A | 1 |
| Okur, E; Ulukaya, E; Yerlikaya, A | 1 |
| Asano, Y; Kadono, T; Sato, S; Sugaya, M; Tada, Y; Yanaba, K | 1 |
| Finegold, MJ; Grompe, M; Loza, LM; Paulk, NK | 1 |
| Hasegawa, S; Hashimoto, M; Lee-Kawabata, M; Masuyama, T; Naito, Y; Ogawa, H; Tamaki, H | 1 |
| Dispenzieri, A; Gertz, MA | 1 |
| Canonico, S; D'Amico, M; Di Filippo, C; Ferretti, M; Freda, F; Petronella, P; Rossi, F; Scorzelli, M | 1 |
| Eiam-Ong, S; Susantitaphong, P; Tiranathanagul, K | 1 |
| Ballanti, S; Baraldi, A; Boccadoro, M; Brioli, A; Califano, C; Callea, V; Carella, AM; Cavo, M; Crippa, C; De Stefano, V; Derudas, D; Dessanti, ML; Donnarumma, D; Falcone, A; Ferrara, F; Furlan, A; Grasso, M; Marcatti, M; Masini, L; Musto, P; Nozza, A; Nozzoli, C; Palumbo, A; Pantani, L; Patriarca, F; Perrone, G; Petrucci, MT; Pezzi, A; Zamagni, E; Zambello, R | 1 |
| Garcia-Sanz, R; Mateos, MV; Ocio, E; San Miguel, JF | 1 |
| Cabanillas, F | 1 |
| Giralt, S | 2 |
| Kyle, RA | 1 |
| Stockler, MR; Wilcken, NR | 1 |
| Amerik, AY; Issaenko, OA | 1 |
| Besio, R; Forlino, A; Giansanti, V; Gioia, R; Marini, JC; Merlini, G; Palladini, G; Panaroni, C; Rossi, A; Scovassi, IA; Tenni, R; Vezzoni, P; Villa, A; Villa, I; Villani, S | 1 |
| Fu, B; Li, Y; Liao, A; Liu, Z; Pan, H; Wang, H; Wang, X; Yang, W | 1 |
| Bo, J; Gao, C; Huang, W; Kang, W; Li, H; Li, J; Yu, L; Zhao, Y; Zhou, D | 1 |
| Anderson, KC; Eng, C; Hideshima, T; Kolesar, J; Richardson, PG | 1 |
| Cheng, SH; Gumlaw, NK; Jiang, JL; Karman, J; Zhang, J; Zhu, Y | 1 |
| Cheson, BD; Koprivnikar, JL | 1 |
| Arias, A; Baumann, G; Dreger, H; Fechner, M; Hewing, B; Ludwig, A; Meiners, S; Stangl, K; Stangl, V; Wilck, N | 1 |
| Ding, ZB; Fan, J; Gu, CY; Hui, B; Liu, WR; Peng, YF; Shi, GM; Shi, YH; Yang, H; Zhou, J | 1 |
| Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T | 1 |
| Cooley, K; Fergusson, D; Fernandes, R; Fritz, H; Kennedy, DA; Seely, D | 1 |
| Haensch, CA; Isenmann, S; Katona, I; Schlemmer, H; Stratogianni, A; Tosch, M; Weis, J | 1 |
| Blanco, B; Caballero-Velázquez, T; Calderon, C; Carrancio, S; del Cañizo, C; Gutierrez-Cosio, S; Herrero, C; Pérez-Simón, JA; San Miguel, JF; Sánchez-Abarca, LI; Serrano, C | 1 |
| Economou, JS; Jazirehi, AR | 1 |
| Arcila, M; Gerecitano, J; Gonzalez, C; Gounder, S; Lin, D; McDonald, A; Mulligan, G; O'Connor, OA; Ogilvie, S; Teruya-Feldstein, J; Zhang, Z; Zheng, J | 1 |
| Adam, Z; Al-Sahmani, M; Antošová, L; Antošová, M; Buliková, A; Hájek, R; Kaisarová, B; Kissová, J; Penka, M; Trnavská, I | 1 |
| Juul, JS; Larsen, T; Marcussen, N; Pedersen, EB | 1 |
| Bathini, V; Bradley, K; Hanrahan-Boshes, M; Hutchinson, L; Perez-Soler, R; Piperdi, B; Walsh, WV; Zhou, Z | 1 |
| Bumpers, K; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; Kaufman, JL; Khoury, HJ; King, N; Lechowicz, MJ; Lewis, C; Lonial, S; Shenoy, PJ; Sinha, R; Tighiouart, M | 1 |
| Bessone, L; Carta, F; Gallo, V; Giribaldi, G; Khadjavi, A; Mandili, G; Minero, VG; Turrini, F | 1 |
| Chang, KC; Chen, KF; Chu, PY; Liu, CY; Shiau, CW; Tseng, LM | 1 |
| Chen, FT; Liu, YC; Yang, CH; Yang, CM | 1 |
| Anderson, KC; Blumenthal, M; Cirstea, D; Fabre, C; French, M; Fulciniti, M; Gorgun, G; Hokenson, M; Hu, Y; Ikeda, H; Kawano, Y; Kertesz, NL; Kiziltepe, T; Malyankar, UM; Mimura, N; Minami, J; Munshi, NC; Ohguchi, H; Patterson, JB; Pham, T; Richardson, PG; Santo, L; Tai, YT; Tam, V; Zeng, Q | 1 |
| Cochran, MC; Eisenbrey, JR; Oum, KL; Wheatley, MA | 1 |
| Chen, XQ; Dong, HJ; Gao, GX; Gu, HT; Wang, YW; Yang, Y | 1 |
| Olie, RA; Taverna, C; Trojan, A; Voegeli, J; von Rohr, A | 1 |
| Heo, DS; Hong, SW; Hong, YS; Jin, DH; Kim, KP; Kim, SM; Kim, TW; Lee, JL; Lee, JS; Shin, JS; Yoon, DH | 1 |
| Chng, WJ; Goh, YT; Khin, MT; Koh, LP; Lee, LH; Ong, KH; Tan, D; Wong, SS | 1 |
| Cao, XX; Duan, MH; Kang, WY; Li, J; Zhang, W; Zhou, DB | 1 |
| Alsina, M; Bahlis, NJ; Belch, A; Gabrail, NY; Jagannath, S; Jakubowiak, AJ; Kaufman, JL; Kukreti, V; Kunkel, LA; Lee, P; Lonial, S; Matous, JV; McDonagh, KT; Orlowski, RZ; Reu, FJ; Rosen, P; Sebag, M; Siegel, DS; Stewart, AK; Vesole, DH; Vij, R; Wang, M; Wear, SM; Wong, AF | 1 |
| Gao, D; Guo, K; Jiang, K; Jin, G; Kang, X; Li, Y; Liu, Y; Shu, H; Sun, C; Sun, H; Sun, L; Wang, C; Wu, W | 1 |
| Jang, WS; Kang, HJ; Kim, A; Lee, JE; Lee, SJ; Lee, SS; Park, S | 1 |
| Finke, J; Houet, L; Moeller, I; Spagnoli, GC; Veelken, H | 1 |
| Feldman, T; Goy, A; Mato, AR | 1 |
| Bloomfield, CD; Blum, W; Byrd, JC; Caligiuri, MA; Chan, KK; Curfman, JP; Devine, SM; Eisfeld, AK; Garr, C; Garzon, R; Geyer, S; Grever, MR; Jacob, S; Kefauver, C; Klisovic, R; Marcucci, G; Perrotti, D; Santhanam, R; Schwind, S; Tarighat, SS; Walker, A; Wang, H; Whitman, S | 1 |
| Korde, N; Kwok, M; Landgren, O | 1 |
| Bai, C; Hu, X; Liu, J; Song, X; Wang, J | 1 |
| Ades, L; Berger, E; Bordessoule, D; Braun, T; Cahn, JY; Charbonnier, A; Chaury, MP; Cheze, S; Dreyfus, F; Etienne, G; Fenaux, P; Guerci-Bresler, A; Legros, L; Natarajan-Amé, S; Park, S; Ravoet, C; Schmidt, A; Stamatoullas, A; Vey, N | 1 |
| Arora, R; Brodsky, JL; Chang, Y; Dömling, A; Feng, H; Guastafierro, A; Moore, PS; Normolle, D; Shuda, M; Tolstov, Y; Toptan, T; Vogt, A; Vollmer, LL | 1 |
| Jimenez-Zepeda, VH; John, R; Trudel, S; Vajpeyi, R | 1 |
| Avet-Loiseau, H; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Davies, F; de la Rubia, J; Delimpasi, S; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Hess, U; Ludwig, H; Mellqvist, UH; Moreau, P; Palumbo, A; San-Miguel, J; Sondergeld, P; Sonneveld, P; Udvardy, M | 1 |
| Backendorf, C; Lanz, HL; Noteborn, MH; Suijker, J | 1 |
| Asimakopoulos, F; Callander, NS; Denu, RA; Dollar, BA; Escalante, LE; Hematti, P; Kim, J; Kuether, JP | 1 |
| Fujita, Y; Fukushima, T; Iwao, H; Masaki, Y; Miki, M; Nakajima, A; Nakamura, T; Sakai, T; Sato, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
| Cantaffa, R; Carillio, G; Kropp, M; Lamberti, AG; Molica, S; Piro, E | 1 |
| Bergamo, S; di Meo, N; Dondas, A; Trevisan, G | 1 |
| Cakana, A; Casassus, P; Chaleteix, C; de Witte, T; Dib, M; Doyen, C; Fontan, J; Gahrton, G; Garderet, L; Gorin, NC; Gratwohl, A; Hajek, R; Harousseau, JL; Hertenstein, B; Iacobelli, S; Ketterer, N; Koenecke, C; Kolb, B; Lafon, I; Ludwig, H; Masszi, T; Michallet, M; Milone, G; Mohty, M; Moreau, P; Morris, C; Niederwieser, D; Onida, F; Pegourie, B; van Os, M | 1 |
| Anagnostopoulos, A; Athanasiou, E; Batsis, I; Fassas, A; Kaloyannidis, P; Papadopoulou, A; Yannaki, E; Yiangou, M; Zogas, N | 1 |
| Chopp, M; Zhang, L; Zhang, ZG | 1 |
| Bai, QX; Zhang, XY | 1 |
| Downward, J; Hancock, DC; Howell, M; Kelly, G; Kuznetsov, H; Marani, M; Molina-Arcas, M; Saunders, B; Steckel, M; Warne, PH; Weigelt, B | 1 |
| Bale, RJ; Eisterer, W; Gabriel, M; Gastl, G; Kendler, D; Kroiss, A; Madleitner, R; Putzer, D; Uprimny, C; Virgolini, IJ | 1 |
| Feng, J; Li, Z; Ma, Y; Ren, H; Wang, Y; Zhao, J | 1 |
| Barrera, LN; Bowles, KM; MacEwan, DJ; Rushworth, SA | 1 |
| Berenson, JR; Chen, H; Li, J; Li, M; Nichols, CM; Sanchez, E; Wang, C | 1 |
| Barthelemy, M; Boulanger, F; Cossment, C; Facon, T; Fouquet, G; Le Ray, E; Leleu, X; Manier, S; Noel, MP; Prod'homme, C; Samarcq, P; Terriou, L | 1 |
| Itoh, K; Sasaki, M; Yamaguchi, T | 1 |
| Ferrara, R; Obeid, KM; Sharma, M | 1 |
| Afqir, S; Belbaraka, R; Benjaafar, N; Elmajjaoui, S; Errihani, H; Ismaili, N; Tahri, A | 1 |
| Choi, KS; Kim, EH; Kwon, TK; Park, SA; Yoon, MJ | 1 |
| Bertoni, F; Catapano, CV; Colombo, N; Del Conte, G; Gadducci, A; Hess, D; Katsaros, D; Mancari, R; Marsoni, S; Parma, G; Rinaldi, A; Scambia, G; Sessa, C; van de Velde, H; Vitali, A | 1 |
| Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Trudel, S; Winter, A | 1 |
| Huang, K; Li, Y; Ma, L; Nie, D; Wang, X; Wu, Y; Xiao, J; Xie, S; Yin, S | 1 |
| Cavo, M; Harousseau, JL; Moreau, P; Orlowski, RZ; Palumbo, A; Richardson, PG; San Miguel, JF | 1 |
| Alcántara, J; Bagazgoitia, L; Carrillo, R; Truchuelo, M; Velasco, D | 1 |
| Rivella, S | 1 |
| Bostrom, BC; Eckroth, E; Gaynon, PS; Malvar, J; Messinger, YH; Sposto, R; van der Giessen, J | 1 |
| Kim, WS; Lee, SJ; Park, C; Yeom, SY | 1 |
| Yerlikaya, A | 1 |
| Grantab, RH; Tannock, IF | 1 |
| Ahmad, N; Al Sayed, Y; Atrash, S; Barlogie, B; Chauhan, N; Crowley, J; Heuck, CJ; Hoering, A; Nair, B; Petty, N; Sexton, R; Usmani, SZ; van Rhee, F; Waheed, S | 1 |
| Ikeda, D; Masuda, T; Momose, I; Nomoto, A; Ohba, S; Tatsuda, D | 1 |
| Klintmalm, GB; O'Leary, JG; Paterno, F; Shiller, M; Susskind, B; Tillery, G; Trotter, J | 1 |
| Chan, EY; Chim, CS; Kwong, YL; Lau, CW; Liang, R; Lie, AK; Liu, HS; Ma, ES; Sim, J; Tse, E; Wan, TS; Yip, SF | 1 |
| Boland, R; D'Elia, N; Gonzalez-Pardo, V; Russo de Boland, A; Verstuyf, A | 1 |
| Bolanos, L; Cloos, J; Cortelezzi, A; Cuzzola, M; Fang, J; Goyama, S; Jansen, G; Mulloy, JC; Oliva, EN; Rasch, C; Rhyasen, G; Rigolino, C; Starczynowski, DT; Varney, M; Wunderlich, M | 1 |
| Martinon, F | 1 |
| Aggarwal, BB; Ahn, KS; Cheung, LH; Cho, MJ; Ford, RJ; Hittelman, WN; Lyu, MA; Marks, JW; Pham, LV; Rosenblum, MG; Sung, B; Tamayo, AT | 1 |
| Chigira, N; Ichikawa, K; Imai, H; Komatsu, N; Noguchi, M; Sawada, T; Sekiguchi, Y; Shirane, S; Sugimoto, K; Wakabayashi, M | 1 |
| Chisholm, R; Houghton, J; O'Driscoll, BR; O'Riordan, D | 1 |
| Arnulf, B; Cakana, A; Deraedt, W; Feng, H; Grosicki, S; Karamanesht, I; Leleu, X; Moreau, P; Pylypenko, H; van de Velde, H | 1 |
| Anderson, KC; Benajiba, L; Fennessy, F; Laubach, J; Richardson, PG; Saboo, SS | 1 |
| Bladé, J; Cibeira, MT; de Larrea, CF; Escoda, L; Rosiñol, L; Rovira, M; Solé, M; Tovar, N | 1 |
| Bonvini, P; Peron, M; Rosolen, A | 1 |
| Brunetti, GA; Cartoni, C; Cupelli, L; D'Elia, GM; Efficace, F; Federico, V; Grammatico, S; Niscola, P; Petrucci, MT; Scaramucci, L; Tendas, A; Truini, A | 1 |
| Kawanami, M; Sato, MM; Tamura, M; Uyama, M | 1 |
| Alimena, G; Breccia, M; Cartoni, C; Federico, V; Levi, A; Loglisci, G; Mansueto, G; Mercanti, C; Musto, P; Petrucci, MT | 1 |
| Molica, S | 1 |
| Hashimoto, S; Nakaseko, C; Sakai, S; Sakuma, I; Shimura, T; Takagi, T; Takeda, Y; Tanaka, H | 1 |
| Charliński, G; Jedrzejczak, WW; Wiater, E | 1 |
| Groll, M; Huber, EM | 1 |
| Ewald, GA; Hassan, A; Joseph, SM; Klein, JL; Uy, GL; Wang, TF; Woodard, PK | 1 |
| Benedetti, V; Cincinelli, R; Corna, E; De Cesare, M; Gatti, L; Perego, P; Zaffaroni, N; Zunino, F | 1 |
| Bretz, J; Chen, I; Chen-Kiang, S; Di Liberto, M; Ely, S; Hahn, WC; Huang, X; Jayabalan, D; Liang, J; Louie, T; Moore, MA; Niesvizky, R; Randolph, S; Shaffer, AL; Staudt, LM | 1 |
| Cheung, J; Cornell, IS; Yau, AH | 1 |
| Chopp, M; Kassis, H; Liu, X; Tang, T; Teng, H; Zhang, L; Zhang, ZG | 1 |
| Esseltine, DL; Mulligan, G | 1 |
| Kirk, CJ | 1 |
| Kapoor, P; Rajkumar, SV; Ramakrishnan, V | 1 |
| Broyl, A; Jongen, JL; Sonneveld, P | 1 |
| Alloway, RR; Sadaka, B; Schmidt, NM; Shields, AR; Woodle, ES | 1 |
| Augusti, V; Ballestrero, A; Carbone, F; Moran, E; Nencioni, A; Patrone, F | 1 |
| Goulston, C; Hanson, KE; Kim, JH; Lampas, M; Sanders, S; Tricot, G; Zangari, M | 1 |
| Liu, ZG; Wang, HT; Wang, JF | 1 |
| Ao, L; Jang, ER; Kim, D; Kim, K; Kim, KB; Lee, DM; Lee, W; Wu, Y | 1 |
| Guo, H; Shao, L; Sun, H; Xu, M; Zhou, X; Zhu, J | 1 |
| Du, SH; Du, X; He, C; Jia, PM; Tong, JH; Zhou, L | 2 |
| Guo, M; Hu, KX; Kang, Y; Qiao, JH; Sun, QY; Yu, CL; Zhao, YY | 1 |
| Bigley, V; Collin, M; Hambleton, S; Jardine, L; Pagan, S; Wang, XN | 1 |
| Al-Otaibi, T; Al-Waheeb, S; Gheith, O; Halim, M; Ibraheim, M; Muzeirei, I; Nair, P; Nampoory, N; Saied, T | 1 |
| Haidl, F; Lund, T; Plesner, T | 1 |
| Asklund, T; Bergenheim, T; Hedman, H; Henriksson, R; Holmlund, C; Kvarnbrink, S; Wibom, C | 1 |
| Borja-Cacho, D; Chinnakotla, S; Dunn, TB; Finger, E; Kandaswamy, R; Kim, Y; Krefting, P; Manivel, C; Matas, A; Maurer, D; Noreen, H; Pruett, T; Tamayo, G; Verghese, P | 1 |
| Hardinger, KL; Murillo, D | 1 |
| Abidi, MH; Abrams, J; Al-Kadhimi, Z; Ayash, L; Deol, A; Gul, Z; Lum, L; Mellon-Reppen, S; Ratanatharathorn, V; Uberti, J; Ventimiglia, M; Zonder, J | 1 |
| Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Matsouka, C; Mparmparoussi, D; Nikitas, N; Psimenou, E; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E | 1 |
| Blanco, JF; Collins, L; Garayoa, M; Garcia-Gomez, A; Hornick, MC; Hurchla, MA; Kirk, CJ; Li, A; Ocio, EM; Pandiella, A; Piwnica-Worms, D; San Miguel, JF; Tomasson, MH; Vij, R; Weilbaecher, KN | 1 |
| Fujiwara, S; Hata, H; Iyama, K; Izaki, M; Kawano, Y; Mitsuya, H; Okuno, Y; Sakai, A; Wada, N; Yamasaki, H; Yuki, H | 1 |
| Bitterman, PB; Dahlberg, PS; Issaenko, OA; Polunovsky, VA | 1 |
| Do, IG; Huh, J; Kang, HJ; Kim, HJ; Kim, HK; Kim, JS; Kim, SJ; Kim, WS; Ko, YH; Lee, J; Lee, SS; Min, SK; Park, SK; Ryoo, BY; Suh, C; Yang, WI; Yoon, DH | 1 |
| De Becker, A; De Raeve, H; Van Camp, B; Van Riet, I; Vanderkerken, K; Xu, S | 1 |
| Cai, X; Ding, K; Duan, Q; Han, Y; Liu, X; Sun, Z; Wang, A; Wu, J; Zhu, W | 1 |
| Chowdhury, RD; Driscoll, JJ | 1 |
| An, N; Chen, SL; Hu, Y; Li, X; Liu, XH; Sun, WJ; Zhang, JJ; Zhong, YP | 1 |
| Chen, M; Huang, BH; Li, J; Liu, JR; Xu, DR; Zheng, D; Zou, WY | 1 |
| Bornfeld, N; Freistuehler, M; Hilger, RA; Scheulen, M; Steuhl, KP; Westekemper, H | 1 |
| Takamatsu, Y | 1 |
| Argiris, A; Arun, P; Feldman, LE; Forastiere, AA; Gilbert, J; Haigentz, M; Jang, M; Lee, JW; Van Waes, C | 1 |
| Alegre, A; Besalduch, J; Bladé, J; Cibeira, MT; de Arriba, F; de la Rubia, J; Díaz-Mediavilla, J; Etxebeste, MA; González, Y; Granell, M; Gutiérrez, NC; Hernández, D; Hernández, MT; Lahuerta, JJ; López-Jiménez, J; Martín-Ramos, ML; Martínez, J; Mateos, MV; Oriol, A; Palomera, L; Rosiñol, L; San Miguel, J; Teruel, AI | 1 |
| Gryczynski, Z; Ranjan, AP; Raut, SL; Thamake, SI; Vishwanatha, JK | 1 |
| Joshi, VR; Nagaraj, S; Sharma, V | 1 |
| Gilbar, P; Seger, AC | 1 |
| Bertsch, U; Blau, IW; Bos, GM; Broyl, A; Duehrsen, U; El Jarari, L; Goldschmidt, HM; Hose, D; Jauch, A; Kersten, MJ; Lindemann, W; Lokhorst, HM; Pfreundschuh, M; Raymakers, R; Salwender, H; Schaafsma, MR; Scheid, C; Schmidt-Wolf, IG; Sonneveld, P; Stevens-Kroef, M; van der Holt, B; van der Velde, H; van Marwijk-Kooy, M; Vellenga, E; Weisel, KC; Wijermans, PW; Wittebol, S; Zweegman, S | 1 |
| Burlingame, AL; Hsu, GW; Mahrus, S; Nguyen, H; Shimbo, K; Trinidad, JC; Wells, JA | 1 |
| Crotty, TB; Dunne, O; Fennelly, D; Holian, J; Ward, F; Watson, A | 1 |
| Ahles, CP; Berenson, JR; Boccia, R; Bonavida, B; Chen, H; Crowley, J; Dreyer, MP; Kirk, DT; Kitto, A; Li, J; Li, M; Madden, E; Nichols, CM; Robinson, A; Sanchez, E; Swift, RA; Vescio, RA; Wang, CS; Waterman, GN; Yellin, O | 1 |
| Anderson, KC; Bobb, K; Carrasco, RD; Cirstea, D; Fabre, C; Gorgun, G; Hideshima, T; Hu, Y; Kong, SY; Meshulam, J; Mimura, N; Minami, J; Ohguchi, H; Richardson, PG; Tai, YT; Zhang, J | 1 |
| Agten, A; Cielen, N; Decramer, M; Dekhuijzen, RP; Gayan-Ramirez, G; Maes, K; Thomas, D; Van Hees, HW | 1 |
| Laghi, F | 1 |
| Bhaskar, B; Kassim, A; Paton, VE; Wamstad, K; White, D; Yi, J | 1 |
| Chung, HM; Clark, WB; Hazlett, AF; Kmieciak, M; Manjili, MH; McCarty, JM; Payne, KK; Roberts, CH; Sabo, RT; Sanford, K; Toor, AA; Williams, DC | 1 |
| Bacovsky, J; Langova, K; Minarik, J; Pika, T; Scudla, V | 1 |
| Bergadà, L; Dolcet, X; Llombart-Cussac, A; Martí, RM; Matias-Guiu, X; Sorolla, A; Valls, J; Yeramian, A | 1 |
| Amodio, N; Anderson, KC; Azab, AK; Blotta, S; Calimeri, T; Foresta, U; Jakubikova, J; Mitsiades, CS; Molica, S; Morabito, F; Munshi, NC; Neri, A; Roccaro, AM; Rossi, M; Tagliaferri, P; Tassone, P; Todoerti, K | 1 |
| Li, XW; Yang, JR | 1 |
| Dennis, PA; Gills, JJ; Hollander, MC; Kawabata, S; Lopiccolo, J; Mercado-Matos, JR; Wilson, W | 1 |
| Alloway, RR; Girnita, AL; Hanseman, DJ; Sadaka, B; Schmidt, N; Shields, AR; Walsh, RC; Woodle, ES | 1 |
| Anderson, KC; Lokhorst, HM; Richardson, PG; van de Donk, NW | 1 |
| Huh, JW; Kim, HJ; Kim, SY; Lee, JH; Lee, SD; Lee, YS; Oh, YM; Park, MK; Ro, JY | 1 |
| Bahlis, N; Belch, A; Jagannath, S; Jakubowiak, AJ; Kunkel, LA; McDonagh, K; Siegel, DS; Stewart, AK; Vij, R; Wang, M; Wear, S; Wong, AF | 1 |
| Liu, X; Su, L; Xu, L | 1 |
| Gilbar, PJ; Seger, AC | 2 |
| Mehta, N; Niesvizky, R; Saxena, A | 1 |
| Gertz, M | 1 |
| Huang, KK; Jiang, XJ; Meng, FY; Qiao, L; Wang, Q; Wang, ZX; Wu, FQ; Yang, M; Ye, JY; Yi, ZS; Zhao, QX; Zhou, HS | 1 |
| Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Cutler, C; Ho, VT; Kim, HT; Koreth, J; McDonough, SM; Ritz, J; Soiffer, RJ; Stevenson, KE | 1 |
| Berenson, JR; Eshaghian, S | 1 |
| Anderson, KC; Avet-Loiseau, H; Casassus, P; Decaux, O; Facon, T; Garderet, L; Godmer, P; Gouraud, W; Hulin, C; Lodé, L; Magrangeas, F; Marit, G; Minvielle, S; Moreau, P; Munshi, NC; Randriamalala, E; Stoppa, AM; Tiab, M; Voillat, L; Voog, E | 1 |
| Borst, J; Rooswinkel, RW; van de Kooij, B; Verheij, M | 1 |
| Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S | 2 |
| Ai, L; Cui, G; Gowrea, B; Hu, Y; Li, M; Wang, Y | 1 |
| Ahern, CH; Ames, MM; Blaney, SM; Espinoza-Delgado, I; Horton, TM; Ingle, AM; McGovern, RM; Muscal, JA; Reid, JM; Thompson, PA; Weigel, BJ | 1 |
| Du, HF; Lv, HY; Meng, J; Meng, YF; Song, XN; Yu, LJ; Zhang, JQ | 1 |
| Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; de Arriba, F; García-Sanz, R; González, Y; Granell, M; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; López de la Guía, A; López, J; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Oriol, A; Palomera, L; Peñalver, FJ; Pérez, M; Polo, M; Ribera, JM; San-Miguel, JF; Teruel, AI | 1 |
| Banerjee, A; Gartel, AL; Halasi, M; Kabirov, K; Landolfi, J; Lyubimov, AV; Wang, M | 1 |
| Baas, P; Busacca, S; Cakana, A; Donnellan, P; Fennell, DA; McCaffrey, J; McDowell, C; Meerbeeck, JV; Moulton, B; O'Byrne, KJ; Webb, G | 1 |
| Kimby, E | 1 |
| Chang, CL; Hsu, YT; Hung, CF; Wang, C; Wu, CC; Wu, TC; Yang, YC | 1 |
| Bauer, F; Codreanu, I; Dasanu, CA; Padmanabhan, P; Rampurwala, M | 1 |
| Dean, RA; Franck, WL; Gokce, E; Han, SO; Muddiman, DC; Oh, Y; Shows, A | 1 |
| Ishiyama, T; Jinguu, A; Kikuchi, J; Matsumoto, H; Suzuki, T; Yamakawa, M | 1 |
| Cui, HX; Hu, W; Jiang, YH; Wang, Y; Yue, D; Zheng, RR | 1 |
| Cilley, J; Evens, AM; Gallot, L; Gordon, LI; Larson, A; Patton, D; Rademaker, A; Roy, R; Spies, S; Variakojis, D; Winter, JN | 1 |
| Cockwell, P; Cook, M; Stringer, S | 1 |
| Bladé, J; Dimopoulos, MA; Kastritis, E | 1 |
| Cockwell, P; Cook, M | 1 |
| Haynes, R; Kyle, R; Leung, N; Winearls, CG | 1 |
| Bashir, Q; Bayraktar, UD; Champlin, RE; Ciurea, SO; Qazilbash, M | 1 |
| Chen, Z; Fayad, L; Kwak, LW; McCarty, N; Romaguera, J; Wang, M | 1 |
| Cvek, B; Skrott, Z | 2 |
| Baladandayuthapani, V; Berkova, Z; Bjorklund, CC; Davis, RE; Jones, RJ; Kuhn, DJ; Lin, P; Ma, W; Madden, TL; Orlowski, RZ; Shah, JJ; Thomas, SK; Wang, H; Wang, M; Weber, DM; Wei, C; Woessner, R | 1 |
| Chang, TC; Chen, SC; Jan, YJ; Ko, BS; Liang, SM; Liou, JY; Liu, TA; Wang, J; Wu, YM | 1 |
| Fuchida, S; Haruyama, H; Hatsuse, M; Itoh, S; Murakami, S; Okano, A; Shimazaki, C | 1 |
| de Jong, S; de Wilt, LH; Jansen, G; Kroon, J; Kruyt, FA; Peters, GJ | 1 |
| Bennett, GJ; Xiao, WH; Zheng, H | 1 |
| Chan, DV; Gibson, HM; Hake, TS; Mishra, A; Porcu, P; Wong, HK | 1 |
| Akashi, K; Chong, Y; Ito, Y; Kamimura, T; Miyamoto, T; Takashima, S; Yokota, N | 2 |
| Basile, I; Cathiard, AM; Garcia, M; Gary-Bobo, M; Gleizes, M; Maynadier, M; Sheikh, MS; Shi, J; Vaillant, O; Wah, JL | 1 |
| Allen, JE; Aqui, N; Dicker, DT; Dolloff, NG; El-Deiry, WS; Malysz, J; Talamo, G; Vogl, D | 1 |
| Bockorny, B; Bockorny, M; Bona, R; Chakravarty, S; Schulman, P | 1 |
| Arbeille, B; Croué, A; Ifrah, N; Levaltier, X; Marchand, A; Martin, L | 1 |
| Chen, Z; Jung, HJ; McCarty, N | 1 |
| Jeong, SJ; Jung, JH; Kim, B; Kim, SH; Lee, MH; Sohn, EJ | 1 |
| Suzuki, K | 2 |
| Abbas, J; Costa, LJ; Kang, Y; Ortiz-Cruz, KL; Stuart, RK | 1 |
| Altun, M; Anderson, KC; Carrasco, R; Chauhan, D; Fulcinniti, M; Hideshima, T; Kessler, BM; Kingsbury, WD; Kodrasov, MP; Kumar, KG; Leach, CA; McDermott, JL; Minvielle, S; Munshi, N; Nicholson, B; Orlowski, R; Richardson, P; Shah, PK; Tian, Z; Weinstock, J; Zhou, B | 1 |
| Barrera, LN; Bowles, KM; MacEwan, DJ; Murray, MY; Rushworth, SA; Zaitseva, L | 1 |
| Hashimoto, N; Hattori, Y; Kato, J; Koda, Y; Mori, T; Okamoto, S; Sadahira, K; Shimizu, T; Tsukada, Y; Yamane, A; Yokoyama, K | 1 |
| Botton, Sd; Boué, F; Bourhis, JH; Crickx, E; Danu, A; Ghez, D; Mariette, X; Miceli, C; Moreau, P; Pasquier, F; Ribrag, V; Wittnebel, S | 1 |
| Chen, KF; Chen, MH; Huang, HP; Kuo, HY; Liu, CY; Shiau, CW; Tzeng, CH | 1 |
| Bruce, JT; Devine, SM; Elder, P; Hofmeister, CC; Mastronarde, JG; Phillips, G; Tran, JM; Wood, KL | 1 |
| Cai, Z; Han, X; He, J; Huang, H; Lin, M; Meng, X; Shi, J; Wei, G; Wu, W; Xie, W; Yang, L; Ye, X; Zhang, J; Zheng, G; Zheng, W | 1 |
| Lee, KY; Levacque, Z; Rosales, JL | 1 |
| Ghielmini, M; Stathis, A | 1 |
| Bantel, H; Kontermann, R; Krech, T; Länger, F; Lehner, F; Manns, MP; Nüssler, A; Pfizenmaier, K; Schulze-Osthoff, K; Siegemund, M; Vondran, F; Wahl, K | 1 |
| Arima, N; Kawada, H | 1 |
| Badros, A; Khan, RZ | 1 |
| Chan, ET; DeLancey, HM; Freilino, ML; Grandis, JR; Johnson, DE; Kirk, CJ; Li, C; Thomas, SM; Zang, Y | 1 |
| Cheng, H; Hu, X; Huang, C; Lü, S; Song, X; Wang, J; Wang, L; Yang, J | 1 |
| Kim, JS; Lee, JW; Lee, MW; Roh, HS; Yu, HJ | 1 |
| Fujisawa, K; Hirose, Y; Matsumoto, T; Murata, Y; Saeki, I; Sakaida, I; Takami, T; Terai, S; Yamamoto, N; Yamasaki, T | 1 |
| Wang, X; Yao, C; Zhang, Z | 1 |
| Bello, C; Comenzo, RL; Flombaum, C; Giralt, S; Hassoun, H; Hoover, E; Landau, H; Liu, J; Maurer, M; Riedel, E; Rosenzweig, MA | 1 |
| Cakana, A; Deraedt, W; Domnikova, N; Doronin, VA; Esseltine, DL; Facon, T; Feng, H; Girgis, S; Hulin, C; Karamanesht, II; Kyselyova, MY; Leleu, X; Moreau, P; Schmidt, A; Skee, D; van de Velde, H; Venkatakrishnan, K; Vilchevska, KV | 1 |
| Alsina, M; Anderson, KC; Bladé, J; Cavenagh, J; Dalton, W; Danaee, H; Esseltine, DL; Façon, T; Lichter, DI; Lonial, S; Mulligan, G; Niesvizky, R; Pickard, MD; Ricci, D; Richardson, PG; Shi, H; Sintchak, M; Sonneveld, P; Tayber, O; Trepicchio, WL; van de Velde, H | 1 |
| Baran, Y; Sanlı-Mohamed, G; Turan, T | 1 |
| Cózar-Castellano, I; Joumady, I; Perdomo, G; Sáez-Benito, A; Tirado-Vélez, JM | 1 |
| Synhaeve, NE; Tijssen, CC; van der Heul, C | 1 |
| Akhundova, FM; Gal'tseva, IV; Gaponova, TV; Gretsov, EM; Kalinin, NN; Kuz'mina, LA; Mendeleeva, LP; Parovichnikova, EN; Pokrovskaia, OS; Savchenko, VG; Urnova, ES | 1 |
| Bahlis, N; Jagannath, S; Jakubowiak, AJ; Kunkel, LA; Lonial, S; Orlowski, RZ; Reiman, T; Siegel, DS; Somlo, G; Stewart, AK; Trudel, S; Vij, R; Wong, A | 1 |
| Graef, T; Hardwick, JS; Hussein, M; Jagannath, S; Lupinacci, L; Schiller, GJ; Sobecks, RM; Weber, DM | 1 |
| Azab, AK; Azab, F; Banwait, R; Flores, L; Ghobrial, IM; Jia, X; Maiso, P; Manier, S; Roccaro, AM; Sacco, A | 1 |
| Altmann, A; Askoxylakis, V; Eisenhut, M; Haberkorn, U; Jesenofsky, R; Markert, A; Schöning, T | 1 |
| Bao, Y; Burks, SG; Gillenwater, HH; Jones, DR; Kozower, BD; Moskaluk, CA; Olazagasti, J; Petroni, GR; Philips, J; Rehm, PK | 1 |
| Bailey, C; Banugaria, SG; Conway, RL; Feldman, JD; Gera, R; Kishnani, PS; Kobori, JA; McGann, JK; Prater, SN; Rosenberg, AS; Tannenbaum, JA; Viskochil, D | 1 |
| Adam, Z; Feit, J; Hájek, R; Krejčí, M; Mayer, J; Pour, L; Szturz, P; Vašků, V | 1 |
| Brown, CO; Goel, A; Salem, K; Schibler, J | 1 |
| Fujii, T; Hiraike, H; Kawana, K; Kozuma, S; Miyamoto, Y; Nagasaka, K; Nakagawa, K; Nakagawa, S; Oda, K; Seiki, T; Sone, K; Taketani, Y; Tanikawa, M; Wada-Hiraike, O; Yano, T | 1 |
| Chavez, M; Cohen, JI; Espey, MG; Levine, M; Shatzer, AN; Tu, H | 1 |
| Joshi, KS; Manohar, SM; Shirsath, NP | 1 |
| Cavenagh, J; Joel, S; Maharaj, L; Oakervee, H; Popat, R | 1 |
| Heelan, K; McKenna, DB | 1 |
| Ahmad, M; Badura, HE; El-Khattouti, A; Ghanjati, F; Haikel, Y; Hassan, M; Porzig, BB; Santourlidis, S; Selimovic, D | 1 |
| Hanzis, C; Hunter, ZR; Ioakimidis, L; Manning, RJ; Patterson, CJ; Sheehy, P; Treon, SP; Tripsas, C; Turnbull, B | 1 |
| Chari, A; Pri-Chen, H | 1 |
| Harvey, RD; Kaufman, JL; Surati, M; Walker, BF; Wilson, N | 1 |
| Buckstein, R; Caballero, D; Coiffier, B; Elsayed, YA; Enny, C; Esseltine, DL; Garicochea, B; Khuageva, NK; Soubeyran, P; Theocharous, P; Van Hoof, A; Walewski, J; Wang, H; Zhu, E; Zinzani, PL | 1 |
| Yang, X | 1 |
| Cakana, A; Dmoszynska, A; Enny, C; Esteves, G; Feng, H; Greil, R; Hajek, R; Harousseau, JL; Ludwig, H; Masszi, T; Paiva, B; Ricci, D; Robinson, D; Shpilberg, O; Spicka, I; Stoppa, AM; van de Velde, H; Vidriales, MB; Viterbo, L | 1 |
| Fierabracci, A | 1 |
| Ceder, R; Fadeel, B; Grafström, RC; Grandér, D; Hedenfalk, I; Heyman, M; Ottosson-Wadlund, A; Pokrovskaja, K; Preta, G; Robertson, JD; Söderhäll, S | 1 |
| Boccadoro, M; Bringhen, S; Foà, R; Gentilini, F; Grammatico, S; Larocca, A; Levi, A; Palumbo, A; Petrucci, MT; Russo, S; Scotti, S; Siniscalchi, A | 1 |
| Camara-Clayette, V; Hermine, O; Ribrag, V | 1 |
| Barley, K; Chari, A; Jagannath, S; Osman, K | 1 |
| Aisa, Y; Ito, C; Mihara, A; Nakazato, T | 1 |
| Giralt, S; Landau, H; Rosenzweig, M | 1 |
| Brem, GJ; Brüning, A; Mylonas, I | 1 |
| Buda, G; Carulli, G; Cervetti, G; Galimberti, S; Ghio, F; Orciuolo, E; Pelosini, M; Petrini, M | 1 |
| Argnani, L; Baccarani, M; Ballerini, F; Broccoli, A; Casadei, B; Derenzini, E; Fabbri, A; Gandolfi, L; Guarini, A; Merla, E; Pavone, V; Pellegrini, C; Puccini, B; Quintini, G; Quirini, F; Stefoni, V; Vigliotti, ML; Zinzani, PL | 1 |
| De Bruyne, E; Hu, J; Menu, E; Schots, R; Van Valckenborgh, E; Vanderkerken, K; Xu, D | 1 |
| Kakpakova, ES; Kalitin, NN; Karamysheva, AF; Kostyukova, MN; Tupitsyn, NN | 1 |
| Chang, MX; Jia, G; Lu, H; Lu, YJ; Ma, YP; Zhang, L | 1 |
| Gosney, JR; Menzies, D; Thahseen, A; Williams, R | 1 |
| Burbury, K; Doo, NW; Harrison, SJ; Joyce, T; Prince, HM; Ritchie, D; Seymour, JF; Stokes, K; Thompson, PA; Wolf, M | 1 |
| Franken, MG; Gaultney, JG; Huijgens, PC; Redekop, WK; Sonneveld, P; Tan, SS; Uyl-de Groot, CA | 1 |
| Amrein, PC; Attar, EC; Bloomfield, CD; Blum, W; DeAngelo, DJ; Johnson, JL; Kolitz, JE; Larson, RA; Lozanski, G; Marcucci, G; Moser, B; Powell, BL; Stone, RM; Voorhees, P; Wadleigh, M; Wang, ES | 1 |
| Araujo, ME; Bates, SE; Bishton, M; Dai, Y; Grant, S; Harrison, SJ; Johnstone, RW; Lee, B; Piekarz, RL; Prince, HM | 1 |
| Mita, N; Murata, S | 2 |
| Ogura, M | 1 |
| Burnett, CT; Santoro, FA | 1 |
| Bouyssié, D; Burlet-Schiltz, O; Calligaris, D; Lutz, PG; Monsarrat, B; Uttenweiler-Joseph, S | 1 |
| Cavalli, M; Chiarenza, A; Consoli, U; Conticello, C; Coppolino, F; Di Raimondo, F; Forte, S; Palumbo, GA; Romano, A; Uccello, G; Vetro, C | 1 |
| Bruno, B; Corradini, P; Dodero, A; Fanin, R; Montanari, M; Montefusco, V; Mussetti, A; Offidani, M; Patriarca, F; Scortechini, I; Sperotto, A; Spina, F; Valagussa, P | 1 |
| Brodie, C; Brodie, S; Cazacu, S; Finniss, SA; Kazimirsky, G; Lee, HK; Lemke, N; Margel, S; Mikklesen, T; Miller, C; Okhrimenko, H; Perlstein, B; Rempel, SA; Rosenblum, M; Umansky, F | 1 |
| Bose, P; Grant, S | 1 |
| Wirk, B | 1 |
| Berenson, JR; Bessudo, A; Boccia, RV; Gorak, EJ; Gravenor, DS; Kewalramani, T; Mayo, D; Nassir, Y; Noga, SJ; Patel-Donnelly, D; Siegel, RS; Swift, RA; Yellin, O | 1 |
| Anderson, KC; Ansell, SM; Garcia-Sanz, R; Gertz, MA; Ghobrial, IM; Joshua, DE; Kastritis, E; Kimby, E; Kyle, RA; Leblond, V; Leleu, X; Merlini, G; Morel, P; Morice, WG; Morra, E; Munshi, NC; Ocio, EM; Owen, RG; Patterson, CJ; Rawstron, AC; Stone, MJ; Tedeschi, A; Terpos, E; Treon, SP | 1 |
| Liang, Y; Liu, H | 1 |
| Cao, B; Li, J; Mao, X | 1 |
| Sun, Y; Zhao, Y | 1 |
| Shi, Y; Wu, ZH | 1 |
| Antonelou, MH; Margaritis, LH; Mpakou, VE; Papassideri, IS; Stravopodis, DJ; Velentzas, AD; Velentzas, PD | 1 |
| Bergsagel, PL; Gutierrez, NC; Mateos, MV; Rajkumar, SV; San Miguel, JF | 1 |
| Bakhanashvili, M; Beery, E; Bulvick, S; Cohen, O; Kanfer, G; Lahav, M; Magen-Nativ, H; Nordenberg, J; Ram, R; Shilo, N; Uziel, O; Weiss, C; Wolach, O | 1 |
| Li, J; Liu, T; Niu, T; Wei, Q; Yang, JR; Yang, YM; Zeng, K | 1 |
| Ludwig, H; Sonneveld, P | 1 |
| Cen, XN; Dong, YJ; Li, Y; Liu, W; Qiu, ZX; Ren, HY; Shi, YJ; Wang, LH; Yin, Y | 1 |
| Hashimoto, N; Okamoto, S; Sadahira, K; Tsukada, Y; Ueda, T; Yokoyama, K | 1 |
| Buac, D; Deshmukh, R; Dou, QP; Kona, FR; Mitra, B; Neslund-Dudas, C; Schmitt, S; Shen, M; Zhang, Z | 1 |
| Cheng, Y; Harvey, H; Huber-Keener, KJ; Jefferson, LS; Kimball, SR; Ren, X; Shan, Y; Yang, JM; Zhang, L; Zhang, Y | 1 |
| Chim, CS; Choi, PT; Lee, WK | 1 |
| Ali, HA; Aßmann, M; Becker, C; Bourgeois, M; Edelmann, T; Hensel, G; Heyn, S; Hoffmann, FA; Hurtz, HJ; Jäkel, N; Krahl, R; Löschcke, K; Mohren, M; Moll, B; Niederwieser, D; Pönisch, W; Rohrberg, R; Schmalfeld, M; Schönfelder, U; Schwarzer, A; Wagner, I; Zehrfeld, T | 1 |
| Gertz, MA; Hayman, SR; Sher, T | 1 |
| Hildebrandt, GC; Panu, LD; Shahan, JL | 1 |
| Agosti, V; Amodio, N; Anderson, KC; Caraglia, M; Conforti, F; Di Martino, MT; Ferrarini, M; Foresta, U; Fulciniti, M; Gullà, AM; Leone, E; Leotta, M; Lionetti, M; Misso, G; Morabito, F; Munshi, NC; Neri, A; Pitari, MR; Rossi, M; Tagliaferri, P; Tassone, P | 1 |
| Benson, DM; Byrd, JC; Devine, SM; Dunavin, NC; Efebera, YA; Elder, P; Greenfield, C; Heerema, N; Hofmeister, CC; Ketcham, J; Merritt, L; Penza, S; Phillips, GS; Rieser, G; Rose, KS; Wei, L | 1 |
| Beretta, M; Maeda, N; Mayer, B; Schmidt, K; Schrammel, A; Stessel, H; Wenzl, MV; Wölkart, G | 1 |
| Benedetti, E; Jeon, H; Joseph, J; Oberholzer, J; Spaggiari, M; Thielke, J; Tzvetanov, I | 1 |
| Henry, RW; Hovde, S; Hurchla, MA; Lansdell, TA; Tepe, JJ; Weilbaecher, KN; Xiang, J | 1 |
| Bogenhagen, DF; Lee, J; Li, M; Lu, B; Morozov, YI; Nie, X; Suzuki, CK; Temiakov, D; Venkatesh, S | 1 |
| Cavenagh, J; Cook, G; Cook, M; Davies, F; Elliott, P; Gumbleton, T; Jacobson, E; Oakervee, H; Plesner, T; Popat, R | 1 |
| Anttila, P; Honkanen, T; Juvonen, V; Kairisto, V; Kuittinen, T; Lundán, T; Luukkaala, T; Opas, J; Pelliniemi, TT; Penttilä, K; Putkonen, M; Remes, K; Säily, M; Sikiö, A; Silvennoinen, R | 1 |
| Chihara, D; Iwama, K; Matsue, K; Nishida, Y; Sugihara, H; Takeuchi, M; Tsuda, K; Ugai, T; Yamakura, M | 1 |
| Arora, S; Hussain, SM; Ko, TY; Marcus, RJ; Nath, P; Nigos, JG; Sureshkumar, KK | 1 |
| Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pascutto, C; Pochintesta, L; Pompa, A | 1 |
| Blumenreich, MS; Dispenzieri, A; Mauermann, ML; Staff, NP | 1 |
| Fujita, Y; Fukushima, T; Iwao, H; Kawanami, T; Masaki, Y; Miki, M; Motoo, Y; Nakajima, A; Nakajima, H; Nakamura, T; Okazaki, T; Sakai, T; Sato, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
| Chrysis, D; Eriksson, E; Heino, TJ; Sävendahl, L; Wehtje, H; Zaman, F | 1 |
| Cavallo, F; Palumbo, A | 1 |
| Locke, FL; Morgan, GJ | 1 |
| Abdulkadyrov, KM; Anderson, KC; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; van de Velde, H | 1 |
| Camaschella, C; Campanella, A; Cenci, S; Fontana, F; Frenquelli, M; Marcatti, M; Santambrogio, P; Sitia, R; Tonon, G | 1 |
| He, Q; Jing, H; Lin, N; Luo, P; Song, H; Yang, B; Yang, X; Ying, M; Zhong, L; Zhou, X | 1 |
| Alsina, M; Anand, P; Anderson, KC; Baz, R; Bilotti, E; Chen, M; Doss, D; Ghobrial, IM; Jacques, C; Kelley, SL; Larkins, G; Laubach, J; Loughney, N; McBride, L; Munshi, NC; Nardelli, L; Richardson, PG; Schlossman, R; Siegel, D; Sullivan, D; Wear, S; Zaki, MH | 1 |
| Arlow, T; Gammie, A; Scott, K; Wagenseller, A | 1 |
| Andrulis, M; Bargou, RC; Beilhack, A; Bogen, B; Bumm, T; Chatterjee, M; Einsele, H; Heimberger, T; Riedel, S; Schraud, H; Stühmer, T | 1 |
| Buurman, W; De Baets, MH; Gomez, AM; Losen, M; Martinez-Martinez, P; Molenaar, PC; Willcox, N | 1 |
| Huang, BH; Li, J; Liu, JR; Su, C; Zheng, D; Zou, WY | 1 |
| Belitsky, G; Budunova, I; Gordon, LI; Kirsanov, K; Lesovaya, E; Popa, A; Rosen, ST; Yakubovskaya, M; Yemelyanov, A | 1 |
| Binkley, P; Blum, KA; Blum, W; Byrd, JC; Garzon, R; Geyer, S; Grever, MR; Jiang, Y; Johnston, JS; Kefauver, C; Klisovic, R; Marcucci, G; Phelps, MA; Walker, AR | 1 |
| Hao, LM; Huang, JQ; Li, XM; Wang, SM; Wei, LY; Wu, HY | 1 |
| Alexanian, R; Delasalle, K; Wang, M | 1 |
| Auberger, J; Clausen, J; Greil, R; Hopfinger, G; Vogt, S | 1 |
| Aggarwal, S; Bhargava, M; Khan, AA; Siraj, F | 1 |
| Hao, P; Li, C; Li, X; Li, Y; Ma, C; Yu, S; Yu, Y; Zheng, L | 1 |
| Bosly, A; Bouabdallah, R; Boue, F; Bron, D; Casasnovas, O; Coiffier, B; Delarue, R; Feugier, P; Haioun, C; Offner, F; Ribrag, V; Tilly, H | 1 |
| Chen, X; Hu, C; Huang, Q; Liu, B; Ma, Y; Miao, P; Qian, L; Shen, L; Wang, L; Wang, P; Yu, Q; Yuan, X; Zhang, D; Zhang, J | 1 |
| Binder, G; Borrello, I; Durie, B; Hussein, M; Khan, Z; Pashos, C | 1 |
| Oh, DH; Opat, SS; Shortt, J | 1 |
| Dou, QP; Guan, L; Guo, H; Huang, H; Li, B; Li, X; Liao, S; Liu, C; Liu, J; Liu, N; Liu, S; Song, W; Tang, P; Xu, L; Yang, C; Zhang, C; Zhao, K | 1 |
| Grosicki, S | 1 |
| Adam, Z; Almasi, M; Berankova, K; Frohlich, J; Greslikova, H; Hajek, R; Jarkovsky, J; Jurczyszyn, A; Kaisarova, P; Krejci, M; Kuglik, P; Kupska, R; Melicharova, H; Mikulasova, A; Nemec, P; Penka, M; Sandecka, V; Sevcikova, S; Smetana, J; Zahradova, L; Zaoralova, R | 1 |
| Doki, N; Endo, I; Kakihana, K; Kamata, N; Kobayashi, T; Kojima, A; Ohashi, K; Oshikawa, G; Sakamaki, H; Tsuda, H | 1 |
| Allietta, N; Angermund, R; Bladé, J; Blau, IW; Broer, E; Corradini, P; Dimopoulos, MA; Drach, J; Giraldo, P; Mitchell, V; Petrucci, MT; Teixeira, A | 1 |
| Atwal, S; D'Sa, S; Johnston, R; Khan, I; Moore, S; Narat, S; Percy, L; Rabin, N; Sachchithanantham, S; Schey, S; Streetly, M; Yong, K | 1 |
| Gatt, ME; Palladini, G | 1 |
| Chen, Q; Du, XL | 1 |
| Ba-Mancini, A; Henk, HJ; Huang, H; Teitelbaum, A | 1 |
| Ba-Mancini, A; Cakana, A; Chen, K; Corzo, D; Dhawan, R; Duh, MS; Garrison, LP; Huang, H; Korves, C; Shi, H; van de Velde, H; Wang, ST | 1 |
| Barbone, D; Battula, S; Broaddus, VC; Bueno, R; Busacca, S; Cheung, P; Fennell, DA; Gray, SG; Longley, DB; Sugarbaker, DJ | 1 |
| Bardag-Gorce, F; Bejaoui, M; Ben Abdennebi, H; Carbonell, T; Oliva, J; Pantazi, E; Rimola, A; Roselló-Catafau, J; Zaouali, MA | 1 |
| Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F | 1 |
| Lonial, S; Miguel, JF | 1 |
| McCarthy, PL | 1 |
| Mina, R; Palumbo, A | 1 |
| Berezniuk, I; Castro, LM; Dasgupta, S; Ferro, ES; Fricker, LD; Gelman, JS; Gozzo, FC; Sironi, J | 1 |
| Heider, U; Kaiser, MF; Mieth, M; Sezer, O; von Metzler, I; Zang, C | 1 |
| Birdsell, CA; Crosby, NA; Ernstoff, MS; Poklepovic, A; Ramakrishnan, V; Roberts, JD; Winning, M; Youseffian, L; Youssefian, LE | 1 |
| Arnulf, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Bréchignac, S; Caillot, D; Decaux, O; Escoffre-Barbe, M; Facon, T; Fermand, JP; Garderet, L; Hennache, B; Hulin, C; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Meuleman, N; Michallet, M; Moreau, P; Pegourie, B; Petillon, MO; Roussel, M; Royer, B; Stoppa, AM; Thielemans, B; Traulle, C | 1 |
| Ren, ZP; Sun, LP; Tong, QX | 1 |
| Anderson, JL; Anderson, KC; Görgün, GT; Hideshima, T; Laubach, J; Maguire, C; Munshi, NC; Raje, N; Richardson, PG; Whitehill, G | 1 |
| Fujiwara, S; Hata, H; Kawano, Y; Mitsuya, H; Nosaka, K; Okuno, Y; Yuki, H | 1 |
| Akintayo, A; Chen, Z; El-Rayes, B; Fanucchi, MP; Harvey, RD; Kauh, JS; Khuri, FR; Lewis, CM; Nadella, P; Owonikoko, TK; Ramalingam, SS; Rogatko, A; Shin, DM; Tighiouart, M | 1 |
| Bagot, M; Bezier, M; Cordoliani, F; Delyon, J; Malphettes, M; Rybojad, M; Szalat, R | 1 |
| Chen, LT; Chen, SH; Chen, TJ; Hsing, CH; Huang, HY; Lee, HH; Lee, SW; Li, CF; Lin, CY; Lin, LC; Pan, HY; Sheu, MJ; Shiue, YL; Tian, YF | 1 |
| Dash, D; Kulkarni, PP; Nayak, MK | 1 |
| Hatzidaki, E; Koukoulis, GK; Papandreou, CN; Stathakis, NE; Vlachostergios, PJ | 1 |
| Fujino, Y; Goto-Koshino, Y; Kojima, K; Ohno, K; Tsujimoto, H | 1 |
| Hoy, SM | 1 |
| Fujisawa, K; Hara, K; Kinouchi, M; Kuribayashi, N; Miyamoto, Y; Nagai, H; Ohe, G; Takamaru, N; Tamatani, T; Uchida, D | 1 |
| Bae, SH; Chung, JS; Eom, HS; Jo, DY; Kim, HJ; Kim, JS; Kim, K; Kim, MK; Kim, SH; Kim, YS; Lee, HS; Lee, JH; Min, CK; Mun, YC; Suh, C; Yoon, SS | 1 |
| Bach, HH; Gamelli, RL; Laporte, HM; Majetschak, M; Wong, YM | 1 |
| Ahn, JS; Bae, SY; Jung, SH; Kang, SJ; Kim, HJ; Kim, YK; Lee, JJ; Yang, DH | 1 |
| Bastian, L; Eckert, C; Fichtner, I; Henze, G; Hof, J; Pfau, M; Prada, J; Seeger, K; Shalapour, S; von Stackelberg, A | 1 |
| Chen-Kiang, S; Christos, PJ; Coleman, M; Ely, S; Jayabalan, DS; Lane, ME; Manco, M; Mark, TM; Mathews, L; Niesvizky, R; Pearse, RN; Pekle, K; Shore, TB; Skerret, D; Stern, J; Ward, M; Xiang, Z; Zafar, F | 1 |
| Dasmahapatra, G; Dent, P; Fisher, RI; Friedberg, J; Grant, S; Patel, H | 1 |
| Admasie, J; Alici, E; Aschan, J; Barendse, M; Carlson, K; Deneberg, S; Liwing, J; Lund, J; Mellqvist, UH; Nahi, H; Uttervall, K | 1 |
| Chen, WM; Chen, ZZ; Shang, J; Wei, TN; Wu, WB | 1 |
| Jia, G; Ma, YP; Zhang, L | 1 |
| Collet, P; Marotte, H; Nizeica, V | 1 |
| Chen, KF; Cheng, AL; Hou, DR; Lin, CS; Liu, CY; Shiau, CW; Yu, HC | 1 |
| Bernstein, SH; de Vos, S; Esseltine, DL; Fisher, RI; Goy, A; Morrison, VA; Neuwirth, R; Solh, M | 1 |
| Catusse, J; Engelhardt, M; Follo, M; Ihorst, G; Schnerch, D; Schüler, J; Udi, J; Waldschmidt, J; Wäsch, R; Wider, D | 1 |
| Akashi, K; Eto, T; Fujisaki, T; Henzan, T; Iwasaki, H; Kamimura, T; Kato, K; Miyamoto, T; Muta, T; Ohno, Y; Takamatsu, Y; Takenaka, K; Teshima, T | 1 |
| Bladé, J; Cibeira, MT; Díaz, T; Fernández de Larrea, C; Martín-Antonio, B; Monzó, M; Navarro, A; Rosiñol, L; Tovar, N; Urbano-Ispizua, A | 1 |
| Cai, J; Qing, X; Tan, J; Terasaki, PI | 1 |
| Li, J; Zhou, DB | 1 |
| Chao, NJ; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Held, LA; Horwitz, ME; Long, GD; Moore, JO; Rizzieri, D | 1 |
| Bosman, MC; Quax, WJ; Schuringa, JJ; Vellenga, E | 1 |
| Lin, B; Wang, Y | 1 |
| Adam, Z; Cermáková, Z; Hájek, R; Král, Z; Krejčí, M; Mayer, J; Navrátil, M; Pospíšilová, Y; Pour, L; Sandecká, V; Stork, M; Zahradová, L | 1 |
| Adam, Z; Cermáková, Z; Král, Z; Krejčí, M; Pour, L; Sčudla, V | 1 |
| Hur, D; Jin, DH; Kim, D; Kim, JE; Lee, WJ; Wu, TC | 1 |
| Casneuf, T; Frank, RC; Hall, B; Jagannath, S; Kranenburg, B; Krishnan, A; Lentzsch, S; Manges, RF; Orlowski, RZ; Qin, X; Somlo, G; Sonneveld, P; Thomas, SK; van de Velde, H; Voorhees, PM; Wijermans, PW; Xie, H; Zweegman, S | 1 |
| Gillet, JP; Gottesman, MM; Varma, S | 1 |
| Davies, FE; Fryer, RA; Graham, TJ; Morgan, GJ; Robinson, SP; Smith, EM; Walker-Samuel, S | 1 |
| Biskup, E; Gniadecki, R; Kamstrup, MR; Manfé, V | 1 |
| Ambinder, RF; Forde, PM; Gladstone, DE; Hourigan, CS | 1 |
| Cao, Q; Miller, J; Warlick, ED | 1 |
| Chao, A; Chen, HW; Chuang, WC; Kao, C; Lai, CH; Lin, CY; Tsai, CL; Wang, HS; Wang, TH; Yen, TC | 1 |
| Chen, J; Lin, J; Zeng, Z | 1 |
| Bergsagel, PL; Chesi, M | 1 |
| Dumontet, C; Plesa, A; Tagoug, I | 1 |
| Downey, SL; Eastman, A; Goddard, AL; Kisselev, AF; Lucas, MM; Screen, M; Shabaneh, TB | 1 |
| Han, J; Jeong, SH; Kim, HK; Kim, N; Ko, KS; Lee, SR; Rhee, BD; Song, IS | 1 |
| Grabher, D; Heufler, C; Hofer, S; Ortner, D | 1 |
| Hatano, Y; Iida, S; Ito, M; Iwamoto, K; Kitabayashi, A; Kume, M; Nara, M; Sawada, K; Tagawa, H; Takahashi, N; Teshima, K; Watanabe, A | 1 |
| Cho, YH; Choi, BS; Choi, YJ; Chung, BH; Hong, YA; Kim, YS; Park, CW; Park, GS; Sun, IO; Yang, CW | 1 |
| Doi, T; Fujimi, A; Hashimoto, A; Ishikawa, K; Kanisawa, Y; Matsuno, T; Minami, S; Okuda, T; Uemura, N | 1 |
| Brandstetter, M; Engelhard, K; Förster, CY; Neuhaus, W; Schaible, EV; Scheffer, D; Thal, SC; Wunder, C | 1 |
| Chiang, AK; Ho, DN; Hui, KF; Lam, BH; Tsao, SW | 1 |
| Aldini, G; Altomare, A; Fusi, C; Geppetti, P; Lodovici, M; Materazzi, S; Nassini, R; Patacchini, R; Trevisan, G | 1 |
| Bauvois, B; Billard, C; Bouchet, S; Dauzonne, D; Piedfer, M; Tang, R | 1 |
| Eriksson, E; Sävendahl, L; Zaman, F | 1 |
| Lacy, MQ | 1 |
| Burmester, GR; Buttgereit, F; Dörner, T; Egerer, K; Faustman, DL; Feist, E; Gaber-Elsner, T; Ghannam, K; Hahne, M; Kloetzel, PM; Kuckelkorn, U; Lesemann, K; Martinez-Gamboa, L; Naumann, L; Scheffler, S | 1 |
| Du, X; Geng, S; Lai, P; Lin, S; Ling, W; Liu, X; Luo, C; Lv, M; Weng, J | 1 |
| Chen, W; Gao, W; Geng, C; Li, Y; Wang, C; Zhang, L | 1 |
| Lu, H; Sheng, Z; Yu, J; Zou, Y | 1 |
| Abe, M; Fujii, S | 1 |
| Chovan, JP; Li, AC; Ring, SC; Yu, E | 1 |
| Biskup, E; Croce, CM; Gasparini, P; Gniadecki, R; Laganá, A; Manfè, V; Palmieri, D; Skov, AG; Willumsgaard, A; Woetmann, A; Ødum, N | 1 |
| Goel, S; Lue, J; Mazumder, A | 1 |
| Hájek, R; Kryukov, F; Kubiczková, L; Matějíková, J; Sedlaříková, L; Sevčíková, S | 1 |
| Hu, Y; Wu, P; Zhang, J | 1 |
| Catley, L; Connor, T; McGee, SL; Mottram, B; Sanchez, WY; Vuckovic, S; Whitehead, JP; Wilkinson, A | 1 |
| Álvarez-Fernández, S; Burrows, FJ; Esparís-Ogando, A; Ocio, EM; Ortiz-Ruiz, MJ; Pandiella, A; Parrott, T; San Miguel, J; Zaknoen, S | 1 |
| Horton, T; Hunger, SP | 1 |
| Baughn, LB; Deshpande, R; Dolloff, NG; Janz, S; Linden, MA; Mansoor, A; Myers, CL; Sarver, A; Stessman, HA; Sunderland, JJ; Van Ness, BG; Walsh, SA; Xia, T; Zhan, F | 1 |
| Brown, CO; Fitzgerald, MP; Goel, A; Salem, K; Schibler, J; Singh, N; Zhan, F | 1 |
| Admon, A; Barnea, E; Bassani-Strenberg, M; Beer, I; Gutter-Kapon, L; Milner, E | 1 |
| Alsina, M; Anasetti, C; Baz, R; Jim, HS; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Pidala, J; Shain, K; Sullivan, D | 1 |
| Ames, MM; Erlichman, C; Hendrickson, AE; Menefee, M; Northfelt, D; Qin, R; Satele, D; Schenk, E; Toft, DO | 1 |
| Minvielle, S; Moreau, P | 1 |
| Chen, J; Li, S; Que, W | 1 |
| Abe, A; Che, XF; Gotoh, A; Inazu, M; Kawaguchi, T; Komatsu, S; Miyazawa, K; Moriya, S; Tomoda, A | 1 |
| Adjibade, P; Côté, MF; Coudert, L; Fournier, MJ; Gareau, C; Gaudreault, RC; Mazroui, R; Mellaoui, S; Sonenberg, N | 1 |
| Cakana, A; Coiffier, B; Crump, M; de Vos, S; Elsayed, YA; Esseltine, DL; Favis, R; Gaffney, D; Henitz, ED; Hong, X; Karkera, JD; Li, W; Mayer, J; Mulligan, G; Offner, F; Osmanov, EA; Ricci, D; Romejko-Jarosinska, J; Rule, S; Schaffer, ME; Scheliga, A; Shapiro, A; Shpilberg, O; Teixeira, A; Theocharous, P; van de Velde, H; Zinzani, PL | 1 |
| Conticello, C; Di Raimondo, F; Romano, A | 1 |
| Arnulf, B; Attal, M; Benajiba, L; Caillot, D; Caulier, A; Chaleteix, C; Chrétien, ML; Facon, T; Fermand, JP; Fouquet, G; Garciaz, S; Garderet, L; Hebraud, B; Leleu, X; Loiseau, HA; Moreau, P; Pegourie, B; Regny, C; Roussel, M; Royer, B; Stoppa, AM; Szalat, R; Touzeau, C | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Annereau, JP; Bailly, C; Bonnet, D; Brel, V; Créancier, L; Currie, E; Fournier, E; Gomes, B; Guilbaud, N; Guminski, Y; Kruczynski, A; Pillon, A; Vandenberghe, I | 1 |
| Dorr, RT; Escalante, AM; Karolak, MR; Landowski, TH; Lynch, RM; McGrath, RT | 1 |
| Bodeen, WJ; Han, YG; Marada, S; Ogden, SK; Stewart, DP | 1 |
| Cassidy, J; Hochster, H | 1 |
| Ando, K; Hotta, T; Iida, S; Ishii, M; Matsue, K; Matsumoto, M; Mukai, HY; Ogawa, Y; Ogura, M; Ohashi, K; Sakai, A; Suzuki, K; Terui, Y; Tobinai, K | 1 |
| Benner, A; Egerer, G; Goldschmidt, H; Heiss, C; Hillengass, J; Ho, AD; Hose, D; Lehners, N; Neben, K; Raab, MS; Sellner, L | 1 |
| Ambrosio, CE; Araujo, KP; Belizario, JE; Bonuccelli, G; Duarte, CN; Feder, D; Gaiad, TP; Lisanti, MP; Miglino, MA; Moreira, DF | 1 |
| Anderson, K; Clynes, M; Delmore, J; Jakubikova, J; Klippel, S; Meiller, J; Mitsiades, CS; O'Connor, R; O'Gorman, P; Ooi, MG; Richardson, P | 1 |
| Abidi, MH; Abrams, J; Al-Kadhimi, Z; Ayash, L; Bhutani, D; Deol, A; Lum, L; Ratanatharathorn, V; Tageja, N; Uberti, J; Valent, J; Zonder, J | 1 |
| Anderl, J; Gupta, S; Kirk, C; Kruger, WD; Slifker, MJ; Wang, L | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kikuchi, J; Nobuyoshi, M; Ohki, M; Park, SY; Shibayama, N; Sugiyama, K; Wada, T; Yamada, S | 1 |
| Cao, ZG; Liu, M; Zhou, HW | 1 |
| Abdallah, AO; Bailey, C; Barlogie, B; Chauhan, N; Cottler-Fox, M; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Johann, D; Muzaffar, J; Petty, N; Rosenthal, A; Sawyer, J; Sexton, R; Singh, Z; Usmani, SZ; van Rhee, F; Waheed, S; Yaccoby, S | 1 |
| Kim, JA; Kwak, JY; Lee, BH; Min, CK; Shin, SH; Yhim, HY | 1 |
| Babcock, JT; He, Y; Hendricks, JW; Nguyen, HB; Quilliam, LA; Wek, RC | 1 |
| Adams, GP; Balachandran, S; Chen, P; Nogusa, S; Peri, S; Shaller, C; Simmons, H; Thapa, RJ | 1 |
| Besada, E; Koldingsnes, W; Nossent, JC; Vik, A | 1 |
| Abildgaard, N; Ahlberg, L; Andersen, NF; Blimark, C; Carlson, K; Dahl, IM; Forsberg, K; Gedde-Dahl, T; Gimsing, P; Gregersen, H; Gruber, A; Guldbrandsen, N; Haukås, E; Hjertner, O; Kvam, AK; Laane, E; Lenhoff, S; Lindås, R; Mellqvist, UH; Nahi, H; Remes, K; Steingrimsdottir, H; Turesson, I; Waage, A; Westin, J | 1 |
| Ramachandran, PV | 1 |
| Banerjee, SK; Das, BC; Das, S; Evans, T; Kambhampati, S; Karki, R; Schinke, C; Thapa, P; Van Veldhuizen, P; Verma, A; Weiss, LM | 1 |
| Friman, S; Hansson, S; Holgersson, J; Mjörnstedt, L; Stelin, G; Westphal, S | 1 |
| Claas, FH; Heidt, S; Mulder, A; Roelen, DL; Vergunst, M | 1 |
| Andreu, AL; Barreiro, E; de Kier Joffé, ED; Fermoselle, C; García-Arumí, E; Puente-Maestu, L; Puig-Vilanova, E; Tejedor, A; Urtreger, AJ | 1 |
| Ashlock, BM; Bhatt, S; Diaz, LA; Lossos, IS; Mesri, EA; Ramos, JC; Toomey, NL | 1 |
| Mahindra, A; Saini, N | 1 |
| Brandi, G; Dika, E; Maibach, H; Patrizi, A; Tacchetti, P; Venturi, M | 1 |
| Fulda, S; Jung, M; Rapino, F | 1 |
| Befani, CD; Hatzidaki, E; Liakos, P; Papandreou, CN; Vlachostergios, PJ | 1 |
| Aldinucci, D; Borghese, C; Carbone, A; Casagrande, N; Celegato, M; Colombatti, A | 1 |
| Boland, R; González-Pardo, V; Russo de Boland, A; Verstuyf, A | 1 |
| Akaogi, T; Fuchida, S; Hatsuse, M; Horiike, S; Iwai, T; Kamitsuji, Y; Kaneko, H; Kawata-Iida, E; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Murakami, S; Nakao, M; Okano, A; Shimazaki, C; Shimizu, D; Takahashi, R; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Uoshima, N | 1 |
| Chai, J; Jiang, Y; Li, Y; Luo, H; Xiao, X; You, Y; Zhou, Y; Zhu, H; Zuo, X | 1 |
| Balachandran, S; Chen, P; Cheung, M; Nogusa, S; Pei, J; Peri, S; Testa, JR; Thapa, RJ | 1 |
| Altıkat, S; Boyaci, I; Cavga, FZ; Irmak, R; Kocacan, SA; Yerlikaya, A | 1 |
| Ahluwalia, R; Carson, KR; Cox, DP; Fiala, MA; Jaenicke, M; Moliske, CC; Stockerl-Goldstein, KE; Tomasson, MH; Trinkaus, KM; Vij, R; Wang, TF; Wildes, TM | 1 |
| Gartel, AL; Halasi, M; Hay, N; Nogueira, V; Pandit, B; Wang, M | 1 |
| Eatock, MM; Gallagher, R; James, CR; Law, D; Millar, J; Morris, M; Napier, E; Purcell, C; Turkington, RC; Wilson, RH | 1 |
| Arakaki, H; Uchihara, JN | 1 |
| An, G; Deng, SH; Feng, XY; Hao, M; Li, F; Qiu, LG; Sui, WW; Wang, YF; Xu, Y | 1 |
| Du, J; Fan, JL; Fu, WJ; Hou, J; Jiang, H; Jin, LN; Lan, HF; Lu, J; Yuan, ZG; Zeng, TM; Zhang, CY; Zhou, F; Zhou, LL | 1 |
| Gu, JL; Li, J; Liu, JR; Wang, HH; Xu, DR; Yan, MS; Zheng, D; Zou, WY | 1 |
| Huang, XJ; Lu, J; Wang, H | 1 |
| Andreeff, M; Carter, BZ; Davis, RE; Ma, W; Mak, DH; Mak, PY; Wang, Z | 1 |
| Eiermann, T; Gräser, C; Koch, M; Kröger, N; Lehnhardt, A; Nashan, B; Pollok, JM; Thaiss, F; Verboom, M | 1 |
| Chettab, K; Dumontet, C; Herveau, S; Huber, AL; Jordheim, LP; Manié, S; Matera, EL; Tagoug, I | 1 |
| Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S | 1 |
| Cerrato, C; Palumbo, A | 2 |
| Hatano, Y; Ikeda, S; Ito, M; Nara, M; Oshima, K; Sawada, K; Seto, M; Tagawa, H; Teshima, K; Watanabe, A | 1 |
| Cao, C; Dang, D; Janbain, M; Maalouf, B; Saba, J; Saba, NS; Safah, H | 1 |
| Chen, FT; Yang, CH; Yang, CM | 1 |
| Alma, E; Cox, MC; Di Napoli, A; Naso, V; Pelliccia, S; Rebecchini, C | 1 |
| Arai, R; Fujimoto, K; Isozumi, Y; Koyama, T | 1 |
| Ahmed, M; Al-Kuraya, KS; Al-Obaisi, KA; Bu, R; Hussain, AR; Uddin, S | 1 |
| Lin, YJ; Liu, XJ; Shang, BY; Zhen, YS; Zhen, YZ | 1 |
| Chan, JY; Ho, DV; Lee, CS | 1 |
| Dimopoulos, MA; Kastritis, E; Terpos, E | 1 |
| Brissot, E; Gaugler, B; Mohty, M; Savani, BN | 1 |
| Cao, B; Du, X; Mao, X; Zhang, Z; Zhao, C; Zhao, Y | 1 |
| Abe, M; Amou, H; Fujii, S; Harada, T; Hiasa, M; Kagawa, K; Kido, S; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Oda, A; Ozaki, S; Takeuchi, K; Watanabe, K | 1 |
| Jongen, JL; Rampen, AJ; Scheltens-de Boer, M; Sonneveld, P; van den Bent, MJ; van Heuvel, I | 1 |
| Hu, H; Liu, Y; Lu, L; Meng, W; Qing, Y; Shen, Y; Xu, J; Zhang, B | 1 |
| Allietta, N; Angermund, R; Beksac, M; Benboubker, L; Broer, E; Couturier, C; Dimopoulos, MA; Facon, T; Mazier, MA; Roddie, H | 1 |
| Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A | 1 |
| Dadhania, D; Everly, MJ; Friedlander, R; Kannabhiran, D; Putheti, P; Sharma, V; Tiongko, S; Walker-McDermott, JK | 1 |
| Ihara, K; Inomata, H; Kato, J; Kikuchi, S; Koyama, R; Muramatsu, H; Nagamachi, Y; Nishisato, T; Nozawa, E; Okamoto, T; Ono, K; Tanaka, S; Yamada, H; Yamauchi, N; Yano, T | 1 |
| Baughn, LB; Janz, S; Linden, MA; Mansoor, A; Stessman, HA; Van Ness, B; Zhan, F | 1 |
| Inui, Y; Kanakura, Y; Kataoka, S; Kawata, S; Kubo, M; Maeda, T; Matsunaga, H; Matsuura, N; Ueda, S | 1 |
| Ahuja, HG; Blank, JH; Campbell, TC; Hernan, HR; Hoang, T; Huie, MS; Johnson, PH; Kim, K; Kirschling, RJ; Kolesar, JM; Larson, MM; Oettel, KR; Robinson, EG; Traynor, AM; Wims, ME; Zhang, C | 1 |
| Baughn, LB; Linden, MA; Mansoor, A; Stessman, HA; Van Ness, B | 1 |
| Li, Zw; Luo, M; Qiu, Jx; Wang, Y; Wen, Xf | 1 |
| Arthur, K; Barbone, D; Broaddus, VC; Busacca, S; Chacko, AD; El-Tanani, M; Fennell, DA; Gaudino, G; Gorski, JJ; Gunasekharan, VK; Klabatsa, A; Mutti, L; Sheaff, M | 1 |
| Ma, L; Shen, B; Sun, H; Sun, L; Sun, Y; Ye, Y; Yu, J; Zhang, D; Zhang, L; Zhu, C | 1 |
| Gumulec, J; Hájek, R; Plonková, H | 1 |
| Awan, F; Chaudhary, L; Craig, M; Cumpston, A; Hamadani, M; Leadmon, S; Tse, W; Watkins, K | 1 |
| Lin, M; Luan, Y; Ma, Y; Wang, YB; Wang, YY; Zhang, X; Zhang, ZH; Zhu, XB | 1 |
| Caballero, D; Caballero-Velázquez, T; Castilla-Llorente, C; Encinas, C; Heras, I; López-Corral, L; Martino, R; Pérez-Simón, JA; Rosiñol, L; Sampol, A; San Miguel, J; Serrano, D | 1 |
| Chen, CI; Chu, CM; Cserti-Gazdewich, C; Jiang, H; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Rabea, A; Reece, DE; Tiedemann, R; Trudel, S; Tsang, R | 1 |
| Gibbs, SD; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Pinney, JH; Roussel, M; Sachchithanantham, S; Venner, CP; Wechalekar, AD | 1 |
| Amrein, PC; Attar, EC; Ballen, KK; Deangelo, DJ; Fathi, AT; Foster, J; Fraser, JW; McAfee, S; Neuberg, D; Steensma, DP; Stone, RM; Wadleigh, M | 1 |
| Eisner, F; Gerger, A; Pichler, M; Samonigg, H; Schaberl-Moser, R | 1 |
| Boccadoro, M; Cavallo, F; Corradini, P; Crippa, C; Ferrari, S; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Magarotto, V; Montefusco, V; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Pescosta, N; Petrucci, MT; Pezzatti, S; Pietrantuono, G | 1 |
| McNeil, C | 1 |
| Carrie, D; Despas, F; Dumonteil, N; Galinier, M; Honton, B; Montastruc, JL; Pathak, A; Roussel, M; Rouvellat, C | 1 |
| Azevedo, LM; Cogan, DP; Fisk, JS; Kuszpit, MR; Lansdell, TA; Ludwig, JR; Mosey, RA; Patten, GP; Tepe, JJ; Woloch, DK | 1 |
| Baas, P; Cufer, T; Danson, S; Gaafar, RM; Grossi, F; Hasan, B; O'Brien, ME; Ottensmeier, C; Pallis, A; Popat, S; Price, A; Talbot, DC; Van Meerbeeck, JP | 1 |
| Che, XF; Kohno, N; Komatsu, S; Miyazawa, K; Moriya, S; Yokoyama, T | 1 |
| Chen, SS; Falchook, G; Fok, JY; Fu, S; Heymach, J; Hong, D; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, S; Stephen, B; Tsimberidou, AM; Wheler, J | 1 |
| Azzarà, A; Carulli, G; Ciabatti, E; Ciancia, EM; Ferreri, MI; Grassi, S; Marini, A; Ottaviano, V; Petrini, M; Rocco, M | 1 |
| Horiike, S; Kaneko, H; Kawata-Iida, E; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Shimazaki, C; Shimura, Y; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Yamamoto-Sugitani, M | 1 |
| Gesheva, VV; Nikolova-Ganeva, KA; Todorov, TA; Vassilev, TL; Voll, RE | 1 |
| Bignon, E; Facon, T; Fermand, JP; Fitoussi, O; Fourrier-Réglat, A; Grelaud, A; Jové, J; Lassalle, R; Marit, G; Moore, N; Noize, P; Robinson, P; Rouyer, M; Thomaré, P | 1 |
| Alsina, M; Baz, R; Dalton, WS; Djulbegovic, B; Ho, VQ; Miladinovic, B; Nishihori, T; Ochoa-Bayona, JL; Patel, A; Shain, KH; Sullivan, DM | 1 |
| Farmer, DG; Kempert, P; Plant, AS; Said, J; Upadhyay, S; Venick, RS | 1 |
| Geltink, RI; Grosveld, GC; Marshall, AD; Picchione, F | 1 |
| Abdulkadyrov, KM; Bessmel'tsev, SS; Martynkevich, IS; Romanenko, NA; Rugal', VI; Udal'eva, VIu; Zenina, MN | 1 |
| Wan, J | 1 |
| Chng, WJ; Durie, BG; Eom, HS; Goh, YT; Kim, JS; Kim, K; Lee, JH; Ong, KH; Tan, D; Teoh, G | 1 |
| Kato, T; Miyao, K; Niimi, K; Ono, Y; Sakai, T; Sakemura, R; Sawa, M; Tsushita, N | 1 |
| Acharya, C; Anderson, KC; Cagnetta, A; Calimeri, T; Cea, M; Chauhan, D; Fulciniti, M; Gobbi, M; Hideshima, T; Munshi, N; Nencioni, A; Patrone, F; Richardson, P; Tai, YT; Zhong, MY | 1 |
| Gao, L; Shi, J; Tao, Y; Wang, H; Wu, X; Yang, G; Zhan, F | 1 |
| Czuczman, MS; Czuczman, NM; Gu, JJ; Hernandez-Ilizaliturri, FJ; Kaufman, GP; Mavis, C; Skitzki, JJ | 1 |
| Hou, L; Liu, T; Liu, ZG; Niu, T; Yang, JR; Yang, YM; Zeng, K | 1 |
| Giannotta, A; Guaragna, G; Mele, G; Melpignano, A; Quarta, G; Spina, A | 1 |
| De Bruyne, E; De Bryune, E; De Raeve, H; Handisides, D; Hart, CP; Hu, J; Menu, E; Van Camp, B; Van Valckenborgh, E; Vanderkerken, K; Xu, D; Xu, S | 1 |
| Hata, H; Higuchi, M; Miyamoto, T; Morimoto, H; Muta, T; Sunami, K; Takamatsu, Y; Tamura, K; Uozumi, K | 1 |
| Bringhen, S; Cerrato, C; Magarotto, V; Palumbo, A; Pautasso, C | 1 |
| Allain-Launay, E; Blancho, G; Blin, N; Cesbron, A; Moreau, A; Roussey, G; Ryckewaert, A | 1 |
| Forsberg, PA; Mark, TM | 1 |
| Dobra, K; Hjerpe, A; Mundt, F; Nilsonne, G; Souri, P; Szulkin, A; Wasik, AM | 1 |
| Chng, WJ; Chung, TH; Fonseca, R; Mulligan, G | 1 |
| Bell, S; Desmond, PV; Goldberg, R; Smith, E; Thompson, A | 1 |
| Barton, MK | 1 |
| Adam, Z; Adamova, D; Bacovsky, J; Gregora, E; Gumulec, J; Hajek, R; Jarkovsky, J; Maisnar, V; Melicharova, H; Minarik, J; Pavlicek, P; Pika, T; Plonkova, H; Pour, L; Radocha, J; Sandecka, V; Scudla, V; Spicka, I; Starostka, D; Straub, J; Walterova, L; Wrobel, M | 1 |
| Bao, L; Huang, X; Jiang, Q; Lai, Y; Liu, Y; Lu, J; Lu, X; Qin, Y; Zhao, X | 1 |
| Abe, D; Amagai, M; Hosokawa, R; Murakami, K; Ohyama, M; Okamoto, S; Yokoyama, K | 1 |
| Brioli, A; Cavo, M; Mancuso, K; Pantani, L; Perrone, G; Pezzi, A; Rocchi, S; Tacchetti, P; Tosi, P; Zamagni, E; Zannetti, BA | 1 |
| Carew, JS; Coffey, M; Espitia, CM; Freeman, JW; Kelly, KR; Nawrocki, ST; Zhao, W | 1 |
| Choi, W; Dinney, C; Guo, C; McConkey, DJ; Qi, W; Siefker-Radtke, A; White, MC | 1 |
| Akashi, K; Choi, I; Ito, Y; Iwasaki, H; Kamimura, T; Kato, K; Miyamoto, T; Muta, T; Shiratsuchi, M; Takamatsu, Y; Takashima, S; Takenaka, K; Teshima, T; Yoshimoto, G | 1 |
| Kariya, R; Matsuda, K; Okada, S; Taura, M; Vaeteewoottacharn, K; Wongkham, C; Wongkham, S | 1 |
| Chan, SM; Feng, W; Huang, M; Li, MX; Majeti, R; Mitchell, BS; Thomas, D | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kikuchi, J; Koyama, D; Nobuyoshi, M; Wada, T; Yamada, S | 1 |
| Egashira, N; Oishi, R | 1 |
| Adjei, AA; Bible, KC; Croghan, G; Erlichman, C; Jett, J; Kaufmann, SH; Kumar, SK; Markovic, SN; Marks, R; Molina, J; Moynihan, T; Qin, R; Quevedo, F; Richardson, R; Tan, A | 1 |
| Bennett, GJ; Bryant, L; Cuzzocrea, S; Doyle, T; Esposito, E; Janes, K; Ryerse, J; Salvemini, D | 1 |
| El Azeeim, HA; El Husseiny, NM; Kasem, N; Mattar, MW | 1 |
| Chang, TP; Gatla, HR; Manna, S; Phyo, SA; Ramaswami, S; Sanacora, S; Singha, B; Vancurova, I | 1 |
| Chang, CI; Huang, KF; Ihara, K; Kuo, CI; Liao, JH; Wakatsuki, S; Wu, SH | 1 |
| Attal, M; Bladé, J; Cakana, A; Cavo, M; Desai, A; Esseltine, DL; Goldschmidt, H; Lahuerta, JJ; Liu, K; Lokhorst, HM; Moreau, P; Rosiñol, L; Sonneveld, P; Tacchetti, P; van de Velde, H; Zamagni, E | 1 |
| Joseph, C; Ribeiro, A; Seikaly, M; Thach, L; Twombley, K | 1 |
| Alberti, D; Bailey, HH; Espinoza-Delgado, I; Hoang, T; Holen, KD; Kim, K; Kolesar, JM; Schelman, WR; Seo, S; Traynor, AM; Wilding, G; Wright, JJ | 1 |
| Goebeler, M; Kneitz, H; Kolb-Mäurer, A | 1 |
| Cırak, MY; Emmez, H; Oner, AY; Pamukçuoğlu, M; Senol, E; Sucak, GT; Tunçcan, OG | 1 |
| Bai, QX; Chen, XQ; Dong, BX; Gao, GX; Gu, HT; Liang, R; Shu, MM; Yang, L; Zhang, T; Zhang, YQ | 1 |
| Klánová, M; Špička, I | 1 |
| Brugge, JS; Coloff, JL; Ince, TA; Iwanicki, MP; Kim, M; Kroemer, G; Ofengeim, D; Pan, L; Vakifahmetoglu-Norberg, H; Xia, HG; Yuan, J | 1 |
| Brüning, A; Friese, K; Rahmeh, M | 1 |
| Erdoğan, E; Genç, O; Savran, B; Yerlikaya, A | 1 |
| Colvin, J; Evens, AM; Gordon, LI; Helenowski, I; Kline, J; Larsen, A; Rosen, ST; Smith, SM; van Besien, KM; Winter, JN | 1 |
| Li, J; Liu, SS; Tsui, J; Wang, HH; Wang, XY | 1 |
| Wang, ZQ; Xie, JL; Zhou, XG | 1 |
| Bakhous, A; Waheed, S; Zhu, H | 1 |
| Chen, Z; Fayad, L; Kwak, L; McCarty, N; McLaughlin, P; Neelapu, SS; Pittman, EF; Romaguera, J; Wang, M | 1 |
| Almeida, GM; Coelho, MA; Coelho, SC; Juzenas, P; Pereira, MC; Rocha, S; Sampaio, P; Silva, FS | 1 |
| Alsina, M; Coutre, SE; Gasparetto, C; Khan, M; Lonial, S; Mukhopadhyay, S; Ondovik, MS; Paley, CS; Richardson, PG; Schlossman, RL; Weber, DM | 1 |
| Blum, W; Byrd, JC; Devine, SM; Garzon, R; Grever, MR; Humphries, K; Klisovic, RB; Marcucci, G; Schaaf, LJ; Walker, AR | 1 |
| Ise, M; Kumagai, K; Sakai, C | 1 |
| De Vita, S; Michieli, M; Quartuccio, L; Rupolo, M | 1 |
| Cao, Y; Chapman, C; Friedman, J; Hamstra, D; Hayman, J; Lao, CD; Lawrence, T; Lee, O; Normolle, DP; Redman, BG; Schipper, M; Tsien, CI; Van Poznak, C | 1 |
| Mangone, M; Marchi, E; O'Connor, OA; Zullo, K | 1 |
| Morgan, GJ | 1 |
| Chan, NG; Hsia, CC | 1 |
| Beppu, M; Fujimaki, Y; Isose, S; Iwai, Y; Kuwabara, S; Misawa, S; Mitsuma, S; Nakaseko, C; Nasu, S; Ohmori, S; Ohwada, C; Sekiguchi, Y; Shibuya, K; Shimizu, N; Takeda, Y | 1 |
| Mark, TM; Meadows, JP | 1 |
| Guo, W; Jiao, G; Lou, Z; Lu, Q; Lu, X; Peng, X; Ren, T; Sun, Y; Zhang, S | 1 |
| Jaffrey, SR; Jiang, X; Xu, G | 1 |
| Belloni, D; Berenzi, A; Caligaris-Cappio, F; Ferrarini, M; Ferrero, E; Girlanda, S; Mazzoleni, G; Ponzoni, M; Steimberg, N | 1 |
| Childs, R; Cook, L; Jaffe, ES; Ramos, C; Vo, P | 1 |
| Cicora, F; Mos, F; Paz, M; Roberti, J | 1 |
| Attal, M; Avet-Loiseau, H; Blaise, D; Cornillon, J; El-Cheikh, J; Harousseau, JL; Labussière, H; Michallet, M; Milpied, N; Mohty, M; Moreau, P; Morisset, S; Nicolini, FE; Reman, O; Sirvent, A; Sobh, M; Tabrizi, R | 1 |
| Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K | 1 |
| Bertsch, U; Blau, IW; Bos, GM; Croockewit, S; Duehrsen, U; el Jarari, L; Goldschmidt, H; Hänel, M; Jie, KS; Kersten, MJ; Lindemann, W; Lokhorst, HM; Martin, H; Neben, K; Peter, N; Pfreundschuh, M; Salwender, H; Schaafsma, MR; Scheid, C; Schmidt-Wolf, IG; Sonneveld, P; van de Velde, H; van der Holt, B; van Marwijk-Kooy, M; Vellenga, E; Weisel, K; Wijermans, P; Wittebol, S; Zweegman, S | 1 |
| Ma, LM; Zhao, J | 1 |
| Cheng, ZY; Jia, ZQ; Li, AM; Wei, YT | 1 |
| Cicero, S; Drach, J; Fu, T; Goy, A; Kalayoglu Besisik, S; Ramchandren, R; Sinha, R; Williams, ME; Witzig, TE; Zhang, L | 1 |
| Dimopoulos, MA; García-Sanz, R; Gavriatopoulou, M; Gika, D; Kartasis, Z; Kastritis, E; Kyrtsonis, MC; Leleu, X; Merlini, G; Michalis, E; Morel, P; Palladini, G; Sonneveld, P; Tedeschi, A | 1 |
| Behera, M; Boise, LH; Flowers, CR; Gleason, C; Kaufman, JL; Langston, A; Lonial, S; Nooka, AK; Waller, EK | 1 |
| Guo, Y; Liu, R; Odusote, G; Priestley, RD; Qu, F | 1 |
| Brnjic, S; D'Arcy, P; Fryknäs, M; Larsson, R; Linder, S; Mazurkiewicz, M; Sun, C; Zhang, X | 1 |
| Anderson, KC; Bladé, J; Bourquelot, PM; Günther, A; LeBlanc, R; Mishra, KK; Mu, S; Richardson, PG; San-Miguel, JF; Sezer, O; Siegel, D; Sopala, M; Sutherland, H; Victoria Mateos, M | 1 |
| Brown, KJ; Cakir, E; Coley, W; Dillingham, BC; Hathout, Y; Kinder, TB; Nagaraju, K; Rayavarapu, S; Tappeta, K; Van der Meulen, JH | 1 |
| Eom, HS; Jo, DY; Jun, HJ; Kim, JS; Kim, K; Kim, KH; Kim, SH; Kim, SJ; Kim, YS; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Min, CK; Moon, JH; Mun, YC; Park, SK; Ryoo, HM; Suh, C; Voelter, V; Yoon, SS | 1 |
| Cheung, G; Chung, KC; Erdmann, N; Keats, JJ; Leung-Hagesteijn, C; Reece, DE; Stewart, AK; Tiedemann, RE | 1 |
| Ahn, C; Han, M; Jeon, HJ; Jeong, JC; Kim, MG; Kim, YJ; Koo, TY; Kwon, HY; Park, HC; Yang, J | 1 |
| Bonkobara, M; Hiroi, T; Ito, K; Iwata, T; Kobayashi, M; Kuroki, S; Kuroki, T; Mori, K; Nakagawa, T; Ono, K; Ozawa, Y; Sasaki, Y; Tetsuka, M; Washizu, T; Yamamoto, H | 1 |
| Bader, M; Grassner, L; Knight, AM; Loprinzi, CL; Paz, J; Podratz, JL; Staff, NP; Trushina, E; Windebank, AJ | 1 |
| Chen, CC; Cron, KR; D'Andrea, AD; Hsieh, G; Kozono, D; Kushwaha, DS; Merzon, D; Rameseder, J; Zhu, K | 1 |
| Aplenc, R; Caparas, M; Cullen, P; Johnston, DL; Nagarajan, R; Schulte, F; Sung, L | 1 |
| Baum, C; Deuse, T; Reichenspurner, H | 1 |
| Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Gkotzamanidou, M; Kanellias, N; Kastritis, E; Manios, E; Migkou, M; Papadimitriou, C; Roussou, M; Terpos, E | 1 |
| Al Ali, H; Andrea, M; Bachmann, A; Becker, C; Bourgeois, M; Edelmann, T; Egert, M; Fricke, S; Heyn, S; Hoffmann, FA; Krahl, R; Kreibich, U; Lindner, T; Moll, B; Niederwieser, D; Petros, S; Pönisch, W; Remane, Y; Schliwa, T; Schmalfeld, M; Schwarzer, A; Stiegler, R; Vucinic, V; Weidhase, L | 1 |
| Beric, A; Hochster, H; Ivy, P; Joseph, SO; Kobrinsky, B; Liebes, L; Malankar, A; Muggia, F | 1 |
| Alinari, L; Baiocchi, RA; Blum, KA; Byrd, JC; Johnston, JS; Li, X; Lin, TS; Lustberg, ME; Porcu, P | 1 |
| Anderson, KC; Blacklock, H; Dimopoulos, M; Eid, JE; Facon, T; Goldschmidt, H; Graef, T; Hajek, R; Houp, J; Hungria, V; Lonial, S; Palumbo, A; Qi, J; Rosinol, L; Siegel, DS; Spencer, A; Sun, L; Vuocolo, S; Williams, C | 1 |
| Sommer, T; Wolf, DH | 1 |
| Cho, NH; Choi, HK; Chun, YJ; Im, HJ; Kim, D; Kwon, Y; Park, N; Park, YS; Shin, S; Sung, CH; Ye, DJ | 1 |
| Anderl, J; Assaraf, YG; Cloos, J; de Haas, V; Degenhardt, J; Franke, NE; Horton, TM; Jansen, G; Kaspers, GJ; Kirk, CJ; Niewerth, D; Schimmer, AD; van Meerloo, J; Zweegman, S | 1 |
| Berciano, MT; Casafont, I; Lafarga, M; Palanca, A | 2 |
| Lin, M; Niu, S; Sheng, Z; Zou, Y | 1 |
| Nace, RA; Russell, SJ; Yarde, DN | 1 |
| Bardini, M; Carozzi, VA; Cavaletti, G; Chiorazzi, A; Dorsey, SG; Fazio, G; Meregalli, C; Oggioni, N; Quartu, M; Renn, CL; Sala, B; Serra, MP; Shanks, K | 1 |
| Bernard, M; Bosq, J; Camara-Clayette, V; Fest, T; Koscielny, S; Lamy, T; Lazar, V; Lenoir, G; Ribrag, V; Roux, S | 1 |
| Afek, A; Arad, M; Aravot, D; El-Ani, D; Eldar, M; Hochhauser, E; Issac, A; Katz, G; Kurtzwald-Josefson, E; Seidman, CE; Seidman, JG; Shainberg, A | 1 |
| Al-Salihi, M; Herhaus, L; Macartney, T; Sapkota, GP; Weidlich, S | 1 |
| Guzman, ML; Hayslip, J; Howard, DS; Jordan, CT; Liesveld, J; Phillips, GL; Weiss, H | 1 |
| Comenzo, R; Cossor, F; Fallo, S; Kaul, E; Klein, A; Miller, K; Shah, G; Smith, H; Sprague, K | 1 |
| Drach, J; Drach-Schauer, B; Eder, S; Lamm, W | 1 |
| Ballester, G; Ballester, O; Yaqub, S | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yoon, JH | 1 |
| Jeong, J; Lee, KH; Yoo, CG | 1 |
| Ahmed, EH; Bernot, KM; Blum, W; Brook, DL; Caligiuri, MA; Dickerson, KE; Dorrance, AM; Garman, S; Lee, RJ; Liu, S; Marcucci, G; Marcucci, GG; McConnell, KK; Mundy-Bosse, BL; Muñoz, MR; Nemer, JS; Santhanam, R; Siebenaler, RF; Whitman, SP; Yang, X; Zhang, J; Zhang, M; Zhang, X; Zorko, NA | 1 |
| Adami, F; Brancalion, A; Cabrelle, A; Cappellesso, R; Colpo, A; Di Maggio, SA; Gurrieri, C; Mandato, E; Manni, S; Marino, F; Piazza, F; Pizzi, M; Semenzato, G; Trentin, L; Tubi, LQ; Zaffino, F; Zambello, R | 1 |
| Cirone, M; D'Orazi, G; Di Renzo, L; Faggioni, A; Frati, L; Garufi, A; Gonnella, R; Granato, M; Lotti, LV; Santarelli, R; Trivedi, P | 1 |
| Alexandru, D; Bigner, D; Bota, DA; Friedman, HS; Keir, ST; Vredenburgh, J | 1 |
| Abt, PL; Lou, Y; Naji, A; Noorchashm, H; Parsons, RF; Redfield, RR; Rodriguez, E; Rostami, S | 1 |
| Al-Homsi, AS; Kouttab, N; Lai, Z; Roy, TS | 1 |
| Chen, SJ; Guo, Y; Janin, A; Leboeuf, C; Romero, M; Wang, L; Wu, LL; Xue, K; Yan, ZX; Zhang, QL; Zhao, WL | 1 |
| Feng, J; Leng, X; Li, J; Li, W; Lian, S; Wang, C; Wang, H; Zhang, X | 1 |
| Bačovský, J; Látalová, P; Lochman, P; Metelka, R; Minařík, J; Pika, T; Ščudla, V; Vymětal, J; Zapletalová, J | 1 |
| Atanackovic, D; Schilling, G | 1 |
| Kuna, M; Mikecin, AM; Raucher, D; Walker, LR | 1 |
| Alberti, D; Ames, MM; Attia, S; Bailey, HH; Eickhoff, J; Espinoza-Delgado, I; Hoang, T; Holen, KD; Jiang, Z; Kolesar, JM; Marnocha, R; McGovern, RM; Reid, JM; Schelman, WR; Traynor, AM; Wilding, G; Wright, JJ | 1 |
| Alberti, D; Ames, MM; Bailey, HH; Deming, DA; Eickhoff, J; Espinoza-Delgado, I; Kolesar, JM; Marnocha, R; McGovern, RM; Ninan, J; Reid, JM; Schelman, WR; Wilding, G; Wright, J | 1 |
| de Jong, H; Schreuder, MF; van Balen, T; van de Kar, NC | 1 |
| Babina, M; Mudnakudu Nagaraju, KK; Worm, M | 1 |
| Alvarez, R; Cabeçadas, J; Calaminici, M; Clear, AJ; Coutinho, R; Gomes da Silva, M; Gribben, JG; Lee, A; Matthews, J; Owen, A; Wilson, A | 1 |
| Chatziaggelidou, C; Christoulas, D; Delimpasi, S; Dimopoulos, MA; Gastari, V; Giannakoulas, N; Katodritou, E; Kelaidi, C; Konstantinidou, P; Kotsopoulou, M; Kyrtsonis, MC; Spyridis, N; Stefanoudaki, A; Symeonidis, A; Terpos, E; Verrou, E; Zervas, K | 1 |
| An, M; Hu, J; Hu, R; Li, X; Ruan, K; Shen, J; Song, G; Wu, N | 1 |
| Fujiwara, S; Hata, H; Kawano, Y; Kikukawa, Y; Mitsuya, H; Okuno, Y; Wada, N | 1 |
| Abdennebi, HB; Bardag-Gorce, F; Bejaoui, M; Carbonell, T; Folch-Puy, E; Oliva, J; Pantazi, E; Rimola, A; Roselló-Catafau, J; Zaouali, MA | 1 |
| Anderson, K; Hideshima, T; Laubach, J; Richardson, P | 1 |
| Moreau, P; Touzeau, C | 2 |
| Liu, H; McCarthy, P | 1 |
| Brioli, A; Cavo, M; Mancuso, K; Tacchetti, P; Zamagni, E; Zannetti, BA | 1 |
| Blouin, JM; Costet, P; de Verneuil, H; Duchartre, Y; Ged, C; Lain, A; Lalanne, M; Millet, O; Richard, E | 1 |
| Cain, R; Waight, CC | 1 |
| Bertomeu, T; Bucur, O; Dewar, R; Goganau, I; Khosravi-Far, R; Pennarun, B; Petrescu, SM; Stancu, AL | 1 |
| Chen, Y; Deng, Y; Deng, ZK; He, ZM; Li, YY; Tao, SD; Yu, L; Zhang, X | 1 |
| Han, J; Heo, HJ; Jeong, SH; Jeong, YJ; Kim, HK; Kim, N; Ko, KS; Ko, TH; Lee, SR; Rhee, BD; Song, IS; Youm, JB | 1 |
| Lentzsch, S; Schecter, J | 1 |
| Akria, L; Azoulay, D; Ben-Yehuda, D; Braester, A; Gatt, ME; Horowitz, N; Lavie, D; Perlman, R; Suriu, C | 1 |
| Hagihara, M; Hattori, Y; Ishigatsubo, Y; Ishii, Y; Ishiyama, Y; Tomita, N; Yamamoto, E; Yamazaki, E | 1 |
| Burlingame, AL; Julien, O; Urisman, A; Weissman, JS; Wells, JA; Wiita, AP; Wiita, PJ; Ziv, E | 1 |
| Fu, CC; Gu, B; Jin, S; Li, WY; Liu, H; Ma, L; Sun, AN; Wu, DP; Wu, Q; Xin, X; Xue, SL; Zhao, SF; Zhu, XM | 1 |
| Cheng, B; Gong, L; Jing, Y; Tang, X; Wu, GJ; Xu, M; Yang, B; Zheng, P | 1 |
| Baughn, LB; Linden, MA; Mansoor, A; Stessman, HA; Van Ness, B; Zhan, F | 1 |
| Kost, CK; Li, S; Li, Y; Martin, DS; Wang, X | 1 |
| Reisman, SA | 1 |
| An, G; Deng, S; Qiu, L; Shi, L; Shizhen, Z; Sui, W; Xie, Z; Xu, Y; Zhan, F | 1 |
| Anaclerico, B; Annino, L; Arcese, W; Avvisati, G; Cerchiara, E; Chierichini, A; Cudillo, L; De Fabritiis, P; Dentamaro, T; Giannotti, F; Marchesi, F; Mengarelli, A; Monarca, B; Montefusco, E; Petti, MC; Picardi, A; Porrini, R; Romeo, A; Tendas, A; Tirindelli, MC | 1 |
| Chen, CH; Chen, JY; Chen, WS; Chen, YJ; Chien, PH; Hsia, TC; Huang, WC; Liu, SH; Shih, CY; Tu, CY; Wei, YL; Yeh, MH; Yu, MC; Yu, YL | 1 |
| Akar, M; Aktan Kosker, T; Buyukasik, S; Ersoy, O; Solakoglu, T | 1 |
| Aróstegui, JI; Bladé, J; Cibeira, MT; Elena, M; Fernández de Larrea, C; Filella, X; Pedrosa, F; Rosiñol, L; Tovar, N; Yagüe, J | 1 |
| Alsop, K; Au-Yeung, G; Bowtell, DD; D'Andrea, AD; Davis, S; Etemadmoghadam, D; George, J; Hahn, WC; Mitchell, G; Simpson, K; Weir, BA | 1 |
| Boise, LH; Casbourne, D; Gleason, C; Heffner, LT; Kaufman, JL; Langston, A; Lonial, S; Muppidi, S; Nooka, AK; Saxe, D | 1 |
| Van Damme, P | 1 |
| Engelhardt, M; Fiebig, HH; Klingner, K; May, AM; Schueler, J; Siegers, GM; Wäsch, R; Wider, D | 1 |
| Gahrton, G; Krishnan, A | 1 |
| Adam, Z; Greil, R; Kasparu, H; Leitgeb, C; Linkesch, W; Ludwig, H; Pour, L; Rauch, E; Seebacher, A; Weißmann, A; Zojer, N | 1 |
| Cao, B; Chen, G; Du, X; Han, K; Li, J; Mao, X; Shi, M; Tang, J; Wang, M; Xu, X; Zhang, Z | 1 |
| Akhtar, S; Ansell, SM; Carr, J; Chanan-Khan, A; Chitta, K; Dispenzieri, A; Foran, J; Kumar, S; Mikhael, JR; Miller, KC; Paulus, A; Personett, D; Reeder, CB; Rivera, CE; Roy, V; Thompson, KJ | 1 |
| Aljama, P; Alonso, C; Alvarez-Lara, MA; Caballero-Villarraso, J; Carracedo, J; Martín-Malo, A; Ojeda-López, R; Pendón-Ruiz de Mier, MV | 1 |
| Caba-Molina, M; Claver-Ferré, C; García-Marcos, SA; Gómez-Morales, M; Martín-Gómez, MA; Palacios-Gómez, ME | 1 |
| Akashi, K; Aoki, T; Ito, Y; Kamimura, T; Miyamoto, T; Yokota, N | 1 |
| Malard, F; Mohty, B; Mohty, M; Moreau, P; Savani, B; Terpos, E | 1 |
| Barbee, MS; Harvey, RD; Hutcherson, DA; Kaufman, JL; Lonial, S; McKibbin, T; Shah, KS; Surati, M; Valla, K; Wilson, NM | 1 |
| Al-Homsi, AS; Al-Malki, MM; Junghans, RP; Kouttab, N; Lai, Z; Roy, TS | 1 |
| Fulda, S; Naumann, I; Rapino, F | 1 |
| Alloway, RR; Cardi, M; Ejaz, NS; Girnita, AL; Mogilishetty, G; Sadaka, B; Shields, AR; Woodle, ES | 1 |
| Lin, M; Luan, Y; Ma, Y; Wang, YB; Wang, ZS; Zhang, X; Zhang, ZH; Zhu, XB | 1 |
| Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S | 1 |
| Ahn, KS; Bae, EK; Choi, JH; Jung, WJ; Lee, C; Park, J; Yoon, SS | 1 |
| Khan, S; Li, WH; Sun, SR; Tang, Z; Wan, JN; Wang, CH; Yao, F; Zhang, YM; Zhu, S | 1 |
| Cavallo, F; Cerrato, C; Mina, R; Palumbo, A | 1 |
| Dou, QP; Hua, X; Huang, H; Li, S; Li, X; Liu, J; Liu, N; Liu, S; Xu, L; Yang, C; Zhao, C | 1 |
| Bokhari, SW; Jones, FM | 1 |
| Alesiani, F; Discepoli, G; Leoni, P; Liberati, S; Morelli, MB; Nabissi, M; Offidani, M; Olivieri, A; Santoni, G; Santoni, M | 1 |
| Chen, L; Fu, JX; Ju, SG; Li, J; Wang, ZY; Yuan, YQ | 1 |
| An, G; Deng, S; Meng, H; Qiu, L; Shi, L; Sui, W; Wang, J; Xu, Y; Zhan, F; Zhu, G; Zou, D | 1 |
| Gaut, D; Hu, K; Koeffler, HP; Lin, L; Yan, H; Yin, D | 1 |
| Condelli, V; Esposito, F; Landriscina, M; Lettini, G; Maddalena, F; Matassa, DS; Sisinni, L | 1 |
| De Maeyer, N; Delforge, M; Dierickx, D; Meersseman, W; Wauters, J | 1 |
| Angelucci, E; Annese, T; Berardi, S; Caivano, A; Catacchio, I; Dammacco, F; De Luisi, A; Derudas, D; Ditonno, P; Frassanito, MA; Guarini, A; Minoia, C; Moschetta, M; Nico, B; Piccoli, C; Ria, R; Ribatti, D; Ruggieri, S; Ruggieri, V; Vacca, A | 1 |
| Fadeel, B; Feng, X; Henter, JI; Ji, C; Ma, D; Shao, N; Wang, J; Wang, X; Zheng, C | 1 |
| Chiba, S; Furukawa, Y; Hiraoka, N; Kikuchi, J; Koyama, D; Kurosawa, H; Wada, T | 1 |
| Aldrin, A; Alici, E; Aschan, J; Blimark, C; Carlson, K; Enestig, J; Flogegård, M; Forsberg, K; Gahrton, G; Gruber, A; Haglöf Kviele, H; Johansson, P; Lauri, B; Liwing, J; Lund, J; Mellqvist, UH; Nahi, H; Näsman, P; Svensson, M; Swedin, A; Uttervall, K | 1 |
| Brooks, TR; Carson, WE; Dao, TV; Grignol, VP; Hade, EM; Kendra, KL; Kondalasula, SV; Lesinski, GB; Luedke, EA; Markowitz, J; Mundy-Bosse, BL; Olencki, T; Paul, BK | 1 |
| Alexanian, R; Delasalle, K; Handy, B; Qazilbash, M; Wang, M; Wang, S; Weber, D | 1 |
| Hahn, T; McCarthy, PL | 1 |
| Anderson, KC; Carrasco, RD; Chauhan, D; D'Arcy, P; Hu, Y; Linder, S; Ray, A; Richardson, P; Tai, YT; Tian, Z; Wang, X | 1 |
| Abramova, EB; Astakhova, TM; Bogomyagkova, YV; Choinzonov, EL; Erokhov, PA; Kondakova, IV; Kuznetsov, NA; Lyupina, YV; Plekhanova, AS; Rodoman, GV; Sharova, NP; Shashova, EE; Slonimskaya, EM; Sumedi, IR | 1 |
| Baldassarre, FG; Cheung, MC; Haynes, AE; Imrie, K; Kouroukis, CT; Reece, DE | 1 |
| Canta, A; Carozzi, V; Cavaletti, G; Chiorazzi, A; Meregalli, C; Monbaliu, J; Oggioni, N; Sala, B; VAN DE Velde, H | 1 |
| Munemoto, S; Murata, R; Nakajima, K; Nakao, S; Takamatsu, H; Terasaki, Y | 1 |
| Baldini, L; Capelli, C; Chiaramonte, R; D'Anca, M; Fabris, S; Inghirami, G; Introna, M; Lombardi, L; Mosca, L; Neri, A; Nobili, L; Pellegrino, E; Piva, R; Todoerti, K; Verdelli, D | 1 |
| Cao, Y; Farjam, R; Feng, FY; Gomez-Hassan, D; Hayman, JA; Lawrence, TS; Tsien, CI | 1 |
| Fukuda, Y; Gemma, A; Hatake, K; Katoh, T; Kudoh, S; Kusumoto, M; Miyao, M; Miyazawa, M; Mukai, HY; Ogawa, Y; Ohyashiki, K; Sakai, F; Sugiyama, Y; Yoshizawa, K | 1 |
| Anchoori, RK; Chen, X; Hung, CF; Jiang, R; Karanam, B; Matsui, W; Orlowski, RZ; Peng, S; Roden, RB; Rudek, MA; Tanno, T; Walters, KJ; Wang, JW; Zhao, M | 1 |
| Anderson, KC; Berenson, JR; Berger, A; Bernard, H; Blakemore, SJ; Bolen, JB; Chattopadhyay, N; Di Bacco, A; Dorner, AJ; Esseltine, DL; Jagannath, S; Koenig, E; Li, B; Lichter, DI; Lonial, S; Mulligan, G; Neuwirth, R; Orlowski, RZ; Ricci, D; Richardson, PG; San Miguel, JF; Schu, M; Sonneveld, P; Stadtmauer, EA; Trepicchio, W; van de Velde, H | 1 |
| Bennett, DL; Canta, A; Carozzi, VA; Cavaletti, G; Ceresa, C; Chiorazzi, A; Colombo, M; Foudah, D; La Russa, F; Marmiroli, P; Meregalli, C; Miloso, M; Nicolini, G; Oggioni, N; Sala, B | 1 |
| Chen, KF; Hou, DR; Huang, AC; Shiau, CW; Wang, CY; Yu, HC | 1 |
| Chen, RL; Huang, BT; Li, BS; Tan, Y; Zeng, QC; Zhao, WH | 1 |
| Chang, TP; Gatla, HR; Manna, S; Poltoratsky, V; Sanacora, S; Singha, B; Vancura, A; Vancurova, I | 1 |
| Barthel, BG; Kostoff, D; Saad, SA; Zobniw, CM | 1 |
| Alarid, ET; Bickford, B; Powers, GL; Rajbhandari, P; Solodin, NM | 1 |
| Ma, A; Mazepa, MA; Moll, S; Park, YA; Raval, JS | 1 |
| Anderson, KC; Mitsiades, CS; Ocio, EM; Orlowski, RZ | 1 |
| Furukawa, Y; Hatano, K; Kikuchi, J; Nagai, T; Ozawa, K; Sripayap, P | 1 |
| Delimpasi, S; Dimopoulos, MA; Gika, D; Kartasis, Z; Kastritis, E; Katodritou, E; Konstantopoulos, K; Kyrtsonis, MC; Michael, M; Michalis, E; Parcharidou, A; Pouli, A; Repousis, P; Symeonidis, A; Terpos, E; Vassou, A | 1 |
| Cheng, Q; Jin, Y; Liang, Y; Liu, H; Ma, S; Wang, Y; Wu, D; Wu, Y; Zhang, Y; Zheng, D | 1 |
| Chen, BY; Chen, WM; Liao, LS; Lin, Y; Qu, S; Wei, TN | 1 |
| Grandjean, C; Horger, M; Oehrlein, K; Schulze, M; Spira, D; Weisel, K; Zago, M | 1 |
| Cui, JW; Elmahi, AY; Hao, SS; Li, D; Li, W; Niu, C; Wang, GJ | 1 |
| Alvarez-Berríos, MP; Castillo, A; Rinaldi, C; Torres-Lugo, M | 1 |
| Anderson, CD; Busch, RA; Chapman, WC; Dines, JN; Gunter, KL; Jia, J; Knolhoff, BL; Mohanakumar, T; Ramachandran, S; Sarma, NJ; Tiriveedhi, V; Upadhya, GA | 1 |
| Domenicotti, C; Fenoglio, D; Furfaro, AL; Marinari, UM; Moretta, L; Nitti, M; Parodi, A; Passalacqua, M; Piras, S; Pronzato, MA; Traverso, N | 1 |
| Arai, S; Iwakura, Y; Kagoya, Y; Kataoka, K; Kobayashi, H; Kumano, K; Kurokawa, M; Nakagawa, M; Saito, T; Yoshimi, A | 1 |
| Borzym-Kluczyk, M; Cechowska-Pasko, M; Krętowski, R | 2 |
| Chen, W; Chen, Z; Gong, D; Huang, X; Liu, Z; Wang, Q; Zeng, C; Zhang, H | 1 |
| Ambati, SR; Chiosis, G; Kosugi, K; Lopes, EC; Meyers, PA; Mony, U; Moore, MA; Moreira, AL; Shah, SK; Taldone, T; Zehir, A | 1 |
| Berno, T; Kamalakar, A; Pappas, L; Suva, LJ; Tricot, G; Xu, H; Yang, Y; Yoon, D; Zangari, M; Zeng, M | 1 |
| Aylı, M; Cevik, C; Mandıroğlu, S | 1 |
| Devine, E; Krause, B; Krieter, DH; Lemke, HD; Storr, M; Wanner, C | 1 |
| Gupta, K; Klimenkova, O; Klimiankou, M; Kuznetsova, I; Meyer, J; Moore, MA; Skokowa, J; Welte, K; Zeidler, C | 1 |
| Zhang, J; Zhong, Y | 1 |
| Beck, P; Cui, H; Dubiella, C; Groll, M; Krüger, A; Schmidt, B; Stein, ML; Voss, C | 1 |
| Avan, A; Cavaletti, G; Ceresa, C; Geldof, AA; Giovannetti, E; Peters, GJ | 1 |
| Alé, A; Bruna, J; Monbaliu, J; Morell, M; Navarro, X; Udina, E; van de Velde, H | 1 |
| Choi, NR; Hoang, MD; Jung, SH; Kim, HJ; Lee, HJ; Lee, JJ; Lee, YK; Lim, MS; Nguyen-Pham, TN; Vo, MC | 1 |
| Cebotaru, L; Cebotaru, V; Guggino, WB; Rapino, D | 1 |
| Anderl, J; Assaraf, YG; Blank, JL; Cloos, J; Jansen, G; Kaspers, GJ; Kirk, CJ; Niewerth, D; van de Ven, PM; van Meerloo, J; Zweegman, S | 1 |
| Anderson, KC; Bahlis, N; Baz, R; Belch, A; Chen, C; Chen, M; Hofmeister, CC; Jacques, C; Jagannath, S; Jakubowiak, A; Lacy, M; Lentzsch, S; Lonial, S; Matous, J; Mikhael, J; Raje, N; Richardson, PG; Shustik, C; Siegel, DS; Song, K; Vesole, D; Vij, R; Yu, Z; Zaki, MH | 1 |
| Cirone, M; D'Orazi, G; Faggioni, A; Farina, A; Gonnella, R; Granato, M; Santarelli, R | 1 |
| Alsina, M; Anderson, KC; Colson, K; Esseltine, DL; Feather, J; Francis, D; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, A; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Maglio, ME; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, D; Weller, E; Xie, W | 1 |
| Liu, G; Liu, L; Wang, SX; Wang, Y; Yao, Y; Zhang, YK | 1 |
| Berenson, JR; Bessudo, A; Boccia, RV; Dichmann, R; Eshaghian, S; Gravenor, D; Hilger, JD; Nassir, Y; Patel-Donnelly, D; Stampleman, L; Swift, RA; Vescio, RA; Yellin, O | 1 |
| Chung, M; Hartono, C; Kuo, SF; Muthukumar, T; Seshan, SV | 1 |
| Allen, MS; Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; William, BM | 1 |
| Blanco Cid, N; Dacal Quintas, R; Santalla Martínez, M | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R | 1 |
| Bryant, J; Clegg, A; Cooper, K; Picot, J | 1 |
| Hata, T; Li, C; Two, AM | 1 |
| Advani, RH; Chang, JE; Gascoyne, RD; Horning, SJ; Kahl, BS; Li, H; Paietta, EM; Smith, MR; Yang, DT | 1 |
| Attal, M; Einsele, H; Giralt, S; McCarthy, PL | 1 |
| Chan, EY; Chim, CS; Ho, S; Kwong, YL; Lie, AK; Liu, H; Wong, M | 1 |
| Chang, CC; Choi, DS; Jiang, B; Su, J; Wen, J; Zhang, L; Zhang, W; Zhou, X | 1 |
| Collins, DJ; Davies, FE; deSouza, NM; Giles, SL; Messiou, C; Morgan, GJ; Morgan, VA; Simpkin, CJ; West, S | 1 |
| Anderson, KC; Chauhan, D; Coffman, RL; Das, DS; Ray, A; Richardson, P; Tian, Z | 1 |
| Anderson, KC; Hide, M; Hideshima, H; Hideshima, T; Ikeda, H; Iwasaki, A; Yoshida, Y | 1 |
| Blum, KA; Maddocks, K | 1 |
| Karthik, S; Ravikumar, V; Sankar, R; Varunkumar, K | 1 |
| Bartlett, DL; Kim, SY; Lee, YJ; Song, X; Zhang, L | 1 |
| Shang, Z; Wei, J; Xiao, Y; Yin, J | 1 |
| Midorikawa, K; Nagata, A; Noto, S; Ootsubo, K; Sekiguchi, N; Takezako, N; Wagatsuma, M; Yamada, K | 1 |
| Boccadoro, M; Corradini, P; Crippa, C; Gambella, M; Gay, F; Ladetto, M; Omedè, P; Palumbo, A; Passera, R; Rocci, A; Romano, A; Rossi, D | 1 |
| Ahn, KS; Chng, WJ; Kannaiyan, R; Kumar, AP; Li, F; Mustafa, N; Sethi, G; Siveen, KS | 1 |
| Bergqvist, M; Bergström, S; Blomquist, E; Edqvist, PH; Ekman, S; Gullbo, J; Jaiswal, A; Johansson, M; Lennartsson, J; Navani, S; Pontén, F; Sooman, L; Tsakonas, G; Wu, X | 1 |
| Alpaugh, RK; Cheng, JD; Cohen, SJ; Cooper, H; Denlinger, CS; Engstrom, PF; Lewis, NL; Li, T; Meropol, NJ; Weiner, LM; Wright, JJ | 1 |
| Anderson, LM; Biswas, D; Holland, RJ; Ji, X; Keefer, LK; Kim, Y; Kumari, V; Luthers, CE; Maciag, AE; Morris, NL; Saavedra, JE; Sehareen, WS | 1 |
| Delafontaine, P; Godard, MP; He, Y; Shen, CC; Song, YH; Wang, JJ; Wang, TX; Xing, SS; Yang, ST; Yang, XL; Yue, YY; Zhang, SB; Zhao, Q | 1 |
| Besanceney-Webler, C; Chen, EX; Cheng, J; Christos, P; Dilts, KT; Holloway, S; Keresztes, R; Lane, ME; Lin, J; Matulich, D; Ocean, AJ; Papetti, M; Schnoll-Sussman, F; Shah, MA; Sparano, JA; Ward, M; Wright, JJ; Xiang, J; Yantiss, RK | 1 |
| Lentzsch, S | 1 |
| Chauncey, T; Deauna-Limayo, D; Dong, Z; Liu, D; Pilz, R; Wang, HY; Wang-Rodriguez, J; Yan, M; Zhao, F | 1 |
| Cui, Y; Huang, ZZ; Li, D; Liu, XG; Pang, RP; Su, YM; Wei, JY; Xin, WJ; Xue, Z; Zhang, J | 1 |
| Alloway, RR; Cardi, MA; Krisl, JC; Shields, AR; Woodle, ES | 1 |
| Bonnet, A; Bourcier, J; Chauvin, C; Lok, A; Mahé, B; Mocquard, J; Moreau, P; Redelsperger, L; Thomaré, P; Touzeau, C | 1 |
| Cao, JY; Cao, MN; Cao, XC; Gao, AH; Gao, LX; Han, MM; Li, J; Sheng, L; Su, MB; Wang, MK; Xu, L; Zhou, YB | 1 |
| Chairopoulos, K; Kilindireas, K; Koulieris, E; Koutra, E; Kyrtsonis, MC; Maltezas, D; Pangalis, GA; Pessach, I; Sachanas, SP; Tzenou, T; Zaroulis, CK | 1 |
| Ji, Z; Jiang, X; Lei, Y; Li, H; Sun, M; Wu, G | 1 |
| Dondero, R; Francis, SM; Liu, Z; Tang, T; Taylor, CA; Thompson, JE; Zheng, Q | 1 |
| Kazi, A; Lawrence, HR; Ozcan, S; Sebti, SM; Sun, Y; Tecleab, A | 1 |
| Cheung, YK | 1 |
| Akar, FG; Chaanine, AH; Hajjar, RJ; Jin, D; Kohlbrenner, E; Kovacic, JC; Nonnenmacher, M; Weber, T | 1 |
| Baiz, D; Chiaretti, S; Consoloni, L; Dapas, B; Farra, R; Fiotti, N; Grassi, G; Pozzato, G; Scaggiante, B; Zanconati, F | 1 |
| Cavallo, F; Genadieva-Stavric, S; Palumbo, A | 1 |
| Bartlett, NL; Beck, JT; Cherfi, A; Cheung, W; Collins, RH; Fan, J; Fanning, SR; Goy, A; Johnston, PB; Kaminski, MS; Kaya, H; Klimovsky, J; Lister, J; O'Connor, OA; Popplewell, LL; Robeva, A; Tuscano, JM; Wang, M; Winter, JN | 1 |
| Fuchida, S; Hino, M; Ishii, K; Kanakura, Y; Kaneko, H; Kobayashi, M; Kosugi, S; Kuroda, J; Matsumura, I; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Shimura, Y; Takaori-Kondo, A; Tanaka, H; Taniwaki, M; Tsudo, M; Uoshima, N | 1 |
| Cohen, P | 1 |
| Eksborg, S; Eriksson, E; Johnsen, JI; Kogner, P; Perup, LS; Sävendahl, L; Wickström, M | 1 |
| Bodie, WW; Chen, S; Dai, Y; Felthousen, J; Grant, S; Kramer, LB; Orlowski, RZ; Pei, XY; Sanderson, MW; Takabatake, Y; Youssefian, LE; Zhou, L | 1 |
| Shah, BK; Sharma, LR; Subedi, A | 1 |
| Amin, HM; Chen, Z; He, Y; Shen, C; Song, YH; Wang, Y; Wu, D; Xing, S; Yang, S; Yue, Y | 1 |
| Appel, GB; Bomback, AS; Canetta, PA; D'Agati, V; Dillon, JJ; Leung, N; Patel, K | 1 |
| Höke, A; Ray, M | 1 |
| Barreiro, E; Chacon-Cabrera, A; de Kier Joffé, ED; Diament, MJ; Fermoselle, C; Mateu-Jimenez, M; Sandri, M; Urtreger, AJ | 1 |
| Barchnicka, A; Grosicka, A; Grosicki, S; Jurczyszyn, A | 1 |
| Fischer, U; Hoffmann, MJ; Jung, M; Niegisch, G; Rosik, L; Schulz, WA | 1 |
| Coccia, M; La Frazia, S; Riccio, A; Rossi, A; Santoro, MG; Trotta, E | 1 |
| Aoi, Y; Kapoor, TM; Kawashima, SA; Sato, M; Shirahige, K; Sutani, T | 1 |
| Dong, LW; Du, J; Fan, JL; Fu, WJ; Hou, J; Jiang, H; Shi, HG; Wang, HY; Xi, H; Ye, F; Zhang, CY; Zhang, J | 1 |
| Hur, DY; Jin, DH; Kim, D; Kim, JE; Kim, S; Kim, YS; Lee, JI; Lee, WJ; Park, GB; Wu, TC | 1 |
| Dudem, S; Jain, N; Kalivendi, SV; Vangala, JR | 1 |
| Ahn, JS; Bae, SY; Jung, SH; Kim, HJ; Kim, YK; Lee, JJ; Yang, DH | 1 |
| Carmignac, V; Durbeej, M; Fontes-Oliveira, CC; Holmberg, J; Körner, Z | 1 |
| Avigan, D; Kufe, D; Kufe, T; Yin, L | 1 |
| Alloway, RR; Budde, K; Dürr, M; Ejaz, NS; Halleck, F; Woodle, ES | 1 |
| Blommestein, HM; Franken, MG; Gaultney, JG; Huijgens, PC; Redekop, WK; Sonneveld, P; Uyl-de Groot, CA | 1 |
| Abar, F; Dibb, J; Dibb, W; Frires, R; Heitner, SB; Kovacsovics, T; Maziarz, RT; Meyers, G; Perez-Avraham, G; Scott, EC; Smith, SD; Stentz, A | 1 |
| Matevosyan, K; Rutherford, C; Sarode, R; Shen, YM; Yates, S | 1 |
| Corchete, LA; Garayoa, M; García-Sanz, R; Gutiérrez, NC; Krzeminski, P; Ocio, EM; Paíno, T; Paiva, B; Redondo, A; San-Miguel, JF; San-Segundo, L; Sarasquete, ME | 1 |
| Asaoku, H; Chou, T; Harada, T; Hayashi, K; Itagaki, M; Kuroda, Y; Mina, R; Murakami, H; Ozaki, S; Palumbo, A; Saitoh, T; Shimazaki, C; Shimizu, K; Suzuki, K; Yoshiki, Y | 1 |
| Aiba, K; Hatake, K; Mishima, Y; Nishimura, N; Sakajiri, S; Suzuki, K; Terui, Y; Ueda, K; Yokoyama, M | 1 |
| Fu, R; Gao, S; Liu, H; Shao, Z; Song, J; Wang, G; Wang, H; Xing, L | 1 |
| Cen, X; Dong, Y; Li, Y; Liang, Z; Liu, W; Ou, J; Qiu, Z; Ren, H; Sun, Y; Wang, L; Wang, M; Wang, Q; Wang, W; Xu, W; Yin, Y | 1 |
| Coombs, KM; Ezatti, P; Shahiduzzaman, M; Xin, G | 1 |
| Johnson, CS; Kalra, VK; Meng, Z; Pullarkat, V; Tahara, SM | 1 |
| Matsue, K; Morita, T; Tanimoto, T; Ugai, T | 1 |
| Cavalli, M; Chiarenza, A; Conticello, C; Cunsolo, R; Di Raimondo, C; Di Raimondo, F; Palumbo, GA; Romano, A; Vetro, C | 1 |
| Bird, J; Bowcock, S; Cook, G; Davies, F; Lai, M; Low, E; Morgan, G; Owen, R; Pratt, G; Rabin, N; Snowden, J; Wechalaker, A; Yong, K | 1 |
| Berger, M; Ford, P; Goy, A; Hernandez-Ilzaliturri, FJ; Kahl, B; Protomastro, E | 1 |
| Hudson, MB; Kavazis, AN; Nelson, WB; Powers, SK; Smuder, AJ | 1 |
| Andoh, T; Kitamura, R; Kuraishi, Y; Mizoguchi, S; Saito, Y; Takahata, H | 1 |
| Iida, S; Ri, M | 1 |
| Ashikaga, T; Keino, D; Kinoshita, A; Kondoh, K; Morimoto, M; Ohyama, R; Yamashita, A | 1 |
| Chen, CY; Chen, YC; Chou, SJ; Chou, WC; Hou, HA; Huang, SY; Lin, CW; Lin, HH; Lu, HY; Tang, JL; Tien, HF; Tsay, W; Wu, SJ; Yao, M | 1 |
| Abildgaard, N; Godskesen, L; Kjeldsen, J; Krag, A | 1 |
| Furukawa, Y; Kikuchi, J; Koyama, D; Mukai, HY | 1 |
| Böhmig, GA; Bond, G; Eskandary, F; Haslacher, H; Kikic, Z; Marinova, L; Oberbauer, R; Regele, H; Schwaiger, E; Wahrmann, M; Winzer, C | 1 |
| Bernal, L; Boise, LH; Chen, J; Gu, Y; Harvey, RD; Kaufman, JL; Lonial, S; Matulis, SM; Sun, SY; Torre, C | 1 |
| Balsas, P; Campo, E; Colomer, D; Martínez, A; Montraveta, A; Moros, A; Normant, E; Pérez-Galán, P; Rodríguez, V; Roué, G; Saborit-Villarroya, I; Sandy, P; Wiestner, A | 1 |
| Chuang, WH; Hsu, LF; Huang, SY; Hwang, SM; Liao, YH; Lin, HH; Sheen, YS; Wu, SJ | 1 |
| Claes, DJ; Goebel, J; Yin, H | 1 |
| Ahn, SY; Choi, CW; Joo, YD; Jung, SH; Kim, K; Kim, SJ; Lee, JJ; Lee, SM; Lee, WS | 1 |
| Levy, Y; Maisel, C; Robinson, S; Tong, AW | 1 |
| Chang, WJ; Kang, ES; Kim, DW; Kim, K; Kim, SH; Kim, SJ; Lee, ST | 1 |
| Coelho, MA; Coelho, SC; Juzenas, P; Pereira, MC; Rocha, S | 1 |
| Cashen, A; Cheng, EH; DiPersio, J; Hsieh, JJ; Kunkle, L; Liu, H; Pham, CG; Piwnica-Worms, DR; Vij, R; Westergard, TD | 1 |
| Bloomfield, CD; Carson, WE; de la Chapelle, A; Eisfeld, AK; Hoag, KW; Huang, X; Jarvinen, TM; Leffel, B; Marcucci, G; Markowitz, J; Patel, R; Perrotti, D; Santhanam, R; Schwind, S; Walker, CJ | 1 |
| Anderl, JL; Assaraf, YG; Cloos, J; Jansen, G; Kale, AJ; Kaspers, GJ; Moore, BS; Niewerth, D; Riethoff, LF; van Meerloo, J; Zweegman, S | 1 |
| Gao, ZY; Hu, W; Wang, W | 1 |
| An, G; Chang, H; Cheng, T; Deng, S; Hao, M; Li, F; Qi, J; Qin, X; Qin, Y; Qiu, L; Ru, K; Shi, L; Sui, W; Wang, H; Wang, J; Xu, Y; Yao, H; Yi, S; Zhu, G | 1 |
| Issaragrisil, S; Kheolamai, P; Klincumhom, N; Manochantr, S; Sanvoranart, T; Supokawej, A; U-Pratya, Y; Wattanapanitch, M | 1 |
| Alì, G; Bellelli, R; Castellone, MD; Fontanini, G; Gutkind, JS; Laukkanen, MO; Santoro, M; Teramoto, H | 1 |
| Bringhen, S; Donato, F; Gay, F; Palumbo, A; Troia, R | 1 |
| Fujishima, Y; Ishida, Y; Ito, S; Kowata, S; Murai, K; Shimoyama, T; Yashima-Abo, A | 1 |
| Adam, Z; Krejčí, M; Pour, L; Ševčíková, E | 1 |
| Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z | 1 |
| Anagnostopoulos, A; Christoforidou, A; Christoulas, D; Delimpasi, S; Dimopoulos, MA; Gastari, V; Giannakoulas, N; Giannopoulou, E; Hadjiaggelidou, C; Kastritis, E; Katodritou, E; Kelaidi, C; Konstantinidou, P; Kotsopoulou, M; Kouraklis, A; Kyrtsonis, MC; Papadaki, S; Papadopoulou, A; Polychronidou, G; Pouli, A; Stefanoudaki, E; Symeonidis, AS; Terpos, E; Verrou, E; Viniou, NA; Zervas, K | 1 |
| Aubert, O; Durrbach, A; Francois, H; Gauthe, R; Obada, EN; Suberbielle, C | 1 |
| Evens, AM; Gordon, LI; Helenowski, I; Lossos, IS; Millenson, M; Rosen, ST; Smith, MR; Winter, JN | 1 |
| Choquet, S; Leblond, V; Nguyen, S; Souchet-Cömpain, L | 1 |
| Boccadoro, M; Bringhen, S; Desai, A; Di Raimondo, F; Esseltine, DL; García-Sanz, R; Lahuerta, JJ; Larocca, A; Londhe, A; Mateos, MV; Oriol, A; Palumbo, A; Richardson, PG; San Miguel, JF; van de Velde, H | 1 |
| Drews, O; Feldner, A; Hecker, M; Korff, T; Meyer, R; Pfisterer, L | 1 |
| Cho, J; Kang, D; Kim, K; Kim, SJ; Lee, JY | 1 |
| Chiang, AK; Hui, KF | 1 |
| Atkins, GB; Jain, MK; Lin, Z; Nayak, L; Schmaier, AH; Shi, H | 1 |
| Burgstaller, G; Cei, D; Eickelberg, O; Lentner, B; Lenz, AG; Meiners, S; Schmid, O; Schmidmeir, M; Semren, N; Stoeger, T | 1 |
| Burhenne, J; Clemens, J; Haefeli, WE; Hose, D; Longo, M; Seckinger, A; Weiss, J | 1 |
| Choi, Y; Hur, DY; Kim, D; Kim, YS; Lee, HK; Park, GB | 1 |
| Du, H; Hu, X; Huang, J; Jiang, H; Xuan, H | 1 |
| Ding, Y; Ju, S; Mao, L; Shi, F; Wang, Y; Wu, X; Zhu, W | 1 |
| Bao, L; Huang, X; Jiang, B; Lai, Y; Li, J; Li, L; Liu, Y; Lu, J; Qin, Y; Shi, H; Wang, Y; Zhu, H | 1 |
| Abdi, J; Garssen, J; Mutis, T; Redegeld, FA | 1 |
| Leffell, MS; Montgomery, RA; Philogene, MC; Sikorski, P; Zachary, AA | 1 |
| Aki, T; Funakoshi, T; Uemura, K; Unuma, K; Watanabe, M | 1 |
| Abildgaard, N; Hansen, CT; Nielsen, LC; Pedersen, PT | 1 |
| Khan, F; Linden, MA; Vercellotti, GM; Zantek, ND | 1 |
| Agnelli, L; Anderson, KC; Antonini, E; Bertilaccio, MT; Blandino, G; Caligaris-Cappio, F; Carrasco, R; Cottini, F; Dori, M; Hideshima, T; Kimmelman, AC; Kuehl, WM; Marcatti, M; Neri, A; Ponzoni, M; Richardson, PG; Sattler, M; ten Hacken, E; Tonon, G; Wong, KK; Xu, C | 1 |
| Butani, L; Gallay, B; Nguyen, S | 1 |
| Bailey, Z; Bolyard, C; Caligiuri, MA; Cripe, TP; Eaves, D; He, S; Hurwitz, BS; Kaur, B; Old, M; Parris, DS; Rath, KS; Selvendiran, K; Yoo, JY; Yu, J; Yu, JG; Zhang, J | 1 |
| Chambers, JE; Clarke, HJ; Liniker, E; Marciniak, SJ | 1 |
| Aktan, C; Cömert, M; Gündüz, C; Kaymaz, BT; Kiper, HD; Kosova, B; Sahin, F; Saydam, G; Selvi, AF; Selvi, N | 1 |
| Blommestein, HM; Franken, MG; Huijgens, PC; Uyl-de Groot, CA; van Agthoven, M; Verelst, SG | 1 |
| Bladé, J; Grosicki, S; Laubach, J; Maloisel, F; Mateos, MV; Min, CK; Orlowski, RZ; Palumbo, A; Polo Zarzuela, M; Prasad, SV; Puchalski, T; Qin, X; Reddy, M; Robak, T; San-Miguel, J; Shpilberg, O; Spencer, A; Tee Goh, Y; Uhlar, C; van de Velde, H; Xie, H | 1 |
| Abujamra, AL; Alemar, B; Ashton-Prolla, P; de Farias, CB; Giacomazzi, J; Hainaut, P; Hautefeuille, A; Izetti, P; Lenz, G; Osvaldt, AB; Roesler, R; Schwartsmann, G | 1 |
| Chen, ZR; Huang, M; Min, H; Xu, M; Zheng, K; Zhou, JD; Zou, XP | 1 |
| Hong, SY; Kang, S; Min, J; Moon, H; Shin, HH; Yang, HJ | 1 |
| Abe, Y; Hamano, A; Hattori, Y; Miyazaki, K; Nakagawa, Y; Sekine, R; Shingaki, S; Suzuki, K; Tsukada, N | 1 |
| Hata, H; Mitsuya, H; Nishimura, N; Nosaka, K; Okuno, Y | 1 |
| Al-Salihi, MA; Bruce, D; Cummins, TD; Dingwell, KS; Ewan, R; Herhaus, L; Macartney, T; Sapkota, GP; Smith, JC; Vogt, J; Wasmus, L; Weidlich, S | 1 |
| Choi, BS; Chung, BH; Jeon, H; Jo, IH; Kim, JI; Kim, YS; Moon, IS; Park, CW; Park, Y; Yang, CW; Yang, KS | 1 |
| Gurocak, S; Kiliccioglu, I; Konac, E; Varol, N; Yucel Bilen, C | 1 |
| Chen, L; Gao, L; Hu, X; Lyu, S; Qiu, H; Song, X; Wang, J; Xu, L; Xu, X; Yang, J; Zhang, W | 1 |
| Bridoux, F; Comenzo, RL; Decaux, O; Gillmore, J; Hari, P; Hawkins, PN; Jaccard, A; Lavergne, D; Lazaro, E; Macro, M; Mercie, P; Mohty, D; Morel, P; Pellegrin, JL; Roussel, M; Venner, CP; Wechalekar, AD | 1 |
| Avigdor, A; Duek, A; Freidman, T; Kedmi, M; Leiba, M; Leiba, R; Nagler, A; Weiss, M | 1 |
| Barchnicka, A; Blajer-Olszewska, B; Blonska, D; Boguradzki, P; Charlinski, G; Dawidowska, D; Dmoszynska, A; Druzd-Sitek, A; Dzierzak-Mietla, M; Gawron, L; Gontarska, A; Grygoruk-Wisniowska, I; Grzasko, N; Holojda, J; Iskierka, E; Jachalska, A; Jurczyszyn, A; Kopacz, A; Lech-Maranda, E; Madro, E; Masternak, A; Nowicki, A; Olszewska-Szopa, M; Potoczek, S; Rybicka, M; Rymko, M; Rzepecki, P; Soroka-Wojtaszko, M; Subocz, E; Swiderska, A; Swistek, W; Torosian, T; Usnarska-Zubkiewicz, L; Walter-Croneck, A; Wisniewska-Piaty, K; Zielinska, P | 1 |
| Badros, AZ; Bao, T; Dorsey, SG; Goloubeva, O; Hester, L; Lao, L; Lapidus, R; Medeiros, M; Pelser, C; Porter, N; Primrose, J; Sadowska, M | 1 |
| Boi, M; Carozzi, VA; Cavaletti, G; Chiorazzi, A; Del Fiacco, M; Dorsey, SG; Marmiroli, P; Melis, T; Meregalli, C; Picci, C; Poddighe, L; Quartu, M; Renn, CL; Serra, MP | 1 |
| Fujimoto, T; Koyama, A; Kurihara, T; Nishikawa, A; Okamoto, Y; Shiotani, C; Tamura, S | 1 |
| Abe, Y; Honda, Y; Iki, S; Inoue, J; Miyazaki, K; Sekine, E; Shingaki, S; Suzuki, K; Tsukada, N | 1 |
| Alexanian, R; Badillo, M; Chen, Y; Chiang, J; Cohen, L; Delasalle, K; Garcia, MK; Green, V; Guo, Y; Lee, R; Orlowski, RZ; Romaguera, J; Shah, J; Thomas, S; Wang, M; Weber, D; Wei, Q; You, B; Zhang, L; Zhou, Y | 1 |
| Anderson, KC; Bianchi, G; Richardson, PG | 1 |
| Amiri, KI; Benson, AB; Berlin, J; Ciombor, KK; Feng, Y; Horton, L; Kauh, JS; Mulcahy, M; Powell, M; Richmond, A; Short, SP; Staley, C; Su, Y | 1 |
| Ashley, JD; Bilgicer, B; Kiziltepe, T; Schroeder, VA; Stefanick, JF; Suckow, MA | 1 |
| Fu, BB; Li, J; Li, YC; Liao, AJ; Liu, ZG; Wang, HH; Yang, W; Yang, Y; Zhang, R | 1 |
| Nixon, NA; Parhar, K | 1 |
| Dougherty, PM; Robinson, CR; Zhang, H | 2 |
| Bringhen, S; Donato, F; Gay, F; Mina, R; Palumbo, A; Troia, R | 1 |
| El-Shentenawy, A; Mohammed, AA | 1 |
| Gatla, HR; Persaud, V; Singha, B; Vancurova, I | 1 |
| Gatla, HR; Phyo, SA; Singha, B; Vancurova, I | 1 |
| Chang, TP; Sanacora, S; Vancurova, I | 1 |
| Draber, P; Graves, J; Montinaro, A; Newsom-Davis, T; Prieske, K; Prieske, S; Tuthill, MH; von Karstedt, S; Walczak, H; Zinngrebe, J | 1 |
| Chen, X; Dou, QP; Guan, L; Hua, X; Huang, H; Lan, X; Li, X; Liao, S; Liu, C; Liu, J; Liu, N; Liu, S; Song, W; Wang, S; Wang, X; Yang, C; Yi, S; Zhang, P; Zhao, C; Zhou, P | 1 |
| Huang, HB; Niu, WY; Wu, SQ; Xu, ZZ; Zhan, R | 1 |
| Johnson, DE; Kirk, CJ; Zang, Y | 1 |
| Cai, Z; Fu, J; Han, X; He, J; Huang, H; Huang, W; Li, L; Shi, J; Wei, G; Wu, W; Xie, W; Yang, L; Ye, X; Zhang, J; Zhang, X; Zhao, Y; Zheng, G; Zheng, W | 1 |
| Akashi, K; Aoki, T; Ito, Y; Iwasaki, H; Kadowaki, M; Kamimura, T; Kato, K; Miyamoto, T; Muta, T; Shima, T; Shiratsuchi, M; Takase, K; Takashima, S; Takenaka, K; Teshima, T; Yoshimoto, G | 1 |
| De Bruyne, E; De Wever, O; Hendrix, A; Hernot, S; Lahoutte, T; Lemaire, M; Menu, E; Van Valckenborgh, E; Vanderkerken, K; Wang, J | 1 |
| Foard, D; Gibbs, SD; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Lane, T; Mahmood, S; Pinney, JH; Rannigan, L; Sachchithanantham, S; Venner, CP; Wechalekar, AD; Whelan, CJ | 2 |
| de Zoysa, JR; Hutchison, CA; Lam-Po-Tang, M; Tan, J | 1 |
| Aggarwal, S; Fagoaga, OR; L'Ecuyer, TJ; Zinn, MD | 1 |
| Dytfeld, D; Gil, L; Kaźmierczak, M; Komarnicki, M; Nowicki, A; Rupa-Matysek, J; Wojtasińska, E | 1 |
| Abu Jawdeh, BG; Alachkar, N; Arend, LJ; Bhasin, B; Gupta, G; Kraus, E; Montgomery, RA; Rabb, H; Racusen, LC; Trollinger, B; Zachary, AA | 1 |
| Wei, W; Wu, C; Wu, Y; Xu, W; Yan, H; Ye, C; Yu, Q | 1 |
| Ding, SH; Wang, QS; Wang, YS; Wang, ZT; Wu, F | 1 |
| Andrea, M; Becker, C; Behre, G; Bourgeois, M; Edelmann, T; Gutsche, K; Hammerschmidt, D; Hennig, E; Heyn, S; Hoffmann, FA; Holzvogt, B; Kaiser, T; Krahl, R; Kreibich, U; Lindner, T; Niederwieser, D; Plötze, M; Pönisch, W; Reifenrath, K; Remane, Y; Schliwa, T; Schwarz, M; Schwarzer, A; Vucinic, V; Winkelmann, C; Zehrfeld, T | 1 |
| Bai, Q; Chen, X; Liang, R; Liu, H; Liu, L; Liu, M; Shi, B; Tian, D; Zhang, Y | 1 |
| Cerchia, C; Ettari, R; Grasso, S; Lavecchia, A; Micale, N; Novellino, E; Pinto, A; Scarbaci, K; Schirmeister, T; Troiano, V; Zappalà, M | 1 |
| Ashcroft, AJ; Bird, JM; Brown, JM; Cairns, DA; Cavenagh, J; Cavet, J; Chalmers, A; Cook, G; Drayson, MT; Fletcher, M; Hunter, H; Morris, TC; O'Connor, S; Parrish, C; Snowden, JA; Williams, C; Yong, K | 1 |
| Eriksson, E; Hou, M; Jahnukainen, K; Meinhardt, A; Sävendahl, L; Söder, O; Svechnikov, K | 1 |
| Chien, W; Ding, LW; Garg, M; Gery, S; Kitajima, S; Koeffler, PH; Lee, KL; Leong, WZ; Lim, SL; Poellinger, L; Sun, H; Sun, QY; Takao, S; Tan, SZ; Tokatly, I; Torres-Fernandez, LA; Xiao, J | 1 |
| Atsumi, M; Ito, T; Kameda, K; Kiba, T; Kido, M; Kimura, A; Miyamae, F; Nakashima, T; Niimi, H; Okikawa, Y; Shitakubo, Y; Sumitani, Y; Tanaka, S | 1 |
| Hu, C; Liu, J; Tian, Y; Tian, Z; Wang, C; Wang, X | 1 |
| Anderson, KC; Cirstea, D; Hu, Y; Lu, D; Munshi, NC; Song, W | 1 |
| Chung, DJ; Devlin, S; Giralt, SA; Hassoun, H; Hilden, P; Koehne, G; Landau, H; Lendvai, N; Lesokhin, AM; Redling, K; Schaffer, WL; Tsakos, I | 1 |
| Asahina, M; Ikeda, S; Kuwabara, S; Sano, K; Shiojiri, T; Sugiyama, A; Takeda, Y | 1 |
| Baritaki, S; Berenson, JR; Bonavida, B; Chen, H; Del Lourdes Cebrera-Muñoz, M; Huerta-Yepez, S; Liu, H; Maldonado-Valenzuela, A; Rivera-Pazos, C; Valencia-Hipolito, A; Vega, MI | 1 |
| Buurman, WA; De Baets, MH; Duimel, H; Gomez, AM; Hummel, J; Losen, M; Martinez-Martinez, P; Molenaar, PC; Nogales-Gadea, G; Saxena, A; Verheyen, F; Vrolix, K; Willcox, N | 1 |
| Grob, SR; Jakobiec, FA; Rashid, A; Yoon, MK | 1 |
| Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M | 1 |
| Bergsagel, PL; Chen, C; Fonseca, R; Kukreti, V; Laumann, K; Leis, JF; Mikhael, JR; Reece, DE; Reeder, CB; Stewart, AK; Tiedemann, R; Trudel, S; Vohra, H | 1 |
| Adlard, K; Alonzo, TA; Ballard, J; Gamis, AS; Gerbing, RB; Horton, TM; Howard, DS; Jenkins, G; Kelder, A; Moscow, JA; Perentesis, JP; Schuurhuis, GJ; Smith, FO | 1 |
| Chiappetta, G; Di Maro, G; Jarzab, B; Masullo, M; Monaco, M; Oczko-Wojciechowska, M; Orlandella, FM; Salerno, P; Salvatore, G; Santoro, M; Thomas, G; Unger, K | 1 |
| Güngör, T; Waespe, N; Zeilhofer, U | 1 |
| Hu, H; Jia, Y; Peng, J; Wang, L; Xu, H | 1 |
| Curtis, BR; Davies, SM; Filipovich, AH; Grimley, MS; Jodele, S; Jordan, MB; Khandelwal, P; Marsh, R | 1 |
| Baron, R; Basto, P; Bertrand, N; Farokhzad, OC; Ghobrial, IM; Glavey, S; Kamaly, N; Liu, J; Lu, ZN; Manier, S; Memarzadeh, M; Mishima, Y; Moschetta, M; Nagano, K; Reagan, MR; Roccaro, AM; Sacco, A; Seevaratnam, D; Shi, J; Swami, A; Wu, J; Zhang, S; Zhang, Y | 1 |
| Amaravadi, RK; Bradner, JE; Chang, YC; Davis, LE; Heitjan, DF; Kaplan, J; Mallon, G; Nichols, CW; Paul, TM; Piao, S; Pontiggia, L; Porter, DL; Rangwala, R; Scott, EC; Stadtmauer, EA; Tan, KS; Vogl, DT | 1 |
| Numata, H; Ohgiya, D; Sasao, T; Suyama, T; Tsuboi, K; Tsuchiya, T; Watanabe, S | 1 |
| Choi, DR; Han, B; Jung, JY; Kim, HJ; Kim, HY; Zang, DY | 1 |
| Ali, SM; Chmielecki, J; Miller, VA; Morosini, D; Palmer, GA; Ross, JS; Sharman, JP; Stafl, J; Stephens, PJ | 1 |
| Goldberg, AL; Sha, Z | 2 |
| Itoh, K; Liu, T; Maruyama, A; Mimura, J; Ohyama, C; Okada, T; Sato, H; Ye, P | 1 |
| Chen, S; Dai, Y; Grant, S; Jones, R; Leng, Y; Lin, H; Orlowski, RZ; Pei, XY; Zhang, Y; Zhou, L | 1 |
| Dolloff, NG; Harding, T; Lulla, A; Mansoor, A; Mitra, A; Myers, CL; Stessman, HA; Van Ness, BG; Xia, T | 1 |
| Chen, D; Dou, QP; Guan, F; Wang, H; Yang, H | 1 |
| Abedi, M; Ames, E; Blazar, BR; Chen, M; Grossenbacher, SK; Jagdeo, J; Mirsoian, A; Murphy, WJ; Pai, CC; Sun, K; Tellez, J | 1 |
| Kaneko, T; Kawakami, J; Mino, Y; Naito, T; Ohnishi, K; Osawa, T; Yamada, H | 1 |
| Kato, H; Kinoshita, T | 1 |
| Yagi, H | 1 |
| Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Cutler, CS; Herrera, AF; Ho, VT; Jones, KT; Kim, HT; Koreth, J; Nikiforow, S; Ritz, J; Soiffer, RJ | 1 |
| Ise, M; Kumagai, K; Sakai, C; Tsujimura, H | 1 |
| Ba-Mancini, A; Comenzo, RL; Duh, MS; Gravel, J; Knopf, KB; Lafeuille, MH; Lefebvre, P; Ma, E; Niculescu, L; Shi, H | 1 |
| Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Chretien, ML; Corre, J; Facon, T; Fruchart, C; Gentil, C; Hebraud, B; Hulin, C; Huynh, A; Lauwers-Cances, V; Leleu, X; Marit, G; Moreau, P; Pegourie, B; Robillard, N; Roussel, M; Stoppa, AM; Wuilleme, S | 1 |
| de Waal, TT; Gorter, MH; Tascilar, M | 1 |
| Advani, RH; Anderson, KC; Barlogie, B; Dimopoulos, MA; García-Sanz, R; Gertz, MA; Ghobrial, IM; Gregory, SA; Kastritis, E; Kimby, E; Kyle, RA; Kyriakou, C; Landgren, O; Leblond, V; Leleu, X; Maloney, D; Merlini, G; Morel, P; Morra, E; Munshi, N; Owen, RG; Rummel, M; Terpos, E; Thomas, SK; Treon, SP | 1 |
| Boccadoro, M; Callea, V; Caltagirone, S; Cangialosi, C; Carovita, T; Cavallo, F; Crippa, C; De Rosa, L; Drandi, D; Falcone, AP; Ferrero, S; Genuardi, E; Grasso, M; Guglielmelli, T; Ladetto, M; Liberati, AM; Musto, P; Oliva, S; Palumbo, A; Passera, R; Pisani, F; Pregno, P; Rossini, F; Terragna, C; Urbano, M | 1 |
| Cantarovich, D; Castagnet, S; Cesbron, A; Couvrat-Desvergnes, G; Giral, M; Renaudin, K; Touzot, M | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G | 1 |
| Cabanillas, F; Chen, CS; Craig, M; Esseltine, DL; Hanna, WT; Neuwirth, R; O'Connor, OA | 1 |
| Joks, M; Jurczyszyn, A; Komarnicki, M; Machaczka, M; Skotnicki, AB | 1 |
| Creamer, A; Gaastra, B; Odogwu, S; Whitelaw, B | 1 |
| Marks, SD | 1 |
| Becherini, P; Brignole, C; Cilli, M; Cossu, I; Destefanis, E; Di Paolo, D; Emionite, L; Giacomini, A; Loi, M; Pastorino, F; Perri, P; Piaggio, F; Ponzoni, M | 1 |
| Cai, Z; Han, XY; He, DH; He, JS; Huang, H; Li, Y; Wang, LJ; Wu, C; Wu, WJ; Yang, L; Yang, Y; Yi, Q; Zhao, Y; Zheng, GF; Zi, FM | 1 |
| Almeida, GM; Coelho, MA; Frasco, MF; Pereira, Mdo C; Santos-Silva, F | 1 |
| Chang, PY; Chao, TY; Chen, JH; Chen, YC; Dai, MS; Ho, CL; Huang, TC; Kao, WY; Wu, YY | 1 |
| Choi, YJ; Eom, KS; Jo, DY; Joo, YD; Kang, HJ; Kim, BS; Kim, CS; Kim, JS; Kim, SH; Kim, SJ; Kim, YJ; Kim, YS; Kwak, JY; Lee, JJ; Min, CK; Mun, YC; Park, CY; Park, JS; Suh, C; Yoon, SS | 1 |
| Ding, Y; Guo, S; Li, X; Shan, B; Shi, P; Shu, X; Wang, J; Wang, Z; Xing, L; Zhang, Y | 1 |
| Azadeh, N; Fonseca, R; Kelemen, K | 1 |
| Fu, W; Hou, J; Huang, H; Peng, L; Zhang, C; Zhou, L | 1 |
| Fu, R; Guan, J; Li, L; Liu, H; Mei, S; Qu, W; Ruan, E; Shao, Z; Song, J; Wang, G; Wang, H; Wang, X; Wu, Y; Xing, L | 1 |
| Basset, M; Foli, A; Lavatelli, F; Merlini, G; Milani, P; Nuvolone, M; Obici, L; Palladini, G; Perlini, S; Vidus Rosin, M | 1 |
| Nekova, TS; Stuhler, G | 1 |
| Abedi, M; Blazar, BR; Chen, M; Hagino, T; Hsiao, HH; Mall, C; Monjazeb, A; Murphy, WJ; Pai, CC; Sun, K; Tellez, J | 1 |
| Abboud, CN; Cashen, AF; DiPersio, JF; Fiala, MA; Fletcher, T; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Wang, TF; Westervelt, P; Wu, N | 1 |
| Argyriou, AA; Bruna, J; Cavaletti, G; Kalofonos, HP; Kyritsis, AP | 1 |
| Aujesky, D; Oestmann, A | 1 |
| Hoseki, J; Maharjan, S; Oku, M; Sakai, Y; Tsuda, M | 1 |
| Castro, LM; Dasgupta, S; Dulman, R; Ferro, ES; Fricker, LD; Schmidt, M; Yang, C | 1 |
| Beimler, J; Breitkreutz, I; Egerer, G; Goldschmidt, H; Heiss, C; Ho, AD; Jäger, D; Neben, K; Perne, A; Raab, MS; Zeier, M | 1 |
| Dou, QP; Zonder, JA | 1 |
| Luesutthiviboon, L; Namkhanisorn, K; Nimkietkajorn, V; Ruangkanchanasetr, P; Satirapoj, B; Suaywan, K; Termmathurapoj, S | 1 |
| Chung, MH; Kim, HS; Kim, I; Kim, KS; Koh, Y; Kwon, JH; Lee, SY; Park, S; Suh, SY; Yoon, SS | 1 |
| Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; de Arriba, F; González, Y; Granell, M; Hernández, JM; Lahuerta, JJ; López de la Guía, A; López, J; Martín-Mateos, ML; Martínez, R; Martínez-López, J; Mateos, MV; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Pérez, M; San-Miguel, JF; Teruel, AI | 1 |
| Auger, MJ; Bowles, KM; Murray, MY | 1 |
| Bamford, RN; Conlon, KC; Ju, W; Maeda, M; Nakagawa, M; Petrus, MN; Waldmann, TA; Yu, P; Zhang, M | 1 |
| Huang, L; Liu, W; Liu, Z; Luo, L; Mao, X; Meng, F; Qin, S; Sun, H; Zeng, W; Zheng, M; Zhou, J | 1 |
| Bianchi, E; Cerretani, D; Ghelardini, C; Menicacci, C | 1 |
| Fujiwara, K; Higo, H; Inomata, T; Kameyama, N; Makimoto, G; Matsushita, M; Rai, K; Sato, K; Shibayama, T; Sunami, K; Watanabe, H | 1 |
| Ho, CH; Lo, CP; Tu, MC | 1 |
| Abdel-Azim, H; Kapoor, N; Mahadeo, K; Mehta, B; Tang, S; Zaw, R | 1 |
| Bachs, O; Coll, MJ; Gascón, P; Girós, M; Guerrero, M; Macías-Vidal, J; Serratosa, J | 1 |
| Chim, CS; Wong, KY | 1 |
| Cerase, A; Gozzetti, A | 1 |
| Aljijakli, A; Arakelyan, N; Bouallegue, S; Chaoui, D; Genet, P; Sutton, L | 1 |
| Akpek, G; Armstrong, E; Elekes, A; Freytes, CO; Kato, K; Patil, S; Ratanatharathorn, V; Reece, DE; Rodriguez, TE; Sahovic, E; Shaughnessy, PJ; Smith, A; Solomon, SR; Stadtmauer, EA; Toro, JJ; Tricot, GJ; White, DJ; Yeh, RF; Yu, LH; Zhao, C | 1 |
| Al-Khalili, L; Cuesta, PG; de Castro Barbosa, T; Katayama, M; Massart, J; Nyström, AC; Oscarsson, J; Osler, ME; Ostling, J; Zierath, JR | 1 |
| Azakir, BA; Di Fulvio, S; Erne, B; Sinnreich, M; Stirnimann, G | 1 |
| Kim, J; Kim, M; Kim, YJ; Lee, SE; Lee, SH; Min, CK | 1 |
| Furtado, M; Johnson, R; Kruger, A; Rule, S; Turner, D | 1 |
| Christian, J; Häcker, G; Krämer, OH; Paul, MC; Saur, D; Schmid, RM; Schneider, G; Stauber, RH; Stojanovic, N; Wirth, M | 1 |
| Drucker, L; Gottfried, M; Zismanov, V | 1 |
| Chiang, AK; Hui, KF; Leung, YY; Middeldorp, JM; Yeung, PL | 1 |
| Cohen, C; Hosoba, S; Jaye, DL; Roback, JD; Waller, EK | 1 |
| Baldini, L; Cavaletti, G; Cavo, M; Elice, F; Galli, M; Gozzetti, A; Lazzaro, A; Martello, M; Montefusco, V; Palumbo, A; Pantani, L; Peccatori, J; Petrucci, MT; Pezzi, A; Rocchi, S; Ruggieri, M; Tacchetti, P; Terragna, C; Tosi, P; Zamagni, E | 1 |
| Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E | 1 |
| Bastani, B; Fesler, M; Jasim, S; Mahmud, G | 1 |
| Chen, A; Guo, F; Hu, W; Li, F; Zhang, W | 1 |
| Ju, D; Xie, Y | 1 |
| Bernstein, D; Chen, S; Hollander, SA; Kaufman, BD; Maeda, K; May, LJ; Rosenthal, DN; Tyan, DB; Yeh, J | 1 |
| Asano, T; Isono, M; Ito, K; Sato, A | 1 |
| Merlini, G; Palladini, G | 1 |
| Chang, H; Chen, GA; Chen, J; Chen, Y; Evans, K; Qiu, L; Reece, D; Saha, MN; Yang, Y | 1 |
| Martin, TG | 1 |
| Hamdy, AA; Neemat, K; Rania, K; Tarek, M | 1 |
| Mateos, MV; Miguel, JF | 1 |
| Vij, R | 1 |
| Awai, K; Date, S; Kaichi, Y; Kiguchi, M; Kuroda, Y; Sakai, A; Sakoda, Y; Takasu, M; Tani, C | 1 |
| Magenau, JM; Reddy, P | 1 |
| Dakhil, C; Haideri, N; Kumar, AK; Teeka Satyan, M | 1 |
| Bladé, J; Cakana, A; Comenzo, RL; Enny, C; Esseltine, DL; Fermand, JP; Hassoun, H; Heffner, L; Hegenbart, U; Kukreti, V; Merlini, G; Palladini, G; Pei, L; Reece, DE; Sanchorawala, V; van de Velde, H; Vescio, RA | 1 |
| Chen, S; Dai, Y; Grant, S; Jones, R; Kmieciak, M; Leng, Y; Lin, H; Orlowski, RZ; Pei, XY; Zhang, Y; Zhou, L | 1 |
| Chinen, Y; Horiike, S; Kobayashi, T; Kuroda, J; Maegawa, S; Matsumoto, Y; Mizuno, Y; Mizutani, S; Nagoshi, H; Shimura, Y; Taniwaki, M; Tatekawa, S; Tsukamoto, T; Yamamoto-Sugitani, M | 1 |
| Ahn, JS; Jang, HC; Jung, SH; Kang, SJ; Kim, HJ; Kim, YK; Lee, JJ; Lee, SS; Yang, DH | 1 |
| Hummers, LK | 1 |
| Amm, HM; Burke, MR; Dobbin, ZC; Jeong, DH; Katre, AA; Landen, CN; Steg, AD | 1 |
| Delić, J; Gobec, M; Markovič, T; Mlinarič-Raščan, I; Prijatelj, M | 1 |
| Reiter, RJ; Vriend, J | 1 |
| Franco, OE; Hayward, SW; Jin, R; Matusik, RJ; Wang, J; Wang, Y; Yamashita, H; Yu, X | 1 |
| Vincent Rajkumar, S | 1 |
| Chen, P; Chen, Z; Gao, X; Hou, J; Hu, R; Ruan, K; Tao, Y; Wang, H; Yang, M; Yu, T; Zhang, T; Zhang, Y | 1 |
| Cao, C; Kai, S; Liu, T; Wang, L; Xiang, B; Zhu, H | 1 |
| Balkaya, M; Boehmerle, W; Endres, M; Huehnchen, P; Peruzzaro, S | 1 |
| Koeppen, S | 1 |
| Anderson, KC; Driscoll, JJ; Jagannathan, S; Vad, N; Vallabhapurapu, S | 1 |
| Beksac, M; Bengoudifa, BR; Binlich, F; Bladé, J; Cavenagh, JD; Chen, W; Chuncharunee, S; Corradini, P; Corrado, C; de la Rubia, J; Dimopoulos, MA; Einsele, H; Elghandour, A; Gimsing, P; Günther, A; Hou, J; Hungria, VT; Jedrzejczak, WW; Kaufman, JL; LeBlanc, R; Lee, JH; Lee, JJ; Lonial, S; Moreau, P; Nahi, H; Nakorn, TN; Numbenjapon, T; Ocio, EM; Pulini, S; Qiu, L; Richardson, PG; Salwender, H; San-Miguel, JF; Schlossman, RL; Shelekhova, T; Siritanaratkul, N; Sohn, SK; Sopala, M; Tan, D; Veskovski, L; Wang, MC; Warzocha, K; White, D; Yong, K; Yoon, SS | 1 |
| Cai, Q; Gao, Y; Wang, C; Wei, D; Wei, J; Zhao, C; Zhao, M | 1 |
| Adjei, AA; Aubry, MC; Bearden, JD; Foster, NR; Johnson, DB; Mandrekar, SJ; Mattar, BI; Meyers, JP; Molina, JR; Northfelt, DW; Rowland, KM; Schild, SE; Thomas, SP; Zhao, Y | 1 |
| Baz, RC; Bose, P; Colevas, AD; Coppola, D; Dawson, J; Doyle, LA; Figg, WD; Grant, S; Hogan, KT; Holkova, B; Honeycutt, C; Kang, L; Kmieciak, M; Peer, CJ; Perkins, EB; Ramakrishnan, V; Roberts, JD; Roodman, GD; Sankala, H; Shrader, E; Stuart, RK; Sullivan, D; Tombes, MB; Wan, W; Weir-Wiggins, C; Wellons, M | 1 |
| Choi, JO; Jeon, ES; Kim, HJ; Kim, JS; Kim, K; Kim, SJ; Lee, GY; Lee, JE; Lee, JY; Lee, SY; Lim, SH; Min, JH | 1 |
| Abbott, DH; Kropp, J; Ringelstetter, AK; Roti Roti, EC; Salih, SM | 1 |
| Cahu, J; DaCosta, L; Gaudichon, J; Martens, AC; Milano, F; Renoir, JM; Sola, B | 1 |
| Chu, SH; Cleeland, CS; Geng, Y; Lee, ES; Lee, YJ; Wang, XS | 1 |
| Anderson, KC; Ataman, O; Beksac, M; Benboubker, L; Couturier, C; Dimopoulos, MA; Facon, T; Feng, H; Orlowski, RZ; Potamianou, A; Richardson, PG; Roddie, H; Sonneveld, P; van de Velde, H | 1 |
| Buchner, K; Eulberg, D; Facchetti, F; Ghobrial, IM; Klussmann, S; Kruschinski, A; Lonardi, S; Maasch, C; Maiso, P; Mishima, Y; Moschetta, M; Purschke, WG; Reagan, MR; Roccaro, AM; Rossi, G; Sacco, A; Ungari, M; Vater, A; Vonhoff, S; Zboralski, D; Zöllner, S | 1 |
| Batalo, MS; Bose, P; Grant, S; Holkova, B | 1 |
| Bories, C; Facon, T; Fouquet, G; Guidez, S; Herbaux, C; Javed, S; Leleu, X; Renaud, L | 1 |
| Hobeika, L; Self, SE; Velez, JC | 1 |
| Ishitsuka, K; Katsuya, H; Kunami, N; Nogami, R; Tamura, K | 1 |
| Abdi, J; Faber, J; Garssen, J; Redegeld, FA | 1 |
| Aoyama, M; Hamasaki, Y; Imataki, O; Kida, J; Kubo, H; Ohue, Y; Oku, M; Ota, S; Uemura, M | 1 |
| Wang, Y; Zhang, Z; Zhou, W | 1 |
| Bauer, M; Boehm, C; Ganten, TM; Haas, TL; Holland, H; Keller, M; Koschny, R; Koschny, T; Krupp, W; Meixensberger, J; Mueller, WC; Sinn, P; Sprick, MR; Walczak, H; Xu, LX | 1 |
| Bandekar, R; Bladé, J; Cavenagh, JD; Dimopoulos, MA; Gercheva, L; Goranova-Marinova, V; Maiolino, A; Masszi, T; Orlowski, RZ; Puchalski, TA; Reddy, M; Robak, T; Rossi, JF; Samoylova, O; Špička, I; Sutherland, H; Suvorov, A; van de Velde, H; Williams, C; Xie, H | 1 |
| Imai, K | 1 |
| Shibayama, H | 1 |
| Nakaseko, C | 1 |
| Tsurumi, H | 1 |
| Huang, Z; Liu, P; Shu, Y; Wu, Y; Xu, J; Zhou, X; Zhu, W | 1 |
| Acılan, C; Baykal, AT; Boyacı, I; Okur, E; Ulukaya, E; Yerlikaya, A | 1 |
| Anderson, KC; Chauhan, D; Cirstea, D; Cottini, F; Gorgun, G; Hideshima, T; Jakubikova, J; Kikuchi, S; Mimura, N; Minami, J; Munshi, NC; Ohguchi, H; Richardson, PG; Suzuki, R; Tai, YT; Utsugi, T; Yoshida, Y | 1 |
| Niles, AL; Riss, TL | 1 |
| Bychkov, ML; Dolgikh, DA; Gasparian, ME; Kirpichnikov, MP | 1 |
| Bátorová, A; Mistrík, M; Roziaková, L | 1 |
| Bearss, DJ; Carpenter, K; Meng, L; Mollard, A; Sharma, S; Tricot, G; Vankayalapati, H; Warner, SL; Zhan, F | 1 |
| Ando, M; Bouchier-Hayes, L; Brenner, MK; Dotti, G; Hoyos, V; Ramos, CA; Tao, W; Yagyu, S | 1 |
| Basnayake, K; Talbot, B; Wright, D | 1 |
| Lovat, PE; Martin, S; Redfern, CP | 1 |
| Izumi, H; Komatsu, N; Nakamura, N; Noguchi, M; Ohta, Y; Sawada, T; Sekiguchi, Y; Shimada, A; Sugimoto, K; Tomita, S; Wakabayashi, M | 1 |
| Jia, ZQ; Rong, HQ; Su, W; Tao, J; Wei, YL; Wei, YT; Yu, CX | 1 |
| Cui, A; Hou, J; Hua, H; Jiang, Y; Luo, T; Song, P | 1 |
| Guo, S; Li, Q; Qu, F; Wang, Y; Xia, B; Yang, H; Yuan, T; Zhang, Q; Zhang, Y; Zhao, W | 1 |
| Ayaz, B; Bullenkamp, J; Kulms, D; Odell, E; Raulf, N; Tavassoli, M; Thavaraj, S; Walczak, H | 1 |
| Cooper, ML; DiPersio, JF; Eissenberg, L; Ghobadi, A; Holt, MS; Rettig, MP; Ritchey, JK | 1 |
| Cheungpasitporn, W; Fervenza, FC; Gertz, MA; Leung, N; Sethi, S | 1 |
| Aitchison, R; Blesing, N; Lau, IJ; Peniket, A; Rabin, N; Ramasamy, K; Roberts, P; Smith, D; Yong, K | 1 |
| Morrison, VA | 1 |
| Bartlett, DL; Kim, SY; Kwon, YT; Lee, YJ; Song, X; Tang, D; Zhang, L | 1 |
| Ádám, E; Andrikovics, H; Balassa, K; Koszarska, M; Kozma, A; Masszi, T; Mikala, G; Tordai, A; Varga, G | 1 |
| Chudej, J; Chudý, P; Dobrota, D; Hatok, J; Kliková, K; Pilchová, I; Račay, P; Štefaniková, A | 1 |
| Dessanti, ML; Ensoli, F; Gumenyuk, S; Marchesi, F; Maschio, M; Mengarelli, A; Palombi, F; Pimpinelli, F; Pisani, F; Romano, A; Spadea, A | 1 |
| Chung, S; Jeon, J; Kamm, RD; Kasuya, J; Kim, C | 1 |
| Dewan, VN; Grannis, CH; Wang, RC | 1 |
| Amin, HM; Angelo, LS; Falchook, GS; Hess, K; Hong, D; Howard, AN; Huang, M; Jackson, EF; Janku, F; Kurzrock, R; Lawhorn, KN; Naing, A; Ng, CS; Parkhurst, KL; Tannir, NM; Vishwamitra, D; Wheler, JJ | 1 |
| Chao, A; Chen, GC; Chuang, WC; Huang, WP; Kao, C; Lai, CH; Lin, CY; Tsai, CL; Wang, HS; Wang, TH | 1 |
| Adamová, D; Bačovský, J; Krejčí, K; Minařík, J; Pika, T; Sčudla, V; Srovnalík, K; Tichý, T; Zadražil, J | 1 |
| Anglaret, B; Avet-Loiseau, H; Banos, A; Benboubker, L; Benramdane, R; Casassus, P; Chaleteix, C; Cony-Makhoul, P; Decaux, O; Dejoie, T; Dib, M; Fitoussi, O; Fontan, J; Garderet, L; Hulin, C; Jardel, H; Kolb, B; Leleu, X; Lenain, P; Mathiot, C; Moreau, P; Pegourie, B; Pétillon, MO; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Tiab, M; Traullé, C; Vilque, JP | 1 |
| Fei, X; Li, J; Lu, H; Tang, Y; Xu, X; Yang, J; Zhu, Y | 1 |
| Bay, JO; Ravinet, A; Tournilhac, O | 1 |
| Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG | 1 |
| Che, XF; Gotoh, A; Hiramoto, M; Hirota, A; Inazu, M; Kawai, Y; Kokuba, H; Komatsu, S; Miyazawa, K; Moriya, S; Yamasaki, K | 1 |
| Chang, HY; Chen, NN; Huang, HC; Huang, TC; Juan, HF | 1 |
| Hata, H; Hirata, S; Ide, K; Kawaguchi, T; Kikukawa, Y; Matsuno, N; Mitsuya, H; Miyakawa, T; Nakata, H; Nosaka, K; Okuno, Y; Yonemura, Y; Yuki, H | 1 |
| Cao, D; Guo, T; Hu, Y; Jin, L; Yu, W; Zhou, H | 1 |
| Ahmed, M; Goldberg, SN; Kumar, G; Levchenko, T; Moussa, M; Sawant, RR; Torchilin, V | 1 |
| Choe, SK; Kim, SG; Kim, SJ; Lee, JN; Lim, JY; Park, R | 1 |
| Acharya, C; An, G; Cheng, T; Deng, S; Feng, X; Hao, M; Li, Z; Qi, J; Qin, X; Qiu, L; Ru, K; Shi, L; Sui, W; Tai, YT; Wang, J; Xu, Y; Yi, S; Zang, M; Zhao, Y; Zou, D | 1 |
| Burhenne, J; Clemens, J; Haefeli, WE; Hose, D; Longo, M; Seckinger, A; Theile, D; Weiss, J | 1 |
| Driscoll, JJ; Jaganathan, S; Malek, E; Vallabhapurapu, S | 1 |
| Abenhardt, W; Aldaoud, A; Grugel, R; Hartmann, H; Knauf, W; Marschner, N; Münz, M; Nusch, A | 1 |
| Brown, RE; Nguyen, ND; Quesada, AE; Rios, A | 1 |
| Harrison, SJ; Slavin, MA; Teh, BW; Thursky, KA; Worth, LJ | 1 |
| Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ | 1 |
| Campo, E; Rule, S | 1 |
| Bittner, S; Ehrenschwender, M; Seibold, K; Wajant, H | 1 |
| Anderson, KC; Ghobrial, IM; Glavey, S; Görgün, GT; Kawano, Y; Manier, S; Moschetta, M; Roccaro, AM | 1 |
| Ahn, YS; Han, SH; Jeong, SJ; Kim, JM; Kim, JS; Shin, JS; Woo, JH | 1 |
| Bouwman, P; Greco, D; Gu, Y; Jonkers, J; Kuznetsov, SG; Saarela, J; Yadav, B | 1 |
| Ando, Y; Fujiwara, S; Hata, H; Iida, S; Kawano, Y; Kikukawa, Y; Mitsuya, H; Nakashima, T; Okuno, Y; Ri, M; Shiotsu, Y; Tasaki, M; Ueda, M; Wada, N; Yoshinaga, K | 1 |
| Hengstler, JG; Schad, A; Schmidt, M; Sleeman, JP; Thaler, S; Thiede, G | 1 |
| Ahn, JS; Ahn, SY; Jung, SH; Kim, HJ; Kim, YK; Lee, JJ; Lee, SS; Yang, DH | 1 |
| Abu Jawdeh, BG; Alloway, RR; Brailey, P; Cardi, MA; Ejaz, NS; Girnita, A; Govil, A; Mogilishetty, G; Roy-Chaudhury, P; Sadaka, B; Shields, AR; Walsh, RC; Woodle, ES | 1 |
| Atisha-Fregoso, Y; Jakez-Ocampo, J; Llorente, L | 1 |
| Amaravadi, RK; Boyiadzis, M; Johnson, DE; Konig, H; Lotze, MT; Sehgal, AR; Tang, D | 1 |
| Dong, F; Jing, HM; Ke, XY; Liu, Y; Wan, WL; Wang, J; Wang, JJ; Zhang, W | 1 |
| Li, Y; Qin, H; Tao, Q; Wang, H; Wang, Y; Wang, Z; Xiao, W; Xiong, S; Zhai, Z; Zhang, L | 1 |
| Anderson, KC; Dimopoulos, MA; Dow, E; Elliott, J; Mateos, MV; Niculescu, L; Palumbo, A; Richardson, PG; San Miguel, JF; Shi, H; van de Velde, H | 1 |
| Manning, ML; Mason-Osann, E; Onda, M; Pastan, I | 1 |
| Aziz, M; Bertrand, J; Coëffier, M; Déchelotte, P; Guérin, C; Herranen, A; Loeuillard, E; Marion-Letellier, R; Melchior, C; Savoye, G | 1 |
| Behler, C; Efebera, YA; Girnius, SK; Grady, T; Han, A; Hayes, TG; Houranieh, A; Kambhampati, S; Klein, CE; Lee, S; Lichtenstein, A; Mehta, P; Mohiuddin, A; Munshi, NC; Prabhala, RH; Roodman, GD; Rose, MG; Yellapragada, SV; Zimelman, A | 1 |
| Alexander, T; Bokarewa, M; Brisslert, M; Dörner, T; Dürr, M; Engelmann, R; Frölich, D; Giesecke, C; Grün, JR; Kühl, AA; Luda, K; Mei, HE; Perka, C; Radbruch, A; Scheel, T; Schmidt, S; Wirries, I | 1 |
| Gu, Y; Hu, Y; Shen, Y; Shu, Y; Sun, Y; Wang, L; Wu, X; Xu, Q | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Kalapanida, D; Kaldara, E; Kastritis, E; Migkou, M; Ntalianis, A; Pamboucas, C; Psimenou, E; Roussou, M; Tasidou, A; Terpos, E; Toumanidis, ST | 1 |
| Armenteros, E; Downward, J; Herledan, G; Kumar, M; Lach, A; Percy, L; Smith, D; Stubbs, M; Yong, K | 1 |
| Gu, J; Huang, B; Li, J; Liu, J; Wang, H; Xu, D; Zheng, D; Zou, W | 1 |
| Bladé, J; Fernández de Larrea, C; Rosiñol, L | 1 |
| Yakovlev, AA; Yakovleva, MV | 1 |
| Arnulf, B; Deraedt, W; Esseltine, DL; Feng, H; Grosicki, S; Karamanesht, I; Leleu, X; Masliak, Z; Moreau, P; Pylypenko, H; Rekhtman, G; Robak, P; van de Velde, H | 1 |
| Pallavi, R | 1 |
| Areethamsirikul, N; Chen, C; Chu, CM; Jimenez-Zepeda, V; Kukreti, V; Masih-Khan, E; Reece, DE; Tiedemann, R; Trudel, S | 1 |
| Groll, M; Heinemeyer, W; Huber, EM | 1 |
| Gu, Y; Zhang, B | 1 |
| Blancho, G; Branchereau, J; Breimer, ME; Charreau, B; Châtelais, M; Cowan, PJ; Cozzi, E; Crossan, C; d'Apice, AJ; Daha, MR; Dilek, N; Diswall, M; Duchi, R; Galli, C; Hervouet, J; Klar, N; Lagutina, I; Lazzari, G; Le Bas-Bernardet, S; Minault, D; Nottle, MB; Perota, A; Poirier, N; Renaudin, K; Robson, SC; Sachs, DH; Salvaris, EJ; Scobie, L; Simioni, P; Soulillou, JP; Takeuchi, Y; Tillou, X; Vanhove, B; Yamada, K | 1 |
| Castillo, JJ; Reagan, JL; Sikov, WM; Winer, ES | 1 |
| Chandra, J; Corrales-Medina, FF; Manton, CA; Orlowski, RZ | 1 |
| Hashimoto, Y; Iida, S; Kimura, Y; Kizaki, M; Nemoto-Anan, T; Ri, M; Sagawa, M; Tabayashi, T; Tokuhira, M; Tomikawa, T; Watanabe, R | 1 |
| Takahashi, N | 1 |
| Furukawa, Y; Kikuchi, J | 1 |
| Nakaseko, C; Sakaida, E; Takeda, Y | 1 |
| Apewokin, S; Atrash, S; Barlogie, B; Crowley, J; Epstein, J; Grazziutti, M; Hoering, A; Khan, R; Kumar, S; Rosenthal, A; Shaughnessy, JD; Usmani, S; van Rhee, F; Waheed, S; Yaccoby, S | 1 |
| Augustson, B; Baker, B; Campbell, P; Catalano, J; Copeman, M; Dean, J; Feng, H; Harrison, SJ; Link, E; Prince, HM; Quach, H; Romeril, K; Schwarer, A; Spencer, A; Van De Velde, H | 1 |
| Abe, Y; Achira, M; Ando, K; Iizuka, K; Kojima, M; Kuroda, J; Maruyama, D; Ogura, M; Suzuki, K; Suzuki, T; Taniwaki, M; Tobinai, K | 1 |
| Castillo, JJ; Ghobrial, IM; Treon, SP | 1 |
| Anusha, C; Karthik, S; Ravikumar, V; Sankar, R; Varunkumar, K | 1 |
| Assaraf, YG; Cloos, J; Jansen, G; Kaspers, GJ; Niewerth, D; Zweegman, S | 1 |
| Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A | 1 |
| Chang, TP; Poltoratsky, V; Vancurova, I | 1 |
| Li, YL | 1 |
| Shen, Q; Zhuang, Y | 1 |
| Ahn, KS; Kim, C; Kim, SH; Lee, JH; Sethi, G | 1 |
| Castillo, JJ; Ghobrial, IM; Leblebjian, H; Noonan, K; Paba-Prada, C; Treon, SP | 1 |
| Alexander, T; Burmester, GR; Cheng, Q; Hiepe, F; Hoyer, BF; Klotsche, J; Kühl, AA; Lorenz, HM; Radbruch, A; Rech, J; Rubbert-Roth, A; Sarfert, R; Schett, G; Taddeo, A; Voll, RE; Waka, A; Wiesener, M | 1 |
| Barth, MJ; Czuczman, MS; Frys, S; Gu, JJ; Hernandez-Ilizaliturri, FJ; Hu, Q; Mavis, C; Simons, Z; Skitzki, J; Song, L | 1 |
| Chauhan, P; Hart, KM; Liu, CG; Liu, R; Liu, X; Mao, X; Wang, L; Wei, S; Yang, WH; Yi, B; Zhang, W | 1 |
| Ding, X; Matsuo, K; Xu, L; Yang, J; Zheng, L | 1 |
| Chen, S; Chen, W; Dong, Y; He, X; Liang, C; Ma, J; Zhang, B; Zhang, X | 1 |
| Alexeeva, J; Cavalli, F; Drach, J; Hong, X; Huang, H; Jin, J; Liu, T; Mayer, J; Okamoto, R; Osmanov, E; Pei, L; Pereira, J; Pylypenko, H; Robak, T; Rooney, B; Samoilova, O; Siritanaratkul, N; van de Velde, H; Verhoef, G; Zhu, J | 1 |
| Aota, Y; Gotoh, A; Hanyu, N; Honma, T; Kitagawa, N; Komatsu, N; Morisaki, M; Yokoyama, T | 1 |
| Chirgwin, JM; Suvannasankha, A | 1 |
| Aljawai, Y; Asara, JM; Ghobrial, IM; Huynh, D; Kimmelman, AC; Maiso, P; Mishima, Y; Moschetta, M; Roccaro, AM; Sacco, A | 1 |
| Tanday, S | 1 |
| Benner, A; Bochtler, T; Goldschmidt, H; Granzow, M; Hegenbart, U; Ho, AD; Hose, D; Jauch, A; Kimmich, C; Kunz, C; Schönland, SO; Seckinger, A | 1 |
| Bertsch, U; Blau, IW; Dürig, J; Gerecke, C; Goldschmidt, H; Haenel, M; Hielscher, T; Hillengass, J; Hose, D; Huegle-Doerr, B; Jauch, A; Kunz, C; Lindemann, HW; Mai, EK; Merz, M; Munder, M; Neben, K; Raab, MS; Salwender, H; Scheid, C; Schmidt-Wolf, IG; Schurich, B; Seckinger, A; Weisel, K; Zeis, M | 1 |
| Açikel, C; Altayli, E; Astarci, E; Avcu, F; Elçi, MP; İde, T; Ilikçi Sağkan, R; Koru, Ö; Öngörü, Ö; Özenç, S; Sarper, M; Tok, D; Ural, AU | 1 |
| Chang, TP; Sanacora, S; Urdinez, J; Vancurova, I | 1 |
| Chai, X; Fang, B; Huang, H; Li, Y; Lin, Q; Song, Y; Xia, Q; Yu, F; Zhang, Y; Zhou, J | 1 |
| Abu Jawdeh, BG; Alloway, RR; Cardi, MA; Ejaz, NS; Sadaka, B; Shields, AR; Wadih, G; Witte, D; Woodle, ES | 1 |
| Oza, A; Rajkumar, SV | 1 |
| Adler, AI; Burke, MJ; George, E | 1 |
| Alonge, MM; Dytfeld, D; Jakubowiak, AJ; Jasielec, J; Kandarpa, M; Mayampurath, A; Mellacheruvu, D; Nesvizhskii, AI; Ngoka, L; Richardson, PG; Rosebeck, S; Sreekumar, A; Volchenboum, S | 1 |
| Izumi, T | 1 |
| Chung, JS; Lee, GW; Lee, IS; Lee, JH; Lee, JJ; Lee, SM; Shin, DY; Song, IC; Song, MK | 1 |
| Agrawal, N; Buxton, A; Chen, L; Cole, PD; De Alarcon, PA; Drachtman, RA; Guillerman, RP; Hogan, SM; Horton, TM; Howard, SC; Liu, H; López-Terrada, D; McCarten, K; Mrazek, MD; Schwartz, CL; Sheehan, AM; Trippet, TM; Voss, S; Wu, MF | 1 |
| Borsi, E; Brioli, A; Cavo, M; De Sanctis, LB; Mancini, E; Mancuso, K; Marzocchi, G; Pantani, L; Pezzi, A; Rizzo, R; Rocchi, S; Santoro, A; Santostefano, M; Tacchetti, P; Terragna, C; Zamagni, E; Zannetti, BA | 1 |
| Cho, Y; Fujisawa, F; Hori, M; Kamoshita, M; Katsura, Y; Kojima, H; Komeno, T; Kudo, D; Mukai, HY; Okoshi, Y; Ota, I; Sasaki, K; Shimizu, S; Shinagawa, A; Tanaka, K; Yoshida, C | 1 |
| Bay, JO | 1 |
| Gotoh, Y; Ihara, K; Inomata, H; Kato, J; Koyama, R; Miyajima, N; Muramatsu, H; Nagamachi, Y; Nishisato, T; Nozawa, E; Okamoto, T; Yamauchi, N | 1 |
| Cai, G; Fu, J; Li, W; Xie, N; Zhang, S; Zhao, J | 1 |
| Keller, S; Leibundgut, K; Mueller, BU; Novak, U; Pabst, T; Seipel, K; Taleghani, BM | 1 |
| Bergsagel, PL; Chesi, M; Colonna, M; Ferrari de Andrade, L; Guillerey, C; Hill, GR; Martinet, L; Miles, K; Ngiow, SF; Ritchie, DS; Smyth, MJ; Teng, MW; Vuckovic, S; Yong, MC | 1 |
| Bodo, J; Chen-Kiang, S; Di Liberto, M; Durkin, L; Elemento, O; Eng, K; Hsi, ED; Shetty, S; Smith, MR; Zhao, X | 1 |
| Chen, Z; Hu, S; Rich, A; Tang, G; Wang, W | 1 |
| Fujimaki, K; Fujisawa, S; Fujita, H; Hagihara, M; Harano, H; Hashimoto, C; Hattori, Y; Ishigatsubo, Y; Kawasaki, R; Koharazawa, H; Kuwabara, H; Matsumoto, K; Numata, A; Sakai, R; Taguchi, J; Takemura, S; Tanaka, M; Tomita, N; Watanabe, R; Yamazaki, E | 1 |
| Chiba, S; Hasegawa, Y; Ito, Y; Kurita, N; Miyamoto, K; Obara, N; Ogawa, S; Otsu, K; Sakata, A; Sakata-Yanagimoto, M; Seki, M; Yokoyama, Y | 1 |
| Basset, M; Foli, A; Gillmore, J; Hawkins, P; Lachmann, H; Merlini, G; Milani, P; Palladini, G; Sachchithanantham, S; Wechalekar, AD | 1 |
| Treon, SP | 1 |
| Miyamoto, K; Saigo, K; Takenokuchi, M; Taniguchi, T | 1 |
| Anderson, KC; Ghobrial, IM; Laubach, J; Maglio, ME; Mitsiades, CS; Munshi, NC; O'Donnell, EK; Paba-Prada, C; Raje, N; Richardson, PG; Schlossman, R; Varga, C; Warren, D; Weinstock, M; Weller, E; Xie, W | 1 |
| Fenichel, MP | 1 |
| Bader, J; Besse, L; de Bruin, G; Driessen, C; Geurink, PP; Kisselev, AF; Kraus, J; Kraus, M; Liu, N; Overkleeft, H | 1 |
| Gazdic, T; Kautzner, J; Kment, M; Kubanek, M; Malek, I; Pagacova, L; Svobodova, E; Viklicky, O | 1 |
| Katzel, JA; Lee-Ma, A; Vesole, DH | 1 |
| Bender, S; Bonaud, A; Bridoux, F; Cogné, M; Delpy, L; Druilhe, A; Javaugue, V; Lacombe, C; Oblet, C; Quellard, N; Sirac, C; Srour, N; Touchard, G | 1 |
| Dai, Y; Doeppner, TR; Hermann, DM; Jin, F; Kuckelkorn, U; Li, F; Li, W; Li, X; Li, Z; Liu, L; Qiu, L; Zang, M; Zhou, W | 1 |
| Aoufouchi, S; De Smet, A; Delbos, F; Gelot, C; Guerrera, IC; Reynaud, CA; Weill, JC | 1 |
| Kang, JH; Kim, HH; Kim, HJ; Kim, JY; Kim, YG; Lee, Y | 1 |
| Beissbarth, T; Cormet-Boyaka, E; Dobbelstein, M; Edmunds, S; Gaedcke, J; Ghadimi, M; Krüger, E; Levine, AJ; Markert, E; Moll, UM; Schulz, R; Zhang, X | 1 |
| Abernethy, DR; Chudasama, VL; Mager, DE; Ovacik, MA | 1 |
| Cowan, AJ; Frayo, SL; Gopal, AK; Green, DJ; Pagel, JM; Palanca-Wessels, MC; Press, OW | 1 |
| Aline-Fardin, A; Aucouturier, P; Bender, S; Boffa, JJ; Brahimi, S; Buob, D; Fabiani, B; Garderet, L; Mothy, M; Ronco, P; Verpont, MC | 1 |
| Böhmig, GA; Bond, G; Eskandary, F; Halloran, P; Haslacher, H; Kikić, Z; Kozakowski, N; Oberbauer, R; Ramassar, V; Regele, H; Wahrmann, M | 1 |
| Huh, KH; Jeong, HJ; Kim, BS; Kim, YS; Lee, J; Lee, JG; Lim, BJ; Park, Y | 1 |
| Guo, S; Li, X; Qu, F; Tian, C; Xia, B; Yu, Y; Zhang, L; Zhang, Y | 1 |
| Abounader, D; Bolwell, B; Dean, R; Gerds, AT; Hamilton, BK; Hill, B; Hong, S; Jagadeesh, D; Kalaycio, ME; Liu, HD; Majhail, NS; Pohlman, B; Reu, F; Rybicki, L; Samaras, C; Sobecks, R; Valent, J | 1 |
| Chakraborty, R; Gertz, MA | 1 |
| Chen, H; Hao, QY; Huang, XJ; Liu, KY; Lu, J; Wen, L | 1 |
| Tew, KD | 1 |
| An, N; Chen, SL; Huang, ZX; Li, X; Shen, M | 1 |
| Gaynon, PS | 1 |
| Ma, J; Shao, ZH; Wang, YH; Zhang, LL | 1 |
| Chen, JF; Li, YX; Meng, XY; Xiao, LF; Zeng, ZH; Zhang, R | 1 |
| Bostrom, BC; Messinger, YH | 1 |
| Wang, CY; Wang, L; Wang, XF; Wang, YF; Xia, B; Xu, YJ; Yang, HL; Yu, Y; Zhang, YZ; Zhao, HF | 1 |
| Gao, D; Liu, D; Ma, X; Sun, M; Xu, D; Yu, H | 1 |
| Abhyankar, S; Kabadi, SM; Signorovitch, J; Song, J; Telford, C; Yao, Z; Zhao, J | 1 |
| Feng, YF; Li, G; Sun, YQ; Wei, XF; Yang, WH; Zhang, QK | 1 |
| Egashira, N; Yamamoto, S | 1 |
| Chiba, T; Iseki, T; Isshiki, Y; Iwama, A; Koide, S; Lennox, W; Mimura, N; Mitsukawa, S; Miyota, M; Muto, T; Nagai, Y; Nakajima-Takagi, Y; Nakaseko, C; Ohwada, C; Oshima, M; Oshima-Hasegawa, N; Rizk, M; Rizq, O; Sakaida, E; Saraya, A; Sheedy, J; Takeda, Y; Takeuchi, M; Tsukamoto, S; Weetall, M; Yokote, K | 1 |
| Gul, E; Gyger, M; Jazubowiak, A; Kaufman, J; Khan, S; Lau, A; Le, LW; LeBlanc, R; Li, Z; Paul, H; Trudel, S; White, D | 1 |
| Garrido, D; Riva, E | 1 |
| Gogal, RM; Laver, T; Lee, BM | 1 |
| Sak, K | 1 |
| Callander, NS; Hematti, P; Mark, C; Miyamoto, S; Warrick, J | 1 |
| Meiners, S; Meul, T; Schlesser, C; Stathopoulos, G | 1 |
| Cui, Y; Ding, H; Gao, Y; Huang, J; Lin, Z; Liu, T; Luo, H; Niu, T; Qu, Y; Wang, F; Xu, J; Yang, Y; Yang, Z; Ye, L; Zhai, X; Zhang, L; Zheng, Y | 1 |
| Allman, D; Alloway, RR; Brailey, P; Burg, AA; Castro-Rojas, CM; Gehman, JM; Hildeman, DA; Rike-Shields, A; Roskin, KM; Rossi, AP; Tremblay, S; Woodle, ES | 1 |
| Berman, AY; Carpenter, AE; Cimini, BA; Han, Y; Kapoor, TM; Kelley, ME; Singh, S; Stirling, DR; Way, GP | 1 |
| Devasia, AJ; Lancman, G; Stewart, AK | 1 |
| Anderson, LD; Banerjee, R; Cowan, AJ; Kaur, G; McCaughan, G; Mehra, N; Rajkumar, SV; Wang, B | 1 |
625 review(s) available for pyrazines and bortezomib
| Article | Year |
|---|---|
New agents in cancer clinical trials.
Topics: Antineoplastic Agents; Benzamides; Benzoquinones; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Enzyme Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Isoquinolines; Lactams, Macrocyclic; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Rifabutin; Stilbenes; Tetrahydrofolates; Tetrahydroisoquinolines; Trabectedin; Vorinostat | 2000 |
The proteasome: a new target for novel drug therapies.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Lewis Lung; Clinical Trials, Phase I as Topic; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Disease Models, Animal; Humans; Multienzyme Complexes; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines | 2001 |
Proteasome inhibition in cancer: development of PS-341.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Cysteine Endopeptidases; Drug Screening Assays, Antitumor; Hematologic Neoplasms; Humans; Multienzyme Complexes; Multiple Myeloma; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Structure-Activity Relationship | 2001 |
The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cysteine Endopeptidases; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; I-kappa B Proteins; Multienzyme Complexes; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Polymorphism, Genetic; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2001 |
[Update on . . . the proteasome inhibitor PS341].
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Humans; Neoplasms; Protease Inhibitors; Pyrazines | 2002 |
Development of the proteasome inhibitor PS-341.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Mice; Mice, Nude; Multicenter Studies as Topic; Protease Inhibitors; Pyrazines; Rats | 2002 |
Proteasome inhibition: a novel approach to cancer therapy.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2002 |
Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Adhesion Molecules; Cytokines; Humans; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Pyrazines; Thalidomide; Treatment Outcome | 2002 |
New drugs in gynecologic cancer.
Topics: Aminopyridines; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cisplatin; Female; Gefitinib; Genital Neoplasms, Female; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Organoplatinum Compounds; Paclitaxel; Protein-Tyrosine Kinases; Pyrazines; Quinazolines; Trastuzumab | 2001 |
Proteasome inhibitors in the treatment of B-cell malignancies.
Topics: Acetylcysteine; Animals; Boronic Acids; Bortezomib; Cell Cycle Proteins; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzymes; Gene Expression Regulation; Hodgkin Disease; Humans; Leukemia, B-Cell; Leupeptins; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mice; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Oncogene Proteins; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Substrate Specificity; Transcription Factors; Treatment Outcome | 2002 |
New drugs in acute myeloid leukemia.
Topics: Acute Disease; Adenine Nucleotides; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Bevacizumab; Boronic Acids; Bortezomib; Clofarabine; Cytosine; Decitabine; Dioxolanes; Humans; Indoles; Leukemia, Myeloid; Phthalazines; Pyrazines; Pyridines; Pyrroles; Thionucleotides | 2002 |
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
Proteasome inhibitors as new anticancer drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Proteins; Clinical Trials as Topic; Cysteine Endopeptidases; Disease Models, Animal; Humans; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Rats; Transcription Factors; Tumor Cells, Cultured | 2002 |
Advances in the biology and treatment of myeloma bone disease.
Topics: Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Clinical Trials as Topic; Cytokines; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Imidazoles; Immunoglobulin Fc Fragments; Intercellular Signaling Peptides and Proteins; Lymphokines; Membrane Glycoproteins; Multiple Myeloma; Osteoprotegerin; Pamidronate; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Zoledronic Acid | 2002 |
Moving disease biology from the laboratory to the clinic.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion Molecules; Clinical Trials as Topic; Cytokines; Endothelial Growth Factors; Humans; Intercellular Adhesion Molecule-1; Intercellular Signaling Peptides and Proteins; Interferons; Killer Cells, Natural; Lymphokines; Multiple Myeloma; Protease Inhibitors; Pyrazines; Signal Transduction; Stem Cell Transplantation; Thalidomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
High-dose therapy and immunomodulatory drugs in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Gene Expression Profiling; Humans; Interferons; Lenalidomide; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide | 2002 |
The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Clinical Trials as Topic; Cysteine Endopeptidases; Female; Humans; Multienzyme Complexes; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Ubiquitins | 2003 |
Potential for proteasome inhibition in the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2003 |
Proteasome inhibition: a new anti-inflammatory strategy.
Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Arthritis, Rheumatoid; Asthma; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Disease Models, Animal; Humans; Inflammation; Lysine; Models, Biological; Models, Chemical; Multienzyme Complexes; Multiple Sclerosis; Neoplasms; NF-kappa B; Peptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Psoriasis; Pyrazines; Reperfusion Injury | 2003 |
Novel biologically based therapies for Waldenstrom's macroglobulinemia.
Topics: Adjuvants, Immunologic; Anti-Bacterial Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Enzyme Inhibitors; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Protease Inhibitors; Pyrazines; Thalidomide; Thiazoles; Waldenstrom Macroglobulinemia | 2003 |
Novel therapies in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2003 |
Management of multiple myeloma: a systematic review and critical appraisal of published studies.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Diphosphonates; Drug Administration Schedule; Epoetin Alfa; Erythropoietin; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Neoplasm Staging; Pyrazines; Randomized Controlled Trials as Topic; Recombinant Proteins; Salvage Therapy; Survival Analysis; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2003 |
The proteasome: structure, function, and role in the cell.
Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Disease Models, Animal; Humans; Multienzyme Complexes; Neoplasms; Polyubiquitin; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2003 |
Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Multienzyme Complexes; Multiple Myeloma; Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2003 |
Clinical update: proteasome inhibitors in hematologic malignancies.
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Down-Regulation; Drug Administration Schedule; Hematologic Neoplasms; Humans; Multienzyme Complexes; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured | 2003 |
Clinical update: proteasome inhibitors in solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Drug Interactions; Humans; Microfilament Proteins; Multienzyme Complexes; Muscle Proteins; Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53 | 2003 |
[Thalidomide treatment in multiple myeloma].
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cysteine Endopeptidases; Dexamethasone; Drug Therapy, Combination; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Recurrence; Thalidomide | 2003 |
Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.
Topics: Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Ubiquitin | 2003 |
Therapy strategies for multiple myeloma: current status.
Topics: Adjuvants, Immunologic; Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Erythropoietin; Glucocorticoids; Growth Inhibitors; Humans; Immunosuppressive Agents; Middle Aged; Multiple Myeloma; Oxides; Peripheral Blood Stem Cell Transplantation; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Transplantation, Homologous | 2003 |
New therapeutic strategies for soft tissue sarcomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Docetaxel; Epothilones; Guanidines; Humans; Indoles; Isoquinolines; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Pyrroles; Sarcoma; Sirolimus; Sunitinib; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin | 2003 |
Bortezomib treatment for multiple myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Pyrazines | 2003 |
[Current screening for molecular target therapy of cancer].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib | 2003 |
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Approval; Humans; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2003 |
Apoptosis meets proteasome, an invaluable therapeutic target of anticancer drugs.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Leupeptins; Models, Biological; Multienzyme Complexes; Neoplasms; Peptide Hydrolases; Phenotype; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2003 |
The proteasome as a target for cancer therapy.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Catalysis; Clinical Trials as Topic; Cysteine Endopeptidases; Enzyme Inhibitors; Humans; Models, Biological; Multienzyme Complexes; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin | 2003 |
Targeting proteasome inhibition in hematologic malignancies.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Hematologic Neoplasms; Humans; Multienzyme Complexes; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Pyrazines | 2003 |
[Proteasome inhibition: a new therapeutic approach for the treatment of multiple myeloma].
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Cysteine Endopeptidases; Drug Administration Schedule; Enzyme Inhibitors; Humans; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Randomized Controlled Trials as Topic | 2004 |
Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Humans; Lung Neoplasms; Peptide Hydrolases; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
Topics: Adjuvants, Immunologic; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arkansas; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Protease Inhibitors; Pyrazines; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome; Universities | 2003 |
Bortezomib and its role in the management of patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
Update on the proteasome inhibitor bortezomib in hematologic malignancies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Death; Clinical Trials as Topic; Cysteine Endopeptidases; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Models, Biological; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
The proteasome: a suitable antineoplastic target.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Transformation, Neoplastic; Cysteine Endopeptidases; Endopeptidases; Humans; Multienzyme Complexes; Nuclear Proteins; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction | 2004 |
Multiple myeloma: the role of transplant and novel treatment strategies.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oxides; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous | 2004 |
The development of proteasome inhibitors as anticancer drugs.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Ubiquitins | 2004 |
A review of the proteasome inhibitor bortezomib in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Dexamethasone; Humans; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
Development of the proteasome inhibitor Velcade (Bortezomib).
Topics: Boronic Acids; Bortezomib; Cell Survival; Clinical Trials as Topic; Cysteine Endopeptidases; Drug Design; Humans; Multienzyme Complexes; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin-Activating Enzymes | 2004 |
The potential role of proteasome inhibitors in the treatment of lung cancer.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Cycle; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines | 2004 |
New oncology strategy: molecular targeting of cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cetuximab; Cysteine Endopeptidases; ErbB Receptors; Gefitinib; Genetics, Medical; Humans; Medical Oncology; Molecular Biology; Multienzyme Complexes; Neoplasms; Neovascularization, Pathologic; Nurse's Role; Oncology Nursing; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A | 2004 |
The role of proteasome inhibitors in solid tumors.
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
Proteasome inhibition in hematologic malignancies.
Topics: Asthenia; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Diarrhea; Hematologic Neoplasms; Humans; Multienzyme Complexes; Nausea; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Survival Analysis; Treatment Outcome | 2004 |
The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Multienzyme Complexes; Proteasome Endopeptidase Complex; Pyrazines; Risk Assessment; Survival Rate | 2004 |
Targeting the ubiquitin-proteasome pathway in breast cancer.
Topics: Animals; Boronic Acids; Bortezomib; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mice; Molecular Biology; Multienzyme Complexes; Neoplasm Transplantation; NF-kappa B; Proteasome Endopeptidase Complex; Protein Transport; Pyrazines; Risk Factors; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Ubiquitin | 2004 |
[Proteasome inhibitors].
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Humans; Kidney Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
[Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells].
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Humans; Leukemia-Lymphoma, Adult T-Cell; Multienzyme Complexes; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
Bortezomib as a potential treatment for prostate cancer.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Male; Multienzyme Complexes; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Protease Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide | 2004 |
Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.
Topics: Anemia; Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Approval; Drug Monitoring; Gastrointestinal Diseases; Humans; Hypotension; Multiple Myeloma; Neutropenia; Nurse's Role; Oncology Nursing; Patient Care Planning; Patient Education as Topic; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Quality of Life; Thrombocytopenia; Water-Electrolyte Imbalance | 2004 |
[Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer].
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Prostate-Specific Antigen; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2004 |
[The role of proteasome in pathophysiology of cancer cachexia].
Topics: Boronic Acids; Bortezomib; Cachexia; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
Use of proteasome inhibition in the treatment of lung cancer.
Topics: Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2004 |
Targeting multiple myeloma cells and their bone marrow microenvironment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cytokines; Disease Progression; Disease-Free Survival; Humans; Ligands; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Protease Inhibitors; Pyrazines; Signal Transduction; Thalidomide | 2004 |
Proteasome inhibition in the treatment of cancer.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Cyclins; Drug Evaluation, Preclinical; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2005 |
Evolving treatment strategies for myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2005 |
Proteasome inhibition as a novel therapeutic target in human cancer.
Topics: Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2005 |
Discovery, Development, and clinical applications of bortezomib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors | 2004 |
Pharmacology, pharmacokinetics, and practical applications of bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors | 2004 |
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
[Multiple myeloma--recent advances in diagnosis and treatment].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Multiple Myeloma; Neoplasm Staging; Pamidronate; Protease Inhibitors; Pyrazines; Thalidomide; Zoledronic Acid | 2005 |
The proteasome.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Hematopoietic Stem Cells; Humans; Neoplasms; NF-kappaB-Inducing Kinase; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Serine-Threonine Kinases; Pyrazines; Structure-Activity Relationship | 2004 |
Clinical update: novel targets in gynecologic malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Cisplatin; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; NF-kappaB-Inducing Kinase; Ovarian Neoplasms; Protease Inhibitors; Protein Serine-Threonine Kinases; Pyrazines | 2004 |
Clinical update: novel targets in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2004 |
Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Glutamates; Guanine; Humans; Lung Neoplasms; Medical Oncology; Pemetrexed; Pyrazines | 2005 |
Proteasome inhibitor therapy in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Models, Biological; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2005 |
Proteasome: an emerging target for cancer therapy.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Substrate Specificity; Treatment Outcome | 2005 |
Targeted therapy in multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; DNA, Antisense; Drug Delivery Systems; Farnesyltranstransferase; Humans; Immunosuppressive Agents; Lovastatin; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide | 2005 |
Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Humans; Membrane Glycoproteins; Neoplasms; Protease Inhibitors; Pyrazines; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2006 |
Treatment of myeloma in patients not eligible for transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Pyrazines; Salvage Therapy; Thalidomide | 2005 |
Future therapies in hormone-refractory prostate cancer.
Topics: Antibodies, Monoclonal; Atrasentan; Boronic Acids; Bortezomib; Diphosphonates; DNA, Antisense; Forecasting; Humans; Immunotherapy; Male; Prostatic Neoplasms; Pyrazines; Pyrrolidines; Receptors, Growth Factor; Thalidomide | 2005 |
Proteasome inhibitors in cancer therapy.
Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2005 |
Novel approaches to the management of myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2005 |
Current treatment options for myeloma.
Topics: Age Factors; Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Doxorubicin; Humans; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous; Vincristine | 2005 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin | 2005 |
Treatment of mantle cell lymphoma: targeting the microenvironment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Clinical Trials as Topic; Humans; Immunosuppressive Agents; Lymphoma, Mantle-Cell; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Rituximab; Thalidomide | 2005 |
Lysosomes and endoplasmic reticulum: targets for improved, selective anticancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cisplatin; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Humans; Lysosomes; Neoplasms; Pyrazines | 2005 |
Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neoplasms; Proteasome Inhibitors; Pyrazines | 2005 |
Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2005 |
Toxic neuropathy.
Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Epothilones; Genetic Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoxazoles; Leflunomide; Neuritis; Neuroprotective Agents; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Pyrazines; Pyridoxine; Thalidomide | 2005 |
The current status of thalidomide in the management of multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Tumor Necrosis Factor-alpha | 2005 |
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Models, Molecular; Multiple Myeloma; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured | 2005 |
Emerging trends in the clinical use of bortezomib in multiple myeloma.
Topics: Antineoplastic Agents; beta 2-Microglobulin; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Therapy; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Transplantation, Autologous | 2005 |
Evolving role of stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Disease-Free Survival; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2005 |
Induction therapy before transplantation in multiple myeloma: new strategies to achieve complete response.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Immunosuppressive Agents; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Treatment Outcome; Vincristine | 2005 |
Proteasome inhibitors as therapeutics.
Topics: Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2005 |
Preclinical data with bortezomib in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Interactions; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2005 |
Sequencing bortezomib with chemotherapy and targeted agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Drug Interactions; Humans; Lung Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin | 2005 |
Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines | 2005 |
The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Radiation-Sensitizing Agents | 2005 |
Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Ubiquitin | 2005 |
Bortezomib: a novel therapy approved for multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2003 |
Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Pyrazines; Treatment Outcome | 2005 |
Anti-angiogenic and anti-tumor properties of proteasome inhibitors.
Topics: Acetylcysteine; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neoplasms; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2005 |
Proteasome inhibition: a new approach for the treatment of malignancies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Gastrointestinal Diseases; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Humans; Multiple Myeloma; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Primates; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Rodentia | 2005 |
Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.
Topics: Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Structure-Activity Relationship; Ubiquitin | 2006 |
Treatment paradigms for the newly diagnosed patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2005 |
Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; Interleukin-6; Lenalidomide; Models, Immunological; Multiple Myeloma; Pyrazines; Signal Transduction; Thalidomide | 2005 |
Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Multicenter Studies as Topic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2005 |
[A new therapy with bortezomib, an oncologic medicinal product of the year 2004].
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Ubiquitin | 2005 |
Overview of drug therapy for multiple myeloma.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Myeloma Proteins; Oxides; Pyrazines; Thalidomide | 2005 |
A practical update on the use of bortezomib in the management of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Prognosis; Pyrazines; Survival Analysis; Thrombocytopenia | 2006 |
The proteasome and proteasome inhibitors in cancer therapy.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Humans; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2006 |
Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Mitochondria; Mitochondrial Proteins; Neoplasm Proteins; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, Tumor Necrosis Factor; Ubiquitin; Ubiquitin-Protein Ligases | 2005 |
Bortezomib: proteasome inhibition as an effective anticancer therapy.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Neoplasms; Protease Inhibitors; Pyrazines | 2006 |
Proteasome inhibitors in lung cancer.
Topics: Animals; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2006 |
Targeting the proteasome as a therapeutic strategy against haematological malignancies.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Hematologic Neoplasms; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2006 |
[Bortezomib].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Humans; Kidney Neoplasms; Leukemia; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Pyrazines | 2006 |
[New strategy for the treatment of multiple myeloma].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Dexamethasone; Drug Design; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oxides; Prognosis; Protease Inhibitors; Purines; Pyrazines; Roscovitine; Thalidomide; Transplantation Conditioning | 2005 |
Other compounds and targets in non-small cell lung cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Ligands; Lung Neoplasms; Membrane Glycoproteins; Proteasome Inhibitors; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2005 |
New developments in chemotherapy for advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epothilones; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Pyrazines | 2006 |
Allosteric regulators of the proteasome: potential drugs and a novel approach for drug design.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Drug Design; Humans; Ligands; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Substrate Specificity | 2006 |
Mantle cell lymphomas.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Humans; Lymphoma, Mantle-Cell; Predictive Value of Tests; Pyrazines; Survival Rate | 2005 |
New treatments for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2005 |
Novel treatment approaches for patients with multiple myeloma.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drug Design; Heat-Shock Proteins; Histones; Humans; Lenalidomide; Multiple Myeloma; Oncogene Protein v-akt; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Recurrence; Remission Induction; Signal Transduction; Thalidomide | 2006 |
Success in translational research: lessons from the development of bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Industry; Intellectual Property; Models, Economic; NF-kappa B; Pharmacology; Pharmacology, Clinical; Pyrazines; Research; United States | 2006 |
[Prognostic factors and new treatments of multiple myeloma].
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2006 |
Bortezomib: proteasome inhibition as an effective anticancer therapy.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Forecasting; Humans; Neoplasms; Proteasome Inhibitors; Pyrazines | 2005 |
Targeting the ubiquitin-proteasome pathway in breast cancer therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Drug Design; Female; Humans; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Ubiquitin | 2006 |
Pharmacotherapy of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2006 |
Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Synergism; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome | 2006 |
Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, Non-Hodgkin; Protease Inhibitors; Pyrazines | 2006 |
Treatment of multiple myeloma: an emphasis on new developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2006 |
Proteasome inhibition: novel therapy for multiple myeloma.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Practice Patterns, Physicians'; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2006 |
[New treatment strategy of multiple myeloma for cure].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Medical Oncology; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide | 2006 |
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Europe; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Multicenter Studies as Topic; Multiple Myeloma; National Institutes of Health (U.S.); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Procarbazine; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; United States; Vinblastine; Vincristine | 2006 |
[The plasma cell myeloma--molecular pathogenesis and target therapies].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Communication; Chromosome Aberrations; Gene Expression; Glycoproteins; Growth Inhibitors; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Osteoporosis; Osteoprotegerin; Oxides; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thalidomide; Time Factors | 2006 |
Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies).
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Farnesyltranstransferase; Humans; Immunologic Factors; Lenalidomide; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Thalidomide | 2006 |
The proteasome: a novel target for anticancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Dexamethasone; Drug Design; Humans; Multiple Myeloma; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Randomized Controlled Trials as Topic; Ubiquitin | 2006 |
Apoptosis: a relevant tool for anticancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Capsid Proteins; Humans; Inhibitor of Apoptosis Proteins; Ligands; Microtubule-Associated Proteins; Neoplasm Proteins; Neoplasms; Pyrazines; Receptors, Death Domain; Sulindac; Survivin; TNF-Related Apoptosis-Inducing Ligand | 2006 |
Bortezomib (Velcade)--a new therapeutic strategy for patients with refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Molecular Structure; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Pyrazines | 2005 |
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
Proteasome inhibition as novel treatment strategy in leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase I as Topic; Forecasting; Humans; Leukemia; NF-kappa B; Protease Inhibitors; Pyrazines; Ubiquitin | 2006 |
[Current therapy for multiple myeloma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Thalidomide | 2005 |
Bortezomib for multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Therapy, Combination; Humans; Multiple Myeloma; Product Surveillance, Postmarketing; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic | 2006 |
The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; History, 18th Century; History, 20th Century; History, 21st Century; History, Ancient; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2006 |
Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Separation; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Stem Cells | 2006 |
Proteasome inhibition in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Ubiquitin | 2006 |
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dose-Response Relationship, Drug; Hematologic Neoplasms; Humans; Lymphoma; Multiple Myeloma; Neoplasms; Protease Inhibitors; Pyrazines; Treatment Outcome | 2006 |
Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Multiple Myeloma; Pyrazines; Waldenstrom Macroglobulinemia | 2006 |
Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2006 |
Emerging role of novel combinations for induction therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Thalidomide; Treatment Outcome | 2006 |
[Proteasome inhibitor bortezomib as an anticancer drug].
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Clinical Trials as Topic; Cytokines; Heat-Shock Proteins; Humans; Multiple Myeloma; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2006 |
Advancing access to myeloma treatment: administration, side effects, and implications for survival.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Health Services Accessibility; Humans; Immunosuppressive Agents; Information Services; Lenalidomide; Multiple Myeloma; Nurse's Role; Oncology Nursing; Patient Education as Topic; Protease Inhibitors; Pyrazines; Radiotherapy, Adjuvant; Stem Cell Transplantation; Survival Rate; Thalidomide | 2006 |
Advances in the treatment of multiple myeloma: a nursing perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Practice Guidelines as Topic; Protease Inhibitors; Pyrazines; Quality of Life; Stem Cell Transplantation; Survival Rate; Thalidomide; Treatment Outcome | 2006 |
[New drugs for myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Can NF-kappaB be a target for novel and efficient anti-cancer agents?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Boronic Acids; Bortezomib; Glucocorticoids; Humans; I-kappa B Kinase; Multiple Myeloma; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines | 2006 |
Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2006 |
Response to bortezomib and activation of osteoblasts in multiple myeloma.
Topics: Alkaline Phosphatase; Biomarkers; Bone Remodeling; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; NF-kappa B; Osteoblasts; Osteoclasts; Osteoprotegerin; Parathyroid Hormone; Prospective Studies; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2006 |
[Recent progress in diagnosis of and therapy for multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Thalidomide | 2006 |
Targeting ubiquitin in cancers.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Communication; Cell Cycle; Genetic Therapy; Heat-Shock Proteins; Humans; Lactones; Neoplasms; Pyrazines; Pyrroles; Ubiquitin | 2006 |
Proteasome inhibitors: antitumor effects and beyond.
Topics: Boronic Acids; Bortezomib; Cardiovascular Diseases; Dendritic Cells; Graft vs Host Disease; Humans; Lymphocytes; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Signal Transduction | 2007 |
Current status of new drugs for the treatment of patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Investigational treatments for multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Design; Drug Resistance, Neoplasm; Drugs, Investigational; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Remission Induction; Risk Factors; Salvage Therapy; Thalidomide; Treatment Outcome | 2006 |
Bortezomib as an antitumor agent.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Ubiquitin | 2006 |
[Use of proteasome inhibitors in the treatment of patients with multiple myeloma].
Topics: Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Humans; Interleukin-6; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines; Remission Induction; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2006 |
The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Catechin; Clinical Trials as Topic; Curcumin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Genistein; Humans; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Radiation-Sensitizing Agents; Resveratrol; Stilbenes; Structure-Activity Relationship; Ubiquitin | 2006 |
[Clinical and hematological characteristics of adult T-cell leukemia/lymphoma].
Topics: Benzamides; Boronic Acids; Bortezomib; Carrier State; Cyclohexanones; HIV Protease Inhibitors; Human T-lymphotropic virus 1; Humans; Infectious Disease Transmission, Vertical; Leukemia-Lymphoma, Adult T-Cell; NF-kappa B; Protease Inhibitors; Pyrazines; Ritonavir; Stem Cell Transplantation; Transplantation, Homologous | 2006 |
Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Models, Biological; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic | 2007 |
Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Administration Schedule; Hemoglobins; Humans; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Quality of Life; Thalidomide | 2006 |
Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Doxorubicin; Drug Synergism; Humans; Models, Biological; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Treatment Outcome | 2007 |
The emerging role of novel therapies for the treatment of relapsed myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Thalidomide | 2007 |
The proteasome and its inhibitors in immune regulation and immune disorders.
Topics: Animals; Antigen Presentation; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Therapy; Humans; Immune System; Immune System Diseases; Lymphoma, Mantle-Cell; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction | 2006 |
Use of systemic proteasome inhibition as an immune-modulating agent in disease.
Topics: Animals; Autoimmune Diseases; Boronic Acids; Bortezomib; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunologic Factors; NF-kappa B; Proteasome Inhibitors; Pyrazines | 2007 |
Emerging drugs in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
[Recent progress in the treatment of multiple myeloma].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Diphosphonates; Drug Design; Football; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Reference Standards; Thalidomide | 2007 |
A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
Topics: Animals; Antineoplastic Agents; Benzoates; Boronic Acids; Bortezomib; Cyclosporine; Dasatinib; Deferasirox; Humans; Iron Chelating Agents; Ophthalmic Solutions; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Randomized Controlled Trials as Topic; Skin Diseases; Skin Neoplasms; Thiazoles; Triazoles | 2007 |
The proteasome: a worthwhile target for the treatment of solid tumours?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2007 |
The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Hematologic Neoplasms; Humans; Pyrazines; Quinolones | 2007 |
[Proteasome inhibitors for multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2007 |
Myeloma bone disease and proteasome inhibition therapies.
Topics: Bone Diseases; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2007 |
Targeting the ubiquitin-proteasome pathway in cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cyclin D1; Humans; Multiple Myeloma; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2007 |
[New treatment of multiple myeloma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2007 |
Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease Progression; Drug Evaluation, Preclinical; Humans; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome | 2007 |
New drugs for myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2007 |
Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.
Topics: Animals; Blood Proteins; Boronic Acids; Bortezomib; Cell Transplantation; Humans; Immunoglobulins; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2007 |
The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma.
Topics: Antineoplastic Agents; Bone and Bones; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Pyrazines | 2007 |
Proteasome inhibition and multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines | 2007 |
[Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Design; Humans; Lymphoma; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2007 |
Bortezomib-associated cutaneous vasculitis.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Female; Humans; Male; Middle Aged; Protease Inhibitors; Pyrazines; Skin Diseases, Vascular; Vasculitis | 2007 |
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2007 |
Incorporating bortezomib into the treatment of lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lung Neoplasms; Pyrazines | 2007 |
[Breast cancer and Her-2].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Drug Therapy, Combination; ErbB Receptors; Female; Gene Targeting; Humans; Lapatinib; Protease Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2007 |
Tandem transplants in the treatment of multiple myeloma. Pro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Remission Induction; Reoperation; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
[Recent progress in rituximab therapy and its resistance--how do we overcome?].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; CD55 Antigens; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Lymphoma, Non-Hodgkin; Point Mutation; Prednisone; Pyrazines; Rituximab; Vincristine | 2007 |
[Effects of proteasome inhibitors on leukemias].
Topics: Animals; Boronic Acids; Bortezomib; Humans; Leukemia; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2007 |
Sensitizing tumor cells to immune-mediated cytotoxicity.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Humans; Immune System; Immunotherapy; Killer Cells, Natural; Ligands; Neoplasms; Proteasome Inhibitors; Pyrazines; Tumor Necrosis Factor-alpha | 2007 |
Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Dendritic Cells; Heat-Shock Proteins; Humans; Models, Biological; Neoplasms; Pyrazines; T-Lymphocytes | 2007 |
Initial Therapy of Multiple Myeloma in Patients who are Candidates for Stem Cell Transplantation.
Topics: Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2007 |
Novel therapeutic avenues in myeloma: changing the treatment paradigm.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Signal Transduction; Thalidomide | 2007 |
Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Female; Humans; Male; Multiple Myeloma; Pyrazines | 2007 |
Targeted treatments to improve stem cell outcome: old and new drugs.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2007 |
Management of novel therapeutics' side effects: a nurse-centric model.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Models, Nursing; Neoplasms; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Advocacy; Patient Education as Topic; Pyrazines; Thalidomide | 2007 |
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.
Topics: Animals; Boronic Acids; Bortezomib; Gene Expression Regulation, Enzymologic; Humans; Multigene Family; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2008 |
[New targeted therapies in hormone-refractory prostate cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Calcitriol; Cancer Vaccines; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Endothelin-1; Epothilones; Humans; Male; Oligonucleotides, Antisense; Organoplatinum Compounds; Prostatic Neoplasms; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Taxoids | 2007 |
alpha-Amido boronic acids: a synthetic challenge and their properties as serine protease inhibitors.
Topics: Boronic Acids; Bortezomib; Pyrazines; Serine Proteinase Inhibitors | 2008 |
Proteasome inhibitors: poisons and remedies.
Topics: Binding Sites; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Threonine | 2008 |
Use of novel proteosome inhibitors as a therapeutic strategy in lymphomas current experience and emerging concepts.
Topics: Active Transport, Cell Nucleus; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Cell Cycle; Cell Differentiation; Clinical Trials, Phase II as Topic; Endoplasmic Reticulum; Humans; Lymphoma; Neoplasm Proteins; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2007 |
[Multiple myeloma and intravenous immunoglobulins].
Topics: Agammaglobulinemia; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulins, Intravenous; Infections; Male; Multicenter Studies as Topic; Multiple Myeloma; Prospective Studies; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Time Factors | 2007 |
Novel therapies in myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Mobilization; Humans; Leukocyte Common Antigens; Mice; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Stem Cell Transplantation; Stem Cells; Transplantation Conditioning | 2007 |
Proteasome inhibitor, bortezomib, for myeloma and lymphoma.
Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2007 |
The role of proteasome in malignant diseases.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome; Ubiquitin | 2007 |
[Therapy of multiple myeloma: indications and options].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Remission Induction; Thalidomide; Tumor Burden | 2007 |
High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Feasibility Studies; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Life Tables; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Registries; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
New therapies in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
[Issues related to basic research on uterine and ovarian tumor pathology].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Human papillomavirus 16; Humans; Ovarian Neoplasms; Papillomavirus Infections; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrazines; ras Proteins; Trastuzumab; Tumor Suppressor Protein p53; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms | 2007 |
Management of relapsed and relapsed refractory myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2007 |
[Pharmacological and clinical profile of Bortezomib (Velcade)].
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Protease Inhibitors; Pyrazines | 2007 |
Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neoplasms; Pyrazines | 2007 |
The treatment of relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2007 |
The role of bortezomib in the treatment of lymphoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Mantle-Cell; Protease Inhibitors; Pyrazines | 2007 |
Clinical updates and nursing considerations for patients with multiple myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Disease Progression; Doxorubicin; Drug Administration Schedule; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Patient Compliance; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Pyrazines; Quality of Life; Survival Rate; Thalidomide; Treatment Outcome | 2007 |
Severe hyponatremia in a patient with mantle cell lymphoma treated with bortezomib: a case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Hyponatremia; Lymphoma, Mantle-Cell; Pyrazines | 2007 |
[Diagnosis and management guideline for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Reference Standards; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2007 |
[Chemotherapy for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Humans; Melphalan; Meta-Analysis as Topic; Multiple Myeloma; Prednisolone; Pulse Therapy, Drug; Pyrazines; Thalidomide; Vincristine | 2007 |
[Role of bortezomib in the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Doxorubicin; Humans; Liposomes; Melphalan; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Thalidomide | 2007 |
[Role of stem cell transplantation in treatment of multiple myeloma].
Topics: Age Factors; Aged; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Meta-Analysis as Topic; Middle Aged; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Heterologous | 2007 |
[Molecular targeting therapy for multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide; TNF-Related Apoptosis-Inducing Ligand; Vascular Endothelial Growth Factor A | 2007 |
[Situation of translational research and development of molecular-targeted agents for multiple myeloma].
Topics: Animals; Antineoplastic Agents; Biomedical Research; Boronic Acids; Bortezomib; Cell Adhesion Molecules; Clinical Trials as Topic; Cytokines; Drug Design; Gene Targeting; Humans; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines | 2007 |
Bortezomib in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Metabolic Networks and Pathways; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin | 2007 |
[Progress in the study of proteasome inhibitor inducing hepatic stellate cell apoptosis].
Topics: Apoptosis; Boronic Acids; Bortezomib; Hepatic Stellate Cells; Protease Inhibitors; Pyrazines | 2007 |
[Advances in therapeutic strategies for multiple myeloma].
Topics: Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Signal Transduction; Thalidomide | 2007 |
An update on drug combinations for treatment of myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Treatment Outcome | 2008 |
Combination treatment approaches and novel therapies for lymphoma.
Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cancer Vaccines; Cytokines; Humans; Immunologic Factors; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Stem Cell Transplantation | 2007 |
Position statement on the use of bortezomib in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2008 |
Bortezomib in the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Neoplasms; Patents as Topic; Proteasome Inhibitors; Pyrazines; Signal Transduction | 2006 |
[Molecular-targeted therapy for prostate cancer].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Neoplasms, Hormone-Dependent; NF-kappa B; Prostatic Neoplasms; Pyrazines; Thalidomide | 2008 |
Multiple myeloma: novel approaches for relapsed disease.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2007 |
The therapeutic potential of the proteasome in leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Gene Expression Regulation, Leukemic; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Models, Biological; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Recurrence | 2008 |
Systemic therapies for recurrent and/or metastatic salivary gland cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Boronic Acids; Bortezomib; Cetuximab; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Trastuzumab | 2008 |
Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Signal Transduction; Vascular Endothelial Growth Factor A | 2008 |
Bortezomib: putting mantle cell lymphoma on death row.
Topics: Apoptosis Regulatory Proteins; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Protease Inhibitors; Pyrazines | 2008 |
[Current concepts and treatment advances in systemic mastocytosis].
Topics: Adult; Boronic Acids; Bortezomib; Child; Forecasting; Humans; Immunohistochemistry; Immunosuppressive Agents; Mastocytosis, Systemic; Mutation; Prognosis; Protease Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazines; Sirolimus; Stem Cell Transplantation; Transduction, Genetic; World Health Organization | 2009 |
Bortezomib in mantle cell lymphoma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2008 |
Current therapy of myeloma induced renal failure.
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide | 2008 |
Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Mitochondria; Neoplasms; Pyrazines; Reactive Oxygen Species; TNF-Related Apoptosis-Inducing Ligand | 2008 |
Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens.
Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines; Renal Insufficiency; Treatment Outcome | 2008 |
Bortezomib in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines | 2008 |
The potential of proteasome inhibitors in cancer therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Drug Screening Assays, Antitumor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Proteins; Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Salvage Therapy; Ubiquitin; Ubiquitination | 2008 |
Proteasome inhibitors: a therapeutic strategy for haematological malignancy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Nucleus; Cytoplasm; Hematologic Neoplasms; Humans; Leukemia; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2008 |
Treatment of plasma cell dyscrasias with lenalidomide.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Pyrazines; Renal Insufficiency; Thalidomide; Thromboembolism; Waldenstrom Macroglobulinemia | 2008 |
Maintenance treatment in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Survival Analysis; Thalidomide | 2008 |
Pathogenesis and treatment of renal failure in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide | 2008 |
Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.
Topics: Acetylcysteine; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Curcumin; Humans; Neoplasms; Pentacyclic Triterpenes; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Triterpenes; Ubiquitin | 2008 |
Frontline treatment of multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Health Services for the Aged; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate; Thalidomide | 2008 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Hematologic Neoplasms; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Pyrazines | 2008 |
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Electrophysiology; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Risk Factors | 2008 |
The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
Topics: Alcohol Deterrents; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disulfiram; Drug Screening Assays, Antitumor; Forecasting; Humans; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thiocarbamates; Ubiquitin | 2008 |
Bortezomib in the front-line treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines | 2008 |
Treatment of relapsed and refractory myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Salvage Therapy; Thalidomide; Treatment Outcome | 2008 |
Targeting TRAIL death receptors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Glioma; HLA-DR4 Antigen; HLA-DR5 Antigen; Humans; Neoplasms; Pyrazines; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2008 |
[Clinical implications of bortezomib in frontline treatment of newly-diagnosed multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Transplantation; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Pyrazines; Transplantation, Homologous | 2008 |
The proteasome and its role in the degradation of oxidized proteins.
Topics: Aging; Animals; Antioxidants; Boronic Acids; Bortezomib; Humans; Models, Biological; Multienzyme Complexes; Oxidation-Reduction; Oxidative Stress; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteins; Pyrazines; Substrate Specificity; Ubiquitin; Ubiquitination | 2008 |
New drugs in multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2008 |
Targeted treatment and new agents in diffuse large B-cell lymphoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Delivery Systems; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Inhibitor of Apoptosis Proteins; Lymphoma, Large B-Cell, Diffuse; Microtubule-Associated Proteins; Neoplasm Proteins; Protease Inhibitors; Protein Kinases; Pyrazines; Survivin; TOR Serine-Threonine Kinases; Treatment Outcome; Vorinostat | 2008 |
The role of novel drugs in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2008 |
Proteasome inhibition: a new therapeutic option in lupus nephritis?
Topics: Animals; Antibodies, Antinuclear; B-Lymphocytes; Boronic Acids; Bortezomib; Humans; Lupus Nephritis; Mice; Plasma Cells; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2008 |
Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Non-Hodgkin; Protease Inhibitors; Pyrazines; Thalidomide | 2008 |
[Treatment for multiple myeloma: current status and future strategy in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Immunologic Factors; Japan; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Thalidomide; Time Factors; Transplantation, Autologous | 2008 |
Advances in therapy of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2008 |
Novel targets for myeloma bone disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Denosumab; Humans; Immunologic Factors; Multiple Myeloma; Pyrazines; RANK Ligand | 2008 |
Targeting NF-kappaB: a promising molecular therapy in inflammatory arthritis.
Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Boronic Acids; Bortezomib; Humans; Immunosuppression Therapy; Inflammation; Mice; NF-kappa B; Nuclear Localization Signals; Oligodeoxyribonucleotides; Pyrazines; Rats; Signal Transduction | 2008 |
Practical considerations for multiple myeloma: an overview of recent data and current options.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide | 2008 |
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Topics: Arsenic Trioxide; Arsenicals; Aspirin; Boronic Acids; Bortezomib; Heparin, Low-Molecular-Weight; Humans; Incidence; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide; Venous Thromboembolism | 2009 |
Treatment of newly diagnosed myeloma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Clinical Trials as Topic; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prognosis; Pyrazines; Risk; Thalidomide; Translocation, Genetic; Transplantation Conditioning | 2009 |
Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines | 2008 |
Pathogenesis of myeloma bone disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Adhesion; Cytokines; Denosumab; Fractures, Spontaneous; Glucocorticoids; Humans; Hypercalcemia; Immunologic Factors; Interleukins; Multiple Myeloma; Neoplasm Proteins; Osteoblasts; Osteoclasts; Osteolysis; Pyrazines; RANK Ligand; Stromal Cells; Wnt Proteins | 2009 |
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Boronic Acids; Bortezomib; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Pyrazines; Rituximab; Thalidomide; Transplantation, Autologous; Transplantation, Homologous; Waldenstrom Macroglobulinemia | 2009 |
From palliation to epigenetic therapy in myelofibrosis.
Topics: Amino Acid Substitution; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Epigenesis, Genetic; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Janus Kinase 2; Mutation; Palliative Care; Primary Myelofibrosis; Pyrazines; Radiotherapy; Signal Transduction; Splenectomy; Transplantation, Homologous | 2008 |
Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity?
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Demyelinating Diseases; Humans; Myelin Sheath; Neoplasms; Neurotoxicity Syndromes; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2008 |
The persisting challenge of selective and specific proteasome inhibition.
Topics: Boronic Acids; Bortezomib; Catalytic Domain; Drug Design; Humans; Models, Molecular; Molecular Structure; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Pyrazines | 2009 |
Diagnosis and the current trends in multiple myeloma therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Protease Inhibitors; Pyrazines; Remission Induction; Thalidomide | 2008 |
Not boring at all. Boron is the new carbon in the quest for novel drug candidates.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Boron; Boron Compounds; Boron Neutron Capture Therapy; Boronic Acids; Bortezomib; Carbon; Drug Design; Humans; Molecular Structure; Neoplasms; Protease Inhibitors; Pyrazines | 2009 |
Treatment of multiple myeloma in the targeted therapy era.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Delivery Systems; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning | 2009 |
Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias.
Topics: Blood Coagulation Disorders; Blood Platelet Disorders; Boronic Acids; Bortezomib; Hemorrhage; Humans; Immunosuppressive Agents; Paraproteinemias; Protease Inhibitors; Pyrazines; Retrospective Studies; Thalidomide; Thrombosis | 2009 |
[Depletion of plasma cells - a novel strategy in the therapy of systemic lupus erythematosus in mice and man].
Topics: Animals; Boronic Acids; Bortezomib; Humans; Immunotherapy; Lupus Erythematosus, Systemic; Mice; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Treatment Outcome | 2009 |
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lactones; Leukemia; Oligopeptides; Protease Inhibitors; Pyrazines; Pyrroles | 2009 |
Initial therapy in multiple myeloma: investigating the new treatment paradigm.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Comorbidity; Evidence-Based Medicine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous | 2009 |
Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide | 2009 |
Bortezomib and Waldenstrom's macroglobulinemia.
Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Pyrazines; Waldenstrom Macroglobulinemia | 2009 |
Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Pyrazines; Waldenstrom Macroglobulinemia | 2009 |
Role of proteasome inhibition in Waldenström's macroglobulinemia.
Topics: Boronic Acids; Bortezomib; Humans; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Waldenstrom Macroglobulinemia | 2009 |
Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lymphoma, T-Cell, Peripheral; Nitrogen Mustard Compounds; Pyrazines; Vidarabine | 2009 |
Monitoring and treating posttransplant human leukocyte antigen antibodies.
Topics: Antibody Formation; Boronic Acids; Bortezomib; Cyclophosphamide; Graft Rejection; HLA Antigens; Humans; Immunoglobulins, Intravenous; Isoantibodies; Monitoring, Physiologic; Organ Transplantation; Plasmapheresis; Prognosis; Pyrazines; Risk Factors; Serologic Tests; Transplantation | 2009 |
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histone Deacetylases; HSP90 Heat-Shock Proteins; Humans; Immunologic Factors; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Pyrazines | 2009 |
Targeting the proteasome pathway.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Biological Products; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Discovery; Humans; Lactones; Neoplasms; Peptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Ubiquitin; Ubiquitin-Activating Enzymes; Ubiquitins | 2009 |
Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Boronic Acids; Bortezomib; Clinical Trials as Topic; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Lymphoma, Non-Hodgkin; Oligonucleotides, Antisense; Proteasome Inhibitors; Protein Kinase C; Pyrazines; Sirolimus | 2009 |
[Multiple myeloma].
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Diphosphonates; Fractures, Bone; Humans; Hypercalcemia; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Protease Inhibitors; Pyrazines | 2009 |
Bortezomib: a review of its use in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2009 |
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Waldenstrom Macroglobulinemia | 2009 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Genetic Predisposition to Disease; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Protease Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Proteasome inhibitors in cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Design; Drug Resistance, Neoplasm; Humans; Neoplasms; Protease Inhibitors; Pyrazines | 2009 |
Proteasome inhibition for antibody-mediated rejection.
Topics: Animals; Antibodies; Boronic Acids; Bortezomib; Disease Models, Animal; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Kidney Transplantation; Plasma Cells; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2009 |
The future of small molecule inhibitors in lymphoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Discovery; Forecasting; Histone Deacetylases; Humans; Lymphoma; Oligopeptides; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2009 |
Neurological adverse effects caused by cytotoxic and targeted therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dacarbazine; Drug Approval; Epothilones; Humans; Imatinib Mesylate; Indoles; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrazines; Pyrimidines; Pyrroles; Sunitinib; Temozolomide; Tubulin Modulators; United States; United States Food and Drug Administration | 2009 |
Proteasome inhibitors in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lactones; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Pyrroles | 2009 |
The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Salvage Therapy; Thalidomide; Treatment Outcome | 2009 |
[Current treatment of follicular lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Prednisone; Prognosis; Pyrazines; Radioimmunotherapy; Radiotherapy, Adjuvant; Risk Factors; Rituximab; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vincristine | 2009 |
Characteristics, pathogenesis, and novel treatments for multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Translocation, Genetic | 2004 |
Proteasome inhibition: mechanism of action.
Topics: Animals; Boronic Acids; Bortezomib; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2004 |
Bortezomib in combination with other therapies for the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2004 |
Proteasome inhibition for treatment of multiple myeloma: clinical update.
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2004 |
The 26 S proteasome: from basic mechanisms to drug targeting.
Topics: Adenosine Triphosphate; Animals; Boronic Acids; Bortezomib; Cell Cycle; Cytosol; Drug Delivery Systems; Endoplasmic Reticulum; Gene Expression Regulation; Humans; Proteasome Endopeptidase Complex; Protein Denaturation; Protein Folding; Pyrazines; Transcription Factors; Transcription, Genetic; Ubiquitin | 2009 |
Novel therapies in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide | 2009 |
Multiple myeloma, painful neuropathy, acupuncture?
Topics: Acupuncture Therapy; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pain; Pain Management; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2009 |
[Hematopoietic stem cell transplantation for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Doxorubicin; Drug Discovery; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vincristine | 2009 |
[New treatment strategies for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Diagnosis, Differential; Doxorubicin; Drug Discovery; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisolone; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide; Vincristine | 2009 |
[IgA pemphigus accompanying multiple myeloma has disappeared following the treatment with bortezomib (Velcade), cyclophosphamide and dexamethasone. Case study and literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin A; Multiple Myeloma; Paraproteinemias; Pemphigus; Pyrazines; Skin Diseases, Vesiculobullous | 2009 |
How to treat a newly diagnosed young patient with multiple myeloma.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Disease Management; Doxorubicin; Endpoint Determination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Molecular Diagnostic Techniques; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning | 2009 |
How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Comorbidity; Disease Management; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Peripheral Nervous System Diseases; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning; Venous Thrombosis | 2009 |
Novel therapies for relapsed myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drugs, Investigational; Heat-Shock Proteins; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Mice; Mice, Transgenic; Multiple Myeloma; Neoplasm Proteins; Nitrogen Mustard Compounds; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Salvage Therapy; Thalidomide | 2009 |
ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Evidence-Based Medicine; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Interferon-alpha; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2009 |
Future directions in immunomodulatory therapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2010 |
Inhibitors of the Ubiquitin-Proteasome System and the cell death machinery: How many pathways are activated?
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Humans; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin | 2008 |
New treatments for myeloma.
Topics: Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Neoplasm Staging; Prednisone; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide | 2010 |
Osteoblastogenesis and tumor growth in myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Intercellular Signaling Peptides and Proteins; Models, Biological; Multiple Myeloma; Osteoblasts; Osteoclasts; Pyrazines; Tumor Burden | 2010 |
Bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2010 |
The therapeutic potential of deubiquitinating enzyme inhibitors.
Topics: Animals; Boronic Acids; Bortezomib; Endopeptidases; Humans; Molecular Structure; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Pyrazines; Ubiquitin; Ubiquitin Thiolesterase; Ubiquitin-Specific Peptidase 7; Ubiquitination; Viruses | 2010 |
Current multiple myeloma treatment strategies with novel agents: a European perspective.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Clinical Trials as Topic; Decision Making; Decision Trees; Humans; Kidney Failure, Chronic; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous | 2010 |
New developments in the treatment of patients with multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Thalidomide | 2010 |
Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2010 |
Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Pyrazines | 2010 |
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2010 |
Proteasomal regulation of pulmonary fibrosis.
Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pulmonary Fibrosis; Pyrazines; Signal Transduction; Smad Proteins; Transforming Growth Factor beta1; Ubiquitin | 2010 |
Allergy for a lifetime?
Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B-Cell Activation Factor Receptor; Boronic Acids; Bortezomib; Cell Survival; Drug Resistance; Humans; Hypersensitivity; Immunoglobulin E; Immunologic Memory; Immunotherapy; Lymphocyte Depletion; Omalizumab; Plasma Cells; Pyrazines; Recombinant Fusion Proteins; Tumor Necrosis Factor Ligand Superfamily Member 13 | 2010 |
Advances in treatment for relapses and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrazines; Recurrence; Thalidomide | 2010 |
Novel agents in development for peripheral T-cell lymphoma.
Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Depsipeptides; Drug Design; Drugs, Investigational; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Lymphoma, T-Cell, Peripheral; Purine Nucleosides; Pyrazines; Pyrimidinones; Salvage Therapy; Thalidomide | 2010 |
How best to use new therapies in multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Glucocorticoids; Humans; Immunologic Factors; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence | 2010 |
Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
Topics: Alkylating Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Boronic Acids; Bortezomib; Humans; Nucleosides; Pyrazines; Recurrence; Rituximab; Signal Transduction; Waldenstrom Macroglobulinemia | 2010 |
[Molecular-targeted therapy of multiple myeloma].
Topics: Boronic Acids; Bortezomib; Drug Delivery Systems; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2010 |
[Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Pyrazines; Thalidomide | 2010 |
Role of autologous stem cell transplantation in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Patient Selection; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
Current status of bortezomib in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Combined Modality Therapy; Cytokines; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Kidney Failure, Chronic; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Stem Cell Transplantation; Stromal Cells; Transplantation, Autologous | 2007 |
Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Pyrazines; Radioimmunotherapy; Sirolimus; Survival Analysis; Treatment Outcome | 2009 |
Treatment of relapsed and refractory myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2009 |
Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.
Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Bone Marrow; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Evidence-Based Medicine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Plasma Cells; Pyrazines; Retreatment; Switzerland; Thalidomide | 2010 |
Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy.
Topics: Activating Transcription Factor 4; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Endoribonucleases; Histone Deacetylase 6; Histone Deacetylases; Humans; JNK Mitogen-Activated Protein Kinases; Mechanistic Target of Rapamycin Complex 1; Membrane Proteins; Microtubule-Associated Proteins; Multiprotein Complexes; Neoplasms; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Proteins; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Ubiquitinated Proteins; Ubiquitins | 2010 |
Management of treatment-related adverse events in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disorders of Excessive Somnolence; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Venous Thromboembolism | 2010 |
Multiple myeloma - current issues and controversies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Management; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2010 |
Optimising patient outcomes in myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Management; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Risk Assessment; Thalidomide; Treatment Outcome | 2010 |
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Transcription, Genetic | 2010 |
Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines | 2010 |
Intracranial multifocal dural involvement in multiple myeloma: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Dura Mater; Fatal Outcome; Humans; Lenalidomide; Male; Meningeal Neoplasms; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2010 |
[Proteasome inhibitor].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Physiological Phenomena; Clinical Trials as Topic; Drug Design; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2010 |
Drug-mediated and cellular immunotherapy in multiple myeloma.
Topics: Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cancer Vaccines; Combined Modality Therapy; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunologic Memory; Immunotherapy; Immunotherapy, Active; Immunotherapy, Adoptive; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Pyrazines; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Thalidomide; Tumor Escape | 2010 |
Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Delivery Systems; Humans; Neoplasms; Pyrazines | 2010 |
Plasma cell leukaemia and other aggressive plasma cell malignancies.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2010 |
Therapeutic options for HIV-associated lymphomas.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Boronic Acids; Bortezomib; Epstein-Barr Virus Infections; HIV Infections; Humans; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Pyrazines; Rituximab; Treatment Outcome | 2010 |
[Bortezomib in multiple myeloma patients after allogeneic stem cell transplantation].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Transplantation, Homologous | 2010 |
Bortezomib: a new player in pre- and post-transplant desensitization?
Topics: Boronic Acids; Bortezomib; Dendritic Cells; Desensitization, Immunologic; Graft Rejection; HLA Antigens; Humans; Isoantibodies; Kidney Transplantation; NF-kappa B; Pyrazines | 2010 |
The spectrum of kidney involvement in lymphoma: a case report and review of the literature.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Kidney; Lymphoma, Non-Hodgkin; Male; Prognosis; Pyrazines; Renal Insufficiency; Rituximab; Treatment Outcome | 2010 |
The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Survival Rate; Sweden; Thalidomide | 2010 |
Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice.
Topics: Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Radioimmunotherapy; Rituximab; Thalidomide | 2010 |
[Current treatment strategies for multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide | 2010 |
[Study on natural products for drug development].
Topics: Animals; Antineoplastic Agents; Aspergillus; Axinella; Biological Products; Boronic Acids; Bortezomib; Drug Design; Enzyme Inhibitors; Humans; Imidazoles; Indole Alkaloids; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteins; Pyrazines; Ubiquitin; Ubiquitin-Activating Enzymes; Ubiquitin-Conjugating Enzymes; Ubiquitin-Protein Ligases | 2010 |
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Incidence; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Risk Assessment; Risk Factors; Thalidomide; Treatment Outcome | 2010 |
[Proteasome inhibitors].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2010 |
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
Topics: Boronic Acids; Bortezomib; Glomerular Filtration Rate; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Thalidomide; Transplantation, Autologous | 2010 |
Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Plasma cell leukemia: concepts and management.
Topics: Aged; Antigens, CD20; Antineoplastic Agents; Boronic Acids; Bortezomib; CD56 Antigen; Humans; Lenalidomide; Leukemia, Plasma Cell; Multiple Myeloma; Neoplasms, Second Primary; Palliative Care; Paraproteinemias; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2010 |
Multiple myeloma.
Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Targeted therapy in lymphoma.
Topics: Boronic Acids; Bortezomib; Everolimus; Humans; Lymphoma; Molecular Targeted Therapy; Pyrazines; Signal Transduction; Sirolimus; Survival Analysis | 2010 |
Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2011 |
Treatment approaches to IgG4-related systemic disease.
Topics: Antibodies, Monoclonal, Murine-Derived; Autoimmune Diseases; Boronic Acids; Bortezomib; Glucocorticoids; Humans; Immunoglobulin G; Immunosuppressive Agents; Pancreatitis; Prognosis; Pyrazines; Recurrence; Rituximab | 2011 |
Ten years of improvement in the management of multiple myeloma: 2000-2010.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Clinical impact of chromosomal aberrations in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Graft vs Host Disease; Humans; Immunomodulation; Models, Animal; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous | 2011 |
Chemotherapy-induced neuropathic pain.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neuralgia; Pyrazines; Thalidomide | 2011 |
Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2011 |
Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematologic Neoplasms; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation | 2012 |
Focal adhesion kinase as a therapeutic target of bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Protease Inhibitors; Pyrazines | 2010 |
Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Gastrointestinal Stromal Tumors; Histones; Humans; Proto-Oncogene Proteins c-kit; Pyrazines | 2010 |
Antibody-mediated rejection in kidney transplantation: an update.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody Formation; Boronic Acids; Bortezomib; Graft Rejection; Humans; Isoantibodies; Kidney Transplantation; Prognosis; Protease Inhibitors; Pyrazines | 2011 |
Management of older patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Primary Myelofibrosis; Protease Inhibitors; Pyrazines; Thalidomide | 2011 |
Treatment of newly diagnosed myeloma in patients not eligible for transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
[Classification and synthesis of ubiquitin-proteasome inhibitor].
Topics: Acetylcysteine; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Dipeptides; Humans; Multiple Myeloma; Peptides, Cyclic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2009 |
[Immunosuppressive agents in kidney transplantation].
Topics: Antibodies; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Cyclosporine; Everolimus; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Kidney Transplantation; Propylene Glycols; Pyrazines; Rituximab; Sirolimus; Sphingosine; T-Lymphocytes; Tacrolimus; TOR Serine-Threonine Kinases | 2011 |
Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2011 |
The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Female; Humans; Male; Medical Oncology; Multiple Myeloma; Neoplasm Staging; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Treatment options for relapsed and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Medical Oncology; Models, Biological; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Thalidomide | 2011 |
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Congresses as Topic; Disease-Free Survival; Europe; Evidence-Based Practice; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
[Malignant lymphoma: individualized treatment according to biological and clinical risk factors].
Topics: Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Ki-1 Antigen; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Precision Medicine; Prognosis; Pyrazines; Risk Factors; Rituximab; Survival Rate; Waldenstrom Macroglobulinemia | 2011 |
[Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chronic Disease; Combined Modality Therapy; Dexamethasone; Down-Regulation; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin lambda-Chains; Kidney Diseases; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Remission Induction; Renal Dialysis; Transplantation, Autologous | 2011 |
[Current treatment of AL amyloidosis].
Topics: Amyloid; Amyloidosis; Biomarkers; Boronic Acids; Bortezomib; Cardiomyopathies; Consensus Development Conferences as Topic; Dexamethasone; Drug Therapy, Combination; Heart Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Failure, Chronic; Kidney Transplantation; Lenalidomide; Melphalan; Natriuretic Peptide, Brain; Paraproteinemias; Paraproteins; Peptide Fragments; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Thalidomide | 2011 |
Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2011 |
Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib.
Topics: ADAM Proteins; ADAMTS13 Protein; Boronic Acids; Bortezomib; Female; Fever of Unknown Origin; Humans; Middle Aged; Multiple Myeloma; Purpura, Thrombotic Thrombocytopenic; Pyrazines | 2011 |
Novel drugs in myeloma: harnessing tumour biology to treat myeloma.
Topics: Alkylating Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromatin; Histone Deacetylase Inhibitors; Humans; Janus Kinase 2; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; NF-kappa B; Pyrazines; Signal Transduction; Unfolded Protein Response; Wnt Proteins | 2011 |
Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Standard of Care; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2011 |
Therapy of relapsed and refractory multiple myeloma.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lactones; Lenalidomide; Middle Aged; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Secondary Prevention; Thalidomide | 2011 |
[New insights in the treatment of myeloma with renal failure].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Fluid Therapy; Humans; Hypercalcemia; Immunoglobulin Light Chains; Kidney Failure, Chronic; Lenalidomide; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Myeloma Proteins; Prospective Studies; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Thalidomide | 2011 |
Role of proteasome inhibition in sensitized transplant candidates.
Topics: Boronic Acids; Bortezomib; Graft Rejection; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Transplants | 2011 |
Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Topics: Antineoplastic Agents, Phytogenic; Bone and Bones; Bone Remodeling; Bone Resorption; Boronic Acids; Bortezomib; Calcium-Binding Proteins; Humans; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Multiple Myeloma; Osteoblasts; Osteoclasts; Protease Inhibitors; Pyrazines; Resveratrol; Signal Transduction; Stilbenes; Wnt Proteins | 2011 |
Degradation-linked ubiquitin signal and proteasome are integral components of DNA double strand break repair: New perspectives for anti-cancer therapy.
Topics: Animals; Boronic Acids; Bortezomib; DNA Breaks, Double-Stranded; DNA Repair; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Pyrazines; Risk; Thalidomide; Venous Thromboembolism | 2011 |
Novel proteasome inhibitors to overcome bortezomib resistance.
Topics: Allosteric Site; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Chloroquine; Clioquinol; Drug Resistance, Neoplasm; Humans; Hydroxyquinolines; Lactones; Neoplasms; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Threonine; Ubiquitinated Proteins; Ubiquitination | 2011 |
Desensitization across the HLA barrier in kidney transplantaion.
Topics: Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Desensitization, Immunologic; Female; Flow Cytometry; HLA Antigens; Humans; Immunoglobulins, Intravenous; Kidney Transplantation; Male; Plasmapheresis; Pyrazines; Rituximab; Sensitivity and Specificity; Sex Factors; Treatment Outcome | 2011 |
Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part I.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Cytokines; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1; Inflammation; Mice; Models, Biological; Neoplasms; NF-kappa B; Pyrazines; Signal Transduction; Transcription Factors; Tumor Suppressor Protein p53 | 2011 |
Targeting the extrinsic apoptosis signaling pathway for cancer therapy.
Topics: Adjuvants, Immunologic; Animals; Antibodies, Monoclonal; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Immunotherapy; Molecular Targeted Therapy; Neoplasms; Proteasome Inhibitors; Pyrazines; Receptors, Tumor Necrosis Factor; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand | 2011 |
New agents in follicular lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Follicular; Mice; Nitrogen Mustard Compounds; Phosphotransferases; Protein Kinase Inhibitors; Pyrazines; Recurrence; Remission Induction; Rituximab; Signal Transduction; Thalidomide; Tumor Microenvironment | 2011 |
[EGFR/HER1: a target life].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasm Proteins; Neoplasms; Panitumumab; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; Quinazolines; ras Proteins | 2012 |
A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Creatinine; Humans; Kidney; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2011 |
Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies.
Topics: Boronic Acids; Bortezomib; Carcinoma; Epstein-Barr Virus Infections; Gene Expression Regulation, Viral; Herpesvirus 4, Human; Herpesvirus 8, Human; Humans; Incidence; Lymphoma; Proteasome Inhibitors; Pyrazines; Sarcoma, Kaposi; Virus Latency; Virus Physiological Phenomena | 2011 |
Bortezomib for previously untreated multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic | 2011 |
Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Topics: Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Transplantation, Autologous | 2012 |
Genomic stratification of multiple myeloma treated with novel agents.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Genomics; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2012 |
Proteasome inhibitor therapy for antibody-mediated rejection.
Topics: Antibodies; Boronic Acids; Bortezomib; Graft Rejection; Humans; Kidney Transplantation; Plasma Cells; Prospective Studies; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome | 2011 |
[Current treatment strategies with novel agents for multiple myeloma].
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous | 2011 |
[Present status and perspective of targeted therapy for B-cell lymphoma].
Topics: Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Discovery; Flavonoids; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Piperidines; Protease Inhibitors; Protein Kinase C; Protein Kinase C beta; Protein-Tyrosine Kinases; Pyrazines; Rituximab; Thalidomide; Vorinostat | 2011 |
Clinical and investigational use of proteasome inhibitors for transplant rejection.
Topics: Animals; Boronic Acids; Bortezomib; Graft Rejection; Humans; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2011 |
[New treatment strategy for Crow-Fukase (POEMS) syndrome].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Combined Modality Therapy; Demyelinating Diseases; Humans; Lenalidomide; Melphalan; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Pyrazines; Thalidomide; Transplantation, Autologous; Vascular Endothelial Growth Factor A | 2010 |
Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia.
Topics: Angiogenesis Inhibitors; Bone Marrow; Boronic Acids; Bortezomib; Endothelial Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Panobinostat; Protease Inhibitors; Proteasome Inhibitors; Protein Kinase C; Pyrazines; TOR Serine-Threonine Kinases; Tumor Microenvironment; Waldenstrom Macroglobulinemia | 2011 |
Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies.
Topics: Boronic Acids; Bortezomib; Cyclin-Dependent Kinases; Enzyme Inhibitors; Flavonoids; Hematologic Neoplasms; Humans; NF-kappa B; Piperidines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2011 |
Bortezomib for previously untreated multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Transplantation, Autologous | 2011 |
Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cutis Laxa; Dexamethasone; Diabetic Nephropathies; Erythropoietin; Fatal Outcome; Female; Heavy Chain Disease; Hematuria; Humans; Hypertension, Renal; Immunoglobulin alpha-Chains; Immunoglobulin gamma-Chains; Immunoglobulin mu-Chains; Kidney Glomerulus; Male; Multiple Myeloma; Paraproteinemias; Proteinuria; Pyrazines; Thalidomide; Urticaria; Vasculitis, Leukocytoclastic, Cutaneous | 2011 |
Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lymphoma, B-Cell; Multiple Myeloma; Oxidation-Reduction; Oxidative Stress; Oxides; Pyrazines; Radiotherapy | 2012 |
Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2011 |
Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.
Topics: Boronic Acids; Bortezomib; Drug Discovery; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Structure-Activity Relationship | 2012 |
Macrocyclic proteasome inhibitors.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Humans; Macrocyclic Compounds; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2011 |
Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2011 |
The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Cyclophosphamide; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Pyrazines; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide | 2011 |
The state of therapy for removal of alloantibody producing plasma cells in transplantation.
Topics: Animals; Boronic Acids; Bortezomib; Graft Rejection; Humans; Isoantibodies; Kidney Transplantation; Mice; Plasma Cells; Protease Inhibitors; Pyrazines; Treatment Outcome | 2012 |
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Early Diagnosis; Humans; Immunologic Factors; Incidence; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Thalidomide | 2012 |
Advances in the understanding of mechanisms and therapeutic use of bortezomib.
Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance; Humans; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin | 2011 |
Emerging therapies in hematopoietic stem cell transplantation.
Topics: Antineoplastic Agents; Azacitidine; Boronic Acids; Bortezomib; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Proteasome Inhibitors; Pyrazines; Vorinostat | 2012 |
Impact of bortezomib on bone health in myeloma: a review of current evidence.
Topics: Animals; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Humans; Multiple Myeloma; Osteogenesis; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic | 2012 |
[Thrombotic complications following the treatment of multiple myeloma with new agents].
Topics: Anthracyclines; Anticoagulants; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Thrombosis | 2011 |
[Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
Topics: Amyloidosis; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Heart Transplantation; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Light Chains; Kidney; Kidney Diseases; Kidney Transplantation; Melphalan; Paraproteinemias; Plasma Exchange; Pyrazines | 2012 |
Management of myeloma-associated renal dysfunction in the era of novel therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Prednisone; Pyrazines; Renal Insufficiency; Thalidomide | 2012 |
Proteasome inhibitors: an expanding army attacking a unique target.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lactones; Multiple Myeloma; Peptides, Cyclic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2012 |
[Current treatment of acute myeloid leukaemia in adults].
Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin | 2012 |
Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide; Treatment Outcome | 2012 |
Latest advances and current challenges in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Prognosis; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Thalidomide | 2012 |
Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
Topics: Adult; Biopsy; Boronic Acids; Bortezomib; Female; Graft Rejection; Humans; Isoantibodies; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome | 2012 |
Future trends in organ transplant recipients--important issues for dermatologists.
Topics: Abatacept; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Calcineurin Inhibitors; Forecasting; Graft Survival; Humans; Immunoconjugates; Immunosuppression Therapy; Immunosuppressive Agents; Organ Transplantation; Pyrazines; Recombinant Fusion Proteins; Risk Assessment; Rituximab; Skin Neoplasms | 2012 |
Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Brentuximab Vedotin; Drug Therapy; Everolimus; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Immunotherapy; Lenalidomide; Protease Inhibitors; Pyrazines; Recurrence; Rituximab; Secondary Prevention; Sirolimus; Thalidomide | 2012 |
Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale.
Topics: Acute Disease; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Chronic Disease; Graft Rejection; Graft Survival; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosorbent Techniques; Isoantibodies; Kidney Transplantation; Plasma Exchange; Pyrazines; Rituximab; Splenectomy | 2012 |
[Multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Denosumab; Diphosphonates; Humans; Imidazoles; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Zoledronic Acid | 2012 |
Light chain deposition disease: novel biological insights and treatment advances.
Topics: Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Kidney Failure, Chronic; Male; Middle Aged; Multiple Organ Failure; Pyrazines | 2012 |
[AL amyloidosis].
Topics: Algorithms; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Heart Failure; Humans; Lenalidomide; Melphalan; Myocardium; Palliative Care; Patient Selection; Prognosis; Pyrazines; Quality of Life; Risk Assessment; Risk Factors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2012 |
SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Evidence-Based Practice; Hematology; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Grading; Practice Guidelines as Topic; Pyrazines; Societies, Medical; Thalidomide | 2012 |
Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Prognosis; Pyrazines; Thalidomide | 2012 |
Green tea and lung cancer: a systematic review.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; DNA Damage; Herb-Drug Interactions; Humans; Lung Neoplasms; Maximum Tolerated Dose; Phytotherapy; Plant Extracts; Pyrazines; Tea | 2013 |
Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Translational Research, Biomedical | 2012 |
European perspective on multiple myeloma treatment strategies: update following recent congresses.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Congresses as Topic; Europe; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2012 |
The neurovascular unit and combination treatment strategies for stroke.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Cerebral Hemorrhage; Drug Therapy, Combination; Erythropoietin; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Minocycline; Pyrazines; Stroke; Tissue Plasminogen Activator | 2012 |
Proteasome inhibitors in multiple myeloma: 10 years later.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Humans; Medical Oncology; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Time Factors | 2012 |
Sweet-like lesions induced by bortezomib: a review of the literature and a report of 2 cases.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Male; Middle Aged; Pyrazines; Sweet Syndrome | 2012 |
Targeting endoplasmic reticulum signaling pathways in cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; HIV Protease Inhibitors; Humans; Neoplasms; Proteasome Endopeptidase Complex; Protein Folding; Pyrazines; Signal Transduction | 2012 |
Proteasome inhibitors in mantle cell lymphoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Signal Transduction; Survival Analysis | 2012 |
Response to low-dose bortezomib in plasma cell leukemia patients with malignant pleural effusion and ascites: a case report and a review of the literature.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Boronic Acids; Bortezomib; Fatal Outcome; Humans; Leukemia, Plasma Cell; Male; Melphalan; Pleural Effusion, Malignant; Prednisone; Pyrazines; Treatment Failure | 2012 |
[Development and clinical application of novel proteasome inhibitors].
Topics: Boronic Acids; Bortezomib; Drug Design; Drug Therapy, Combination; Drug Tolerance; Lymphoma; Molecular Targeted Therapy; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic | 2012 |
Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
Topics: Antineoplastic Agents; Autoimmune Diseases; Boronic Acids; Bortezomib; Drug Discovery; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; T-Lymphocytes | 2012 |
An historic perspective of proteasome inhibition.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Screening Assays, Antitumor; Hematologic Neoplasms; History, 20th Century; History, 21st Century; Humans; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Structure-Activity Relationship; Ubiquitin | 2012 |
Discovery and development of second-generation proteasome inhibitors.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Structure-Activity Relationship | 2012 |
Bortezomib combination therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2012 |
General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Quality of Life | 2012 |
Proteasome inhibition for antibody-mediated allograft rejection.
Topics: Animals; Antibodies; Antineoplastic Agents; Boronic Acids; Bortezomib; Graft Rejection; Humans; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2012 |
Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience.
Topics: Animals; Antibodies; Boronic Acids; Bortezomib; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2012 |
Proteasome inhibitors.
Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2012 |
[A research advance on bortezomib-induced peripheral neuropathy].
Topics: Boronic Acids; Bortezomib; Humans; Peripheral Nervous System Diseases; Pyrazines | 2012 |
Effective therapy for acute antibody-mediated rejection with mild chronic changes: case report and review of the literature.
Topics: Adult; Antibodies; Biopsy; Boronic Acids; Bortezomib; Chronic Disease; Drug Therapy, Combination; Female; Graft Rejection; Humans; Immunity, Humoral; Immunosuppressive Agents; Kidney; Kidney Transplantation; Male; Pyrazines; Time Factors; Treatment Outcome; Young Adult | 2012 |
(Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2012 |
Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implications.
Topics: Adenine; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Chloroquine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drug Synergism; Forecasting; Humans; Inclusion Bodies; Medical Oncology; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Translational Research, Biomedical; Ubiquitin | 2012 |
How I treat plasma cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Middle Aged; Prognosis; Pyrazines; Transplantation, Autologous | 2012 |
Waldenström macroglobulinemia: my way.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Pyrazines; Rituximab; Survival Analysis; Thalidomide; Waldenstrom Macroglobulinemia | 2013 |
Multiple myeloma: improved outcomes with new therapeutic approaches.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2012 |
Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biological Products; Boronic Acids; Bortezomib; Drug Therapy, Combination; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon-alpha; Lenalidomide; Lymphoma, Follicular; Pyrazines; Rituximab; Thalidomide; Tumor Microenvironment | 2012 |
Achieving an early myeloma response in patients with kidney impairment.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Glomerular Filtration Rate; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Time Factors | 2012 |
Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Pyrazines; Thalidomide | 2012 |
The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunoglobulin Light Chains; Multiple Myeloma; Plasma Exchange; Pyrazines; Renal Dialysis | 2012 |
Myeloma kidney: improving clinical outcomes?
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Humans; Immunoglobulin Light Chains; Immunosuppressive Agents; Multiple Myeloma; Plasma Exchange; Prognosis; Proteasome Inhibitors; Pyrazines; Renal Dialysis; Stem Cell Transplantation | 2012 |
Fifty years of melphalan use in hematopoietic stem cell transplantation.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2013 |
Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Neoplasms; Pyrazines; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand | 2013 |
Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature.
Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Failure; Humans; Middle Aged; Multiple Myeloma; Myocarditis; Proteasome Inhibitors; Pyrazines | 2012 |
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.
Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Kidney; Lenalidomide; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Renal Insufficiency; Thalidomide | 2012 |
[Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs].
Topics: Boronic Acids; Bortezomib; Drug Design; Humans; Immunologic Factors; Kidney Neoplasms; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Plasmacytoma; Pyrazines; Thalidomide | 2012 |
Distinct variant of Sweet's syndrome: bortezomib-induced histiocytoid Sweet's syndrome in a patient with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Pyrazines; Sweet Syndrome | 2012 |
Proteasome inhibitors: a new perspective for treating autoimmune diseases.
Topics: Animals; Autoimmune Diseases; Boronic Acids; Bortezomib; Humans; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2012 |
Emerging agents for the treatment of mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drugs, Investigational; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Prognosis; Pyrazines; Recurrence; Salvage Therapy; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Watchful Waiting | 2012 |
Light-chain amyloidosis: SCT, novel agents and beyond.
Topics: Amyloidosis; Animals; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Immunologic Factors; Immunosuppressive Agents; Immunotherapy; Lenalidomide; Melphalan; Pyrazines; Survival Analysis; Thalidomide | 2013 |
Proteasome inhibition in transplantation-focusing on the experience with bortezomib.
Topics: Animals; Antibodies; B-Lymphocytes; Boronic Acids; Bortezomib; Dendritic Cells; Drug Design; Graft Rejection; Graft vs Host Disease; Humans; Organ Transplantation; Proteasome Inhibitors; Pyrazines; T-Lymphocytes | 2013 |
Dissecting bortezomib: development, application, adverse effects and future direction.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2013 |
Cullin-RING Ligases as attractive anti-cancer targets.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cullin Proteins; Drug Design; Humans; Molecular Targeted Therapy; Neoplasms; Proteasome Inhibitors; Pyrazines; Ubiquitin-Protein Ligases | 2013 |
When ubiquitin meets NF-κB: a trove for anti-cancer drug development.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Humans; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin; Ubiquitination | 2013 |
Effective induction therapy with subcutaneous administration of bortezomib for newly diagnosed POEMS syndrome: a case report and a review of the literature.
Topics: Administration, Oral; Boronic Acids; Bortezomib; Dexamethasone; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoadjuvant Therapy; POEMS Syndrome; Pyrazines; Remission Induction | 2013 |
Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Time Factors | 2012 |
How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comprehension; Drug-Related Side Effects and Adverse Reactions; Humans; Kinetics; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Thalidomide; Time Factors | 2012 |
From bortezomib to other inhibitors of the proteasome and beyond.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines | 2013 |
The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature.
Topics: Acute Disease; Adult; Boronic Acids; Bortezomib; Drug Substitution; Female; Graft Rejection; Graft Survival; Histocompatibility; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney; Kidney Transplantation; Male; Middle Aged; Pyrazines; Time Factors; Treatment Outcome | 2012 |
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; Humans; Imidazoles; In Situ Hybridization, Fluorescence; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Proteinuria; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Time Factors; Translocation, Genetic; Treatment Outcome; Zoledronic Acid | 2012 |
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy; Humans; Lenalidomide; Medical Oncology; Melphalan; Models, Biological; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Risk; Thalidomide; Treatment Outcome | 2012 |
Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?
Topics: Autoantibodies; Boronic Acids; Bortezomib; Humans; Myasthenia Gravis; Plasma Cells; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2012 |
Carfilzomib (Kryprolis) for multiple myeloma.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Pyrazines | 2012 |
[Subcutaneous bortezomib as a new promising way to successful maintenance therapy in multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Injections, Subcutaneous; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines | 2012 |
Bortezomib-induced posterior reversible encephalopathy syndrome in a patient with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Posterior Leukoencephalopathy Syndrome; Pyrazines; Recovery of Function; Risk Assessment; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2013 |
Current therapeutic strategy for multiple myeloma.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid | 2013 |
Light chain amyloidosis 2012: a new era.
Topics: Alkylating Agents; Amyloid; Amyloidosis; Biomarkers; Boronic Acids; Bortezomib; Cardiomyopathies; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Forecasting; Humans; Immunoglobulin Light Chains; Immunologic Factors; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Pyrazines; Risk; Severity of Illness Index; Stem Cell Transplantation; Troponin C; Troponin T | 2013 |
Recent advancements of bortezomib in acute lymphocytic leukemia treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Thrombocytopenia; Valproic Acid | 2013 |
Induction therapy for newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2013 |
Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Zoledronic Acid | 2013 |
Part II: role of maintenance therapy in transplant-ineligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Vincristine | 2013 |
[Advanced in studies of proteasome inhibitor bortezomib and hepatic disease].
Topics: Boronic Acids; Bortezomib; Humans; Liver Diseases; Proteasome Inhibitors; Pyrazines | 2012 |
Subcutaneous bortezomib: in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Injections, Intravenous; Injections, Subcutaneous; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Humoral theory of transplantation: some hot topics.
Topics: Antibodies; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Boronic Acids; Bortezomib; Complement C4b; Graft Rejection; Humans; Isoantibodies; Peptide Fragments; Pyrazines; Rituximab; Transplantation | 2013 |
New advances in the diagnosis and treatment of POEMS syndrome.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Castleman Disease; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease Management; Drug Therapy, Combination; Genes, Immunoglobulin; Humans; Hypertension, Pulmonary; Lenalidomide; Melphalan; Osteosclerosis; Peripheral Blood Stem Cell Transplantation; Plasma Cells; POEMS Syndrome; Prognosis; Pyrazines; Severity of Illness Index; Symptom Assessment; Thalidomide; Transplantation, Autologous; Vascular Endothelial Growth Factor A | 2013 |
[Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
Topics: Amyloidosis; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Humans; Immunoglobulin Light-chain Amyloidosis; Immunosuppressive Agents; Lenalidomide; Pyrazines; Thalidomide | 2013 |
Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Doxorubicin; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Vincristine | 2013 |
Molecular pathogenesis of multiple myeloma: basic and clinical updates.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Chromosomes, Human; Cyclin D; Disease-Free Survival; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin M; Incidence; Multiple Myeloma; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Pyrazines; ras Proteins; Risk Factors; Sex Factors; Somatic Hypermutation, Immunoglobulin; Survival Rate; Translocation, Genetic; Trisomy; United States | 2013 |
Continuous treatment with new agents for newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2013 |
[Proteasome inhibitors in treatment of multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines | 2013 |
Clinical and marketed proteasome inhibitors for cancer treatment.
Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Lactones; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Threonine | 2013 |
Bortezomib for the treatment of previously untreated multiple myeloma.
Topics: Boronic Acids; Bortezomib; Drug Evaluation; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Remission Induction | 2013 |
New oxaliplatin-based combinations in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes | 2003 |
Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Cryoglobulinemia; Female; Humans; Pyrazines; Rituximab; Treatment Failure; Treatment Outcome; Vasculitis | 2013 |
Boron chemicals in diagnosis and therapeutics.
Topics: Boron Compounds; Boron Neutron Capture Therapy; Boronic Acids; Bortezomib; Fluorescent Dyes; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species | 2013 |
Therapeutic strategies for the treatment of multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeostasis; Humans; Immune System; Immunotherapy; Lenalidomide; Multiple Myeloma; Oligopeptides; Prognosis; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Thalidomide | 2013 |
Diagnosis and therapy of multiple myeloma.
Topics: Age Factors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide | 2013 |
Bortezomib in plasmablastic lymphoma: a case report and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Large-Cell, Immunoblastic; Male; Middle Aged; Pyrazines; Treatment Outcome | 2013 |
Current treatments for renal failure due to multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney Transplantation; Multiple Myeloma; Pyrazines; Renal Insufficiency | 2013 |
Effects of bortezomib on the immune system: a focus on immune regulation.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immune System; Multiple Myeloma; Pyrazines | 2013 |
Safety and effectiveness of low-dose lenalidomide therapy for multiple myeloma complicated with bortezomib-associated interstitial pneumonia.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunologic Factors; Lenalidomide; Lung Diseases, Interstitial; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
Stringent complete remission of primary plasma cell leukemia with reduced-dose bortezomib, lenalidomide and dexamethasone: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Remission Induction; Thalidomide | 2013 |
[Thalidomide in the treatment of multiple myeloma: focus on combination with bortezomib].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Multiple Myeloma; Polyneuropathies; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
[Treatment for POEMS syndrome with subcutaneous administration of bortezomib followed by autologous peripheral blood stem cell transplantation: a case report and literatures review].
Topics: Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Pyrazines; Transplantation, Autologous | 2013 |
The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma.
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines | 2013 |
[Peripheral neuropathy induced by anticancer drugs].
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cold Temperature; Drugs, Chinese Herbal; Humans; Hyperalgesia; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Sensation Disorders; Vincristine; Vitamin B 12 | 2013 |
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Double-Blind Method; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2013 |
[Multiple myeloma].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Oligopeptides; Prognosis; Pyrazines; Thalidomide | 2013 |
Management of double-refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Retreatment; Thalidomide | 2013 |
Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Rate | 2013 |
Bortezomib and lenalidomide as front-line therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Odds Ratio; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2014 |
Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2013 |
Second autologous transplant as salvage therapy in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Interferon-alpha; Maintenance Chemotherapy; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Reoperation; Retrospective Studies; Salvage Therapy; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2013 |
Clinical translation in multiple myeloma: from bench to bedside.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Humans; Mice; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2013 |
Initial treatment of transplant candidates with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Evidence-Based Medicine; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2013 |
New developments in post-transplant maintenance treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Glucocorticoids; Humans; Lenalidomide; Multiple Myeloma; Postoperative Period; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Role of consolidation therapy in transplant eligible multiple myeloma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consolidation Chemotherapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Multiple myeloma: Defining the high-risk patient and determining the optimal treatment strategy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Oligopeptides; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Thalidomide | 2013 |
Management of antibody-mediated rejection in transplantation.
Topics: Antibodies; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Graft Rejection; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosorbent Techniques; Kidney Transplantation; Plasma Cells; Plasmapheresis; Pyrazines; Rituximab; Splenectomy | 2013 |
Allogeneic transplantation in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Chromosome Aberrations; Gamma Rays; Graft vs Host Disease; Histocompatibility Testing; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Transplantation, Homologous | 2014 |
The effects of bortezomib on bone disease in patients with multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers; Bone and Bones; Bone Density; Bone Diseases; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Evidence-Based Medicine; Humans; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteogenesis; Pyrazines; Signal Transduction | 2014 |
Role of consolidation/maintenance therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Hyperammonemia, resolved by chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Coma; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; Humans; Hyperammonemia; Paraproteinemias; Plasmapheresis; Purpura, Thrombotic Thrombocytopenic; Pyrazines; Respiration, Artificial | 2014 |
Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Autografts; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Remission Induction; Thalidomide; Time Factors; Transplantation Conditioning | 2013 |
Future agents and treatment directions in multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines | 2014 |
The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
Topics: Boronic Acids; Bortezomib; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2014 |
Ibrutinib in B-cell Lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thalidomide; Treatment Outcome | 2014 |
Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Heart Diseases; Humans; Incidence; Neoplasms; Odds Ratio; Pyrazines; Risk | 2014 |
New approaches to management of multiple myeloma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Depsipeptides; Frail Elderly; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Pyrazines; Quality of Life; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Bortezomib-induced acute congestive heart failure: a case report and review of literature.
Topics: Acute Disease; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Heart Failure; Humans; Male; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2014 |
Rodent models of chemotherapy-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents; Axons; Boronic Acids; Bortezomib; Cisplatin; Disease Models, Animal; Mice; Nerve Degeneration; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Rats; Vincristine | 2014 |
Review of bortezomib treatment of antibody-mediated rejection in renal transplantation.
Topics: Boronic Acids; Bortezomib; Graft Rejection; Humans; Isoantibodies; Kidney Transplantation; Pyrazines | 2014 |
[Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma].
Topics: Activating Transcription Factor 3; Activating Transcription Factor 4; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase 5; Cytokines; Dexamethasone; DNA-Binding Proteins; Drug Discovery; Drug Resistance, Neoplasm; Humans; Hydroxamic Acids; Indoles; Kruppel-Like Transcription Factors; Molecular Targeted Therapy; Multiple Myeloma; Nicotinamide Phosphoribosyltransferase; Oligopeptides; Panobinostat; Phosphorylcholine; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Regulatory Factor X Transcription Factors; Toyocamycin; Transcription Factors | 2014 |
[Efficacy of chemotherapy combined with bortezomib for two cases of relapsed/refractory acute lymphoblastic leukemia].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Octreotide; Pancreatitis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Recurrence; Salvage Therapy; Treatment Outcome; Vincristine | 2014 |
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Tumor Microenvironment | 2014 |
[Therapy of Waldenström´s macroglobulinaemia in the year 2014].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Immunologic Factors; Immunosuppressive Agents; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2014 |
Bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasms; Proteasome Inhibitors; Pyrazines | 2014 |
Current and future therapeutic approach for Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Disease Progression; Everolimus; Forecasting; Guillain-Barre Syndrome; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Immunotherapy; Incidence; Lenalidomide; Myelin-Associated Glycoprotein; Protein Kinase Inhibitors; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Thalidomide; Transplantation, Autologous; Treatment Outcome; Waldenstrom Macroglobulinemia; Watchful Waiting | 2014 |
Endoplasmic reticulum stress in malignancy.
Topics: Activating Transcription Factor 6; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; eIF-2 Kinase; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Endoribonucleases; Humans; Neoplasms; Neovascularization, Pathologic; Protein Folding; Protein Serine-Threonine Kinases; Pyrazines; Unfolded Protein Response | 2014 |
Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dexamethasone; Humans; Induction Chemotherapy; Middle Aged; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2014 |
Linking the activity of bortezomib in multiple myeloma and autoimmune diseases.
Topics: Animals; Antineoplastic Agents; Autoimmune Diseases; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines | 2014 |
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Drug Design; Humans; Multiple Myeloma; Neoplasm Staging; Proteasome Inhibitors; Pyrazines | 2014 |
Advanced thyroid cancers: new era of treatment.
Topics: Anilides; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; ErbB Receptors; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Lithium; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinazolines; Stilbenes; Thalidomide; Thyroid Neoplasms | 2014 |
An analysis of the safety profile of proteasome inhibitors for treating various cancers.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Design; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasms; Proteasome Inhibitors; Pyrazines | 2014 |
[Molecular target therapy for non-Hodgkin lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Pyrazines; Rituximab; Signal Transduction | 2014 |
[Proteasome inhibitor].
Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Molecular Targeted Therapy; Neoplasms; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2014 |
Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Hematologic Diseases; Humans; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Pneumonia; Proteasome Inhibitors; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2014 |
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease Progression; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2014 |
The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2015 |
Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Induction Chemotherapy; Multiple Myeloma; Neoadjuvant Therapy; Neutropenia; Peripheral Nervous System Diseases; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Bortezomib-induced peripheral neurotoxicity: an update.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Incidence; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Risk Factors; Severity of Illness Index | 2014 |
Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Humans; Molecular Targeted Therapy; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Signal Transduction; Ubiquitin-Protein Ligase Complexes; Ubiquitin-Protein Ligases; Ubiquitin-Specific Proteases; Ubiquitination | 2014 |
Overcoming bortezomib resistance in multiple myeloma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Mesenchymal Stem Cells; Multiple Myeloma; Protein-Tyrosine Kinases; Pyrazines | 2014 |
Novel agents in CNS myeloma treatment.
Topics: Animals; Blood-Brain Barrier; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature.
Topics: Allografts; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Boronic Acids; Bortezomib; Erythropoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Count; Male; Middle Aged; Plasma Cells; Pyrazines; Recovery of Function | 2015 |
Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence | 2013 |
Current challenges in the management of patients with relapsed/refractory multiple myeloma.
Topics: Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2011 |
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Recurrence | 2011 |
Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney; Multiple Myeloma; Nervous System Diseases; Oligopeptides; Pyrazines; Recurrence; Thalidomide; Venous Thromboembolism | 2011 |
The future of proteasome inhibitors in relapsed/refractory multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Recurrence | 2011 |
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2014 |
Scleromyxedema.
Topics: Boronic Acids; Bortezomib; Humans; Immunoglobulins, Intravenous; Pyrazines; Scleromyxedema; Thalidomide; Treatment Outcome | 2014 |
Melatonin as a proteasome inhibitor. Is there any clinical evidence?
Topics: Animals; Apoptosis; beta Catenin; Boronic Acids; Bortezomib; Caspases; Humans; Melatonin; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2014 |
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Risk Assessment; Thalidomide; Translocation, Genetic | 2014 |
Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Duodenum; Epirubicin; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pyrazines; Remission Induction; Stomach; Thalidomide; Tomography, X-Ray Computed; Vincristine | 2014 |
Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.
Topics: Amitriptyline; Anticonvulsants; Antidepressive Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Carbamazepine; Central Nervous System; Cyclohexanols; Duloxetine Hydrochloride; Epothilones; Humans; Neoplasms; Neuralgia; Oxcarbazepine; Peripheral Nervous System Diseases; Pyrazines; Taxoids; Thalidomide; Thiophenes; Venlafaxine Hydrochloride; Vinca Alkaloids | 2015 |
Bortezomib for the treatment of non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Proteasome Inhibitors; Pyrazines | 2014 |
Pomalidomide for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Thalidomide | 2014 |
[Treatment of adult Ph-negative acute lymphoblastic leukemia].
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Combined Modality Therapy; Consolidation Chemotherapy; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Recurrence; Transplantation Conditioning; Young Adult | 2014 |
[Supportive care in multiple myeloma for continuing anti-myeloma therapies].
Topics: Anemia; Bone Density Conservation Agents; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Diphosphonates; Humans; Hypercalcemia; Kidney Diseases; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2014 |
[Treatment of transplant-eligible symptomatic multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Nitrogen Mustard Compounds; Pyrazines; Remission Induction; Thalidomide; Transplantation Conditioning | 2014 |
[Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Practice Guidelines as Topic; Prednisone; Pyrazines; Risk Factors; Thalidomide | 2014 |
Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Neoplasms; Pyrazines; Treatment Outcome | 2014 |
[Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Topics: Administration, Oral; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide | 2014 |
Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Bacterial Infections; Boronic Acids; Bortezomib; Female; Humans; Immune Tolerance; Male; Middle Aged; Mycoses; Neoplasms; Opportunistic Infections; Pyrazines; Tumor Necrosis Factor-alpha; Virus Diseases | 2014 |
Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
Topics: Age Factors; Amyloidosis; Antineoplastic Agents; Biomarkers; Bone Marrow; Boronic Acids; Bortezomib; Creatinine; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light Chains; Melphalan; Pyrazines; Stem Cell Transplantation; Subcutaneous Fat; Survival Analysis; Troponin T | 2014 |
[Plasma cell leukemia].
Topics: Aged; Antineoplastic Agents; Biomedical Research; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Prognosis; Pyrazines; Rare Diseases; Thalidomide | 2014 |
Current treatment landscape for relapsed and/or refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2015 |
Mantle cell lymphoma: evolving management strategies.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cytarabine; Humans; Lymphoma, Mantle-Cell; Medical Oncology; Mutation; Positron-Emission Tomography; Prognosis; Pyrazines; Rituximab; Treatment Outcome | 2015 |
Targeting the bone marrow microenvironment in multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Plasma Cells; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome; Tumor Microenvironment | 2015 |
You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia.
Topics: Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Survival; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gene Expression; HMGB1 Protein; Humans; Hydroxychloroquine; Leukemia; Leukocytes; Lysosomes; Phagosomes; Pyrazines; Sirolimus | 2015 |
Treatment-related symptom management in patients with multiple myeloma: a review.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Quality of Life; Thalidomide | 2015 |
Biology, prognosis, and therapy of Waldenström Macroglobulinemia.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Everolimus; Humans; Piperidines; Prognosis; Proteasome Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Salvage Therapy; Sirolimus; Stem Cell Transplantation; Waldenstrom Macroglobulinemia | 2015 |
Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Proteasome Inhibitors; Pyrazines | 2015 |
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Europe; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Thalidomide | 2015 |
Role of bone-anabolic agents in the treatment of breast cancer bone metastases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Everolimus; Female; Humans; Oligopeptides; Osteoblasts; Parathyroid Hormone; Proteasome Inhibitors; Pyrazines; Recombinant Fusion Proteins; Sirolimus; Thiophenes; Transforming Growth Factor beta | 2014 |
Waldenstrom macroglobulinemia: prognosis and management.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunoglobulin M; Lenalidomide; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Thalidomide; Waldenstrom Macroglobulinemia | 2015 |
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Benzamides; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Treatment Outcome | 2019 |
Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines | 2021 |
533 trial(s) available for pyrazines and bortezomib
| Article | Year |
|---|---|
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multienzyme Complexes; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Time Factors | 2002 |
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Drug Administration Schedule; Enzyme Inhibitors; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Multienzyme Complexes; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome; United States | 2002 |
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemoglobins; Humans; Male; Middle Aged; Multienzyme Complexes; Multiple Myeloma; Peripheral Nervous System Diseases; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Recurrence | 2003 |
A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Pyrazines; Safety; Treatment Outcome | 2003 |
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cysteine Endopeptidases; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Multienzyme Complexes; Neoplasm Metastasis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome | 2004 |
New developments with bortezomib in treating multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Division; Doxorubicin; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Liposomes; Lymphoma, Non-Hodgkin; Multiple Myeloma; Peripheral Nervous System Diseases; Polyethylene Glycols; Pyrazines; Renal Insufficiency; Treatment Outcome | 2004 |
Phase I study of bortezomib in refractory or relapsed acute leukemias.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Recurrence; Time Factors | 2004 |
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multienzyme Complexes; Neoplasms; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Statistics, Nonparametric | 2004 |
Approval summary for bortezomib for injection in the treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Approval; Female; Humans; Male; Middle Aged; Models, Chemical; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Time Factors; United States; United States Food and Drug Administration | 2004 |
Phase II trial of bortezomib for patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Female; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Pyrazines; Treatment Outcome | 2004 |
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoid Tumor; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome | 2004 |
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Protease Inhibitors; Pyrazines; Recurrence; Survival Rate | 2004 |
Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma.
Topics: Boronic Acids; Bortezomib; Cost-Benefit Analysis; Delphi Technique; Economics, Pharmaceutical; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2004 |
Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).
Topics: Biological Availability; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasms; Probability; Proportional Hazards Models; Proteasome Inhibitors; Pulse Therapy, Drug; Pyrazines; Risk Assessment; Salvage Therapy; Survival Rate; Treatment Outcome | 2004 |
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Protease Inhibitors; Pyrazines; Survival Rate; Treatment Outcome | 2005 |
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Protease Inhibitors; Pyrazines | 2005 |
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Female; Hematologic Neoplasms; Humans; Liposomes; Male; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2005 |
Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prostatic Neoplasms; Pyrazines; Taxoids | 2004 |
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Drug Administration Schedule; Fatigue; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2005 |
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; I-kappa B Proteins; Male; Middle Aged; Nausea; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Thrombocytopenia; Treatment Outcome; Tumor Suppressor Proteins; Vomiting | 2005 |
A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Proteasome Inhibitors; Pyrazines; Skin Neoplasms; Survival Rate; Treatment Failure | 2005 |
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Treatment Outcome | 2005 |
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Stem Cell Transplantation; Survival Analysis; Treatment Outcome | 2005 |
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Follow-Up Studies; Hematologic Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Platelet Count; Protease Inhibitors; Pyrazines; Recurrence; Survival Rate | 2005 |
Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Herpes Zoster; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Time Factors; Treatment Outcome | 2005 |
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome | 2005 |
A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Carbonic Anhydrase IX; Carbonic Anhydrases; Colorectal Neoplasms; Disease Progression; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Liver; Male; Microcirculation; Middle Aged; Neoplasm Metastasis; Neoplasm Transplantation; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Serine; Time Factors; Treatment Outcome; Tumor Suppressor Protein p53 | 2005 |
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazines; Survival Analysis; Treatment Outcome | 2005 |
Proteasome inhibitor for treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Pyrazines; Recurrence; Survival Analysis; Treatment Outcome | 2005 |
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Mice; Mice, Inbred BALB C; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Risk Factors; Thrombocytopenia; Treatment Outcome | 2005 |
A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Korea; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pilot Projects; Pyrazines; Survival Analysis; Thrombocytopenia; Time Factors | 2005 |
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Leukopenia; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Thrombocytopenia; Transplantation, Homologous | 2006 |
Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrazines | 2005 |
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lymphoma; Male; Middle Aged; Neoplasms; Peripheral Nervous System; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2005 |
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Time Factors; Treatment Outcome | 2005 |
APEX (Assessment of Proteasome inhibition for Extending remissions) trial: phase III randomized, multicenter, placebo-controlled trial to evaluate the efficacy and safety of bortezomib versus dexamethasone in patients with recurrent or treatment-resistant
Topics: Boronic Acids; Bortezomib; Clinical Protocols; Dexamethasone; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Patient Selection; Protease Inhibitors; Pyrazines; Recurrence; Salvage Therapy | 2003 |
Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Treatment Outcome | 2006 |
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.
Topics: Adult; Aged; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pleural Neoplasms; Protease Inhibitors; Pyrazines; Receptors, Estrogen; Receptors, Progesterone; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome | 2006 |
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Drug Synergism; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2006 |
Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Europe; Female; Humans; Male; Middle Aged; Multiple Myeloma; Patient Satisfaction; Predictive Value of Tests; Prognosis; Pyrazines; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2006 |
Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Hodgkin Disease; Humans; Male; Middle Aged; Pyrazines; Recurrence; Stem Cell Transplantation; Treatment Outcome | 2006 |
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Time Factors; Treatment Outcome | 2006 |
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Taxoids; Treatment Outcome | 2006 |
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cytokines; Doxorubicin; Female; Humans; Lymphoma; Male; Middle Aged; Pyrazines; Recurrence; Tumor Necrosis Factor-alpha | 2006 |
Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; CD3 Complex; Chronic Disease; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Herpes Zoster; Humans; Leukopenia; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Remission Induction; Stem Cell Transplantation; Thrombocytopenia; Transplantation, Homologous | 2006 |
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines | 2006 |
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Carboplatin; Disease Progression; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome | 2007 |
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Disease-Free Survival; Humans; Immunophenotyping; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Prednisone; Pyrazines | 2006 |
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Thalidomide | 2006 |
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy; Treatment Outcome | 2006 |
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Protease Inhibitors; Pyrazines; Treatment Outcome; Vidarabine | 2006 |
Dexamethasone reduces the risk of bortezomib-induced pulmonary complications in Japanese myeloma patients.
Topics: Adult; Aged; Anti-Inflammatory Agents; Asian People; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Japan; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Transplantation, Homologous | 2006 |
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
Topics: Aged; Boronic Acids; Bortezomib; Drug Hypersensitivity; Female; Humans; Logistic Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Protease Inhibitors; Pyrazines; Skin; Skin Diseases, Vascular; Treatment Outcome | 2006 |
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Middle Aged; Multiple Myeloma; Osteoblasts; Osteocalcin; Osteolysis; Protease Inhibitors; Pyrazines | 2006 |
A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Survival Rate; Treatment Outcome | 2007 |
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pyrazines; Survival Analysis; Urologic Neoplasms; Urothelium | 2007 |
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2006 |
Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Survival Rate | 2006 |
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2006 |
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; France; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous | 2006 |
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Taxoids; Treatment Outcome; United States | 2006 |
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Proteasome Inhibitors; Pyrazines | 2006 |
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Cohort Studies; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Recurrence; Survival Analysis | 2007 |
Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.
Topics: Aged; Boronic Acids; Bortezomib; Doxorubicin; Drug Therapy, Combination; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Time Factors; Treatment Outcome | 2007 |
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Tolerance; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Safety; Salvage Therapy; Thalidomide | 2007 |
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
Topics: Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Models, Biological; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Predictive Value of Tests; Prospective Studies; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2007 |
Targeting aurora kinases as therapy in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Aurora Kinases; Boronic Acids; Bortezomib; Cell Line, Transformed; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Activation; Extracellular Matrix Proteins; G2 Phase; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Silencing; Hematopoietic Stem Cells; Histones; Humans; Hyaluronan Receptors; Interleukin-6; Lymphocytes; Multiple Myeloma; Mutation; Phosphorylation; Ploidies; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyrazines | 2007 |
Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2006 |
Bortezomib-induced tumor lysis syndrome in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Chromosome Deletion; Dexamethasone; Female; Humans; Male; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Treatment Outcome; Tumor Lysis Syndrome | 2006 |
Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Docetaxel; Dose-Response Relationship, Drug; Humans; Interleukin-6; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines; Taxoids | 2007 |
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.
Topics: Adolescent; Antineoplastic Agents; Boronic Acids; Bortezomib; Child; Child, Preschool; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Humans; I-kappa B Kinase; Immunoblotting; Infant; Leukemia; Male; Maximum Tolerated Dose; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines | 2007 |
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Boronic Acids; Bortezomib; Canada; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Probability; Protease Inhibitors; Pyrazines; Risk Assessment; Salvage Therapy; Severity of Illness Index; Survival Rate; Treatment Outcome; Waldenstrom Macroglobulinemia | 2007 |
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence; Survival Analysis; Treatment Failure; Treatment Outcome | 2007 |
Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclosporine; Drug Interactions; Humans; Immunosuppressive Agents; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Pyrazines; Transplantation, Homologous | 2007 |
Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Multiple Myeloma; Neoplasm Proteins; Ploidies; Pyrazines; Recurrence; Survival Rate | 2007 |
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Diploidy; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Multigene Family; Multiple Myeloma; Prognosis; Protein Biosynthesis; Pyrazines; Trisomy | 2007 |
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Small Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Probability; Pyrazines; Remission Induction; Risk Assessment; Survival Analysis | 2006 |
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Bone Marrow; Boronic Acids; Bortezomib; Cisplatin; Creatinine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2007 |
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chi-Square Distribution; Dexamethasone; Disease Progression; Disease-Free Survival; Fatigue; Glucocorticoids; Humans; Multiple Myeloma; Nausea; Neutropenia; Pyrazines; Risk; Thrombocytopenia | 2007 |
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Hypercalcemia; Kidney Failure, Chronic; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Proteinuria; Pyrazines; Thalidomide; Treatment Outcome; Vincristine | 2007 |
Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hodgkin Disease; Humans; Male; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Treatment Failure | 2007 |
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Differentiation; Cell Proliferation; Cell Survival; Cytotoxins; Dexamethasone; Dose-Response Relationship, Drug; Interleukin-6; Lenalidomide; Ligands; Macrophage Colony-Stimulating Factor; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Neoplasm Transplantation; Osteoclasts; Phosphorylcholine; Pyrazines; RANK Ligand; Stromal Cells; Thalidomide; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2007 |
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Humans; Immunoglobulin M; Male; Middle Aged; Pyrazines; Recurrence; Time Factors; Treatment Outcome; Waldenstrom Macroglobulinemia | 2007 |
Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Boronic Acids; Bortezomib; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrazines; Taxoids; Treatment Outcome | 2007 |
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2007 |
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines | 2007 |
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2007 |
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.
Topics: Adult; Boronic Acids; Bortezomib; Disease Progression; Female; Hodgkin Disease; Humans; Male; Middle Aged; Pyrazines; Salvage Therapy; Survival Analysis; Treatment Failure | 2007 |
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chi-Square Distribution; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Survival Rate | 2007 |
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2007 |
First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma.
Topics: Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Salvage Therapy; Simvastatin | 2007 |
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines | 2007 |
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Follow-Up Studies; Humans; Multiple Myeloma; Pyrazines; Recurrence; Time Factors; Treatment Outcome | 2007 |
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Mycosis Fungoides; Protease Inhibitors; Pyrazines; Recurrence; Remission Induction; Skin Neoplasms; Treatment Outcome | 2007 |
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Linear Models; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous | 2007 |
[Velcade in multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2007 |
Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteogenesis; Protease Inhibitors; Pyrazines; Treatment Outcome | 2007 |
Bortezomib for the treatment of mantle cell lymphoma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Approval; Female; Humans; Lymphoma, Mantle-Cell; Male; Prospective Studies; Pyrazines; United States; United States Food and Drug Administration | 2007 |
Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prospective Studies; Proteasome Inhibitors; Pyrazines | 2008 |
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines; Risk Assessment; Survival Rate; Treatment Outcome | 2007 |
A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Female; Humans; Middle Aged; Protease Inhibitors; Pyrazines; Treatment Outcome | 2007 |
Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2008 |
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pyrazines; Survival Rate; Treatment Outcome | 2007 |
Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Celecoxib; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Pyrazines; Pyrazoles; Sulfonamides | 2007 |
Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Drug Approval; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; United States | 2007 |
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Pemetrexed; Pyrazines; Survival Analysis | 2007 |
Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Electrophoresis; Female; Humans; Immunoglobulin Light Chains; Lactate Dehydrogenases; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Recurrence | 2007 |
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; California; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Neutropenia; Proteasome Inhibitors; Pyrazines; Thrombocytopenia; Treatment Outcome | 2008 |
Bortezomib inhibits osteoclast activity in patients with multiple myeloma.
Topics: Adult; Antineoplastic Agents; Blood Component Removal; Boronic Acids; Bortezomib; Combined Modality Therapy; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Melphalan; Multiple Myeloma; Osteoclasts; Patient Selection; Pyrazines; Stem Cell Transplantation; Transplantation, Autologous | 2007 |
Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin.
Topics: Alleles; alpha 1-Antitrypsin; Animals; Antineoplastic Agents; Antithrombins; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Case-Control Studies; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Endoplasmic Reticulum; Factor Xa Inhibitors; Fibrinogen; Humans; Immunohistochemistry; Injections, Intravenous; Leukocyte Elastase; Liver; Liver Neoplasms; Male; Mice; Molecular Chaperones; Multiple Myeloma; Proteasome Inhibitors; Proteins; Pyrazines; Serpins; Ubiquitin | 2008 |
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Survival Analysis; Treatment Outcome | 2008 |
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Hematologic Diseases; Humans; Maximum Tolerated Dose; Peripheral Nervous System Diseases; Pyrazines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Transitional Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Middle Aged; Protease Inhibitors; Pyrazines; Salvage Therapy; Treatment Failure; Urologic Neoplasms | 2008 |
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide | 2008 |
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Epidemiologic Methods; Female; Gene Expression Profiling; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Remission Induction; Treatment Outcome | 2008 |
Bortezomib therapy in myelofibrosis: a phase II clinical trial.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Primary Myelofibrosis; Pyrazines | 2008 |
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cohort Studies; Cytarabine; Female; Gene Expression Profiling; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Pyrazines; Tissue Distribution; Treatment Outcome | 2008 |
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karnofsky Performance Status; Male; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Survival Analysis | 2008 |
A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Doxorubicin; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasms; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Salvage Therapy; Treatment Outcome; Ubiquitination | 2008 |
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy | 2008 |
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Doxorubicin; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasms; Polyethylene Glycols; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Treatment Outcome | 2008 |
Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Survival Analysis; Treatment Outcome | 2008 |
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pyrazines | 2008 |
The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Liposomes; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2008 |
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2008 |
Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Cardia; Disease Progression; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Paclitaxel; Pyrazines; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2008 |
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.
Topics: Adult; Aged; Alopecia; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Belgium; Boronic Acids; Bortezomib; Breast Neoplasms; Breast Neoplasms, Male; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Pyrazines; Spain; Taxoids; Treatment Outcome; United Kingdom; Vomiting | 2008 |
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thrombocytopenia | 2008 |
Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Pyrazines; Survival Rate | 2008 |
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Proteasome Endopeptidase Complex; Pyrazines | 2008 |
Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Factor V; Female; Hemostasis; Humans; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Platelet Aggregation; Protein C; Pyrazines; Recurrence; Treatment Outcome | 2008 |
Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Evaluation; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Survival Analysis | 2008 |
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
Topics: Antineoplastic Agents; B-Cell Activating Factor; Bone Remodeling; Bone Resorption; Boronic Acids; Bortezomib; Cathepsin K; Cathepsins; Cells, Cultured; Chemokine CCL3; Humans; Integrin alphaVbeta3; Lenalidomide; Multiple Myeloma; Osteoclasts; Osteoprotegerin; Proto-Oncogene Proteins; Pyrazines; RANK Ligand; Thalidomide; Trans-Activators; Transcription Factor AP-1; Tumor Necrosis Factor Ligand Superfamily Member 13 | 2008 |
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Thrombocytopenia | 2009 |
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Pyrazines; Treatment Outcome | 2008 |
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclophosphamide; Female; Glucocorticoids; Humans; Male; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis | 2008 |
[Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Constipation; Cyclophosphamide; Dexamethasone; Dizziness; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide; Treatment Outcome | 2008 |
[Bortezomib-based combination therapy for newly diagnosed multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Treatment Outcome; Vincristine | 2008 |
Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, T-Cell; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Proteasome Endopeptidase Complex; Pyrazines; Vincristine | 2008 |
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Herpes Zoster; Humans; Multiple Myeloma; Pyrazines; Recurrence; Virus Activation | 2008 |
[Clinical study of bortezomib in combination with dexamethasone for the treatment of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Time Factors; Treatment Outcome | 2008 |
Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Routes; Humans; Middle Aged; Multiple Myeloma; Prospective Studies; Proteasome Inhibitors; Pyrazines | 2008 |
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone and Bones; Bone Remodeling; Boronic Acids; Bortezomib; Cytokines; Dexamethasone; Female; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Neovascularization, Physiologic; Pyrazines; Recurrence; Survival Rate; Thalidomide | 2008 |
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epidemiologic Methods; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome | 2008 |
An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Colorectal Neoplasms; Disease-Free Survival; DNA Repair; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Pyrazines; Survival Rate | 2009 |
Update on recent developments for patients with newly diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2008 |
Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Interactions; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome; Young Adult | 2008 |
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Recurrence; Treatment Outcome | 2008 |
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Flow Cytometry; Histone Acetyltransferases; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; NF-kappa B; Nuclear Receptor Coactivator 3; Phosphorylcholine; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; RNA Interference; Trans-Activators | 2008 |
Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Herpesvirus 3, Human; Humans; Killer Cells, Natural; Lymphocyte Subsets; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Survival Analysis; T-Lymphocytes, Cytotoxic; Transplantation, Autologous; Treatment Outcome; Virus Activation | 2009 |
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Recurrence; Treatment Outcome | 2009 |
[Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines; Treatment Outcome | 2008 |
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Survival Rate; Treatment Outcome | 2009 |
Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Boronic Acids; Bortezomib; Dexamethasone; Epirubicin; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome | 2009 |
Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Pyrazines; Radiotherapy; Temozolomide; Treatment Outcome | 2009 |
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Survival Rate; Treatment Outcome | 2009 |
[Experience with velcade administration in multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Multiple; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2008 |
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Protocols; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Statistics, Nonparametric; Survival Rate | 2009 |
Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Statistics, Nonparametric; Thrombocytopenia | 2009 |
A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Drug Administration Schedule; Ethylenediamines; Humans; Maximum Tolerated Dose; Multiple Myeloma; Organophosphonates; Platelet Count; Pyrazines; Radioisotopes; Recurrence; Samarium | 2009 |
Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Electrophysiology; Humans; Middle Aged; Multiple Myeloma; Neurotoxicity Syndromes; Pain Measurement; Peripheral Nervous System Diseases; Pyrazines | 2008 |
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phas
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Female; Humans; Lymphoma, Mantle-Cell; Male; Neoplasm Recurrence, Local; Protease Inhibitors; Pyrazines; Remission Induction | 2009 |
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Treatment Outcome | 2009 |
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Boronic Acids; Bortezomib; Humans; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Treatment Outcome | 2009 |
[Bortezomib combined with other drugs for treating 60 cases of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2009 |
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cystatin C; Female; Humans; Immunoassay; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Pyrazines; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Nervous System Diseases; Prospective Studies; Protease Inhibitors; Pyrazines; Remission Induction | 2009 |
A phase II study of bortezomib in patients with MALT lymphoma.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Diarrhea; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Nausea; Nervous System Diseases; Pyrazines; Treatment Outcome | 2009 |
A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Salvage Therapy; Survival Analysis | 2009 |
Bortezomib in relapsed multiple myeloma: results of a non-interventional study by office-based haematologists.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Germany; Hematology; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Physicians' Offices; Pyrazines; Secondary Prevention; Treatment Outcome | 2009 |
Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Interactions; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Pyrazines | 2009 |
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
Topics: Aged; Anti-Ulcer Agents; Antineoplastic Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Boronic Acids; Bortezomib; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Interactions; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasms; Omeprazole; Proton Pump Inhibitors; Pyrazines | 2009 |
Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cetuximab; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Humans; Immunohistochemistry; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; NF-kappa B; Pyrazines; Young Adult | 2009 |
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Remission Induction; Salvage Therapy; Steroids; Thalidomide; Treatment Outcome | 2009 |
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.
Topics: Adult; Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pyrazines; Treatment Outcome | 2009 |
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Viscosity; Bone Marrow Neoplasms; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematocrit; Herpes Zoster; Humans; Immunoglobulin M; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Count; Pyrazines; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia | 2009 |
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Early Termination of Clinical Trials; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protease Inhibitors; Pyrazines; Treatment Failure; Tumor Burden; Venous Thrombosis | 2010 |
Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Early Termination of Clinical Trials; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Postoperative Complications; Protease Inhibitors; Pyrazines; Radiotherapy; Respiratory Insufficiency | 2010 |
Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Prednisone; Pyrazines; Rituximab; Vincristine | 2009 |
Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Analysis; Treatment Outcome | 2009 |
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Protease Inhibitors; Pyrazines | 2009 |
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nervous System Diseases; Neutropenia; Opportunistic Infections; Pyrazines; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2009 |
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Vorinostat | 2009 |
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.
Topics: Activities of Daily Living; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Neuralgia; Peripheral Nervous System Diseases; Pyrazines; Risk Factors | 2010 |
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Therapy, Combination; Dyspnea; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Pyrazines; Survival Analysis; Thrombocytopenia | 2010 |
Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Docetaxel; Female; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Taxoids | 2009 |
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Young Adult | 2009 |
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Living Donors; Male; Methotrexate; Pyrazines; Stem Cell Transplantation; Survival Rate; Tacrolimus; Time Factors; Transplantation Conditioning; Transplantation, Homologous | 2009 |
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Case-Control Studies; Female; Flow Cytometry; Gene Expression Profiling; Humans; Immunohistochemistry; Membrane Glycoproteins; Mice; Mice, SCID; Multiple Myeloma; Pyrazines; Transplantation, Heterologous | 2009 |
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome | 2009 |
Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence | 2009 |
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Statistics as Topic; Transplantation, Autologous; Treatment Outcome | 2010 |
Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Stem Cell Transplantation; Survival Analysis | 2009 |
Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Feasibility Studies; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Middle Aged; Pyrazines; Rituximab; Treatment Outcome | 2009 |
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cytokines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Neutropenia; Paclitaxel; Proliferating Cell Nuclear Antigen; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2010 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2009 |
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; NF-kappa B; Pyrazines; Recurrence; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Renal Insufficiency; Treatment Outcome | 2009 |
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Melphalan; Multiple Myeloma; Multivariate Analysis; Prednisone; Prognosis; Pyrazines; Treatment Outcome | 2009 |
Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cohort Studies; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2010 |
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Demography; Disease Progression; Dose-Response Relationship, Drug; Female; France; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2010 |
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2010 |
Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Secondary Prevention; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Treatment Outcome | 2010 |
Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Combined Modality Therapy; Constipation; Cyclophosphamide; Dexamethasone; Diarrhea; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infections; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Transplantation, Autologous; Treatment Outcome | 2010 |
Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multip
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Korea; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Prednisolone; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Female; Hepatocyte Growth Factor; Humans; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Pyrazines; Recurrence; Thrombospondins | 2010 |
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemokines; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Skin Neoplasms; Temozolomide; Treatment Outcome | 2010 |
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Polyethylene Glycols; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome | 2010 |
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Pyrazines; Recurrence; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.
Topics: Antifungal Agents; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Prospective Studies; Pyrazines | 2009 |
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Pyrazines; Risk Factors; Thalidomide | 2010 |
Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Colorado; Combined Modality Therapy; Diarrhea; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Infusions, Intravenous; Lymphopenia; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Palliative Care; Pyrazines; Radiography | 2010 |
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunoglobulin M; Male; Middle Aged; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Rituximab; Survival Analysis; Waldenstrom Macroglobulinemia | 2010 |
Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Middle Aged; Neoplasms; Pyrazines | 2010 |
Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Interleukin-6; Male; Middle Aged; Multiple Myeloma; Neuralgia; Prospective Studies; Pyrazines; Th2 Cells | 2010 |
Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome | 2010 |
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2011 |
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chi-Square Distribution; Dexamethasone; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Genes, Immunoglobulin Heavy Chain; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Polymerase Chain Reaction; Pyrazines; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome; Tumor Burden | 2010 |
Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Europe; Female; Humans; Israel; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2010 |
A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Therapy, Combination; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Pyrazines; Rectal Neoplasms | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Fatigue; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Pain; Pyrazines; Remission Induction; Sensation Disorders; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome | 2010 |
Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Multiple Myeloma; Neoplasm Staging; Pyrazines | 2010 |
Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial.
Topics: Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Leukapheresis; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Transplantation, Autologous | 2010 |
A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome; Vincristine | 2010 |
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; Cells, Cultured; Female; Glucocorticoids; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteogenesis; Osteolysis; Pyrazines | 2010 |
Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Treatment Outcome | 2010 |
Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bone Marrow; Boronic Acids; Bortezomib; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Primary Myelofibrosis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Risk; Salvage Therapy; Thrombocytopenia; Treatment Failure; Young Adult | 2010 |
Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Melphalan; Multiple Myeloma; Pyrazines; Treatment Outcome | 2010 |
A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrazines; Skin Neoplasms | 2010 |
Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase Inhibitor p27; Female; Humans; Intracellular Signaling Peptides and Proteins; Lymphoma, Mantle-Cell; Male; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; NF-kappa B; Protease Inhibitors; Pyrazines; Stomach Neoplasms; Treatment Outcome | 2011 |
Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Treatment Outcome | 2010 |
Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Boronic Acids; Bortezomib; Child; Child, Preschool; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protease Inhibitors; Pyrazines; Salvage Therapy; Treatment Outcome; Vincristine | 2010 |
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; HSP70 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukocyte Count; Male; Middle Aged; Multiple Myeloma; Neutrophils; Platelet Count; Pyrazines; Recurrence; Treatment Outcome | 2010 |
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Prednisone; Prognosis; Pyrazines; Remission Induction; Time Factors; Treatment Outcome | 2010 |
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Pyrazines; Rituximab; Time Factors; Waldenstrom Macroglobulinemia | 2010 |
Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Autocrine Communication; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Female; Humans; Interleukin-10; Interleukin-6; Janus Kinases; Lymphoma, Mantle-Cell; Male; Middle Aged; Phosphorylation; Protease Inhibitors; Pyrazines; Receptors, Antigen, B-Cell; Signal Transduction; STAT3 Transcription Factor | 2010 |
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Pyrazines; Rituximab; Vincristine | 2010 |
Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide; Treatment Outcome; Young Adult | 2010 |
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Pyrazines; Rituximab; Vincristine | 2010 |
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Protease Inhibitors; Pyrazines; Risk Assessment; Risk Factors; Spain; Thalidomide; Time Factors; Treatment Outcome | 2010 |
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Transplantation Conditioning | 2010 |
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Pyrazines; Recurrence; Treatment Failure; Treatment Outcome | 2011 |
Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare®) for chemotherapy-induced peripheral neuropathy.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Pain Measurement; Peripheral Nervous System Diseases; Pilot Projects; Pyrazines; Taxoids; Transcutaneous Electric Nerve Stimulation; Treatment Outcome | 2010 |
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chi-Square Distribution; Dexamethasone; Disease-Free Survival; Doxorubicin; Europe; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Neoplasm Staging; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Treatment Outcome; Vincristine | 2010 |
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Europe; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Prospective Studies; Protease Inhibitors; Pyrazines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2010 |
A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2010 |
An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Asia; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; North America; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome; Young Adult | 2012 |
[Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Secondary Prevention | 2010 |
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chi-Square Distribution; Europe; Gene Expression Profiling; Gene Frequency; Genetic Predisposition to Disease; Humans; Middle Aged; Multiple Myeloma; Neoplasm Staging; Odds Ratio; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Prospective Studies; Pyrazines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vincristine; Young Adult | 2010 |
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Risk Factors | 2011 |
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Pyrazines; Rituximab; Survival Analysis; Treatment Outcome; Waldenstrom Macroglobulinemia | 2010 |
A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease Progression; Disease-Free Survival; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Pyrazines; Time Factors; Transplantation, Autologous; Treatment Failure; United States | 2012 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.
Topics: ADP-ribosyl Cyclase 1; Aged; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Gene Expression Profiling; Humans; Interferon Regulatory Factors; Lymphoma, Mantle-Cell; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Plasma Cells; Proteasome Endopeptidase Complex; Pyrazines | 2011 |
Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Erythroid Cells; Female; Fever; Gene Expression; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thrombocytopenia; Treatment Outcome; WT1 Proteins | 2011 |
Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Cell-Derived Microparticles; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Thromboplastin; Venous Thrombosis; Vincristine | 2011 |
[The efficacy and safety of PAD and VAD regimens for untreated multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome; Vincristine | 2010 |
Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Calcium-Calmodulin-Dependent Protein Kinases; Death-Associated Protein Kinases; Dexamethasone; Disease-Free Survival; Factor Analysis, Statistical; Humans; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous | 2010 |
Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasms; Pyrazines | 2011 |
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Remission Induction; Reoperation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2010 |
Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Polyethylene Glycols; Pyrazines; Survival Analysis; Treatment Outcome | 2010 |
Successful treatment with a modified bortezomib schedule of weekly and longer intervals for patients with refractory/resistance multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Survival Analysis; Treatment Outcome | 2011 |
[Therapeutic efficacy of bortezomib-based chemotherapy on 40 patients with multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome; Young Adult | 2010 |
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Pyrazines; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2011 |
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chymotrypsin; Farnesyltranstransferase; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Quinolones | 2011 |
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Pyrazines; Rituximab | 2011 |
Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Disease Progression; Doxorubicin; Female; Head and Neck Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrazines; Recurrence; Survival Analysis | 2011 |
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; California; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pyrazines; Taxoids | 2011 |
The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo.
Topics: Adult; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Graft Rejection; Humans; Incidence; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Plasma Cells; Plasma Exchange; Prospective Studies; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Tissue Donors; Treatment Outcome | 2011 |
Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Receptor, IGF Type 1; Survival Rate; Tissue Distribution; Treatment Outcome | 2011 |
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Canada; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphoma, Mantle-Cell; Male; Medical Oncology; Middle Aged; National Health Programs; Pyrazines; Recurrence; Societies, Medical | 2011 |
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Humans; Multiple Myeloma; Myeloma Proteins; Polyethylene Glycols; Pyrazines; Recurrence | 2011 |
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Sirolimus | 2011 |
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
Topics: Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Fever; Follow-Up Studies; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Prednisone; Pyrazines; Recurrence; Rituximab; Treatment Outcome | 2011 |
Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Retrospective Studies; Thalidomide; Transplantation, Autologous | 2012 |
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Diseases; Bone Remodeling; Boronic Acids; Bortezomib; Cell Differentiation; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Osteoblasts; Prednisone; Pyrazines; Radiotherapy, Adjuvant | 2011 |
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agent
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Erythrocyte Transfusion; Female; Hematinics; Humans; Incidence; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Pyrazines; Survival Rate; Thromboembolism | 2011 |
Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-X Protein; Boronic Acids; Bortezomib; Drug Synergism; Female; Histone Deacetylase 6; Histone Deacetylases; HL-60 Cells; Humans; Hydroxamic Acids; I-kappa B Kinase; Jurkat Cells; Leukemia, Myeloid, Acute; Male; Membrane Proteins; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins; Pyrazines; Signal Transduction; Sulfonamides; Transcription Factor RelA; Tubulin; U937 Cells; X-Linked Inhibitor of Apoptosis Protein | 2011 |
The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cohort Studies; Disease Progression; Female; Humans; Immunoglobulin Light Chains; Male; Pyrazines; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia | 2011 |
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Thalidomide; Treatment Outcome | 2011 |
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Piperidines; Pyrazines; Recurrence; Treatment Failure | 2011 |
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
Topics: Alkaline Phosphatase; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Osteogenesis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Treatment Outcome | 2011 |
Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Pyrazines; Recurrence; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome | 2011 |
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Blood Cells; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Europe; Humans; Infusions, Intravenous; Injections, Subcutaneous; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Recurrence; South America; Treatment Outcome | 2011 |
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Multiple Myeloma; Pyrazines; Salvage Therapy | 2011 |
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Pyrazines; Recurrence; Treatment Outcome; Young Adult | 2011 |
Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines | 2011 |
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Lactams, Macrocyclic; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome | 2011 |
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Glucocorticoids; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Protease Inhibitors; Pyrazines; Recurrence | 2011 |
Carfilzomib: a novel second-generation proteasome inhibitor.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Hematologic Neoplasms; Humans; Multiple Myeloma; Neutropenia; Oligopeptides; Proteasome Inhibitors; Protein Binding; Pyrazines; Thrombocytopenia | 2011 |
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Survival Rate; Thalidomide | 2011 |
[The efficacy and safety of bortezomib plus thalidomide in treatment of newly diagnosed multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Time Factors | 2011 |
Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Busulfan; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neutropenia; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2011 |
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Child; Cyclams; Europe; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2011 |
Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; MAP Kinase Signaling System; Maximum Tolerated Dose; Middle Aged; Mitogen-Activated Protein Kinases; Neoplasms; Paclitaxel; Pyrazines; Treatment Outcome | 2011 |
The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Pyrazines; Radiography; Radiopharmaceuticals; Rituximab; Waldenstrom Macroglobulinemia | 2011 |
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Treatment Failure; Treatment Outcome | 2011 |
Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-bas
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Models, Statistical; Multiple Myeloma; Myeloma Proteins; Polyethylene Glycols; Prognosis; Pyrazines; Survival Analysis; Treatment Outcome | 2011 |
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; California; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Survival Rate; Treatment Outcome | 2011 |
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Infusion Pumps; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Staging; Pyrazines; Recurrence; Rituximab; Young Adult | 2011 |
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2011 |
Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Cytokines; Disease Progression; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Protease Inhibitors; Pyrazines; Radiotherapy, Intensity-Modulated; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transcription Factors; Treatment Outcome | 2011 |
Bortezomib (Velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Grading; Pyrazines; Rituximab; Treatment Outcome | 2012 |
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Heart Diseases; Humans; Kidney Diseases; Liver Diseases; Male; Maximum Tolerated Dose; Middle Aged; Paraproteinemias; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Treatment Outcome | 2011 |
Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2012 |
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Multiple Myeloma; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Pyrazines; Risk Factors | 2011 |
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Canada; Cyclophosphamide; Feasibility Studies; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Pyrazines; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Vincristine | 2011 |
Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Radioimmunotherapy; Salvage Therapy; Survival Rate | 2012 |
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Sarcoma, Myeloid; Survival Rate; Thalidomide | 2012 |
VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Peripheral Nervous System Diseases; Proportional Hazards Models; Protease Inhibitors; Pyrazines; Remission Induction; Rituximab; Treatment Outcome; Vincristine | 2011 |
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Analysis; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome | 2011 |
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Induction; Fatigue; Female; Humans; Liver; Lymphopenia; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Pyrazines; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Pilot Projects; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2011 |
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Blood Transfusion, Autologous; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prognosis; Pyrazines; Transplantation Conditioning | 2012 |
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; DNA, Neoplasm; Drug Administration Schedule; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Multiple Myeloma; Ploidies; Prognosis; Pyrazines; Time Factors; Treatment Outcome | 2011 |
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Depsipeptides; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Secondary Prevention; Survival Analysis; Thrombocytopenia | 2011 |
An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2011 |
A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Prospective Studies; Pyrazines | 2011 |
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Induction Chemotherapy; Kidney Diseases; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoadjuvant Therapy; Prednisone; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Female; Graft Rejection; Heart Transplantation; Humans; Immunoglobulins, Intravenous; Infections; Isoantibodies; Male; Middle Aged; Pilot Projects; Plasmapheresis; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Risk Assessment; Risk Factors; Rituximab; Treatment Outcome | 2011 |
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Phosphorylcholine; Pyrazines; Recurrence | 2011 |
Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chlorambucil; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Pyrazines; Rituximab; Treatment Outcome | 2012 |
Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines | 2011 |
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Cytochrome P-450 CYP3A; Dexamethasone; Drug Combinations; Enzyme Induction; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Rifampin | 2011 |
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Brain Neoplasms; Disease Progression; Female; Glioblastoma; Humans; Hydroxamic Acids; Male; Middle Aged; Pyrazines; Survival Analysis; Vorinostat | 2012 |
Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine | 2011 |
A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Boronic Acids; Bortezomib; Breast Neoplasms; Cytokines; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukocytes, Mononuclear; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Tamoxifen | 2012 |
Emergence of central nervous system myeloma in the era of novel agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2012 |
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Cohort Studies; Female; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Smith-Magenis Syndrome; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Young Adult | 2012 |
Preliminary experience with personalized and targeted therapy for pediatric brain tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Boronic Acids; Bortezomib; Brain Neoplasms; Child; Child, Preschool; Curcumin; Disease-Free Survival; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Infant; Male; Niacinamide; Phenylurea Compounds; Pyrazines; Pyridines; Sirolimus; Sorafenib; Survival Rate | 2012 |
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Pyrazines; Survival Rate | 2012 |
Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2012 |
Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Pyrazines; Treatment Outcome; Young Adult | 2012 |
Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with
Topics: Arthritis, Rheumatoid; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Leukocytes, Mononuclear; Mutation; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2012 |
Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemoradiotherapy; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pyrazines; Radiotherapy Dosage; Therapeutics | 2012 |
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Etoposide; Humans; Ifosfamide; Immunotherapy; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Proteasome Endopeptidase Complex; Pyrazines; Recurrence; Rituximab; Time Factors; Treatment Outcome | 2012 |
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Panobinostat; Pyrazines; Recurrence; Remission Induction; Thalidomide; Thrombocytopenia; Treatment Outcome | 2012 |
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2012 |
CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Head and Neck Neoplasms; In Vitro Techniques; Male; Membrane Proteins; Mice; Mice, Nude; Neoplasms, Experimental; Polymerase Chain Reaction; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; Signal Transduction | 2012 |
A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Polyethylene Glycols; Prognosis; Prospective Studies; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide | 2012 |
Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Dosage Calculations; Female; Humans; Liver; Liver Diseases; Male; Middle Aged; Neoplasms; Pyrazines | 2012 |
Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Pancreatic Neoplasms; Panobinostat; Pyrazines | 2012 |
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cross-Over Studies; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Recurrence; Thalidomide | 2012 |
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Thalidomide; Treatment Outcome | 2012 |
Integrated protein quality-control pathways regulate free α-globin in murine β-thalassemia.
Topics: Alpha-Globulins; Animals; Antineoplastic Agents; beta-Thalassemia; Boronic Acids; Bortezomib; Cells, Cultured; Child; Child, Preschool; Erythroid Precursor Cells; Female; Humans; Male; Mice; Mice, Transgenic; Mutation; Nuclear Respiratory Factor 1; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Ubiquitination | 2012 |
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Fanconi Anemia Complementation Group Proteins; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy; Signal Transduction; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2012 |
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Quality of Life; Treatment Outcome | 2012 |
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous | 2012 |
High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bipolar Disorder; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Pyrazines; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2012 |
Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Proteins; Protein Array Analysis; Pyrazines; Recurrence; Treatment Outcome | 2012 |
Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Pyrazines; Survival Rate; Treatment Outcome; United States; Vascular Endothelial Growth Factor A | 2012 |
A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neural Conduction; Prednisone; Pyrazines; Rituximab; Vincristine | 2012 |
The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: an analysis of the Singapore multiple myeloma study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Risk Factors; Singapore; Survival Rate; Time Factors | 2012 |
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Demography; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Pyrazines; Recurrence; Time Factors; Treatment Outcome | 2012 |
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Boronic Acids; Bortezomib; Cell Line, Tumor; Decitabine; Drug Evaluation, Preclinical; Female; Gene Expression Regulation, Leukemic; HEK293 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pyrazines; Treatment Outcome; Validation Studies as Topic | 2012 |
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pyrazines; Survival Analysis; Treatment Outcome | 2012 |
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomi
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Quality of Life; Thyroid Neoplasms; Treatment Failure | 2012 |
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; CA-125 Antigen; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2012 |
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
Topics: Adolescent; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Boronic Acids; Bortezomib; Child; Child, Preschool; Dexamethasone; Doxorubicin; Female; Humans; Infant; Kaplan-Meier Estimate; Male; Opportunistic Infections; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Recurrence; Remission Induction; Treatment Outcome; Vincristine; Young Adult | 2012 |
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Incidence; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Thalidomide | 2012 |
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Injections, Intravenous; Injections, Subcutaneous; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Survival Rate | 2012 |
[Clinical study of bortezomib for treating multiple myeloma with renal impairment].
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency | 2012 |
Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Female; Humans; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous | 2012 |
Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Staging; NF-kappa B; Prednisone; Pyrazines; Vincristine | 2012 |
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Squamous Cell; Cytokines; Disease Progression; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; NF-kappa B; Pyrazines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2013 |
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cells; Thalidomide; Transplantation, Autologous | 2012 |
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Vincristine | 2012 |
Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Proportional Hazards Models; Pyrazines; Treatment Outcome | 2013 |
Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Boronic Acids; Bortezomib; Dexamethasone; DNA Methylation; Doxorubicin; Drug Administration Schedule; Epigenesis, Genetic; Female; Humans; Immunity, Cellular; Lenalidomide; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Prospective Studies; Pyrazines; T-Cell Antigen Receptor Specificity; Thalidomide; Transplantation, Autologous | 2012 |
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Fatigue; Female; Gastrointestinal Neoplasms; Hematologic Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2012 |
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
Topics: Adult; Aged; Antilymphocyte Serum; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Lymphocyte Depletion; Male; Methotrexate; Middle Aged; Pyrazines; Tacrolimus; Unrelated Donors | 2012 |
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Dose-Response Relationship, Drug; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Hydroxamic Acids; Infant; Male; Maximum Tolerated Dose; Neoplasms; Pyrazines; Vorinostat; Young Adult | 2013 |
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Maintenance Chemotherapy; Male; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Remission Induction; Survival Rate; Thalidomide | 2012 |
Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.
Topics: Aged; Boronic Acids; Bortezomib; Disease Progression; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Survival Rate | 2012 |
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Pyrazines; Radioimmunotherapy; Recurrence; Treatment Outcome; Yttrium Radioisotopes | 2013 |
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.
Topics: Adult; Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Melphalan; Middle Aged; Pyrazines; Stem Cell Transplantation | 2013 |
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Humans; Injections, Subcutaneous; Middle Aged; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Recurrence | 2012 |
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Dexamethasone; Drug Resistance, Neoplasm; Gene Frequency; Genotype; Humans; Multiple Myeloma; Polymorphism, Single Nucleotide; Proteasome Endopeptidase Complex; Protein Subunits; Pyrazines; Recurrence; Sequence Analysis, DNA; Survival Analysis; Treatment Outcome | 2012 |
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Tolerance; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Pilot Projects; Proteasome Inhibitors; Pyrazines; Secondary Prevention | 2012 |
Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Drug Synergism; Female; Humans; Hydroxamic Acids; Male; Middle Aged; Multiple Myeloma; Pyrazines; Secondary Prevention; Vorinostat | 2012 |
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Follow-Up Studies; Gene Expression Profiling; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Proteasome Endopeptidase Complex; Pyrazines; Vorinostat | 2012 |
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Pyrazines; Rituximab | 2012 |
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Risk Assessment; Thalidomide | 2013 |
Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Recurrence | 2013 |
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
Topics: Aged; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Drug Synergism; Female; Follow-Up Studies; Histocompatibility Antigens Class II; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Nervous System; Pyrazines; Remission Induction; Survival Analysis; Treatment Outcome | 2013 |
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence; Remission Induction; Siblings; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Unrelated Donors | 2013 |
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Treatment Outcome | 2013 |
A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Creatinine; Dehydration; Drug Resistance, Neoplasm; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Resveratrol; Salvage Therapy; Stilbenes; Treatment Failure; Vomiting | 2013 |
Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Remission Induction; Transplantation, Autologous; Young Adult | 2013 |
Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide | 2013 |
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Peripheral Nervous System Diseases; Pyrazines; Secondary Prevention; Severity of Illness Index; Survival Analysis; Thrombocytopenia | 2013 |
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Neoplasms, Second Primary; Odds Ratio; Prednisone; Proportional Hazards Models; Pyrazines; Risk; Spain; Treatment Outcome | 2013 |
Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen.
Topics: Adipose Tissue; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies | 2013 |
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2012 |
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Electrocardiography; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukemia, Myeloid, Acute; Male; Middle Aged; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Pyrazines; Recurrence; Torsades de Pointes; Treatment Outcome | 2013 |
Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Salvage Therapy; Survival Rate | 2013 |
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Europe; Female; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prospective Studies; Protease Inhibitors; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Treatment Outcome | 2013 |
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Melanoma; Middle Aged; Pyrazines; Radiography; Sarcoma; Treatment Outcome; Young Adult | 2013 |
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; France; Humans; Lenalidomide; Medical Oncology; Middle Aged; Multiple Myeloma; Pyrazines; Societies, Medical; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Pyrroles; Sunitinib; Thyroid Neoplasms | 2013 |
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Filgrastim; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplastic Stem Cells; Pyrazines; Recombinant Proteins; Signal Transduction | 2013 |
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence | 2013 |
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; C-Reactive Protein; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Infection Control; Interleukin-6; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy | 2013 |
Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Lactams, Macrocyclic; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome | 2013 |
Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Pyrazines; Treatment Outcome | 2013 |
[Clinical study of bortezomib in the treatment of multiple myeloma patients with renal failure].
Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency | 2013 |
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Quality of Life; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous | 2013 |
A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Deoxycytidine; Epirubicin; Female; Gastrointestinal Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Proteasome Inhibitors; Pyrazines | 2014 |
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Pyrazines; Treatment Outcome; Vorinostat | 2014 |
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclosporine; Drug Synergism; Female; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Reoperation; Salvage Therapy; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2013 |
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Survival Rate; Thalidomide | 2013 |
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Europe; Female; Humans; Kaplan-Meier Estimate; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Prospective Studies; Pyrazines; Time Factors; Treatment Outcome; Young Adult | 2013 |
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Quinazolines; Retrospective Studies; Sirolimus; Survival; Thiazoles; Treatment Outcome | 2013 |
[Therapeutic efficacy analysis of VD regimen and VAD regimen for multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Vincristine | 2013 |
Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate | 2013 |
Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Boronic Acids; Bortezomib; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Transplantation Conditioning; Transplantation, Autologous | 2013 |
The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
Topics: Administration, Oral; Animals; Anisoles; Antineoplastic Agents; Azepines; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Pyrazines | 2013 |
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Treatment Outcome; Young Adult | 2013 |
Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Boronic Acids; Bortezomib; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Leukocytes, Mononuclear; Neoplasms; Nuclear Receptor Subfamily 4, Group A, Member 1; Proto-Oncogene Proteins c-akt; Pyrazines; Time Factors; Transcription, Genetic; Vorinostat | 2013 |
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Pyrazines; Recurrence; Treatment Outcome | 2013 |
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Panobinostat; Pyrazines | 2013 |
Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Boronic Acids; Bortezomib; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2014 |
Concurrent whole brain radiotherapy and bortezomib for brain metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pyrazines | 2013 |
Pralatrexate pharmacology and clinical development.
Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Depsipeptides; Disease-Free Survival; Drug Approval; Drug Synergism; Gemcitabine; Humans; Lymphoma, T-Cell; Male; Pyrazines; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2013 |
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Creatinine; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Insufficiency; Transplantation, Autologous; Treatment Outcome | 2014 |
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Recurrence; Thalidomide | 2013 |
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Immunoglobulin M; Male; Middle Aged; Peripheral Nervous System Diseases; Pyrazines; Rituximab; Survival Analysis; Treatment Outcome; Waldenstrom Macroglobulinemia | 2013 |
Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Rate | 2013 |
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Hydroxamic Acids; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Panobinostat; Pyrazines | 2013 |
Reasons for non-completion of health related quality of life evaluations in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Boronic Acids; Bortezomib; Child; Child, Preschool; Female; Group Processes; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Niacinamide; Parents; Phenylurea Compounds; Pyrazines; Quality of Life; Self Report; Sorafenib; Surveys and Questionnaires; Survival Analysis; Young Adult | 2013 |
A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Dose-Response Relationship, Drug; Drug Monitoring; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Tumor Burden | 2013 |
Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Mice; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Proteasome Inhibitors; Pyrazines; Receptors, IgG; Recurrence; Rituximab; Treatment Outcome | 2011 |
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Salvage Therapy; Survival Rate; Vorinostat | 2013 |
A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Survival Rate | 2013 |
Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2013 |
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Vorinostat; Young Adult | 2013 |
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Vorinostat | 2014 |
[Efficacy and safety study of subcutaneous injection of bortezomib in the treatment of de novo patients with multiple myeloma].
Topics: Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Injections, Subcutaneous; Multiple Myeloma; Pyrazines; Remission Induction | 2013 |
Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 1; Disease-Free Survival; Female; Follow-Up Studies; Gene Dosage; Humans; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Pyrazines; Survival Rate | 2014 |
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Survival Analysis | 2014 |
Post-transplant cyclophosphamide and bortezomib inhibit dendritic cell maturation and function and alter their IκB and NFκB.
Topics: Antigen Presentation; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cyclophosphamide; Dendritic Cells; Gene Expression Regulation; Graft vs Host Disease; Humans; I-kappa B Proteins; Immunosuppressive Agents; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; NF-kappa B; Postoperative Care; Pyrazines | 2014 |
Randomized controlled pilot study of B cell-targeted induction therapy in HLA sensitized kidney transplant recipients.
Topics: Adult; Animals; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; B-Lymphocytes; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Graft Rejection; HLA Antigens; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Pilot Projects; Postoperative Complications; Prospective Studies; Pyrazines; Rabbits; Renal Insufficiency; Rituximab; Treatment Outcome | 2013 |
A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytokines; Female; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrazines; Recombinant Proteins; Treatment Outcome | 2014 |
Value of novel agents and intensive therapy for patients with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Middle Aged; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Dose-Response Relationship, Drug; GTP Phosphohydrolases; Humans; Membrane Proteins; Multiple Myeloma; Mutation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; ras Proteins; Survival Analysis | 2014 |
[Effect of bortezomib combined with bisphosphonates on bone metabolism index in multiple myeloma].
Topics: Adult; Aged; Boronic Acids; Bortezomib; Diphosphonates; Drug Therapy, Combination; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Multiple Myeloma; Pyrazines; RANK Ligand | 2013 |
Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.
Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kidney Diseases; Male; Middle Aged; Prospective Studies; Pyrazines; Survival Rate; Transplantation, Autologous | 2014 |
Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Line, Tumor; Female; HSP90 Heat-Shock Proteins; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Purines; Pyrazines; Sarcoma, Ewing; Xenograft Model Antitumor Assays | 2014 |
Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Death; Cytokines; Dendritic Cells; Down-Regulation; Female; Humans; Male; Multiple Myeloma; Pyrazines; STAT3 Transcription Factor; Triterpenes; Tumor Cells, Cultured; Up-Regulation | 2014 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Substitution; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Oligopeptides; Pyrazines; Treatment Outcome | 2014 |
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous | 2014 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Thrombocytopenia; Treatment Outcome | 2014 |
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Rituximab; Survival Rate; Vincristine | 2014 |
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Disease-Free Survival; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Multiple Myeloma; Neoplasm Proteins; Pyrazines; Regulatory Factor X Transcription Factors; Survival Rate; Transcription Factors; X-Box Binding Protein 1 | 2014 |
A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Boronic Acids; Bortezomib; Cholangiocarcinoma; Disease Progression; Female; Follow-Up Studies; Gallbladder Neoplasms; Humans; Male; Middle Aged; Proteasome Inhibitors; Pyrazines; Survival Rate; Time Factors; Treatment Outcome | 2014 |
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Proteasome Inhibitors; Pyrazines; Stomach Neoplasms | 2014 |
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Pain; Pneumonia; Pyrazines; Salvage Therapy; Sirolimus; Treatment Outcome | 2014 |
Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Cost-Benefit Analysis; Feasibility Studies; Follow-Up Studies; Health Policy; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Netherlands; Outcome Assessment, Health Care; Policy Making; Pyrazines; Reimbursement Mechanisms; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Uncertainty | 2014 |
Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the nrf2 pathway.
Topics: Active Transport, Cell Nucleus; Anemia, Sickle Cell; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Nucleus; Erythroid Precursor Cells; Female; Fetal Hemoglobin; Humans; K562 Cells; Male; NF-E2-Related Factor 2; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Transcription, Genetic | 2014 |
A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Treatment Outcome | 2014 |
Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
Topics: Administration, Intravenous; Austria; Biomarkers; Biopsy; Boronic Acids; Bortezomib; Clinical Protocols; Double-Blind Method; Glomerular Filtration Rate; Graft Rejection; Graft Survival; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney; Kidney Transplantation; Proteasome Inhibitors; Pyrazines; Research Design; Sample Size; Time Factors; Treatment Outcome | 2014 |
Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Patient Selection; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous; Young Adult | 2014 |
Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prospective Studies; Pyrazines; Rituximab; Survival Analysis; Treatment Outcome | 2014 |
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Monitoring; Female; Half-Life; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prospective Studies; Pyrazines; Sensitivity and Specificity; Thalidomide; Treatment Outcome | 2014 |
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 17; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin A; Interleukin-6; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate | 2014 |
A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
Topics: Acupuncture Therapy; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Feasibility Studies; Humans; Middle Aged; Multiple Myeloma; Pain Measurement; Peripheral Nervous System Diseases; Pilot Projects; Pyrazines; Time Factors; Treatment Outcome | 2014 |
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Electroacupuncture; Feasibility Studies; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Time Factors; Treatment Outcome | 2014 |
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Chemokine CCL5; Cytokines; Disease-Free Survival; Doxorubicin; Female; Humans; Liver Neoplasms; Male; Middle Aged; Pyrazines; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2014 |
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label,
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Induction Chemotherapy; Intention to Treat Analysis; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Proportional Hazards Models; Pyrazines; Recurrence; Retreatment; Salvage Therapy; Stem Cell Transplantation; Thrombocytopenia; Time Factors; Transplantation, Autologous | 2014 |
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Pyrazines; Risk Factors; Thalidomide; Treatment Outcome | 2014 |
Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate | 2014 |
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Rabbits; Salvage Therapy; Treatment Outcome; Young Adult | 2014 |
Bortezomib for refractory autoimmunity in pediatrics.
Topics: Adolescent; Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Autoimmunity; Boronic Acids; Bortezomib; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Infant; Male; Neutropenia; Plasma Cells; Plasmapheresis; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Rituximab; Thrombocytopenia | 2014 |
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Recurrence | 2014 |
Treatment of chronic graft-versus-host disease with bortezomib.
Topics: Animals; Boronic Acids; Bortezomib; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines; Scleroderma, Systemic; Skin; Transplantation, Homologous; Treatment Outcome; Tumor Cells, Cultured | 2014 |
A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Cohort Studies; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Prednisone; Prospective Studies; Pyrazines | 2014 |
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélo
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Female; France; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2014 |
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Heavy Chains; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Polymerase Chain Reaction; Pyrazines; Recurrence; Survival Analysis; Thalidomide; Transplantation, Autologous | 2015 |
Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Pyrazines; Recurrence; Rituximab; Treatment Outcome | 2014 |
Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study.
Topics: Adult; Biomarkers; Bone and Bones; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Steroids; Treatment Outcome | 2014 |
A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning | 2014 |
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2014 |
Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Autografts; Boronic Acids; Bortezomib; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prospective Studies; Pyrazines; Survival Rate; Transplantation Conditioning | 2014 |
Proteasome inhibitors increase missense mutated dysferlin in patients with muscular dystrophy.
Topics: Administration, Intravenous; Adult; Alleles; Boronic Acids; Bortezomib; Cell Membrane; Cells, Cultured; Dysferlin; Humans; Male; Membrane Proteins; Monocytes; Muscle Proteins; Muscular Dystrophies; Mutation, Missense; Myoblasts; Proteasome Inhibitors; Pyrazines | 2014 |
Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Pyrazines; Treatment Outcome; Vincristine | 2015 |
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
Topics: Actin Cytoskeleton; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axons; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Dexamethasone; Drug Monitoring; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neurogenesis; Peripheral Nervous System Diseases; Plasma Cells; Pyrazines; Survival Analysis; Syndecan-1; Thalidomide; Transplantation, Autologous | 2014 |
Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo
Topics: Acetylcarnitine; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neurologic Examination; NF-kappa B; Nootropic Agents; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Severity of Illness Index; Treatment Outcome | 2014 |
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Pyrazines; Recurrence; Survival Analysis | 2014 |
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxamic Acids; Indoles; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Panobinostat; Prognosis; Pyrazines; Remission Induction; Survival Analysis; Treatment Outcome | 2014 |
A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pyrazines; Survival Analysis | 2015 |
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Boronic Acids; Bortezomib; Combined Modality Therapy; Drug Administration Schedule; Drug Monitoring; Female; Flavonoids; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Pyrazines; Recurrence; Retreatment; Treatment Outcome | 2014 |
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Double-Blind Method; Female; Humans; Interleukin-6; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2015 |
NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Homozygote; Humans; Male; Middle Aged; Multiple Myeloma; NF-kappa B p50 Subunit; Polymorphism, Genetic; Pyrazines; Retrospective Studies; Sequence Deletion; Survival Rate | 2015 |
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma, Renal Cell; Fatigue; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Pyrazines; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prognosis; Pyrazines; Survival Rate | 2015 |
Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Humans; L-Lactate Dehydrogenase; Middle Aged; Multiple Myeloma; Multivariate Analysis; Mutation; Predictive Value of Tests; Pyrazines; Risk Factors; Survival Analysis; Thalidomide | 2015 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult | 2015 |
Clinical outcome of bortezomib retreatment in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2014 |
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis | 2015 |
A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Rate; Veterans | 2015 |
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Topics: Administration, Cutaneous; Administration, Intravenous; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Renal Insufficiency; Treatment Outcome | 2015 |
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Odds Ratio; Prospective Studies; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome | 2015 |
Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Interleukin-6; Japan; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines | 2015 |
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.
Topics: Administration, Intravenous; Adult; Antibodies; Boronic Acids; Bortezomib; Dexamethasone; DNA; Drug Therapy, Combination; Female; Germany; Humans; Interferon Type I; Lupus Erythematosus, Systemic; Male; Plasma Cells; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome | 2015 |
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Pyrazines; Rituximab; Vincristine | 2015 |
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazines; Remission Induction; Survival Rate | 2015 |
Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Plasma Cells; Polyethylene Glycols; Precision Medicine; Proteomics; Pyrazines; Thalidomide | 2015 |
A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Disease-Free Survival; Hodgkin Disease; Humans; Ifosfamide; Neoplasm Recurrence, Local; Pyrazines; Vinblastine; Vinorelbine; Young Adult | 2015 |
Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Susceptibility; Female; Follow-Up Studies; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Proteasome Endopeptidase Complex; Pyrazines | 2015 |
Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients--Preliminary Results of the Screening Phase of the BORTEJECT Trial.
Topics: Aged; Austria; Biomarkers; Boronic Acids; Bortezomib; Cross-Sectional Studies; Double-Blind Method; Drug Administration Schedule; Female; Graft Rejection; Histocompatibility; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Predictive Value of Tests; Prevalence; Prospective Studies; Pyrazines; Risk Factors; Serologic Tests; Time Factors; Treatment Outcome | 2014 |
[Prophylaxis of Bortezomib-Induced Peripheral Neuropathy in Patients with Multiple Myeloma by High-Dose Intravenous Mecobalamin].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Vitamin B 12; Vitamins | 2017 |
A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Imidazoles; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines | 2021 |
2677 other study(ies) available for pyrazines and bortezomib
| Article | Year |
|---|---|
The proteasome inhibitor PS-341 in cancer therapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Cisplatin; Cyclophosphamide; Dipeptides; Drug Synergism; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Protease Inhibitors; Pyrazines; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Ubiquitins | 1999 |
Proteasome inhibition measurements: clinical application.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Humans; In Vitro Techniques; Kinetics; Male; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2000 |
Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
Topics: Acetylcysteine; Acrylates; Amino Acid Chloromethyl Ketones; Apoptosis; Boronic Acids; Bortezomib; Calpain; Cathepsins; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Drug Synergism; Genes, p53; Humans; Jurkat Cells; Leupeptins; Multienzyme Complexes; Neoplasm Proteins; Neoplasms; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; U937 Cells | 2000 |
Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Carcinoma; Caspase Inhibitors; Caspases; Cell Adhesion; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Resistance, Neoplasm; Female; Humans; Male; Ovarian Neoplasms; Phosphorylation; Prostatic Neoplasms; Protease Inhibitors; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Spheroids, Cellular; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2000 |
Clinical trials referral resource. Current clinical trials for the proteasome inhibitor PS-341.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Hematologic Neoplasms; Humans; Neoplasms; Protease Inhibitors; Pyrazines | 2000 |
Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival.
Topics: Amino Acid Chloromethyl Ketones; Aminopeptidases; Animals; Antigen Presentation; Antigens; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Survival; Cysteine Endopeptidases; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Drug Resistance; Endopeptidases; Enzyme Activation; H-2 Antigens; Leupeptins; Lymphoma, T-Cell; Mice; Multienzyme Complexes; Neoplasm Proteins; Oligopeptides; Peptide Fragments; Phenols; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Pyrazines; Selection, Genetic; Serine Endopeptidases; Sulfones; Thymus Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tyramine; Ubiquitins | 2001 |
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Division; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Activation; Growth Inhibitors; Humans; I-kappa B Proteins; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Multiple Myeloma; NF-KappaB Inhibitor alpha; Protease Inhibitors; Pyrazines; Stromal Cells; Tumor Cells, Cultured | 2001 |
Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.
Topics: Adenoviridae; Animals; Apoptosis; Boronic Acids; Bortezomib; Colorectal Neoplasms; Cysteine Endopeptidases; DNA-Binding Proteins; Female; Humans; I-kappa B Proteins; Mice; Mice, Nude; Multienzyme Complexes; NF-kappa B; NF-KappaB Inhibitor alpha; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Repressor Proteins; Transduction, Genetic; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Camptothecin; Colorectal Neoplasms; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Nude; Multienzyme Complexes; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Blood Vessels; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cysteine Endopeptidases; Cytokines; Disease Models, Animal; Gene Expression; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Multienzyme Complexes; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Cyclosporins; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; DNA Fragmentation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epothilones; Epoxy Compounds; Flavonoids; Hematopoietic Stem Cells; HL-60 Cells; Humans; Jurkat Cells; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oligopeptides; Paclitaxel; Piperidines; Poly(ADP-ribose) Polymerases; Pyrazines; Substrate Specificity; Thiazoles | 2001 |
The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.
Topics: Antigens, CD; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Division; Cysteine Endopeptidases; Gene Expression Regulation, Neoplastic; Humans; Integrin alpha4; Intercellular Adhesion Molecule-1; Interleukin-6; Lymphocyte Function-Associated Antigen-1; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Models, Biological; Mucin-1; Multienzyme Complexes; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Stromal Cells; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2001 |
Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Peptide Hydrolases; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Molecular pathways that modify tumor radiation response.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Drug Synergism; Humans; Leupeptins; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radiation Tolerance; Signal Transduction; Tumor Cells, Cultured; Ubiquitins | 2001 |
Aggresome formation in liver cells in response to different toxic mechanisms: role of the ubiquitin-proteasome pathway and the frameshift mutant of ubiquitin.
Topics: Animals; Antifungal Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Frameshift Mutation; Galactosamine; Hepatocytes; Liver; Male; Mice; Mice, Inbred C3H; Microscopy, Fluorescence; Multienzyme Complexes; Proteasome Endopeptidase Complex; Proteins; Pyrans; Pyrazines; Spiro Compounds; Thioacetamide; Ubiquitin | 2001 |
Ethanol withdrawal induced CYP2E1 degradation in vivo, blocked by proteasomal inhibitor PS-341.
Topics: Animals; Boronic Acids; Bortezomib; Chymases; Cytochrome P-450 CYP2E1; Ethanol; Liver; Male; Protease Inhibitors; Pyrazines; Rats; Rats, Wistar; Serine Endopeptidases; Substance Withdrawal Syndrome | 2002 |
Cancer research. Taking garbage in, tossing cancer out?
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Multiple Myeloma; Neoplasm Proteins; Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines | 2002 |
Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341.
Topics: Boronic Acids; Bortezomib; Cell Nucleus; Cysteine Endopeptidases; DNA Repair; DNA, Fungal; Fungal Proteins; Gene Deletion; Gene Expression Profiling; Genome, Fungal; Genomics; Microbial Sensitivity Tests; Multienzyme Complexes; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; RNA, Fungal; Saccharomyces cerevisiae; Transcription, Genetic | 2002 |
Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.
Topics: Adult; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Daclizumab; DNA-Binding Proteins; DNA, Neoplasm; Drug Synergism; Humans; I-kappa B Proteins; Immunoglobulin G; Leukemia-Lymphoma, Adult T-Cell; Mice; Mice, Inbred NOD; Mice, SCID; Monocytes; Multienzyme Complexes; Neutrophils; NF-kappa B; NF-KappaB Inhibitor alpha; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Receptors, IgG | 2002 |
NF-kappa B as a therapeutic target in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Cell Division; Cell Line; Cells, Cultured; Dexamethasone; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; Heterocyclic Compounds, 3-Ring; Humans; I-kappa B Kinase; Immunoblotting; Intercellular Adhesion Molecule-1; Models, Chemical; Multiple Myeloma; NF-kappa B; Phosphorylation; Protease Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Pyridines; Time Factors; Tumor Cells, Cultured; Up-Regulation | 2002 |
Proteasome inhibitor holds promise for patients with refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2001 |
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Dose-Response Relationship, Drug; Humans; Male; Mice; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Differentiation; Cell Division; Chloramphenicol O-Acetyltransferase; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Regulation; HeLa Cells; Humans; I-kappa B Proteins; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Promoter Regions, Genetic; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrophosphatases; Transcriptional Activation; Tumor Cells, Cultured; Up-Regulation | 2002 |
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Down-Regulation; Gene Expression Profiling; Heat-Shock Proteins; Humans; Insulin-Like Growth Factor I; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured; Ubiquitin | 2002 |
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Cycle Proteins; Cell Death; DNA-Activated Protein Kinase; DNA-Binding Proteins; Enzyme Activation; Gene Expression; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; Nuclear Proteins; Phosphorylation; Phosphoserine; Protease Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2003 |
Role of the bone marrow microenvironment in multiple myeloma.
Topics: Adjuvants, Immunologic; Bone and Bones; Bone Marrow; Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Cell Division; Chemokine CCL3; Chemokine CCL4; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Macrophage Inflammatory Proteins; Membrane Glycoproteins; Multiple Myeloma; Osteoclasts; Osteolysis; Osteoprotegerin; Protease Inhibitors; Protein Prenylation; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Melphalan; Middle Aged; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines; Recurrence; Tumor Cells, Cultured | 2003 |
PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line; Cysteine Endopeptidases; DNA Fragmentation; Flow Cytometry; G2 Phase; Humans; Mitosis; Models, Biological; Multienzyme Complexes; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Subcellular Fractions; Time Factors; Tosylphenylalanyl Chloromethyl Ketone; Tumor Cells, Cultured | 2002 |
Function of nuclear factor kappaB in pancreatic cancer metastasis.
Topics: Animals; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Enzyme Inhibitors; Genes, Reporter; Humans; Immunohistochemistry; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; NF-kappa B; Pancreatic Neoplasms; Phenotype; Pyrazines; Retroviridae; Time Factors; Tumor Cells, Cultured | 2003 |
Moving disease biology from the lab to the clinic.
Topics: Bone Marrow; Boronic Acids; Bortezomib; Cell Division; Drug Delivery Systems; Heterocyclic Compounds, 3-Ring; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Protease Inhibitors; Pyrazines; Pyridines; Thalidomide | 2003 |
Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
Topics: Animals; Antibodies, Monoclonal; Boronic Acids; Bortezomib; Carrier Proteins; Chemokine CCL3; Chemokine CCL4; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Disease Models, Animal; Glycoproteins; Macrophage Inflammatory Proteins; Membrane Glycoproteins; Mice; Multienzyme Complexes; Multiple Myeloma; Osteolysis; Osteoprotegerin; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor | 2003 |
[Perspectives on the oncologist pharmacopoeia].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Dioxoles; Indoles; Isoquinolines; Neoplasms; Organoplatinum Compounds; Protease Inhibitors; Pyrazines; Pyrroles; Quinazolines; Sesquiterpenes; Tetrahydroisoquinolines; Trabectedin | 2003 |
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
Topics: Active Transport, Cell Nucleus; Adenoviridae; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Division; Cell Nucleus; Cell Survival; Cysteine Endopeptidases; Cytosol; Dose-Response Relationship, Drug; Genes, Dominant; Humans; I-kappa B Proteins; Melphalan; Microscopy, Fluorescence; Multienzyme Complexes; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Proteasome Endopeptidase Complex; Pyrazines; Tetrazolium Salts; Thiazoles; Time Factors; Transfection; Tumor Cells, Cultured; Ubiquitin | 2003 |
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Dose-Response Relationship, Drug; G2 Phase; Humans; Immunohistochemistry; Lung Neoplasms; Microtubules; Mitosis; Multienzyme Complexes; Mutation; Precipitin Tests; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 2003 |
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bone Marrow Purging; Boronic Acids; Bortezomib; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Disease-Free Survival; Drug Synergism; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Mice; Neoplasms, Experimental; Protease Inhibitors; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Transplantation, Isogeneic; Treatment Outcome; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2003 |
Clinical trials referral resource. Current clinical trials of bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Neoplasms; Humans; National Institutes of Health (U.S.); Neoplasms; Patient Selection; Protease Inhibitors; Pyrazines; United States | 2003 |
First proteasome inhibitor approved for multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Drug Approval; Drugs, Investigational; Humans; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; United States; United States Food and Drug Administration | 2003 |
Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocyte Subsets; bcl-X Protein; Biopsy; Boronic Acids; Bortezomib; Cell Cycle; Growth Inhibitors; Humans; Hydrolysis; I-kappa B Proteins; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Minor Histocompatibility Antigens; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Organic Chemicals; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfones; Tumor Cells, Cultured | 2003 |
Imaging 26S proteasome activity and inhibition in living mice.
Topics: Acetylcysteine; Animals; Boronic Acids; Bortezomib; Coleoptera; Cysteine Proteinase Inhibitors; Genes, Reporter; HeLa Cells; Humans; Kinetics; Leupeptins; Luciferases; Luminescent Measurements; Male; Mice; Mice, Nude; Molecular Biology; Peptide Hydrolases; Proteasome Endopeptidase Complex; Pyrazines; Transfection; Ubiquitin; Xenograft Model Antitumor Assays | 2003 |
Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Antineoplastic Agents; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Cell Survival; Cysteine Endopeptidases; Cytochrome c Group; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Immunoblotting; Indicators and Reagents; Lung Neoplasms; Membrane Potentials; Mitochondria; Models, Chemical; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Reactive Oxygen Species; Time Factors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
The proteasome--an emerging therapeutic target in cancer.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; NF-kappa B; Peptide Hydrolases; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2003 |
Bortezomib (velcade) for multiple myeloma.
Topics: Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Economics, Pharmaceutical; Fees, Pharmaceutical; Humans; Multiple Myeloma; Nausea; Pyrazines | 2003 |
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Butyrates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protease Inhibitors; Pyrazines; Pyrimidines; Reactive Oxygen Species; Signal Transduction; Tumor Cells, Cultured; Vorinostat | 2003 |
The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 9; Caspases; Humans; Membrane Glycoproteins; Protease Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2003 |
Bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Industry; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Treatment Outcome; United States | 2003 |
The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Topics: Apoptosis; Benzamides; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; DNA-Binding Proteins; Drug Combinations; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Genes, abl; Humans; I-kappa B Proteins; Imatinib Mesylate; Leukemia, Lymphoid; Leukemia, Myeloid; Multienzyme Complexes; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Piperazines; Proteasome Endopeptidase Complex; Pyrazines; Pyrimidines | 2003 |
Can smart bombs win the war on cancer? By pinpointing abnormalities specific to tumor cells, a novel generation of cancer drugs may usher in a whole new era of cancer treatment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Enzyme Inhibitors; Humans; Neoplasms; Protease Inhibitors; Protein-Tyrosine Kinases; Pyrazines | 2003 |
Molecule of the month. Bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; National Institutes of Health (U.S.); Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; United States | 2003 |
Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Cycle Proteins; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2003 |
Innovative strategies in lymphoma therapy.
Topics: Alemtuzumab; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Forecasting; Genetic Therapy; Humans; Immunoconjugates; Immunotherapy; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Prednisone; Protease Inhibitors; Proteomics; Pyrazines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Rituximab; Signal Transduction; Survival Analysis; Thalidomide; Time Factors; Vincristine | 2003 |
Bortezomib in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Disease Progression; Humans; Multiple Myeloma; Paraproteins; Protease Inhibitors; Pyrazines | 2003 |
Bortezomib in multiple myeloma.
Topics: Amyloid beta-Peptides; Boronic Acids; Bortezomib; Diagnostic Techniques, Neurological; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines | 2003 |
The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cysteine Endopeptidases; Cytochrome c Group; Dexamethasone; Humans; Membrane Potentials; Mitochondria; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured | 2003 |
Promoting proteasomes: trash to treasure.
Topics: Allosteric Regulation; Antimicrobial Cationic Peptides; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2003 |
Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
Topics: Androgens; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Survival; Cysteine Endopeptidases; Drug Interactions; Electrophoretic Mobility Shift Assay; Humans; Luciferases; Male; Membrane Glycoproteins; Multienzyme Complexes; NF-kappa B; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2003 |
Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Complement Membrane Attack Complex; Complement System Proteins; Cysteine Endopeptidases; Cytochromes c; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Enzyme Activation; Glucocorticoids; Glycoproteins; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Mitochondria; Multienzyme Complexes; Neoplasm Recurrence, Local; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines; Tumor Cells, Cultured; Vidarabine; X-Linked Inhibitor of Apoptosis Protein | 2003 |
Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cysteine Endopeptidases; Endothelium, Vascular; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Multienzyme Complexes; Neoplasm Transplantation; Neovascularization, Pathologic; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2003 |
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Leupeptins; Lymphoma; Molecular Chaperones; Multienzyme Complexes; Neoplasm Proteins; Proteasome Endopeptidase Complex; Pyrazines; RNA, Messenger; Transfection | 2003 |
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Topics: Anisomycin; Antineoplastic Agents; Apoptosis; Blast Crisis; Boronic Acids; Bortezomib; Cyclin-Dependent Kinases; Cysteine Endopeptidases; Enzyme Inhibitors; Flavonoids; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia, Myeloid, Acute; Leupeptins; Mitogen-Activated Protein Kinases; Multienzyme Complexes; NF-kappa B; Piperidines; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; U937 Cells | 2003 |
The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA, Neoplasm; Etoposide; Humans; Male; Nuclear Proteins; Oncogene Proteins, Viral; Papillomaviridae; Peptide Hydrolases; Phosphorylation; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrazines; Subcellular Fractions; Transcriptional Activation; Transfection; Tumor Suppressor Protein p53 | 2003 |
Combinations of targeted therapies take aim at multiple pathways.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Boronic Acids; Bortezomib; Clinical Trials as Topic; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Research Design | 2003 |
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Caspases; Contactins; Cysteine Endopeptidases; Down-Regulation; Humans; Interleukin-6; Multienzyme Complexes; Multiple Myeloma; Neural Cell Adhesion Molecules; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction | 2003 |
[Gene expression profile changes in human multiple myeloma].
Topics: Adult; Aged; Boronic Acids; Bortezomib; Epidermal Growth Factor; Female; Gene Expression; Gene Expression Profiling; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Multiple Myeloma; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Protein Tyrosine Phosphatases; Pyrazines; RNA, Messenger | 2003 |
The proteasome inhibitor, PS-341, causes cytokeratin aggresome formation.
Topics: Actins; Animals; Boronic Acids; Bortezomib; Cell Membrane; Cells, Cultured; Chlormethiazole; Dicarbethoxydihydrocollidine; Disease Models, Animal; Dose-Response Relationship, Drug; Fluorescent Antibody Technique; Fluorescent Antibody Technique, Indirect; Hepatocytes; Inclusion Bodies; Keratins; Male; Membrane Proteins; Mice; Mice, Inbred C3H; Microscopy, Confocal; Phosphoproteins; Protease Inhibitors; Pyrazines; Zonula Occludens-1 Protein | 2004 |
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Division; Cell Line, Tumor; Docetaxel; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitosis; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Protease Inhibitors; Pyrazines; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2004 |
Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme-Linked Immunosorbent Assay; Genes, jun; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Transcription Factor AP-1; Tumor Suppressor Protein p53 | 2004 |
2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
Topics: 2-Methoxyestradiol; Actins; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Estradiol; Heat-Shock Proteins; Humans; Multiple Myeloma; Peptides; Proteasome Inhibitors; Pyrazines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2004 |
Proteasome inhibition induces cytokeratin accumulation in vivo.
Topics: Alcoholism; Animals; Blotting, Western; Boronic Acids; Bortezomib; Cells, Cultured; Cysteine Endopeptidases; Heat-Shock Proteins; Hepatocytes; Keratins; Liver; Liver Diseases, Alcoholic; Male; Mice; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Rats | 2004 |
Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells.
Topics: Androgens; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Division; Cell Line; Down-Regulation; Humans; In Situ Nick-End Labeling; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines; Receptors, Androgen | 2004 |
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; CDC2-CDC28 Kinases; Cell Death; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Deoxycytidine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-8; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Multienzyme Complexes; Neoplasm Transplantation; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2004 |
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Flavonoids; Fusion Proteins, bcr-abl; Humans; I-kappa B Proteins; Imatinib Mesylate; In Vitro Techniques; JNK Mitogen-Activated Protein Kinases; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk Proteins; Mitochondria; Mitogen-Activated Protein Kinases; NF-kappa B; Nuclear Proteins; Phosphoprotein Phosphatases; Phosphorylation; Piperazines; Piperidines; Pyrazines; Pyrimidines; RNA Polymerase II; src-Family Kinases; STAT3 Transcription Factor; STAT5 Transcription Factor; Trans-Activators | 2004 |
[Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2004 |
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Butyrates; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Cysteine Endopeptidases; Histone Deacetylases; Humans; Interleukin-8; Lung Neoplasms; Multienzyme Complexes; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Transcription, Genetic; Transcriptional Activation; Treatment Outcome; Tumor Cells, Cultured | 2004 |
Proteinase inhibitors - IBC's Third International Conference. New approaches, new discoveries, new targets.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Boronic Acids; Bortezomib; Cathepsins; Drug Evaluation, Preclinical; Endopeptidases; Humans; Inflammation; Peptide Library; Protease Inhibitors; Pyrazines | 2004 |
[Targeted in therapies multiple myeloma].
Topics: Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2004 |
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Genes, bcl-2; Humans; Imidazoles; Insulin-Like Growth Factor I; Interleukin-6; Lymphocytes; Membrane Potentials; Mitochondria; Multiple Myeloma; Mutation; NF-kappa B; Oleanolic Acid; Protease Inhibitors; Pyrazines; Recombinant Proteins; Transfection | 2004 |
Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Division; Crosses, Genetic; Cysteine Endopeptidases; DNA Replication; Genes, pX; HTLV-I Infections; Humans; Interleukin-10; Interleukin-6; Leukemia, T-Cell; Mice; Mice, Inbred C57BL; Mice, Transgenic; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cytochromes c; Enzyme Activation; Enzyme Inhibitors; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia; MAP Kinase Signaling System; Membrane Potentials; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Models, Biological; Protease Inhibitors; Pyrazines; Pyridines; Reactive Oxygen Species; Signal Transduction; U937 Cells | 2004 |
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.
Topics: Anaphase-Promoting Complex-Cyclosome; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Pyrazines; Ubiquitin-Conjugating Enzymes; Ubiquitin-Protein Ligase Complexes | 2004 |
Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Down-Regulation; Doxycycline; Fibroblasts; Humans; I-kappa B Kinase; I-kappa B Proteins; Mice; NF-kappa B; Nuclear Proteins; Phosphorylation; Protease Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrazines; Superoxides; Transcription Factor RelA; Tumor Suppressor Protein p53; Up-Regulation | 2004 |
Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein.
Topics: Animals; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Fractionation; Chlorocebus aethiops; COS Cells; Cysteine Endopeptidases; Detergents; Down-Regulation; Humans; Lactams, Macrocyclic; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Pyrazines; Rifabutin; Transfection; Ubiquitin; Ubiquitin-Protein Ligases | 2004 |
Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
Topics: Antibodies, Monoclonal; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Carrier Proteins; Caspases; CD40 Antigens; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Survival; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Hodgkin Disease; Humans; I-kappa B Proteins; Ki-1 Antigen; Membrane Glycoproteins; Multienzyme Complexes; Mutation; NF-kappa B; NF-KappaB Inhibitor alpha; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2004 |
Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity.
Topics: Antineoplastic Agents; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Viral; Cycloheximide; Detergents; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Oncogene Proteins, Viral; Papillomavirus E7 Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteins; Pyrazines; Quinones; Repressor Proteins; Rifabutin; Solubility; Ubiquitins; Vacuoles | 2004 |
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.
Topics: Acute Disease; Animals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Cell Line, Tumor; Female; Graft vs Host Disease; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; NF-kappa B; Protease Inhibitors; Pyrazines; Survival Analysis; T-Lymphocytes, Cytotoxic; Transplantation, Homologous | 2004 |
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cytosol; Dose-Response Relationship, Drug; Enzyme Inhibitors; Free Radical Scavengers; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Intracellular Membranes; Membrane Glycoproteins; Membrane Potentials; Mitochondria; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oxidative Stress; Oxygen; Protease Inhibitors; Proteins; Proteoglycans; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Sodium Oxybate; Syndecan-1; Syndecans; Tumor Suppressor Proteins; Vorinostat; X-Linked Inhibitor of Apoptosis Protein | 2004 |
Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Topics: Adenocarcinoma; Annexin A5; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Line, Tumor; Cinnamates; Colonic Neoplasms; Depsipeptides; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Free Radicals; Gastrointestinal Neoplasms; Histones; Humans; Microscopy, Confocal; Oligopeptides; Oxygen; Phosphorylation; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Time Factors | 2004 |
Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Transformed; Cell Line, Tumor; Cysteine Endopeptidases; HTLV-I Infections; Humans; Leukemia-Lymphoma, Adult T-Cell; Mice; Mice, SCID; Multienzyme Complexes; Neoplasm Transplantation; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Transplantation, Heterologous | 2004 |
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2004 |
"Development of the proteasome inhibitor Velcade (Bortezomib)" by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D.
Topics: Biomedical Research; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Design; Drug Industry; Federal Government; Humans; Interinstitutional Relations; Neoplasms; Protease Inhibitors; Pyrazines | 2004 |
Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured | 2004 |
Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Kidney Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2004 |
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Survival; Cytochromes c; Drug Resistance, Neoplasm; Drug Synergism; GABA-A Receptor Antagonists; Humans; Insulin-Like Growth Factor I; Interleukin-6; Isoquinolines; JNK Mitogen-Activated Protein Kinases; Lymphocytes; Membrane Potentials; Mitochondria; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Stromal Cells; Superoxides; Tumor Cells, Cultured | 2004 |
Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; B-Lymphocytes; Boronic Acids; Bortezomib; Child; Dexamethasone; Humans; Male; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Serine-Threonine Kinases; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recurrence | 2004 |
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Gene Expression; Humans; Melanoma; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Pyrazines; Temozolomide | 2004 |
Identification of a potent and rapidly reversible inhibitor of the 20S-proteasome.
Topics: Boronic Acids; Bortezomib; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stereoisomerism; Structure-Activity Relationship | 2004 |
Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Division; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Drug Synergism; Humans; Lymphoma; Membrane Glycoproteins; NF-kappa B; Paclitaxel; Pleural Effusion, Malignant; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2004 |
The bortezomib-induced mitochondrial damage is mediated by accumulation of active protein kinase C-delta.
Topics: Acetophenones; Antineoplastic Agents; Apoptosis; Benzopyrans; Boronic Acids; Bortezomib; Enzyme Inhibitors; Humans; Mitochondria; Peptide Fragments; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Kinase C; Protein Kinase C-delta; Pyrazines; U937 Cells | 2004 |
New drugs 04. Part III.
Topics: Adrenergic alpha-Antagonists; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiemetics; Antineoplastic Agents; Aprepitant; Boronic Acids; Bortezomib; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Glucans; Glucose; Glucosylceramidase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Icodextrin; Immunosuppressive Agents; Isoquinolines; Morpholines; Nurse's Role; Omalizumab; Palonosetron; Patient Education as Topic; Pyrazines; Pyrimidines; Quinazolines; Quinuclidines; Rosuvastatin Calcium; Sulfonamides | 2004 |
Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Breast; Breast Neoplasms; Cell Cycle Proteins; Cell Line; Cell Line, Transformed; Cell Line, Tumor; Dual Specificity Phosphatase 1; Fibroblasts; Genes, myc; Humans; Immediate-Early Proteins; Mice; Mice, Knockout; Mice, Nude; Phosphoprotein Phosphatases; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Phosphatase 1; Protein Tyrosine Phosphatases; Pyrazines; Recombinant Proteins; Transplantation, Heterologous | 2004 |
Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Pyrazines; Tumor Lysis Syndrome | 2004 |
Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Proteins; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factor RelA; Transcription, Genetic; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2004 |
Bortezomib data show improved survival in patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Multiple Myeloma; Pyrazines; Survival Analysis; Treatment Outcome | 2004 |
Proteasome inhibition therapy: assessing the clinical implications in hematologic diseases.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nursing Assessment; Oncology Nursing; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2004 |
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Heat-Shock Proteins; Humans; Multiple Myeloma; p38 Mitogen-Activated Protein Kinases; Pyrazines | 2004 |
Bortezomib rapidly suppresses ubiquitin thiolesterification to ubiquitin-conjugating enzymes and inhibits ubiquitination of histones and type I inositol 1,4,5-trisphosphate receptor.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Calcium Channels; Cell Line; Cells, Cultured; Dithiothreitol; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; HeLa Cells; Histones; Humans; I-kappa B Proteins; Inositol 1,4,5-Trisphosphate Receptors; Mice; NF-KappaB Inhibitor alpha; Protease Inhibitors; Proteasome Inhibitors; Protein Binding; Pyrazines; Receptors, Cytoplasmic and Nuclear; Time Factors; Ubiquitin; Ubiquitin-Conjugating Enzymes | 2004 |
Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Pamidronate; Piperazines; Pyrazines; Pyrimidines; ras Proteins; Sirolimus | 2004 |
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Caveolin 1; Caveolins; Cell Line, Tumor; Cell Movement; Crk-Associated Substrate Protein; Endothelium, Vascular; Humans; Multiple Myeloma; Phosphorylation; Proteins; Pyrazines; Recombinant Proteins; Retinoblastoma-Like Protein p130; src-Family Kinases; Transfection; Tyrosine; Vascular Endothelial Growth Factor A | 2004 |
Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspases; Cell Line, Tumor; Endoplasmic Reticulum; Gene Expression Profiling; Head and Neck Neoplasms; Humans; NF-kappa B; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Signal Transduction | 2004 |
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Mitochondria; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Transcription, Genetic; Vorinostat | 2004 |
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Glioblastoma; Humans; Models, Biological; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma.
Topics: Adult; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line; Cell Line, Tumor; Cell Survival; Ceramides; Humans; Jurkat Cells; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-Cell; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2005 |
Activity of bortezomib in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Taxoids | 2004 |
Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Primers; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptor, Notch2; Receptors, Cell Surface; Receptors, IgE; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
Select forms of tumor cell apoptosis induce dendritic cell maturation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dendritic Cells; fas Receptor; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Pyrazines; Signal Transduction; Tamoxifen | 2005 |
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Camptothecin; Cell Communication; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA, Neoplasm; Doxorubicin; Drug Synergism; Enzyme Activation; fas Receptor; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Lymphoma; Multiple Myeloma; Poly(ADP-ribose) Polymerases; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Stromal Cells; Up-Regulation | 2004 |
[Proteasome inhibitors--new option in the treatment of tumor diseases].
Topics: Animals; Boronic Acids; Bortezomib; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2004 |
Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Line; Deoxycytidine; Enzyme Activation; Gemcitabine; Humans; Immunoblotting; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Ribonucleotide Reductases; Tumor Cells, Cultured | 2004 |
Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Carcinoma, Transitional Cell; Caspase 8; Caspase Inhibitors; Caspases; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Activation; Humans; Interferon Type I; Membrane Glycoproteins; Pyrazines; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms | 2004 |
VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Division; Cell Line, Tumor; Cell Survival; Genes, Tumor Suppressor; Humans; Kidney Neoplasms; NF-kappa B; Paclitaxel; Pyrazines; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein | 2005 |
Bortezomib is an efficient agent in plasma cell leukemias.
Topics: Anemia; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Proliferation; Cell Survival; Female; Humans; Leukemia, Plasma Cell; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Pyrazines; Thrombocytopenia; Time Factors | 2005 |
Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Protease Inhibitors; Pyrazines | 2005 |
Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma.
Topics: Antigens, Neoplasm; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Intraductal, Noninfiltrating; Cell Hypoxia; Cell Survival; Down-Regulation; Estrogen Receptor alpha; Female; Glucose Transporter Type 1; Humans; Immunoenzyme Techniques; Monosaccharide Transport Proteins; Neoplasm Invasiveness; Oxygen; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured | 2004 |
Emerging advances in the management of lung cancer.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Paclitaxel; Polyglutamic Acid; Protease Inhibitors; Pyrazines; Taxoids | 2004 |
A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival.
Topics: Autocrine Communication; Boronic Acids; Bortezomib; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Cell Survival; Coculture Techniques; Dexamethasone; Humans; Multiple Myeloma; Nerve Growth Factors; Paracrine Communication; Pyrazines; Receptor, trkB; Signal Transduction; Stromal Cells | 2005 |
The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Herpesviridae Infections; Herpesvirus 8, Human; Humans; Lymphoma, Non-Hodgkin; Pyrazines; Tumor Cells, Cultured | 2005 |
Missing the target: ubiquitin ligase drugs stall.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; NEDD8 Protein; Nuclear Proteins; Protease Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrazines; Ubiquitin-Protein Ligases; Ubiquitins | 2005 |
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Kidney Function Tests; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Prognosis; Protease Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome | 2005 |
Multifunctional role of Erk5 in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Dexamethasone; Enzyme Activation; Humans; Interleukin-6; Mitogen-Activated Protein Kinase 7; Multiple Myeloma; Pyrazines; Signal Transduction; Tumor Cells, Cultured | 2005 |
[Multiple myeloma -- therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Radiotherapy, Adjuvant; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2005 |
Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.
Topics: Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Tomography, X-Ray Computed; Transplantation, Autologous; Transplantation, Homologous | 2005 |
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
Topics: Acyltransferases; Adenosine Triphosphate; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspase 9; Caspases; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; G2 Phase; Humans; Immunoblotting; In Situ Nick-End Labeling; Multiple Myeloma; Necrosis; Phosphorylation; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Inhibitors; Proteins; Pyrazines; Time Factors; Treatment Outcome | 2005 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2005 |
Bortezomib-induced severe hepatitis in multiple myeloma: a case report.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury, Chronic; Humans; L-Lactate Dehydrogenase; Male; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2005 |
Bortezomib therapy following first relapse.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome | 2005 |
Bortezomib in combination with dexamethasone for relapsed multiple myeloma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Salvage Therapy; Sequence Deletion; Treatment Outcome | 2005 |
Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Gastrointestinal Agents; Humans; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Statistics, Nonparametric; Treatment Outcome; Weight Loss | 2005 |
Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
Topics: Antineoplastic Agents; Asthenia; Biopsy; Bone Marrow Cells; Boronic Acids; Bortezomib; Female; Humans; Immunosuppressive Agents; Liver; Liver Neoplasms; Middle Aged; Multiple Myeloma; Plasma Cells; Plasmacytoma; Pyrazines; Recurrence; Thalidomide | 2005 |
Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.
Topics: Boronic Acids; Bortezomib; Humans; Isoenzymes; Microsomes, Liver; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2005 |
Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Carrier Proteins; Cell Line; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gene Expression Regulation; Genes, ras; Humans; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Knockout; Neoplasms, Glandular and Epithelial; Paclitaxel; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyrazines; Tumor Suppressor Protein p53 | 2005 |
The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Boronic Acids; Bortezomib; Carrier Proteins; Cell Line; Cell Line, Tumor; Cell Survival; Cells, Cultured; Colonic Neoplasms; Dose-Response Relationship, Drug; Down-Regulation; Fibroblasts; Green Fluorescent Proteins; Humans; Immunoprecipitation; Male; Membrane Glycoproteins; Membrane Proteins; Mice; Mitochondrial Proteins; Peptide Fragments; Plasmids; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA Interference; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Necrosis Factor-alpha | 2005 |
Severe irreversible bilateral hearing loss after bortezomib (VELCADE) therapy in a multiple myeloma (MM) patient.
Topics: Boronic Acids; Bortezomib; Hearing Loss, Bilateral; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2005 |
Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Doxorubicin; Drug Synergism; Gene Expression Regulation, Neoplastic; Gene Silencing; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Membrane Glycoproteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Quinones; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2005 |
Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
Topics: Boronic Acids; Bortezomib; Breast Neoplasms; Cyclin D1; Female; Gene Expression Regulation, Neoplastic; Humans; Male; NF-kappa B; Pancreatic Neoplasms; Prostatic Neoplasms; Protease Inhibitors; Pyrazines; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured | 2005 |
NF-kappaB and not the MAPK signaling pathway regulates GADD45beta expression during acute inflammation.
Topics: Animals; Antigens, Differentiation; Apoptosis; Arsenites; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Dexamethasone; DNA Damage; Extracellular Signal-Regulated MAP Kinases; Female; Gene Library; Genetic Vectors; I-kappa B Proteins; Inflammation; Lipopolysaccharides; Luciferases; Male; MAP Kinase Signaling System; Mice; Mice, Transgenic; NF-kappa B; NF-KappaB Inhibitor alpha; Oxidative Stress; Promoter Regions, Genetic; Proteasome Inhibitors; Protein Binding; Pyrazines; RNA, Messenger; Signal Transduction; Sodium Compounds; Thalidomide; Time Factors; Tissue Distribution; Tumor Necrosis Factor-alpha | 2005 |
Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Electroporation; Flow Cytometry; Heat-Shock Proteins; Hot Temperature; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Immunoblotting; Immunoprecipitation; K562 Cells; Lactams, Macrocyclic; Mice; Mice, Transgenic; Proteasome Endopeptidase Complex; Protein Binding; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-pim-1; Pyrazines; Quinones; Time Factors; Ubiquitin | 2005 |
Side effects and good effects from new chemotherapeutic agents. Case 3. Bortezomib in primary refractory plasmacytoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Mediastinal Neoplasms; Middle Aged; Plasmacytoma; Pyrazines; Treatment Outcome | 2005 |
Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Camptothecin; Disease Models, Animal; DNA Topoisomerases, Type I; Down-Regulation; Female; Humans; Mice; Mice, Nude; Protease Inhibitors; Pyrazines; RNA, Messenger; S Phase; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2005 |
In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Survival; Cladribine; Dose-Response Relationship, Drug; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured | 2005 |
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Colonic Neoplasms; Female; Humans; Kidney; Membrane Proteins; Mitochondrial Proteins; NF-kappa B; Ovarian Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2005 |
High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation.
Topics: Alkaline Phosphatase; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Pyrazines; Spinal Fractures | 2005 |
Intracellular inhibitory effects of Velcade correlate with morphoproteomic expression of phosphorylated-nuclear factor-kappaB and p53 in breast cancer cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Division; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Phosphorylation; Protease Inhibitors; Proteome; Pyrazines; Tumor Suppressor Protein p53 | 2005 |
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Leupeptins; Mice; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2005 |
Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Calcium; Caspases; Cell Line, Tumor; Endoplasmic Reticulum; Enzyme Activation; Gene Expression; Humans; Isoenzymes; Mitochondria; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Pyrazines | 2005 |
The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.
Topics: Animals; Antibodies, Monoclonal; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Cytotoxicity, Immunologic; Disease Models, Animal; Drug Synergism; Hodgkin Disease; Humans; Intracellular Signaling Peptides and Proteins; Ki-1 Antigen; Mice; NF-kappa B; Pyrazines; Signal Transduction; Xenograft Model Antitumor Assays | 2005 |
Lung cancer - Second Annual Winter Conference.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Paclitaxel; Pyrazines; Quinazolines | 2005 |
Genotypic guidance for chemotherapy choices.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Therapy, Combination; Genotype; Humans; Membrane Proteins; Paclitaxel; Protease Inhibitors; Proto-Oncogene Proteins; Pyrazines | 2005 |
Velcade displays promising activity in primary effusion lymphoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Humans; Lymphoma, B-Cell; Pleural Effusion, Malignant; Pyrazines | 2005 |
Measuring ubiquitin conjugation in cells.
Topics: Benzoquinones; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Humans; Lactams, Macrocyclic; Protein Processing, Post-Translational; Pyrazines; Quinones; Ubiquitin | 2005 |
Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Male; Membrane Glycoproteins; Prostatic Neoplasms; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms | 2005 |
Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Line; Cell Survival; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Flow Cytometry; Humans; Immunoblotting; Jurkat Cells; Leupeptins; Membrane Glycoproteins; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; NF-kappa B; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2005 |
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Topics: Anilides; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Flow Cytometry; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Inhibitory Concentration 50; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteins; Pyrazines; RNA, Small Interfering; Tubulin | 2005 |
Serum amyloid A-luciferase transgenic mice: response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition.
Topics: Acute Disease; Animals; Arthritis, Experimental; Boronic Acids; Bortezomib; Dermatitis, Contact; Disease Models, Animal; Enzyme Induction; Female; Genetic Vectors; Lipopolysaccharides; Luciferases; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Organ Specificity; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sepsis; Serum Amyloid A Protein; Tumor Necrosis Factor-alpha | 2005 |
Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2005 |
Images in clinical Medicine. Bortezomib-induced skin lesions.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Female; Humans; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2005 |
Bortezomib for myeloma -- much ado about something.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Research Design | 2005 |
Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity.
Topics: Acute Disease; Animals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Enzyme Inhibitors; Female; Gastrointestinal Tract; Graft vs Host Disease; Mice; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptors, Tumor Necrosis Factor, Type I; RNA, Messenger | 2005 |
PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Multiple Myeloma; Pyrazines; Radiation-Sensitizing Agents; Radiation, Ionizing | 2005 |
Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib.
Topics: Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Multiple Myeloma; Plasmacytoma; Pyrazines; Remission Induction; Salvage Therapy; Spinal Neoplasms | 2005 |
Stability of bortezomib 1-mg/mL solution in plastic syringe and glass vial.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Calibration; Chromatography, High Pressure Liquid; Drug Packaging; Drug Stability; Drug Storage; Glass; Pharmaceutical Solutions; Plastics; Pyrazines; Reference Standards; Reproducibility of Results; Syringes; Temperature | 2005 |
Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction.
Topics: Animals; Boronic Acids; Bortezomib; Death, Sudden, Cardiac; Dogs; Electrocardiography; G-Protein-Coupled Receptor Kinase 5; Immunoblotting; Ligation; Male; Microscopy, Confocal; Microscopy, Fluorescence; Myocardial Infarction; Myocardial Ischemia; Myocardium; Pericardium; Proteasome Endopeptidase Complex; Protein Serine-Threonine Kinases; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Tachycardia, Ventricular | 2005 |
Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect.
Topics: Boronic Acids; Bortezomib; Follow-Up Studies; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Plasmacytoma; Pyrazines; Remission Induction; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2005 |
[Therapeutic outcomes in systemic lymphatic diseases and plasmacytoma. New hope for palliative patients].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lymphoma; Multiple Myeloma; Prognosis; Pyrazines; Radioimmunotherapy; Thalidomide | 2005 |
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cytokines; Female; Gene Expression; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mouth Mucosa; Neoplasm Recurrence, Local; NF-kappa B; Protease Inhibitors; Pyrazines; Stomatitis; Transcription Factor RelA | 2005 |
Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Fatal Outcome; Humans; Immunoglobulin D; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Thalidomide | 2005 |
Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide | 2005 |
Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.
Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Small Cell; Gene Expression Regulation, Neoplastic; Humans; Luciferases; Lung Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured | 2005 |
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Female; Humans; Melanocytes; Melanoma; Mice; Mice, Nude; Mitochondria; Multiple Myeloma; Oligonucleotides, Antisense; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Messenger; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2005 |
Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cisplatin; Cytochromes c; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Female; Humans; Melanocytes; Melanoma; Mice; Mice, Nude; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA Interference; Up-Regulation; Xenograft Model Antitumor Assays | 2005 |
Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Colonic Neoplasms; Disease Progression; DNA Damage; Drug Interactions; Humans; Mice; Mice, Nude; Oxidative Stress; Pyrazines; Reactive Oxygen Species; Sulindac; Transplantation, Heterologous | 2005 |
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Line, Tumor; Hepatocytes; Humans; Liver Neoplasms; Membrane Glycoproteins; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; RNA Interference; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2005 |
Severe acute enteritis in a multiple myeloma patient receiving bortezomib and spinal radiotherapy: case report.
Topics: Acute Disease; Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Enteritis; Female; Humans; Multiple Myeloma; Palliative Care; Pyrazines; Radiation Injuries; Spinal Neoplasms | 2005 |
Phosphorylation of AML1/RUNX1 regulates its degradation and nuclear matrix association.
Topics: Animals; Boronic Acids; Bortezomib; Core Binding Factor Alpha 2 Subunit; DNA-Binding Proteins; Immunoprecipitation; Mice; Mice, Knockout; Mutation; Nuclear Matrix; Phosphorylation; Protease Inhibitors; Proto-Oncogene Proteins; Pyrazines; Serine; Threonine; Transcription Factors; Transcription, Genetic; Ubiquitin | 2005 |
No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance; Female; Humans; Multiple Myeloma; Mutation; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2006 |
Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-kappaB.
Topics: Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Head and Neck Neoplasms; Humans; NF-kappa B; Pyrazines; RNA, Small Interfering; Transfection | 2005 |
Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Colonic Neoplasms; Cysteine Proteinase Inhibitors; Cytochromes c; Drug Resistance, Neoplasm; Humans; Intracellular Signaling Peptides and Proteins; Leupeptins; Membrane Glycoproteins; Membrane Proteins; Mitochondrial Proteins; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2005 |
Control of ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function.
Topics: Anthracyclines; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Carrier Proteins; Cell Line; Cell Line, Tumor; Dose-Response Relationship, Drug; E2F Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Proteasome Endopeptidase Complex; Pyrazines; Retinoblastoma Protein; RNA; RNA Interference; RNA Processing, Post-Transcriptional; RNA, Small Interfering; Time Factors; Transcription, Genetic; Tumor Suppressor Protein p53; Ubiquitin | 2005 |
Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
Topics: Analysis of Variance; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Fluorescent Antibody Technique; Humans; Lymphoma; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Statistics, Nonparametric; Tumor Cells, Cultured | 2005 |
Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
Topics: Antibodies, Monoclonal; Aryl Hydrocarbon Hydroxylases; Boronic Acids; Bortezomib; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Humans; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Protease Inhibitors; Pyrazines; Recombinant Proteins | 2005 |
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melphalan; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Protein Prenylation; Pyrazines; Quinolones; ras Proteins; Staurosporine; Tunicamycin | 2005 |
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
Topics: Apoptosis; Boronic Acids; Bortezomib; Down-Regulation; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Insulin-Like Growth Factor I; Interleukin-6; Multiple Myeloma; Phosphorylation; Piperidines; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyridines; Time Factors; Tumor Cells, Cultured | 2005 |
[Proteasome inhibitors].
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Docetaxel; Drug Therapy, Combination; Female; Graft vs Host Reaction; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Mice; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases.
Topics: Animals; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Disease Progression; Humans; Male; Mice; Mice, SCID; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2005 |
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
Topics: Animals; Bone Marrow; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytokines; HeLa Cells; Humans; Interferon-gamma; Mice; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2005 |
Development of effective new treatments for multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Approval; Drug Design; Humans; Multiple Myeloma; Pyrazines; United States; United States Food and Drug Administration | 2005 |
[Bortezomib in second-line therapy].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Neoplasms; Pyrazines; Randomized Controlled Trials as Topic | 2005 |
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Dexamethasone; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Galectin 3; Humans; I-kappa B Proteins; Lymphocytes; Multiple Myeloma; NF-KappaB Inhibitor alpha; Polysaccharides; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Vascular Endothelial Growth Factor A | 2005 |
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Boronic Acids; Bortezomib; Free Radical Scavengers; Humans; Lymphoma, Mantle-Cell; Membrane Potentials; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 2006 |
New therapies for the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Platelet Aggregation Inhibitors; Polydeoxyribonucleotides; Protease Inhibitors; Pyrazines; Thalidomide | 2005 |
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Differentiation; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Parathyroid Hormone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Treatment Outcome | 2005 |
NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145.
Topics: Animals; Antineoplastic Agents; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Colon; Cytokines; Graft Survival; Graft vs Host Disease; H-2 Antigens; Heterocyclic Compounds, 3-Ring; Leukocyte Common Antigens; Mice; Mice, Knockout; NF-kappa B; Pyrazines; Pyridines; Survival Rate | 2006 |
Bortezomib in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Drug Costs; Humans; Multiple Myeloma; Pyrazines; Recurrence; Survival Rate | 2005 |
Bortezomib in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Data Interpretation, Statistical; Dexamethasone; Follow-Up Studies; Humans; Multiple Myeloma; Pyrazines; Recurrence; Research Design; Survival Analysis | 2005 |
[Bortezomib (Velcade) in relapsed/refractory multiple myeloma--the first experience in the Czech Republic].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence | 2005 |
Bortezomib-induced Sweet syndrome.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Glucocorticoids; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Sweet Syndrome | 2005 |
Multiple myeloma: the present and the future.
Topics: Antineoplastic Agents, Alkylating; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Immunosuppressive Agents; Medical Oncology; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2005 |
Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram.
Topics: Alcohol Deterrents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line; Cell Nucleus; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; Cycloheximide; Disulfiram; Dose-Response Relationship, Drug; Humans; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Transport; Pyrazines; Pyrrolidines; Thiocarbamates; Tumor Necrosis Factor-alpha | 2006 |
Bortezomib increases survival of patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines; Survival Rate | 2005 |
Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus.
Topics: Boronic Acids; Bortezomib; Cell Line; Gene Expression Regulation, Viral; Herpesvirus 8, Human; Humans; Immediate-Early Proteins; Phorbol Esters; Protease Inhibitors; Pyrazines; Trans-Activators; Viral Proteins; Virus Activation; Virus Latency | 2005 |
Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, T-Cell, Cutaneous; Middle Aged; NF-kappa B; NF-kappa B p50 Subunit; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sezary Syndrome; Skin Neoplasms; Transcription Factor RelA | 2006 |
New agents and approaches in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2003 |
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Enzyme Activation; Humans; Insulin Receptor Substrate Proteins; Insulin-Like Growth Factor I; Mice; Mice, SCID; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Phosphoproteins; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor, IGF Type 1; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2005 |
Anti-angiogenic effect of bortezomib in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Microcirculation; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Pyrazines; Ribonuclease, Pancreatic; Vascular Endothelial Growth Factor A | 2005 |
N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Small Cell; Carrier Proteins; Cell Growth Processes; Cyclin D1; Cyclooxygenase 2; Down-Regulation; Drug Synergism; Enzyme Activation; Fenretinide; Genes, myc; Humans; I-kappa B Kinase; I-kappa B Proteins; Lung Neoplasms; Membrane Glycoproteins; NF-kappa B; NF-KappaB Inhibitor alpha; Oncogene Protein v-akt; Osteoclasts; Phosphorylation; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2005 |
Antimyeloma activity of heat shock protein-90 inhibition.
Topics: Androgens; Antineoplastic Agents; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Drug Synergism; Estrogens; Fusion Proteins, bcr-abl; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; I-kappa B Kinase; Lactams, Macrocyclic; Multiple Myeloma; Proto-Oncogene Proteins c-akt; Pyrazines; raf Kinases; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Interleukin-6; Rifabutin; Signal Transduction; Tumor Cells, Cultured | 2006 |
Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Cancer mouse models and other techniques for improved prediction of efficacy.
Topics: Angiogenesis Inhibitors; Animals; Boronic Acids; Bortezomib; Camptothecin; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Forecasting; Gemcitabine; Green Fluorescent Proteins; Humans; Image Enhancement; Irinotecan; Luminescent Proteins; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Pyrazines; Red Fluorescent Protein; Technology, Pharmaceutical; Treatment Outcome | 2005 |
Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Antineoplastic Agents; Antioxidants; Binding, Competitive; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Death; Cell Line; Cell Line, Tumor; Cell Survival; Drug Antagonism; Fibroblasts; Free Radicals; Humans; Immunoblotting; Kinetics; Leupeptins; Melanocytes; Melanoma; Membrane Potentials; Models, Biological; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Skin; Time Factors | 2006 |
Proteasome inhibitors in non-Hodgkin's lymphoma.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, Non-Hodgkin; Protease Inhibitors; Pyrazines | 2005 |
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Cytokines; Graft vs Host Disease; Humans; In Vitro Techniques; Isoantigens; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Protease Inhibitors; Pyrazines; T-Lymphocytes; Th1 Cells | 2006 |
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Movement; Cell Proliferation; Drug Synergism; Genes, bcl-2; Humans; Lactones; Lymphocytes; Mice; Mitochondria; Multiple Myeloma; NF-kappa B; Plasmacytoma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Pyrroles; Tumor Cells, Cultured | 2005 |
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
Topics: Adolescent; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Child; Child, Preschool; Drug Interactions; Heat-Shock Proteins; Histone Deacetylase Inhibitors; Humans; Infant; Inhibitory Concentration 50; Leukemia; Male; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Cells, Cultured | 2006 |
The ubiquitin proteasome pathway from bench to bedside.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2005 |
Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Female; Humans; Leukemia, Plasma Cell; Middle Aged; Pyrazines; Tumor Lysis Syndrome | 2005 |
Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Mobilization; Humans; Immunophenotyping; Leukemia, Plasma Cell; Pyrazines; Remission Induction; Treatment Outcome | 2006 |
Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Communication; Cell Survival; Coculture Techniques; Cytarabine; Endothelial Cells; Humans; Leukemia, Myeloid, Acute; Proteasome Inhibitors; Pyrazines | 2005 |
Waldenström's macroglobulinemia and bortezomib.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Diseases; Humans; Peripheral Nervous System Diseases; Pyrazines; Salvage Therapy; Waldenstrom Macroglobulinemia | 2005 |
Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Drug Evaluation; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Waldenstrom Macroglobulinemia | 2005 |
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Calcium; Caspase Inhibitors; Caspases; Caspases, Initiator; Cycloheximide; eIF-2 Kinase; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Molecular Chaperones; Oxidative Stress; Pancreas; Pancreatic Neoplasms; Phosphorylation; Protein Biosynthesis; Protein Processing, Post-Translational; Pyrazines; RNA, Small Interfering; Thapsigargin; Transcription Factor CHOP; Ubiquitin | 2005 |
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Calcium; Carcinogens; Caspase Inhibitors; Caspases; Cell Line, Tumor; Cisplatin; Cytochromes c; Drug Interactions; Endoplasmic Reticulum; Enzyme Activation; Humans; Immunoblotting; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Pyrazines; RNA, Small Interfering; Thapsigargin; Tumor Stem Cell Assay; Tunicamycin | 2005 |
Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin.
Topics: 14-3-3 Proteins; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cysteine Proteinase Inhibitors; DNA Damage; DNA Primers; Down-Regulation; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Proteins; Proteasome Inhibitors; Pyrazines; Survivin; Tumor Suppressor Protein p53 | 2005 |
The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Ligands; Membrane Glycoproteins; Neoplasms; Proteasome Inhibitors; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53 | 2005 |
New treatment approaches in multiple myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Congresses as Topic; Female; Humans; Incidence; Israel; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide | 2005 |
Response to bortezomib (velcade) in a case of advanced bronchiolo-alveolar carcinoma (BAC). A case report.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lung Neoplasms; Male; Pyrazines; Tomography, X-Ray Computed | 2006 |
Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Neuroblastoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Vincristine | 2006 |
Velcade and vitamin C: too much of a good thing?
Topics: Antineoplastic Agents; Ascorbic Acid; Boronic Acids; Bortezomib; Humans; Pyrazines; Vitamins | 2006 |
Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Ascorbic Acid; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Drug Interactions; Humans; Proteasome Endopeptidase Complex; Pyrazines | 2006 |
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Topics: Angiogenesis Inhibitors; Angiopoietin-1; Angiopoietin-2; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Growth Processes; Cells, Cultured; Chick Embryo; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Down-Regulation; Endothelial Cells; Humans; Insulin-Like Growth Factor I; Interleukin-6; Multiple Myeloma; Neovascularization, Pathologic; Neovascularization, Physiologic; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A | 2006 |
Successful treatment of lymph node extramedullary plasmacytoma with bortezomib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Doxorubicin; Etoposide; Humans; Injections, Intravenous; Lymph Nodes; Male; Middle Aged; Peritoneal Neoplasms; Plasmacytoma; Pyrazines; Radiotherapy Dosage; Stem Cell Transplantation; Tomography, X-Ray Computed; Transplantation, Autologous | 2006 |
Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts.
Topics: Acetylcysteine; Anthracenes; Boronic Acids; Bortezomib; Collagen Type I; Dose-Response Relationship, Drug; Down-Regulation; Extracellular Matrix; Fibroblasts; Fibrosis; Genes, jun; Humans; JNK Mitogen-Activated Protein Kinases; Leupeptins; Matrix Metalloproteinase 1; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-jun; Pyrazines; RNA Polymerase II; RNA, Messenger; Scleroderma, Systemic; Skin; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Up-Regulation | 2006 |
Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Japan; Lung; Male; Middle Aged; Multiple Myeloma; Pleural Effusion; Protease Inhibitors; Pyrazines; Respiratory Insufficiency | 2006 |
Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Models, Animal; Female; Mice; Mice, Inbred C57BL; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Protease Inhibitors; Pyrazines; Radiopharmaceuticals | 2006 |
Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
Topics: 14-3-3 Proteins; Antibiotics, Antineoplastic; Antigens, Nuclear; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspase 9; Caspase Inhibitors; Caspases; Cytochromes c; Depsipeptides; DNA-Binding Proteins; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histone Deacetylases; HL-60 Cells; Humans; K562 Cells; Ku Autoantigen; Leukemia; Mitochondria; Mitochondrial Membranes; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Transport; Pyrazines | 2006 |
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fibronectins; Humans; Leukemia, Myeloid, Acute; Multiple Myeloma; Pyrazines; Quinolones; Stromal Cells; Tumor Cells, Cultured | 2006 |
Proteasome inhibition induces hepatic stellate cell apoptosis.
Topics: Animals; Apoptosis; Bile Ducts; Boronic Acids; Bortezomib; Cell Line; Humans; Leupeptins; Ligation; Liver; Liver Cirrhosis; Mice; NF-kappa B; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Rats; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor | 2006 |
Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Female; Humans; Kinetics; Liver; Microsomes, Liver; Organ Size; Pyrazines; Rats; Rats, Sprague-Dawley | 2006 |
[Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2005 |
PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 2; Cathepsin B; Cysteine Endopeptidases; Cytochromes c; Down-Regulation; Enzyme Inhibitors; Humans; Lysosomes; Membrane Proteins; Mitochondrial Membranes; Mitochondrial Proteins; Pancreatic Neoplasms; Permeability; Phosphatidylserines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; RNA, Messenger; Tumor Cells, Cultured | 2006 |
Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines.
Topics: Boronic Acids; Bortezomib; Cytokines; Humans; Inflammation; Male; Middle Aged; Multiple Myeloma; Pyrazines; Skin; Vasculitis, Leukocytoclastic, Cutaneous | 2006 |
Bulbar palsy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Bulbar Palsy, Progressive; Combined Modality Therapy; Cranial Fossa, Posterior; Cranial Nerve Diseases; Cyclosporine; Dexamethasone; Disease Progression; Doxorubicin; Fatal Outcome; Female; Graft vs Host Disease; Humans; Immunocompromised Host; Immunoglobulin Light Chains; Immunosuppressive Agents; Magnetic Resonance Imaging; Methylprednisolone; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pneumonia, Aspiration; Pyrazines; Reflex, Abnormal; Transplantation, Homologous; Vincristine | 2005 |
Bortezomib-induced Sweet's syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Erectile Dysfunction; Humans; Immunosuppressive Agents; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Prednisolone; Protease Inhibitors; Pyrazines; Recurrence; Sleep Initiation and Maintenance Disorders; Sweet Syndrome; Testicular Diseases | 2005 |
Skin lesions induced by bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cetirizine; Combined Modality Therapy; Dexamethasone; Drug Eruptions; Exanthema; Histamine H1 Antagonists, Non-Sedating; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Salvage Therapy | 2005 |
Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate.
Topics: Binding Sites; Boronic Acids; Bortezomib; Crystallography, X-Ray; Dipeptides; Molecular Structure; Mycobacterium tuberculosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Substrate Specificity | 2006 |
Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl.
Topics: Adamantane; Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Hydroquinones; Imatinib Mesylate; Kinetics; Mutation; Oxidative Stress; Piperazines; Point Mutation; Pyrazines; Pyrimidines; Reactive Oxygen Species | 2006 |
The proteasome inhibitor VELCADE reduces infarction in rat models of focal cerebral ischemia.
Topics: Animals; Boronic Acids; Bortezomib; Brain Infarction; Brain Ischemia; Disease Models, Animal; Infarction, Middle Cerebral Artery; Intracranial Embolism; Male; Neuroprotective Agents; Proteasome Inhibitors; Pyrazines; Rats; Rats, Inbred WKY; Rats, Sprague-Dawley | 2006 |
Cell cycle-dependent cytotoxic and cytostatic effects of bortezomib on colon carcinoma cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma; Cell Cycle; Colonic Neoplasms; Cyclin B; Humans; Pyrazines; Transcription Factor RelA | 2006 |
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Humans; Multiple Myeloma; Neoplasm Proteins; Plasma Cells; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Folding; Pyrazines; Signal Transduction | 2006 |
Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation.
Topics: Animals; Boronic Acids; Bortezomib; Gene Expression Regulation; Male; Muscle Denervation; Muscle, Skeletal; Muscular Atrophy; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sciatic Nerve; Testosterone; Ubiquitin | 2006 |
Closing the gap.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Pharmacology; Pharmacology, Clinical; Pyrazines; Research; Research Support as Topic; United States | 2006 |
Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials as Topic; Deubiquitinating Enzyme CYLD; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Tumor Suppressor Proteins; Ubiquitin; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2006 |
JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Caspases; Cell Line; Cell Line, Tumor; Fas Ligand Protein; Heat-Shock Proteins; Humans; Liver; Liver Neoplasms; Membrane Glycoproteins; Mitochondria; Mitogen-Activated Protein Kinase 8; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-jun; Pyrazines; Signal Transduction; Transcription Factor AP-1; Tumor Necrosis Factors | 2006 |
Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Soft Tissue Neoplasms; Treatment Outcome | 2006 |
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Catalytic Domain; Crystallization; Leucine; Mammals; Models, Molecular; Peptides; Phenylalanine; Proteasome Endopeptidase Complex; Protein Structure, Quaternary; Pyrazinamide; Pyrazines; Structure-Activity Relationship; Substrate Specificity; Yeasts | 2006 |
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation.
Topics: Adaptor Proteins, Signal Transducing; Boronic Acids; Bortezomib; Cells, Cultured; Chemotaxis; Cytokines; Dendritic Cells; Gene Expression Regulation; Humans; Immune System; Immunologic Factors; Lipopolysaccharides; Myeloid Differentiation Factor 88; Phagocytosis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Signal Transduction; Toll-Like Receptor 4 | 2006 |
Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator.
Topics: Animals; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Brain; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Fibrinolytic Agents; Humans; Infarction, Middle Cerebral Artery; Intracranial Embolism; Male; NF-kappa B; Nitric Oxide Synthase Type III; Platelet Aggregation; Protease Inhibitors; Pyrazines; Rats; Rats, Wistar; Recombinant Proteins; Stroke; Time Factors; Tissue Plasminogen Activator; Vascular Patency | 2006 |
SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; NF-kappa B; Oropharyngeal Neoplasms; Pyrazines; SUMO-1 Protein | 2006 |
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells.
Topics: Boronic Acids; Bortezomib; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Enzyme Activation; ErbB Receptors; Female; Humans; Immediate-Early Proteins; MAP Kinase Kinase 4; MAP Kinase Kinase Kinases; Mitogen-Activated Protein Kinase 1; Phosphoprotein Phosphatases; Phosphorylation; Proteasome Inhibitors; Protein Phosphatase 1; Protein Serine-Threonine Kinases; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-akt; Pyrazines; raf Kinases; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2 | 2006 |
Medullary renal cell carcinoma and response to therapy with bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Humans; Kidney Medulla; Kidney Neoplasms; Neoplasm Metastasis; Pyrazines; Treatment Outcome | 2006 |
Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Drug Resistance; Drug Resistance, Neoplasm; Female; Humans; Protease Inhibitors; Proteasome Inhibitors; PTEN Phosphohydrolase; Pyrazines; Trastuzumab | 2006 |
Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2005 |
[Effects of proteasome inhibitor PS-341 on the multiple cytokine expressions of mesenchymal stem cells from bone marrow in patients with multiple myeloma].
Topics: Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cytokines; Humans; Interleukin-1beta; Interleukin-6; Mesenchymal Stem Cells; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Factor | 2006 |
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Division; Cell Line, Tumor; Female; G2 Phase; Humans; Leupeptins; Mice; Mice, Nude; Oligopeptides; Ovarian Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin; Xenograft Model Antitumor Assays | 2006 |
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Vorinostat; Xenograft Model Antitumor Assays | 2006 |
Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cytotoxicity, Immunologic; Dendritic Cells; Immunization; Immunotherapy; In Vitro Techniques; Killer Cells, Natural; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Knockout; Protease Inhibitors; Pyrazines; Tumor Necrosis Factor-alpha | 2006 |
Hematologic malignancies: from clinical science to clinical practice - 2nd European Congress.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematologic Neoplasms; Humans; Ki-1 Antigen; Molecular Structure; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous | 2006 |
Oxidative deboronation of the peptide boronic acid proteasome inhibitor bortezomib: contributions from reactive oxygen species in this novel cytochrome P450 reaction.
Topics: Boranes; Boronic Acids; Bortezomib; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Microsomes, Liver; Oxidation-Reduction; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species | 2006 |
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation.
Topics: Adult; Aged; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Graft Survival; Humans; Male; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Time Factors; Transplantation, Homologous | 2006 |
Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; In Vitro Techniques; Indoles; Injections, Intravenous; Leupeptins; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 14; Molecular Chaperones; Multiple Myeloma; Neoplasm Proteins; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2006 |
Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells.
Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 3; Cell Death; Cells, Cultured; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Pyrazines; Rituximab | 2006 |
Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytokines; Disease Models, Animal; Growth Inhibitors; Interleukin-12; Interleukin-2; Liver Neoplasms; Male; Mice; Mice, Inbred A; Neuroblastoma; Proteasome Inhibitors; Pyrazines | 2006 |
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
Topics: Animals; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Genes, bcl-2; Humans; Kinetics; Lymphoma, B-Cell; Mice; Mice, SCID; Oligonucleotides, Antisense; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Thionucleotides; Transplantation, Heterologous | 2006 |
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Comorbidity; Deoxycytidine; Gemcitabine; Heart Failure; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Risk Factors; Ventricular Dysfunction, Left | 2006 |
The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; B-Lymphocytes; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 3; Caspase 8; Caspases; Cell Line, Tumor; Cell Survival; Cysteine Proteinase Inhibitors; Drug Synergism; Gene Expression; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Leupeptins; Membrane Glycoproteins; Middle Aged; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2006 |
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Disease Progression; Drug Approval; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; United States; United States Food and Drug Administration | 2006 |
[Promising targeted molecular therapies for the future years in non-small-cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Forecasting; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Randomized Controlled Trials as Topic; Research; Signal Transduction; Taxoids; Vascular Endothelial Growth Factor A | 2006 |
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
Topics: Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydrolases; Hydroxamic Acids; Indoles; Multiple Myeloma; Panobinostat; Poly(ADP-ribose) Polymerase Inhibitors; Protease Inhibitors; Pyrazines; Tubulin; Tubulin Modulators; Tumor Cells, Cultured | 2006 |
Bortezomib induces in HepG2 cells IkappaBalpha degradation mediated by caspase-8.
Topics: Boronic Acids; Bortezomib; Caspase 8; Cell Line; Cell Line, Tumor; Humans; I-kappa B Proteins; Liver; Liver Neoplasms; NF-kappa B; NF-KappaB Inhibitor alpha; Pyrazines | 2006 |
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Indoles; Melphalan; Multiple Myeloma; Panobinostat; Pyrazines | 2006 |
Differential regulation of eotaxin-1/CCL11 and eotaxin-3/CCL26 production by the TNF-alpha and IL-4 stimulated human lung fibroblast.
Topics: Asthma; Boronic Acids; Bortezomib; Cell Line; Chemokine CCL11; Chemokine CCL26; Chemokines, CC; Drug Synergism; Enzyme Inhibitors; Fibroblasts; Humans; Hypersensitivity; Immunoblotting; Interleukin-4; Leupeptins; Lung; Mitogen-Activated Protein Kinases; NF-kappa B; Pyrazines; Recombinant Proteins; STAT6 Transcription Factor; Tumor Necrosis Factor-alpha | 2006 |
Life-threatening motor neurotoxicity in association with bortezomib.
Topics: Aged; Boronic Acids; Bortezomib; Critical Illness; Female; Humans; Middle Aged; Multiple Myeloma; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Pyrazines | 2006 |
A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Korea; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2006 |
Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2006 |
Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation.
Topics: Antineoplastic Agents; Bone Marrow Neoplasms; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Drug Therapy, Combination; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Transplantation, Autologous; Treatment Outcome | 2006 |
Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Nucleus; Cell Transformation, Neoplastic; Enzyme Activation; Genes, ras; HCT116 Cells; Histones; Humans; Intracellular Signaling Peptides and Proteins; Mutation; Phosphorylation; Protease Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; ras Proteins; Signal Transduction | 2006 |
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.
Topics: Apoptosis; Boronic Acids; Bortezomib; Catalysis; Cell Line, Tumor; Glyoxal; HeLa Cells; Humans; Leucine; Leupeptins; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Substrate Specificity | 2006 |
Inhibition of bortezomib-induced apoptosis by red blood cell uptake.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Erythrocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines | 2006 |
Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse.
Topics: Animals; Bile Ducts; Boronic Acids; Bortezomib; Cell Count; Cholestasis; Hepatocytes; Liver Cirrhosis; Macrophage Activation; Macrophages; Mice; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2006 |
[Recurrent varicella in a woman with mantle cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chickenpox; Combined Modality Therapy; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Lymphoma, Mantle-Cell; Middle Aged; Postoperative Complications; Pyrazines; Recurrence; Transplantation, Autologous | 2006 |
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
Topics: Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Transformed; Cell Line, Tumor; Dual Specificity Phosphatase 1; Female; Humans; Immediate-Early Proteins; p38 Mitogen-Activated Protein Kinases; Phosphoprotein Phosphatases; Protease Inhibitors; Protein Phosphatase 1; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-akt; Pyrazines | 2006 |
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib.
Topics: Aged; Boronic Acids; Bortezomib; Electrodiagnosis; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Nervous System Diseases; Prostatic Neoplasms; Protease Inhibitors; Pyrazines | 2006 |
Additional dexamethasone improves the response rate among patients with multiple myeloma treated with single agent bortezomib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Pyrazines; Remission Induction | 2006 |
Perspective on the current use of bortezomib in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2006 |
Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 5; Female; Humans; Interleukin-4; Interleukin-6; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Platelet Count; Pyrazines; Thrombocytosis; Tumor Necrosis Factor-alpha | 2007 |
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Pyrazines; Quality of Life; Recurrence | 2006 |
The safety and efficacy of bortezomib in relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Pyrazines; Recurrence; Survival Rate; Treatment Outcome | 2006 |
Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Neovascularization, Pathologic; Pyrazines; Receptor, IGF Type 1; Structure-Activity Relationship; Survival Rate; Xenograft Model Antitumor Assays | 2007 |
Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Thrombocytopenia; Treatment Outcome | 2006 |
Enhancing care and managing side effects in patients receiving bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Management; Dose-Response Relationship, Drug; Humans; Kinetics; Oncology Nursing; Patient Education as Topic; Platelet Count; Pyrazines; Quality of Life; Treatment Outcome | 2006 |
Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Polymerase Chain Reaction; Proteasome Inhibitors; Pyrazines; TCF Transcription Factors; Transcription Factor 7-Like 2 Protein; Tumor Cells, Cultured | 2006 |
Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain.
Topics: Animals; Biomarkers; Boronic Acids; Bortezomib; Carbonic Anhydrases; Cell Line; Enzyme Activation; Gene Expression Regulation; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Isoenzymes; p300-CBP Transcription Factors; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Structure, Tertiary; Pyrazines; Recombinant Fusion Proteins; Transcription, Genetic; Vascular Endothelial Growth Factor A | 2006 |
[Molecular-targeted therapy for hormone-refractory prostate cancer].
Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D | 2006 |
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Medullary; Caspases; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Enzyme Inhibitors; Humans; Insulin-Like Growth Factor I; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Proto-Oncogene Proteins c-jun; Pyrazines; Thyroid Neoplasms; Tumor Suppressor Protein p53 | 2006 |
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Depsipeptides; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Killer Cells, Natural; Membrane Glycoproteins; Neoplasms; Protease Inhibitors; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2006 |
Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease.
Topics: Blood Transfusion; Boronic Acids; Bortezomib; Castleman Disease; Female; Humans; Interleukin-6; Middle Aged; Protease Inhibitors; Pyrazines; Treatment Outcome | 2006 |
Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Multiple Myeloma; Pyrazines; Renal Insufficiency | 2006 |
Severe pulmonary complication after bortezomib treatment for multiple myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Humans; Lung Diseases; Male; Multiple Myeloma; Pyrazines | 2006 |
Proteasome inhibitor drugs on the rise.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Ubiquitin; United States; United States Food and Drug Administration | 2006 |
Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress.
Topics: Apoptosis; Boronic Acids; Bortezomib; Endoplasmic Reticulum; Humans; Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2006 |
Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Tumor Lysis Syndrome | 2006 |
Ariad Pharmaceuticals wins first round over Eli Lilly, patents on methods can be far-reaching.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Biotechnology; Boronic Acids; Bortezomib; Celecoxib; Cyanides; Drug Industry; Etanercept; Guanidines; Humans; Immunoglobulin G; Interleukin 1 Receptor Antagonist Protein; NF-kappa B; Patents as Topic; Protein C; Pyrazines; Pyrazoles; Raloxifene Hydrochloride; Receptors, Tumor Necrosis Factor; Recombinant Proteins; Rituximab; Sialoglycoproteins; Sulfonamides; United States | 2006 |
VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Etoposide; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Protease Inhibitors; Pyrazines; Remission Induction | 2006 |
Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Treatment Failure | 2007 |
The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles | 2006 |
Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunohistochemistry; Liver Diseases; Male; Middle Aged; Multiple Myeloma; Pancreatic Neoplasms; Pyrazines; Tomography, X-Ray Computed | 2006 |
Estrogen-triggered delays in mammary gland gene expression during the estrous cycle: evidence for a novel timing system.
Topics: Animals; Base Sequence; Boronic Acids; Bortezomib; Carrier Proteins; Cytoplasm; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor alpha; Estrous Cycle; Feedback, Physiological; Female; Gene Expression; Genes, Regulator; Mammary Glands, Animal; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Knockout; Molecular Sequence Data; Ovariectomy; PAX2 Transcription Factor; Progesterone; Protease Inhibitors; Proto-Oncogene Proteins; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Progesterone; Sequence Analysis, DNA; Time Factors; Wnt Proteins; Wnt4 Protein | 2006 |
Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; NF-kappa B; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2006 |
Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Fragmentation; Fluorescent Antibody Technique; Humans; Immunohistochemistry; Mice; Mitotic Index; Neovascularization, Pathologic; Neuroblastoma; Protease Inhibitors; Pyrazines; Transplantation, Heterologous; Tumor Stem Cell Assay | 2006 |
[Multiple myeloma cell line U266 apoptosis induced by velcade].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Messenger | 2006 |
Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cisplatin; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Eukaryotic Initiation Factor-2; Humans; Mice; Phosphorylation; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2006 |
Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Division; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Humans; Male; Prostatic Neoplasms; Pyrazines; Taxoids; Tumor Cells, Cultured | 2006 |
Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Synergism; Humans; Lymphoma, T-Cell; Male; Pyrazines; Radiography; Remission Induction | 2006 |
Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Plasmacytoma; Pyrazines; Treatment Outcome | 2007 |
Burn-induced increase in atrogin-1 and MuRF-1 in skeletal muscle is glucocorticoid independent but downregulated by IGF-I.
Topics: Animals; Blotting, Northern; Boronic Acids; Bortezomib; Burns; Down-Regulation; Glucocorticoids; Hormone Antagonists; Immunoblotting; Insulin-Like Growth Factor I; Leucine; Male; Mifepristone; Muscle Proteins; Muscle, Skeletal; Myocardium; Organ Size; Polyubiquitin; Protein Synthesis Inhibitors; Pyrazines; Rats; Rats, Wistar; RNA, Messenger; SKP Cullin F-Box Protein Ligases; Tripartite Motif Proteins; Ubiquitin; Ubiquitin-Protein Ligases; Wasting Syndrome | 2007 |
Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Biomarkers, Tumor; Boronic Acids; Bortezomib; Breast Neoplasms; Calcium; Caspase 3; Caspases; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Microarray Analysis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; STAT3 Transcription Factor; Transplantation, Heterologous; Up-Regulation | 2006 |
Bortezomib is effective in primary plasma cell leukemia.
Topics: Bone Marrow Examination; Boronic Acids; Bortezomib; Female; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Remission Induction; Treatment Outcome | 2006 |
Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade.
Topics: Adenosine Triphosphatases; Animals; Benzoquinones; Boronic Acids; Bortezomib; Cell Cycle Proteins; Chlorocebus aethiops; COS Cells; Endoplasmic Reticulum; Genes, erbB-2; HSP90 Heat-Shock Proteins; Lactams, Macrocyclic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Transport; Pyrazines; RNA, Small Interfering; Tunicamycin; Ubiquitins; Vacuoles; Valosin Containing Protein | 2006 |
[A cure for multiple myeloma?].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2006 |
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; I-kappa B Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; NF-KappaB Inhibitor alpha; Pancreatic Neoplasms; Pyrazines; Pyridines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2006 |
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; K562 Cells; MAP Kinase Signaling System; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2006 |
[Bortezomib-induced tumor lysis syndrome with a remarkable elevation of LDH in a case of relapsed and therapy-resistant multiple myeloma].
Topics: Antineoplastic Agents; Bence Jones Protein; Biomarkers; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; L-Lactate Dehydrogenase; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome; Tumor Lysis Syndrome | 2006 |
Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carrier Proteins; CDC2-CDC28 Kinases; Chromosome Deletion; Cyclin-Dependent Kinases; Disease-Free Survival; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Rate; Translocation, Genetic | 2007 |
Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Colonic Neoplasms; Drug Synergism; Enzyme Activation; Humans; Intracellular Signaling Peptides and Proteins; Leupeptins; Mitochondria; Mitochondrial Proteins; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; TNF-Related Apoptosis-Inducing Ligand | 2006 |
Bortezomib-induced rhabdomyolysis in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Rhabdomyolysis; Salvage Therapy | 2006 |
Bortezomib-induced skin lesion.
Topics: Aged, 80 and over; Boronic Acids; Bortezomib; Drug Eruptions; Female; Humans; Multiple Myeloma; Pyrazines | 2006 |
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-X Protein; Biphenyl Compounds; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Division; Cell Survival; Humans; Multiple Myeloma; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; Tumor Cells, Cultured | 2007 |
Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Melanoma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protease Inhibitors; Protein Interaction Mapping; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Ultraviolet Rays; Vidarabine | 2006 |
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Catalytic Domain; Cell Line, Tumor; Drug Screening Assays, Antitumor; Hematologic Neoplasms; Humans; Leukemia; Mice; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2007 |
Bortezomib dosing in relapsed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Survival Rate | 2006 |
Multiple myeloma associated with porphyria cutanea tarda: a possible role of bortezomib?
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Porphyria Cutanea Tarda; Pyrazines | 2006 |
Bortezomib inhibits T-cell function versus infective antigenic stimuli in a dose-dependent manner in vitro.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cytomegalovirus; Dose-Response Relationship, Drug; Enterotoxins; Humans; In Vitro Techniques; Pyrazines; T-Lymphocytes | 2007 |
Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Drug Eruptions; Drug Therapy, Combination; Erythema; Fever; Glucocorticoids; Histamine H1 Antagonists; Humans; Male; Medical Records; Middle Aged; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Skin; Skin Ulcer | 2006 |
Dual alterations in casein kinase I-epsilon and GSK-3beta modulate beta-catenin stability in hyperproliferating colonic epithelia.
Topics: Animals; Axin Protein; beta Catenin; Boronic Acids; Bortezomib; Casein Kinase 1 epsilon; Cell Nucleus; Citrobacter rodentium; Colon; Cyclic AMP Response Element-Binding Protein; Cytoskeleton; DNA; Enterobacteriaceae Infections; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hyperplasia; Immunoprecipitation; Intestinal Mucosa; Mice; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Binding; Protein Kinase C; Pyrazines; Repressor Proteins; Serine; TCF Transcription Factors; Threonine; Transcription Factor 7-Like 2 Protein | 2007 |
Are the Scots getting a better deal on prescribed drugs than the English?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Delivery of Health Care; Drug Prescriptions; England; Humans; Multiple Myeloma; Pyrazines; Scotland; State Medicine | 2006 |
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid | 2006 |
Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells.
Topics: Acetylcysteine; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Chymases; Cysteine Proteinase Inhibitors; Dendritic Cells; Endocytosis; Humans; Interleukin-12; Lymphocyte Activation; Monocytes; Oligopeptides; Pinocytosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Receptors, Cell Surface | 2007 |
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.
Topics: Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytogenetic Analysis; Humans; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Survival Analysis | 2007 |
Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Cytarabine; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Promyelocytic, Acute; Multidrug Resistance-Associated Proteins; Protease Inhibitors; Pyrazines; Tumor Suppressor Protein p53 | 2007 |
Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
Topics: Adult; Amino Acid Sequence; Animals; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Line; Cell Line, Tumor; Drug Synergism; Epitopes, T-Lymphocyte; Female; Flow Cytometry; Gene Expression; HLA-A Antigens; HLA-A24 Antigen; Humans; Interferon-gamma; Mice; Middle Aged; NIH 3T3 Cells; Oncogene Proteins, Viral; Protease Inhibitors; Pyrazines; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; T-Lymphocytes, Cytotoxic; Uterine Cervical Neoplasms | 2007 |
New drugs for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Design; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome | 2006 |
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Remodeling; Boronic Acids; Bortezomib; Case-Control Studies; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; Isoenzymes; Male; Middle Aged; Multiple Myeloma; Osteocalcin; Osteoprotegerin; Peptides; Protease Inhibitors; Pyrazines; RANK Ligand; Recurrence; Statistics, Nonparametric; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2006 |
Can survivin expression predict the response to bortezomib in cases with mantle cell lymphoma?
Topics: Boronic Acids; Bortezomib; Humans; Inhibitor of Apoptosis Proteins; Lymphoma, Mantle-Cell; Microtubule-Associated Proteins; Neoplasm Proteins; NF-kappa B; Pyrazines; Survivin | 2006 |
Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cells, Cultured; Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neovascularization, Physiologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sensitivity and Specificity; Up-Regulation | 2007 |
Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure.
Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Salvage Therapy; Treatment Outcome | 2006 |
NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Colonic Neoplasms; Drug Administration Routes; Drug Synergism; Female; Humans; Lactones; Mice; Mice, Nude; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Pyrroles; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2006 |
Late onset of bortezomib-associated cutaneous reaction following herpes zoster.
Topics: Acyclovir; Anti-Inflammatory Agents; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Dexamethasone; Exanthema; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Skin; Treatment Outcome | 2007 |
The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.
Topics: Adult; Aged; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chickenpox; Dexamethasone; Disease Susceptibility; Doxorubicin; Female; Herpesvirus 3, Human; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Virus Activation | 2007 |
Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Pleural Effusion; Pyrazines; Respiratory Insufficiency; Vasculitis | 2007 |
Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; I-kappa B Kinase; I-kappa B Proteins; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; NF-kappa B; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-6; Pyrazines; Sulfones; Tumor Cells, Cultured; ZAP-70 Protein-Tyrosine Kinase | 2006 |
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Renal Insufficiency; Retrospective Studies | 2007 |
Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Drug Synergism; Humans; NF-kappa B; Pyrazines; Receptor, ErbB-2; Trastuzumab | 2006 |
EGF receptor activity modulates apoptosis induced by inhibition of the proteasome of vascular smooth muscle cells.
Topics: Animals; Apoptosis; bcl-Associated Death Protein; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Cells, Cultured; ErbB Receptors; Mitochondria; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Quinazolines; Rats; RNA Interference | 2007 |
Management of toxicities associated with bortezomib.
Topics: Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Pyrazines; Treatment Outcome | 2006 |
[Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor].
Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Caspases; Flow Cytometry; HL-60 Cells; Humans; Leukemia, Myeloid; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2006 |
Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Multiple Myeloma; NF-kappa B; Proto-Oncogene Proteins c-akt; Pyrazines; Resveratrol; STAT3 Transcription Factor; Stilbenes; Syndecan-1; Thalidomide; Tumor Cells, Cultured | 2007 |
An internationally recognized uniform cytogenetic classification system is needed for multiple myeloma.
Topics: Boronic Acids; Bortezomib; Chromosome Aberrations; Cytogenetic Analysis; Humans; Multiple Myeloma; Predictive Value of Tests; Prognosis; Pyrazines | 2007 |
Novel agents for multiple myeloma treatment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Design; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Detection of a proteasome in Pneumocystis carinii and its modulation by specific proteasome inhibitors.
Topics: Acetylcysteine; Animals; Boronic Acids; Bortezomib; Cell Line; Coumarins; Genes, Fungal; HIV Protease Inhibitors; Humans; Lopinavir; Models, Animal; Oligopeptides; Pneumocystis carinii; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrimidinones; Rats | 2006 |
Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Growth Processes; Fibroblast Growth Factor 2; Humans; Interferon-alpha; Interleukin-8; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2006 |
Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib.
Topics: Animals; Antineoplastic Agents; Binding, Competitive; Boronic Acids; Bortezomib; Drug Stability; Female; HeLa Cells; HT29 Cells; Humans; Lactones; Mice; Mice, Nude; Mice, SCID; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Xenograft Model Antitumor Assays | 2006 |
Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia.
Topics: Animals; Boronic Acids; Bortezomib; CD4 Antigens; CD8 Antigens; Cell Line; Cell Line, Tumor; Cell Survival; Chlorocebus aethiops; COS Cells; DNA-Binding Proteins; Gene Expression Profiling; Green Fluorescent Proteins; Humans; Interleukin Receptor Common gamma Subunit; Leukemia, Experimental; Leukemia, T-Cell; Mice; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Confocal; Mutation; NF-kappa B; Pyrazines; Receptor, Notch1; Signal Transduction; Survival Analysis | 2007 |
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cytotoxicity Tests, Immunologic; Dexamethasone; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Immunoblotting; Interleukin-6; Intracellular Signaling Peptides and Proteins; Lactams, Macrocyclic; Multiple Myeloma; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Signal Transduction; Stem Cells; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2007 |
[Follicular keratosis and multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Female; Humans; Keratolytic Agents; Keratosis; Middle Aged; Multiple Myeloma; Pyrazines; Skin | 2006 |
Quantitative sensory findings in patients with bortezomib-induced pain.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Cold Temperature; Female; Hot Temperature; Humans; Lymphoma, B-Cell; Male; Middle Aged; Multiple Myeloma; Pain; Pain Measurement; Pain Threshold; Psychomotor Performance; Pyrazines; Sensation; Sensation Disorders; Thermosensing; Touch | 2007 |
NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs.
Topics: Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Hodgkin Disease; Humans; Jurkat Cells; Neoplasm Proteins; NF-kappa B; Pyrazines; Reed-Sternberg Cells; X-Linked Inhibitor of Apoptosis Protein | 2007 |
Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical h
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Boronic Acids; Bortezomib; Drug Approval; Female; Hematology; Humans; Japan; Lung Diseases; Lung Injury; Male; Multiple Myeloma; Pyrazines; Societies, Medical; Stem Cell Transplantation; Surveys and Questionnaires | 2006 |
[Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Protease Inhibitors; Pyrazines; Salvage Therapy | 2006 |
WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP).
Topics: Actins; Animals; Arginine; Boronic Acids; Bortezomib; Calpain; Carrier Proteins; Cytoskeletal Proteins; Enzyme Inhibitors; Humans; Interleukin-2; Intracellular Signaling Peptides and Proteins; Jurkat Cells; Lymphocytes; Mice; Mice, Knockout; Molecular Chaperones; Mutation, Missense; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Binding; Pyrazines; Wiskott-Aldrich Syndrome; Wiskott-Aldrich Syndrome Protein | 2007 |
Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.
Topics: Animals; Boronic Acids; Bortezomib; Female; Ganglia, Spinal; Microscopy, Electron; Neural Conduction; Neurons, Afferent; Neurotoxins; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Wistar; Sciatic Nerve; Spinal Cord; Tail | 2007 |
Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Communication; Cell Line, Tumor; Colony-Forming Units Assay; Dendritic Cells; Flow Cytometry; Humans; Lymphoma; Multiple Myeloma; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2007 |
Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Head and Neck Neoplasms; Humans; Pyrazines; Radiation Dosage; Radiation-Sensitizing Agents | 2007 |
The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Boronic Acids; Bortezomib; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Lymphoma, Mantle-Cell; Molecular Mimicry; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Peptide Fragments; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Tumor Cells, Cultured | 2007 |
[Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Female; Hematology; Humans; Japan; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Protease Inhibitors; Pyrazines; Recurrence; Risk Factors; Societies, Medical; Stem Cell Transplantation; Surveys and Questionnaires | 2006 |
Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer.
Topics: Adherens Junctions; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cell Movement; Desmoglein 2; Desmoplakins; Desmosomal Cadherins; Drug Synergism; ErbB Receptors; Focal Adhesion Kinase 1; Humans; Pyrazines; Tongue Neoplasms | 2007 |
The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Genes, p53; Genetic Therapy; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Transfection; Tumor Cells, Cultured | 2007 |
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Mice; Mice, SCID; NF-kappa B p50 Subunit; Proteasome Inhibitors; Protein Binding; Pyrazines; RNA, Small Interfering; Sulfonamides; Transcription Factor RelA; Xenograft Model Antitumor Assays | 2007 |
Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Cycle; Cell Death; Cell Survival; Drug Administration Schedule; Drug Synergism; ErbB Receptors; Inhibitory Concentration 50; Kidney Neoplasms; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines | 2007 |
Pseudomembranous colitis following bortezomib therapy in a myeloma patient.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Enterocolitis, Pseudomembranous; Female; Humans; Magnetic Resonance Imaging; Metronidazole; Multiple Myeloma; Pyrazines | 2007 |
Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Female; Humans; Leupeptins; Membrane Proteins; Mitochondria; Ovarian Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand | 2007 |
Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Division; Cell Line, Tumor; Enzyme Inhibitors; G2 Phase; Humans; Lymphoma, Large B-Cell, Diffuse; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2007 |
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radioimmunotherapy; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Yttrium Radioisotopes | 2007 |
Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Autoradiography; Boronic Acids; Bortezomib; Carbon Radioisotopes; Chromatography, Liquid; Drug Administration Schedule; Injections, Intravenous; Male; Protease Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Scintillation Counting; Tandem Mass Spectrometry; Tissue Distribution | 2007 |
American Society of Hematology--48th Annual Meeting and Exposition. Updates on hematological therapies. 9-12 December 2006 Orlando, FL, USA.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Hematologic Neoplasms; Hematology; Humans; Indoles; Janus Kinase 2; Lactams, Macrocyclic; Myeloproliferative Disorders; Phosphorylcholine; Pyrazines | 2007 |
Bortezomib-associated rash: a new recognizable and avoidable side-effect.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Exanthema; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2007 |
Medical management update: multiple myeloma.
Topics: Adrenal Cortex Hormones; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dental Care for Chronically Ill; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Jaw Diseases; Jaw Neoplasms; Multiple Myeloma; Oral Hemorrhage; Osteonecrosis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Thalidomide | 2007 |
Impact of differential recovery in bioanalysis: the example of bortezomib in whole blood.
Topics: Animals; Boronic Acids; Bortezomib; Haplorhini; Mice; Molecular Structure; Pyrazines; Rats; Time Factors | 2007 |
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Dendritic Cells; Gamma Rays; HSP90 Heat-Shock Proteins; Humans; Interferon-gamma; Lactams, Macrocyclic; Leukocytes, Mononuclear; Multiple Myeloma; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines | 2007 |
Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Multiple Myeloma; Pyrazines; Recurrence; Reproducibility of Results; Thalidomide | 2007 |
Community experience with bortezomib in patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Community Medicine; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate | 2007 |
Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Female; Humans; Middle Aged; Multiple Myeloma; Pulmonary Fibrosis; Pyrazines; Recurrence; Respiratory Insufficiency; Steroids; Treatment Failure | 2007 |
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.
Topics: Adamantane; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cell Growth Processes; Dexamethasone; Humans; Hydroquinones; Imatinib Mesylate; Leukemia, Erythroblastic, Acute; Melphalan; Multiple Myeloma; Piperazines; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-jun; Pyrazines; Pyrimidines; Transfection; Up-Regulation | 2007 |
Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Boronic Acids; Bortezomib; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Squamous Cell; Caspase 3; Cell Hypoxia; Cell Line, Tumor; Cell Nucleus; Colonic Neoplasms; E1A-Associated p300 Protein; Enzyme Activation; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leupeptins; Male; Prostatic Neoplasms; Protease Inhibitors; Protein Binding; Pyrazines; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Topics: Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Immunoglobulin G; Immunoglobulin mu-Chains; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transcription Factor AP-1 | 2007 |
p27 degradation by an ellipticinium series of compound via ubiquitin-proteasome pathway.
Topics: Animals; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Cysteine Proteinase Inhibitors; Ellipticines; Glioblastoma; Humans; Leupeptins; Mice; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Radiation-Sensitizing Agents; S-Phase Kinase-Associated Proteins; Transcription, Genetic; Tumor Cells, Cultured; Ubiquitin; Ubiquitin-Protein Ligases | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |
Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Fatal Outcome; Humans; Male; Multiple Myeloma; Pyrazines; Respiratory Distress Syndrome | 2007 |
TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Hepatocytes; Humans; Liver; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand | 2007 |
Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Flow Cytometry; Humans; Immunohistochemistry; Proteasome Inhibitors; Pyrazines; Retroviridae; Reverse Transcriptase Polymerase Chain Reaction; Thyroid Neoplasms; TNF-Related Apoptosis-Inducing Ligand | 2007 |
NICE: friend and foe.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Approval; Government Agencies; Multiple Myeloma; Public Opinion; Public Policy; Pyrazines; Quality-Adjusted Life Years; United Kingdom | 2007 |
Proteasomal inhibition in intracerebral hemorrhage: neuroprotective and anti-inflammatory effects of bortezomib.
Topics: Animals; Anti-Inflammatory Agents; Biomarkers; Boronic Acids; Bortezomib; Brain Edema; Cerebral Cortex; Cerebral Hemorrhage; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Encephalitis; Gliosis; Inflammation Mediators; Male; Microglia; Neuroprotective Agents; Neutrophils; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Treatment Outcome | 2007 |
Virus-associated tumor imaging by induction of viral gene expression.
Topics: Animals; Antineoplastic Agents; Arabinofuranosyluracil; Boronic Acids; Bortezomib; Burkitt Lymphoma; Diagnostic Imaging; Gene Expression; Gene Transfer Techniques; Genes, Viral; Herpesvirus 4, Human; Humans; Immunoblotting; Mice; Neoplasms, Experimental; Oncogenic Viruses; Pyrazines; Radionuclide Imaging; Radiopharmaceuticals; Reverse Transcriptase Polymerase Chain Reaction; Thymidine Kinase | 2007 |
Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Chemokines; Chemotaxis; DNA Replication; Female; Hematopoietic Cell Growth Factors; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; NF-kappa B; Pyrazines; Receptors, Chemokine; Recombinant Fusion Proteins; T-Lymphocytes; Tumor Stem Cell Assay | 2007 |
The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Oligopeptides; Protease Inhibitors; Pyrazines | 2007 |
[Bortezomib in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2006 |
Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
Topics: Adult; Antigen Presentation; Antigens, CD; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cells, Cultured; Dendritic Cells; Electrophoretic Mobility Shift Assay; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunophenotyping; Interleukin-4; Lymphocyte Culture Test, Mixed; Monocytes; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2007 |
SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Caspase 8; Cell Line, Tumor; Fas Ligand Protein; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Membrane Potential, Mitochondrial; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Vorinostat | 2007 |
Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Caspases; Cisplatin; Cytochromes c; Humans; Lung Neoplasms; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Cells, Cultured; Up-Regulation | 2007 |
A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cell Nucleus; Colonic Neoplasms; Cysteine Proteinase Inhibitors; Cytochromes c; Humans; Leupeptins; Mice; Mitochondria; Proteasome Inhibitors; Protein Transport; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2007 |
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Enzyme Activation; Humans; Lymphoma, B-Cell; Mitosis; NF-kappa B; Nitriles; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfones; Tumor Suppressor Protein p53 | 2007 |
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; CCAAT-Binding Factor; Cell Differentiation; Cells, Cultured; Core Binding Factor Alpha 1 Subunit; Humans; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; Osteoblasts; Protease Inhibitors; Pyrazines | 2007 |
TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Topics: Alternative Splicing; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; DNA-Binding Proteins; Drug Synergism; Drug Therapy, Combination; Endoplasmic Reticulum; Female; Gene Expression; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microscopy, Fluorescence; Neoplasms, Experimental; Nuclear Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Folding; Protein Subunits; Pyrazines; Regulatory Factor X Transcription Factors; Transcription Factor RelA; Transcription Factors; Tumor Necrosis Factor-alpha; X-Box Binding Protein 1 | 2007 |
Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.
Topics: Animals; Boronic Acids; Bortezomib; Disease Models, Animal; Mice; NF-kappa B; Osteosclerosis; Primary Myelofibrosis; Protease Inhibitors; Pyrazines; Survival Rate; Thrombopoietin | 2007 |
Proteasome inhibition specifically sensitizes leukemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteins.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leupeptins; Male; Membrane Proteins; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyrazines; Tumor Cells, Cultured | 2007 |
Assessment of apoptosis-inducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Survivin; Taxoids; Tumor Cells, Cultured | 2007 |
Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Drug Therapy, Combination; Humans; Oxidation-Reduction; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptor, ErbB-2; Receptors, Estrogen; Transcription, Genetic | 2007 |
Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunoglobulin A; Immunoglobulin Light Chains; Leukemia, Plasma Cell; Male; Multiple Myeloma; Pyrazines; Retreatment; Transplantation Chimera; Transplantation, Homologous | 2007 |
Multiple myeloma therapies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Clinical Trials as Topic; HSP90 Heat-Shock Proteins; Humans; Immunosuppressive Agents; Lactams, Macrocyclic; Melphalan; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; In Vitro Techniques; Mice; Mice, Inbred Strains; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protease Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2008 |
Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Feedback, Physiological; Humans; Leupeptins; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Temperature; Tetrazolium Salts; Thiazoles | 2008 |
Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Leukemia, Plasma Cell; Middle Aged; Pyrazines; Skull; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Efficacy and safety of bortezomib in patients with plasma cell leukemia.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Retrospective Studies; Stem Cell Transplantation; Survival Rate | 2007 |
Immune-modulatory effects of bortezomib in GVHD.
Topics: Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cytokines; Graft vs Host Disease; Humans; Immune System; Inflammation; Multiple Myeloma; NF-kappa B; Plasmacytoma; Pyrazines; Spleen; Stem Cell Transplantation; T-Lymphocytes; Transplantation, Homologous | 2007 |
Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib.
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Boronic Acids; Bortezomib; Chronic Disease; gamma-Glutamyltransferase; Graft vs Host Disease; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Remission Induction | 2007 |
[Induction of apoptosis in HL-60 cells by bortezomib alone or in combination with harringtonine in vitro].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Harringtonines; HL-60 Cells; Humans; Pyrazines | 2007 |
Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice.
Topics: Animals; Boronic Acids; Bortezomib; Dipeptides; Dystrophin; Dystrophin-Associated Proteins; Male; Mice; Mice, Inbred mdx; Microscopy, Fluorescence; Muscle, Skeletal; Muscular Dystrophy, Duchenne; NF-kappa B; Protease Inhibitors; Pyrazines | 2007 |
Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
Topics: Adult; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Enzyme Activation; Humans; Leukemia; Middle Aged; Mitogen-Activated Protein Kinases; Oxides; Protease Inhibitors; Protein Kinase C-delta; Pyrazines; Tumor Cells, Cultured | 2007 |
Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cells, Cultured; Cytokines; Dendritic Cells; Humans; Immunity; Killer Cells, Natural; Neoplasms; Protease Inhibitors; Pyrazines | 2007 |
Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Capsaicin; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Cell Proliferation; Cyclin D1; DNA; Extracellular Signal-Regulated MAP Kinases; G1 Phase; Humans; Inhibitor of Apoptosis Proteins; Interleukin-6; Janus Kinase 1; Microtubule-Associated Proteins; Multiple Myeloma; Neoplasm Proteins; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; STAT3 Transcription Factor; Survivin; Thalidomide; Vascular Endothelial Growth Factor A | 2007 |
Severe epidermal necrolysis after bortezomib treatment for multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Fatal Outcome; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stevens-Johnson Syndrome; Vasculitis, Leukocytoclastic, Cutaneous | 2007 |
Proteasome inhibitors.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Contraindications; Female; Humans; NF-kappa B; Peptide Hydrolases; Protease Inhibitors; Pyrazines | 2007 |
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; Survivin; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2007 |
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Transformed; Cell Line, Tumor; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcr; Pyrazines; Pyrimidines; Sulfonamides | 2007 |
Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Glycoproteins; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Molecular Chaperones; Neoplasm Proteins; Polyubiquitin; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Tumor Suppressor Protein p53; Ubiquitination | 2008 |
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Genes, Intracisternal A-Particle; Glutamates; Guanine; Humans; Mesothelioma; Neoplasm Proteins; Pemetrexed; Pleural Neoplasms; Proteasome Inhibitors; Pyrazines; Survival Analysis | 2008 |
Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Leukemia, Plasma Cell; Male; Pyrazines | 2007 |
Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Gossypol; Humans; Melanoma, Experimental; Mice; Neoplasm Transplantation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transplantation, Heterologous | 2007 |
Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Humans; I-kappa B Kinase; Melphalan; Multiple Myeloma; NF-kappa B; Pyrazines; Pyrimidines | 2007 |
Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Topics: Adolescent; Adult; Aged; Apoptosis; Astrocytoma; Boronic Acids; Bortezomib; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Down-Regulation; Female; Humans; Immunotherapy; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrazines; TNF-Related Apoptosis-Inducing Ligand | 2007 |
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Humans; Membrane Proteins; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA Interference; RNA, Small Interfering; Up-Regulation | 2007 |
Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.
Topics: Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers; Boronic Acids; Bortezomib; Chi-Square Distribution; Clinical Trials as Topic; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Logistic Models; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Predictive Value of Tests; Pyrazines; Time Factors | 2007 |
Drugs "refund" scheme proposed for England and Wales.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; England; Humans; Pyrazines; Reimbursement Mechanisms; State Medicine; Treatment Failure; Wales | 2007 |
Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Intestinal Pseudo-Obstruction; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Radiography | 2007 |
Successful treatment of extramedullary gastric plasmacytoma with the combination of bortezomib and dexamethasone: first reported case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Middle Aged; Plasmacytoma; Pyrazines; Stomach Neoplasms | 2008 |
Unexpected cardiotoxicity in haematological bortezomib treated patients.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Female; Heart Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2007 |
Repeated complete responses with bortezomib in a heavily pretreated primary refractory patient with light chain multiple myeloma.
Topics: Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunoglobulin Light Chains; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Time Factors; Treatment Outcome | 2007 |
Multiple myeloma involving the cavernous sinus: a report of 3 cases and response to bortezomib.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cavernous Sinus; Fatal Outcome; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Sensitivity and Specificity; Treatment Outcome | 2007 |
PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Herpesvirus 8, Human; Humans; Interferon-alpha; Lymphoma; Membrane Potential, Mitochondrial; NF-kappa B; Oxides; Protease Inhibitors; Pyrazines | 2007 |
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; DNA Damage; DNA, Neoplasm; Doxorubicin; Drug Synergism; Enzyme Inhibitors; Humans; Multiple Myeloma; Pyrazines | 2007 |
Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Killer Cells, Natural; Leukemia, T-Cell; Lymphoma, T-Cell; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2007 |
Bortezomib inhibits human osteoclastogenesis.
Topics: Antineoplastic Agents; Apoptosis; Bone Resorption; Boronic Acids; Bortezomib; Cell Differentiation; Cell Lineage; Female; Heterocyclic Compounds, 3-Ring; Humans; In Vitro Techniques; Male; Multiple Myeloma; NF-kappa B; Osteoclasts; p38 Mitogen-Activated Protein Kinases; Pyrazines; Pyridines; RANK Ligand; Signal Transduction; Stem Cells; Transcription Factor AP-1; Vascular Endothelial Growth Factor A | 2007 |
Allografting or autografting for myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Pyrazines; Survival Rate; Transplantation, Autologous; Transplantation, Homologous | 2007 |
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin G; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Oxides; Pyrazines; Xenograft Model Antitumor Assays | 2007 |
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Models, Biological; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Signal Transduction; Tumor Cells, Cultured; Ubiquitin | 2007 |
Possible mechanism(s) of action of bortezomib in a patient with bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lung Neoplasms; Male; Models, Biological; Proteasome Inhibitors; Pyrazines; Tumor Suppressor Protein p53 | 2007 |
Hsp72 controls bortezomib-induced HepG2 cell death via interaction with pro-apoptotic factors.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; HSP72 Heat-Shock Proteins; Humans; Immunoprecipitation; Liver Neoplasms; Protease Inhibitors; Protein Binding; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tumor Suppressor Protein p53 | 2007 |
Bortezomib and lenalidomide effective in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
Bortezomib plus doxorubicin combination slows progression of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Doxorubicin; Drug Therapy, Combination; Humans; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement.
Topics: Aged; Ataxia; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Humans; Male; Myelin Sheath; Neural Conduction; Protease Inhibitors; Pyrazines; Reaction Time | 2007 |
Looking beyond the headlines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Humans; Insurance Benefits; Multiple Myeloma; Pyrazines | 2007 |
Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Treatment Outcome | 2007 |
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Chymotrypsin; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Male; Mice; Neoplasm Transplantation; Oligopeptides; Proteasome Endopeptidase Complex; Pyrazines; Rats; Rats, Sprague-Dawley | 2007 |
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Models, Biological; NF-kappa B; Proteasome Inhibitors; Pyrazines; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand | 2007 |
Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; bcl-X Protein; Boronic Acids; Bortezomib; Burkitt Lymphoma; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Transformation, Viral; Herpesvirus 4, Human; Humans; Inhibitor of Apoptosis Proteins; Mice; Mice, SCID; Multiple Myeloma; NF-kappa B p50 Subunit; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Transcription Factor RelA; Ubiquitin-Protein Ligases; Viral Matrix Proteins; Virus Latency; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2007 |
PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression; Genes, Wilms Tumor; Humans; Leukemia, Megakaryoblastic, Acute; NF-kappaB-Inducing Kinase; Primary Myelofibrosis; Protease Inhibitors; Protein Serine-Threonine Kinases; Pyrazines | 2008 |
Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Male; Medical Oncology; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Switzerland; Thrombocytopenia; Treatment Outcome | 2007 |
Drug pricing: No cure, no cost.
Topics: Antineoplastic Agents; Behavioral Research; Boronic Acids; Bortezomib; Drug Costs; Drug Industry; Humans; Interprofessional Relations; Marketing; Multiple Myeloma; Pyrazines; Remission Induction; State Medicine; Treatment Failure; United Kingdom | 2007 |
Severe intestinal vasculitis in a patient under treatment with bortezomib.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Gastrointestinal Hemorrhage; Hematopoietic Stem Cell Transplantation; Humans; Intestinal Diseases; Middle Aged; Multiple Myeloma; Postoperative Complications; Pyrazines; Salvage Therapy; Vasculitis, Leukocytoclastic, Cutaneous | 2007 |
Choline induces transcriptional repression and proteasomal degradation of the malarial phosphoethanolamine methyltransferase.
Topics: Animals; Boronic Acids; Bortezomib; Choline; Cytidine Diphosphate Choline; Gene Expression Regulation; Methyltransferases; Plasmodium falciparum; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Biosynthesis; Protozoan Proteins; Pyrazines; Transcription, Genetic | 2007 |
The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Evaluation; Female; Hematologic Diseases; Humans; Infections; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Treatment Outcome | 2007 |
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cell Line, Tumor; Doxorubicin; Humans; Melphalan; Mice; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Up-Regulation | 2008 |
TIEG1 induces apoptosis through mitochondrial apoptotic pathway and promotes apoptosis induced by homoharringtonine and velcade.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; DNA-Binding Proteins; Early Growth Response Transcription Factors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Harringtonines; Homoharringtonine; Humans; K562 Cells; Kruppel-Like Transcription Factors; Melanoma, Experimental; Mice; Mitochondria; Pyrazines; Transcription Factors | 2007 |
Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Gene Expression; Gene Expression Profiling; Hodgkin Disease; Humans; Immunohistochemistry; Oligonucleotide Array Sequence Analysis; Pyrazines; Reed-Sternberg Cells; Reverse Transcriptase Polymerase Chain Reaction; Tissue Array Analysis; TNF-Related Apoptosis-Inducing Ligand | 2008 |
Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cryptogenic Organizing Pneumonia; Glucocorticoids; Humans; Male; Methylprednisolone; Multiple Myeloma; Pyrazines; Tomography, X-Ray Computed | 2007 |
[HL-60 cell apoptosis induced by bortezomib alone or in combination with arsenic trioxide in vitro].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Electrophoresis; Flow Cytometry; HL-60 Cells; Humans; Oxides; Pyrazines; Time Factors | 2007 |
Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
Topics: Ataxia Telangiectasia Mutated Proteins; Blotting, Western; Boronic Acids; Bortezomib; BRCA1 Protein; Cell Cycle Proteins; Cells, Cultured; DNA Damage; DNA Repair; DNA-Binding Proteins; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Female; Flow Cytometry; Gamma Rays; HeLa Cells; Humans; Leupeptins; Microscopy, Fluorescence; Nuclear Proteins; Ovarian Neoplasms; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Rad51 Recombinase; RNA-Binding Proteins; RNA, Small Interfering; Signal Transduction; Tumor Suppressor Proteins; Ubiquitin | 2007 |
Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; In Vitro Techniques; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Neuroblastoma; Pyrazines; Soft Tissue Neoplasms; Subcutaneous Tissue; Xenograft Model Antitumor Assays | 2007 |
Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Pyrazines; Taxoids | 2008 |
Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Suppressor Protein p53 | 2008 |
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Benzamides; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Gemcitabine; Histone Deacetylase Inhibitors; Humans; L-Lactate Dehydrogenase; Niacinamide; Phenylurea Compounds; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyridines; Sorafenib | 2007 |
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Genes, Wilms Tumor; Humans; Hydroxamic Acids; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelomonocytic, Chronic; Megakaryocytes; Neoplasm Proteins; Pyrazines; Vorinostat; WT1 Proteins | 2008 |
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Inhibitor of Apoptosis Proteins; Mice; Microtubule-Associated Proteins; Models, Animal; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Phosphorylcholine; Protease Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; RNA Interference; RNA, Small Interfering; Survivin; Transplantation, Heterologous | 2007 |
Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytological Techniques; Diploidy; Drug Resistance, Neoplasm; Humans; Immunophenotyping; Karyotyping; Mice; Mice, SCID; Models, Animal; Multiple Myeloma; Pyrazines | 2007 |
Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Drug Interactions; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Tumor Cells, Cultured | 2007 |
Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Stomach Neoplasms | 2007 |
Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma.
Topics: Acute Kidney Injury; Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2007 |
Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2007 |
The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells.
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Histone Deacetylases; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sarcoma, Ewing; Transplantation, Heterologous; Tumor Cells, Cultured | 2007 |
Advances in the treatment of MDS, multiple myeloma, and CLL.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Prognosis; Pyrazines; Risk Assessment; Thalidomide | 2007 |
Managing patients with multiple myeloma and mantle cell lymphoma: where are we now?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Multiple Myeloma; Nurse's Role; Nursing Assessment; Oncology Nursing; Pyrazines; Thalidomide | 2007 |
Multiple myeloma patient care: treatment options and nursing considerations.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Pyrazines; Thalidomide | 2007 |
MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.
Topics: Adenoviridae; Boronic Acids; Bortezomib; Catalytic Domain; Cell Line, Tumor; Female; Genetic Therapy; Humans; Interleukins; Lung Neoplasms; Lysosomes; Ovarian Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Tumor Suppressor Proteins; Ubiquitin; Ubiquitination | 2008 |
Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; L-Lactate Dehydrogenase; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Tumor Lysis Syndrome | 2008 |
Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; BH3 Interacting Domain Death Agonist Protein; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Medullary; Cell Line, Tumor; Colorimetry; Doxorubicin; Genes, bcl-2; Humans; Membrane Potentials; Oncogene Protein v-akt; Protease Inhibitors; Pyrazines; RNA, Neoplasm; Tetrazolium Salts; Thiazoles; Thyroid Neoplasms; Transcription, Genetic | 2007 |
Gene mutation revelation points to new target for myeloma treatment, studies say.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; I-kappa B Kinase; Multiple Myeloma; Mutation; NF-kappa B; Pyrazines; Signal Transduction; TNF Receptor-Associated Factor 3 | 2007 |
Deafness associated with the use of Bortezomib in multiple myeloma.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Female; Hearing Loss, Sensorineural; Humans; Immunoglobulin A; Multiple Myeloma; Pyrazines; Risk Factors | 2008 |
Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 9; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Non-Hodgkin; Mice; Mice, SCID; Phosphorylation; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2007 |
Neutrophilic dermatitis associated with bortezomib in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Male; Middle Aged; Multiple Myeloma; Neutrophil Infiltration; Pyrazines | 2007 |
Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Electrophoretic Mobility Shift Assay; Gene Expression; Gene Expression Profiling; Heme Oxygenase-1; Humans; I-kappa B Proteins; Leukemia, T-Cell; Mice; NF-kappa B; Oligonucleotide Array Sequence Analysis; Protoporphyrins; Pyrazines; Rats; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis.
Topics: Aldehyde Dehydrogenase; Apoptosis; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 3; Caspase 8; Cells, Cultured; Fas-Associated Death Domain Protein; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Monocytic, Acute; Leukemia, Myelomonocytic, Acute; Protease Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Stem Cells; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein | 2007 |
The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Flow Cytometry; Formazans; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Indicators and Reagents; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Pyrazines; Retinal Neoplasms; Retinoblastoma; Reverse Transcriptase Polymerase Chain Reaction; Tetrazolium Salts; Tumor Cells, Cultured; Up-Regulation | 2007 |
Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Cyclophosphamide; Drug Synergism; Immunophenotyping; In Vitro Techniques; Lymphoma, Mantle-Cell; Male; Mice; Mice, SCID; Poly(ADP-ribose) Polymerases; Pyrazines; Rituximab; Survival Rate; Transplantation, Heterologous | 2008 |
Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Enzyme Inhibitors; Humans; Male; Mesothelioma; Mice; Mice, Nude; NF-kappa B; Nitriles; Proteasome Inhibitors; Pyrazines; Sulfones; Tumor Necrosis Factor-alpha | 2007 |
The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; DNA, Neoplasm; Drug Evaluation, Preclinical; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Multiple Myeloma; Neoplasm Proteins; Osteogenesis; Oxidative Stress; Proto-Oncogene Proteins; Pyrazines; Reactive Oxygen Species; Sulfonamides | 2007 |
Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Dose-Response Relationship, Drug; Intercellular Signaling Peptides and Proteins; Mice; Mice, Inbred ICR; Organ Culture Techniques; Osteoblasts; Osteogenesis; Protease Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Skull | 2007 |
Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro.
Topics: Adenosine Triphosphate; Blood Platelets; Boronic Acids; Bortezomib; Humans; Nitric Oxide; Platelet Aggregation; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2008 |
Satisfaction guaranteed--"payment by results" for biologic agents.
Topics: Biological Products; Boronic Acids; Bortezomib; Drug Approval; Drug Costs; Drug Industry; Humans; Pyrazines; Quality Assurance, Health Care; Reimbursement Mechanisms; State Medicine; United Kingdom | 2007 |
Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice.
Topics: Animals; Apoptosis; Apoptosis Inducing Factor; Boronic Acids; Bortezomib; Chondrocytes; Growth Disorders; Humans; Male; Mice; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Tumor Suppressor Protein p53; Ubiquitin; Up-Regulation | 2007 |
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
Topics: Boronic Acids; Bortezomib; Cell Membrane; Cell Survival; Down-Regulation; Histocompatibility Antigens Class I; Humans; Killer Cells, Natural; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptors, KIR; Sensitivity and Specificity; Tumor Cells, Cultured | 2008 |
Bortezomib in combination with thalidomide and dexamethasone--a successful treatment regimen in refractory extramedullary multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasmacytoma; Pyrazines; Radiography; Remission Induction; Spinal Neoplasms; Thalidomide; Transplantation, Autologous | 2008 |
Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B.
Topics: Animals; Antimalarials; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; DNA Replication; Dose-Response Relationship, Drug; Drug Resistance; Erythrocytes; Inhibitory Concentration 50; Life Cycle Stages; Oligopeptides; Plasmodium falciparum; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2007 |
[Effect of bortezomib used alone or in combination with arsenic trioxide on HL-60 cell xenograft in nude mice].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Disease Models, Animal; HL-60 Cells; Humans; Leukemia; Male; Mice; Mice, Nude; Oxides; Pyrazines; Random Allocation; Xenograft Model Antitumor Assays | 2007 |
Proteasome inhibition therapies in childhood cancer.
Topics: Animals; Bone Development; Boronic Acids; Bortezomib; Child; Chondrocytes; Humans; Mice; Neoplasms; Protease Inhibitors; Pyrazines | 2008 |
Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; DNA Fragmentation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HSP70 Heat-Shock Proteins; Humans; Immunotherapy; Interleukin-6; Multiple Myeloma; Pyrazines; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Syndecan-1 | 2007 |
Bortezomib sensitizes human astrocytoma cells to tumor necrosis factor related apoptosis-inducing ligand induced apoptosis.
Topics: Apoptosis; Astrocytoma; Boronic Acids; Bortezomib; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Humans; Immunotherapy; Proto-Oncogene Proteins c-bcl-2; Pyrazines; TNF-Related Apoptosis-Inducing Ligand | 2007 |
Use of intrapleural bortezomib in myelomatous pleural effusion.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Pleural Effusion; Pyrazines | 2007 |
Bortezomib induces apoptosis in T-cell prolymphocytic leukemia (T-PLL).
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Survival; Cryopreservation; Dactinomycin; Drug Evaluation, Preclinical; Flow Cytometry; Humans; Leukemia, Prolymphocytic, T-Cell; Pyrazines; Time Factors; Tumor Cells, Cultured | 2007 |
Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Doxorubicin; Female; Humans; Imidazoles; Mandibular Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Protease Inhibitors; Pyrazines; Tooth Extraction; Transplantation, Autologous; Vincristine; Zoledronic Acid | 2007 |
Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Plasmacytoma; Pyrazines; Radiotherapy Dosage | 2008 |
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Survival; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, Mantle-Cell; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Treatment Outcome; Vorinostat | 2008 |
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Cell Survival; Endoplasmic Reticulum; Heat-Shock Proteins; Humans; Lactones; Mice; Multiple Myeloma; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Pyrroles; Xenograft Model Antitumor Assays | 2008 |
The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; Cell Line, Tumor; Humans; Lung Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Sensitivity and Specificity | 2007 |
[STI571 enhances the effect of arsenic trioxide and Velcade on bcr/abl+-CD34+ cell proliferation and apoptosis].
Topics: Adult; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Oxides; Piperazines; Pyrazines; Pyrimidines; Tumor Cells, Cultured | 2007 |
Bortezomib in the treatment of AL amyloidosis: targeted therapy?
Topics: Amyloidosis; Animals; Boronic Acids; Bortezomib; Humans; Kidney; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2007 |
Bortezomib-induced peripheral neurotoxicity: still far from a painless gain.
Topics: Animals; Boronic Acids; Bortezomib; Humans; Neurotoxicity Syndromes; Pain; Pyrazines | 2007 |
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Humans; Indoles; Melanoma; Mice; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles | 2007 |
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Boronic Acids; Bortezomib; Drug Design; E2F1 Transcription Factor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Melanocytes; Melanoma; Promoter Regions, Genetic; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines; RNA Interference; RNA, Messenger; Skin Neoplasms; Transcriptional Activation; Tumor Suppressor Protein p53 | 2007 |
Fold up or perish: unfolded protein response and chemotherapy.
Topics: Anilides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Endoplasmic Reticulum; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Folding; Pyrazines | 2008 |
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Endothelial Cells; Enzyme Inhibitors; Humans; Macrophage Colony-Stimulating Factor; Mice; Mice, Nude; Multiple Myeloma; Neoplasms; NF-kappa B; Osteogenesis; Proteasome Inhibitors; Pyrazines; RANK Ligand; Threonine; Treatment Outcome; Ubiquitin; Xenograft Model Antitumor Assays | 2008 |
Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide).
Topics: Antigens, Neoplasm; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Humans; Isoquinolines; Multiple Myeloma; Protease Inhibitors; Pyrazines; Topoisomerase II Inhibitors | 2008 |
What is the correct philosophy for the treatment of multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines | 2007 |
Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Salvage Therapy | 2007 |
Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.
Topics: Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Cell Line, Tumor; Cell Survival; Cells, Cultured; Epithelial Cells; Fas Ligand Protein; Half-Life; Humans; Male; Prostate; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptors, Death Domain; TNF-Related Apoptosis-Inducing Ligand | 2008 |
Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Immunophenotyping; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Remission Induction; Treatment Outcome | 2008 |
Alkylating agents induce activation of NFkappaB in multiple myeloma cells.
Topics: Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Cell Line, Tumor; Doxorubicin; Humans; Melphalan; Multiple Myeloma; NF-kappa B; Pyrazines | 2008 |
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Silencing; Humans; Leukemia, Myeloid, Acute; NF-kappa B; Protein Kinases; Pyrazines; Transcription, Genetic | 2008 |
A novel bioluminescent mouse model and effective therapy for adult T-cell leukemia/lymphoma.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Survival; Disease Models, Animal; Genes, Reporter; HTLV-I Infections; Humans; Jurkat Cells; Luciferases; Male; Mice; Mice, Inbred NOD; Mice, SCID; Protease Inhibitors; Pyrazines | 2007 |
Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation.
Topics: Animals; Blood Vessels; Boronic Acids; Bortezomib; Drug Evaluation, Preclinical; Intercellular Adhesion Molecule-1; Intracellular Signaling Peptides and Proteins; Laser-Doppler Flowmetry; Male; Mice; Microscopy, Video; Muscle, Skeletal; NF-kappa B p50 Subunit; Nitric Oxide Synthase Type II; Protease Inhibitors; Proteasome Inhibitors; Proteins; Pyrazines; Random Allocation; Reperfusion Injury; Surgical Flaps; Tyrosine | 2007 |
Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Cytotoxicity, Immunologic; Fas Ligand Protein; Immunotherapy; Killer Cells, Natural; Leukemia; Mice; Mice, Inbred Strains; Neoplasms; Perforin; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2008 |
Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; bcl-2-Associated X Protein; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Mitochondria; Polyubiquitin; Protein Processing, Post-Translational; Pyrazines; Thermodynamics; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Ubiquitination | 2008 |
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Topics: Aged; Antigens, CD34; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Middle Aged; Phenotype; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2008 |
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Clone Cells; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Mice; Mice, Inbred Strains; Multiple Myeloma; Neoplastic Stem Cells; Plasma Cells; Pyrazines; Syndecan-1; Thalidomide; Tumor Necrosis Factor Receptor Superfamily, Member 7; Tumor Stem Cell Assay | 2008 |
Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1.
Topics: Adaptation, Biological; Boronic Acids; Bortezomib; Cell Hypoxia; Cell Line; DNA-Binding Proteins; Humans; Hypoxia-Inducible Factor 1; Mixed Function Oxygenases; Neoplasms; p300-CBP Transcription Factors; Pyrazines; Repressor Proteins; Trans-Activators; Transcription Factors; Transcription, Genetic | 2008 |
Antioxidants block proteasome inhibitor function in endometrial carcinoma cells.
Topics: Antioxidants; Antipyrine; Apoptosis; Ascorbic Acid; Blotting, Western; Boronic Acids; Bortezomib; Butylated Hydroxyanisole; Caspase 3; Caspase 9; Caspase Inhibitors; Cell Line, Tumor; Cell Survival; Coumarins; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Edaravone; Endometrial Neoplasms; Ergothioneine; Female; Humans; Leupeptins; Oligopeptides; Proteasome Inhibitors; Pyrazines; Ubiquitin; Vitamin E; Vitamins | 2008 |
Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
Topics: Aged; Angiogenic Proteins; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Capillaries; Cytokines; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Prognosis; Pyrazines; Thalidomide | 2008 |
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits.
Topics: Acetylcysteine; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine Endopeptidases; Drug Screening Assays, Antitumor; Humans; Interferon-gamma; Lymphoma; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Subunits; Pyrazines | 2008 |
High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Models, Biological; Multiple Myeloma; Neoplasm Proteins; Predictive Value of Tests; Pyrazines; Risk Factors; Time Factors | 2008 |
Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspases.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Colorimetry; Cyclin D3; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum; Estradiol; Estrogen Receptor Modulators; Flow Cytometry; G1 Phase; Humans; Immunoprecipitation; Mitochondria; Multiple Myeloma; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Selective Estrogen Receptor Modulators; Signal Transduction; Tumor Cells, Cultured | 2008 |
Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
Topics: Animals; Apoptosis; B-Lymphocyte Subsets; Bone Marrow Cells; Boronic Acids; Bortezomib; Cells, Cultured; Female; Lymphocyte Count; Lymphoid Tissue; Mice; Mice, Inbred BALB C; NF-kappa B; Precursor Cells, B-Lymphoid; Precursor Cells, T-Lymphoid; Protease Inhibitors; Proteasome Inhibitors; Protein Folding; Pyrazines; T-Lymphocyte Subsets; Thymus Gland | 2008 |
Bortezomib is able to reduce angiogenesis in half of patients affected by idiopathic myelofibrosis: an ex vivo study.
Topics: Boronic Acids; Bortezomib; Colony-Forming Units Assay; Female; Humans; Male; Middle Aged; Neovascularization, Pathologic; Primary Myelofibrosis; Pyrazines; Tissue Culture Techniques | 2008 |
Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction.
Topics: Animals; Blotting, Western; Boronic Acids; Bortezomib; Catecholamines; Chymotrypsin; Coronary Vessels; Death, Sudden, Cardiac; Dogs; Electrocardiography; Electrophysiology; G-Protein-Coupled Receptor Kinase 3; Heart Ventricles; HSP72 Heat-Shock Proteins; Ligation; Male; Myocardial Infarction; Myocardial Ischemia; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Tachycardia; Trypsin | 2008 |
Concurrent radiation therapy and bortezomib in myeloma patient.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose Fractionation, Radiation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Radiotherapy Dosage | 2008 |
Revealing targeted therapy for human cancer by gene module maps.
Topics: Algorithms; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Chromosome Mapping; Electronic Data Processing; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Gene Targeting; Genes, Mitochondrial; Genetic Therapy; Humans; Neoplasm Invasiveness; Neoplasms; Oligonucleotide Array Sequence Analysis; Prognosis; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; Wounds and Injuries | 2008 |
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cross-Priming; Dendritic Cells; Disease Progression; Histocompatibility Antigens Class I; Humans; Isoantibodies; Ligands; Multiple Myeloma; Prognosis; Pyrazines; Tumor Cells, Cultured | 2008 |
Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Multiple; Female; Humans; Male; Melanoma; Protease Inhibitors; Pyrazines; Skin Neoplasms; Treatment Outcome | 2008 |
Bortezomib-induced skin eruption.
Topics: Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Eruptions; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Skin | 2008 |
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
Topics: Acetylcysteine; Antigens, CD; Apoptosis; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Cytokines; Dose-Response Relationship, Immunologic; Humans; Immunosuppressive Agents; Lymphocyte Activation; NFATC Transcription Factors; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Translocation, Genetic; Tumor Suppressor Protein p53 | 2008 |
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.
Topics: Animals; Bone Regeneration; Boronic Acids; Bortezomib; Cell Differentiation; Female; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Osteoblasts; Protease Inhibitors; Pyrazines | 2008 |
Bone building with bortezomib.
Topics: Animals; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Cell Differentiation; Humans; Mesenchymal Stem Cells; Mice; Multiple Myeloma; Osteoblasts; Osteogenesis; Protease Inhibitors; Pyrazines | 2008 |
Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
Topics: Apoptosis; Benzopyrans; Boronic Acids; Bortezomib; Caspases; Cell Line, Transformed; Cell Proliferation; Enzyme Activation; Herpesvirus 4, Human; Humans; Lymphocytes; Lymphoproliferative Disorders; Nitriles; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines | 2008 |
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Depsipeptides; Drug Synergism; Histone Deacetylases; Humans; Hydroxamic Acids; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; Protease Inhibitors; Pyrazines; Sulfonamides | 2008 |
Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL.
Topics: Apoptosis; Bone Neoplasms; Boronic Acids; Bortezomib; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; Humans; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Sarcoma, Ewing; TNF-Related Apoptosis-Inducing Ligand | 2008 |
PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.
Topics: Boronic Acids; Bortezomib; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; I-kappa B Proteins; Interferon Regulatory Factors; Lymphoma, T-Cell; Microdissection; Neoplasm Staging; NF-KappaB Inhibitor alpha; Positive Regulatory Domain I-Binding Factor 1; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-myc; Pyrazines; Repressor Proteins; Survival Rate; Transcription Factors | 2008 |
Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Celecoxib; Cell Death; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Glioblastoma; Heat-Shock Proteins; Humans; Male; Mice; Mice, Nude; Molecular Chaperones; Pyrazines; Pyrazoles; Sulfonamides; Transfection; Xenograft Model Antitumor Assays | 2008 |
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.
Topics: Amyloidosis; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Immunosuppressive Agents; Male; Protease Inhibitors; Pyrazines; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide | 2008 |
Dampening Ab responses using proteasome inhibitors following in vivo B cell activation.
Topics: Animals; Antibody Formation; Antibody-Producing Cells; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Differentiation; Immunoglobulin M; Immunoglobulin mu-Chains; Lipopolysaccharides; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Ovalbumin; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Spleen | 2008 |
Unusual discordant responses in two multiple myeloma patients during bortezomib treatment.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cerebellum; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Male; Meninges; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Staging; Plasma Cells; Pyrazines; Skin | 2008 |
Persistent supravenous eruption induced by intravenous bortezomib therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Infusions, Intravenous; Male; Middle Aged; Pyrazines; Vascular Diseases; Veins | 2008 |
High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Fatigue; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Analysis; Thrombocytopenia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2008 |
Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-1; Angiopoietin-2; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neovascularization, Pathologic; Protease Inhibitors; Pyrazines; Receptor, TIE-2; Salvage Therapy; Treatment Outcome | 2008 |
[Effect of arsenic trioxide combined with bortezomib on proliferation, apoptosis and beta-catenin level in myeloma cell lines].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; beta Catenin; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; Multiple Myeloma; Oxides; Pyrazines; Tumor Cells, Cultured | 2008 |
Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Calcium; Down-Regulation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Humans; Immunoglobulins; Lymphoma, B-Cell; Membrane Microdomains; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Rituximab; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured | 2008 |
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.
Topics: Boronic Acids; Bortezomib; Cell Adhesion; Cell Death; Cell Movement; Cells, Cultured; Drug Delivery Systems; Drug Synergism; Humans; Lactones; Proteasome Inhibitors; Pyrazines; Pyrroles; Waldenstrom Macroglobulinemia | 2008 |
Bortezomib-induced reversible posterior leucoencephalopathy syndrome.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Magnetic Resonance Imaging; Male; Posterior Leukoencephalopathy Syndrome; Pyrazines | 2008 |
Targeting NF-kappaB in Waldenstrom macroglobulinemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; NF-kappa B; Phosphorylcholine; Pyrazines; Signal Transduction; Waldenstrom Macroglobulinemia | 2008 |
Sensitivity of mesenchymal stem cells and their progeny to medicines used for the treatment of hematoproliferative diseases.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Busulfan; Cyclophosphamide; Cytarabine; Female; Fibroblasts; Mesenchymal Stem Cells; Methotrexate; Mice; Mice, Inbred Strains; Pyrazines; Stromal Cells | 2008 |
Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib.
Topics: Acetylcysteine; Activating Transcription Factor 4; Antineoplastic Agents; Antioxidants; Boronic Acids; Bortezomib; Cell Death; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glutathione; Homeostasis; Humans; Multiple Myeloma; Neoplasm Proteins; Oxidation-Reduction; Protease Inhibitors; Pyrazines; Transcription Factor CHOP; Tumor Cells, Cultured | 2008 |
Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Herpesviridae Infections; Herpesvirus 8, Human; Humans; Lymphoma, AIDS-Related; Lymphoma, Primary Effusion; Male; Middle Aged; Pyrazines | 2008 |
Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Rhabdomyosarcoma; Transplantation, Heterologous; Tumor Cells, Cultured | 2008 |
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Boronic Acids; Bortezomib; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Dexamethasone; Drug Evaluation, Preclinical; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukocytes; Oligonucleotide Array Sequence Analysis; Pyrazines; Resveratrol; Signal Transduction; Stilbenes; TCF Transcription Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2008 |
Controversies regarding the use of dexamethasone in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Doxorubicin; Glucocorticoids; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Vincristine | 2008 |
Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Immunohistochemistry; Lymphoma, Mantle-Cell; Male; Prednisone; Prognosis; Pyrazines; Rituximab; Severity of Illness Index; Treatment Outcome; Vincristine | 2008 |
Multiple myeloma with testicular involvement.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Male; Multiple Myeloma; Prognosis; Protease Inhibitors; Pyrazines; Radiography; Skin Neoplasms; Testicular Neoplasms; Treatment Outcome | 2008 |
MYC-induced sensitivity of human malignant melanoma to proteasome inhibitors - a KaMYCaze effect.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines | 2008 |
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Humans; Proteasome Inhibitors; Pyrazines; Stomach Neoplasms; Taxoids; Tumor Suppressor Protein p53 | 2008 |
Treatment for elderly patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide | 2008 |
[Effect of Velcade on the gene expression profiles of K562 cells: study of its molecular mechanism].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Chymases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Oligonucleotide Array Sequence Analysis; Pyrazines | 2008 |
[Bortezomib in relapsed or refractory multiple myeloma: results in a cohort of 39 patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence | 2008 |
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Piperidines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Signal Transduction | 2008 |
Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication.
Topics: Boronic Acids; Bortezomib; DNA; DNA Replication; Eukaryotic Initiation Factor-2; HeLa Cells; Humans; Leupeptins; Models, Biological; Poliovirus; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Transfection; Vesiculovirus; Viral Proteins; Virus Replication | 2008 |
Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
Topics: Antineoplastic Agents; Bone Resorption; Boronic Acids; Bortezomib; Cell Nucleus; Cell Proliferation; Humans; Multiple Myeloma; NF-kappa B; Osteoblasts; Osteoclasts; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pulse Therapy, Drug; Pyrazines; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2008 |
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Heat-Shock Proteins; Hematopoietic Stem Cells; Humans; Imidazoles; MAP Kinase Signaling System; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Osteoclasts; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyrazines; Pyridines; Tumor Cells, Cultured | 2008 |
Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Lymphoma, Mantle-Cell; NF-kappa B; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Up-Regulation | 2008 |
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Fluorescent Antibody Technique; G2 Phase; Humans; Microtubule-Associated Proteins; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Tubulin; Tubulin Modulators | 2008 |
[Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Kidney; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2008 |
Proteasome inhibition as a novel therapy in treating rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Apoptosis; Arthritis, Rheumatoid; Boronic Acids; Bortezomib; Cell Proliferation; Humans; Models, Biological; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Synovial Membrane | 2008 |
Proteasome inhibition improves diaphragm function in congestive heart failure rats.
Topics: Animals; Boronic Acids; Bortezomib; Caspase 3; Diaphragm; Heart Failure; Male; Myosin Heavy Chains; Myosins; Proteasome Inhibitors; Pyrazines; Rats; Rats, Wistar; Ubiquitination | 2008 |
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Hematopoietic Stem Cells; Humans; Lactones; Neoplasms; NF-kappa B; Protease Inhibitors; Pyrazines; Pyrroles; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Messenger; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Up-Regulation; YY1 Transcription Factor | 2008 |
[Efficiency of bortezomib and dexamethasone in relapsed multiple myeloma treatment: retrospective study in consecutive cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Survival Rate | 2008 |
Role of decorin in the antimyeloma effects of osteoblasts.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Coculture Techniques; Cyclin-Dependent Kinase Inhibitor p21; Decorin; Extracellular Matrix Proteins; Genetic Vectors; Humans; Lentivirus; Mesenchymal Stem Cells; Multiple Myeloma; Neovascularization, Pathologic; Osteoblasts; Plasma Cells; Proteoglycans; Pyrazines; RNA Interference; RNA, Messenger; RNA, Small Interfering | 2008 |
Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Line; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Immunophenotyping; Melphalan; Multiple Myeloma; Protein Isoforms; Protein Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2008 |
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Glioma; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Mitochondria; Panobinostat; Proteasome Inhibitors; Protein Transport; Pyrazines; RNA, Small Interfering | 2008 |
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Survival; Female; Flow Cytometry; Humans; Immunoblotting; Kidney Neoplasms; Lung Neoplasms; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Mitochondrial Membranes; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand | 2008 |
Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p27; Female; Humans; Male; Mice; Mice, Nude; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; S-Phase Kinase-Associated Proteins; Tissue Array Analysis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Adverse events of unapproved drugs in Japan.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consumer Product Safety; Drug Approval; Drug Labeling; Government Regulation; Health Knowledge, Attitudes, Practice; Humans; Japan; Marketing of Health Services; Patient Education as Topic; Patient Rights; Patient Selection; Pyrazines | 2008 |
Autophagy activation by rapamycin eliminates mouse Mallory-Denk bodies and blocks their proteasome inhibitor-mediated formation.
Topics: Animals; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Hepatocytes; Humans; Immunosuppressive Agents; Inclusion Bodies; Keratin-8; Mice; Mice, Knockout; Mice, Transgenic; Models, Animal; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Sirolimus; Transfection | 2008 |
In vivo investigations on anti-fibrotic potential of proteasome inhibition in lung and skin fibrosis.
Topics: Animals; Bleomycin; Boronic Acids; Bortezomib; Cells, Cultured; Collagen Type I; Fibrosis; Hydroxyproline; Leupeptins; Lung; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Pulmonary Fibrosis; Pyrazines; Scleroderma, Systemic; Signal Transduction; Skin; Transforming Growth Factor beta | 2008 |
Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
Topics: Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Survival; Female; HeLa Cells; Humans; NF-kappa B; Protease Inhibitors; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Uterine Cervical Neoplasms | 2009 |
Asymmetric copper-catalyzed synthesis of alpha-amino boronate esters from N-tert-butanesulfinyl aldimines.
Topics: Aldehydes; Amines; Antineoplastic Agents; Boronic Acids; Bortezomib; Catalysis; Copper; Imines; Protease Inhibitors; Pyrazines; Sulfinic Acids | 2008 |
Comment on the role of FIH in the inhibitory effect of bortezomib on hypoxia-inducible factor-1.
Topics: Boronic Acids; Bortezomib; Cell Line; Humans; Hypoxia-Inducible Factor 1; Mixed Function Oxygenases; Pyrazines; Repressor Proteins; Transcription Factors | 2008 |
Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Male; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Messenger; Transfection; Ubiquitin | 2008 |
Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.
Topics: 2-Methoxyestradiol; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; beta Catenin; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Estradiol; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oxides; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2008 |
Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2008 |
Multiple myeloma presenting with advanced renal failure: a case report and new treatment options.
Topics: Adult; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Male; Multiple Myeloma; Pyrazines; Renal Dialysis; Renal Insufficiency; Thalidomide | 2008 |
Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Genetic Vectors; Humans; Jurkat Cells; Point Mutation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Retroviridae; Tumor Stem Cell Assay | 2008 |
[Treatment of myeloma in the elderly].
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Diphosphonates; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide | 2008 |
Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Fluorescent Antibody Technique; GPI-Linked Proteins; Histocompatibility Antigens Class I; Humans; Intercellular Signaling Peptides and Proteins; Interferon-gamma; Killer Cells, Natural; Liver Neoplasms; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction | 2008 |
Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Imidazoles; Molecular Chaperones; Mutation; Neoplasm Proteins; Neuroblastoma; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyridines; Tumor Suppressor Protein p53 | 2008 |
A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma.
Topics: Animals; Bone Marrow; Boronic Acids; Bortezomib; Cell Proliferation; Chromosome Aberrations; Clone Cells; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Hematopoiesis; Humans; Melphalan; Models, Biological; Multiple Myeloma; Neoplastic Stem Cells; Plasma Cells; Pyrazines; Rats; Stromal Cells; Tumor Cells, Cultured | 2008 |
Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation.
Topics: Animals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Cytokines; Female; Graft vs Leukemia Effect; Graft vs Tumor Effect; Interferon-gamma; Lymphocyte Depletion; Mice; Pyrazines; T-Lymphocyte Subsets; T-Lymphocytes; Transplantation, Homologous; Treatment Outcome; Tumor Necrosis Factor-alpha | 2008 |
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
Topics: Animals; Boronic Acids; Bortezomib; Lupus Erythematosus, Systemic; Mice; Mice, Inbred BALB C; Mice, Inbred MRL lpr; Mice, Inbred NZB; Models, Immunological; Nephritis; Ovalbumin; Plasma Cells; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors | 2008 |
Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Calreticulin; Cancer Vaccines; Drug Therapy, Combination; Mice; Mice, Inbred C57BL; Papillomavirus E7 Proteins; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured; Vaccines, DNA | 2008 |
[Proteasome inhibitor induces apoptosis and influences the expression of Notch1 and NF-kappaB in multiple myeloma RPMI8226 cells].
Topics: Apoptosis; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines; Receptor, Notch1; Signal Transduction; Tumor Cells, Cultured | 2008 |
The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib.
Topics: Acetyltransferases; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Chromatography, High Pressure Liquid; Colony-Forming Units Assay; Drug Synergism; Drug Therapy, Combination; Humans; Immunoblotting; Immunoenzyme Techniques; In Situ Nick-End Labeling; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mice; Mice, SCID; Multiple Myeloma; Oxidoreductases Acting on CH-NH Group Donors; Polyamine Oxidase; Polyamines; Pyrazines; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.
Topics: Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Carcinoma; Cell Membrane Permeability; Colonic Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Mitochondria; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2008 |
Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Survival; Chymotrypsin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Jurkat Cells; K562 Cells; Leukemia, T-Cell; Lymphoma, T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin | 2008 |
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
Topics: Binding Sites; Boronic Acids; Bortezomib; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Mutation; Proteasome Endopeptidase Complex; Pyrazines; RNA, Small Interfering | 2008 |
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histones; Humans; Ketones; Membrane Potential, Mitochondrial; Mice; Mitochondria; Multiple Myeloma; Oxidative Stress; Protein Transport; Pyrazines; Pyridines; Signal Transduction; Sulfonamides; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2008 |
Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Membrane Proteins; Mitochondrial Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Up-Regulation | 2008 |
[Aggravated post-herpetic neuralgia due to bortezomib].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Neuralgia, Postherpetic; Protease Inhibitors; Pyrazines; Recurrence | 2008 |
Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunoglobulins; Male; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Scleromyxedema; Thalidomide | 2008 |
Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Mice; Pyrazines; Random Allocation; Transplantation, Heterologous; Tumor Cells, Cultured; Ultrasonic Therapy | 2008 |
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
Topics: Alkaline Phosphatase; Apoptosis; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Osteoblasts; Osteoclasts; Pyrazines; Thalidomide; Transforming Growth Factor beta | 2008 |
Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Fatal Outcome; Female; Humans; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Remission Induction; T-Lymphocyte Subsets; Transplantation, Autologous; Vincristine | 2008 |
The proteasome inhibitor bortezomib inhibits intimal hyperplasia of autologous vein grafting in rat model.
Topics: Animals; Boronic Acids; Bortezomib; DNA Primers; Gene Expression Regulation; Hyperplasia; Interleukins; Jugular Veins; Male; Models, Animal; Protease Inhibitors; Pyrazines; Rats; Rats, Wistar; RNA, Messenger; Transplantation, Autologous; Tumor Necrosis Factor-alpha; Tunica Intima | 2008 |
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Health; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Membrane Potential, Mitochondrial; Mice; Microscopy, Confocal; Molecular Mimicry; Nitrophenols; Piperazines; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; Tissue Donors; Xenograft Model Antitumor Assays | 2008 |
Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bacitracin; Boronic Acids; Bortezomib; Cell Death; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; Endoplasmic Reticulum; Enzyme Inhibitors; Fenretinide; Humans; Melanoma; Oxidative Stress; Protein Disulfide-Isomerases; Pyrazines; Treatment Outcome; Tumor Cells, Cultured | 2008 |
Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Nucleus; DNA; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Models, Biological; NF-kappa B; Phosphorylation; Pyrazines; Recurrence; Signal Transduction; Subcellular Fractions | 2008 |
[Serum free light chains for diagnosis and follow-up of multiple myeloma].
Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Humans; Immunoelectrophoresis; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Pyrazines; Reagent Kits, Diagnostic | 2008 |
Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Docetaxel; Down-Regulation; Humans; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Radiation-Sensitizing Agents; Taxoids; Tumor Cells, Cultured | 2008 |
BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Drug Synergism; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mitochondria; Phosphorylation; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Tumor Cells, Cultured | 2008 |
A novel role for a familiar protein in apoptosis induced by proteasome inhibition.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blood Vessels; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Humans; Intracellular Signaling Peptides and Proteins; Necrosis; Neoplasms; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Time Factors; Up-Regulation | 2008 |
Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blood Vessels; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; HCT116 Cells; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Necrosis; Neoplasms; Neovascularization, Pathologic; Peptides, Cyclic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; RNA Interference; RNA, Small Interfering; Time Factors; Transfection; Up-Regulation; Xenograft Model Antitumor Assays | 2008 |
New treatments in multiple myeloma: beyond optimal treatment.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2008 |
Productively combining proteasome inhibition with the immunotherapy of cancer.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cancer Vaccines; Drug Therapy, Combination; Humans; Immunotherapy; Models, Biological; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2008 |
Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.
Topics: Antineoplastic Agents; Bone Resorption; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Osteoclasts; Pulse Therapy, Drug; Pyrazines | 2008 |
Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo.
Topics: Antineoplastic Agents; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma; Cell Line, Tumor; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyrazines; Pyridines; Sorafenib; Thyroid Neoplasms | 2008 |
HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Division; Cell Line; Cell Membrane; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; G2 Phase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myeloid Cell Leukemia Sequence 1 Protein; Polyisoprenyl Phosphates; Proto-Oncogene Proteins c-bcl-2; Pyrazines; rhoA GTP-Binding Protein; Simvastatin | 2008 |
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p27; Enzyme Inhibitors; Humans; Mice; Mice, Inbred C57BL; Multiple Myeloma; Neoplasm Transplantation; Piperazines; Pyrazines; Pyridines | 2008 |
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Boric Acids; Boronic Acids; Bortezomib; Cell Line, Transformed; Cell Line, Tumor; Cytochromes c; Diet; Flavonoids; Free Radical Scavengers; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Multiple Myeloma; Protease Inhibitors; Pyrazines; Quercetin | 2008 |
Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib.
Topics: Acute Disease; Antineoplastic Agents; Boronic Acids; Bortezomib; Heart Failure; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2008 |
Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Glucocorticoids; Humans; Male; Microcirculation; Middle Aged; Multiple Myeloma; Pyrazines; Thrombosis | 2008 |
Can tumor growth be further inhibited by combining drugs such as bortezomib with image-guided interventional oncologic procedures?
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Mice; Pyrazines; Ultrasonic Therapy | 2008 |
Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus Structures; Cycloheximide; Diploidy; Drug Synergism; Endoplasmic Reticulum; Fibroblasts; Histone Deacetylase 6; Histone Deacetylases; Humans; Hydroxamic Acids; Multiple Myeloma; Protein Biosynthesis; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines; RNA, Small Interfering; Vorinostat | 2008 |
Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Drug Screening Assays, Antitumor; Endoplasmic Reticulum; G2 Phase; Humans; Neoplasm Proteins; Proteasome Inhibitors; Protein Biosynthesis; Protein Folding; Protein Subunits; Pyrazines; Ritonavir; Sarcoma | 2008 |
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Drug Synergism; Genes, Reporter; Head and Neck Neoplasms; Humans; Keratinocytes; Mice; Mice, Inbred BALB C; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Transcription Factor AP-1; Ubiquitination; Xenograft Model Antitumor Assays | 2008 |
An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulins; Male; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; United States | 2008 |
Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Rate; Thalidomide | 2008 |
Targeted therapy--possible new therapeutic option for malignant mesothelioma?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Screening Assays, Antitumor; Humans; Mesothelioma; Oligosaccharides; Proteasome Endopeptidase Complex; Proteoglycans; Pyrazines; Sodium Selenite; Thioredoxins | 2008 |
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chi-Square Distribution; Clinical Trials, Phase III as Topic; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Time; Treatment Outcome | 2008 |
Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways.
Topics: Animals; Antigens, CD34; Azo Compounds; Boronic Acids; Bortezomib; Case-Control Studies; Endometriosis; Eosine Yellowish-(YS); Female; Ki-67 Antigen; Methyl Green; NF-kappa B; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrrolidines; Rats; Thiocarbamates | 2008 |
Dynamic effect of bortezomib on nuclear factor-kappaB activity and gene expression in tumor cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Models, Theoretical; NF-kappa B; Pyrazines; Tumor Necrosis Factor-alpha | 2008 |
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dental Prophylaxis; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pyrazines; Retrospective Studies; Thalidomide; Young Adult; Zoledronic Acid | 2009 |
Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Extracellular Signal-Regulated MAP Kinases; Genes, Reporter; Humans; Interleukin-6; Interleukin-7; Luciferases; Multiple Myeloma; NF-kappa B; Phosphorylation; Pyrazines; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2008 |
Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Etoposide; Hepatic Veno-Occlusive Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2008 |
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Down-Regulation; Doxorubicin; Etoposide; Female; Fluorescent Antibody Technique; Fluorouracil; Genes, p53; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasms, Experimental; Paclitaxel; Protein Kinases; Pyrazines; RNA, Small Interfering; Transfection; Xenograft Model Antitumor Assays | 2008 |
Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Cycle; Down-Regulation; Flow Cytometry; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; NF-kappa B; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Enhancing transduction of the liver by adeno-associated viral vectors.
Topics: Animals; Antibodies, Viral; Boronic Acids; Bortezomib; Dependovirus; Factor IX; Female; Gene Expression; Genetic Therapy; Genetic Vectors; Humans; Injections, Intravenous; Liver; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Protease Inhibitors; Pyrazines; Transduction, Genetic; Transgenes | 2009 |
Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.
Topics: Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Genes, Reporter; Green Fluorescent Proteins; Humans; Multiple Myeloma; NF-kappa B; Proteasome Inhibitors; Pyrazines; Stromal Cells | 2008 |
20S ways to apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase Inhibitor p27; Humans; Multiple Myeloma; Peptides, Cyclic; Protease Inhibitors; Protein Folding; Pyrazines | 2008 |
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Erythropoietin; Female; Humans; Immunosuppressive Agents; Logistic Models; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pulmonary Embolism; Pyrazines; Recombinant Proteins; Recurrence; Risk; Treatment Outcome; Venous Thrombosis | 2008 |
Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Cycle Proteins; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Protease Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand | 2008 |
[Synergistic effects of arsenic trioxide and proteasome inhibitor bortezomib on apoptosis induction in Raji cell line].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line, Tumor; Drug Synergism; Humans; Oxides; Protease Inhibitors; Pyrazines | 2008 |
Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Remission Induction; Treatment Outcome | 2008 |
Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Caspase 2; Cell Line, Tumor; Endoplasmic Reticulum; Flow Cytometry; Humans; Mitochondria; Multiple Myeloma; Pyrazines; RNA Interference; Subcellular Fractions | 2008 |
Treatment of myeloma--are we making progress?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Outcome Assessment, Health Care; Prednisone; Pyrazines | 2008 |
Response to bortezomib in refractory type I cryoglobulinemia.
Topics: Boronic Acids; Bortezomib; Cryoglobulinemia; Humans; Male; Middle Aged; Protease Inhibitors; Pyrazines; Vasculitis | 2008 |
Infiltration of the spinal cord in a patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Dexamethasone; Disease Progression; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Pyrazines; Spinal Cord Neoplasms | 2008 |
[Clinical characteristics of velcade cumulative effect in resistant and recurrent multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2008 |
Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2008 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles | 2008 |
Bortezomib as a therapeutic candidate for neuroblastoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Brain Neoplasms; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Genes, p53; Humans; Irinotecan; Neuroblastoma; NF-kappa B; Pyrazines | 2008 |
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis.
Topics: Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; HCT116 Cells; HSC70 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Kinetics; Lactams, Macrocyclic; Neoplasms; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Isoforms; Proto-Oncogene Proteins c-raf; Pyrazines; RNA, Small Interfering; Transfection; Ubiquitination | 2008 |
Bortezomib-induced survival signals and genes in human proximal tubular cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Survival; Gene Expression Regulation; HSP70 Heat-Shock Proteins; Humans; I-kappa B Proteins; Kidney Tubules, Proximal; Mesangial Cells; Mitogen-Activated Protein Kinase 3; NF-KappaB Inhibitor alpha; Pyrazines; Signal Transduction; Transcription Factor RelA | 2008 |
Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors.
Topics: Animals; Antineoplastic Agents; Arabinofuranosyluracil; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line, Tumor; Herpesviridae Infections; Herpesvirus 4, Human; Humans; Iodine Radioisotopes; Male; Mice; Mice, SCID; Pyrazines; Radiopharmaceuticals; Sarcoma, Kaposi; Stomach Neoplasms; Thymidine Kinase | 2008 |
Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Differentiation; Down-Regulation; Humans; Macrophage Colony-Stimulating Factor; Monocytes; Multiple Myeloma; Osteoclasts; Pyrazines; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; TNF Receptor-Associated Factor 6 | 2009 |
A C-terminal fragment of Cyclin E, generated by caspase-mediated cleavage, is degraded in the absence of a recognizable phosphodegron.
Topics: Antigens, Nuclear; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Cullin Proteins; Cyclin E; DNA-Binding Proteins; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Half-Life; Hematologic Neoplasms; Humans; Isoenzymes; Ku Autoantigen; Neoplasm Proteins; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-mdm2; Pyrazines; S-Phase Kinase-Associated Proteins; Ubiquitin-Protein Ligases; Ubiquitination | 2008 |
Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspase 3; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Esophageal Neoplasms; G2 Phase; Histones; Mice; Mice, Inbred NOD; Mitosis; Neovascularization, Pathologic; p38 Mitogen-Activated Protein Kinases; Pyrazines; Remission Induction; Xenograft Model Antitumor Assays | 2008 |
Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.
Topics: Animals; Boronic Acids; Bortezomib; Brain; Cathepsins; Dipeptides; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Female; Glycoproteins; Lymphoid Tissue; Lysosomes; Mice; Mice, Inbred C57BL; Myelin-Oligodendrocyte Glycoprotein; Neuroglia; Neurons; NF-kappa B; Peptide Fragments; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Sulfones; T-Lymphocytes | 2008 |
Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Psoriasis; Pyrazines; Remission Induction | 2008 |
From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Male; Menthol; Middle Aged; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; TRPM Cation Channels | 2008 |
Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade).
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Dendritic Cells; Humans; Immunosuppressive Agents; Monocytes; Protease Inhibitors; Pyrazines | 2009 |
Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dexamethasone; Diterpenes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Activation; Epoxy Compounds; Humans; I-kappa B Proteins; Inhibitor of Apoptosis Proteins; Mitochondria; Multiple Myeloma; NF-kappa B; Phenanthrenes; Phosphatidylinositol 3-Kinases; Protein Transport; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, Glucocorticoid; Up-Regulation | 2008 |
[Proteasome inhibitor bortezomib sensitizes Hep-2 human laryngeal squamous cell carcinoma cells to ionizing radiation in vitro and in vivo].
Topics: Animals; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Laryngeal Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents | 2008 |
Bortezomib in combination with dexamethasone for a young multiple myeloma with t(8; 14).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Dexamethasone; Fractures, Bone; Humans; Humerus; In Situ Hybridization, Fluorescence; Male; Multiple Myeloma; Pyrazines; Translocation, Genetic | 2009 |
Immune-mediated neuropathies in myeloma patients treated with bortezomib.
Topics: Action Potentials; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Neural Conduction; Polyneuropathies; Pyrazines; Reaction Time | 2008 |
Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates.
Topics: Amino Acids; Animals; Boronic Acids; Bortezomib; Cattle; Humans; Inhibitory Concentration 50; Kinetics; Mutation; Mycobacterium tuberculosis; Oligopeptides; Peptides; Proteasome Endopeptidase Complex; Protein Binding; Pyrazines; Rhodococcus; Substrate Specificity | 2008 |
Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Survival; Cetuximab; Esophageal Neoplasms; Fibroblasts; Humans; Mouth Neoplasms; Multiple Myeloma; Pyrazines | 2009 |
Bortezomib-induced neurogenic bladder in patients with multiple myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome; Urinary Bladder, Neurogenic | 2009 |
Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.
Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Cyclosporine; Dexamethasone; Drug Hypersensitivity; Exanthema Subitum; Herpesvirus 3, Human; Herpesvirus 6, Human; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Pyrazines; Syndrome; Virus Activation | 2009 |
A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin G; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Multiple Myeloma; Pleura; Pleural Effusion, Malignant; Pyrazines; Tomography, X-Ray Computed | 2009 |
[Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation].
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Leukemia, Plasma Cell; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Transplantation, Autologous; Treatment Outcome | 2008 |
[Study on the relationship of beta-catenin level and sensitivity to Bortezomib of myeloma cell lines].
Topics: Apoptosis; beta Catenin; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Pyrazines; RNA, Messenger | 2008 |
Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Topics: Antibodies; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Dexamethasone; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Integrin alpha Chains; Integrin alpha4; Integrin alpha4beta1; Multiple Myeloma; Neoplasm Proteins; Pyrazines; Vincristine | 2009 |
S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Pyrazines; RNA, Small Interfering; S-Phase Kinase-Associated Proteins | 2008 |
Proteasome inhibitors in pediatric cancer treatment.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Child; Humans; Leukemia; Neoplasms; Protease Inhibitors; Pyrazines | 2008 |
A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Herpesviridae Infections; Herpesvirus 8, Human; HIV; Humans; Immunohistochemistry; Liposomes; Lymphoma, Primary Effusion; Male; Positron-Emission Tomography; Pyrazines; Rituximab | 2008 |
Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.
Topics: Adolescent; Adult; Antigens, CD34; Boronic Acids; Bortezomib; Cell Separation; Cells, Cultured; Female; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Genotype; Humans; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monomeric GTP-Binding Proteins; Pyrazines; Receptors, Death Domain; Up-Regulation | 2009 |
IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Caspase 3; Caspase 8; Fas-Associated Death Domain Protein; Humans; Interferon-alpha; Kidney Neoplasms; Melanoma; Mice; Mice, Inbred BALB C; Myeloid Cell Leukemia Sequence 1 Protein; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2008 |
[Effects of proteasome inhibitor bortezomib on NF-kappaB activity and ICAM-1 mRNA expression of K562 cells].
Topics: Boronic Acids; Bortezomib; Humans; Intercellular Adhesion Molecule-1; K562 Cells; NF-kappa B; Protease Inhibitors; Pyrazines | 2008 |
[Inducing-apoptosis effect of bortezomib on acute monocytic leukemia cell SHI-1 and its influence on expressions of Bcl2l12, Bcl-2 and Bax genes].
Topics: Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Leukemia, Monocytic, Acute; Muscle Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Messenger | 2008 |
Simultaneous inhibition of the constitutively activated nuclear factor kappaB and of the interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells.
Topics: Adenoviridae; Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Coumarins; Ergosterol; Genetic Vectors; Humans; Interleukin-6; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines; S Phase; Signal Transduction; STAT3 Transcription Factor; Withanolides | 2008 |
Effects of combination treatment of bortezomib and dexamethasone in SCCHN cell lines depend on tumor cell specificity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Dexamethasone; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Pyrazines | 2008 |
Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Female; Glioma; Humans; Mice; Mice, Nude; Proteasome Endopeptidase Complex; Pyrazines; Xenograft Model Antitumor Assays | 2008 |
Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Harringtonines; Homoharringtonine; Humans; Mice; Mice, SCID; Multiple Myeloma; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclohexanones; Drug Resistance, Neoplasm; Humans; Lymphoma, AIDS-Related; Lymphoma, B-Cell; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Rituximab | 2008 |
Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production.
Topics: Antibody Specificity; Apoptosis; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Graft Rejection; Humans; Isoantibodies; Kidney Transplantation; Plasma Cells; Proteasome Inhibitors; Pyrazines | 2009 |
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Development; Boronic Acids; Bortezomib; Disease Models, Animal; Humans; Mice; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteolysis; Protease Inhibitors; Pyrazines; Rabbits | 2009 |
Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytokines; Female; Fever; Humans; Inflammation Mediators; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stromal Cells | 2008 |
A threshold regression mixture model for assessing treatment efficacy in a multiple myeloma clinical trial.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Data Interpretation, Statistical; Dexamethasone; Health Status Indicators; Humans; Likelihood Functions; Multiple Myeloma; Proportional Hazards Models; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Stochastic Processes; Time Factors; Treatment Outcome | 2008 |
Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Retreatment; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
Deborah Dunsire.
Topics: Anti-Inflammatory Agents; Biopharmaceutics; Biotechnology; Boronic Acids; Bortezomib; Drug Industry; Entrepreneurship; History, 21st Century; Humans; Inflammation; Neoplasms; Organizational Objectives; Pyrazines | 2008 |
Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vincristine | 2008 |
Cooperative relationship between pharmaceutical companies, academia, and media explains sharp decrease in frequency of pulmonary complications after bortezomib in Japan.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cooperative Behavior; Drug Industry; Health Knowledge, Attitudes, Practice; Humans; Interdisciplinary Communication; Internet; Japan; Lung Diseases; Mass Media; Medical Staff; Multiple Myeloma; Newspapers as Topic; Patient Selection; Periodicals as Topic; Practice Guidelines as Topic; Pyrazines; Risk Assessment; Societies, Medical | 2008 |
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrazines; RGS Proteins; Vascular Endothelial Growth Factor A | 2008 |
Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor.
Topics: Blotting, Western; Boronic Acids; Bortezomib; Cell Death; Cell Movement; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Female; Fluorescent Antibody Technique; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Immunohistochemistry; Immunoprecipitation; Ovarian Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Tissue Array Analysis; Ubiquitin | 2008 |
Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways.
Topics: Activating Transcription Factor 4; Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Hypoxia; Cell Line, Tumor; DNA-Binding Proteins; Endoplasmic Reticulum; Humans; Microtubule-Associated Proteins; Necrosis; Protease Inhibitors; Protein Folding; Pyrazines; Regulatory Factor X Transcription Factors; Signal Transduction; Stress, Physiological; Thapsigargin; Transcription Factors | 2008 |
In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytotoxins; Drug Interactions; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured | 2009 |
Generalized cutis laxa and fibrillar glomerulopathy resulting from IgG Deposition in IgG-lambda Monoclonal Gammopathy: pulmonary hemorrhage during stem cell mobilization and complete hematological response with bortezomib and dexamethasone therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cutis Laxa; Dexamethasone; Granulocyte Colony-Stimulating Factor; Hemorrhage; Humans; Immunoglobulin G; Kidney Diseases; Kidney Glomerulus; Lung; Male; Middle Aged; Paraproteinemias; Pyrazines | 2009 |
Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin D2; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Dexamethasone; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Phosphorylation; Pyrazines; Retinoblastoma Protein; Thalidomide; Time Factors; Transfection; Up-Regulation; Vincristine | 2008 |
Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Humans; Inhibitory Concentration 50; Melanoma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Suppressor Protein p53 | 2008 |
Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response.
Topics: Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Doxorubicin; Drug Resistance; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Large B-Cell, Diffuse; NF-kappa B; Prognosis; Pyrazines; Systems Biology; Tumor Suppressor Protein p53 | 2008 |
Delayed complete remission in a patient with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Female; Humans; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Remission Induction; Time Factors | 2008 |
Novel agents in myeloma: an exciting saga.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Thrombosis | 2009 |
Velcade sensitizes prostate cancer cells to TRAIL induced apoptosis and suppresses tumor growth in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Humans; In Situ Nick-End Labeling; Male; Mice; Prostatic Neoplasms; Pyrazines; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand | 2009 |
Effects of bortezomib on bone disease in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Humans; Mice; Multiple Myeloma; Osteoclasts; Osteolysis; Pyrazines | 2009 |
[Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2008 |
Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Endoplasmic Reticulum Stress; Female; G2 Phase Cell Cycle Checkpoints; Humans; M Phase Cell Cycle Checkpoints; Ovarian Neoplasms; Paclitaxel; Protein Array Analysis; Pyrazines; Stress, Physiological; Time Factors; Up-Regulation | 2009 |
Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.
Topics: Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; E2F1 Transcription Factor; G2 Phase; Humans; Liver Neoplasms; Pyrazines; RNA, Messenger; S Phase; Time Factors | 2009 |
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
Topics: Anti-Inflammatory Agents; Apoptosis; Binding, Competitive; Boronic Acids; Bortezomib; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 13; Dexamethasone; Dipeptides; Drug Resistance, Neoplasm; Drug Synergism; Endothelium, Vascular; Humans; Immunoblotting; Multiple Myeloma; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Umbilical Veins | 2009 |
Bortezomib-associated tumor lysis syndrome in multiple myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Pyrazines; Tumor Lysis Syndrome | 2008 |
Bortezomib attenuates murine collagen-induced arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Inflammation Mediators; Male; Mice; Mice, Inbred DBA; Protease Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome; X-Ray Microtomography | 2009 |
Regulation of multiple myeloma survival and progression by CD1d.
Topics: Antibodies, Monoclonal; Antigens, CD1d; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Aggregation; Cell Survival; Dexamethasone; Disease Progression; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Plasma Cells; Pyrazines; Tumor Cells, Cultured | 2009 |
Elucidation of potential bortezomib response markers in mutliple myeloma patients.
Topics: Aged; Antineoplastic Agents; Apolipoprotein C-I; Biomarkers; Blood Proteins; Boronic Acids; Bortezomib; Chromatography, Liquid; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Male; Mass Spectrometry; Middle Aged; Molecular Weight; Multiple Myeloma; Protein Isoforms; Pyrazines; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry; Time Factors | 2009 |
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Creatinine; Doxorubicin; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Renal Insufficiency; Retrospective Studies | 2008 |
Treatment of light chain deposition disease with bortezomib and dexamethasone.
Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Paraproteinemias; Pyrazines; Treatment Outcome | 2009 |
Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.
Topics: Adult; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Humans; Immunoprecipitation; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-Cell, Cutaneous; Membrane Potential, Mitochondrial; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation | 2009 |
The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; G1 Phase; Humans; Imidazoles; Melphalan; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Phosphorylation; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Quinolines; Recombinant Proteins; Ribosomal Protein S6 Kinases, 70-kDa; TOR Serine-Threonine Kinases | 2009 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2008 |
Induction therapy in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Humans; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2008 |
microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.
Topics: Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Case-Control Studies; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Lymphocytes; Male; Mice; MicroRNAs; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasms, Experimental; NF-kappa B; Oligonucleotide Array Sequence Analysis; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins c-akt; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Rituximab; RNA, Messenger; Signal Transduction; Waldenstrom Macroglobulinemia | 2009 |
Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cellular Senescence; DNA Fragmentation; Flow Cytometry; Humans; Inhibitory Concentration 50; Killer Cells, Natural; Lymphoma; Mitosis; Models, Biological; Multiple Myeloma; Pyrazines | 2008 |
New evidence in oncologic and cardiocirculatory medicine.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Breast Neoplasms; Cardiology; Diagnosis, Computer-Assisted; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Mammography; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines | 2009 |
[Proteasome inhibitors sensitize ovarian cancer cells to paclitaxel induced apoptosis].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Female; Flow Cytometry; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction | 2008 |
Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Female; Gene Expression; Granulosa Cell Tumor; Humans; NF-kappa B; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Transfection; X-Linked Inhibitor of Apoptosis Protein | 2009 |
High-content functional screen to identify proteins that correct F508del-CFTR function.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line; Cystic Fibrosis Transmembrane Conductance Regulator; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunoblotting; Microscopy, Confocal; Mutant Proteins; Proteome; Proteomics; Pyrazines; Reproducibility of Results; Temperature | 2009 |
Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy.
Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Herpes Zoster; Herpesvirus 3, Human; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Virus Activation | 2009 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate | 2008 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Thalidomide | 2008 |
Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Eruptions; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Salvage Therapy; Vincristine | 2008 |
Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Communication; Cell Line, Tumor; Diffusion; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Nitrophenols; Phosphatidylinositol 3-Kinases; Piperazines; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recombinant Proteins; Signal Transduction; Spheroids, Cellular; Sulfonamides; Time Factors; TNF-Related Apoptosis-Inducing Ligand; TOR Serine-Threonine Kinases | 2009 |
Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Multiple Myeloma; Pyrazines; TNF-Related Apoptosis-Inducing Ligand | 2009 |
Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
Topics: Acute Disease; Biopsy; Boronic Acids; Bortezomib; Creatinine; Graft Rejection; Humans; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Paresthesia; Protease Inhibitors; Pyrazines; Thrombocytopenia; United States; United States Food and Drug Administration | 2008 |
Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Carcinoma; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Iodides; Lovastatin; Neoplasm Metastasis; Oxides; Pyrazines; Sirolimus; Thymus Gland; Thyroid Neoplasms; Tretinoin | 2009 |
BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 3; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Gene Silencing; Humans; Leukemia; Mice; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering | 2009 |
Combination therapy with TRAIL: Recent developments and potential pitfalls.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Drug Therapy, Combination; Humans; Male; Mice; Prostatic Neoplasms; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Transplantation, Heterologous | 2009 |
Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Cell Survival; Daclizumab; DNA-Binding Proteins; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin G; Inhibitor of Apoptosis Proteins; Leukemia-Lymphoma, Adult T-Cell; Male; Microtubule-Associated Proteins; Middle Aged; Pyrazines; RNA Interference; Survivin; Transcription Factor 4; Transcription Factors; Tumor Cells, Cultured | 2009 |
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Apoptosis; Benzylamines; Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Cell Movement; Cell Survival; Coculture Techniques; Colony-Forming Units Assay; Cyclams; Drug Resistance, Neoplasm; Fibronectins; Flow Cytometry; Heterocyclic Compounds; Humans; Immunoblotting; Immunoenzyme Techniques; Integrin alpha4beta1; Intercellular Adhesion Molecule-1; Lentivirus; Male; Mice; Mice, SCID; Multiple Myeloma; Pyrazines; Receptors, CXCR4; RNA, Messenger; RNA, Small Interfering; Stromal Cells; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
The Isopeptidase Inhibitor G5 Triggers a Caspase-independent Necrotic Death in Cells Resistant to Apoptosis: A COMPARATIVE STUDY WITH THE PROTEASOME INHIBITOR BORTEZOMIB.
Topics: Actins; Animals; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Boronic Acids; Bortezomib; Carbon-Nitrogen Lyases; Cell Adhesion; Cell Line, Transformed; Collagen; Cyclosporine; Cytoskeleton; Extracellular Matrix; Fibronectins; HMGB1 Protein; MAP Kinase Kinase 4; Membrane Potential, Mitochondrial; Mice; Mice, Knockout; Necrosis; Peroxisome Proliferator-Activated Receptors; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrans; Pyrazines; Sulfhydryl Compounds | 2009 |
Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 4; Dexamethasone; Enzyme Inhibitors; Fibroblast Growth Factor 3; Humans; In Situ Hybridization, Fluorescence; Multiple Myeloma; Mutation; Protein-Tyrosine Kinases; Pyrazines; Translocation, Genetic | 2009 |
Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cation Transport Proteins; Cell Line, Tumor; Cisplatin; Copper Transporter 1; Drug Delivery Systems; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Peritoneal Neoplasms; Proteasome Endopeptidase Complex; Pyrazines | 2009 |
Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cohort Studies; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Female; Humans; Immunohistochemistry; Male; Middle Aged; Multiple Myeloma; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Treatment Outcome; Tumor Suppressor Protein p53 | 2009 |
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Marrow; Boronic Acids; Bortezomib; Caspases; Cell Adhesion; Cell Cycle; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor Proteins; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Flavones; Gene Expression Profiling; Humans; Insulin-Like Growth Factor I; Interleukin-6; Male; Mice; Mice, SCID; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Pyrazines; Retinoblastoma Protein; Stromal Cells; Transplantation, Heterologous; Tumor Cells, Cultured | 2009 |
"Change can happen" by PKA: proteasomes in in vivo hearts.
Topics: Animals; Boronic Acids; Bortezomib; Cyclic AMP-Dependent Protein Kinases; Models, Biological; Myocardium; Myocytes, Cardiac; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2009 |
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Endoplasmic Reticulum; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Hydrazones; Hydroxyurea; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Transcription, Genetic; Ubiquitin | 2009 |
A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Proliferation; Enzyme Activation; Humans; Leukocyte Common Antigens; Multiple Myeloma; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptor, IGF Type 1; Tumor Cells, Cultured | 2009 |
Topical analgesic combinations for bortezomib neuropathy.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Amines; Analgesics; Boronic Acids; Bortezomib; Clonidine; Cyclohexanecarboxylic Acids; Drug Combinations; Excitatory Amino Acid Antagonists; Gabapentin; gamma-Aminobutyric Acid; Gels; Humans; Ketamine; Male; Middle Aged; Pain Measurement; Paraproteinemias; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Walking | 2009 |
Bortezomib-related colon mucositis in a multiple myeloma patient.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Colonic Diseases; Humans; Male; Middle Aged; Mucositis; Multiple Myeloma; Pyrazines; Renal Insufficiency | 2009 |
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
Topics: Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Death; Cell Line, Tumor; Death Domain Receptor Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Humans; Lung Neoplasms; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2009 |
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Hydroxamic Acids; Pyrazines; Signal Transduction; Vorinostat | 2009 |
[In vitro effect of bortezomib alone or in combination with harringtonine or arsenic trioxide on proliferation and apoptosis of multidrug resistant leukemia cells].
Topics: Adolescent; Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Child; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Harringtonines; HL-60 Cells; Humans; Male; Oxides; Pyrazines; Young Adult | 2008 |
[The influence of bortezomib on HL-60 cell function induced by all-trans retinoic acid plus bufalin and its mechanism].
Topics: Boronic Acids; Bortezomib; Bufanolides; Cell Adhesion; Cell Proliferation; Focal Adhesion Kinase 2; HL-60 Cells; Humans; Paxillin; Pyrazines; Tretinoin | 2008 |
Proteasome inhibition blocks ligand-induced dynamic processing and internalization of epidermal growth factor receptor via altered receptor ubiquitination and phosphorylation.
Topics: Boronic Acids; Bortezomib; Epidermal Growth Factor; ErbB Receptors; Genes, Reporter; HeLa Cells; Humans; Luciferases, Firefly; Microscopy, Fluorescence; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Recombinant Fusion Proteins; Transfection; Ubiquitination | 2009 |
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
Topics: Acetylation; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Drug Synergism; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Immunoprecipitation; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Oxidative Stress; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Superoxides; Tumor Cells, Cultured; Vorinostat | 2009 |
MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.
Topics: AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Humans; Imidazoles; Lymphoma, Mantle-Cell; Membrane Proteins; Nuclear Proteins; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; PTEN Phosphohydrolase; Pyrazines; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2009 |
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Color; Cytoprotection; Endoplasmic Reticulum; Enzyme Inhibitors; Flavonoids; Glioblastoma; Humans; Mice; Mice, Nude; Molecular Structure; Phenols; Plant Extracts; Polyphenols; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stress, Physiological; Tea | 2009 |
Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Death; Cell Survival; Endoplasmic Reticulum Chaperone BiP; Eukaryotic Initiation Factor-2; G1 Phase; Humans; Leupeptins; Multiple Myeloma; Phosphorylation; Pyrazines; Resting Phase, Cell Cycle | 2009 |
Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Electrophysiology; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prevalence; Pyrazines; Thalidomide | 2008 |
Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.
Topics: Animals; beta Catenin; Boronic Acids; Bortezomib; Cadherins; Calcification, Physiologic; Calcium; Cell Differentiation; Cell Nucleus; Cells, Cultured; Fibroblasts; Fluorescent Antibody Technique; Humans; Immunoblotting; Luciferases; Mesenchymal Stem Cells; Mice; Osteoblasts; Protease Inhibitors; Protein Transport; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Stem Cells; TCF Transcription Factors; Wnt Proteins | 2009 |
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.
Topics: Adoptive Transfer; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Lewis Lung; Caspase 8; Cell Proliferation; Granzymes; Humans; Kidney Neoplasms; Killer Cells, Natural; Lymphocyte Depletion; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines; T-Lymphocytes, Regulatory | 2009 |
Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Transformation, Neoplastic; Cerebellar Neoplasms; Disease Models, Animal; Gene Knock-In Techniques; Hedgehog Proteins; Humans; Immunoblotting; Immunoprecipitation; Loss of Heterozygosity; Medulloblastoma; Mice; Mice, Knockout; Patched Receptors; Patched-1 Receptor; PAX7 Transcription Factor; Proteasome Endopeptidase Complex; Protein Isoforms; Protein Processing, Post-Translational; Pyrazines; Receptors, Cell Surface | 2009 |
Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Adenosine Triphosphate; Apoptosis; Boronic Acids; Bortezomib; Catalytic Domain; Cell Line, Tumor; Flow Cytometry; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamate-Cysteine Ligase; Glutathione; Glutathione Synthase; Humans; Intracellular Space; Oxidative Stress; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Spectrophotometry; Thyroid Neoplasms | 2009 |
AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib.
Topics: Adult; Boronic Acids; Bortezomib; Humans; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Male; Pyrazines; Remission Induction; Shock, Septic | 2009 |
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, T-Cell, Cutaneous; Pharmacokinetics; Pyrazines; Reactive Oxygen Species; Vorinostat | 2009 |
Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; Cytotoxicity, Immunologic; Female; Humans; Immunotherapy, Adoptive; Killer Cells, Natural; Mice; Mice, SCID; Protease Inhibitors; Pyrazines; Receptors, Death Domain; RNA, Messenger; Xenograft Model Antitumor Assays | 2009 |
Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance; Gene Expression Regulation; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Protein Biosynthesis; Protein Stability; Protein Subunits; Pyrazines; Ubiquitin; Up-Regulation | 2009 |
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).
Topics: Age Factors; Aged; Analysis of Variance; Boronic Acids; Bortezomib; Drug Evaluation; Female; Greece; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Staging; Pyrazines; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma.
Topics: Antibodies; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Middle Aged; Multiple Myeloma; Platelet Transfusion; Pyrazines; Salvage Therapy; Transplantation, Homologous | 2009 |
Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; Drug Synergism; Endoplasmic Reticulum; Female; Fenretinide; G2 Phase; Humans; Ki-67 Antigen; Melanoma; Mice; Pyrazines | 2009 |
The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Endoplasmic Reticulum; Fenretinide; Humans; Mice; Neuroblastoma; Pyrazines; Xenograft Model Antitumor Assays | 2009 |
Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cells, Cultured; Cytotoxicity, Immunologic; Humans; Killer Cells, Natural; Natural Cytotoxicity Triggering Receptor 1; Proteasome Inhibitors; Pyrazines | 2009 |
Bortezomib-induced histiocytoid Sweet syndrome.
Topics: Aged; Biopsy; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Male; Multiple Myeloma; Protease Inhibitors; Pyrazines; Sweet Syndrome | 2009 |
[Bortezomib-induced BiP expression and apoptosis in multiple myeloma cells].
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Multiple Myeloma; Pyrazines; RNA, Messenger | 2009 |
Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression.
Topics: Basic Helix-Loop-Helix Transcription Factors; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Eukaryotic Initiation Factor-2; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lactones; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Biosynthesis; Pyrazines; Pyrroles; RNA, Messenger; Vascular Endothelial Growth Factor A | 2009 |
ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Biphenyl Compounds; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Synergism; Head and Neck Neoplasms; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Sulfonamides | 2009 |
Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARgamma ligand troglitazone.
Topics: Angiogenesis Inducing Agents; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Caspase 3; Cell Line, Tumor; Chromans; Cytokines; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Mitogen-Activated Protein Kinases; NF-kappa B; PPAR gamma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Thiazolidinediones; Troglitazone | 2009 |
The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Chymotrypsin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; K562 Cells; Leukemia; Pyrazines | 2010 |
Cutaneous involvement in multiple myeloma and bortezomib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin A; Melphalan; Multiple Myeloma; Myeloma Proteins; Paresthesia; Peripheral Nervous System Diseases; Plasma Cells; Prednisone; Pyrazines; Remission Induction; Skin; Thalidomide; Xerophthalmia | 2009 |
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromones; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Liver Neoplasms; Morpholines; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand | 2009 |
[Development of an extramedullary plasmacytoma despite disappearing M protein in multiple myeloma by bortezomib treatment].
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lumbar Vertebrae; Male; Multiple Myeloma; Myeloma Proteins; Neoplasms, Second Primary; Plasmacytoma; Protease Inhibitors; Pyrazines; Spinal Neoplasms | 2009 |
Bmf is upregulated by PS-341-mediated cell death of glioma cells through JNK phosphorylation.
Topics: Adaptor Proteins, Signal Transducing; Analysis of Variance; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Fragmentation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioma; Humans; MAP Kinase Kinase 4; Phosphorylation; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Signal Transduction; Tetrazolium Salts; Thiazoles | 2010 |
Inhibitors of the ubiquitin-proteasome system are not all alike: identification of a new necrotic pathway.
Topics: Animals; Autophagy; Boronic Acids; Bortezomib; Enzyme Inhibitors; Fibroblasts; Mice; Necrosis; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin | 2009 |
Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Enzyme Activation; Enzyme Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Lymphoma, Large B-Cell, Diffuse; Nitriles; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction | 2009 |
Proteasome inhibition promotes functional recovery after peripheral nerve reperfusion injury.
Topics: Animals; Boronic Acids; Bortezomib; Female; Injections, Intravenous; Isometric Contraction; Locomotion; Muscle, Skeletal; Muscular Atrophy; Nerve Compression Syndromes; Premedication; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Retrograde Degeneration; Sciatic Nerve; Synaptic Transmission | 2009 |
The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Jurkat Cells; Leukemia, T-Cell; Lymphoma, T-Cell; Mice; Mice, Nude; Neoplasm Proteins; Protease Inhibitors; Proteasome Inhibitors; Protein Kinases; Pyrazines; Signal Transduction; Vorinostat; Xenograft Model Antitumor Assays | 2009 |
Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib.
Topics: Adenovirus Infections, Human; Adenoviruses, Human; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cystitis; Female; Hemorrhage; Humans; Multiple Myeloma; Pyrazines | 2009 |
A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta 2-Microglobulin; Boronic Acids; Bortezomib; Disease Progression; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome | 2009 |
Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
Topics: Animals; Bone Marrow; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Cell Line, Tumor; Enzyme Activation; Immunoglobulin G; Mice; Multiple Myeloma; Neoplasm Transplantation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Burden | 2009 |
Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multiple Myeloma; Opportunistic Infections; Pneumocystis carinii; Pneumonia, Pneumocystis; Pyrazines | 2009 |
Does bortezomib induce de facto varicella zoster virus reactivation in patients with multiple myeloma?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Herpesvirus 3, Human; Humans; Killer Cells, Natural; Leukocyte Common Antigens; Multiple Myeloma; Pyrazines; Virus Activation | 2009 |
Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
Topics: Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Culture Techniques; Cell Proliferation; Cryopreservation; Cytokines; Cytotoxicity, Immunologic; Fas Ligand Protein; Humans; Immunophenotyping; Immunotherapy; K562 Cells; Killer Cells, Natural; Lymphocyte Activation; NK Cell Lectin-Like Receptor Subfamily K; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2009 |
2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma.
Topics: Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Electrophoresis, Gel, Two-Dimensional; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Protein Interaction Mapping; Pyrazines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2009 |
Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Multiple Myeloma; Pyrazines; Receptor, Fibroblast Growth Factor, Type 3; Signal Transduction; STAT3 Transcription Factor; Transfection | 2009 |
Restoration of chemosensitivity by bortezomib: implications for refractory myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Multiple Myeloma; Pancreatic Neoplasms; Pleural Neoplasms; Protease Inhibitors; Pyrazines; Treatment Outcome | 2009 |
Early gene expression changes induced by the bacterial superantigen staphylococcal enterotoxin B and its modulation by a proteasome inhibitor.
Topics: Animals; Boronic Acids; Bortezomib; Cytokines; Enterotoxins; Gene Expression Profiling; Gene Expression Regulation; HLA-DR alpha-Chains; HLA-DR Antigens; Inflammation Mediators; Mice; Mice, Transgenic; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Pyrazines; Receptors, Chemokine; Receptors, Cytokine; Signal Transduction; Superantigens | 2009 |
Targeted therapy and hematological malignancy.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Benzamides; Biomedical Research; Boronic Acids; Bortezomib; CD52 Antigen; Drug Design; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Glycoproteins; Hematologic Neoplasms; Humans; Imatinib Mesylate; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pulse Therapy, Drug; Pyrazines; Pyrimidines; Rituximab; Survival Rate | 2009 |
Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.
Topics: Antibodies, Monoclonal; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Glucocorticoids; Humans; Interleukin-6; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence | 2009 |
[Therapeutic news in multiple myeloma. Congress of the French National Society of Internal Medicine, December 2008, Bordeaux].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; France; Humans; Internal Medicine; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Societies, Medical; Thalidomide | 2009 |
Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Dexamethasone; DNA Fragmentation; Doxorubicin; Histocompatibility Antigens Class II; Humans; Mice; Mice, SCID; Multiple Myeloma; Pyrazines | 2009 |
GC-1 mRHBDD1 knockdown spermatogonia cells lose their spermatogenic capacity in mouse seminiferous tubules.
Topics: Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line; Cell Proliferation; ErbB Receptors; Flow Cytometry; Gene Expression Profiling; Gene Knockdown Techniques; Green Fluorescent Proteins; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Pyrazines; Recombinant Fusion Proteins; Regeneration; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Seminiferous Tubules; Spermatogenesis; Spermatogonia; Testis; Transfection; Ultraviolet Rays | 2009 |
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Topics: Acetophenones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzenesulfonates; Benzopyrans; Biphenyl Compounds; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Mutation; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2009 |
Ascorbic acid inhibits antitumor activity of bortezomib in vivo.
Topics: Animals; Antineoplastic Agents; Antioxidants; Ascorbic Acid; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Multiple Myeloma; Proteasome Inhibitors; Pyrazines | 2009 |
Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Australia; Boronic Acids; Bortezomib; Cohort Studies; Female; Gastrointestinal Diseases; Humans; International Cooperation; Male; Middle Aged; Multiple Myeloma; New Zealand; Pyrazines; Recurrence; Treatment Outcome | 2009 |
Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Curcumin; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Multiple Myeloma; NF-kappa B; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Thalidomide; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction.
Topics: Animals; Atrophy; Boronic Acids; Bortezomib; Caspase 3; Cysteine Proteinase Inhibitors; Diaphragm; Endotoxemia; Enzyme Activation; Leupeptins; Male; Muscle Contraction; Muscle Weakness; Oligopeptides; Organ Size; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Sepsis; Tyrosine | 2009 |
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Tumor; Boronic Acids; Bortezomib; Doxorubicin; Female; Gene Expression Profiling; Germinal Center; Humans; Immunoenzyme Techniques; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Prognosis; Pyrazines; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Curcumin; Cytokines; Drug Synergism; Humans; Inflammation Mediators; Multiple Myeloma; Pyrazines; Stromal Cells | 2008 |
Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis.
Topics: Anilides; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Burkitt Lymphoma; Caspase 3; Cell Line, Tumor; Cell Transformation, Viral; Drug Synergism; Enzyme Inhibitors; Genes, Viral; Herpesvirus 4, Human; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Protease Inhibitors; Pyrazines; Reactive Oxygen Species | 2009 |
Hematology: Bortezomib in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Disease Progression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Survival Rate; Time Factors; Treatment Outcome | 2009 |
Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells.
Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Brefeldin A; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Gene Expression; Heat-Shock Proteins; Humans; Protease Inhibitors; Pyrazines; Regulatory Factor X Transcription Factors; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Thapsigargin; Transcription Factor CHOP; Transcription Factors; X-Box Binding Protein 1 | 2009 |
Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Humans; Interferon Type I; Janus Kinases; Leukocytes, Mononuclear; Melanoma; Phosphorylation; Proteasome Inhibitors; Pyrazines; Recombinant Proteins; Signal Transduction; STAT1 Transcription Factor; Up-Regulation | 2009 |
Potent anti-inflammatory effects of low-dose proteasome inhibition in the vascular system.
Topics: Animals; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; Endothelial Cells; Enzyme Inhibitors; Gene Expression Regulation; Humans; Leupeptins; Male; Monocytes; NF-kappa B; Oxidative Stress; Proteasome Inhibitors; Pyrazines; Rats; Rats, Inbred Dahl; Reactive Oxygen Species; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2009 |
Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Castleman Disease; Humans; Male; Multiple Myeloma; Neoplasms, Multiple Primary; Pyrazines; Remission Induction | 2009 |
Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Positron-Emission Tomography; Prednisone; Pyrazines; Vinblastine; Vinorelbine | 2009 |
Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib.
Topics: Acyclovir; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Virus Activation | 2009 |
Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type II; Drug Synergism; Etoposide; Humans; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Topoisomerase II Inhibitors | 2009 |
Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Movement; Cell Proliferation; Female; Humans; Immunoenzyme Techniques; Male; Mice; Mice, SCID; Mitosis; Neuroblastoma; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
Topics: Aged; Antineoplastic Agents; Apoptosis; Benzofurans; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma; Lymphoma, Non-Hodgkin; Male; Membrane Potential, Mitochondrial; Middle Aged; NF-kappa B; Pyrazines; Reactive Oxygen Species; Tumor Cells, Cultured | 2009 |
The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
Topics: Activating Transcription Factor 4; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Division; Cell Line, Tumor; Female; Flow Cytometry; Humans; Immunohistochemistry; Neoplasm Proteins; Polymerase Chain Reaction; Pyrazines; RNA, Neoplasm; RNA, Small Interfering | 2009 |
Proteasome inhibitors block HIV-1 replication by affecting both cellular and viral targets.
Topics: Animals; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; HIV Long Terminal Repeat; HIV-1; Humans; Mice; Mice, Inbred Strains; NF-kappa B; Promoter Regions, Genetic; Proteasome Inhibitors; Pyrazines; Virus Replication | 2009 |
Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.
Topics: Antineoplastic Agents; Base Sequence; Boronic Acids; Bortezomib; DNA Primers; Drug Resistance, Neoplasm; Humans; Jurkat Cells; Leukemia-Lymphoma, Adult T-Cell; Mutation; Proteasome Endopeptidase Complex; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Down-Regulation; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; I-kappa B Proteins; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Protease Inhibitors; Protein Processing, Post-Translational; Pyrazines; Receptor-Interacting Protein Serine-Threonine Kinase 2; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
[Bortezomib-induced eruption: Sweet syndrome? Two case reports].
Topics: Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Colchicine; Dexamethasone; Female; Humans; Leukemia, Plasma Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Skin Ulcer; Sweet Syndrome; Treatment Outcome | 2009 |
[Bortezomib-induced neutrophilic dermatosis with CD30+ lymphocytic infiltration].
Topics: Antigens, CD; Antineoplastic Agents; Boronic Acids; Bortezomib; Exanthema; Female; Humans; Ki-1 Antigen; Lymphocytes; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Skin Diseases | 2009 |
[Bortezomib-induced acute neutrophilic dermatosis].
Topics: Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Neutrophils; Pyrazines; Skin Diseases; Sweet Syndrome | 2009 |
High levels of tRNA abundance and alteration of tRNA charging by bortezomib in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Proteasome Inhibitors; Protein Biosynthesis; Protein Transport; Pyrazines; RNA, Transfer; Transfer RNA Aminoacylation | 2009 |
New targets of PS-341: BAFF and APRIL.
Topics: Aged; Antineoplastic Agents; B-Cell Activating Factor; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Drug Delivery Systems; Female; Growth Inhibitors; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Transcription Factors; Tumor Cells, Cultured | 2010 |
Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma.
Topics: Aged, 80 and over; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2009 |
The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Boronic Acids; Bortezomib; CD4 Lymphocyte Count; Creatinine; Cyclin-Dependent Kinase Inhibitor p21; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Injections, Intravenous; Kidney; Kidney Diseases; Male; Mice; Mice, Inbred C57BL; Necrosis; Nephritis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reperfusion Injury; Time Factors | 2009 |
Piling up the JNK: drug synergy through ER stress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Boronic Acids; Bortezomib; Drug Synergism; Endoplasmic Reticulum; Enzyme Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Lymphoma, Large B-Cell, Diffuse; Nitriles; Protease Inhibitors; Pyrazines; Signal Transduction | 2009 |
Abrogation of anti-HLA antibodies via proteasome inhibition.
Topics: Adult; Boronic Acids; Bortezomib; Graft Rejection; Graft Survival; Histocompatibility Antigens Class I; HLA Antigens; HLA-D Antigens; Humans; Isoantibodies; Kidney Transplantation; Living Donors; Male; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Transplantation, Homologous; Young Adult | 2009 |
Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chymotrypsin; Cyclin-Dependent Kinase Inhibitor p27; Drug Discovery; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Neoplasms; Proteasome Inhibitors; Protein Conformation; Pyrazines; Serine Proteinase Inhibitors; Small Molecule Libraries; Xenograft Model Antitumor Assays | 2009 |
Bortezomib-induced lupus erythematosus tumidus.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Exanthema; Female; Humans; Lupus Erythematosus, Cutaneous; Pyrazines | 2009 |
Simultaneous proteosome inhibition and heat shock protein induction by bortezomib is beneficial in experimental pancreatitis.
Topics: Animals; Boronic Acids; Bortezomib; Heat-Shock Proteins; Male; Multienzyme Complexes; Pancreas; Pancreatitis; Protease Inhibitors; Pyrazines; Rats; Rats, Wistar | 2009 |
Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Autologous; Treatment Outcome; Vincristine | 2009 |
Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Drug Interactions; Flavonoids; Humans; Multiple Myeloma; Phenols; Polyphenols; Pyrazines | 2009 |
Bortezomib in treatment of extramedullary plasmacytoma of the pancreas.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Middle Aged; Pancreatic Neoplasms; Plasmacytoma; Pyrazines; Retreatment; Treatment Outcome; Vincristine | 2009 |
Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD28 Antigens; CD3 Complex; CD4-Positive T-Lymphocytes; Cell Proliferation; Coculture Techniques; Humans; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Leukocytes, Mononuclear; Lymphocyte Subsets; Phenotype; Proteasome Inhibitors; Pyrazines; T-Lymphocytes | 2009 |
Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cullin Proteins; Cyclopentanes; Humans; NEDD8 Protein; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrimidines; RING Finger Domains; Signal Transduction; Ubiquitin-Activating Enzymes; Ubiquitin-Conjugating Enzymes; Ubiquitin-Protein Ligases; Ubiquitins | 2009 |
Effect of autophagy on multiple myeloma cell viability.
Topics: Adenine; Antifungal Agents; Antimalarials; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Boronic Acids; Bortezomib; Cell Proliferation; Chloroquine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Immunoblotting; Membrane Proteins; Microscopy, Fluorescence; Multiple Myeloma; Pyrazines; RNA, Small Interfering; Sirolimus; Thapsigargin; Tumor Cells, Cultured | 2009 |
Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Multiple; Humans; Multiple Myeloma; Oligopeptides; Phenotype; Protease Inhibitors; Pyrazines | 2009 |
Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Retrospective Studies; Time Factors | 2009 |
From orbital hybridization to chemotherapeutics neutralization.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Interactions; Flavonoids; Humans; Molecular Structure; Neoplasms; Phenols; Plant Extracts; Polyphenols; Protease Inhibitors; Pyrazines; Tea | 2009 |
Multiple significant bortezomib-related toxicities in one patient: case report and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Humans; Male; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Pruritus; Pyrazines; Testis | 2009 |
Rounding up apoptosis resistance targets in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Communication; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recombinant Proteins; Signal Transduction; Spheroids, Cellular; TNF-Related Apoptosis-Inducing Ligand | 2009 |
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Polyneuropathies; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Treatment Outcome | 2009 |
Combination effect between bortezomib and tumor necrosis factor alpha on gefitinib-resistant non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Pyrazines; Quinazolines; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2009 |
Successful mobilization of peripheral blood stem cells with bortezomib + high-dose cyclophosphamide + G-CSF in a light chain myeloma patient after failure with Total Therapy 2.
Topics: Adult; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Immunoglobulin Light Chains; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Transplantation, Autologous | 2009 |
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
Topics: Animals; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Disease Models, Animal; Hydroxamic Acids; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Multiple Myeloma; Neovascularization, Pathologic; Osteolysis; Pyrazines | 2009 |
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Meta-Analysis as Topic; Multiple Myeloma; Pyrazines; Research Design; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous | 2009 |
Effects of the BH3-only protein human Noxa on mitochondrial dynamics.
Topics: Amino Acid Sequence; Animals; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Death; HeLa Cells; Humans; Leucine; Mitochondria; Molecular Sequence Data; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction | 2009 |
Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Drug Eruptions; Exanthema; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2009 |
[Apoptosis of Burkitt's lymphoma Raji cell line induced by bortezomib].
Topics: Apoptosis; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Humans; NF-kappa B; Pyrazines; Tumor Suppressor Protein p53 | 2009 |
MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Chromones; Cisplatin; Dual Specificity Phosphatase 1; Humans; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Morpholines; NF-kappa B; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; RNA Interference; Signal Transduction; Sulfones | 2009 |
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Consensus Development Conferences as Topic; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Medical Oncology; Multiple Myeloma; Pyrazines; Thalidomide | 2009 |
Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Caspase 10; Caspase 8; Cell Line, Tumor; Drug Synergism; fas Receptor; Fas-Associated Death Domain Protein; Flow Cytometry; Fluorescent Antibody Technique; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia, T-Cell; Membrane Microdomains; Microscopy, Confocal; Mitochondria; Multiple Myeloma; Phosphorylcholine; Pyrazines; Resveratrol; Signal Transduction; Stilbenes | 2009 |
Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors.
Topics: Animals; Boronic Acids; Bortezomib; Leupeptins; Male; Myocardium; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Wistar | 2010 |
Bortezomib for the treatment of multiple myeloma patients.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Humans; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Technology Assessment, Biomedical | 2009 |
Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
Topics: Aldehyde Reductase; Aldo-Keto Reductases; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cohort Studies; Colorectal Neoplasms; Cyclooxygenase 2; Electrophoresis, Gel, Two-Dimensional; HSP72 Heat-Shock Proteins; Humans; Phosphorylation; Protease Inhibitors; Proteome; Proto-Oncogene Proteins c-akt; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Tissue Array Analysis; Tumor Cells, Cultured | 2009 |
[Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy].
Topics: Acyclovir; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Retrospective Studies | 2009 |
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Carcinoma; Cell Line, Tumor; Cell Survival; Chloroquine; Colonic Neoplasms; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; HT29 Cells; Humans; Hydroxamic Acids; Lysosomes; Mice; Mice, Inbred BALB C; Mice, Nude; Proteasome Endopeptidase Complex; Pyrazines; Superoxides; Ubiquitinated Proteins; Vorinostat; Xenograft Model Antitumor Assays | 2010 |
Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy.
Topics: Animals; Antimalarials; Apoptosis; Autophagy; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Chloroquine; Colonic Neoplasms; Drug Therapy, Combination; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2009 |
Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Female; Fibrosis; Gadolinium; Heart Failure; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Myocardium; Pyrazines | 2010 |
Cutaneous myeloma and bortezomib.
Topics: Aged; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines; Skin Neoplasms; Treatment Outcome | 2009 |
The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.
Topics: Actins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cyclin D1; Cyproheptadine; Disease Models, Animal; Histamine H1 Antagonists; Histone Deacetylase Inhibitors; Lymphoma, Mantle-Cell; Mice; Protease Inhibitors; Pyrazines | 2009 |
Worsening low back pain.
Topics: Acute Kidney Injury; Adult; Biopsy, Needle; Bone Marrow; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diagnosis, Differential; Disease Progression; Family Practice; Follow-Up Studies; Humans; Immunohistochemistry; Kidney Function Tests; Low Back Pain; Male; Multiple Myeloma; Pain Measurement; Plasmapheresis; Pyrazines; Renal Dialysis; Risk Assessment; Severity of Illness Index; Tomography, X-Ray Computed | 2009 |
Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Drug Synergism; Enzyme Activation; HSP27 Heat-Shock Proteins; Humans; Multiple Myeloma; Oxides; p38 Mitogen-Activated Protein Kinases; Pyrazines; STAT3 Transcription Factor | 2010 |
Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons.
Topics: Adaptor Proteins, Signal Transducing; Animals; Boronic Acids; Bortezomib; Cell Nucleus; Ganglia, Spinal; Gene Expression Regulation; Male; Microscopy, Electron, Transmission; Poly(A)-Binding Protein II; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sensory Receptor Cells; Time Factors; Ubiquitin; Uridine | 2010 |
[A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Plasmacytoma; Prognosis; Pyrazines; Thalidomide | 2009 |
[Establishment of a GFP-based cellular model for screening novel proteasome inhibitors].
Topics: Boronic Acids; Bortezomib; Cell Line; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Genetic Vectors; Green Fluorescent Proteins; Humans; Lentivirus; Models, Biological; Protease Inhibitors; Pyrazines | 2009 |
Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Separation; Cyclophosphamide; Dexamethasone; Female; Flow Cytometry; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Prognosis; Prospective Studies; Pyrazines; Thalidomide; Treatment Outcome | 2009 |
Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo.
Topics: Animals; Boronic Acids; Bortezomib; Cell Differentiation; Dendritic Cells; Humans; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2009 |
Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Enzyme Activation; Female; Gene Expression Profiling; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Mitochondria; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Proteasome Inhibitors; Pyrazines; S-Phase Kinase-Associated Proteins; Tissue Array Analysis; Transplantation, Heterologous; Up-Regulation | 2009 |
Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant).
Topics: Boronic Acids; Bortezomib; Castleman Disease; Humans; Male; Middle Aged; POEMS Syndrome; Protease Inhibitors; Pyrazines; Treatment Outcome | 2010 |
Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Pyrazines; Signal Transduction; STAT3 Transcription Factor; Up-Regulation | 2009 |
An audience with...Joseph Bolen. Interview by Bethan Hughes.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Drug Industry; Humans; Medical Oncology; Neoplasms; Pyrazines | 2009 |
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Female; Forkhead Transcription Factors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia; Mice; Mice, Nude; Piperazines; Proteasome Inhibitors; Pyrazines; Pyrimidines; Remission Induction; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2009 |
Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
Topics: Antineoplastic Agents; Bone Morphogenetic Protein 2; Boronic Acids; Bortezomib; Case-Control Studies; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; Down-Regulation; Humans; Lenalidomide; Multiple Myeloma; Osteoblasts; Pyrazines; RNA, Messenger; Sp7 Transcription Factor; Thalidomide; Transcription Factors; Tumor Cells, Cultured | 2010 |
Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cyclin-Dependent Kinase Inhibitor p21; DNA Methylation; Gene Expression Profiling; Humans; Inhibitor of Apoptosis Proteins; Kidney Neoplasms; Microtubule-Associated Proteins; Mutation; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Survivin; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Von Hippel-Lindau Tumor Suppressor Protein | 2009 |
Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Krüppel-like transcription factors.
Topics: Animals; Boronic Acids; Bortezomib; Cells, Cultured; Endothelial Cells; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Male; Mice; Mice, Inbred C3H; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Protein C; Pyrazines; Thrombomodulin | 2009 |
Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Humans; Hyperthermia, Induced; Lymphoma, Mantle-Cell; Pyrazines | 2009 |
Successful bortezomib-based treatment in POEMS syndrome.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Depression, Chemical; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Humans; Male; Melphalan; Plasma Cells; POEMS Syndrome; Prednisone; Protease Inhibitors; Pyrazines; Remission Induction; Vascular Endothelial Growth Factor A; Vincristine | 2009 |
Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways.
Topics: Animals; Boronic Acids; Bortezomib; Endometriosis; Female; Mice; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrrolidines; Thiocarbamates | 2009 |
[Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Time Factors | 2009 |
Donor cell-derived acute lymphocytic leukemia after allogeneic stem cell transplantation for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Dexamethasone; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Tissue Donors; Transplantation, Homologous | 2009 |
Proteasome inhibitor bortezomib promotes a rupture-prone plaque phenotype in ApoE-deficient mice.
Topics: Animals; Apolipoproteins E; Apoptosis; Atherosclerosis; Boronic Acids; Bortezomib; Cells, Cultured; Female; Macrophages; Mice; Mice, Knockout; Myocytes, Smooth Muscle; Phenotype; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rabbits; Rupture, Spontaneous | 2010 |
The ubiquitin-proteasome system regulates the stability of neuronal nicotinic acetylcholine receptors.
Topics: Animals; Boronic Acids; Bortezomib; Cell Compartmentation; Cell Membrane; Endoplasmic Reticulum; Enzyme Inhibitors; Golgi Apparatus; Nerve Tissue Proteins; Neurons; PC12 Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Stability; Protein Subunits; Protein Transport; Pyrazines; Rats; Receptors, Nicotinic; Ubiquitin; Ubiquitination; Up-Regulation | 2010 |
Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats.
Topics: Animals; Antineoplastic Agents; Behavior, Animal; Blood Cell Count; Blood Chemical Analysis; Body Weight; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Hot Temperature; Neural Conduction; Neurotoxicity Syndromes; Pain; Pain Measurement; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Wistar; Sciatic Nerve | 2010 |
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Follow-Up Studies; Gene Deletion; Humans; Multiple Myeloma; Prognosis; Pyrazines; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2009 |
Activation of SHIP via a small molecule agonist kills multiple myeloma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; DNA Replication; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Humans; Inositol Phosphates; Inositol Polyphosphate 5-Phosphatases; Mice; Multiple Myeloma; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphoric Monoester Hydrolases; Phosphorylation; Polycyclic Compounds; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction | 2009 |
Elimination of post-transplant donor-specific HLA antibodies with bortezomib.
Topics: Adult; Antibodies; Boronic Acids; Bortezomib; Graft Rejection; HLA Antigens; Humans; Immunosuppressive Agents; Kidney Transplantation; Living Donors; Male; Middle Aged; Plasma Cells; Plasmapheresis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2008 |
[Pharmacodynamic characteristics of velcade efficacy in resistant and recurrent multiple myeloma: determination of free light chains of blood serum immunoglobulins].
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunoglobulin Light Chains; Middle Aged; Multiple Myeloma; Neoplasm Staging; Predictive Value of Tests; Prognosis; Pyrazines; Recurrence | 2009 |
GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib.
Topics: Angiogenesis Inhibitors; Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; MAP Kinase Signaling System; Neoplasm Proteins; Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Protein Folding; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2009 |
Bortezomib: the subtle line between drug-induced peripheral neuropathy and post-herpetic neuralgia.
Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neuralgia, Postherpetic; Peripheral Nervous System Diseases; Pyrazines | 2009 |
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Pyrazines; Recurrence; Renal Insufficiency; Risk Factors; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Nuclear factor kappaB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos.
Topics: Animals; Boronic Acids; Bortezomib; Embryo, Nonmammalian; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyruvates; Reverse Transcriptase Polymerase Chain Reaction; Zebrafish | 2009 |
Cord blood transplantation with a reduced-intensity conditioning regimen for patients with relapsed aggressive multiple myeloma after cytoreduction with bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Female; Humans; Insomnia, Fatal Familial; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Transplantation Conditioning | 2009 |
Severe pulmonary complications after bortezomib treatment in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Respiratory Insufficiency; Survival Rate | 2010 |
Bortezomib and liposomal doxorubicin are highly effective in obtaining the best possible response before autologous transplant for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Female; Humans; Liposomes; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation | 2009 |
MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Polymorphism, Single Nucleotide; Prognosis; Pyrazines | 2009 |
[PAD regimen for relapsed or refractory patients with multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2009 |
Bortezomib: a new therapeutic option for POEMS syndrome.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Glycoproteins; Humans; Male; POEMS Syndrome; Pyrazines; Remission Induction | 2010 |
Proteasome inhibition activates the mitochondrial pathway of apoptosis in human CD4+ T cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; CD4-Positive T-Lymphocytes; Cytochromes c; Dendritic Cells; Dimerization; Enzyme Activation; Gene Expression Regulation, Enzymologic; Humans; Membrane Potentials; Mitochondria; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2009 |
Therapeutic use of tea derivatives: all that glitters is not gold.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Color; Cytoprotection; Endoplasmic Reticulum; Enzyme Inhibitors; Flavonoids; Glioblastoma; Humans; Mice; Mice, Nude; Molecular Structure; Phenols; Plant Extracts; Polyphenols; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stress, Physiological; Tea | 2009 |
Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Leukemia, Experimental; Magnetic Resonance Spectroscopy; Mice; Peptides, Cyclic; Proteasome Endopeptidase Complex; Pyrazines; Spectrometry, Mass, Electrospray Ionization | 2009 |
Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
Topics: Benzoquinones; Boronic Acids; Bortezomib; Cell Degranulation; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Histocompatibility Antigens Class I; HSP90 Heat-Shock Proteins; Humans; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Lactams, Macrocyclic; Ligands; Multiple Myeloma; Protein Folding; Pyrazines; Up-Regulation | 2009 |
Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis.
Topics: Adult; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Separation; Cells, Cultured; Drug Synergism; Esthesioneuroblastoma, Olfactory; Flow Cytometry; Humans; Immunohistochemistry; Male; Nose Neoplasms; Pyrazines; TNF-Related Apoptosis-Inducing Ligand | 2010 |
Selectively killing transformed cells through proteasome inhibition.
Topics: Anthracyclines; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Transformation, Neoplastic; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitination | 2009 |
Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2009 |
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Enzyme-Linked Immunosorbent Assay; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Tissue Inhibitor of Metalloproteinase-1 | 2010 |
Relapse/Refractory myeloma patient: potential treatment guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2009 |
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.
Topics: Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2004 |
Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
Topics: Boronic Acids; Bortezomib; Gene Expression Profiling; Humans; Paraproteinemias; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2004 |
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Case-Control Studies; Cell Communication; Cell Proliferation; Cell Survival; Chemotaxis; Coculture Techniques; Cytokines; Dendritic Cells; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Immunophenotyping; Mice; Mice, SCID; Multiple Myeloma; Oligodeoxyribonucleotides; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Receptors, Immunologic; Signal Transduction; T-Lymphocytes; Time Factors; Toll-Like Receptors; Transplantation, Heterologous; Tumor Cells, Cultured | 2009 |
Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells.
Topics: Androgens; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Male; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2010 |
Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Daunorubicin; Drug Resistance, Neoplasm; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Leupeptins; Male; Middle Aged; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured; U937 Cells | 2010 |
Home administration of bortezomib: making a difference to myeloma patients' lives.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Home Care Services; Humans; Injections, Intravenous; Ireland; Male; Multiple Myeloma; Pilot Projects; Pyrazines; Treatment Outcome | 2010 |
Captivating bortezomib: an active but still mysterious drug.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; NF-kappa B; Pyrazines; Signal Transduction; Treatment Outcome | 2010 |
BU-32: a novel proteasome inhibitor for breast cancer.
Topics: Animals; Apoptosis; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Chymotrypsin; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrazoles; Xenograft Model Antitumor Assays | 2009 |
[Establishment of a bortezomib-resistant myeloma cell line and differential proteins analysis by MALDI-OF-MS].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Myeloma Proteins; Proteome; Pyrazines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2009 |
Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2.
Topics: Boronic Acids; Bortezomib; Celecoxib; Cell Death; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Endoplasmic Reticulum; Humans; Lymphoma; Pyrazines; Pyrazoles; Stress, Physiological; Sulfonamides | 2010 |
[Update in multiple myeloma: international criteria for treatment response and renal complications].
Topics: Antineoplastic Agents; Biomarkers; Boronic Acids; Bortezomib; France; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Immunologic Factors; International Cooperation; Kidney Diseases; Multiple Myeloma; Practice Guidelines as Topic; Prevalence; Pyrazines; Renal Dialysis; Renal Insufficiency; Sensitivity and Specificity; Societies, Medical | 2009 |
First report of a medullar cord compression secondary to osseous plasmacytoma successfully treated with bortezomib and dexamethasone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Middle Aged; Plasmacytoma; Pyrazines; Spinal Cord Compression; Treatment Outcome | 2010 |
Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Early Growth Response Protein 1; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Mesenchymal Stem Cells; Microtubule-Associated Proteins; Multiple Myeloma; Osteoclasts; Phenotype; Plasma Cells; Prognosis; Protein Binding; Proto-Oncogene Proteins c-jun; Pyrazines; Risk Factors; Signal Transduction; Survivin | 2010 |
[Synergistic effects of proteasome inhibitor and histone deacetylase inhibitor on apoptosis and aggresome formation in T lymphoma cells].
Topics: Apoptosis; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Jurkat Cells; Lymphoma, T-Cell; Proteasome Inhibitors; Pyrazines | 2009 |
The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cytotoxicity, Immunologic; Epitopes; Interferon-gamma; Lymphocytic Choriomeningitis; Lymphocytic choriomeningitis virus; Mice; Mice, Inbred C57BL; Peptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2009 |
Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cisplatin; Humans; Lactones; Leupeptins; Male; Melanoma; Membrane Potential, Mitochondrial; NF-kappa B; Phosphatidylethanolamine Binding Protein; Prostatic Neoplasms; Proteasome Inhibitors; Proto-Oncogene Proteins c-raf; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Snail Family Transcription Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription Factors; Transfection; Tumor Cells, Cultured | 2009 |
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Flow Cytometry; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mast Cells; Mastocytosis, Systemic; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Staurosporine; Transfection | 2009 |
Multiple lipoma with hyperlipidemia in a multiple myeloma patient treated with bortezomib/dexamethazone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Hyperlipidemias; Lipoma; Male; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Pyrazines | 2010 |
Bortezomib and restoration of chemosensitivity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines | 2009 |
Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells.
Topics: Animals; Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Cell Survival; Humans; Immunoblotting; Lactones; Lysosomes; Male; Microscopy, Electron, Transmission; Microtubule-Associated Proteins; Phagosomes; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Ubiquitin-Activating Enzymes | 2010 |
Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system.
Topics: Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Death; Cell Line, Tumor; Gene Expression Profiling; Glioblastoma; Glutathione; Humans; Microarray Analysis; Necrosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrans; Pyrazines; Sulfhydryl Compounds; Ubiquitin | 2009 |
Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clone Cells; Disease Progression; Female; Humans; Leukemia, Plasma Cell; Multiple Myeloma; Pyrazines; Recurrence | 2010 |
TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.
Topics: Acetylcysteine; ADAM Proteins; ADAM17 Protein; Antibodies, Monoclonal; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Hydroxamic Acids; Ki-1 Antigen; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Sulfonamides; Syndecan-1 | 2010 |
DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Intercellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous; Vincristine | 2010 |
Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Primers; Humans; Immunohistochemistry; Mice; Mice, Nude; Osteosarcoma; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterologous | 2010 |
Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Female; Humans; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Prognosis; Pyrazines; Thalidomide | 2010 |
Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications.
Topics: Antimalarials; Antineoplastic Agents; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; DNA-Binding Proteins; Heat Shock Transcription Factors; Heat-Shock Response; HeLa Cells; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Neoplasms; Pyrazines; Quinacrine; RNA, Small Interfering; Transcription Factors | 2009 |
Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant.
Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Pyrazines; Recurrence; Transplantation, Autologous | 2010 |
Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.
Topics: Animals; Antigen Presentation; Boronic Acids; Bortezomib; Capsid Proteins; CD8-Positive T-Lymphocytes; Cell Line; Dependovirus; Genes, MHC Class I; Genetic Vectors; Hemophilia B; Humans; Mice; Protease Inhibitors; Pyrazines; Transduction, Genetic | 2010 |
Commentary on Perrone et al.: 'vitamin C: not for breakfast anymore...if you have myeloma'.
Topics: Antineoplastic Agents; Antioxidants; Ascorbic Acid; Boronic Acids; Bortezomib; Drug Interactions; Humans; Multiple Myeloma; Pyrazines | 2009 |
Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents.
Topics: Acneiform Eruptions; Aged; Boronic Acids; Bortezomib; Candida albicans; Candidiasis; Desonide; Dexamethasone; Doxycycline; ErbB Receptors; Fluconazole; Folliculitis; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2010 |
CYT997 causes apoptosis in human multiple myeloma.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; Fluorescent Antibody Technique; G2 Phase; Humans; Mice; Mitosis; Multiple Myeloma; Polymerization; Pyrazines; Pyridines; Pyrimidines; Survival Analysis; Time Factors; Tubulin | 2011 |
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Niacinamide; Okadaic Acid; Phenylurea Compounds; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; Pyridines; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Adhesion; Cell Movement; Cell Proliferation; Diphosphonates; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Macrophages; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; NF-kappa B; Phosphorylation; Pyrazines; Vascular Endothelial Growth Factor Receptor-2; Zoledronic Acid | 2010 |
Bortezomib induces autophagic death in proliferating human endothelial cells.
Topics: Adenine; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Endothelial Cells; Fibroblast Growth Factors; Humans; Microtubule-Associated Proteins; Multiple Myeloma; Protease Inhibitors; Pyrazines; Reactive Oxygen Species | 2010 |
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Rituximab; Vidarabine | 2010 |
Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angiopoietin-2; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cells, Cultured; Chemokines; Coculture Techniques; Culture Media, Serum-Free; Cytarabine; Diterpenes; Endothelial Cells; Female; Humans; Imidazoles; Leukemia, Myeloid; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Middle Aged; Neoplasm Proteins; NF-kappa B; Protease Inhibitors; Pyrazines; Quinoxalines; Receptor, TIE-2; Recombinant Proteins; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured | 2010 |
Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma.
Topics: Apoptosis; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Cytokines; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Neoplasm Proteins; Protease Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; Stromal Cells; TNF-Related Apoptosis-Inducing Ligand; Tumor Escape | 2010 |
Heat stress triggers apoptosis by impairing NF-kappaB survival signaling in malignant B cells.
Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA; DNA-Binding Proteins; Heat Shock Transcription Factors; Heat-Shock Response; Hot Temperature; Humans; Inhibitor of Apoptosis Proteins; Lymphoma, B-Cell; NF-kappa B; Protein Biosynthesis; Pyrazines; Signal Transduction; Transcription Factor RelA; Transcription Factors; Ubiquitin-Protein Ligases | 2010 |
High-throughput detection of nuclear factor-kappaB activity using a sensitive oligo-based chemiluminescent enzyme-linked immunosorbent assay.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD40 Ligand; Cell Nucleus; Enzyme-Linked Immunosorbent Assay; HeLa Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Luminescent Measurements; Lymphocytes; NF-kappa B; Oligonucleotides; Pyrazines; Tumor Necrosis Factor-alpha | 2010 |
Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Myeloma Proteins; Neoplasm Proteins; Protease Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays | 2010 |
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Gastrointestinal Diseases; Glomerular Filtration Rate; Hematologic Diseases; Humans; Italy; Kidney Diseases; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide | 2010 |
Treatment of human respiratory syncytial virus infected Balb/C mice with the proteasome inhibitor bortezomib (Velcade, PS-341) results in increased inflammation and mortality.
Topics: Animals; Antiviral Agents; Boronic Acids; Bortezomib; Chlorocebus aethiops; Cytokines; Enzyme Inhibitors; Inflammation; Mice; Mice, Inbred BALB C; Proteasome Inhibitors; Pyrazines; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Vero Cells; Virus Replication | 2010 |
The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Humans; Magnetic Resonance Imaging; Male; Metabolic Clearance Rate; Mice; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2009 |
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Survival; Humans; Imidazoles; Multiple Myeloma; Mutation, Missense; Neoplasms, Glandular and Epithelial; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-mdm2; Pyrazines; Tumor Suppressor Protein p53 | 2009 |
Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Gene Expression; Humans; Imidazoles; Melphalan; Multiple Myeloma; NF-kappa B; Pyrazines; Quinoxalines; Transcription Factor RelB | 2009 |
Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Betulinic Acid; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Drug Therapy, Combination; Electrophoretic Mobility Shift Assay; Enzyme Activation; Flow Cytometry; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Interleukin-6; Janus Kinase 1; Janus Kinase 2; Luciferases; Multiple Myeloma; Pentacyclic Triterpenes; Protease Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrazines; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Thalidomide; Triterpenes; Tumor Cells, Cultured | 2010 |
NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Lung Neoplasms; Melanoma; Mice; NF-kappa B; Oxazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyridines; Skin Neoplasms | 2010 |
Hematology: first-line bortezomib benefits patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Prognosis; Pyrazines | 2009 |
Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.
Topics: Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Chymotrypsin; Dose-Response Relationship, Drug; Estrogen Receptor alpha; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Promoter Regions, Genetic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA Polymerase II; Signal Transduction | 2010 |
[IgA pemphigus accompanying multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin A; Multiple Myeloma; Paraproteinemias; Pemphigus; Proteasome Inhibitors; Pyrazines | 2009 |
Bortezomib inhibits hepatitis B virus replication in transgenic mice.
Topics: Animals; Antiviral Agents; Boronic Acids; Bortezomib; Cytokines; DNA, Viral; Hepatitis B; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Immunohistochemistry; Liver; Mice; Mice, Transgenic; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Virus Replication | 2010 |
[Effect of bortezomib on acute graft-versus-host disease in mice model and its mechanism].
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Survival; Cells, Cultured; Disease Models, Animal; Female; Graft vs Host Disease; Interferon-gamma; Interleukin-2; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines; Tumor Necrosis Factor-alpha | 2009 |
Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2009 |
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Dexamethasone; Disease Models, Animal; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Panobinostat; Pyrazines; Random Allocation; Thalidomide; Xenograft Model Antitumor Assays | 2010 |
Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney Failure, Chronic; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2010 |
[Combination of bortezomib and dexamethasone for newly diagnosed multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Treatment Outcome | 2009 |
The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Death; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Male; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Threonine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Synergism; Female; Flow Cytometry; Humans; Mesothelioma; Pilot Projects; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Signal Transduction; Time Factors | 2010 |
Prophylactic antivirals may be helpful in prevention of varicella-zoster virus reactivation in myeloma, but are they safe?
Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Drug Monitoring; Herpes Zoster; Herpesvirus 3, Human; Humans; Incidence; Multiple Myeloma; Neurotoxicity Syndromes; Pyrazines; Renal Insufficiency; Virus Activation | 2010 |
Bortezomib induces erythema multiforme-like cutaneous adverse effects: report of two cases.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Erythema Multiforme; Humans; Male; Middle Aged; Pyrazines | 2009 |
Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Melphalan; Multiple Myeloma; Paraproteinemias; Pyrazines; Recurrence; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2009 |
The potential effect of proteasome inhibitor PS-341 on severe acute pancreatitis detected by positron emission tomography in ICR mice.
Topics: Amylases; Animals; Apoptosis; Boronic Acids; Bortezomib; C-Reactive Protein; Ceruletide; Female; Inflammation; Interleukin-1beta; L-Lactate Dehydrogenase; Mice; Mice, Inbred ICR; Pancreatitis; Positron-Emission Tomography; Protease Inhibitors; Pyrazines; Radiography | 2010 |
Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Down-Regulation; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Focal Adhesion Protein-Tyrosine Kinases; Humans; In Situ Nick-End Labeling; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Multiple myeloma with multiple and bulky extramedullary plasmacytomas as initial presentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy; Tomography, X-Ray Computed; Vincristine | 2009 |
Potentiation of (-)-epigallocatechin-3-gallate-induced apoptosis by bortezomib in multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Catechin; Cell Line, Tumor; Humans; Multiple Myeloma; Polymerase Chain Reaction; Pyrazines; RNA, Messenger; Tea; Transcription Factor RelA | 2009 |
Salmonella enteritidis necrotising fasciitis in a multiple myeloma patient receiving bortezomib.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Fasciitis, Necrotizing; Humans; Male; Multiple Myeloma; Pyrazines; Salmonella enteritidis; Salmonella Infections | 2010 |
An unusual case of transient dermatological reaction to bortezomib in AL amyloidosis.
Topics: Amyloidosis; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Paraproteinemias; Protease Inhibitors; Pyrazines | 2010 |
Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells.
Topics: Activating Transcription Factor 4; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Endoplasmic Reticulum; Fenretinide; Humans; Neuroectodermal Tumors; Pyrazines; Signal Transduction; Stress, Physiological | 2010 |
Treatment of multiple myeloma: 2009 update.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2009 |
Cutting edge: bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Transformed; Cell Line, Tumor; Cells, Cultured; Clone Cells; Coculture Techniques; Cytotoxicity Tests, Immunologic; Epitopes, T-Lymphocyte; Immunity, Innate; Immunization; Killer Cells, Natural; Melanoma, Experimental; Mice; Mice, SCID; Pyrazines; T-Lymphocytes, Cytotoxic | 2010 |
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Flow Cytometry; Fluorescent Antibody Technique; Gastrointestinal Stromal Tumors; Gene Expression; Histones; Humans; Immunoprecipitation; Proto-Oncogene Proteins c-kit; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2010 |
Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates.
Topics: Animals; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Resistance; Graft Rejection; Immunologic Memory; Immunosuppressive Agents; Lymphocyte Activation; Macaca mulatta; Male; Pancreas Transplantation; Protease Inhibitors; Pyrazines; Sirolimus; Swine; Swine, Miniature; T-Lymphocytes; T-Lymphocytes, Regulatory | 2009 |
Combined effects of bortezomib and daunorubicin on multiple myeloma cell KM3 in vitro.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Drug Synergism; Humans; Inhibitory Concentration 50; Multiple Myeloma; Pyrazines | 2009 |
[Retrospective analysis of 71 cases of multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2009 |
Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.
Topics: Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Outcome Assessment, Health Care; Pyrazines; Thalidomide; Transplantation, Autologous; Vincristine | 2010 |
[IgA multiple myeloma with adverse prognostic factors--a case report].
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Drug Resistance, Neoplasm; Humans; Immunoglobulin A; Male; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2009 |
Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-1; Angiopoietin-2; Antibodies; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Coculture Techniques; Endothelial Cells; Female; Fibroblasts; Hepatocyte Growth Factor; Humans; Imidazoles; Interleukin-8; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Osteoblasts; Proteoglycans; Pyrazines; Quinoxalines; Receptor Cross-Talk; Receptor, TIE-2; Signal Transduction | 2010 |
The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Child; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Neuroblastoma; Protease Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, Death Domain; Signal Transduction; Transgenes | 2010 |
Cutaneous lymphoid perivascular reaction with atypical CD30+ T cells in a patient with multiple myeloma treated with bortezomib.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Ki-1 Antigen; Male; Multiple Myeloma; Pyrazines; T-Lymphocyte Subsets | 2009 |
New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.
Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Synergism; Humans; Male; Nitrophenols; Nucleosides; Peptides; Piperazines; Prostate; Pyrazines; Pyrimidines; Sulfonamides; Thiostrepton | 2010 |
Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib.
Topics: Aged; Antineoplastic Agents; Biomarkers; Boronic Acids; Bortezomib; Creatinine; Female; Humans; Kidney; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recovery of Function; Renal Insufficiency; Time Factors; Treatment Outcome | 2010 |
Acute humoral rejection in a lung recipient: reversion with bortezomib.
Topics: Adult; Biopsy; Boronic Acids; Bortezomib; Cadaver; Female; Graft Rejection; Humans; Immunity, Humoral; Lung Transplantation; Middle Aged; Postoperative Complications; Protease Inhibitors; Pyrazines; T-Lymphocytes; Tissue Donors; Treatment Outcome | 2010 |
Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line; Cells, Cultured; Cystathionine beta-Synthase; Enzyme Activation; Enzyme Inhibitors; Fibroblasts; Gene Expression; Homocystinuria; HSP70 Heat-Shock Proteins; Humans; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Proteasome Inhibitors; Pyrazines; Saccharomyces cerevisiae | 2010 |
Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Depsipeptides; Dose-Response Relationship, Drug; Drug Synergism; Humans; Hydroxamic Acids; Lymphoma, Mantle-Cell; Mice; Pyrazines; Sulfonamides; Xenograft Model Antitumor Assays | 2010 |
Identification of USP18 as an important regulator of the susceptibility to IFN-alpha and drug-induced apoptosis.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carbon-Nitrogen Lyases; Cell Line, Tumor; Down-Regulation; Endopeptidases; Etoposide; Gene Silencing; Humans; Interferon alpha-2; Interferon-alpha; Protease Inhibitors; Pyrazines; Recombinant Proteins; RNA Interference; RNA, Messenger; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Ubiquitin Thiolesterase | 2010 |
Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.
Topics: Animals; Antigens, CD34; Apoptosis; Boronic Acids; Bortezomib; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Mutant Proteins; Proteasome Inhibitors; Pyrazines; Pyrimidines; Thiazoles; Time Factors; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2010 |
[IgM-lambda multiple myeloma presenting with systemic amyloidosis].
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Fatal Outcome; Humans; Immunoglobulin M; Male; Middle Aged; Multiple Myeloma; Paraproteinemias; Pyrazines; Vincristine | 2009 |
The AJT report: news and issues that affect organ and tissue transplantation. Wrestling with positive cross-matches. A look at some of the newer desensitization therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Desensitization, Immunologic; Graft Rejection; Histocompatibility Testing; Humans; Immunoglobulins, Intravenous; Immunosuppression Therapy; Plasmapheresis; Pyrazines; Rituximab; Transplantation Immunology | 2010 |
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2010 |
INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Coculture Techniques; Humans; Interleukin-6; Janus Kinase 1; Janus Kinase 2; Melphalan; Mice; Mice, SCID; Molecular Structure; Multiple Myeloma; Phosphorylation; Protein Kinase Inhibitors; Pyrazines; Pyridines; STAT3 Transcription Factor; Stromal Cells; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Drug discovery and assay development in the ubiquitin-proteasome system.
Topics: Antineoplastic Agents; Biological Assay; Boronic Acids; Bortezomib; Drug Discovery; Drug Resistance, Neoplasm; Molecular Structure; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2010 |
Bortezomib upregulates [corrected] the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease.
Topics: Antineoplastic Agents; Bone Remodeling; Boronic Acids; Bortezomib; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Osteoblasts; Osteolysis, Essential; Pyrazines; Sp7 Transcription Factor; Transcription Factors | 2010 |
[The effects and safety of bortezomib combined with dexamethasone in the treatment of primary systemic amyloidosis].
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Drug Combinations; Female; Humans; Male; Middle Aged; Pyrazines; Treatment Outcome | 2009 |
Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclin D1; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppression Therapy; Lenalidomide; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Second Primary; Pyrazines; Rituximab; Thalidomide; Transplantation, Autologous | 2010 |
Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Electrophoresis, Gel, Two-Dimensional; Gene Expression Profiling; High-Throughput Screening Assays; Humans; Indoles; Lymphoma, Mantle-Cell; Prognosis; Protease Inhibitors; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recurrence | 2010 |
A proteasome inhibitor to treat acute pancreatitis? Maybe...
Topics: Animals; Boronic Acids; Bortezomib; Pancreatitis, Acute Necrotizing; Proteasome Inhibitors; Pyrazines | 2010 |
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Bortezomib: a new pro-apoptotic agent in cancer treatment.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Dexamethasone; Humans; Mice; Multiple Myeloma; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Proteasome Inhibitors; Pyrazines | 2010 |
Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, p53; HCT116 Cells; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasms; Pyrazines; RNA, Small Interfering; Survivin | 2010 |
Inhibition of mTORC1 activity by REDD1 induction in myeloma cells resistant to bortezomib cytotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Size; Dexamethasone; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Pyrazines; Transcription Factors; Transcriptional Activation | 2010 |
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Interferons; Interleukins; Janus Kinase 1; Melanoma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Pyrazines; Signal Transduction; Skin Neoplasms; STAT Transcription Factors; Temozolomide | 2010 |
Functional evaluation of therapeutic response for a mouse model of medulloblastoma.
Topics: Animals; Antineoplastic Agents; Ataxia; Boronic Acids; Bortezomib; Cerebellar Neoplasms; Disease Models, Animal; Disease Progression; Drug Screening Assays, Antitumor; Gait Disorders, Neurologic; Lameness, Animal; Magnetic Resonance Imaging; Medulloblastoma; Mice; Mice, Knockout; Patched Receptors; Patched-1 Receptor; Protease Inhibitors; Psychomotor Performance; Pyrazines; Receptors, Cell Surface | 2010 |
Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Autoantibodies; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin M; Protease Inhibitors; Pyrazines | 2010 |
Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells.
Topics: Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Breast Neoplasms; Caspases; Cathepsins; Cell Death; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Estrogen Receptor Modulators; Female; Humans; Metabolism; Pyrazines; Receptors, Estrogen; Signal Transduction; Stress, Physiological; Tumor Cells, Cultured | 2010 |
Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies.
Topics: Adult; Biopsy; Boronic Acids; Bortezomib; Female; Graft Survival; HLA Antigens; Humans; Immunohistochemistry; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2010 |
Effect of proteasome inhibitors with different chemical structures on the ubiquitin-proteasome system in vitro.
Topics: Acetylcysteine; Animals; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Immunohistochemistry; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Oligopeptides; PC12 Cells; Peripheral Nervous System Diseases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Ubiquitin | 2010 |
Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Middle Aged; Ovarian Neoplasms; Proteasome Inhibitors; Pyrazines; TNF-Related Apoptosis-Inducing Ligand | 2010 |
[2-methoxyestradiol disrupts aggresomes induction by bortezomib and potentiates apoptosis in multiple myeloma cells.].
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Multiple Myeloma; Pyrazines | 2009 |
Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Clone Cells; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Karyotyping; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplastic Stem Cells; Peripheral Blood Stem Cell Transplantation; Polyploidy; Protease Inhibitors; Pyrazines; Thalidomide; Translocation, Genetic; Transplantation, Autologous | 2010 |
Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Prognosis; Pyrazines; Risk Management; Risk Reduction Behavior; Thalidomide | 2010 |
Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Biopsy; Boronic Acids; Bortezomib; Creatinine; Female; Graft Rejection; HLA Antigens; Humans; Immunologic Factors; Immunosuppression Therapy; Isoantibodies; Kidney Failure, Chronic; Kidney Transplantation; Protease Inhibitors; Pyrazines; Rituximab; Transplantation, Homologous; Young Adult | 2010 |
Recurrent capillary leak syndrome following bortezomib therapy in a patient with relapsed myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Capillary Leak Syndrome; Dexamethasone; Dose-Response Relationship, Drug; Female; Glucocorticoids; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Protease Inhibitors; Pyrazines; Secondary Prevention | 2010 |
The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro.
Topics: Apoptosis; Benzophenanthridines; Boronic Acids; Bortezomib; Brefeldin A; Carcinoid Tumor; Carcinoma, Bronchogenic; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Lung Neoplasms; Naphthoquinones; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrazines | 2010 |
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Topics: Animals; Boron Compounds; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Drug Screening Assays, Antitumor; Female; Glycine; HCT116 Cells; HT29 Cells; Humans; Lymphoma; Mice; Mice, SCID; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2010 |
The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack.
Topics: Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 8; Cell Line, Tumor; Combined Modality Therapy; Enzyme Activation; Granzymes; Humans; Immunotherapy, Adoptive; Intracellular Signaling Peptides and Proteins; Lymphocyte Activation; Melanoma; Mitochondria; Mitochondrial Proteins; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, Cell Surface; RNA, Small Interfering; T-Lymphocytes, Cytotoxic; Transfection; X-Linked Inhibitor of Apoptosis Protein | 2010 |
Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice.
Topics: Action Potentials; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Electrophysiology; Female; Ganglia, Spinal; Immunohistochemistry; Mice; Microscopy, Electron; Motor Neurons; Myelin Sheath; Nerve Fibers, Unmyelinated; Neural Conduction; Pain; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Sciatic Nerve; Sensory Receptor Cells; Skin; Tibial Nerve | 2010 |
The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.
Topics: 3T3 Cells; Acyltransferases; Animals; Base Sequence; Boronic Acids; Bortezomib; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; DNA Primers; Fibroblast Growth Factor 2; Humans; Mice; Models, Biological; Multiple Myeloma; Osteoblasts; Osteogenesis; Osteolysis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recombinant Proteins; RNA, Messenger; Transcription Factors | 2010 |
[Apoptosis in Jurkat cells induced by bortezomib combined with adriamycin].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Humans; Inhibitory Concentration 50; Jurkat Cells; Poly(ADP-ribose) Polymerases; Pyrazines | 2009 |
Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Biotinylation; Blotting, Western; Boronic Acids; Bortezomib; Cells, Cultured; Cytotoxicity, Immunologic; Flow Cytometry; Humans; Immunoprecipitation; Lymphoma, B-Cell; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Rituximab; RNA, Messenger | 2010 |
Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Galectins; Gene Expression Profiling; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Multiple Myeloma; Mutation; Oligonucleotide Array Sequence Analysis; Phosphorylation; Proto-Oncogene Proteins; Pyrazines; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Whole-Body Irradiation; Xenograft Model Antitumor Assays | 2010 |
Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia.
Topics: Aging; Animals; Boronic Acids; Bortezomib; Brain Ischemia; Drug Administration Schedule; Drug Therapy, Combination; Intracranial Embolism; Male; Neuroprotective Agents; Protease Inhibitors; Pyrazines; Rats; Rats, Wistar; Tissue Plasminogen Activator | 2010 |
Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Female; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Transgenic; Oligodeoxyribonucleotides; Pyrazines; Rats; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Toll-Like Receptor 9; Treatment Outcome | 2010 |
A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Culture Techniques; Dacarbazine; Glioblastoma; Humans; Mice; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; RNA Interference; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured | 2009 |
Multiple myeloma patients experience high response rate with new three-drug combination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Humans; Lenalidomide; Leukocytes; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2009 |
Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Inflammation; Inflammation Mediators; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Neovascularization, Pathologic; NF-kappa B; Pleural Effusion, Malignant; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2010 |
The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Calreticulin; Caspase 8; Cell Line, Tumor; Child; Flow Cytometry; Fluorescent Antibody Technique; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pyrazines; Vorinostat | 2010 |
Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Multiple Myeloma; Polyethylene Glycols; Pyrazines | 2010 |
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Chymotrypsin; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; In Vitro Techniques; JNK Mitogen-Activated Protein Kinases; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Nude; Mitochondria; NF-kappa B; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays | 2010 |
[Effect of bortezomib and arabinoside on proliferation and apoptosis of K562 cell.].
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Humans; K562 Cells; Pyrazines | 2010 |
Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies.
Topics: Animals; Boronic Acids; Bortezomib; Disease Models, Animal; Dystroglycans; Evans Blue; Gene Expression Regulation; Glycoproteins; Mice; Mice, Inbred C57BL; Muscular Dystrophy, Duchenne; Mutation; Proteasome Inhibitors; Pyrazines; Sarcoglycans; Ubiquitin | 2010 |
Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Caspases; Cell Growth Processes; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; NF-kappa B; Phosphorylation; Piperazines; Pyrazines; Pyrimidines; Retinoblastoma Protein | 2010 |
Bortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissions.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Tissue Donors; Transplantation, Homologous | 2011 |
A novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Division; Cell Line, Tumor; Chymotrypsin; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Humans; Lymphoma, Mantle-Cell; Membrane Potential, Mitochondrial; Neoplasm Proteins; Organometallic Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrones | 2010 |
Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.
Topics: Active Transport, Cell Nucleus; Apoptosis; Boronic Acids; Bortezomib; Calpain; Caspase 8; Cell Line, Tumor; Cell Nucleus; Humans; I-kappa B Proteins; Multiple Myeloma; NF-KappaB Inhibitor alpha; Protease Inhibitors; Pyrazines; Transcription Factor RelA | 2010 |
Acute dyspnea from treatment of AL amyloidisis with bortezomib.
Topics: Acute Disease; Aged; Amyloidosis; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Dyspnea; Humans; Kidney Diseases; Male; Middle Aged; Protease Inhibitors; Pyrazines | 2011 |
Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Histocompatibility Antigens Class I; HLA-D Antigens; Humans; Immunity, Humoral; Kidney Transplantation; Male; Monitoring, Immunologic; Nephritis, Interstitial; Protease Inhibitors; Pyrazines; Renal Dialysis | 2010 |
Lupus tumidus induced by bortezomib not requiring discontinuation of the drug.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lupus Erythematosus, Cutaneous; Male; Multiple Myeloma; Pyrazines | 2010 |
High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Doxorubicin; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Outcome Assessment, Health Care; Proportional Hazards Models; Prospective Studies; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thalidomide; Thrombosis; Vincristine | 2010 |
Bortezomib for the treatment of refractory Type-1 cryoglobulinaemia.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Cryoglobulinemia; Humans; Male; Protease Inhibitors; Pyrazines; Skin Diseases, Vascular; Vasculitis | 2010 |
Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Female; Frail Elderly; Humans; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Salvage Therapy; Treatment Outcome | 2010 |
Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Cell Line, Tumor; Depsipeptides; Down-Regulation; Drug Synergism; Gene Knockdown Techniques; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Pyrazines; RNA, Small Interfering; Sp1 Transcription Factor; Xenograft Model Antitumor Assays | 2010 |
Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kidney; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Insufficiency; Thalidomide; Time Factors; Treatment Outcome; X-Rays | 2010 |
Hyperlipidemia in a myeloma patient after bortezomib treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Hyperlipidemias; Multiple Myeloma; Pyrazines | 2010 |
[Waldenström's macroglobulinemia].
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Diagnosis, Differential; Humans; Male; Nucleosides; Phosphorylcholine; Prognosis; Protease Inhibitors; Pyrazines; Rituximab; Waldenstrom Macroglobulinemia | 2010 |
Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Capillary Permeability; CDC2 Protein Kinase; Cell Division; Cell Proliferation; Cells, Cultured; Cyclin B; Cyclin-Dependent Kinases; Endothelial Cells; G2 Phase; Humans; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Vascular Endothelial Growth Factor A | 2010 |
Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib.
Topics: Acyclovir; Boronic Acids; Bortezomib; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Multiple Myeloma; Pyrazines; T-Lymphocytes | 2010 |
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Compassionate Use Trials; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Research; Stem Cell Transplantation; Thalidomide | 2010 |
Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Disease Progression; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Vorinostat | 2010 |
Rapid fatal pulmonary complications in a Chinese patient after bortezomib treatment for ALK-negative anaplastic large-cell lymphoma.
Topics: Aged; Asian People; Boronic Acids; Bortezomib; Enzyme Inhibitors; Fatal Outcome; Hematologic Neoplasms; Humans; Lung; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Male; Pyrazines | 2010 |
Detrimental effect of the proteasome inhibitor, bortezomib in bacterial superantigen- and lipopolysaccharide-induced systemic inflammation.
Topics: Acetylcysteine; Animals; Apoptosis; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Cytokines; HLA-DR3 Antigen; Lipopolysaccharides; Liver; Mice; Mice, Transgenic; NF-kappa B; Proteasome Inhibitors; Pyrazines; Superantigens; Systemic Inflammatory Response Syndrome | 2010 |
Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient.
Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lung Diseases, Interstitial; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2010 |
Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Cells, Cultured; Ubiquitination | 2010 |
[Analysis of high-risk multiple myeloma patients treated with high-dose chemotherapy].
Topics: Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prognosis; Pulse Therapy, Drug; Pyrazines; Risk; Survival Rate; Thalidomide; Transplantation, Autologous | 2010 |
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Aurora Kinases; Azepines; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Doxorubicin; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Pyrimidines; Spindle Apparatus; Time Factors; Transplantation, Heterologous; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2010 |
Bortezomib induces apoptosis in human neuroblastoma CHP126 cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Coloring Agents; Dose-Response Relationship, Drug; Enzyme Activation; Gene Expression; Humans; Indicators and Reagents; Neuroblastoma; NF-kappa B; Oncogene Protein p21(ras); Poly(ADP-ribose) Polymerases; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Tetrazolium Salts; Thiazoles; Up-Regulation | 2010 |
Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.
Topics: Adipocytes; Animals; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Cell Communication; Coculture Techniques; Enzyme Activation; Female; HeLa Cells; Humans; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred NOD; Pyrazines; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Transduction, Genetic; Uterine Cervical Neoplasms | 2010 |
The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Feasibility Studies; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Multiple Myeloma; Panobinostat; Pyrazines; Thalidomide; Treatment Failure; Treatment Outcome | 2010 |
Bortezomib synergizes TRAIL-induced apoptosis in gastric cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; Pyrazines; Stomach Neoplasms; TNF-Related Apoptosis-Inducing Ligand | 2010 |
Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib.
Topics: Apoptosis; Aspirin; bcl-Associated Death Protein; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclooxygenase 2; Down-Regulation; Drug Synergism; Humans; NF-kappa B; Proto-Oncogene Proteins c-akt; Pyrazines | 2010 |
Complete heart block secondary to bortezomib use in multiple myeloma.
Topics: Aged, 80 and over; Antineoplastic Agents; Autonomic Nervous System; Boronic Acids; Bortezomib; Cardiac Pacing, Artificial; Electrocardiography; Female; Heart Block; Humans; Multiple Myeloma; Pacemaker, Artificial; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2011 |
ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination.
Topics: Benzoquinones; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Clathrin; Down-Regulation; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lysosomes; Mass Spectrometry; Microscopy, Fluorescence; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptor, ErbB-2; Ubiquitination | 2010 |
Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
Topics: Adenocarcinoma; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cadherins; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cell Movement; Epithelial Cells; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Mesoderm; Neoplasm Invasiveness; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA, Messenger; Spheroids, Cellular; Time Factors; Transfection; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Up-Regulation; Vorinostat | 2010 |
What should work, may not.
Topics: Boronic Acids; Bortezomib; Drug Approval; Drug Labeling; Drug Prescriptions; Humans; Immunosuppressive Agents; Off-Label Use; Organ Transplantation; Pyrazines; Research Design; United States; United States Food and Drug Administration | 2010 |
The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Dermatitis, Allergic Contact; Interferon-gamma; Mice; Mice, Inbred C57BL; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; T-Lymphocytes | 2010 |
MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Piperazines; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2010 |
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Female; Hematologic Diseases; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Nervous System Diseases; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Time Factors; Transplantation, Autologous | 2010 |
Treatment of newly diagnosed multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2008 |
Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance.
Topics: Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Protease Inhibitors; Pyrazines; von Willebrand Diseases | 2010 |
Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts.
Topics: Boronic Acids; Bortezomib; Cell Line; Collagen; Collagen Type I; Fibroblasts; Gene Expression; Immunoglobulins; Matrix Metalloproteinase 1; Protease Inhibitors; Proto-Oncogene Proteins c-jun; Pyrazines; RNA, Messenger; Skin; Transcription, Genetic | 2010 |
Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Topics: Age Factors; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Cohort Studies; Female; Humans; Incidence; L-Lactate Dehydrogenase; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neurologic Examination; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Recurrence; Risk Factors; Severity of Illness Index; Vincristine | 2010 |
Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Caspase 8; Cell Line, Tumor; Death Domain Receptor Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Kidney Neoplasms; Pyrazines; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2010 |
Bortezomib-induced acute pancreatitis.
Topics: Acute Disease; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Multiple Myeloma; Pancreatitis; Pyrazines | 2010 |
Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Coronary Vessels; Dexamethasone; Female; Humans; Multiple Myeloma; Myocardial Infarction; Pyrazines | 2010 |
Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Colonic Neoplasms; DNA Damage; Gene Knockdown Techniques; HCT116 Cells; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Melanoma; Protease Inhibitors; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-myc; Pyrazines; Ribosomes; RNA, Small Interfering; TOR Serine-Threonine Kinases; Transfection | 2010 |
Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.
Topics: Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 8; Cell Death; Cell Line, Tumor; Down-Regulation; Drug Interactions; Drug Synergism; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Melanoma; Mitochondrial Proteins; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein | 2010 |
Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat.
Topics: Animals; Boronic Acids; Bortezomib; Chronic Disease; Graft Rejection; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Lymphocyte Depletion; Male; Plasma Cells; Pyrazines; Rats; Rats, Inbred F344; Rats, Inbred Lew; Sirolimus; Spleen; T-Lymphocytes; Transplantation, Homologous | 2010 |
[Severe bortezomib-induced peripheral neuropathy in a patient with multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunoglobulin A; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Severity of Illness Index | 2010 |
Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blast Crisis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 8; Cell Cycle; Cell Proliferation; Drug Synergism; Gene Expression Profiling; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; NF-kappa B; Oligonucleotide Array Sequence Analysis; Oxides; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand | 2010 |
Clinical management of myeloma--state of the art.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line; GTP-Binding Protein alpha Subunits, G12-G13; Humans; In Situ Nick-End Labeling; Liver Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA, Messenger | 2010 |
Characterization of bortezomib-adapted I-45 mesothelioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression; Humans; Mesothelioma; Oligopeptides; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Transcription Factor CHOP; Transfection; Unfolded Protein Response | 2010 |
The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle.
Topics: Animals; Boronic Acids; Bortezomib; Cats; Cell Line; Chlorocebus aethiops; Coronavirus Infections; Coronavirus, Feline; Leupeptins; Mice; Murine hepatitis virus; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Severe acute respiratory syndrome-related coronavirus; Ubiquitin; Virus Internalization; Virus Release; Virus Replication | 2010 |
The proteasome inhibitor Velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice.
Topics: Animals; Antiviral Agents; Boronic Acids; Bortezomib; Coronavirus Infections; Hepatitis, Viral, Animal; Mice; Mice, Inbred C57BL; Murine hepatitis virus; Protease Inhibitors; Pyrazines; Survival Analysis | 2010 |
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Treatment Outcome; Zoledronic Acid | 2010 |
Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.
Topics: Aminopterin; Animals; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Caspase 9; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Humans; Lymphoma, T-Cell; Mice; Mice, SCID; Neoplasm Transplantation; Pyrazines; Xenograft Model Antitumor Assays | 2010 |
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Pyrazines; Receptors, Glucocorticoid; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Hydroxyquinolines; Immunoblotting; Inhibitory Concentration 50; Male; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Transplantation, Heterologous | 2010 |
Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide | 2010 |
Treatment with bortezomib of a patient having hyper IgG4 disease.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Eyelid Diseases; Female; Humans; Immune System Diseases; Immunoglobulin G; Middle Aged; Plasma Cell Granuloma, Pulmonary; Prednisone; Pyrazines; Tomography, X-Ray Computed | 2010 |
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytogenetic Analysis; Female; Humans; Immunomodulation; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy; Thalidomide | 2010 |
Regulation of autophagy by ATF4 in response to severe hypoxia.
Topics: Activating Transcription Factor 4; Antineoplastic Agents; Autophagy; Base Sequence; Boronic Acids; Bortezomib; Cell Hypoxia; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HCT116 Cells; HeLa Cells; Humans; Neoplasms; Oligonucleotide Array Sequence Analysis; Oxygen; Pyrazines; RNA, Small Interfering; Tumor Cells, Cultured; Unfolded Protein Response; Validation Studies as Topic | 2010 |
The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Caspase 3; Cell Adhesion; Cell Death; Cell Line, Tumor; DNA; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; NF-kappa B; Protein Binding; Pyrazines; Sesquiterpenes; Transcription Factor RelA | 2010 |
Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Cell Line, Tumor; Death Domain Receptor Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Esophageal Neoplasms; Humans; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2010 |
Cardiotoxicity of the anticancer therapeutic agent bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Cell Respiration; Echocardiography; Female; Heart; Heart Diseases; Humans; Male; Mice; Mice, Inbred C57BL; Mitochondria, Heart; Myocytes, Cardiac; Protease Inhibitors; Pyrazines; Rats; Rats, Wistar; Ventricular Dysfunction, Left | 2010 |
Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-induced apoptosis for melanoma therapy.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Female; Fenretinide; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; In Vitro Techniques; Male; Melanoma; Middle Aged; Mutation; Nevus, Pigmented; Proto-Oncogene Proteins B-raf; Pyrazines; RNA, Small Interfering; Skin Neoplasms; Stress, Physiological; X-Linked Inhibitor of Apoptosis Protein | 2010 |
Removal of physiologic corticosteroid doses results in HLA antibody appearance and allograft dysfunction in patients transplanted under a clonal deletion protocol.
Topics: Adrenal Cortex Hormones; Adult; Biopsy; Boronic Acids; Bortezomib; Clonal Deletion; Creatinine; Follow-Up Studies; Graft Rejection; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; India; Kidney Transplantation; Living Donors; Prednisone; Protease Inhibitors; Pyrazines; Young Adult | 2009 |
A summary of bortezomib use in transplantation across 29 centers.
Topics: Adult; Aged; Antilymphocyte Serum; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Graft Rejection; Heart Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Kidney Transplantation; Lung Transplantation; Male; Middle Aged; Plasmapheresis; Protease Inhibitors; Pyrazines; Safety | 2009 |
Bortezomib in kidney transplant desensitization: a case report.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; B-Lymphocytes; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Histocompatibility Testing; HLA-A Antigens; Humans; Immunologic Factors; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Mycophenolic Acid; Pyrazines; Rituximab; Waiting Lists | 2009 |
Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Boronic Acids; Bortezomib; Creatinine; Female; Graft Rejection; HLA Antigens; HLA-DQ Antigens; Humans; Immunity, Cellular; Immunity, Humoral; Immunologic Factors; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Peritoneal Dialysis; Plasmapheresis; Polycystic Kidney Diseases; Protease Inhibitors; Pyrazines; Renal Dialysis; Reoperation; Rituximab; Treatment Failure | 2009 |
Use of bortezomib as adjunctive therapy for densensitization in combined heart and kidney transplantation--a case report.
Topics: Autoantibodies; Boronic Acids; Bortezomib; Desensitization, Immunologic; Flow Cytometry; Heart Transplantation; Humans; Immunoglobulins, Intravenous; Kidney Transplantation; Male; Middle Aged; Plasmapheresis; Protease Inhibitors; Pyrazines | 2009 |
Successful desensitization in a crossmatch positive living-related kidney transplant recipient using a bortezomib-based protocol.
Topics: Adult; Boronic Acids; Bortezomib; Creatinine; Desensitization, Immunologic; Graft Survival; Humans; Isoantibodies; Kidney Neoplasms; Living Donors; Lymphocytes; Male; Protease Inhibitors; Pyrazines; Treatment Outcome | 2009 |
Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases.
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Female; Graft Rejection; Histocompatibility Testing; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Plasma Exchange; Protease Inhibitors; Pyrazines; Rituximab; Treatment Outcome | 2009 |
Bortezomib for antibody mediated rejection treatment: experience at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City.
Topics: Adult; Autoantibodies; Biopsy; Boronic Acids; Bortezomib; Cadaver; Creatinine; Female; Graft Rejection; HLA Antigens; Humans; Living Donors; Male; Mexico; Protease Inhibitors; Pyrazines; T-Lymphocytes; Tissue Donors; Treatment Outcome | 2009 |
The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib.
Topics: Adult; Autoantibodies; Boronic Acids; Bortezomib; Cadaver; Creatinine; Female; Histocompatibility Antigens Class I; HLA Antigens; HLA-D Antigens; HLA-DQ Antigens; Humans; Kidney Failure, Chronic; Kidney Transplantation; Living Donors; Male; Middle Aged; Protease Inhibitors; Pyrazines; Tissue Donors | 2009 |
Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Boronic Acids; Bortezomib; Graft Rejection; HLA Antigens; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Plasmapheresis; Protease Inhibitors; Pyrazines; Rituximab | 2009 |
Bortezomib affects the function of human B cells: possible implications for desensitization protocols.
Topics: Antigens, CD19; Apoptosis; Autoantibodies; B-Lymphocytes; Blood Banks; Boronic Acids; Bortezomib; Desensitization, Immunologic; HLA Antigens; Humans; Immunoglobulin G; Immunoglobulin M; Leukocytes, Mononuclear; Lymphocyte Activation; Protease Inhibitors; Pyrazines | 2009 |
Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Cardiomyopathies; Desensitization, Immunologic; Female; Heart Transplantation; Humans; Immunoglobulins, Intravenous; Isoantibodies; Lung Transplantation; Male; Middle Aged; Plasmapheresis; Protease Inhibitors; Pyrazines; Transfusion Reaction; Waiting Lists | 2009 |
Bortezomib in kidney transplant recipients with antibody mediated rejection: three case reports.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; B-Lymphocytes; Boronic Acids; Bortezomib; Female; Graft Rejection; Histocompatibility Testing; HLA Antigens; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Kidney Transplantation; Male; Protease Inhibitors; Pyrazines; Renal Dialysis; Rituximab; T-Lymphocytes; Treatment Failure; Treatment Outcome | 2009 |
Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
Topics: Adrenal Cortex Hormones; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Boronic Acids; Bortezomib; Creatinine; Female; Graft Rejection; HLA Antigens; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Protease Inhibitors; Pyrazines; Rituximab; Treatment Outcome | 2009 |
Proteasome inhibition for recipient desensitization? A report of two sensitized kidney transplant candidates subjected to bortezomib treatment.
Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Flow Cytometry; Graft Rejection; Humans; Immunization; Immunophenotyping; Kidney Transplantation; Male; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Renal Dialysis | 2009 |
Bortezomib in lung transplantation: a promising start.
Topics: Adult; Boronic Acids; Bortezomib; Female; Graft Rejection; Humans; Lung Transplantation; Male; Middle Aged; Protease Inhibitors; Pyrazines | 2009 |
Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?
Topics: B-Lymphocytes; Boronic Acids; Bortezomib; Creatinine; Follow-Up Studies; Graft Rejection; Hepatitis C; Humans; Immunity, Cellular; Immunity, Humoral; Immunoglobulins, Intravenous; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Protease Inhibitors; Pyrazines; T-Lymphocytes | 2009 |
Bortezomib rescue in refractory acute humoral rejection--report of a case.
Topics: Acute Disease; Boronic Acids; Bortezomib; Creatinine; Female; Graft Rejection; Histocompatibility Antigens Class I; HLA-D Antigens; Humans; Immunity, Humoral; Immunoglobulins, Intravenous; Immunologic Factors; Isoantibodies; Kidney Failure, Chronic; Kidney Transplantation; Middle Aged; Plasmapheresis; Protease Inhibitors; Pyrazines | 2009 |
Bortezomib alone fails to decrease donor specific anti-HLA antibodies: 4 case reports.
Topics: Adult; Boronic Acids; Bortezomib; Female; HLA Antigens; HLA-DQ Antigens; Humans; Isoantibodies; Male; Middle Aged; Protease Inhibitors; Pyrazines; Treatment Failure; Treatment Outcome | 2009 |
Bortezomib successfully reduces monoclonal serum free light chain levels in a patient with recurrent myeloma and cast nephropathy in the renal transplant.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin kappa-Chains; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Living Donors; Multiple Myeloma; Mycophenolic Acid; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Tacrolimus | 2009 |
Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.
Topics: Adult; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Creatinine; Female; Graft Rejection; Humans; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Pancreas Transplantation; Protease Inhibitors; Pyrazines; Transplantation, Homologous; Treatment Outcome | 2009 |
Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases.
Topics: Biopsy; Boronic Acids; Bortezomib; Creatinine; Female; Graft Rejection; HLA Antigens; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Pancreas Transplantation; Pyrazines; Transplantation, Homologous; Young Adult | 2009 |
Rescue therapy for early antibody mediated rejection with a proteasome inhibitor: a case report.
Topics: Adult; Antilymphocyte Serum; Boronic Acids; Bortezomib; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diuresis; Graft Rejection; Histocompatibility Testing; HLA Antigens; Humans; Isoantibodies; Kidney Failure, Chronic; Kidney Transplantation; Male; Pancreas Transplantation; Plasmapheresis; Protease Inhibitors; Pyrazines; Renal Dialysis; Reoperation; Tissue Donors; Treatment Outcome | 2009 |
Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation.
Topics: Adrenal Cortex Hormones; Antilymphocyte Serum; Biopsy; Boronic Acids; Bortezomib; Child, Preschool; Female; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Intestines; Protease Inhibitors; Pyrazines; Short Bowel Syndrome; Tacrolimus; Treatment Outcome; Viscera | 2009 |
Acute rejection in a highly sensitized lung transplant recipient with pre-formed donor-directed anti-HLA class II antibodies: role of bortezomib therapy.
Topics: Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Histocompatibility Antigens Class I; HLA-A Antigens; HLA-B Antigens; HLA-D Antigens; HLA-DR Antigens; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Isoantibodies; Lung Diseases, Interstitial; Lung Transplantation; Middle Aged; Protease Inhibitors; Pyrazines | 2009 |
Bortezomib for refractory antibody-mediated cardiac allograft rejection.
Topics: Aged; Biopsy; Boronic Acids; Bortezomib; Cardiomyopathies; Female; Flow Cytometry; Graft Rejection; Heart Transplantation; Humans; Isoantibodies; Protease Inhibitors; Pyrazines; Transplantation, Homologous; Treatment Outcome | 2009 |
Bortezomib for acute humoral rejection in two repeat transplant recipients.
Topics: Acute Disease; Adult; B-Lymphocytes; Boronic Acids; Bortezomib; Creatinine; Female; Flow Cytometry; Graft Rejection; HLA-DQ Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Pyrazines; Reoperation; T-Lymphocytes | 2009 |
Bortezomib as a rescue therapy for hyperacute and multi-drug resistant mixed acute rejection after kidney transplantation.
Topics: Acute Disease; Adult; Boronic Acids; Bortezomib; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diuresis; Drug Resistance, Multiple; Graft Rejection; Humans; Immunization; Kidney Transplantation; Male; Pancreas Transplantation; Protease Inhibitors; Pyrazines | 2009 |
Bortezomib does not reduce ABO-isoagglutinin titers and may not be useful for ABO-incompatible transplant desensitization.
Topics: ABO Blood-Group System; Antiviral Agents; Blood Group Incompatibility; Boronic Acids; Bortezomib; Cytomegalovirus Infections; Doxorubicin; Ganciclovir; Hemagglutinins; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Valganciclovir | 2009 |
Modulation of antibody response in a sensitized patient with ongoing antibody-mediated injury.
Topics: ABO Blood-Group System; Adult; Boronic Acids; Bortezomib; Female; Histocompatibility Testing; HLA Antigens; HLA-DQ Antigens; HLA-DR Antigens; HLA-DRB4 Chains; Humans; Immunosuppressive Agents; Isoantibodies; Kidney Diseases; Kidney Transplantation; Lupus Erythematosus, Systemic; Male; Protease Inhibitors; Pyrazines; Reoperation; Siblings; Tissue Donors; Treatment Failure | 2009 |
Use of bortezomib for prevention and treatment of rejection in sensitized patients.
Topics: Adult; Boronic Acids; Bortezomib; Graft Rejection; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Plasmapheresis; Protease Inhibitors; Pyrazines; Young Adult | 2009 |
Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series.
Topics: Boronic Acids; Bortezomib; Creatinine; Female; Graft Rejection; Histocompatibility Antigens Class I; HLA-D Antigens; Humans; Immunity, Humoral; Kidney Transplantation; Living Donors; Male; Protease Inhibitors; Pyrazines; Renal Dialysis; Reoperation; Treatment Outcome | 2009 |
PRDM1 is required for mantle cell lymphoma response to bortezomib.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Intracellular Signaling Peptides and Proteins; Lymphoma, Mantle-Cell; Nuclear Proteins; Positive Regulatory Domain I-Binding Factor 1; Proliferating Cell Nuclear Antigen; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Repressor Proteins | 2010 |
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Sub-Family B Member 4; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Doxorubicin; Humans; Kaplan-Meier Estimate; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrazines; Recurrence; Retrospective Studies; Time Factors | 2010 |
Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; beta 2-Microglobulin; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 1; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Survival Analysis | 2011 |
The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
Topics: Adult; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Degranulation; Cell Line, Tumor; Cytotoxicity, Immunologic; DNA Primers; Down-Regulation; Humans; In Vitro Techniques; Interleukin-2; K562 Cells; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand | 2010 |
Targeting GRP78 to enhance melanoma cell death.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Fenretinide; Heat-Shock Proteins; Humans; Melanoma; Pyrazines; RNA, Small Interfering; Unfolded Protein Response | 2010 |
Frontline regimens for multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Design; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2010 |
Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; DNA Primers; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Humans; Multiple Myeloma; Mutation; Neoplasm Proteins; Point Mutation; Proteasome Endopeptidase Complex; Protein Denaturation; Pyrazines; Ubiquitin | 2010 |
Experiences with bortezomib in multiple myeloma - from Phase II studies to daily practice.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Humans; Multiple Myeloma; Pyrazines | 2010 |
IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; IgA Deficiency; Middle Aged; Multiple Myeloma; Paraproteinemias; Pemphigus; Pyrazines; Remission Induction | 2010 |
Reversible posterior encephalopathy syndrome associated with bortezomib.
Topics: Boronic Acids; Bortezomib; Female; Humans; Hypertensive Encephalopathy; Middle Aged; Posterior Leukoencephalopathy Syndrome; Pyrazines | 2010 |
[Effect of bortezomib on sensitization of HL-60 cells to TRAIL].
Topics: Apoptosis; Boronic Acids; Bortezomib; Caspase 8; HL-60 Cells; Humans; Pyrazines; TNF-Related Apoptosis-Inducing Ligand | 2010 |
[Effect of bortezomib on VEGF gene expression of endothelial cell line HMEC-1 and its possible mechanisms].
Topics: Annexin A2; Antigens, Neoplasm; Boronic Acids; Bortezomib; Carbonic Anhydrase IX; Carbonic Anhydrases; Cell Line; Down-Regulation; Endothelial Cells; Gene Expression; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Pyrazines; Vascular Endothelial Growth Factor A | 2010 |
Bortezomib: friend or foe of hemolytic anemia?
Topics: Anemia, Hemolytic; Animals; Autoimmune Diseases; Boronic Acids; Bortezomib; Evidence-Based Medicine; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Risk Assessment; Risk Factors | 2011 |
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Time Factors | 2010 |
Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Middle Aged; Perivascular Epithelioid Cell Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Retroperitoneal Neoplasms; Sirolimus; Topotecan; TOR Serine-Threonine Kinases; Treatment Failure | 2010 |
Mantle cell lymphoma activation enhances bortezomib sensitivity.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Clone Cells; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Isoenzymes; Lymphocyte Activation; Lymphoma, Mantle-Cell; Mice; Oligodeoxyribonucleotides; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Retinal Dehydrogenase; Toll-Like Receptor 9; Unfolded Protein Response | 2010 |
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Mice; Mice, Nude; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA Interference; Xenograft Model Antitumor Assays | 2010 |
Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Interactions; Female; Humans; Itraconazole; Japan; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Secondary Prevention; Thrombocytopenia; Treatment Outcome | 2010 |
Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cyclin D1; Cyclin D2; Cyclin D3; DNA; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pilot Projects; Polymerase Chain Reaction; Pyrazines; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Individualizing cancer therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclin D1; Humans; Multiple Myeloma; Precision Medicine; Pyrazines; Treatment Outcome | 2010 |
Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Boronic Acids; Bortezomib; Colitis; Dextran Sulfate; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Immunity, Mucosal; Inflammation Mediators; Interleukin-17; Mice; Mice, Inbred C57BL; Multienzyme Complexes; Neutrophil Infiltration; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; T-Lymphocyte Subsets; Th1 Cells | 2010 |
[Mechanism of bortezomib in inducing apoptosis and improving chemosensitivity of Ishikawa cells].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; Cell Line, Tumor; Drug Synergism; Endometrial Neoplasms; Female; Humans; Inhibitory Concentration 50; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species | 2010 |
Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results.
Topics: Aged; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Pyrazines; Reproducibility of Results; Sensitivity and Specificity; Spin Labels; Thalidomide; Treatment Outcome | 2010 |
The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state.
Topics: Antiviral Agents; Boronic Acids; Bortezomib; Cell Line; Epithelial Cells; GTP-Binding Proteins; Humans; Influenza A virus; Interferon Type I; Interleukin-6; Myxovirus Resistance Proteins; Pyrazines; Vesiculovirus | 2010 |
Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts.
Topics: Animals; Boronic Acids; Bortezomib; Calcineurin; Cells, Cultured; Desmin; Heart Failure; Mice; Mice, Transgenic; Models, Animal; Myocytes, Cardiac; NFATC Transcription Factors; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Stress, Physiological | 2010 |
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.
Topics: Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Humans; Interleukin-8; Multiple Myeloma; NF-kappa B; Pyrazines; Stromal Cells | 2010 |
Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Cyanoacrylates; Cyclin D1; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Leukemic; Humans; Lymphoma, Mantle-Cell; Mice; Mice, SCID; NF-kappa B; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-myc; Pyrazines; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; STAT3 Transcription Factor; Survival Analysis; Xenograft Model Antitumor Assays | 2010 |
Clinical value of absolute lymphocyte counts before bortezomib-dexamethasone therapy in relapsed multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Prognosis; Pyrazines; Recurrence; Remission Induction; Salvage Therapy | 2010 |
Amyloid myopathy: a therapeutic trial for the rare and underdiagnosed myopathy with bortezomib.
Topics: Aged; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Muscular Diseases; Plaque, Amyloid; Protease Inhibitors; Pyrazines | 2010 |
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma.
Topics: Aged, 80 and over; Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Chlorocebus aethiops; DNA Replication; Down-Regulation; E2F3 Transcription Factor; Fatal Outcome; Gene Expression Regulation, Neoplastic; Herpesvirus 8, Human; Humans; Lymphoma, Primary Effusion; Male; Mice; NF-kappa B; Proto-Oncogene Proteins c-myc; Pyrazines; Survival Analysis; Treatment Outcome; Unfolded Protein Response; Vero Cells; Virion; Xenograft Model Antitumor Assays | 2010 |
MicroCT-based virtual histology evaluation of preclinical medulloblastoma.
Topics: Animals; Boronic Acids; Bortezomib; Cerebellum; Magnetic Resonance Imaging; Medulloblastoma; Mice; Organ Size; Pyrazines; Tumor Burden; User-Computer Interface; X-Ray Microtomography | 2011 |
Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Communication; Cell Movement; Endothelial Cells; Enzyme Inhibitors; Humans; Jurkat Cells; Leukemia, T-Cell; Lymphoma, T-Cell; Mice; Mice, Nude; Molecular Targeted Therapy; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Characterization of side populations in HNSCC: highly invasive, chemoresistant and abnormal Wnt signaling.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; beta Catenin; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Etoposide; Flow Cytometry; Head and Neck Neoplasms; Humans; Neoplasm Proteins; Pyrazines; Signal Transduction; Stem Cells; Wnt Proteins | 2010 |
Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
Topics: Amino Acid Sequence; Binding Sites; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; HCT116 Cells; HT29 Cells; Humans; Kinetics; Luciferases; Models, Molecular; Molecular Sequence Data; Molecular Structure; NF-kappa B; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Binding; Protein Structure, Tertiary; Protein Subunits; Pyrazines; RNA Interference; Sequence Homology, Amino Acid; Ubiquitin | 2010 |
Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access.
Topics: Adult; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Boronic Acids; Bortezomib; Catheters, Indwelling; Creatinine; Desensitization, Immunologic; Drainage; Drug Therapy, Combination; Female; Femoral Vein; Humans; Iliac Vein; Immunoglobulins, Intravenous; Kidney Failure, Chronic; Kidney Transplantation; Living Donors; Plasmapheresis; Protease Inhibitors; Pyrazines; Splanchnic Circulation; Therapies, Investigational; Tissue and Organ Procurement; Vena Cava, Inferior; Vena Cava, Superior; Venous Thrombosis | 2010 |
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 4; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; France; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Neoadjuvant Therapy; Prospective Studies; Protease Inhibitors; Pyrazines; Time Factors; Translocation, Genetic; Treatment Outcome; Vincristine | 2010 |
Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients.
Topics: Adolescent; Adult; Aged; Boronic Acids; Bortezomib; Child; Clonal Deletion; Female; Follow-Up Studies; Humans; Immune Tolerance; Informed Consent; Kidney Transplantation; Male; Middle Aged; Patient Selection; Protease Inhibitors; Pyrazines; Transplantation, Homologous | 2010 |
Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Endoplasmic Reticulum; Fluorescent Antibody Technique; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Indoles; Lymphoma, Mantle-Cell; Mice; Microscopy, Confocal; Panobinostat; Protein Folding; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Stress, Physiological; Survival Rate; Transcription Factor CHOP; Xenograft Model Antitumor Assays | 2010 |
The treatment of traumatic brain injury with velcade.
Topics: Animals; Boronic Acids; Bortezomib; Brain Injuries; Disease Models, Animal; Male; Pyrazines; Rats; Rats, Wistar; Spatial Behavior; Treatment Outcome | 2010 |
Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Lymphoma; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptor, Fibroblast Growth Factor, Type 3; STAT1 Transcription Factor; STAT3 Transcription Factor; U937 Cells | 2010 |
Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia.
Topics: Adolescent; Antineoplastic Agents; Boronic Acids; Bortezomib; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines | 2010 |
Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calcium Channel Blockers; Cell Death; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; Endoplasmic Reticulum; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stress, Physiological; Treatment Outcome; Tumor Cells, Cultured; Unfolded Protein Response; Verapamil | 2010 |
Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Leukemia, Plasma Cell; Melphalan; Prednisolone; Pyrazines; Remission Induction | 2010 |
NF-κB localization in multiple myeloma plasma cells and mesenchymal cells.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Flow Cytometry; Humans; Immunohistochemistry; Mesoderm; Multiple Myeloma; NF-kappa B; Plasma Cells; Pyrazines | 2011 |
Rectal bleeding and diarrhea caused by bortezomib-induced colitis.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Colitis; Diarrhea; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Rectum | 2010 |
Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Combined Modality Therapy; Endoplasmic Reticulum; Female; Immunity, Cellular; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Oncolytic Virotherapy; Proteasome Inhibitors; Pyrazines; Stress, Physiological; Tumor Cells, Cultured; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2010 |
Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2011 |
No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Boronic Acids; Bortezomib; Cyclophosphamide; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; DNA, Neoplasm; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Phenotype; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Pyrazines; Retrospective Studies; Survival Rate; Thalidomide | 2010 |
Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Retrospective Studies | 2010 |
Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carrier Proteins; Cell Line; Cell Proliferation; Cells, Cultured; Drug Synergism; Gene Knockdown Techniques; Humans; Mice; Mice, SCID; Multiple Myeloma; Multiprotein Complexes; Protein Kinase Inhibitors; Pyrazines; Rapamycin-Insensitive Companion of mTOR Protein; TOR Serine-Threonine Kinases | 2010 |
Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application.
Topics: Animals; Blood Coagulation; Boronic Acids; Bortezomib; Cell Nucleus; Combined Modality Therapy; Dependovirus; Disease Models, Animal; Dogs; Factor IX; Factor VIII; Female; Genetic Therapy; Genetic Vectors; Genome, Viral; Hemophilia B; Humans; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Protease Inhibitors; Pyrazines; Transgenes | 2010 |
Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor, ErbB-2 | 2010 |
Pro-inflammatory genes as biomarkers and therapeutic targets in oral squamous cell carcinoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Biomarkers; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cells, Cultured; Dose-Response Relationship, Drug; Gene Expression Profiling; Humans; Inflammation; Interleukin-8; Microarray Analysis; Mouth Neoplasms; NF-kappa B; Pyrazines; RNA, Small Interfering | 2010 |
Potentiation of bortezomib-induced apoptosis by TGF-beta in cultured human Tenon's fibroblasts: contribution of the PI3K/Akt signaling pathway.
Topics: Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Synergism; Fibroblasts; Flow Cytometry; Gene Expression Regulation; Genes, bcl-2; Humans; Phosphatidylinositol 3-Kinases; Phosphorylation; Protease Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tenon Capsule; Tetrazolium Salts; Thiazoles; Time Factors; Transforming Growth Factor beta; Tumor Suppressor Protein p53 | 2010 |
The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Female; Forkhead Transcription Factors; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Lymphoma, Follicular; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.
Topics: Algorithms; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Gene Expression Profiling; Humans; Hydroxamic Acids; Lung Neoplasms; Multigene Family; Pyrazines; Vorinostat | 2010 |
γ-Tocotrienol but not γ-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Chromans; Enzyme Induction; G1 Phase; gamma-Tocopherol; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Inhibitor of Apoptosis Proteins; Janus Kinase 1; Janus Kinase 2; Mice; Neoplasm Proteins; Neoplasms; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrazines; RNA, Small Interfering; src-Family Kinases; STAT3 Transcription Factor; Thalidomide; Vitamin E | 2010 |
An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cohort Studies; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Karyotyping; Male; Metaphase; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Retrospective Studies; Salvage Therapy; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome | 2010 |
The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats.
Topics: Analysis of Variance; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Bone Diseases; Boronic Acids; Bortezomib; Cell Proliferation; Cytokines; Flow Cytometry; Immunohistochemistry; Inflammation; Joints; Pyrazines; Rats; Rats, Inbred Lew; Reverse Transcriptase Polymerase Chain Reaction; Spleen; Synovial Membrane; Toll-Like Receptors; Treatment Outcome | 2010 |
[Effect of bortezomib on lymphoma cell line CA46 and its relative mechanisms].
Topics: Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Lymphoma; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2010 |
[Adverse effects of PAD and VAD regimens in multiple myeloma patients].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Vincristine | 2010 |
CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
Topics: Animals; Apoptosis; Autoantigens; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Mice, Nude; Phosphoproteins; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; Transcription, Genetic; Up-Regulation; Xenograft Model Antitumor Assays | 2010 |
Optimising bortezomib in newly diagnosed multiple myeloma.
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thalidomide; Time Factors; Treatment Outcome | 2010 |
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
[Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy].
Topics: Acidosis; Aged; Antifungal Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Echinocandins; Fatal Outcome; Humans; Lipopeptides; Male; Micafungin; Multiple Myeloma; Pyrazines; Pyrimidines; Triazoles; Tumor Lysis Syndrome; Voriconazole; Zygomycosis | 2010 |
A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome | 2011 |
Inhibition of NF-κB signaling retards eosinophilic dermatitis in SHARPIN-deficient mice.
Topics: Animals; Boronic Acids; Bortezomib; Dermatitis; Eosinophilia; Eosinophils; Gene Expression Profiling; Immunohistochemistry; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Nerve Tissue Proteins; NF-kappa B p50 Subunit; Phenotype; Phosphorylation; Protease Inhibitors; Pyrazines; Signal Transduction; Transcription Factor RelA | 2011 |
Proteomics of apoptosis of multiple myeloma cells induced by proteasome inhibitor PS-341.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Electrophoresis, Gel, Two-Dimensional; Humans; Multiple Myeloma; Neoplasm Proteins; Protease Inhibitors; Proteasome Inhibitors; Proteome; Proteomics; Pyrazines | 2010 |
[Effect of Velcade combined with Dexamethasone on multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2010 |
Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Pyrazines; Remission Induction; Retrospective Studies; Treatment Outcome | 2011 |
Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Boronic Acids; Bortezomib; Cytarabine; Deoxycytidine; Dexamethasone; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; HIV Infections; Humans; Lenalidomide; Lymphoma, Large-Cell, Immunoblastic; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Pyrazines; Recombinant Proteins; Thalidomide; Young Adult | 2010 |
Lenalidomide for bortezomib-resistant multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Health Status Indicators; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Failure | 2010 |
Lenalidomide efficacy in bortezomib-resistant myeloma.
Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Gene Deletion; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Risk Factors; Thalidomide; Treatment Failure | 2010 |
Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy.
Topics: Adaptation, Physiological; Animals; Axons; Boronic Acids; Bortezomib; Disease Models, Animal; Endoplasmic Reticulum; Female; Macrophages; Mice; Mice, Inbred C57BL; Myelin Proteins; Myelin Sheath; Oligonucleotide Array Sequence Analysis; Peripheral Nerves; Peripheral Nervous System Diseases; Protease Inhibitors; Protein Unfolding; Pyrazines; Schwann Cells; Stress, Physiological | 2010 |
Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Body Weight; Boronic Acids; Bortezomib; Cisplatin; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Ganglia, Spinal; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nerve Fibers, Myelinated; Neural Conduction; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Sciatic Nerve | 2010 |
Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Thromboembolism | 2011 |
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Neoplasm Metastasis; Osteolysis; Positron-Emission Tomography; Protease Inhibitors; Pyrazines; Radiopharmaceuticals; Xenograft Model Antitumor Assays | 2010 |
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.
Topics: Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Quinolones; Ubiquitination | 2010 |
MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Lymphoma, Mantle-Cell; Mitochondria; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Piperazines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53 | 2010 |
Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells.
Topics: Acetylcysteine; Animals; Biological Assay; Boronic Acids; Bortezomib; Cell Extracts; Cells, Cultured; Chymotrypsin; High-Throughput Screening Assays; Inhibitory Concentration 50; Leupeptins; Mice; Models, Biological; Oligopeptides; Ornithine Decarboxylase; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Recombinant Fusion Proteins; Time Factors | 2011 |
Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome.
Topics: Animals; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Coronavirus Infections; Cytokines; DNA Primers; Gene Expression Regulation; Histological Techniques; Leupeptins; Lung; Mice; Murine hepatitis virus; Phosphorylation; Pneumonia; Proline; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; STAT Transcription Factors; Survival Analysis; Thiocarbamates; Ubiquitination; Virus Replication | 2010 |
Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Child; Child, Preschool; Dexamethasone; Female; Gene Expression Regulation, Neoplastic; Hemangioma, Capillary; Humans; Infant; Infant, Newborn; Male; Molecular Targeted Therapy; Neoplastic Stem Cells; Neoplastic Syndromes, Hereditary; NF-kappa B; Pyrazines; Skin Neoplasms; Vascular Endothelial Growth Factor A | 2010 |
Bortezomib-associated late hepatitis B reactivation in a case of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hepatitis B; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2010 |
Continual reassessment method with multiple toxicity constraints.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Clinical Trials, Phase I as Topic; Computer Simulation; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epidemiologic Research Design; Humans; Lymphoma, Non-Hodgkin; Maximum Tolerated Dose; Models, Statistical; Neoplasms; Neurotoxicity Syndromes; Prednisolone; Probability; Pyrazines; Statistical Distributions; Thrombocytopenia; Vincristine | 2011 |
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cytokines; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Hodgkin Disease; Humans; NF-kappa B; Protease Inhibitors; Pyrazines; Pyrimidines; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Up-Regulation | 2010 |
Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway.
Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Inositol Polyphosphate 5-Phosphatases; Interleukin-6; Janus Kinase 2; Multiple Myeloma; Phosphoric Monoester Hydrolases; Phosphorylation; Pyrazines; Signal Transduction; STAT3 Transcription Factor; Thalidomide; Vanadates | 2010 |
Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome | 2010 |
Too much of a good thing is bad: proteasome inhibition induces stressed hearts to fail.
Topics: Adaptation, Physiological; Animals; Boronic Acids; Bortezomib; Calcineurin; Dose-Response Relationship, Drug; Heart Failure; Hypertrophy, Left Ventricular; Mice; Models, Animal; Myocytes, Cardiac; NFATC Transcription Factors; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Stress, Physiological; Ubiquitin | 2010 |
Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Nucleus; Cell Proliferation; Gene Expression Regulation; Gene Silencing; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Membrane Potentials; Multiple Myeloma; Phosphorylation; Pyrazines; RNA Interference; Signal Transduction | 2010 |
The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib.
Topics: Animals; Antibody Formation; B-Lymphocyte Subsets; B-Lymphocytes; Boronic Acids; Bortezomib; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Immunoblotting; Mice; Mice, Inbred BALB C; Plasma Cells; Protease Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Spleen | 2010 |
Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Secondary Prevention; Young Adult | 2010 |
Stability of unused reconstituted bortezomib in original manufacturer vials.
Topics: Boronic Acids; Bortezomib; Chromatography, Liquid; Drug Packaging; Drug Stability; Drug Storage; Mass Spectrometry; Pyrazines; Tandem Mass Spectrometry; Time Factors | 2011 |
Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Humans; Multiple Myeloma; Phosphoproteins; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteomics; Pyrazines | 2010 |
Complete remission following treatment with bortezomib, doxorubicin, dexamethasone and autologous stem cell transplant in patient with immunoglobulin E multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin E; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Transplantation, Autologous | 2010 |
Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Brain Diseases; Cyclophosphamide; Dexamethasone; Humans; Hyperammonemia; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Time Factors; Treatment Outcome | 2010 |
Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Immunoprecipitation; Lymphoma, B-Cell; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Cells, Cultured; Ubiquitination | 2010 |
Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carrier Proteins; CDC2-CDC28 Kinases; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 1; MAP Kinase Kinase 1; Multiple Myeloma; Pyrazines; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; Tumor Cells, Cultured | 2010 |
Amino acid starvation sensitizes cancer cells to proteasome inhibition.
Topics: Amino Acids; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cells, Cultured; Humans; Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Retinoblastoma Protein; Tumor Suppressor Protein p53 | 2010 |
An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Piperazines; Pyrazines; Pyrimidines; Signal Transduction; Sirolimus; Thiazoles; TOR Serine-Threonine Kinases; Up-Regulation | 2011 |
Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Plasmacytoma; Pyrazines; Tomography, X-Ray Computed | 2010 |
Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma.
Topics: Alkaline Phosphatase; Antineoplastic Agents; Bone and Bones; Boronic Acids; Bortezomib; Diagnostic Imaging; Humans; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Osteoblasts; Protective Agents; Pyrazines | 2011 |
Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study.
Topics: Acyclovir; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
The impact of bortezomib on the risk of thrombosis in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines; Risk Factors; Thrombosis | 2011 |
A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients.
Topics: Alkaline Phosphatase; Biomarkers; Bone Remodeling; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Parathyroid Hormone; Prognosis; Prospective Studies; Protease Inhibitors; Pyrazines | 2011 |
The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Everolimus; Humans; Immunosuppressive Agents; Leupeptins; Mice; Mice, Inbred NOD; Mice, SCID; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protease Inhibitors; Pyrazines; Radiation, Ionizing; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases; Whole-Body Irradiation | 2011 |
Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Death; Cell Line, Tumor; Cisplatin; Humans; Kidney Neoplasms; Leiomyomatosis; Mice; Mice, SCID; Neoplasm Transplantation; Pyrazines; Reactive Oxygen Species; Transplantation, Heterologous | 2010 |
Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Separation; Cytokines; Dendritic Cells; DNA-Binding Proteins; Endoplasmic Reticulum; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Homeostasis; Humans; Microscopy, Confocal; Protease Inhibitors; Protein Transport; Pyrazines; Regulatory Factor X Transcription Factors; Reverse Transcriptase Polymerase Chain Reaction; Toll-Like Receptors; Transcription Factors; X-Box Binding Protein 1 | 2011 |
Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents; Autophagy; Benzoquinones; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Clonazepam; HSP90 Heat-Shock Proteins; Lactams, Macrocyclic; Multiple Myeloma; Neurilemmoma; Protein Folding; Proteostasis Deficiencies; Pyrazines; Rats; Schwann Cells | 2010 |
Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Everolimus; Humans; Jurkat Cells; Lymphoma, T-Cell; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrazines; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Vincristine | 2012 |
First-line treatment of elderly multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2010 |
Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib.
Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Echocardiography; Heart Diseases; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Myocardium; Protease Inhibitors; Pyrazines; Stroke Volume; Treatment Outcome | 2010 |
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.
Topics: Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Oxides; Polymerase Chain Reaction; Pyrazines; Zoledronic Acid | 2011 |
Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2010 |
Stroke after treatment with bortezomib and dexamethasone in a Chinese patient with extramedullary relapse of multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Dexamethasone; Humans; Male; Multiple Myeloma; Pyrazines; Recurrence; Stroke; Thrombosis; Treatment Outcome | 2010 |
[Proteasome inhibitors sensitize ovarian cancer cells to cisplatin].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Ovarian Neoplasms; Protease Inhibitors; Pyrazines | 2010 |
Proteasome inhibitor up regulates liver antioxidative enzymes in rat model of alcoholic liver disease.
Topics: Animals; Boronic Acids; Bortezomib; Cytochrome P-450 CYP2E1; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ethanol; Glutamate-Cysteine Ligase; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glutathione Synthase; Liver; Liver Diseases, Alcoholic; Male; Oxidative Stress; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Wistar; Superoxide Dismutase; Time Factors; Up-Regulation | 2011 |
Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Cytarabine; Deoxycytidine; Doxorubicin; Drug Screening Assays, Antitumor; Gemcitabine; Glutathione S-Transferase pi; Humans; Lectins; Lymphoma, Mantle-Cell; Pyrazines | 2010 |
Protective immunity remains intact after antibody removal by means of proteasome inhibition.
Topics: Apoptosis; Boronic Acids; Bortezomib; Combined Modality Therapy; Creatinine; Enzyme-Linked Immunosorbent Assay; Follow-Up Studies; Graft Survival; HLA Antigens; Humans; Immunity; Immunoglobulin G; Kidney Transplantation; Living Donors; Plasmapheresis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Transplantation, Homologous; Treatment Failure | 2010 |
The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation.
Topics: Actuarial Analysis; Adrenal Cortex Hormones; Adult; Aged; Antibody Specificity; Boronic Acids; Bortezomib; Combined Modality Therapy; Creatinine; Female; Graft Rejection; Graft Survival; Humans; Isoantibodies; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Pancreas Transplantation; Plasmapheresis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2010 |
Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Gene Expression Profiling; Gene Frequency; Genetic Predisposition to Disease; Humans; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Pyrazines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vincristine | 2010 |
The combination of bortezomib and resveratrol may prevent muscle wasting in diabetes.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Boronic Acids; Bortezomib; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Humans; Inflammation; Models, Biological; Muscular Atrophy; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Rats; Resveratrol; Stilbenes | 2011 |
Synthesis, in vitro and in vivo biological evaluation, and comprehensive understanding of structure-activity relationships of dipeptidyl boronic acid proteasome inhibitors constructed from β-amino acids.
Topics: Amino Acids; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Dipeptides; Drug Screening Assays, Antitumor; Humans; Male; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship | 2010 |
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; Immunohistochemistry; Inhibitory Concentration 50; K562 Cells; Ki-67 Antigen; Lenalidomide; Leukemia, Myeloid; Lymphoma; Multiple Myeloma; Phosphorylcholine; Pyrazines; Thalidomide; Time Factors | 2012 |
Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cells, Cultured; Cytotoxins; Dose-Response Relationship, Drug; Endoribonucleases; Humans; Mice; Models, Biological; Multiple Myeloma; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Substrate Specificity; Sulfonamides; Thiophenes; Xenograft Model Antitumor Assays | 2011 |
Role of bortezomib for the treatment of previously untreated multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Transplantation, Autologous | 2008 |
Ubiquitin-regulated nuclear-cytoplasmic trafficking of the Nipah virus matrix protein is important for viral budding.
Topics: Amino Acid Sequence; Animals; Blotting, Western; Boronic Acids; Bortezomib; Cell Nucleus; Chlorocebus aethiops; Cytoplasm; Fluorescent Antibody Technique; HeLa Cells; Henipavirus Infections; Humans; Immunoprecipitation; Kidney; Molecular Sequence Data; Mutation; Nipah Virus; Nuclear Localization Signals; Protease Inhibitors; Protein Processing, Post-Translational; Protein Transport; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Amino Acid; Ubiquitin; Vero Cells; Viral Matrix Proteins; Virus Assembly; Virus Shedding | 2010 |
Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cells, Cultured; Chemokine CCL2; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Epithelial Cells; Humans; I-kappa B Kinase; Immunoglobulin Light Chains; Kidney; NF-kappa B; Phosphorylation; Pyrazines; Signal Transduction; src-Family Kinases; Tyrosine | 2011 |
The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Benzoquinones; Boronic Acids; Bortezomib; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lymphoma, Mantle-Cell; Male; Mice; Mice, SCID; Mice, Transgenic; Middle Aged; Molecular Chaperones; Pyrazines; Receptors, Estrogen; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Chemotherapy: Failure of bevacizumab in early-stage colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Treatment Failure | 2011 |
Decursin chemosensitizes human multiple myeloma cells through inhibition of STAT3 signaling pathway.
Topics: Apoptosis; Benzopyrans; Boronic Acids; Bortezomib; Butyrates; Caspase 3; Cell Line, Tumor; Cyclin D1; DNA; G1 Phase; Humans; Interleukin-6; Janus Kinase 2; Multiple Myeloma; Phosphorylation; Pyrazines; Signal Transduction; STAT3 Transcription Factor | 2011 |
Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Discovery; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
[Effects of xbp-1 gene silencing on bortezomib-induced apoptosis in human multiple myeloma cells].
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA-Binding Proteins; Gene Silencing; Humans; Multiple Myeloma; Pyrazines; Regulatory Factor X Transcription Factors; RNA, Small Interfering; Transcription Factors; X-Box Binding Protein 1 | 2010 |
[Bortezomib depresses osteoblast apoptosis induced by mouse myeloma cells].
Topics: 3T3 Cells; Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Mice; Multiple Myeloma; Pyrazines | 2010 |
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Survival Rate; Thalidomide; Transplantation, Autologous; Young Adult | 2011 |
Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Coumarins; Cyclin D1; Drug Synergism; Drug Therapy, Combination; Flow Cytometry; HSP90 Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Immunoprecipitation; Lymphoma, Mantle-Cell; Mutation; Oncogene Protein v-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
A new standard of care in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Standard of Care; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2010 |
Successful treatment with bortezomib and thalidomide for POEMS syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; POEMS Syndrome; Pyrazines; Radionuclide Imaging; Remission Induction; Thalidomide; Treatment Outcome | 2011 |
Complete atrioventricular block secondary to bortezomib use in multiple myeloma.
Topics: Atrioventricular Block; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Multiple Myeloma; Pyrazines | 2011 |
Salvage therapy for refractory rejection and persistence of donor-specific antibodies after intestinal transplantation using the proteasome inhibitor bortezomib.
Topics: Antigens, CD20; Bone Marrow Cells; Boronic Acids; Bortezomib; Graft Rejection; Humans; Immunity, Humoral; Intestines; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Short Bowel Syndrome; Syndecan-1; Transplantation, Homologous; Treatment Outcome | 2011 |
[Bortezomib-based regimen for the treatment of 110 multiple myeloma patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Treatment Outcome | 2010 |
Radiosensitizing properties of bortezomib depend on therapeutic schedule.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioma; Mice; Mice, Nude; NF-kappa B; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Random Allocation; Xenograft Model Antitumor Assays | 2011 |
Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Child; Enzyme Activation; Epstein-Barr Virus Infections; Female; Humans; Killer Cells, Natural; Lymphoma; Lymphoma, T-Cell; Male; NF-kappa B; Proteasome Inhibitors; Pyrazines; T-Lymphocytes | 2011 |
Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 2; Multiple Myeloma; Pyrazines; Signal Transduction; STAT3 Transcription Factor; Thalidomide | 2011 |
Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Treatment Outcome | 2011 |
Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; HL-60 Cells; Humans; Lysosomes; Macrolides; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Stress, Physiological; U937 Cells; Unfolded Protein Response | 2011 |
Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Therapy, Combination; Female; Hemodiafiltration; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Plasma Exchange; Pyrazines; Treatment Outcome | 2010 |
[Effect of bortezomib on MAPK signaling pathway of K562/DNR cells].
Topics: Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; K562 Cells; MAP Kinase Signaling System; Pyrazines | 2010 |
Hematology: Bortezomib and dexamethasone induction for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Humans; Multiple Myeloma; Pyrazines; Remission Induction | 2011 |
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Mitoxantrone; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine | 2011 |
Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrimidines | 2011 |
Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Drug Costs; Drug Resistance, Neoplasm; Drug Utilization; Female; France; Health Care Costs; Hospitals, University; Humans; Lenalidomide; Male; Medical Records; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Pyrazines; Recurrence; Retrospective Studies; Thalidomide | 2011 |
Bortezomib-induced inflammatory neuropathy.
Topics: Boronic Acids; Bortezomib; Humans; Inflammation; Inflammation Mediators; Male; Middle Aged; Multiple Myeloma; Neural Conduction; Peripheral Nervous System Diseases; Pyrazines | 2010 |
High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Basic-Leucine Zipper Transcription Factors; Blotting, Western; Boronic Acids; Bortezomib; Cell Nucleus; Cell Separation; Chromatin Immunoprecipitation; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group Proteins; Flow Cytometry; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; NF-E2-Related Factor 2; Proteasome Endopeptidase Complex; Pyrazines; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Docetaxel; Enzyme-Linked Immunosorbent Assay; Humans; Interleukin-6; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; Taxoids; Tumor Cells, Cultured | 2011 |
Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Topics: 20-Hydroxysteroid Dehydrogenases; 3-Hydroxysteroid Dehydrogenases; Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductase Family 1 Member C3; Aldo-Keto Reductases; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Induction; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Hydroxyprostaglandin Dehydrogenases; Isothiocyanates; Leupeptins; Maleates; Multidrug Resistance-Associated Protein 2; NF-E2-Related Factor 2; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; RNA, Messenger; Sulfoxides; Thiocyanates; Time Factors | 2011 |
Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; DNA, Neoplasm; Drug Synergism; Gene Knockdown Techniques; Glioma; Humans; NF-kappa B; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Transcription Factor RelA; Transfection | 2011 |
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Coculture Techniques; Cyclin-Dependent Kinases; Cytokines; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Drug Interactions; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Pyrazines; Signal Transduction; Stromal Cells; Survival Analysis; Transcription, Genetic; Treatment Outcome; Tumor Cells, Cultured | 2011 |
Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.
Topics: Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus; DNA, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; I-kappa B Proteins; Leupeptins; Lymphoma, T-Cell, Cutaneous; Molecular Sequence Data; NF-kappa B; NF-kappa B p50 Subunit; NF-KappaB Inhibitor alpha; Protein Binding; Protein Subunits; Protein Transport; Pyrazines; Transcription Factor RelA; Transcription, Genetic | 2011 |
A promising new regimen for the treatment of advanced extranodal NK/T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Treatment Outcome | 2011 |
Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Boronic Acids; Bortezomib; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; I-kappa B Proteins; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; NF-kappa B p52 Subunit; Polymorphism, Single Nucleotide; Pyrazines; Risk Assessment; Risk Factors; TNF Receptor-Associated Factor 3; Treatment Outcome | 2011 |
Genetic variation associated with bortezomib-induced peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Boronic Acids; Bortezomib; Cathepsins; Clinical Trials, Phase III as Topic; CTLA-4 Antigen; Female; Genetic Association Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Pyrazines; Randomized Controlled Trials as Topic; Schwann Cells; Transcription Factor 4; Transcription Factors | 2011 |
Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis.
Topics: Animals; Antibodies, Antineutrophil Cytoplasmic; Autoantibodies; Bone Marrow Cells; Boronic Acids; Bortezomib; Enzyme-Linked Immunospot Assay; Glomerulonephritis; Macrophages; Mice; Mice, Inbred C57BL; Neutrophil Infiltration; Peroxidase; Plasma Cells; Protease Inhibitors; Pyrazines; Spleen | 2011 |
Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis.
Topics: Animals; Autoantibodies; Boronic Acids; Bortezomib; Female; Lymphocyte Depletion; Myasthenia Gravis, Autoimmune, Experimental; Plasma Cells; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Rats; Rats, Inbred Lew | 2011 |
Farnesyl transferase inhibitors, autophagy, and proteasome inhibition: synergy for all the right reasons.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Survival; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Models, Biological; Multiple Myeloma; Phagosomes; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Denaturation; Pyrazines | 2011 |
Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells.
Topics: Animals; Boronic Acids; Bortezomib; Enzyme-Linked Immunosorbent Assay; Factor VIII; Immunoglobulin G; Male; Mice; Mice, Inbred C57BL; Pyrazines; Serine Proteinase Inhibitors | 2011 |
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Retrospective Studies; Survival Rate; Thalidomide; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
Clinical and biological features of t(4;14) multiple myeloma: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 4; Female; Flow Cytometry; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Pyrazines; Receptor, Fibroblast Growth Factor, Type 3; Salvage Therapy; Survival Rate; Translocation, Genetic | 2011 |
Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biphenyl Compounds; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Endoplasmic Reticulum; Female; Fenretinide; Humans; Luminescent Proteins; Melanoma; Mice; Microscopy, Fluorescence; Microtubule-Associated Proteins; Nitrophenols; Piperazines; Proto-Oncogene Proteins B-raf; Pyrazines; RNA Interference; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2011 |
Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide.
Topics: Anemia, Hemolytic, Autoimmune; Boronic Acids; Bortezomib; Complement System Proteins; Cyclophosphamide; Female; Humans; Immunoglobulin G; Middle Aged; Pyrazines | 2011 |
Constitutively active FGFR3 with Lys650Glu mutation enhances bortezomib sensitivity in plasma cell malignancy.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Immunoenzyme Techniques; Multiple Myeloma; Plasma Cells; Point Mutation; Pyrazines; Receptor, Fibroblast Growth Factor, Type 3; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2011 |
Re-transplantation after bortezomib-based therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies | 2011 |
Feasibility and efficacy of administration of bortezomib-containing regimens to patients over the age of 70 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Female; Health Services for the Aged; Humans; Male; Multiple Myeloma; Pyrazines | 2011 |
Bortezomib-induced peripheral neuropathy: facts and genes.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Gene Expression Profiling; Humans; Peripheral Nervous System Diseases; Pyrazines; Severity of Illness Index | 2011 |
Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Fusion Proteins, bcr-abl; Humans; Male; Middle Aged; Philadelphia Chromosome; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Remission Induction; Young Adult | 2011 |
RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase 5; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genome, Human; High-Throughput Screening Assays; Humans; Microarray Analysis; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering; Tumor Cells, Cultured | 2011 |
Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Autonomic Nervous System Diseases; Boronic Acids; Bortezomib; Fluorescent Antibody Technique; Humans; Male; Middle Aged; Multiple Myeloma; Neuralgia; Polyneuropathies; Pyrazines; Skin | 2011 |
Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Female; Fluorescent Antibody Technique; Fulvestrant; Green Fluorescent Proteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrazines; Receptors, Estrogen; Tamoxifen; Tumor Burden; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2011 |
Myc overexpression brings out unexpected antiapoptotic effects of miR-34a.
Topics: ADP-Ribosylation Factors; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; MicroRNAs; Neoplasms; Proto-Oncogene Proteins c-mdm2; Proto-Oncogene Proteins c-myc; Pyrazines; Tumor Suppressor Protein p53 | 2011 |
[Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Daunorubicin; Drug Synergism; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Tumor Cells, Cultured; Young Adult | 2010 |
[The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Daunorubicin; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Pyrimidines | 2010 |
Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.
Topics: Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2010 |
Development of a brain metastatic canine prostate cancer cell line.
Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Brain Neoplasms; Carcinogenicity Tests; Carcinoma; Cell Division; Cell Line, Tumor; Dogs; Immunohistochemistry; Incidence; Injections, Subcutaneous; Keratin-18; Keratin-7; Keratin-8; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Connective Tissue; Parathyroid Hormone-Related Protein; Phenylbutyrates; Prostatic Neoplasms; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Spinal Cord Neoplasms; Subcutaneous Tissue; Transplantation, Heterologous | 2011 |
Multiple myeloma: interplay between osteoblastogenesis and adipogenesis.
Topics: Adipogenesis; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Humans; Multiple Myeloma; Osteoblasts; Osteogenesis; Protease Inhibitors; Pyrazines | 2011 |
Clinical perspective of acute humoral rejection after blood type-compatible liver transplantation.
Topics: Aged; Blood Grouping and Crossmatching; Boronic Acids; Bortezomib; Female; Graft Rejection; Humans; Immunity, Humoral; Incidence; Infant; Liver Transplantation; Male; Middle Aged; Plasmapheresis; Protease Inhibitors; Pyrazines; Retrospective Studies | 2011 |
Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazines; Signal Transduction; Valproic Acid | 2011 |
Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.
Topics: Antigen Presentation; Blotting, Western; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line; Epitopes, T-Lymphocyte; Epstein-Barr Virus Nuclear Antigens; Fluorescent Antibody Technique; Humans; Leupeptins; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; T-Lymphocytes, Cytotoxic | 2011 |
De novo AL amyloidosis in the kidney allograft.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Kidney Transplantation; Male; Melphalan; Middle Aged; Prednisone; Proteinuria; Pyrazines; Remission Induction; Treatment Outcome | 2011 |
Signal transducer and activator of transcription 3 pathway mediates genipin-induced apoptosis in U266 multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; Humans; In Situ Nick-End Labeling; Iridoid Glycosides; Iridoids; Multiple Myeloma; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; STAT3 Transcription Factor | 2011 |
Synergistic efficacy in human ovarian cancer cells by histone deacetylase inhibitor TSA and proteasome inhibitor PS-341.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Cytochromes c; Drug Resistance, Neoplasm; Drug Synergism; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Ovarian Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA Interference; Time Factors | 2011 |
A new combination for advanced multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Multiple Myeloma; Pyrazines | 2011 |
Proteasome inhibition induces a p38 MAPK pathway-dependent antiapoptotic program via Nrf2 in thyroid cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Glutamate-Cysteine Ligase; Glutathione; Humans; Microscopy, Confocal; NF-E2-Related Factor 2; p38 Mitogen-Activated Protein Kinases; Plasmids; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Small Interfering; Signal Transduction; Thyroid Neoplasms; Transcriptional Activation; Translocation, Genetic | 2011 |
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glioma; Humans; Neoplastic Stem Cells; Neural Stem Cells; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Temozolomide | 2011 |
Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Hypoxia; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Pyrazines | 2011 |
Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Denmark; Female; Genetic Association Studies; Humans; Interferon-alpha; Interleukin-1beta; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; NF-kappa B p50 Subunit; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prognosis; Promoter Regions, Genetic; Pyrazines; Recombinant Proteins; Survival Analysis; Thalidomide | 2011 |
Recent advances in myeloma treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Quality of Life; Salvage Therapy; Stem Cell Transplantation; Thalidomide | 2011 |
Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Caspases; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Chemokine CXCL12; Chymotrypsin; Coculture Techniques; DNA Fragmentation; Drug Synergism; Enzyme Activation; Female; Humans; JNK Mitogen-Activated Protein Kinases; Lymphoma; Mice; Mice, SCID; Oligopeptides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteasome Inhibitors; Pyrazines; Serine Proteinase Inhibitors; Unfolded Protein Response; Waldenstrom Macroglobulinemia | 2011 |
Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azocines; Benzhydryl Compounds; Boronic Acids; Bortezomib; Breast Neoplasms; Caspases; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Female; Genes, bcl-2; Gossypol; Humans; Mice; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured | 2011 |
Out foxing bcr-abl.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Forkhead Box Protein O3; Forkhead Transcription Factors; Fusion Proteins, bcr-abl; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; TNF-Related Apoptosis-Inducing Ligand | 2011 |
Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
Topics: Animals; Arthritis; Bone and Bones; Bone Resorption; Boronic Acids; Bortezomib; Cartilage, Articular; Chronic Disease; Disease Models, Animal; Humans; Mice; Mice, Transgenic; Osteoclasts; Osteoprotegerin; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RANK Ligand; Synovial Membrane; Tumor Necrosis Factor-alpha | 2011 |
[Screening drugs for regulating tissue factor gene expression].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Screening Assays, Antitumor; Gene Expression; Humans; Molecular Sequence Data; Promoter Regions, Genetic; Pyrazines; Thromboplastin; Transcription Factors; Transcriptional Activation; U937 Cells | 2011 |
Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cells, Cultured; Cysteine Endopeptidases; Drug Delivery Systems; Drug-Related Side Effects and Adverse Reactions; Hep G2 Cells; Humans; Male; Models, Biological; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley | 2011 |
Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; HCT116 Cells; Humans; Neoplasms; Pyrazines; Thiazoles; Thiostrepton | 2011 |
[Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Creatine; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency | 2011 |
Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Germany; Humans; International Agencies; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Retreatment; Retrospective Studies; Survival Rate; Switzerland; Treatment Outcome | 2010 |
Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2011 |
Successful treatment of early relapse of ocular myeloma with bortezomib and steroid after autologous stem cell transplantation.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Eye Neoplasms; Glucocorticoids; Humans; Male; Middle Aged; Multiple Myeloma; Orbital Neoplasms; Plasmacytoma; Prednisolone; Pyrazines; Recurrence; Stem Cell Transplantation | 2010 |
[Case report; a case of acute kidney injury due to intravenous zoledronic acid hydrate, improved with bortezomib plus dexamethazone therapy in a patient with multiple myeloma].
Topics: Acute Kidney Injury; Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Injections, Intravenous; Male; Multiple Myeloma; Pyrazines; Zoledronic Acid | 2011 |
Bortezomib attenuates acute graft-vs.-host disease through interfering with host immature dendritic cells.
Topics: Acute Disease; Animals; Boronic Acids; Bortezomib; Cytokines; Dendritic Cells; Flow Cytometry; Graft vs Host Disease; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines | 2011 |
Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A.
Topics: Animals; Antibodies, Neoplasm; Apoptosis; Autoantigens; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Membrane Proteins; Mice; Mice, Nude; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2011 |
Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea.
Topics: Animals; Antineoplastic Agents; Ascorbic Acid; Boronic Acids; Bortezomib; Catechin; Chromatography, Liquid; Drug Screening Assays, Antitumor; Female; Humans; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazines; Tandem Mass Spectrometry; Tea; Xenograft Model Antitumor Assays | 2011 |
[Significance of bortezomib and dexamethasone therapy for multiple myeloma showing a serum creatinine level above 2 mg/dl].
Topics: Aged; Biomarkers; Boronic Acids; Bortezomib; Creatinine; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Treatment Outcome | 2011 |
[A case of aggressive multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Biopsy; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Prednisolone; Pyrazines | 2011 |
Calibration of prior variance in the Bayesian continual reassessment method.
Topics: Algorithms; Antineoplastic Agents; Bayes Theorem; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Humans; Lymphoma, B-Cell; Maximum Tolerated Dose; Models, Statistical; Pyrazines | 2011 |
Cutaneous macroglobulinosis treated with bortezomib and rituximab.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Humans; Immunoglobulin M; Male; Pyrazines; Recurrence; Rituximab; Skin Diseases; Waldenstrom Macroglobulinemia | 2011 |
[Study on mechanism of bortezomib inducing peripheral neuropathy and the reversing effect of reduced glutathione].
Topics: Animals; Boronic Acids; Bortezomib; Female; Glutathione; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Wistar; Reactive Oxygen Species | 2011 |
[In vitro synergistic effect of bortezomib and pirarubicin on proliferation and apoptosis of T cell lymphoma cell line Hut-78 cells].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Humans; Lymphoma, T-Cell; Pyrazines | 2011 |
Renal failure caused by plasma cell infiltration in multiple myeloma.
Topics: Bence Jones Protein; Boronic Acids; Bortezomib; Female; Humans; Kidney; Middle Aged; Multiple Myeloma; Plasma Cells; Pyrazines; Renal Insufficiency | 2011 |
Velcade combinations in mantle cell lymphoma: are we learning anything?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Protease Inhibitors; Pyrazines | 2011 |
Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Biomarkers; Boronic Acids; Bortezomib; Case-Control Studies; Cytokine Receptor gp130; Female; GATA2 Transcription Factor; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Receptors, CXCR4; T-Lymphocyte Subsets; Thalidomide; Transplantation, Autologous | 2011 |
Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Astrocytes; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Glioma; Humans; Leupeptins; Mutagenesis, Site-Directed; Neoplastic Stem Cells; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase C-epsilon; Proto-Oncogene Proteins c-akt; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNFα/NFκB pathway.
Topics: ADAM Proteins; ADAM10 Protein; Amyloid Precursor Protein Secretases; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cysteine Proteinase Inhibitors; Enzyme Activation; Female; Humans; Leupeptins; Lymphoma, Mantle-Cell; Male; Membrane Proteins; Palatine Tonsil; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Tonsillar Neoplasms; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2011 |
[Meningeal plasmacytoma: delayed diagnosis with sequelae].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Brain Edema; Cerebral Hemorrhage; Contrast Media; Delayed Diagnosis; Dexamethasone; Diagnostic Errors; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Multiple Myeloma; Neurologic Examination; Pyrazines; Tomography, X-Ray Computed | 2011 |
Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Drug Synergism; HCT116 Cells; Heat-Shock Response; HeLa Cells; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Hyperthermia, Induced; Mice; Mice, Inbred BALB C; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteostasis Deficiencies; Puromycin; Pyrazines | 2011 |
Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Chromones; Humans; Indoles; Melanoma; Morpholines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha; RNA, Small Interfering; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma.
Topics: Activating Transcription Factor 4; Activating Transcription Factor 6; Antineoplastic Agents; Boronic Acids; Bortezomib; Burkitt Lymphoma; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; DNA-Binding Proteins; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; HEK293 Cells; Herpesvirus 4, Human; Humans; Pyrazines; Regulatory Factor X Transcription Factors; Response Elements; Thapsigargin; Trans-Activators; Transcription Factor CHOP; Transcription Factors; Unfolded Protein Response; Virus Activation; X-Box Binding Protein 1 | 2011 |
Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli.
Topics: Anilides; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cisplatin; Humans; Male; Nitriles; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptors, Androgen; Tosyl Compounds | 2011 |
Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspases; Child, Preschool; Drug Interactions; Female; Humans; Male; Mice; Mice, SCID; Myelodysplastic Syndromes; NF-kappa B; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Tumor Cells, Cultured | 2011 |
Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Humans; Male; Multiple Myeloma; Polyethylene Glycols; Prognosis; Pyrazines; Retrospective Studies | 2011 |
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.
Topics: Aged; Amyloidosis; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin M; Lymphatic Diseases; Male; Middle Aged; Pyrazines; Rituximab | 2011 |
Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Male; Polymerase Chain Reaction; Pyrazines; Waldenstrom Macroglobulinemia | 2011 |
Inhibition of p53 DNA binding function by the MDM2 protein acidic domain.
Topics: Antibodies; Boronic Acids; Bortezomib; Cell Line; DNA; Epitopes; Humans; Methyltransferases; Multiprotein Complexes; Promoter Regions, Genetic; Protease Inhibitors; Proteasome Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-mdm2; Pyrazines; Repressor Proteins; Transcription, Genetic; Tumor Suppressor Protein p53; Ubiquitination | 2011 |
Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Jurkat Cells; Lymphocytes; Myeloid Cell Leukemia Sequence 1 Protein; Protein Binding; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2011 |
Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5; Boronic Acids; Bortezomib; Caspase 3; Caspase 7; Caspase 8; Fas-Associated Death Domain Protein; Flow Cytometry; Fluorescence Resonance Energy Transfer; HeLa Cells; Humans; Immunoblotting; Mice; Mice, Mutant Strains; Microscopy, Fluorescence; Microtubule-Associated Proteins; Peptide Hydrolases; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Analysis of two commercially available bortezomib products: differences in assay of active agent and impurity profile.
Topics: Boronic Acids; Bortezomib; Chemistry, Pharmaceutical; Drug Contamination; Humans; Pyrazines; Random Allocation | 2011 |
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin | 2011 |
Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Chick Embryo; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Mitochondria; Pyrazines; Receptors, Death Domain; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2011 |
Proteasome inhibition improves diaphragm function in an animal model for COPD.
Topics: Animals; Biomechanical Phenomena; Boronic Acids; Bortezomib; Contractile Proteins; Cricetinae; Diaphragm; Disease Models, Animal; Male; Organ Specificity; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Pyrazines | 2011 |
Cervical amyloidoma successfully treated with bortezomib and dexamethasone.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cervical Vertebrae; Dexamethasone; Humans; Magnetic Resonance Imaging; Male; Pyrazines; Spinal Neoplasms | 2011 |
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.
Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Transformation, Neoplastic; Gene Expression Profiling; Humans; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Mutation; Proto-Oncogene Proteins c-myc; Pyrazines; ras Proteins; Survival Rate | 2011 |
[Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease Progression; Drug Therapy, Combination; Graft vs Tumor Effect; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2011 |
Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Boronic Acids; Bortezomib; Cadherins; Cell Adhesion; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Coculture Techniques; Drug Resistance, Neoplasm; Fibronectins; Focal Adhesion Kinase 1; Gene Knockdown Techniques; Gene Silencing; Humans; Integrin beta Chains; Melphalan; Mice; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Transplantation; Phosphorylation; Proto-Oncogene Proteins c-maf; Pyrazines; rac1 GTP-Binding Protein; src-Family Kinases; Stem Cell Transplantation; Sumoylation; Transcription Factor RelA; Transplantation, Autologous; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2011 |
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Creatinine; Female; Humans; Kidney Diseases; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines | 2011 |
Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure.
Topics: Acute Kidney Injury; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Humans; Immunoglobulin kappa-Chains; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Remission Induction | 2012 |
Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays | 2011 |
Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo.
Topics: Animals; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; Cerebellar Neoplasms; Curcumin; Ditiocarb; Humans; I-kappa B Proteins; Medulloblastoma; Mice; Mice, Inbred C57BL; Mice, Nude; NF-kappa B; Pyrazines; Pyrrolidines; Signal Transduction; Sulfasalazine; Thiocarbamates; Transgenes; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Female; Humans; Japan; Leukopenia; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Survival; Thalidomide; Thrombocytopenia; Time Factors | 2011 |
Subcutaneous bortezomib: a step towards optimised drug use.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Injections, Subcutaneous; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Quality of Life; Recurrence | 2011 |
Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Liver Neoplasms; Magnetic Resonance Spectroscopy; Metabolomics; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sulfonamides | 2011 |
History of multiple myeloma.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Bence Jones Protein; Boronic Acids; Bortezomib; History, 19th Century; History, Ancient; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Proteinuria; Pyrazines; Stem Cell Transplantation; Thalidomide; Urethane | 2011 |
Allogeneic transplantation in multiple myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Mice; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2011 |
Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Cycle; Colorectal Neoplasms; Cyclins; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Mice; Mice, Nude; Prognosis; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Tissue Array Analysis; Ubiquitin-Conjugating Enzymes; Xenograft Model Antitumor Assays | 2011 |
[NB4 cell apoptosis induced by bortezomib combined with As(2)O(3) and its mechanism].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; Cell Line, Tumor; Humans; Oxides; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Transfection | 2011 |
Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
Topics: Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Death Domain Receptor Signaling Adaptor Proteins; Glioblastoma; Humans; Mitochondria; Neoplastic Stem Cells; Protein Stability; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand | 2011 |
Delayed treatment with vitamin C and N-acetyl-L-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Antioxidants; Ascorbic Acid; Autophagy; Boronic Acids; Bortezomib; Cell Line; Endoplasmic Reticulum; Free Radical Scavengers; Multiple Myeloma; Neuroprotective Agents; Peripheral Nervous System Diseases; Pyrazines; Rats; Schwann Cells | 2011 |
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
Topics: Adult; Aged; Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Immunosuppressive Agents; Lenalidomide; Male; Melphalan; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2012 |
Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression.
Topics: Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Leukemic; Humans; MicroRNAs; Multiple Myeloma; Pyrazines; Stromal Cells; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2011 |
[Effect of proteasome inhibitor bortezomib on proliferation, apoptosis and XIAP expression in K562 cells].
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Humans; K562 Cells; Leukemia; Pyrazines; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Toxicity burden score: a novel approach to summarize multiple toxic effects.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Feasibility Studies; Health Status Indicators; Humans; Neoplasms; Pyrazines; Toxicity Tests | 2012 |
Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Comorbidity; Endemic Diseases; Female; Hepatitis B; Humans; Immunologic Factors; Incidence; Lamivudine; Male; Middle Aged; Multiple Myeloma; Prevalence; Prospective Studies; Pyrazines; Retrospective Studies; Risk Factors; Secondary Prevention; Stem Cell Transplantation; Transplantation, Autologous; Virus Activation | 2012 |
Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma.
Topics: Aged; Antineoplastic Agents; Autoimmune Diseases; Boronic Acids; Bortezomib; Female; Humans; Magnetic Resonance Imaging; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Pyrazines; Transplantation, Autologous; Treatment Outcome | 2011 |
[The significances of 13q14 deletion for development and prognosis of multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 13; Female; Flow Cytometry; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines | 2011 |
[Effect of different regimens on bone disease of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Resorption; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Multiple Myeloma; Pyrazines; RANK Ligand; Thalidomide | 2011 |
[The clinical study on treatment with bortezomib for multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2011 |
[Mechanism of apoptosis induced by bortezomib and As2O3 in APL cell line NB4].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Leukemia, Promyelocytic, Acute; Oxides; Pyrazines | 2011 |
A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia.
Topics: Amyloidosis; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Protease Inhibitors; Pyrazines | 2011 |
Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Catalytic Domain; Cell Line, Tumor; Cell Membrane Permeability; Humans; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Trypsin | 2011 |
Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study.
Topics: Acyclovir; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Secondary Prevention; Treatment Outcome | 2011 |
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 1; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Middle Aged; Multiple Myeloma; Pharmacogenetics; Prognosis; Proteasome Endopeptidase Complex; Pyrazines; Risk; RNA-Binding Proteins; Up-Regulation | 2011 |
Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Cyclophosphamide; Drug Resistance, Neoplasm; Hospitals, University; Humans; Immunologic Factors; Leukemia, Plasma Cell; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Retrospective Studies; Salvage Therapy; Severity of Illness Index; Survival Analysis | 2011 |
Proteasome inhibitor treatment in alcoholic liver disease.
Topics: Animals; Boronic Acids; Bortezomib; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Ethanol; Humans; Liver Diseases, Alcoholic; Oxidative Stress; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Rats; Reactive Oxygen Species | 2011 |
Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cells, Cultured; Cerebellar Neoplasms; Gene Expression Profiling; Immunohistochemistry; Medulloblastoma; Mice; Mice, Mutant Strains; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering | 2011 |
Proteotoxic stress targeted therapy (PSTT).
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Combined Modality Therapy; Cytoprotection; Drug Resistance, Neoplasm; Drug Synergism; Heat-Shock Proteins; Humans; Hyperthermia, Induced; Molecular Chaperones; Molecular Targeted Therapy; Multiple Myeloma; Proteasome Inhibitors; Protein Folding; Pyrazines | 2011 |
p21(WAF1/CIP1) upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis.
Topics: Apoptosis; Boronic Acids; Bortezomib; CELF1 Protein; Cyclin-Dependent Kinase Inhibitor p21; Cytoplasmic Granules; Drug Resistance, Neoplasm; HeLa Cells; Humans; Protein Binding; Protein Biosynthesis; Pyrazines; RNA Stability; RNA-Binding Proteins; RNA, Messenger; Stress, Physiological; Up-Regulation | 2011 |
Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Separation; Hematopoietic Stem Cells; Humans; Magnetics; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Rituximab; Transplantation, Autologous | 2011 |
Levels of p27 sensitize to dual PI3K/mTOR inhibition.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Drug Synergism; Gene Expression Regulation, Neoplastic; Mice; Multiple Endocrine Neoplasia; Phosphoinositide-3 Kinase Inhibitors; Pituitary Neoplasms; Proteasome Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Rats; Signal Transduction; TOR Serine-Threonine Kinases | 2011 |
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; p38 Mitogen-Activated Protein Kinases; Pyrazines; Stress, Physiological; Vorinostat; Waldenstrom Macroglobulinemia | 2011 |
Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cytomegalovirus; Cytomegalovirus Infections; Dose-Response Relationship, Drug; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; In Vitro Techniques; Interferon-gamma; Lymphocyte Activation; Lymphocyte Depletion; Proteasome Inhibitors; Pyrazines; T-Lymphocytes; Transplantation, Homologous | 2011 |
Renal improvement in myeloma with bortezomib plus plasma exchange.
Topics: Acute Kidney Injury; Antineoplastic Agents; Biomarkers; Boronic Acids; Bortezomib; Combined Modality Therapy; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Multiple Myeloma; Plasma Exchange; Pyrazines | 2011 |
Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swed
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Kaplan-Meier Estimate; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Sweden; Thalidomide | 2011 |
Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Time Factors; Treatment Outcome | 2012 |
An update on antibody reduction and rejection reversal following bortezomib use: a report of 52 cases across 10 centers.
Topics: Acute Disease; Boronic Acids; Bortezomib; Chronic Disease; Down-Regulation; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Isoantibodies; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Transplants; Treatment Outcome | 2010 |
Bortezomib for desensitization of patients on a waiting list for deceased donor kidney transplant: experience in Mexico City.
Topics: Adult; Boronic Acids; Bortezomib; Down-Regulation; Female; Graft Survival; HLA Antigens; Humans; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Mexico; Middle Aged; Patient Selection; Plasmapheresis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Tissue Donors; Treatment Outcome; Waiting Lists | 2010 |
Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
Topics: Acute Disease; Adjuvants, Immunologic; Adult; Boronic Acids; Bortezomib; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Saudi Arabia; Time Factors; Treatment Outcome | 2010 |
Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report.
Topics: Biopsy; Boronic Acids; Bortezomib; Chronic Disease; Complement C4b; Drug Therapy, Combination; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Peptide Fragments; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome | 2010 |
Targeting alloantibody production with bortezomib: does it make more sense?
Topics: Biopsy; Boronic Acids; Bortezomib; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Cellular; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome | 2010 |
1.7 year follow-up after bortezomib therapy for refractory antibody mediated rejection.
Topics: BK Virus; Boronic Acids; Bortezomib; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Middle Aged; Polyomavirus Infections; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome | 2010 |
Bortezomib alone fails to decrease donor specific anti-HLA antibodies: even after one year post-treatment.
Topics: Adult; Biopsy; Boronic Acids; Bortezomib; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome | 2010 |
Bortezomib as rescue therapy for antibody mediated rejection: a single-center experience.
Topics: Adult; Biopsy; Boronic Acids; Bortezomib; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Time Factors; Treatment Outcome | 2010 |
Reduction in proteinuria with bortezomib based therapy for antibody mediated rejection.
Topics: Adult; Biopsy; Boronic Acids; Bortezomib; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; New York City; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteinuria; Pyrazines; Retrospective Studies; Salvage Therapy; Time Factors; Treatment Outcome | 2010 |
Bortezomib for acute humoral rejection treatment at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City: an update.
Topics: Academies and Institutes; Acute Disease; Adult; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Mexico; Middle Aged; Plasmapheresis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome; Young Adult | 2010 |
Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases.
Topics: Adult; Boronic Acids; Bortezomib; Chronic Disease; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome; Young Adult | 2010 |
Rescue therapy for acute antibody mediated rejection with a proteosome inhibitor after kidney transplantation.
Topics: Acute Disease; Adult; Boronic Acids; Bortezomib; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Time Factors; Treatment Outcome | 2010 |
Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pain; Pain Measurement; Peripheral Nervous System Diseases; Pilot Projects; Pyrazines | 2011 |
Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.
Topics: Antineoplastic Agents; Antioxidants; Boronic Acids; Bortezomib; Cell Survival; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Gene Expression Profiling; Humans; Lymphoma, Mantle-Cell; NF-E2-Related Factor 2; Oxidative Stress; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stress, Physiological; Transcription, Genetic; Tumor Cells, Cultured | 2011 |
[Regression of an osteolytic lesion in a patient with multiple myeloma treated with clodronate after a successful therapy with bortezomib-based regimen].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clodronic Acid; Femur; Humans; Male; Multiple Myeloma; Osteolysis; Pyrazines; Radiography; Recurrence; Remission Induction | 2011 |
Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation.
Topics: Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Cell Survival; Coculture Techniques; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Multiple Myeloma; Pyrazines; Stromal Cells; Up-Regulation | 2011 |
Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cells, Cultured; Dasatinib; Dexamethasone; Drug Synergism; Gene Expression Profiling; Humans; Multiple Myeloma; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Thiazoles; Transcriptome | 2012 |
The challenge of recurrent follicular lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Follicular; Male; Pyrazines; Rituximab | 2011 |
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Blotting, Western; Boron Compounds; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Drug Synergism; Enzyme Activation; Glycine; Humans; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thalidomide; Xenograft Model Antitumor Assays | 2011 |
[Effect of different concentrations of bortezomib on the expression of ERK, JNK and P38 in daunorubicin-resistant K562 cells].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; JNK Mitogen-Activated Protein Kinases; K562 Cells; p38 Mitogen-Activated Protein Kinases; Protease Inhibitors; Pyrazines | 2011 |
[Effect of curcumin in combination with bortezomib on proliferation and apoptosis of human multiple myeloma cell line H929 and its mechanism].
Topics: Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Curcumin; Cyclin D1; Drug Therapy, Combination; Humans; Multiple Myeloma; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transcription Factor RelA | 2011 |
[Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Treatment Outcome; Young Adult | 2011 |
Apoptotic role of IKK in T-ALL therapeutic response.
Topics: Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-myc; Pyrazines; Receptor, Notch1; Signal Transduction; Vincristine | 2011 |
Inhibition of heat shock protein response enhances PS-341-mediated glioma cell death.
Topics: Antineoplastic Agents; Apoptosis; Benzhydryl Compounds; Boronic Acids; Bortezomib; Brain; Cell Line, Tumor; Cell Nucleus; DNA-Binding Proteins; Gene Knockdown Techniques; Glioblastoma; Heat Shock Transcription Factors; Hot Temperature; HSP40 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; Humans; JNK Mitogen-Activated Protein Kinases; Phosphorylation; Pyrazines; Pyrrolidinones; RNA, Small Interfering; Transcription Factors; Up-Regulation | 2012 |
Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2011 |
The micros in harmony: microRNA and microenvironment.
Topics: Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Humans; MicroRNAs; Multiple Myeloma; Pyrazines | 2011 |
Heavy-chain amyloidosis in TGFBI-negative and gelsolin-negative atypical lattice corneal dystrophy.
Topics: Amyloid; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Corneal Dystrophies, Hereditary; Dexamethasone; DNA Mutational Analysis; Extracellular Matrix Proteins; Gelsolin; Glucocorticoids; Humans; Immunoglobulin Heavy Chains; Male; Mass Spectrometry; Melphalan; Microscopy, Confocal; Middle Aged; Mutation; Nephrotic Syndrome; Paraproteinemias; Pyrazines; Sequence Analysis, Protein; Transforming Growth Factor beta | 2011 |
Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-κB activity.
Topics: Adolescent; Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; NF-kappa B; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protease Inhibitors; Pyrazines; Treatment Outcome | 2011 |
In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors.
Topics: Annexin A5; Antigens, CD34; Boronic Acids; Bortezomib; Caspases; Colony-Forming Units Assay; Doxorubicin; Flow Cytometry; Health; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Lenalidomide; Phosphorylcholine; Pyrazines; Staining and Labeling; Thalidomide; Tissue Donors; Trypan Blue | 2012 |
Catechol polymers for pH-responsive, targeted drug delivery to cancer cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Catechols; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Humans; Hydrogen-Ion Concentration; Molecular Structure; Polymers; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Structure-Activity Relationship | 2011 |
Proteasome inhibitor treatment of antibody-mediated allograft rejection.
Topics: Animals; Boronic Acids; Bortezomib; Graft Rejection; Graft Survival; Heart Transplantation; Histocompatibility; HLA Antigens; Humans; Immunologic Factors; Isoantibodies; Kidney Transplantation; Lung Transplantation; Organ Transplantation; Plasma Cells; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Transplantation Tolerance; Transplantation, Homologous; Treatment Outcome | 2011 |
Small compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma.
Topics: Animals; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Dexamethasone; Doxorubicin; Female; Humans; Inhibitory Concentration 50; Insulin-Like Growth Factor I; Interleukin-6; Lactones; Mice; Mitosis; Multiple Myeloma; Protective Agents; Pyrazines; Rats; Rats, Sprague-Dawley; Sesquiterpenes; Stromal Cells; Xenograft Model Antitumor Assays | 2011 |
Bortezomib in patients with renal impairment.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytochrome P-450 Enzyme System; Diarrhea; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Retrospective Studies; Survival Analysis | 2011 |
Identification of genes affecting the toxicity of anti-cancer drug bortezomib by genome-wide screening in S. pombe.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Segregation; Genes, Fungal; Genetic Testing; Metaphase; Mitosis; Models, Biological; Mutation; Proteasome Endopeptidase Complex; Pyrazines; Schizosaccharomyces | 2011 |
Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Cycle; Drug Synergism; Female; HIV Protease Inhibitors; Humans; Membrane Potential, Mitochondrial; Nelfinavir; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2011 |
Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotaxis; Dependovirus; Drug Synergism; Endothelial Cells; Fibroblast Growth Factor 2; Galectin 3; Green Fluorescent Proteins; Humans; Immunoglobulin E; Immunoglobulin lambda-Chains; Integrin alphaVbeta3; Mice; Multiple Myeloma; Neoplasm Invasiveness; Neovascularization, Pathologic; Pyrazines; Umbilical Veins; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
Topics: Acetylation; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Biphenyl Compounds; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Hodgkin Disease; Humans; Indoles; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Nitrophenols; Piperazines; Protein Processing, Post-Translational; Pyrazines; Pyridines; Pyrroles; Sulfonamides; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2011 |
SCF(FBXO22) regulates histone H3 lysine 9 and 36 methylation levels by targeting histone demethylase KDM4A for ubiquitin-mediated proteasomal degradation.
Topics: Basic Helix-Loop-Helix Transcription Factors; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Chromatin; Cyclopentanes; Epigenesis, Genetic; F-Box Proteins; Gene Expression Regulation; HEK293 Cells; HeLa Cells; Histone Demethylases; Histones; Humans; Jumonji Domain-Containing Histone Demethylases; Mass Spectrometry; Methylation; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Pyrazines; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Signal Transduction; Ubiquitination | 2011 |
[Effect of bortezomib on the drug sensitivity of imatinib resistant K562/G01 cells].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Checkpoints; Cyclooxygenase 2; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Piperazines; Pyrazines; Pyrimidines | 2011 |
Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Humans; Male; MAP Kinase Kinase 4; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Signal Transduction; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2011 |
The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Bone Marrow; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Humans; Interleukin-6; Janus Kinase 1; Melphalan; Multiple Myeloma; Phosphorylation; Pyrazines; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Stromal Cells | 2011 |
Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link.
Topics: Animals; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Humans; Neoplasms; Proteasome Inhibitors; Protein Folding; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Escape | 2011 |
Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts.
Topics: Animals; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Glioma; HEK293 Cells; Humans; Immunohistochemistry; Jurkat Cells; Male; Mice; Mice, Nude; Neural Stem Cells; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2011 |
Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens, Neoplasm; Autophagy; Boronic Acids; Bortezomib; Cancer Vaccines; Cross Reactions; Methylcholanthrene; Mice; Mice, Inbred C57BL; Phagosomes; Protein Synthesis Inhibitors; Proteins; Pyrazines; Sarcoma, Experimental; Sequestosome-1 Protein; T-Lymphocytes | 2011 |
The TEMPI syndrome--a novel multisystem disease.
Topics: Adult; Boronic Acids; Bortezomib; Erythropoietin; Female; Humans; Hydronephrosis; Lymphangiectasis; Male; Middle Aged; Paraproteinemias; Polycythemia; Protease Inhibitors; Pyrazines; Syndrome; Telangiectasis | 2011 |
A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy.
Topics: Animals; Boronic Acids; Bortezomib; Iodine Radioisotopes; Lymphoma; Mice; Models, Biological; Monte Carlo Method; Pyrazines; Radiometry; Radiopharmaceuticals | 2011 |
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.
Topics: Aged; Apoptosis; Basophils; Benzamides; Boronic Acids; Bortezomib; Drug Resistance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrimidines | 2011 |
Proteasomal inhibition promotes ATP-binding cassette transporter A1 (ABCA1) and ABCG1 expression and cholesterol efflux from macrophages in vitro and in vivo.
Topics: Animals; Apolipoprotein A-I; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Boronic Acids; Bortezomib; Cells, Cultured; Cholesterol; Hep G2 Cells; Humans; Lipoproteins; Lipoproteins, HDL; Macrophages; Mice; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin-Protein Ligases; Ubiquitination | 2011 |
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide; Tissue Donors; Transplantation Conditioning; Transplantation, Autologous | 2012 |
Response to bortezomib of a patient with scleromyxedema refractory to other therapies.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Male; Pyrazines; Salvage Therapy; Scleromyxedema; Treatment Outcome | 2011 |
Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis.
Topics: Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Humans; Melphalan; Pyrazines; Stem Cell Transplantation | 2011 |
Bortezomib in systemic AL amyloidosis: a single center experience.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Pyrazines | 2011 |
Bortezomib (Velcade) treatment of AL amyloidosis: Indiana University experience.
Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin Light Chains; Indiana; Male; Middle Aged; Pyrazines | 2011 |
Quick response to bortezomib plus dexamethasone in a patient with AL amyloidosis in first relapse.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Echocardiography; Female; Humans; Immunoglobulin Light Chains; Pyrazines; Recurrence | 2011 |
Complementary cell-based high-throughput screens identify novel modulators of the unfolded protein response.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspases; Cell Proliferation; CHO Cells; Cricetinae; Drug Evaluation, Preclinical; eIF-2 Kinase; Eukaryotic Initiation Factor-2; Genes, Reporter; High-Throughput Screening Assays; Humans; Luciferases; Mouth Neoplasms; Mycotoxins; Pyrazines; Signal Transduction; Transcription Factor CHOP; Transduction, Genetic; Unfolded Protein Response | 2011 |
Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Child; Female; Graft Rejection; Graft Survival; Humans; Immunoglobulins, Intravenous; Kidney Transplantation; Male; Middle Aged; Plasmapheresis; Prognosis; Pyrazines; Rituximab; Survival Rate; Young Adult | 2012 |
Multiple myeloma associated IgA pemphigus: treatment with bortezomib- and lenalidomide-based regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin A; Lenalidomide; Middle Aged; Multiple Myeloma; Pemphigus; Pyrazines; Remission Induction; Thalidomide | 2011 |
Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; HIV Infections; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Pyrazines; Tumor Lysis Syndrome | 2010 |
Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Checkpoints; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; G1 Phase; HSP90 Heat-Shock Proteins; Humans; MAP Kinase Kinase Kinases; Multiple Myeloma; Pyrazines; Pyridones; Pyrimidines; Signal Transduction; STAT3 Transcription Factor | 2011 |
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromosome Aberrations; Comparative Genomic Hybridization; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; Models, Biological; Multiple Myeloma; Peptide Hydrolases; Pyrazines; RNA, Small Interfering; Thalidomide; Ubiquitin-Protein Ligases | 2011 |
Successful bone reconstruction after bortezomib therapy in a myeloma patient.
Topics: Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Radiography; Treatment Outcome | 2011 |
Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B.
Topics: Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Estrogens; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Neoplasms, Hormone-Dependent; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Transcription, Genetic; Ubiquitination | 2011 |
Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Dinitrofluorobenzene; Disease Models, Animal; Drug Compounding; Drug Evaluation, Preclinical; Drug Stability; Female; Hypersensitivity, Delayed; Imiquimod; Immunologic Factors; Irritants; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Peritonitis; Psoriasis; Pyrazines; Random Allocation; Temperature; Thioglycolates | 2011 |
[Comparison of protein expression profiles between bortezomib-resistant JurkatB cells with PSMB5 mutation and their parent cells].
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Multiple; Gene Expression Profiling; Humans; Jurkat Cells; Mutation; Proteasome Endopeptidase Complex; Pyrazines | 2011 |
[Proteasome inhibitor bortezomib inducing apoptosis of K562 cells not affected by bone marrow mesenchymal stem cells in vitro].
Topics: Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Coculture Techniques; Humans; K562 Cells; Mesenchymal Stem Cells; Proteasome Inhibitors; Pyrazines; RNA, Messenger; Vascular Cell Adhesion Molecule-1 | 2011 |
[Effects of bortezomib alone or combined with arsenic trioxide on the apoptosis of Jurkat cells and expression of livin mRNA].
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Humans; Inhibitor of Apoptosis Proteins; Jurkat Cells; Neoplasm Proteins; Oxides; Pyrazines; RNA, Messenger | 2011 |
[Effects of bortezomib combined with methylprednisolone in treatment of 33 cases of relapsed or refractory multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Retrospective Studies; Treatment Outcome | 2011 |
Modulation of cisplatin cytotoxicity due to its combination with bortezomib and the nature of its administration.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Drug Administration Routes; Humans; Pyrazines | 2011 |
Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib.
Topics: ABO Blood-Group System; Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Pyrazines; Red-Cell Aplasia, Pure; Transplantation, Homologous | 2012 |
Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Lung Neoplasms; Mice; Mice, 129 Strain; NF-kappa B; Nitriles; Pyrazines; Signal Transduction; Sulfones; Survival Rate; Transcription Factor RelA | 2011 |
Cardiac amyloidosis: a treatable disease, often overlooked.
Topics: Adrenergic beta-Antagonists; Amyloidosis; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Boronic Acids; Bortezomib; Calcium Channel Blockers; Dexamethasone; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Humans; Lenalidomide; Melphalan; Middle Aged; Myocardium; Prealbumin; Pyrazines; Severity of Illness Index; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Proteasome inhibition prevents development of experimental dermal fibrosis.
Topics: Actins; Animals; Bleomycin; Boronic Acids; Bortezomib; Collagen Type I; Female; Fibrosis; Inflammation; Interleukin-4; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 8; NF-kappa B; Proteasome Inhibitors; Pyrazines; Random Allocation; Scleroderma, Localized; Skin; Transforming Growth Factor beta1 | 2012 |
Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A.
Topics: Actinobacteria; Biological Products; Boronic Acids; Bortezomib; Drug Resistance, Bacterial; Humans; Lactones; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Pyrroles; Substrate Specificity | 2011 |
Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney Failure, Chronic; Male; Middle Aged; Multiple Myeloma; Prognosis; Proteinuria; Pyrazines; Remission Induction | 2012 |
Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease.
Topics: Adult; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Castleman Disease; Drug Therapy, Combination; Humans; Male; POEMS Syndrome; Pyrazines; Thalidomide; Vascular Endothelial Growth Factor A | 2011 |
Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Computer Simulation; Cost-Benefit Analysis; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Models, Economic; Multiple Myeloma; Norway; Pyrazines; Quality of Life; Quality-Adjusted Life Years; Thalidomide | 2011 |
Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
Topics: Acetylation; Acetyltransferases; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Drug Synergism; Drug Therapy, Combination; Flow Cytometry; Fluorine Radioisotopes; Histones; Humans; Hydroxamic Acids; Kidney Neoplasms; Mice; Pyrazines; Tumor Cells, Cultured; Ubiquitination; Vorinostat | 2012 |
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
Topics: Animals; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Glycine; Humans; Lymphoma, B-Cell; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Neoplasms, Plasma Cell; Osteolysis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2011 |
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.
Topics: Animals; Antibody-Producing Cells; Autoantibodies; Boronic Acids; Bortezomib; Disease Progression; Humans; Interferon Type I; Leukocytes, Mononuclear; Lupus Erythematosus, Systemic; Lupus Nephritis; Mice; Oligopeptides; Protease Inhibitors; Pyrazines | 2012 |
The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclophosphamide; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Protease Inhibitors; Pyrazines; Receptors, Neuropeptide; RNA, Messenger; RNA, Small Interfering; Survival Analysis; Treatment Outcome; Unfolded Protein Response; Vincristine; Young Adult | 2011 |
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.
Topics: Animals; Boronic Acids; Bortezomib; Brain; Brain Neoplasms; Cell Proliferation; Centrosome; Drug Screening Assays, Antitumor; Ependymoma; Fluorouracil; High-Throughput Screening Assays; Insulin; Mice; Mice, Nude; Neural Stem Cells; Pyrazines; Signal Transduction; Tumor Cells, Cultured | 2011 |
[Pneumonia and Rothia dentocariosa].
Topics: Actinomycetales Infections; Amoxicillin; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Immunocompromised Host; Melphalan; Micrococcaceae; Middle Aged; Multiple Myeloma; Pneumonia, Bacterial; Pyrazines | 2011 |
Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mitogen-Activated Protein Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases; Transcription, Genetic | 2012 |
Methylseleninic acid antagonizes the cytotoxic effect of bortezomib in mantle cell lymphoma cell lines through modulation of Bcl-2 family proteins.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Interactions; Female; Humans; Lymphoma, Mantle-Cell; Male; Organoselenium Compounds; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2012 |
Myeloma cast nephropathy: a rare cause of primary renal allograft dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Graft Survival; Humans; Kidney Diseases; Kidney Transplantation; Multiple Myeloma; Plasmapheresis; Pyrazines; Remission Induction | 2011 |
Managing light chain deposition disease.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney Failure, Chronic; Male; Multiple Myeloma; Pyrazines | 2012 |
[POEMS syndrome. An interdisciplinary clinical challenge].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Cooperative Behavior; Dexamethasone; Drug Therapy, Combination; Humans; Immunoglobulin lambda-Chains; Interdisciplinary Communication; Male; Middle Aged; Paraproteinemias; POEMS Syndrome; Pyrazines; Vascular Endothelial Growth Factor A | 2011 |
Renal improvement in myeloma with plasma exchange.
Topics: Acute Kidney Injury; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Multiple Myeloma; Plasma Exchange; Pyrazines | 2011 |
Renal improvement in myeloma with plasma exchange.
Topics: Acute Kidney Injury; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Immunoglobulin Light Chains; Multiple Myeloma; Plasma Exchange; Pyrazines | 2011 |
Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.
Topics: Adult; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; BRCA1 Protein; Cell Line, Tumor; Cells, Cultured; DNA Repair; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Multiple Myeloma; Poly(ADP-ribose) Polymerase Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rad51 Recombinase; RNA, Messenger; Survival Analysis; Xenograft Model Antitumor Assays | 2011 |
Sudden significant total protein concentration change: not an analytical problem.
Topics: Aged; Antineoplastic Agents; Blood Proteins; Boronic Acids; Bortezomib; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Serum Albumin; Serum Globulins; Thalidomide | 2011 |
Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Proteasome Endopeptidase Complex; Pyrazines; Thalidomide; Up-Regulation | 2011 |
A third-generation IMiD for MM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Proteasomal inhibition after injury prevents fibrosis by modulating TGF-β(1) signalling.
Topics: Animals; Autocrine Communication; Bleomycin; Boronic Acids; Bortezomib; Cells, Cultured; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Fibroblasts; Fibrosis; Gene Expression Regulation; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; PPAR gamma; Proteasome Inhibitors; Pulmonary Fibrosis; Pyrazines; Scleroderma, Systemic; Signal Transduction; Skin; Transforming Growth Factor beta1 | 2012 |
An autophagy inhibitor enhances the inhibition of cell proliferation induced by a proteasome inhibitor in MCF-7 cells.
Topics: Adenine; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Green Fluorescent Proteins; Humans; Microtubule-Associated Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Recombinant Fusion Proteins | 2012 |
Radioresistance of prostate cancer cells with low proteasome activity.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Male; Mice; Mice, Nude; Phenotype; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Radiation Tolerance; Radiotherapy; Treatment Failure | 2012 |
FoxM1 knockdown sensitizes human cancer cells to proteasome inhibitor-induced apoptosis but not to autophagy.
Topics: Apoptosis; Autophagy; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Forkhead Box Protein M1; Forkhead Transcription Factors; Humans; Leupeptins; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering; Thiostrepton | 2011 |
Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Topics: Amino Acid Substitution; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Mutation; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2012 |
Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Immunohistochemistry; Mice; Multiple Myeloma; Pyrazines; Random Allocation; Xenograft Model Antitumor Assays | 2011 |
Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Failure; Humans; Multiple Myeloma; Pyrazines | 2012 |
Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplastic Cells, Circulating; Plasma Cells; Prognosis; Prospective Studies; Pyrazines; Recurrence; Survival Analysis; Time Factors; Treatment Outcome | 2012 |
Knockdown of ubiquitin ligases in glioblastoma cancer stem cells leads to cell death and differentiation.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Gene Knockdown Techniques; Glioblastoma; Humans; Neoplastic Stem Cells; Nocodazole; Pyrazines; RNA Interference; RNA, Small Interfering; Signal Transduction; Ubiquitin-Protein Ligases | 2012 |
Therapeutic potential of the proteasome inhibitor Bortezomib on titanium particle-induced inflammation in a murine model.
Topics: Animals; Boronic Acids; Bortezomib; Female; I-kappa B Kinase; Inflammation; Inflammation Mediators; Joint Prosthesis; Mice; Mice, Inbred BALB C; NF-kappa B; Osteolysis; Prosthesis Failure; Proteasome Inhibitors; Pyrazines; Random Allocation; Titanium; Tumor Necrosis Factor-alpha | 2012 |
Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma.
Topics: Amyloid Precursor Protein Secretases; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Flow Cytometry; Humans; Multiple Myeloma; Pyrazines; Real-Time Polymerase Chain Reaction | 2011 |
Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Drug Resistance, Neoplasm; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Multiple Myeloma; Polyploidy; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2012 |
Differential action of 3-hydroxyanthranilic acid on viability and activation of stimulated lymphocytes.
Topics: 3-Hydroxyanthranilic Acid; Boronic Acids; Bortezomib; Cell Survival; Cells, Cultured; Humans; Lymphocyte Activation; Lymphocytes; Manganese; Pyrazines | 2011 |
NICE guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Drug Costs; Evidence-Based Medicine; Humans; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Quality-Adjusted Life Years; State Medicine; Thalidomide; Treatment Outcome; United Kingdom | 2011 |
Different effects of bortezomib on the expressions of various protein kinase C isoenzymes in T cells of patients with systemic lupus erythematosus and in Jurkat cells.
Topics: Adult; Apoptosis; Boronic Acids; Bortezomib; Case-Control Studies; Cell Proliferation; Dose-Response Relationship, Drug; Female; Gene Expression; Humans; Isoenzymes; Jurkat Cells; Lupus Erythematosus, Systemic; Male; Middle Aged; Organ Specificity; Primary Cell Culture; Proteasome Inhibitors; Protein Kinase C; Protein Kinase C-delta; Protein Kinase C-epsilon; Protein Kinase C-theta; Pyrazines; T-Lymphocytes | 2012 |
Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation.
Topics: Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Enzyme Activation; Head and Neck Neoplasms; Humans; JNK Mitogen-Activated Protein Kinases; Phosphorylation; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Squamous Cell Carcinoma of Head and Neck | 2012 |
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
Topics: Activating Transcription Factor 6; Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; HEK293 Cells; HeLa Cells; Humans; Immunoglobulins; Jurkat Cells; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Regulatory Factor X Transcription Factors; RNA Splicing; RNA, Messenger; Transcription Factors; Treatment Outcome; Unfolded Protein Response; X-Box Binding Protein 1 | 2012 |
Acquired STAT4 deficiency as a consequence of cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Carmustine; Cells, Cultured; Drug Interactions; Etoposide; Flow Cytometry; Gene Expression; Humans; Interleukin-12; Interleukin-2; Leukocytes, Mononuclear; Lymphoma; Melanoma; Mice; Mice, Inbred C57BL; Protein Biosynthesis; Pyrazines; RNA Stability; Skin Neoplasms; STAT4 Transcription Factor; Ubiquitin | 2011 |
Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; In Vitro Techniques; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; Male; Mice; Mice, Inbred NOD; Mice, SCID; Pyrazines; Spiro Compounds; Survival Rate | 2012 |
Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia.
Topics: Adult; Antigens, CD; Antineoplastic Agents; Benzamides; Blast Crisis; Boronic Acids; Bortezomib; Cadherins; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrazines; Pyrimidines; RNA Interference; S-Phase Kinase-Associated Proteins; Young Adult | 2012 |
Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cells, Cultured; Endoplasmic Reticulum Stress; Humans; Mice; Multiple Myeloma; Neoplasm Transplantation; Oncolytic Virotherapy; Orthoreovirus, Mammalian; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transplantation, Heterologous | 2012 |
Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Female; Immunohistochemistry; Mice; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Pyrazines; Risk Factors | 2011 |
Changes in the ratio of free NEDD8 to ubiquitin triggers NEDDylation by ubiquitin enzymes.
Topics: Animals; Boronic Acids; Bortezomib; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Enzyme Inhibitors; HEK293 Cells; HeLa Cells; Humans; NEDD8 Protein; Pyrazines; Transfection; Ubiquitin; Ubiquitin-Protein Ligases; Ubiquitination; Ubiquitins | 2012 |
Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.
Topics: Adenocarcinoma, Follicular; Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Papillary; Caspase 3; Cell Cycle Checkpoints; Cell Proliferation; Flow Cytometry; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thyroid Neoplasms; Tumor Cells, Cultured | 2012 |
Involvement of mitogen-activated protein kinase in signal transducer and activator of transcription-1 mediated differentiation induced by bortezomib in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; Enzyme Inhibitors; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Phosphorylation; Pyrazines; STAT1 Transcription Factor; Tumor Cells, Cultured | 2013 |
Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Synergism; Humans; Immunoblotting; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2012 |
Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.
Topics: Adolescent; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line; Cell Survival; Child; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Killer Cells, Natural; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Pyrazines; T-Lymphocytes; Valproic Acid | 2012 |
Molecular pathways: targeting proteasomal protein degradation in cancer.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Signal Transduction; Ubiquitin | 2012 |
AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors.
Topics: Acute Disease; Animals; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Transformation, Neoplastic; Core Binding Factor Alpha 2 Subunit; Cytoplasm; Female; Gene Expression Regulation, Leukemic; HEK293 Cells; Humans; I-kappa B Kinase; Leukemia, Myeloid; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mutation; NF-kappa B; Protein Binding; Pyrazines; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.
Topics: Antigens, CD19; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Leukocyte Common Antigens; Lymphoma, Mantle-Cell; Neoplastic Stem Cells; NF-kappa B; Pyrazines | 2012 |
Scleromyxedema and dermato–neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Scleromyxedema | 2011 |
Proteasome inhibitors improve the function of mutant lysosomal α-glucosidase in fibroblasts from Pompe disease patient carrying c.546G>T mutation.
Topics: alpha-Glucosidases; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Enzyme Stability; Fibroblasts; Glycogen Storage Disease Type II; Humans; Leupeptins; Mutation; Proteasome Inhibitors; Protein Transport; Pyrazines | 2011 |
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
Topics: Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Proteasome Endopeptidase Complex; Protein Binding; Pyrazines | 2012 |
Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Monitoring; Drugs, Investigational; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin M; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm, Residual; Prognosis; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Thalidomide | 2012 |
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine | 2012 |
[Effect of proteasome inhibitor on migration ability and hepatocyte growth factor expression of bone marrow mesenchymal stem cells in multiple myeloma patients].
Topics: Adult; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Movement; Female; Hepatocyte Growth Factor; Humans; Male; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Pyrazines | 2011 |
[Bortezomib combined with autologous peripheral blood hematopoietic stem cell transplantation for therapy of patients with multiple myeloma].
Topics: Adult; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Transplantation Conditioning | 2011 |
Successful treatment of immunoglobulin D myeloma by bortezomib and dexamethasone therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin D; Multiple Myeloma; Pyrazines; Treatment Outcome | 2011 |
Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Embryo, Nonmammalian; Flow Cytometry; Humans; Multiple Myeloma; Neoplasm Transplantation; Pyrazines; Real-Time Polymerase Chain Reaction; Turkeys; Xenograft Model Antitumor Assays | 2011 |
Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; CDC2-CDC28 Kinases; Cell Nucleus; Chromosomes, Human, Pair 1; Disease-Free Survival; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Pyrazines | 2012 |
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Morphogenetic Proteins; Bone Remodeling; Boronic Acids; Bortezomib; Female; Genetic Markers; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2012 |
Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cluster Analysis; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Microarray Analysis; Multicenter Studies as Topic; Multiple Myeloma; Prognosis; Pyrazines; Recurrence; Treatment Failure; Up-Regulation | 2012 |
Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Breast Neoplasms; Carboxypeptidases; Cell Line, Tumor; Disease Models, Animal; Female; Gene Expression Regulation, Enzymologic; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Microarray Analysis; Multiple Myeloma; Piperidones; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Suppressor Protein p53; Ubiquitin; Ubiquitin Thiolesterase; Ubiquitination | 2011 |
Fluorescence-based proteasome activity profiling.
Topics: Animals; Biochemistry; Biological Assay; Boron Compounds; Boronic Acids; Bortezomib; Cell Line; Cell Survival; Chromatography, Reverse-Phase; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Fluorescent Dyes; Humans; Mice; Proteasome Endopeptidase Complex; Protein Subunits; Pyrazines; Spectrometry, Fluorescence; Staining and Labeling | 2012 |
Proteasome inhibitors suppress expression of NPM and ARF proteins.
Topics: ADP-Ribosylation Factors; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression; HeLa Cells; Humans; Leupeptins; Nuclear Proteins; Nucleophosmin; Proteasome Inhibitors; Pyrazines; RNA, Messenger; Thiostrepton | 2011 |
Influence of proteasome inhibitor bortezomib on the expression of multidrug resistance genes and Akt kinase activity.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Enzyme Inhibitors; Gene Expression; Humans; Multidrug Resistance-Associated Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Y-Box-Binding Protein 1 | 2011 |
Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A.
Topics: Animals; Apoptosis; Autoantigens; Boronic Acids; Bortezomib; Cell Line, Tumor; Chemoradiotherapy; Dose-Response Relationship, Drug; Down-Regulation; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Mice, Nude; Neoplasms, Experimental; Pyrazines; Radiation-Sensitizing Agents; RNA Interference; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Central Nervous System Neoplasms; Cytochromes c; DNA Damage; Glioblastoma; Glioma; Histones; Humans; Hydroxamic Acids; Membrane Potential, Mitochondrial; Membrane Proteins; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Tumor Cells, Cultured; Vorinostat | 2013 |
The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mice; Neuroblastoma; Protease Inhibitors; Pyrazines; Rats; Tretinoin; Xenograft Model Antitumor Assays | 2011 |
Varicella-zoster virus prophylaxis with the traditional Chinese medicine Radix isatidis (Banlangen) in patients with multiple myeloma treated with bortezomib.
Topics: Adult; Aged; Antibiotic Prophylaxis; Boronic Acids; Bortezomib; Drugs, Chinese Herbal; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Isatis; Male; Middle Aged; Multiple Myeloma; Phytotherapy; Plant Roots; Pyrazines | 2011 |
Amyloidosis.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Delayed Diagnosis; Dexamethasone; Dyspnea; Heart Diseases; Humans; Kidney; Kidney Diseases; Male; Narration; Pyrazines; Quality of Life; Serum Amyloid A Protein; Thalidomide | 2011 |
Intramural delivery of bortezomib inhibits restenosis following arterial injury.
Topics: Animals; Boronic Acids; Bortezomib; Constriction, Pathologic; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Iliac Artery; Immunoenzyme Techniques; Male; Muscle, Smooth, Vascular; Neointima; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Rabbits | 2011 |
Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231 breast cancer cell migration.
Topics: Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Female; Humans; Protease Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Up-Regulation | 2012 |
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2012 |
Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Proliferation; G2 Phase; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Proteins; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering | 2011 |
Antitumor effect of non-steroid glucocorticoid receptor ligand CpdA on leukemia cell lines CEM and K562.
Topics: Acetates; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytostatic Agents; Fluocinolone Acetonide; Humans; K562 Cells; Leukemia; Ligands; NF-kappa B; Pyrazines; Receptors, Glucocorticoid; Tacrolimus Binding Proteins; Transcription Factor AP-1; Tyramine | 2011 |
p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Glioma; Humans; Leupeptins; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Up-Regulation | 2011 |
Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition.
Topics: Activating Transcription Factor 4; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Chromatin Immunoprecipitation; DNA-Binding Proteins; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Real-Time Polymerase Chain Reaction; Regulatory Factor X Transcription Factors; RNA Splicing; RNA, Messenger; RNA, Small Interfering; Transcription Factors; Transcription, Genetic; Unfolded Protein Response | 2012 |
The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line, Tumor; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrazines; Reactive Oxygen Species; Sialic Acid Binding Ig-like Lectin 2; Xenograft Model Antitumor Assays | 2011 |
Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Indoles; Kruppel-Like Transcription Factors; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Panobinostat; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription Factors | 2012 |
Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; G2 Phase Cell Cycle Checkpoints; Humans; K562 Cells; Leukemia; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2012 |
[Renal tolerance of targeted therapies].
Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2012 |
Inhibition of intraerythrocytic proteasome retards the generation of hemorphins.
Topics: Boronic Acids; Bortezomib; Cells, Cultured; Dose-Response Relationship, Drug; Erythrocytes; Hemoglobins; Humans; Peptide Fragments; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2012 |
What is the benefit of maintenance therapy with lenalidomide or bortezomib after autologous stem cell transplantation in multiple myeloma and what is the risk of developing a secondary primary malignancy?
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Risk Factors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2011 |
From the observation DAC: romidepsin revisited.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Depsipeptides; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Multiple Myeloma; Pyrazines | 2011 |
Innovation in myeloma treatments PARP excellence!
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Enzyme Inhibitors; Humans; Multiple Myeloma; Poly(ADP-ribose) Polymerase Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2011 |
Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Drug Synergism; Female; Flow Cytometry; Humans; Indoles; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Pyrazines; Real-Time Polymerase Chain Reaction; Xenograft Model Antitumor Assays | 2012 |
[Effect of BAFF/APRIL mRNA expression induced by glucocorticoid and bortezomib in multiple myeloma cells in vitro].
Topics: B-Cell Activating Factor; Boronic Acids; Bortezomib; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glucocorticoids; Humans; Multiple Myeloma; Pyrazines; RNA, Messenger; Tumor Necrosis Factor Ligand Superfamily Member 13 | 2011 |
[Mechanism associated to enhancing the sensitivity of myeloma cells U266 to bortezomib by 2-methoxyestradiol].
Topics: 2-Methoxyestradiol; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Estradiol; Humans; Pyrazines | 2011 |
Drugs: More shots on target.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine | 2011 |
Orthopaedics: Structural support.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Boronic Acids; Bortezomib; Diphosphonates; Etidronic Acid; Humans; Intercellular Signaling Peptides and Proteins; Kyphoplasty; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteogenesis; Proteasome Inhibitors; Pyrazines | 2011 |
Hyponatremia is not a rare adverse event in bortezomib-treated patients.
Topics: Aged; Boronic Acids; Bortezomib; Humans; Hyponatremia; Male; Pyrazines; Treatment Outcome | 2011 |
Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.
Topics: Adolescent; Adult; Boronic Acids; Bortezomib; Child; Graft Rejection; Heart Transplantation; HLA Antigens; Humans; Infant; Isoantibodies; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Tissue Donors | 2012 |
The proteasome as a target for prevention of restenosis following vascular injury.
Topics: Animals; Boronic Acids; Bortezomib; Iliac Artery; Male; Neointima; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2011 |
Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Neuroblastoma; Peptides, Cyclic; Proteasome Inhibitors; Pyrazines; Urea | 2012 |
Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Clarithromycin; Cytotoxicity, Immunologic; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Female; Gene Expression; Humans; Pyrazines; Transcription Factor CHOP | 2012 |
Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
Topics: Boronic Acids; Bortezomib; Female; Graft Rejection; HLA Antigens; Humans; Isoantibodies; Lung Transplantation; Middle Aged; Protease Inhibitors; Pyrazines; Tissue Donors; Treatment Outcome | 2012 |
The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
Topics: Acetylation; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Synergism; Histone Deacetylase Inhibitors; Histones; Humans; Multiple Myeloma; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Signal Transduction; Sulfonamides; Tumor Cells, Cultured | 2012 |
Long-term bortezomib treatment reduces allergen-specific IgE but fails to ameliorate chronic asthma in mice.
Topics: Allergens; Animals; Anti-Asthmatic Agents; Asthma; Boronic Acids; Bortezomib; Chronic Disease; Disease Models, Animal; Eosinophils; Female; Immunoglobulin E; Immunoglobulin G; Lung; Mice; Mice, Inbred BALB C; Plasma Cells; Pyrazines; Treatment Failure | 2012 |
Molecular mechanisms of bortezomib resistant adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Humans; Pyrazines | 2011 |
Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Androgen Receptor Antagonists; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Stability; Pyrazines; Receptors, Androgen; Receptors, Glucocorticoid; Transcription Factor CHOP; Transcriptional Activation; Tyramine | 2012 |
The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Administration Schedule; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Jurkat Cells; Lymphoma, Mantle-Cell; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2012 |
[Lung injury associated with bortezomib therapy in Japan].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Product Surveillance, Postmarketing; Pyrazines | 2011 |
Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody.
Topics: Adult; Aged; Antibodies; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Cohort Studies; Female; Graft Rejection; Heart Transplantation; HLA Antigens; Humans; Immunoglobulins, Intravenous; Incidence; Kaplan-Meier Estimate; Lymph Nodes; Male; Middle Aged; Pyrazines; Retrospective Studies; Rituximab; Survival Rate; Time Factors; Tissue Donors; Treatment Outcome | 2012 |
Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Gene Expression Profiling; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; NEDD8 Protein; Pyrazines; Treatment Outcome; Ubiquitin-Activating Enzymes; Ubiquitination; Ubiquitins; Xenograft Model Antitumor Assays | 2012 |
Durability of antibody removal following proteasome inhibitor-based therapy.
Topics: Adult; Boronic Acids; Bortezomib; Calcineurin Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Prognosis; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Tissue Donors; Transplantation, Homologous | 2012 |
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Endoplasmic Reticulum Stress; Fluorescent Antibody Technique; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Male; Mice; Mice, SCID; Plasmacytoma; Pyrazines; Pyrimidines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Microscale functional cytomics for studying hematologic cancers.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cells, Cultured; Cellular Microenvironment; Coculture Techniques; Dose-Response Relationship, Drug; Hematologic Neoplasms; Humans; Immunohistochemistry; Multiple Myeloma; NF-kappa B; Pyrazines; STAT3 Transcription Factor; Stromal Cells; Tumor Necrosis Factor-alpha | 2012 |
Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Pancreatic Ductal; Caspase 12; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Endoplasmic Reticulum; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Mitochondria; Mucins; NF-kappa B; Pancreatic Neoplasms; Polymerase Chain Reaction; Protease Inhibitors; Pyrazines; Regulatory Factor X Transcription Factors; RNA Interference; Time Factors; Transcription Factor CHOP; Transcription Factors; Transfection; Unfolded Protein Response; X-Box Binding Protein 1 | 2012 |
Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Remission Induction; Retrospective Studies; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vincristine | 2012 |
Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression; Humans; Immunohistochemistry; Ki-67 Antigen; Lymphoma, Large B-Cell, Diffuse; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Molecular Targeted Therapy; Primary Cell Culture; Proliferating Cell Nuclear Antigen; Pyrazines; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Signal Transduction; Thiostrepton; Tumor Stem Cell Assay | 2012 |
The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Dose-Response Relationship, Drug; Drug Synergism; Genes, Reporter; Histone Deacetylase Inhibitors; HIV Protease Inhibitors; Humans; Luciferases; Mice; Multiple Myeloma; Nelfinavir; Plasma Cells; Proteasome Endopeptidase Complex; Pyrazines; Xenograft Model Antitumor Assays | 2012 |
Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
Topics: Acute Kidney Injury; Aged; Boronic Acids; Bortezomib; Combined Modality Therapy; Databases, Factual; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Dialysis; Thalidomide | 2012 |
[Unusual skin alterations in a 72-year-old patient with multiple myeloma].
Topics: Aged; Amyloidosis; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Female; Humans; Multiple Myeloma; Pyrazines; Skin Diseases; Treatment Outcome | 2012 |
[Modern times: back to past, back to future].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multiple Myeloma; Pyrazines; Rituximab; Vidarabine | 2012 |
The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture.
Topics: Animals; Boronic Acids; Bortezomib; Collagen Type IV; Disease Models, Animal; Female; Humans; Immunohistochemistry; Injections, Intravenous; Kidney Glomerulus; Kidney Tubules; Lupus Nephritis; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Microscopy, Electron; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Survival Rate; Time Factors; Treatment Outcome | 2012 |
Ischemia-reperfusion injury in rat steatotic liver is dependent on NFκB P65 activation.
Topics: Animals; Boronic Acids; Bortezomib; Chemokine CXCL2; Disease Models, Animal; Fatty Liver; Humans; Inflammation Mediators; Interleukin-1beta; Liver; Proteasome Inhibitors; Pyrazines; Rats; Rats, Zucker; Reperfusion Injury; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2012 |
HHV-8-associated multicentric Castleman's disease in HIV-negative patient: a novel therapy for an orphan disease.
Topics: Adult; Boronic Acids; Bortezomib; Castleman Disease; Ganciclovir; Herpesviridae Infections; Herpesvirus 8, Human; HIV; Humans; Male; Pyrazines; Rare Diseases | 2012 |
Opposing effects of bortezomib-induced nuclear factor-κB inhibition on chemical lung carcinogenesis.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; NF-kappa B; Pyrazines | 2012 |
Incorporating monoclonal antibodies into the therapy of multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Multiple Myeloma; Pyrazines | 2012 |
Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Calcium; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; GTP-Binding Proteins; Humans; Immunoenzyme Techniques; Lymphoma, Mantle-Cell; Mice; Mice, Inbred NOD; Mice, SCID; Monoterpenes; NF-kappa B; Perilla; Protein Glutamine gamma Glutamyltransferase 2; Pyrazines; Transglutaminases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fatal Outcome; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Neoplasms, Second Primary; Pyrazines; Recurrence; Remission Induction; Thalidomide | 2012 |
Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Endoplasmic Reticulum; Histones; HIV Protease Inhibitors; Mice; Mice, Nude; Pyrazines; Ritonavir; Ubiquitinated Proteins; Ubiquitination; Xenograft Model Antitumor Assays | 2012 |
Bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Humans; Multiple Myeloma; Nursing Assessment; Oncology Nursing; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Severity of Illness Index | 2012 |
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2012 |
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Growth Differentiation Factor 15; Humans; Lenalidomide; Male; Melphalan; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Signal Transduction; Thalidomide | 2012 |
Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Humans; Leukemia; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-kit; Pyrazines; Translocation, Genetic | 2012 |
Abrogation of antibodies improves outcome of renal transplantation.
Topics: Adult; Biomarkers; Biopsy; Blood Transfusion; Boronic Acids; Bortezomib; Clonal Deletion; Creatinine; Female; Graft Rejection; Graft Survival; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Immunization; Immunosuppression Therapy; Immunosuppressive Agents; India; Isoantibodies; Kidney Transplantation; Living Donors; Lymphatic Irradiation; Male; Mesenchymal Stem Cell Transplantation; Pyrazines; T-Lymphocytes; Time Factors; Treatment Outcome; Young Adult | 2012 |
Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-Associated Death Protein; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; Cerebellar Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cytochromes c; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Medulloblastoma; NF-kappa B; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Sorafenib; Tumor Cells, Cultured | 2012 |
A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide | 2012 |
Multiple myeloma presenting with hepatosplenomegaly.
Topics: Abdomen; Adult; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Fatal Outcome; Female; Hepatomegaly; Humans; Multiple Myeloma; Pyrazines; Splenomegaly; Tomography, X-Ray Computed; Ultrasonography | 2011 |
Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells.
Topics: Acetylcysteine; Alleles; Amino Acid Substitution; Antineoplastic Agents; Boronic Acids; Bortezomib; Cells, Cultured; Cysteine Proteinase Inhibitors; Distal Myopathies; Dysferlin; Humans; Membrane Proteins; Muscle Fibers, Skeletal; Muscle Proteins; Muscular Atrophy; Muscular Dystrophies, Limb-Girdle; Mutation, Missense; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; RNA, Messenger | 2012 |
Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Comparative Genomic Hybridization; Female; Fibrosarcoma; Gene Amplification; Gene Dosage; Guanine Nucleotide Exchange Factors; Humans; Male; Mice; Mice, SCID; Middle Aged; Prognosis; Protein Serine-Threonine Kinases; Pyrazines; Racemases and Epimerases; RNA, Messenger; S-Phase Kinase-Associated Proteins; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; Bombesin; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Endothelin-1; Humans; Interleukin-8; Male; Mitogen-Activated Protein Kinases; NF-kappa B; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; RNA, Messenger; Signal Transduction; Translocation, Genetic; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2012 |
Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.
Topics: Boronic Acids; Bortezomib; Epitopes; Female; Follow-Up Studies; Graft Rejection; HLA Antigens; Humans; Immunity, Humoral; Immunization; Immunoglobulin G; Kidney Transplantation; Lymphocyte Activation; Male; Plasma Cells; Proteasome Inhibitors; Pyrazines; Reoperation; Transplantation Conditioning | 2012 |
Synergistic effects of combination treatment with bortezomib and doxorubicin in human neuroblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Humans; Neuroblastoma; Pyrazines | 2012 |
Using transcriptome sequencing to identify mechanisms of drug action and resistance.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrazines; Sequence Analysis, DNA; Transcriptome | 2012 |
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.
Topics: Amyloid; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clonal Evolution; Cohort Studies; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome | 2012 |
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.
Topics: Amyloid; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Cytogenetic Analysis; Dexamethasone; Humans; Kidney; Pyrazines; Remission Induction; Retrospective Studies; Survival Analysis; Time Factors | 2012 |
[Effect of omega-3 fish oil fat emulsion on the peripheral neuropathy caused by bortezomib].
Topics: Boronic Acids; Bortezomib; Fatty Acids, Omega-3; Fish Oils; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Pyrazines | 2011 |
[Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; HL-60 Cells; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid; Panobinostat; Pyrazines; Signal Transduction | 2011 |
Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Inhibitory Concentration 50; Multiple Myeloma; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor Protein-Tyrosine Kinases; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
[Clinical analysis of bortezomib combined with chemotherapy for one case of refractory acute lymphocytic leukemia].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Treatment Outcome | 2011 |
[Autologous hematopoietic stem cell transplantation following bortezomib-based chemotherapy for one case with POEMS syndrome].
Topics: Adult; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; POEMS Syndrome; Pyrazines | 2011 |
[Comparative plasma proteomic analysis of patients with multiple myeloma treated with bortezomib-based regimens].
Topics: Aged; Antineoplastic Agents; Biomarkers; Blood Proteins; Boronic Acids; Bortezomib; Electrophoresis, Gel, Two-Dimensional; Female; Humans; Male; Mass Spectrometry; Multiple Myeloma; Proteomics; Pyrazines | 2012 |
Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Lactones; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Saccharomyces cerevisiae; Threonine | 2012 |
Timing of the high-dose therapy in the area of new drugs.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Melphalan; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2011 |
Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Female; Humans; Male; Mice; Mice, Nude; Nanocapsules; Proteasome Endopeptidase Complex; Pyrazines; Random Allocation; Thiostrepton; Tissue Distribution; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Dephosphorylation-induced ubiquitination and degradation of FMRP in dendrites: a role in immediate early mGluR-stimulated translation.
Topics: Analysis of Variance; Animals; Boronic Acids; Bortezomib; Cells, Cultured; Dendrites; Disks Large Homolog 4 Protein; Drosophila Proteins; Embryo, Mammalian; Enzyme Inhibitors; Female; Fragile X Mental Retardation Protein; Gene Expression Regulation; Green Fluorescent Proteins; Hippocampus; Immunoprecipitation; Intracellular Signaling Peptides and Proteins; Leupeptins; Male; Membrane Proteins; Methoxyhydroxyphenylglycol; Mutation; Neurons; Okadaic Acid; Phosphoprotein Phosphatases; Phosphorylation; Protein Biosynthesis; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; RNA, Messenger; Serine; Signal Transduction; Synapses; Transfection; Ubiquitination | 2012 |
Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC).
Topics: Animals; Body Weight; Boronic Acids; Bortezomib; Disease Models, Animal; Humans; Immunoblotting; Immunohistochemistry; Kidney Diseases, Cystic; Kidney Neoplasms; Metformin; Mice; Pyrazines; Treatment Outcome; Tuberous Sclerosis | 2012 |
[Successful treatment with bortezomib for a patient with plasma cell leukemia accompanied by severe hyperbilirubinemia].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Hyperbilirubinemia; Leukemia, Plasma Cell; Prednisolone; Pyrazines; Severity of Illness Index; Treatment Outcome | 2012 |
Renal Fanconi syndrome as a cause of chronic kidney disease in patients with monoclonal gammopathy of undetermined significance: partially reversed renal function by high-dose dexamethasone with bortezomib.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fanconi Syndrome; Humans; Kidney; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Pyrazines; Renal Insufficiency, Chronic; Treatment Outcome | 2012 |
Effects of arsenic trioxide combined with bortezomib on apoptosis of multiple myeloma cell line KM3 and its mechanisms.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Bcl-2-Like Protein 11; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Humans; Membrane Proteins; Multiple Myeloma; Oxides; Proto-Oncogene Proteins; Pyrazines | 2012 |
Protection against titanium particle-induced inflammatory osteolysis by the proteasome inhibitor bortezomib in vivo.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Apoptosis; Arthroplasty, Replacement; Boronic Acids; Bortezomib; Female; Inflammation; Mice; Mice, Inbred BALB C; Osteolysis; Osteoprotegerin; Prosthesis Failure; Proteasome Inhibitors; Pyrazines; Random Allocation; RANK Ligand; Titanium; TNF Receptor-Associated Factor 6; Vascular Endothelial Growth Factors | 2012 |
ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
Topics: Annexins; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; BH3 Interacting Domain Death Agonist Protein; Biphenyl Compounds; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Glioma; Humans; Mitochondrial Diseases; NF-kappa B; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-akt; Pyrazines; Sulfonamides | 2012 |
Diltiazem enhances the apoptotic effects of proteasome inhibitors to induce prostate cancer cell death.
Topics: Acetylcysteine; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Calcium; Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Humans; Male; Prostatic Neoplasms; Protease Inhibitors; Pyrazines; Transfection; Tumor Cells, Cultured | 2012 |
Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Flow Cytometry; Gene Expression; Humans; I-kappa B Proteins; Lymphoma; Mitochondria; NF-kappa B; NF-KappaB Inhibitor alpha; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin | 2012 |
HSPA2 overexpression protects V79 fibroblasts against bortezomib-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line; Cell Survival; Cold-Shock Response; Cricetinae; Cysteine Proteinase Inhibitors; Fibroblasts; Gene Expression; HSP70 Heat-Shock Proteins; Humans; Leupeptins; Pyrazines; Recombinant Proteins; Stress, Physiological | 2012 |
The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare disease with new clinical insights.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Pyrazines; Scleromyxedema | 2012 |
Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Enzyme Activation; HeLa Cells; Humans; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand | 2012 |
Bortezomib is effective to treat acute humoral rejection after liver transplantation.
Topics: Acute Disease; Aged; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Graft Rejection; Graft Survival; Humans; Immunity, Humoral; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Plasmapheresis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pulse Therapy, Drug; Pyrazines; Retrospective Studies; Rituximab; Steroids; Taiwan; Time Factors; Treatment Outcome | 2012 |
Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Calreticulin; Cell Line; Dendritic Cells; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Kinetics; Low Density Lipoprotein Receptor-Related Protein-1; Lymphoma, Primary Effusion; Phagocytosis; Protein Transport; Pyrazines; Tyrphostins | 2012 |
Low-dose cyclosporine mediates donor hyporesponsiveness in a fully mismatched rat kidney transplant model.
Topics: Adoptive Transfer; Animals; Antibodies; Boronic Acids; Bortezomib; Cyclosporine; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Kidney Transplantation; Proteasome Inhibitors; Pyrazines; Rats; T-Lymphocytes; T-Lymphocytes, Regulatory; Tissue Donors; Transplantation Conditioning | 2012 |
Successful use of cyclophosphamide, bortezomib, and dexamethasone to treat a case of relapsed POEMS.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Male; Paraneoplastic Syndromes; POEMS Syndrome; Pyrazines; Recurrence | 2012 |
In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells.
Topics: Adipose Tissue; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Proliferation; Chemotaxis; Coculture Techniques; Culture Media, Conditioned; Gene Expression; Humans; Mesenchymal Stem Cells; Multiple Myeloma; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand | 2012 |
Regulatory mechanism of transforming growth factor beta receptor type II degradation by interleukin-1 in primary chondrocytes.
Topics: Aged; Aged, 80 and over; Biological Transport; Boronic Acids; Bortezomib; Caveolae; Caveolin 1; Cells, Cultured; Chondrocytes; Humans; Interleukin-1beta; Lysosomes; Middle Aged; Nystatin; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Proteolysis; Pyrazines; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta | 2012 |
Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 13; Dexamethasone; Female; Humans; Male; Metaphase; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome | 2012 |
Inhibition of titanium particle-induced inflammation by the proteasome inhibitor bortezomib in murine macrophage-like RAW 264.7 cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Boronic Acids; Bortezomib; Cell Line; Cell Survival; Chemokine CCL2; Cyclooxygenase 2; Inflammation; Interleukin-10; Interleukin-1beta; Interleukin-6; Macrophage Inflammatory Proteins; Macrophages; Mice; Nitric Oxide Synthase Type II; Proteasome Inhibitors; Pyrazines; Titanium; Tumor Necrosis Factor-alpha | 2012 |
Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Middle Aged; Neoplasms, Plasma Cell; Pyrazines; Scleromyxedema; Thalidomide | 2012 |
Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Female; Hodgkin Disease; Humans; Mast Cells; Mice; Mice, Inbred C57BL; Mice, SCID; Pyrazines; Tumor Microenvironment | 2012 |
Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Humans; Mice; Mice, SCID; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2012 |
[Current perspectives in the treatment of multiple myeloma - news and views].
Topics: Age Factors; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Risk Factors; Stem Cell Transplantation; Transplantation, Homologous | 2012 |
Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Mice; Mice, SCID; Microarray Analysis; Neuroblastoma; NF-kappa B; Pyrazines; RNA, Small Interfering; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2012 |
Bortezomib and panobinostat combination is effective against PTCL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Hydroxamic Acids; Indoles; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Multimodal Imaging; Panobinostat; Positron-Emission Tomography; Pyrazines; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis.
Topics: Alcohol Drinking; Animals; Antineoplastic Agents; Apolipoproteins; Boronic Acids; Bortezomib; Cholesterol; Down-Regulation; Fatty Acids; Fatty Liver, Alcoholic; Intestinal Absorption; Lipid Metabolism; Male; Proteasome Inhibitors; Pyrazines; Rats; Rats, Wistar; Triglycerides | 2012 |
Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma.
Topics: 2-Methoxyestradiol; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Estradiol; Humans; Multiple Myeloma; Pyrazines; Regulatory Factor X Transcription Factors; Transcription Factors; Tretinoin; Tumor Cells, Cultured; X-Box Binding Protein 1 | 2012 |
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Genes, myc; Humans; Mice; Mice, Congenic; Mice, Inbred C57BL; Mice, Transgenic; Multiple Myeloma; Myeloma Proteins; Neoplasm Transplantation; Predictive Value of Tests; Pyrazines | 2012 |
Bortezomib-associated fatal liver failure in a haemodialysis patient with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury; Cholestasis; Fatal Outcome; Humans; Liver Failure; Male; Multiple Myeloma; Pyrazines; Renal Dialysis | 2012 |
Vincristine and bortezomib cause axon outgrowth and behavioral defects in larval zebrafish.
Topics: Animals; Antineoplastic Agents; Axons; Behavior, Animal; Boronic Acids; Bortezomib; Immunohistochemistry; Larva; Pyrazines; Vincristine; Zebrafish | 2012 |
High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Renal Dialysis; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2012 |
The use of a reversible proteasome inhibitor in a model of Reduced-Size Orthotopic Liver transplantation in rats.
Topics: Animals; Boronic Acids; Bortezomib; Endoplasmic Reticulum Stress; Enzyme Inhibitors; Heme Oxygenase (Decyclizing); HSP70 Heat-Shock Proteins; Liver Regeneration; Liver Transplantation; Male; Mitochondria, Liver; Nitric Oxide Synthase Type III; Organ Size; Oxidative Stress; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 2012 |
Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer.
Topics: Antineoplastic Agents; Aurora Kinases; Benzazepines; Boronic Acids; Bortezomib; Carcinoma; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Humans; Indicators and Reagents; Protein Serine-Threonine Kinases; Pyrazines; Signal Transduction; Thyroid Neoplasms; Vascular Endothelial Growth Factor A | 2012 |
The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Humans; Pyrazines; Tumor Suppressor Protein p53 | 2012 |
Proteasome inhibitor bortezomib ameliorates intestinal injury in mice.
Topics: Animals; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Colitis; Dextran Sulfate; Enzyme Inhibitors; Interferon-gamma; Intestines; Mice; Mice, Inbred C57BL; Proteasome Inhibitors; Pyrazines | 2012 |
AAV-mediated gene targeting is significantly enhanced by transient inhibition of nonhomologous end joining or the proteasome in vivo.
Topics: Animals; Antineoplastic Agents; Benzaldehydes; Boronic Acids; Bortezomib; Dependovirus; Disease Models, Animal; DNA End-Joining Repair; Gene Targeting; Genetic Vectors; Immunohistochemistry; Mice; Mice, Knockout; Plasmids; Polymerase Chain Reaction; Proteasome Endopeptidase Complex; Pyrazines; Recombinant Proteins | 2012 |
Curative resection of double primary lung cancer after 15-month bortezomib administration.
Topics: Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Pneumonectomy; Pyrazines; Treatment Outcome | 2012 |
Involvement of the ubiquitin-proteasome system in the formation of experimental postsurgical peritoneal adhesions.
Topics: Animals; Boronic Acids; Bortezomib; Interleukin-6; Male; NF-kappa B; Peritoneal Diseases; Proteasome Endopeptidase Complex; Pyrazines; Rats; Rats, Sprague-Dawley; Tissue Adhesions; Tumor Necrosis Factor-alpha; Ubiquitin | 2012 |
Extended high cutoff on-line hemodiafiltration is superior to extended high cutoff hemodialysis in removal of free light chain immunoglobulin of myeloma cast nephropathy.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Hemodiafiltration; Humans; Immunoglobulin Light Chains; Kidney; Kidney Diseases; Multiple Myeloma; Pyrazines | 2012 |
Multiple myeloma: treatment evolution.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Young Adult | 2012 |
New developments in the field of diffuse large cell lymphoma.
Topics: Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Breast Implants; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Pyrazines | 2012 |
Frontline treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide | 2012 |
Myeloma: diagnosis complications and supportive care.
Topics: Amyloidosis; Anemia; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pyrazines; Quality of Life; Renal Insufficiency; Thrombosis; Zoledronic Acid | 2012 |
Stem cell transplantation for multiple myeloma: current and future status.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Developing Countries; History, 20th Century; History, 21st Century; Humans; Lenalidomide; Multiple Myeloma; Patient Care; Pyrazines; Stem Cell Transplantation; Thalidomide | 2012 |
Targeted therapy of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Secondary Prevention; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2012 |
Why is management of cancer pain still a problem?
Topics: Analgesics; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Colorectal Neoplasms; Female; Healthcare Disparities; Humans; Lung Neoplasms; Male; Multiple Myeloma; Pain Management; Practice Patterns, Physicians'; Prostatic Neoplasms; Pyrazines | 2012 |
Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes.
Topics: Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Boronic Acids; Bortezomib; Breast Neoplasms; Catalytic Domain; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Chalcone; Cyclin D1; Cysteine; Dose-Response Relationship, Drug; Endopeptidases; Female; HeLa Cells; Humans; Ovarian Neoplasms; Phenotype; Piperidones; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Ubiquitin Thiolesterase; Ubiquitins | 2012 |
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy.
Topics: Adipogenesis; Adult Stem Cells; Animals; Autophagy; Blotting, Western; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; Cells, Cultured; Flow Cytometry; Immunohistochemistry; Mice; Osteoblasts; Osteogenesis; Osteogenesis Imperfecta; Pyrazines | 2012 |
The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Survival; Coloring Agents; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; I-kappa B Proteins; Indicators and Reagents; K562 Cells; NF-kappa B; Polymerase Chain Reaction; Proteasome Inhibitors; Pyrazines; RNA, Messenger; Signal Transduction; Tetrazolium Salts; Thiazoles; Transcription Factor RelA | 2012 |
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Drug Evaluation, Preclinical; Fluorouracil; Humans; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Pyrazines; Randomized Controlled Trials as Topic | 2012 |
Proteasome inhibition is partially effective in attenuating pre-existing immunity against recombinant adeno-associated viral vectors.
Topics: Animals; Boronic Acids; Bortezomib; Cytokines; Dependovirus; Flow Cytometry; Genetic Vectors; Immunity; Male; Mice; Proteasome Inhibitors; Pyrazines | 2012 |
Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, B-Cell; Proteasome Inhibitors; Pyrazines; Recurrence | 2012 |
Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta; Aortic Diseases; Atherosclerosis; Boronic Acids; Bortezomib; Chemokine CCL2; Cholesterol; Computational Biology; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Inflammation Mediators; Injections, Intraperitoneal; Interleukin-6; Lipid Peroxidation; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptors, LDL; Superoxides; Time Factors; Vascular Cell Adhesion Molecule-1; Vasodilation; Vasodilator Agents | 2012 |
Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma.
Topics: Adenine; Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chloroquine; Cysteine Proteinase Inhibitors; Humans; Leupeptins; Membrane Proteins; Microtubule-Associated Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2012 |
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Multiple Myeloma; Nausea; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Vomiting | 2012 |
Bortezomib-induced severe autonomic neuropathy.
Topics: Aged; Antineoplastic Agents; Autonomic Nervous System Diseases; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Severity of Illness Index | 2012 |
The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Cell Proliferation; Cytokines; Female; Flow Cytometry; Graft vs Host Disease; Graft vs Tumor Effect; Leukemia, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred NOD; Pyrazines; Sirolimus; T-Lymphocytes; T-Lymphocytes, Regulatory; Transplantation, Homologous | 2012 |
Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.
Topics: Antigens, Neoplasm; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytotoxicity, Immunologic; Drug Resistance, Neoplasm; Humans; MAP Kinase Signaling System; MART-1 Antigen; NF-kappa B; Proteasome Inhibitors; Pyrazines; Receptors, Antigen, T-Cell; T-Lymphocytes, Cytotoxic | 2012 |
[Prognostic significance of morphology in multiple myeloma].
Topics: Aged; Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous | 2012 |
[Improved prognosis in light chain nephropathy due to multiple myeloma].
Topics: Acute Kidney Injury; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Kidney Diseases; Middle Aged; Multiple Myeloma; Paraproteinemias; Prognosis; Pyrazines; Stem Cell Transplantation | 2012 |
Characterization of the protein ubiquitination response induced by Doxorubicin.
Topics: Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Doxorubicin; HSP27 Heat-Shock Proteins; Humans; Immunoprecipitation; L-Lactate Dehydrogenase; Phosphopyruvate Hydratase; Pyrazines; Ubiquitination | 2012 |
CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; MCF-7 Cells; Membrane Proteins; Mice; Mice, Nude; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Receptors, Estrogen; Xenograft Model Antitumor Assays | 2012 |
Anti-inflammatory effect of the proteasome inhibitor bortezomib on endotoxin-induced uveitis in rats.
Topics: Animals; Anterior Chamber; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Disease Models, Animal; DNA; Dose-Response Relationship, Drug; Down-Regulation; Electrophoretic Mobility Shift Assay; Immunohistochemistry; Male; NF-kappa B; Polymerase Chain Reaction; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Inbred Lew; Uveitis, Anterior | 2012 |
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; eIF-2 Kinase; Endoplasmic Reticulum Stress; Endoribonucleases; Enzyme Activation; Enzyme Inhibitors; Humans; Interleukin-6; Lactams, Macrocyclic; Mice; Multiple Myeloma; Protein Serine-Threonine Kinases; Pyrazines; Regulatory Factor X Transcription Factors; RNA Splicing; RNA, Messenger; Signal Transduction; Stromal Cells; Transcription Factors; Unfolded Protein Response; X-Box Binding Protein 1 | 2012 |
Cellular signal transduction can be induced by TRAIL conjugated to microcapsules.
Topics: Annexin A5; Apoptosis; Boronic Acids; Bortezomib; Capsules; Cell Line, Tumor; Contrast Media; Doxorubicin; Flow Cytometry; Humans; Lactic Acid; Melanoma; Membranes, Artificial; Particle Size; Polyesters; Polymers; Pyrazines; Signal Transduction; Staining and Labeling; TNF-Related Apoptosis-Inducing Ligand; Ultrasonics | 2012 |
[Effects of triptolide on bortezomib-induced apoptosis in multiple myeloma cells].
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Diterpenes; Epoxy Compounds; Humans; Multiple Myeloma; Phenanthrenes; Pyrazines | 2012 |
Effective response with bortezomib retreatment in relapsed multiple myeloma--a multicentre retrospective survey in Switzerland.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Switzerland; Time Factors; Treatment Outcome | 2012 |
Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1.
Topics: Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Colonic Neoplasms; Cyclin B; Cyclin-Dependent Kinases; DNA-Binding Proteins; G2 Phase Cell Cycle Checkpoints; Humans; Phosphorylation; Protein Kinases; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Pyrazines; Reactive Oxygen Species; Tumor Suppressor Proteins | 2012 |
Bortezomib and dexamethasone as first-line therapy for a patient with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome complicated by renal failure.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Induction Chemotherapy; Male; Middle Aged; POEMS Syndrome; Pyrazines; Renal Insufficiency; Treatment Outcome | 2012 |
Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Proto-Oncogene Proteins c-akt; Pyrazines; Sirolimus; TOR Serine-Threonine Kinases; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2012 |
The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Imidazoles; Lymphoma, Mantle-Cell; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinolines; TOR Serine-Threonine Kinases | 2012 |
Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes.
Topics: Antigen-Antibody Complex; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Gamma Rays; Humans; Melanoma; Multiple Myeloma; Neoplasm Proteins; Pinocytosis; Pyrazines; Skin Neoplasms; Treatment Outcome | 2012 |
Bortezomib to treat the TEMPI syndrome.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Erythropoietin; Female; Humans; Lymphangiectasis; Middle Aged; Paraproteinemias; Polycythemia; Pyrazines; Syndrome; Telangiectasis | 2012 |
Bortezomib combined with thalidomide and dexamethasone is effective for patient with crystal-storing histiocytosis associated with monoclonal gammopathy of undermined significance.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Female; Histiocytosis; Humans; Paraproteinemias; Pyrazines; Thalidomide | 2012 |
Survivin is a therapeutic target in Merkel cell carcinoma.
Topics: Animals; Antigens, Viral, Tumor; Antineoplastic Agents; Base Sequence; Boronic Acids; Bortezomib; Carcinoma, Merkel Cell; Cell Line, Tumor; Female; Gene Expression Profiling; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Merkel cell polyomavirus; Mice; Mice, Inbred NOD; Mice, SCID; Naphthoquinones; Polyomavirus Infections; Pyrazines; RNA, Messenger; RNA, Neoplasm; Survivin; Translational Research, Biomedical; Tumor Virus Infections; Xenograft Model Antitumor Assays | 2012 |
Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Gastrointestinal Tract; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Kidney Transplantation; Lenalidomide; Male; Middle Aged; Paraproteinemias; Pyrazines; Thalidomide; Treatment Outcome | 2012 |
Proteasomal insensitivity of apoptin in tumor cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Capsid Proteins; Cell Line; Cell Line, Tumor; Fibroblasts; Humans; Mutation; Neoplasms; Phosphorylation; Proteasome Endopeptidase Complex; Protein Stability; Proteolysis; Pyrazines; Tumor Suppressor Protein p53 | 2012 |
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.
Topics: Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; Coculture Techniques; Humans; Interleukin-6; Lipopolysaccharide Receptors; Macrophages; Mesenchymal Stem Cells; Multiple Myeloma; Pyrazines | 2012 |
[Once-weekly bortezomib plus dexamethasone therapy induced complete response, reducing severe gastrointestinal adverse events for a patient with relapsed multiple myeloma - a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Constipation; Dexamethasone; Female; Humans; Intestinal Pseudo-Obstruction; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence | 2012 |
Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib.
Topics: Antineoplastic Agents; Antiprotozoal Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Immunosuppressive Agents; Italy; Leishmania donovani; Leishmaniasis, Visceral; Male; Middle Aged; Multiple Myeloma; Opportunistic Infections; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2012 |
Bortezomib and bilateral herpes zoster.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Multiple Myeloma; Pyrazines; Virus Activation | 2012 |
Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Boronic Acids; Bortezomib; Disease Models, Animal; Flow Cytometry; Mesenchymal Stem Cell Transplantation; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pyrazines; Rats; Rats, Inbred F344; Rats, Inbred Lew; Real-Time Polymerase Chain Reaction; T-Lymphocytes | 2012 |
Curcumin enhances cytotoxic effects of bortezomib in human multiple myeloma H929 cells: potential roles of NF-κB/JNK.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Curcumin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Multiple Myeloma; p38 Mitogen-Activated Protein Kinases; Pyrazines; Transcription Factor RelA | 2012 |
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
Topics: Alleles; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Colonic Neoplasms; Deoxycytidine; DNA Topoisomerases, Type I; GATA2 Transcription Factor; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mutation; Nuclear Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; ras Proteins; RNA Interference; RNA, Small Interfering; Topoisomerase I Inhibitors; Topotecan; Transcriptional Activation | 2012 |
Effects of brucine on bone metabolism in multiple myeloma.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone and Bones; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Culture Media; Humans; Inhibitory Concentration 50; Multiple Myeloma; Osteoblasts; Osteocalcin; Osteoclasts; Osteoprotegerin; Polymerase Chain Reaction; Pyrazines; RANK Ligand; RNA, Messenger; RNA, Neoplasm; Stem Cells; Strychnine | 2012 |
Bortezomib induces heme oxygenase-1 expression in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Heme Oxygenase-1; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Tumor Cells, Cultured | 2012 |
Anti-myeloma effects of the novel anthracycline derivative INNO-206.
Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Humans; Hydrazones; Mice; Multiple Myeloma; Neoplasms, Experimental; Neovascularization, Pathologic; Pyrazines | 2012 |
Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Stem Cells; Thalidomide; Vincristine | 2012 |
Bortezomib-induced pneumonitis during bortezomib retreatment in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Humans; Male; Middle Aged; Multiple Myeloma; Pneumonia; Pyrazines; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Cutaneous lesion induced by a subcutaneous administration of bortezomib.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Eruptions; Humans; Infusions, Subcutaneous; Male; Multiple Myeloma; Pyrazines | 2012 |
[Urological cancers: ECCO/ESMO congress 2011].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Hydroxamic Acids; Medical Oncology; Pyrazines; Societies, Medical; Sulfonamides; Sweden; Urologic Neoplasms | 2012 |
Simultaneous mitochondrial Ca(2+) overload and proteasomal inhibition are responsible for the induction of paraptosis in malignant breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Calcium; Cell Death; Cell Line, Tumor; Clonazepam; Curcumin; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Female; Humans; Mitochondria; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sodium-Calcium Exchanger; Thiazepines; Time Factors | 2012 |
Autologous stem cell transplant for light chain deposition disease: incorporating bortezomib to the induction therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Male; Paraproteinemias; Pyrazines; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous | 2012 |
Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells.
Topics: Acute Disease; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Cyclin D1; Drug Synergism; Gene Expression; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Telomerase; Valproic Acid | 2012 |
Do not super-excess me!
Topics: Alpha-Globulins; Animals; Antineoplastic Agents; beta-Thalassemia; Boronic Acids; Bortezomib; Erythroid Precursor Cells; Female; Humans; Male; Proteasome Inhibitors; Proteolysis; Pyrazines; Ubiquitination | 2012 |
Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Jurkat Cells; K562 Cells; Leukemia; Lymphoma; Mitochondria; Pyrazines; ras Proteins; RNA, Small Interfering; Up-Regulation | 2012 |
Expression of heme oxygenase-1 in response to proteasomal inhibition.
Topics: Animals; Base Sequence; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Induction; Female; Genes, p53; Heme Oxygenase-1; Humans; Leupeptins; Melanoma, Experimental; Mice; Molecular Sequence Data; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Regulatory Sequences, Nucleic Acid | 2012 |
Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Extracellular Fluid; Humans; Male; Mice; Mice, Nude; Neoplasms; Pyrazines; Tissue Distribution; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2012 |
In vivo imaging of proteasome inhibition using a proteasome-sensitive fluorescent reporter.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Female; Genes, Reporter; Green Fluorescent Proteins; HEK293 Cells; Humans; Mice; Mice, Nude; Molecular Imaging; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2012 |
Bortezomib for acute antibody-mediated rejection in liver transplantation.
Topics: Adult; Antibodies; Boronic Acids; Bortezomib; Female; Graft Rejection; Humans; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Pyrazines; Retrospective Studies | 2012 |
Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; International Agencies; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome; Vincristine | 2012 |
NFκB pathway is down-regulated by 1α,25(OH)(2)-vitamin D(3) in endothelial cells transformed by Kaposi sarcoma-associated herpes virus G protein coupled receptor.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Calcitriol; Cell Line, Transformed; Cell Proliferation; Endothelial Cells; Gene Expression Regulation; Herpesvirus 8, Human; Humans; I-kappa B Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Protein Transport; Pyrazines; Receptors, Calcitriol; Receptors, Chemokine; Receptors, Virus; Signal Transduction | 2012 |
Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.
Topics: Antineoplastic Agents; Autophagy; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials, Phase II as Topic; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Lysosomes; Multicenter Studies as Topic; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; TNF Receptor-Associated Factor 6 | 2012 |
The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; B-Cell Activating Factor; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Neoplasm Transplantation; NF-kappa B; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Recombinant Fusion Proteins; Ribosome Inactivating Proteins, Type 1; Signal Transduction; Toxins, Biological; Transplantation, Heterologous | 2012 |
Breathless on bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Pneumonia; Pyrazines | 2011 |
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Liver Neoplasms; Middle Aged; Multimodal Imaging; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Recurrence; Thalidomide; Tomography, X-Ray Computed; Treatment Failure | 2012 |
Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease.
Topics: Adult; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Pyrazines | 2012 |
Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Proteasome Endopeptidase Complex; Pyrazines; Rhabdomyosarcoma; Ubiquitin | 2012 |
Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma.
Topics: Administration, Oral; Aged; Analgesics, Opioid; Antineoplastic Agents; Boronic Acids; Bortezomib; Delayed-Action Preparations; Humans; Middle Aged; Multiple Myeloma; Oxycodone; Peripheral Nervous System Diseases; Pyrazines; Rome | 2012 |
Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib.
Topics: Animals; beta Catenin; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line; Core Binding Factor Alpha 1 Subunit; Gene Expression Profiling; Gene Expression Regulation; Mice; MicroRNAs; Muscle Fibers, Skeletal; Osteoblasts; Osteocalcin; Promoter Regions, Genetic; Proteasome Inhibitors; Pyrazines; Smad1 Protein; Smad4 Protein; Transcriptional Activation | 2012 |
Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Plasma Cells; Pyrazines | 2012 |
Extramedullary involvement: an emerging problem in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Pyrazines | 2012 |
Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy : case report.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; DNA, Viral; Hepatitis B; Hepatitis B virus; Humans; Male; Multiple Myeloma; Pyrazines; Virus Activation | 2012 |
[Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
Topics: Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Lenalidomide; Melphalan; Prednisone; Pyrazines; Thalidomide | 2012 |
Plasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Neoplasms; Heart Transplantation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Lymphoproliferative Disorders; Plasmacytoma; Pyrazines | 2012 |
Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Benzothiazoles; Boronic Acids; Bortezomib; Carcinoma; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Neoplasm Proteins; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Toluene; Tumor Suppressor Protein p53 | 2012 |
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cytotoxins; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Interferon Regulatory Factors; Mice; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Multiple Myeloma; Protein Kinase Inhibitors; Pyrazines; Substrate Specificity; Time Factors; Xenograft Model Antitumor Assays | 2012 |
Jejunal amyloidosis: a rare cause of severe gastrointestinal bleeding.
Topics: Aged, 80 and over; Amyloidosis; Antineoplastic Agents; Biopsy; Blood Transfusion; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Female; Gastrointestinal Hemorrhage; Glucocorticoids; Humans; Jejunal Diseases; Pyrazines | 2012 |
Combination therapy with VELCADE and tissue plasminogen activator is neuroprotective in aged rats after stroke and targets microRNA-146a and the toll-like receptor signaling pathway.
Topics: Aging; Animals; Boronic Acids; Bortezomib; Cells, Cultured; Down-Regulation; Drug Therapy, Combination; Humans; Male; MicroRNAs; Neuroprotective Agents; NF-kappa B; Pyrazines; Rats; Rats, Wistar; Signal Transduction; Stroke; Tissue Plasminogen Activator; Toll-Like Receptors | 2012 |
Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.
Topics: Aged; Antiviral Agents; Boronic Acids; Bortezomib; Cytomegalovirus; Cytomegalovirus Infections; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Pyrazines; Retrospective Studies; Risk Factors; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Viral Load; Viremia; Virus Activation | 2012 |
Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Oligopeptides; Peptides; Proteasome Inhibitors; Pyrazines; Verapamil | 2012 |
Family haploidentical donor-derived cytokine-induced killer cell biotherapy combined with bortezomib in two patients with relapsed multiple myeloma in a non-allogeneic transplant setting.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Cytokine-Induced Killer Cells; Humans; Immunotherapy, Adoptive; Male; Multiple Myeloma; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome | 2013 |
[Effect of bortezomib and low concentration cytarabine on apoptosis in U937 cell line].
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cytarabine; Humans; Pyrazines; U937 Cells | 2012 |
Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands.
Topics: Boronic Acids; Bortezomib; Cell Degranulation; Cell Line, Tumor; Chromans; Humans; Killer Cells, Natural; Ligands; NK Cell Lectin-Like Receptor Subfamily K; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Thiazolidinediones; Troglitazone; Up-Regulation; Valproic Acid | 2013 |
Treatment with bortezomib in multiple myeloma is associated with only a transient and brief increase of bone specific alkaline phosphatase.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Bone and Bones; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines | 2012 |
Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplastic Stem Cells; Neural Stem Cells; Phenylbutyrates; Pyrazines; Valproic Acid; Vorinostat | 2012 |
High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.
Topics: Adult; Biopsy; Boronic Acids; Bortezomib; Desensitization, Immunologic; Fatal Outcome; Female; Graft Rejection; Graft Survival; Histocompatibility; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Isoantibodies; Kidney Failure, Chronic; Kidney Transplantation; Living Donors; Male; Monitoring, Immunologic; Phlebography; Pyrazines; Risk Assessment; Risk Factors; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Topics: Adult; Biopsy; Boronic Acids; Bortezomib; Female; Graft Rejection; Histocompatibility; HLA Antigens; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Missouri; Monitoring, Immunologic; Plasmapheresis; Pyrazines; Retrospective Studies; Time Factors; Treatment Outcome | 2011 |
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Renal Insufficiency; Survival Rate; Thalidomide; Vincristine | 2013 |
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Bone Marrow; Bone Resorption; Boronic Acids; Bortezomib; Calcification, Physiologic; Cell Differentiation; Cell Proliferation; Epoxy Compounds; Humans; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Oligopeptides; Osteoblasts; Osteoclasts; Osteogenesis; Proteasome Inhibitors; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stromal Cells; Tumor Cells, Cultured; Tumor Microenvironment | 2013 |
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.
Topics: Aged; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Methylation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; PAX5 Transcription Factor; Phenotype; Positive Regulatory Domain I-Binding Factor 1; Prognosis; Proto-Oncogene Proteins c-bcl-6; Pyrazines; Regulatory Factor X Transcription Factors; Repressor Proteins; Syndecan-1; Thalidomide; Transcription Factors; X-Box Binding Protein 1 | 2012 |
Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Boronic Acids; Bortezomib; Case-Control Studies; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; Esophageal Neoplasms; Eukaryotic Initiation Factor-4F; Feedback, Physiological; Gene Expression Regulation, Neoplastic; Gene Silencing; Gene Targeting; Humans; Phenotype; Phosphoproteins; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Biosynthesis; Proteolysis; Pyrazines; Receptor, ErbB-2; Repressor Proteins; RNA Caps; RNA, Messenger; RNA, Small Interfering; Sirolimus; Ubiquitin | 2012 |
In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo.
Topics: Animals; Antigens, CD34; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Transformation, Neoplastic; Female; Hydroxamic Acids; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Pyrazines; Receptors, Notch; Sarcoma; Vorinostat; Wnt Proteins | 2012 |
[Clinical analysis of multiple myeloma with extramedullary plasmacytomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Plasmacytoma; Prognosis; Pyrazines; Retrospective Studies | 2012 |
[The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2012 |
Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents.
Topics: Antineoplastic Agents; Benzophenones; Boronic Acids; Bortezomib; Cell Proliferation; Conjunctival Neoplasms; Drug Screening Assays, Antitumor; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyrazines; Ribonucleases; Sorafenib; Tumor Cells, Cultured | 2013 |
[It is not necessary to use novel agents to all patients with newly diagnosed myeloma as an initial therapy].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide | 2012 |
Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Curcumin; Drug Carriers; Female; Humans; Lactic Acid; Mice; Mice, Nude; Nanoparticles; Neoplasm Metastasis; Osteoporosis; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines | 2012 |
Shoulder X-ray--a clue to multiple myeloma.
Topics: Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Diagnosis, Differential; Female; Humans; Multiple Myeloma; Pyrazines; Radiography; Shoulder Joint; Shoulder Pain; Synovitis; Treatment Outcome | 2012 |
Deaths reported from the accidental intrathecal administration of bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Injections, Spinal; Medication Errors; Pyrazines; Syringes | 2012 |
Transplantation for myeloma: work in progress.
Topics: Boronic Acids; Bortezomib; Female; Humans; Male; Multiple Myeloma; Pyrazines | 2012 |
Quantitative profiling of caspase-cleaved substrates reveals different drug-induced and cell-type patterns in apoptosis.
Topics: Activating Transcription Factor 4; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Caspases; Cytotoxins; Drug Screening Assays, Antitumor; Humans; Jurkat Cells; Kinetics; Multiple Myeloma; Neoplasm Proteins; Proteome; Pyrazines | 2012 |
Successful use of combined high cut-off haemodialysis and bortezomib for acute kidney injury associated with myeloma cast nephropathy.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Humans; Ireland; Kidney Function Tests; Middle Aged; Multiple Myeloma; Pyrazines; Renal Dialysis | 2012 |
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.
Topics: Animals; B-Cell Maturation Antigen; Bone Marrow; Boronic Acids; Bortezomib; Cell Membrane; Culture Media, Conditioned; Cyclophosphamide; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Immunoglobulin G; Kaplan-Meier Estimate; Mice; Mice, SCID; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Plasma Cells; Pyrazines; Tumor Burden; Tumor Cells, Cultured | 2012 |
Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.
Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Cyclohexanones; Doxorubicin; Epoxy Compounds; Humans; Leukocytes, Mononuclear; Mice; Multiple Myeloma; NF-kappa B; Osteoclasts; Pyrazines; RANK Ligand; Signal Transduction; Transplantation, Heterologous | 2012 |
Bortezomib partially protects the rat diaphragm from ventilator-induced diaphragm dysfunction.
Topics: Animals; Boronic Acids; Bortezomib; Calpain; Caspase 3; Diaphragm; Male; Muscle Contraction; Muscular Atrophy; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Wistar; Respiration, Artificial | 2012 |
Proteasome inhibition and ventilator-induced diaphragmatic dysfunction: is the glass half full or half empty?
Topics: Animals; Boronic Acids; Bortezomib; Diaphragm; Male; Proteasome Inhibitors; Pyrazines; Respiration, Artificial | 2012 |
Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients.
Topics: Acyclovir; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2012 |
Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endometrial Neoplasms; Endometrium; Female; Humans; Indoles; NF-kappa B; Pyrazines; Pyrroles; Sunitinib | 2012 |
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Mice; Mice, SCID; Multiple Myeloma; Patched Receptors; Patched-1 Receptor; Plasma Cells; Pyrazines; Pyridines; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Syndecan-1 | 2012 |
[Effects of secoisolariciresinol diglucoside combined with bortezomib on induction of apoptosis in lung cancer cell line A549].
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Butylene Glycols; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Therapy, Combination; Flow Cytometry; Glucosides; Humans; Lung Neoplasms; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Real-Time Polymerase Chain Reaction; RNA, Messenger | 2012 |
Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.
Topics: Activating Transcription Factor 3; Animals; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspases; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Mice; Mice, Nude; Multiple Myeloma; Nelfinavir; Protease Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering; Transplantation, Heterologous | 2012 |
Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients.
Topics: Adult; Boronic Acids; Bortezomib; Female; Graft Rejection; Humans; Kidney Transplantation; Male; Middle Aged; Peripheral Nervous System Diseases; Prospective Studies; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Thrombocytopenia | 2012 |
Bortezomib alleviates experimental pulmonary arterial hypertension.
Topics: Animals; Boronic Acids; Bortezomib; Caspase 3; Cell Hypoxia; Cell Proliferation; Cells, Cultured; Endothelial Cells; Endothelium, Vascular; Heart Ventricles; Humans; Hypertension, Pulmonary; Liver; Liver Function Tests; Male; Mice; Mice, Inbred C57BL; Monocrotaline; Nitric Oxide Synthase Type III; Proteasome Inhibitors; Pulmonary Artery; Pyrazines; Rats; Rats, Sprague-Dawley | 2012 |
PKCδ regulates death receptor 5 expression induced by PS-341 through ATF4-ATF3/CHOP axis in human lung cancer cells.
Topics: Activating Transcription Factor 3; Activating Transcription Factor 4; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Endoplasmic Reticulum Stress; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gene Silencing; Humans; Lung Neoplasms; Phosphorylation; Protein Binding; Protein Kinase C-delta; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Ribosomal Protein S6 Kinases, 90-kDa; Time Factors; Transcription Factor CHOP; Up-Regulation | 2012 |
Fatalities resulting from accidental intrathecal administration of bortezomib: strategies for prevention.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Labeling; Drug Packaging; Humans; Injections, Spinal; Medication Errors; Pyrazines | 2012 |
Bortezomib-induced thrombotic thrombocytopaenic purpura.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Boronic Acids; Bortezomib; Confusion; Female; Humans; Multiple Myeloma; Plasma Exchange; Plasmapheresis; Platelet Count; Prognosis; Purpura, Thrombotic Thrombocytopenic; Pyrazines; Severity of Illness Index; Treatment Outcome | 2012 |
Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-κB pathways.
Topics: Acetylation; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Drug Synergism; HL-60 Cells; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; NF-kappa B; Panobinostat; Poly(ADP-ribose) Polymerases; Proteolysis; Proto-Oncogene Proteins c-akt; Pyrazines | 2012 |
Graft-versus-host disease: have we solved the problem?
Topics: Antigens, CD34; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Pyrazines; Siblings; T-Lymphocyte Subsets | 2012 |
Minor clone provides a reservoir for relapse in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Boronic Acids; Bortezomib; Chromosome Aberrations; Clone Cells; Dexamethasone; Disease Progression; Evolution, Molecular; Female; Follow-Up Studies; Gene Deletion; Gene Expression Profiling; Humans; Male; Middle Aged; Molecular Sequence Data; Multiple Myeloma; Mutation; Neoplasm Recurrence, Local; NF-kappa B; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Pyrazines; Real-Time Polymerase Chain Reaction; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Nucleic Acid; Tumor Suppressor Protein p53 | 2013 |
Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-X Protein; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Humans; Minor Histocompatibility Antigens; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; T-Lymphocytes; Tumor Suppressor Protein p53 | 2012 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Muscle Weakness; Neutropenia; Pneumonia; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
Once- versus twice-weekly Bortezomib induction therapy with dexamethasone in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2012 |
Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; I-kappa B Kinase; I-kappa B Proteins; Male; Mice; Mice, Nude; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Pyrazines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Combination treatment with bortezomib and thiostrepton is effective against tumor formation in mouse models of DEN/PB-induced liver carcinogenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Diethylnitrosamine; Disease Models, Animal; Liver; Liver Neoplasms; Mice; Phenobarbital; Pyrazines; Thiostrepton | 2012 |
Immune mechanism of the antitumor effects generated by bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chaperonin 60; Female; HSP90 Heat-Shock Proteins; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Nude; Mitochondrial Proteins; Neoplasm Transplantation; Ovarian Neoplasms; Pyrazines; Up-Regulation | 2012 |
Plasmablastic haemato-lymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib.
Topics: Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Burkitt Lymphoma; Fatal Outcome; Genes, myc; Herpesvirus 4, Human; Humans; Immunoglobulin M; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasms, Second Primary; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrazines; Retroperitoneal Neoplasms; Transcriptome; Translocation, Genetic | 2013 |
Polyubiquitin is required for growth, development and pathogenicity in the rice blast fungus Magnaporthe oryzae.
Topics: Boronic Acids; Bortezomib; Cluster Analysis; Fungal Proteins; Gene Expression Profiling; Gene Expression Regulation, Fungal; Germination; Magnaporthe; Mutation; Nitrogen; Oryza; Plant Diseases; Polyubiquitin; Proteasome Inhibitors; Proteolysis; Proteomics; Pyrazines; Ubiquitination | 2012 |
[A case of adult primitive neuroectodermal tumor(PNET)with multiple lung metastases effectively treated with ADM, IFM(AI)regimen].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Boronic Acids; Bortezomib; Doxorubicin; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melphalan; Middle Aged; Mitolactol; Mitomycins; Neuroectodermal Tumors, Primitive; Pyrazines; Salvage Therapy; Suicide; Tomography, X-Ray Computed | 2012 |
Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity.
Topics: Antineoplastic Agents; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; DNA Primers; Flow Cytometry; Histocompatibility Antigens Class I; Humans; Killer Cells, Natural; Male; Prostatic Neoplasms; Pyrazines; Real-Time Polymerase Chain Reaction | 2012 |
Complete and partial responses of the TEMPI syndrome to bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Erythropoietin; Female; Humans; Male; Middle Aged; Paraproteinemias; Polycythemia; Pyrazines; Syndrome; Telangiectasis | 2012 |
Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Pyrazines; Reactive Oxygen Species; Tumor Cells, Cultured; Vasodilator Agents; Verapamil | 2012 |
Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Coordination Complexes; Copper; Ditiocarb; Humans; Oxidative Stress; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2012 |
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Profiling; Humans; Imidazoles; Insulin-Like Growth Factor I; Mice; Mice, SCID; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Pyrazines; Receptor, IGF Type 1; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Upregulation of focal adhesion kinase by 14-3-3ε via NFκB activation in hepatocellular carcinoma.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Survival; Drug Screening Assays, Antitumor; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; NF-kappa B; Pyrazines; Structure-Activity Relationship; Tumor Cells, Cultured; Up-Regulation | 2013 |
Serial measurement of free light chain detects poor response to therapy early in three patients with multiple myeloma who have measurable M-proteins.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Immunoglobulins; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2012 |
Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy.
Topics: Acetylcarnitine; Activating Transcription Factor 3; Adenosine Triphosphate; Analysis of Variance; Animals; Antineoplastic Agents; Axons; Boronic Acids; Bortezomib; Citrate (si)-Synthase; Disease Models, Animal; Electron Transport Complex II; Ganglia, Spinal; Hyperalgesia; Male; Mitochondria; Pain; Pain Measurement; Pain Threshold; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Sprague-Dawley; Schwann Cells; Sciatic Nerve; Time Factors; Ubiquitin Thiolesterase | 2012 |
Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sézary syndrome.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cells, Cultured; CTLA-4 Antigen; Female; GATA3 Transcription Factor; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lymphocyte Culture Test, Mixed; Male; Middle Aged; Polyubiquitin; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Pyrazines; Sezary Syndrome; Skin Neoplasms; T-Lymphocytes | 2013 |
Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Erythema; Humans; Injections, Subcutaneous; Multiple Myeloma; Phlebitis; Pyrazines | 2012 |
Roles of estrogen receptor and p21(Waf1) in bortezomib-induced growth inhibition in human breast cancer cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Estrogen Receptor alpha; Female; HCT116 Cells; Humans; MCF-7 Cells; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2012 |
Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Drug Screening Assays, Antitumor; Flavonoids; Humans; Mice; Multiple Myeloma; Oncogenes; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrimidine Nucleosides; Translocation, Genetic; Treatment Outcome; Tubercidin | 2012 |
Cutaneous amyloid elastosis revealing multiple myeloma with systemic amyloidosis.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Diagnostic Errors; Elastic Tissue; Fatal Outcome; Female; Humans; Melphalan; Multiple Myeloma; Predictive Value of Tests; Pseudoxanthoma Elasticum; Pyrazines; Skin; Treatment Outcome | 2013 |
Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Drug Synergism; Humans; Lymphoma, Mantle-Cell; Oxides; Pyrazines | 2012 |
Brazilin induces apoptosis and G2/M arrest via inactivation of histone deacetylase in multiple myeloma U266 cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Multiple Myeloma; Protein Binding; Pyrazines | 2012 |
Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Creatinine; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Plasma Exchange; Pyrazines; Renal Insufficiency; Retrospective Studies; Treatment Outcome | 2012 |
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dexamethasone; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Lenalidomide; Mice; Mice, SCID; Molecular Sequence Data; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Proto-Oncogene Proteins c-mdm2; Pyrazines; Random Allocation; Thalidomide; Thiophenes; Ubiquitin Thiolesterase; Ubiquitin-Specific Peptidase 7; Xenograft Model Antitumor Assays | 2012 |
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amides; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Cell Survival; Humans; I-kappa B Proteins; Lenalidomide; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA, Messenger; Signal Transduction; Thalidomide; Tumor Cells, Cultured | 2013 |
[Early onset of paralytic ileus caused by simultaneous administration of bortezomib and azole antifungals in multiple myeloma patients].
Topics: Aged; Antifungal Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Interactions; Drug Therapy, Combination; Humans; Intestinal Pseudo-Obstruction; Itraconazole; Middle Aged; Multiple Myeloma; Mycoses; Pyrazines; Pyrimidines; Triazoles; Voriconazole | 2012 |
Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Humans; Immunologic Factors; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Salvage Therapy; Stem Cell Transplantation | 2013 |
Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Replication; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia; Membrane Proteins; Mice; Proteasome Endopeptidase Complex; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; Transcription, Genetic; Xenograft Model Antitumor Assays | 2013 |
Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Pyrazines; Respiratory Function Tests; Risk Factors; Thalidomide | 2012 |
A retrospective analysis of cytogenetic and clinical characteristics in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2013 |
Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase 5; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Multiple Myeloma; Pyrazines; Recurrence | 2012 |
How to select among available options for the treatment of multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
New agents for the treatment of lymphoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Immunotoxins; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Proteasome Inhibitors; Pyrazines | 2012 |
Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; ErbB Receptors; Hepatocytes; Humans; Liver Neoplasms; Molecular Targeted Therapy; Pyrazines; Recombinant Fusion Proteins; TNF-Related Apoptosis-Inducing Ligand | 2013 |
Role of carfilzomib in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Multiple Myeloma; Oligopeptides; Peptide Hydrolases; Proteasome Inhibitors; Pyrazines; Thalidomide | 2012 |
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
Topics: Activating Transcription Factor 4; Autophagy; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Head and Neck Neoplasms; Humans; Models, Biological; Oligopeptides; Proteasome Inhibitors; Pyrazines; Squamous Cell Carcinoma of Head and Neck; Unfolded Protein Response | 2012 |
Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Mice; Mice, Nude; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Receptor, Notch1; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Death; Liver Cirrhosis; Liver Neoplasms; Male; Pyrazines; Rats; Rats, Wistar | 2013 |
Bortezomib inhibits the angiogenesis mediated by mesenchymal stem cells.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Cell Movement; Cell Proliferation; Cells, Cultured; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Human Umbilical Vein Endothelial Cells; Humans; Mesenchymal Stem Cells; Multiple Myeloma; Neovascularization, Pathologic; Pyrazines; Vascular Endothelial Growth Factor A | 2012 |
Bortezomib: 3 deaths following intrathecal injection.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cause of Death; Humans; Infusions, Intravenous; Injections, Intravenous; Injections, Spinal; Medication Errors; Pyrazines | 2012 |
Changes in protein profiles of multiple myeloma cells in response to bortezomib.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Matrix Metalloproteinases; Multiple Myeloma; Proteome; Proteomics; Pyrazines | 2013 |
Inhibition of fatty acid metabolism reduces human myeloma cells proliferation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Carbohydrate Metabolism; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cerulenin; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Epoxy Compounds; Fatty Acids; G1 Phase Cell Cycle Checkpoints; Glucose; Humans; Lactones; Lipid Metabolism; Multiple Myeloma; Orlistat; Oxidation-Reduction; Pyrazines; Retinoblastoma Protein | 2012 |
Intracranial mass of multiple myeloma with good response to chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Brain Neoplasms; Dexamethasone; Drug Therapy, Combination; Humans; Magnetic Resonance Imaging; Male; Melphalan; Multiple Myeloma; Pyrazines; Treatment Outcome | 2012 |
[Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2012 |
Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Bone Marrow; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cell Survival; Clinical Trials, Phase II as Topic; Drug Synergism; Everolimus; Humans; Mechanistic Target of Rapamycin Complex 1; MicroRNAs; Multiprotein Complexes; Pyrazines; Rituximab; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Cells, Cultured; Tumor Microenvironment; Waldenstrom Macroglobulinemia | 2012 |
Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Female; Humans; Mice; Mice, Inbred BALB C; Organ Specificity; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease.
Topics: Antibodies; Antineoplastic Agents; Boronic Acids; Bortezomib; Child; Child, Preschool; Drug Therapy, Combination; Glycogen Storage Disease Type II; Humans; Immunoglobulins, Intravenous; Male; Methotrexate; Plasma Cells; Pyrazines; Treatment Outcome | 2013 |
Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Phenotype; Pyrazines; Remission Induction; Scleredema Adultorum | 2013 |
Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Coculture Techniques; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Protease Inhibitors; Pyrazines; Radiation Tolerance; Signal Transduction; Stromal Cells; Superoxide Dismutase; Transcriptional Activation; Tumor Cells, Cultured | 2013 |
Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carboplatin; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Membrane Proteins; Mice; Mice, Inbred ICR; Mice, SCID; Paclitaxel; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Uterine Cervical Neoplasms | 2013 |
Ascorbic acid kills Epstein-Barr virus positive Burkitt lymphoma cells and Epstein-Barr virus transformed B-cells in vitro, but not in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Ascorbic Acid; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line, Transformed; Cell Line, Tumor; Cell Survival; Cell Transformation, Viral; Female; Herpesvirus 4, Human; Humans; Mice; Pyrazines; Reactive Oxygen Species; Virus Replication | 2013 |
P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
Topics: Animals; Antigens, Surface; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cyclin D1; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Flavones; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Neoplasm Proteins; Protein Kinase Inhibitors; Pyrazines; RNA, Small Interfering; Survival Analysis; Xenograft Model Antitumor Assays | 2012 |
Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Synergism; Humans; Melphalan; Multiple Myeloma; Pyrazines | 2013 |
Bortezomib-induced cutaneous lupus in a patient with myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lupus Erythematosus, Cutaneous; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2013 |
Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Calcium; Caspase 3; Cell Line, Tumor; Endoplasmic Reticulum Stress; HSP70 Heat-Shock Proteins; Humans; MAP Kinase Kinase Kinase 5; Melanoma; Membrane Potential, Mitochondrial; Microtubule-Associated Proteins; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Inhibitors; Proto-Oncogene Protein c-ets-1; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Signal Transduction | 2013 |
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Disease Progression; Disease-Free Survival; Genetic Predisposition to Disease; Humans; Middle Aged; Pyrazines; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
Erectile dysfunction associated with bortezomib treatment in a patient with multiple myeloma and amyloidosis.
Topics: Amyloidosis; Boronic Acids; Bortezomib; Erectile Dysfunction; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2013 |
Bortezomib administration with severe hyperbilirubinemia caused by hepatic plasma cell infiltration: a case report.
Topics: Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Female; Humans; Hyperbilirubinemia; Liver; Middle Aged; Multiple Myeloma; Plasma Cells; Pyrazines | 2013 |
Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.
Topics: Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Humans; Hydroxamic Acids; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Prostatic Neoplasms; Pyrazines; Random Allocation; RNA, Small Interfering; Sensitivity and Specificity; Ubiquitinated Proteins; Vorinostat; Xenograft Model Antitumor Assays | 2012 |
Proteasome inhibitor bortezomi-induced the apoptosis of laryngeal squamous cell carcinoma Hep-2 cell line via disrupting redox equilibrium.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspase 3; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Humans; Laryngeal Neoplasms; Membrane Potential, Mitochondrial; Oxidation-Reduction; Oxidative Stress; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species | 2012 |
Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells.
Topics: Adolescent; Antineoplastic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; Boronic Acids; Bortezomib; Caspase 3; Child; Child, Preschool; Cytochromes c; fas Receptor; Fas-Associated Death Domain Protein; Gene Silencing; Humans; Jurkat Cells; Leukemia, Myeloid; Membrane Potential, Mitochondrial; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Transcriptome | 2013 |
Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis.
Topics: Adult; Aged; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Pyrazines; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide is effective for the treatment of bortezomib-resistant extramedullary disease in patients with multiple myeloma: report of 2 cases.
Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Synergism; Endoplasmic Reticulum Stress; Female; HeLa Cells; Humans; Hydrazones; Hydroxyurea; Membrane Potential, Mitochondrial; Pyrazines; Transcription Factor CHOP; Ubiquitin; Up-Regulation; Uterine Cervical Neoplasms | 2013 |
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Immunophenotyping; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Proteins; Off-Label Use; Peripheral Nervous System Diseases; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Rituximab; Signal Transduction; Transplantation, Autologous; Treatment Outcome | 2013 |
Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Benzoflavones; Boronic Acids; Bortezomib; Calcium-Binding Proteins; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Drug Resistance, Neoplasm; Humans; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Mice; Multiple Myeloma; Pyrazines; Receptors, Notch; Up-Regulation | 2012 |
Expression of vascular endothelial growth factor receptors VEGFR1 in cultured multiple myeloma cells: correlation with immunophenotype and drug resistance.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD56 Antigen; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression; Humans; Immunophenotyping; Leukocyte Common Antigens; Multiple Myeloma; Organ Specificity; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor D; Vascular Endothelial Growth Factor Receptor-1 | 2012 |
[Inhibitory effect of histone deacetylase inhibitor LBH589 on multiple myeloma MM1R cells in vitro].
Topics: Acetylation; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Panobinostat; Pyrazines | 2012 |
Making light of an interstitial process.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lung Diseases, Interstitial; Microscopy, Polarization; Middle Aged; Pyrazines; Radiography, Thoracic; Respiratory Sounds; Tomography, X-Ray Computed | 2012 |
Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Transplantation Conditioning; Treatment Outcome | 2013 |
Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Drug Costs; Health Care Costs; Hospitalization; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Multivariate Analysis; Netherlands; Prognosis; Pyrazines; Recurrence; Regression Analysis; Retrospective Studies; Thalidomide; Young Adult | 2013 |
A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Depsipeptides; Drug Evaluation, Preclinical; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lymphoma, T-Cell, Cutaneous; Neovascularization, Pathologic; Proteasome Inhibitors; Pyrazines | 2012 |
[Proteasome oncology: pioneer a new field in drug development].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin | 2012 |
[Diagnosis and treatment for plasma cell leukemia].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Glucocorticoids; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Plasma Cell; Melphalan; Pyrazines; Rituximab; Thalidomide | 2012 |
Extramedullary plasmacytomas presenting as asymptomatic nodules on the buttocks and thighs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Buttocks; Dexamethasone; Humans; Middle Aged; Multimodal Imaging; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Skin Diseases; Thigh; Tomography, X-Ray Computed | 2012 |
Quantitative proteomic analysis to decipher the differential apoptotic response of bortezomib-treated APL cells before and after retinoic acid differentiation reveals involvement of protein toxicity mechanisms.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Evaluation Studies as Topic; Humans; Leukemia, Promyelocytic, Acute; Peptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteins; Pyrazines; Receptors, Retinoic Acid; Stress, Physiological; Tretinoin; Ubiquitin | 2013 |
Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome | 2013 |
TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Combined Modality Therapy; Female; Ferric Compounds; Gamma Rays; Glioma; Humans; Immunoenzyme Techniques; In Vitro Techniques; Nanoparticles; Neoplastic Stem Cells; Pyrazines; Rats; Rats, Nude; Recombinant Proteins; Survival Rate; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Checkpoint Kinase 1; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Pyrazines | 2012 |
Bortezomib-related diffuse alveolar hemorrhage.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Hemorrhage; Humans; Lung Diseases; Male; Multiple Myeloma; Pulmonary Alveoli; Pyrazines | 2012 |
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.
Topics: Antibodies, Monoclonal; Antimetabolites; Bone Marrow Examination; Boronic Acids; Bortezomib; Densitometry; Disease Progression; Disease-Free Survival; Forecasting; Hematopoiesis; Humans; Immunoglobulin Light Chains; Immunoglobulin M; Immunosuppressive Agents; Neoplasm, Residual; Nephelometry and Turbidimetry; Positron-Emission Tomography; Pyrazines; Remission Induction; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Waldenstrom Macroglobulinemia | 2013 |
Detrimental effects of proteasome inhibition activity in Drosophila melanogaster: implication of ER stress, autophagy, and apoptosis.
Topics: Animals; Animals, Genetically Modified; Apoptosis; Autophagy; Behavior, Animal; Boronic Acids; Bortezomib; Drosophila melanogaster; Endoplasmic Reticulum Stress; Female; Kaplan-Meier Estimate; Larva; Longevity; Male; Motor Activity; Ovarian Follicle; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Survival Rate | 2013 |
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Thalidomide; Treatment Outcome | 2013 |
Differential downregulation of telomerase activity by bortezomib in multiple myeloma cells-multiple regulatory pathways in vitro and ex vivo.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; DNA Methylation; Down-Regulation; Humans; Multiple Myeloma; Phosphorylation; Promoter Regions, Genetic; Protein Kinase C-alpha; Proto-Oncogene Proteins c-akt; Pyrazines; Telomerase | 2012 |
Accidental intrathecal administration of bortezomib: preventing fatalities.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Injections, Spinal; Medication Errors; Pyrazines | 2013 |
Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis.
Topics: Adult; Apoptosis; Boronic Acids; Bortezomib; Cells, Cultured; Chemokine CCL19; Chemokine CXCL9; Chemotaxis; Depression, Chemical; Down-Regulation; Drug Evaluation, Preclinical; Graft vs Host Disease; Humans; Lymphocyte Activation; Mitogen-Activated Protein Kinase 1; Phosphorylation; Protease Inhibitors; Protein Processing, Post-Translational; Pyrazines; Receptors, CCR7; Receptors, CXCR3; T-Lymphocyte Subsets | 2012 |
Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy.
Topics: Adult; Aged; Antifungal Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytochrome P-450 Enzyme System; Dexamethasone; Diabetes Complications; Drug Synergism; Female; Humans; Inactivation, Metabolic; Incidence; Itraconazole; Male; Middle Aged; Multiple Myeloma; Mycoses; Opportunistic Infections; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Proton Pump Inhibitors; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy | 2012 |
Integrated regulation of autophagy and apoptosis by EEF2K controls cellular fate and modulates the efficacy of curcumin and velcade against tumor cells.
Topics: Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Lineage; Curcumin; Elongation Factor 2 Kinase; Endoplasmic Reticulum Stress; Enzyme Activation; Gene Silencing; Humans; Models, Biological; Phosphorylation; Phosphoserine; Pyrazines; Thapsigargin; Transcription Factors; Tunicamycin | 2013 |
Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Combined Modality Therapy; Dacarbazine; Dexamethasone; Doxorubicin; Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Vincristine | 2013 |
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Recurrence; Retrospective Studies | 2013 |
Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Melphalan; Myeloablative Agonists; Myocardium; Pyrazines; Steroids; Survival Analysis; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.
Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Combined Modality Therapy; Creatine Kinase, MM Form; Cyclohexanecarboxylic Acids; Dexamethasone; Drug Synergism; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunologic Factors; Kidney Diseases; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyneuropathies; Pravastatin; Pyrazines; Rhabdomyolysis; Thalidomide | 2012 |
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Down-Regulation; Feedback, Physiological; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, SCID; MicroRNAs; Multiple Myeloma; Pyrazines; Sp1 Transcription Factor; Tumor Cells, Cultured | 2012 |
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Tolerance to nitroglycerin through proteasomal down-regulation of aldehyde dehydrogenase-2 in a genetic mouse model of ascorbate deficiency.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Animals; Aorta; Ascorbic Acid Deficiency; Boronic Acids; Bortezomib; Drug Tolerance; Female; Gene Expression Regulation, Enzymologic; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Models, Animal; Nitroglycerin; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitination | 2013 |
Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; HeLa Cells; Humans; I-kappa B Proteins; Imidazoles; Mice; Molecular Structure; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Structure-Activity Relationship; Tumor Cells, Cultured | 2013 |
Phosphorylation of human TFAM in mitochondria impairs DNA binding and promotes degradation by the AAA+ Lon protease.
Topics: Amino Acid Substitution; Base Sequence; Binding Sites; Boronic Acids; Bortezomib; Cyclic AMP-Dependent Protein Kinases; DNA-Binding Proteins; DNA, Mitochondrial; Gene Knockdown Techniques; Genome, Mitochondrial; HEK293 Cells; HeLa Cells; Humans; Mitochondria; Mitochondrial Proteins; Models, Molecular; Phosphorylation; Protease La; Protein Binding; Protein Processing, Post-Translational; Protein Structure, Tertiary; Proteolysis; Pyrazines; RNA Interference; Transcription Factors; Transcriptional Activation | 2013 |
Treatment of antibody-mediated rejection in kidney transplant recipients: a single-center experience with a bortezomib-based regimen.
Topics: Adult; Antibodies; Boronic Acids; Bortezomib; Graft Rejection; Humans; Kidney Transplantation; Male; Plasma Cells; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Tissue Donors | 2012 |
A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Neural Conduction; Peripheral Nerves; Pyrazines; Systemic Vasculitis | 2012 |
Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
Topics: Acyclovir; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Valacyclovir; Valine; Virus Activation | 2012 |
Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Bone Development; Boronic Acids; Bortezomib; Cartilage; Caspases; Cell Line; Chondrocytes; Chondrogenesis; Enzyme Activation; Growth Plate; Homeostasis; Humans; Metatarsal Bones; Mice; Mitochondrial Membranes; Proteasome Inhibitors; Protein Stability; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Rats; Time Factors; Tumor Suppressor Protein p53 | 2012 |
Have drug combinations supplanted stem cell transplantation in myeloma?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Therapy; Female; Genomics; Humans; Male; Medical Oncology; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Pyrazines; Stem Cell Transplantation; Time Factors; Treatment Outcome | 2012 |
News & views in ... Immunotherapy.
Topics: Allergens; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cattle; Female; Glycogen Storage Disease Type II; Human papillomavirus 16; Human papillomavirus 18; Humans; Hypersensitivity; Immunotherapy; Leukotriene B4; Melanoma; Milk; Milk Proteins; Papillomavirus Infections; Pyrazines; Receptors, Leukotriene B4; Skin Neoplasms; Tumor Escape; Uterine Cervical Neoplasms; Viral Vaccines | 2012 |
Iron increases the susceptibility of multiple myeloma cells to bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Ferritins; Humans; Inhibitory Concentration 50; Iron; Multiple Myeloma; Plasma Cells; Pyrazines | 2013 |
Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARα/STAT1 axis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; Drug Synergism; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Pyrazines; Random Allocation; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; STAT1 Transcription Factor; Tretinoin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Proteasome inhibition rescues clinically significant unstable variants of the mismatch repair protein Msh2.
Topics: Boronic Acids; Bortezomib; Cisplatin; Colorectal Neoplasms, Hereditary Nonpolyposis; DNA Mismatch Repair; DNA Primers; DNA Sequence, Unstable; Gene Dosage; Gene Expression Regulation; Humans; Immunoblotting; Immunohistochemistry; Immunoprecipitation; Models, Molecular; Mutation, Missense; MutS Homolog 2 Protein; Plasmids; Polymerase Chain Reaction; Proteasome Endopeptidase Complex; Pyrazines; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Ubiquitin; Ubiquitin-Protein Ligases | 2013 |
The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cells, Cultured; Diterpenes; DNA-Binding Proteins; Down-Regulation; Epoxy Compounds; Female; Gene Knockdown Techniques; Heat Shock Transcription Factors; Heat-Shock Proteins; Humans; Immunohistochemistry; Isoxazoles; Mice; Mice, Inbred BALB C; Multiple Myeloma; Neoplasm Transplantation; Phenanthrenes; Plasma Cells; Proteasome Endopeptidase Complex; Pyrazines; Resorcinols; RNA, Small Interfering; Transcription Factors; Transplantation, Heterologous | 2013 |
Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Dimerization; Drug Synergism; Hematologic Neoplasms; Humans; K562 Cells; Lymphoma; NF-kappa B; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Receptors, Glucocorticoid; RNA Interference; RNA, Small Interfering; Transcription Factor AP-1; Transcriptional Activation; Triazoles; Tumor Cells, Cultured | 2013 |
[Mechanism of apoptosis synergistically induced by bortezomib combined with cytarabine in U937 cell line].
Topics: Apoptosis; Boronic Acids; Bortezomib; Cytarabine; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Phosphorylation; Pyrazines; Reactive Oxygen Species; U937 Cells | 2012 |
[Effects of arsenic trioxide combined with bortezomib on proliferation and apoptosis of K562 cells and their mechanism].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; K562 Cells; NF-kappa B; Oxides; Pyrazines | 2012 |
High frequencies of response after limited primary therapy for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
Topical evening primrose oil for reduction of bortezomib-induced skin reactions.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Boronic Acids; Bortezomib; Drug Eruptions; Drug Evaluation; gamma-Linolenic Acid; Humans; Injections, Subcutaneous; Linoleic Acids; Oenothera biennis; Phytotherapy; Plant Oils; Protease Inhibitors; Pyrazines | 2013 |
Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Castleman Disease; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction | 2012 |
Causal co-expression method with module analysis to screen drugs with specific target.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Data Mining; DNA Damage; Drug Discovery; Drug Evaluation, Preclinical; Gene Regulatory Networks; Humans; Oligonucleotide Array Sequence Analysis; Peptides, Cyclic; Pyrazines; Transcription Factors | 2013 |
BlyS: a potential hallmark of multiple myeloma.
Topics: Aged; Aged, 80 and over; Apoptosis; B-Cell Activating Factor; B-Cell Activation Factor Receptor; B-Lymphocytes; Bone Marrow; Boronic Acids; Bortezomib; Cell Line, Tumor; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2013 |
Total cost comparison in relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Fees, Pharmaceutical; Health Expenditures; Humans; Lenalidomide; Models, Economic; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2013 |
ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.
Topics: ADAM Proteins; ADAMTS13 Protein; Autoantibodies; B-Lymphocytes; Boronic Acids; Bortezomib; Female; Humans; Immunosuppressive Agents; Middle Aged; Plasma Cells; Protease Inhibitors; Purpura, Thrombotic Thrombocytopenic; Pyrazines | 2013 |
HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
Topics: Acetylation; Animals; Antineoplastic Agents; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Carnitine; Caspases; Cell Death; Cell Proliferation; Chromatin; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Endoplasmic Reticulum Stress; Enzyme Activation; Hep G2 Cells; Histone Deacetylase Inhibitors; Histones; Humans; Male; Mice; Models, Biological; Poly(ADP-ribose) Polymerases; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2012 |
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosomes, Human, Pair 1; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Thalidomide; Treatment Outcome; Trisomy | 2013 |
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Treatment Outcome | 2013 |
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Health Care Costs; Health Resources; Hospitalization; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide | 2013 |
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Thalidomide; United States | 2013 |
Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Hydroxamic Acids; Membrane Proteins; Mesothelioma; Myeloid Cell Leukemia Sequence 1 Protein; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Spheroids, Cellular; Up-Regulation; Vorinostat | 2012 |
Proteasome inhibitors protect the steatotic and non-steatotic liver graft against cold ischemia reperfusion injury.
Topics: Adiponectin; Animals; Boronic Acids; Bortezomib; Cold Ischemia; Cysteine Proteinase Inhibitors; Cytoprotection; Fatty Liver; Interleukin-1; Leupeptins; Liver Transplantation; Mitochondria, Liver; Organ Preservation; Organ Preservation Solutions; Oxidative Stress; Proteasome Inhibitors; Pyrazines; Rats; Rats, Zucker; Reperfusion Injury; Tumor Necrosis Factor-alpha | 2013 |
Multiple myeloma, version 1.2013.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat | 2013 |
Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib.
Topics: Amino Acid Sequence; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; HEK293 Cells; Humans; Molecular Sequence Data; Neuroblastoma; Peptides; Proteasome Inhibitors; Proteomics; Pyrazines | 2013 |
The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
Topics: Base Sequence; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Humans; Mesenchymal Stem Cells; Multiple Myeloma; Osteoblasts; Osteocalcin; Osteoclasts; Osteopontin; Proteasome Inhibitors; Pyrazines; Receptors, Calcitriol; Recombinant Proteins; RNA, Messenger; Signal Transduction; Transfection; Up-Regulation; Vitamin D Deficiency | 2013 |
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD11b Antigen; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Coculture Techniques; Cytokines; Flow Cytometry; HLA-DR Antigens; Humans; Immunologic Factors; Lenalidomide; Lewis X Antigen; Lipopolysaccharides; Multiple Myeloma; Myeloid Cells; Pyrazines; Reactive Oxygen Species; Sialic Acid Binding Ig-like Lectin 3; T-Lymphocytes; Thalidomide; Tumor Burden; Tumor Microenvironment | 2013 |
PDK1 inhibition is a novel therapeutic target in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Dichloroacetic Acid; Glucose; Glycolysis; Humans; Lactate Dehydrogenases; Lactic Acid; Molecular Targeted Therapy; Multiple Myeloma; Protein Serine-Threonine Kinases; Pyrazines; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; RNA, Small Interfering | 2013 |
[Cutaneous manifestations revealing cryofibrinogenaemia associated with monoclonal gammopathy].
Topics: Acute Kidney Injury; Adult; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Cryoglobulinemia; Cryoglobulins; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Fibrinogens, Abnormal; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Kidney; Leg Ulcer; Microscopy, Fluorescence; Necrosis; Paraproteinemias; Plasmapheresis; Prednisone; Pyrazines; Skin | 2013 |
SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Chemoradiotherapy; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Rectal Neoplasms; Retrospective Studies; S-Phase Kinase-Associated Proteins; Survival Rate; Tumor Cells, Cultured | 2013 |
Regulatory role of proteasome in determination of platelet life span.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blood Platelets; Blotting, Western; Boronic Acids; Bortezomib; Humans; Macrophages; Mice; Microscopy, Fluorescence; Oligopeptides; Phagocytosis; Platelet Count; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Pyrazines; Time Factors; Up-Regulation | 2013 |
Bortezomib downregulates MGMT expression in T98G glioblastoma cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Cell Survival; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Eukaryotic Initiation Factor-2; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; NF-kappa B; Pyrazines; Signal Transduction; Tumor Suppressor Proteins | 2013 |
Analyses on activation of NF-κB and effect of bortezomib in canine neoplastic lymphoid cell lines.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Dogs; Gene Expression Regulation, Neoplastic; Lymphocytes; NF-kappa B; Pyrazines | 2013 |
Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Female; Humans; I-kappa B Proteins; Interleukin-6; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Neoplasm Transplantation; Neovascularization, Pathologic; NF-kappa B; NF-KappaB Inhibitor alpha; Poly(ADP-ribose) Polymerases; Pyrazines; Radiation-Sensitizing Agents; Transcription Factor RelA; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Pyrazines; Registries; Retrospective Studies; Stem Cell Transplantation; Treatment Outcome | 2013 |
Proteasome inhibition prolongs survival during lethal hemorrhagic shock in rats.
Topics: Adenosine Triphosphate; Animals; Blotting, Western; Boronic Acids; Bortezomib; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Male; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Inbred Lew; Shock, Hemorrhagic | 2013 |
Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Infections; Lymphopenia; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors | 2013 |
Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Leukemia, B-Cell; Mice; NF-kappa B; Phosphatidylinositol 3-Kinases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-akt; Pyrazines; Transcription Factor RelA; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mitochondria; NF-kappa B; Piperidines; Proteasome Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrazoles; Pyrimidines; Reactive Oxygen Species; Tumor Cells, Cultured | 2013 |
A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sweden; Treatment Outcome; Vincristine | 2013 |
[Proliferation-inhibiting and multidrug-resistant reversing effect of bortezomib on human HL-60 cells].
Topics: Boronic Acids; Bortezomib; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Leukemia; NF-kappa B; Pyrazines; RNA, Messenger | 2012 |
[Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Panobinostat; Pyrazines | 2012 |
Bortezomib induced a phrenic palsy in a multiple myeloma patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diagnosis, Differential; Diphosphonates; gamma-Aminobutyric Acid; Humans; Imidazoles; Male; Melphalan; Multiple Myeloma; Nerve Compression Syndromes; Neuralgia; Phrenic Nerve; Prednisone; Pregabalin; Protease Inhibitors; Pyrazines; Respiratory Paralysis; Zoledronic Acid | 2013 |
Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome.
Topics: Acridine Orange; Autoantigens; Autophagy; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Membrane Proteins; Microscopy, Fluorescence; Phosphorylation; Proteasome Endopeptidase Complex; Protein Phosphatase 2; Pyrazines; Time Factors | 2013 |
Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Herpes Zoster; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Pyrazines; Recurrence; Risk Factors | 2013 |
Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.
Topics: Actins; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemokine CXCL12; Chemotaxis; Dose-Response Relationship, Drug; Down-Regulation; Female; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Polymerization; Pyrazines; Sorafenib; Syndecan-1; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2013 |
[Effect of bortezomib-based induction therapy on the peripheral blood stem cell harvest in multiple myeloma].
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Treatment Outcome | 2013 |
Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Substrate Specificity | 2013 |
Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
Topics: Antigens, CD34; Boronic Acids; Bortezomib; Coculture Techniques; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; I-kappa B Kinase; Imidazoles; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplastic Stem Cells; NF-kappa B; Primary Cell Culture; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Quinoxalines; Recombinant Proteins; RNA, Small Interfering; Stromal Cells; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured | 2013 |
In silico investigations of potential anabolic treatments in multiple myeloma-induced bone disease.
Topics: Anabolic Agents; Bone Diseases; Boronic Acids; Bortezomib; Calibration; Cell Count; Computer Simulation; Diphosphonates; Drug Therapy, Combination; Humans; Models, Biological; Multiple Myeloma; Organ Size; Osteoblasts; Osteoclasts; Pamidronate; Pyrazines; Reproducibility of Results; User-Computer Interface | 2013 |
Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Oncogene Proteins, Viral; Papillomavirus E7 Proteins; Papillomavirus Infections; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Repressor Proteins; RNA Interference; RNA, Messenger; RNA, Small Interfering; Squamous Cell Carcinoma of Head and Neck; Tumor Suppressor Protein p53; Ubiquitination | 2013 |
[Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Male; Multiple Myeloma; Pyrazines | 2012 |
Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Down-Regulation; Female; Gene Deletion; Mice; Mice, Inbred C57BL; Models, Molecular; Neoplasms; Proteasome Inhibitors; Pyrazines; STAT3 Transcription Factor; T-Lymphocytes, Cytotoxic; Tumor Suppressor Protein p53 | 2013 |
The clinical relevance of cancer cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Transcriptome; Translational Research, Biomedical; Xenograft Model Antitumor Assays | 2013 |
Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Disease Models, Animal; Gene Expression; Genes, Reporter; Graft Survival; Humans; Injections; Luciferases; Luminescent Measurements; Magnetic Resonance Imaging; Melphalan; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Paraproteins; Plasma Cells; Pyrazines; Syndecan-1; Tibia; Tumor Microenvironment | 2013 |
Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease Management; Drug Administration Routes; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Plasma Cells; Prognosis; Pyrazines; Recurrence; Risk; Thalidomide; Translocation, Genetic; Transplantation, Autologous | 2013 |
Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
Topics: Amyloid Precursor Protein Secretases; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Enzyme Inhibitors; Humans; Leupeptins; Lymphoma, T-Cell, Cutaneous; NF-kappa B; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptor, Notch1; Skin Neoplasms; Tumor Suppressor Protein p53 | 2013 |
Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Pyrazines; Salvage Therapy; Treatment Outcome | 2013 |
Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazines; Treatment Outcome; Vorinostat | 2013 |
Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cisplatin; DNA-Binding Proteins; Female; Heat Shock Transcription Factors; HSP70 Heat-Shock Proteins; Humans; Janus Kinases; Mice; Mice, Inbred C57BL; Ovarian Neoplasms; Phosphorylation; Pyrazines; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT1 Transcription Factor; Transcription Factors; Transplantation, Heterologous | 2013 |
Bortezomib influences the expression of malignant plasma cells membrane antigens.
Topics: Animals; Antigens; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Insulin-Like Growth Factor I; Interleukin-6; Membrane Proteins; Mice; Mice, SCID; Multiple Myeloma; Plasma Cells; Proteasome Inhibitors; Pyrazines; STAT3 Transcription Factor; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2013 |
Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Multiple Myeloma; Neoplasm Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Time Factors | 2013 |
Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells.
Topics: Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Calcium; Cell Line, Tumor; Cyclophilins; Drug Resistance, Neoplasm; Female; Humans; Membrane Potential, Mitochondrial; Mitochondria; Multiple Myeloma; Peptidyl-Prolyl Isomerase F; Pyrazines; Reactive Oxygen Species; Superoxide Dismutase; Transcriptome | 2013 |
In human monocyte derived dendritic cells SOCS1 interacting with CYTIP induces the degradation of CYTIP by the proteasome.
Topics: Blotting, Western; Boronic Acids; Bortezomib; Dendritic Cells; Flow Cytometry; Humans; Monocytes; Proteasome Endopeptidase Complex; Proteolysis; Pyrazines; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins; Transcription Factors; Two-Hybrid System Techniques; Ubiquitination | 2013 |
Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-2; Mice; Mice, Inbred NOD; Mice, SCID; Mitosis; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Piperazines; Polycomb-Group Proteins; Primary Cell Culture; Pyrazines; Side-Population Cells; Signal Transduction; Syndecan-1; Ubiquitins | 2013 |
Plasma cell-rich acute rejection with monoclonal gammopathy in a renal transplant recipient.
Topics: Acute Disease; Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Paraproteinemias; Patient Compliance; Plasma Cells; Pyrazines | 2013 |
[Loss of CD23 expression after bortezomib plus dexamethasone therapy in CCND1/IGH-positive multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclin D1; Dexamethasone; Humans; Male; Multiple Myeloma; Pyrazines; Receptors, IgE | 2013 |
Inhibition of proteasomal glucocorticoid receptor degradation restores dexamethasone-mediated stabilization of the blood-brain barrier after traumatic brain injury.
Topics: Animals; Blood Gas Analysis; Blood-Brain Barrier; Blotting, Western; Boronic Acids; Bortezomib; Brain Edema; Brain Injuries; Dexamethasone; Disease Models, Animal; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Multivariate Analysis; Proteasome Endopeptidase Complex; Pyrazines; Random Allocation; Real-Time Polymerase Chain Reaction; Receptors, Glucocorticoid; Reference Values; RNA, Messenger; Sensitivity and Specificity; Statistics, Nonparametric | 2013 |
Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Herpesvirus 4, Human; Heterografts; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Pyrazines; Reactive Oxygen Species; Signal Transduction; Tumor Burden; Virus Replication; Vorinostat | 2013 |
Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade.
Topics: Acetanilides; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Mice; Mice, Inbred C57BL; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Purines; Pyrazines; Thioctic Acid; Transient Receptor Potential Channels; TRPA1 Cation Channel | 2013 |
p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Cycle; Cell Proliferation; Colony-Forming Units Assay; Drug Resistance, Neoplasm; Flavonoids; Flow Cytometry; Humans; Immunoenzyme Techniques; Leukemia, Myeloid, Acute; Membrane Potential, Mitochondrial; Middle Aged; Phosphorylation; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Ribosomal Protein S6 Kinases, 70-kDa; Tumor Cells, Cultured | 2013 |
Bortezomib and bone health in adults: can we extend these findings to children?
Topics: Adult; Animals; Antineoplastic Agents; Bone Resorption; Boronic Acids; Bortezomib; Child; Child, Preschool; Female; Humans; Infant; Male; Mice; Multiple Myeloma; Pyrazines | 2013 |
"IM iD"eally treating multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Gene expression of catalytic proteasome subunits and resistance toward proteasome inhibition of B lymphocytes from patients with primary sjogren syndrome.
Topics: Adult; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Catalytic Domain; Cells, Cultured; Female; Gene Expression Regulation; Humans; Male; Middle Aged; Outpatients; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Sjogren's Syndrome | 2013 |
Bortezomib modulates regulatory T cell subpopulations in the process of acute graft-versus-host disease.
Topics: Acute Disease; Animals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Graft vs Host Disease; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines; T-Lymphocytes, Regulatory | 2013 |
Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2013 |
[Proteasome inhibitors: from early stages to future prospects].
Topics: Animals; Boronic Acids; Bortezomib; Humans; Molecular Targeted Therapy; Neoplasms; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2012 |
[Molecular targeting agents for multiple myeloma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Glycine; Histone Deacetylases; Humans; Immunologic Factors; Lactones; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Pyrroles; Thalidomide | 2012 |
Boronic acid-containing proteasome inhibitors: alert to potential pharmaceutical bioactivation.
Topics: Amides; Biotransformation; Boronic Acids; Bortezomib; Cytosol; Glutathione; Humans; Microsomes, Liver; Proteasome Inhibitors; Pyrazines | 2013 |
cMyc/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Boronic Acids; Bortezomib; Chromatin Immunoprecipitation; Computational Biology; DNA Primers; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; In Situ Hybridization; Kaplan-Meier Estimate; Luciferases; Lymphoma, T-Cell; Mice; MicroRNAs; Proteasome Inhibitors; Proto-Oncogene Proteins c-myc; Pyrazines; Repressor Proteins; RNA, Small Interfering; Signal Transduction; Skin Neoplasms | 2013 |
Carfilzomib for the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Oligopeptides; Pyrazines | 2013 |
Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib.
Topics: Aerobiosis; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; Chloroacetates; Drug Synergism; Glycolysis; Humans; Mice; Multiple Myeloma; Oxygen Consumption; Pyrazines; Pyruvate Dehydrogenase Complex; Superoxides | 2013 |
Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
Topics: Animals; Blotting, Western; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 9; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 4 or More Rings; Humans; Lenalidomide; Mice, SCID; Mitogen-Activated Protein Kinase 7; Multiple Myeloma; Protein Kinase Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Xenograft Model Antitumor Assays | 2013 |
Children are not large mice.
Topics: Adolescent; Animals; Antineoplastic Agents; Apoptosis; Bone Resorption; Boronic Acids; Bortezomib; Child; Child, Preschool; Chondrocytes; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Infant; Mice; Pyrazines | 2013 |
Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.
Topics: Animals; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, myc; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Mice, Transgenic; Multiple Myeloma; Pyrazines | 2013 |
Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma.
Topics: Antineoplastic Agents; Azacitidine; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Decitabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Hydrogen Peroxide; Hydroxamic Acids; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Oxidants; Prognosis; Pyrazines; Radiation, Ionizing; Reverse Transcriptase Polymerase Chain Reaction; Scavenger Receptors, Class A | 2013 |
The effect of proteasome inhibition on the generation of the human leukocyte antigen (HLA) peptidome.
Topics: Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Histocompatibility Antigens Class I; Humans; MCF-7 Cells; Oligopeptides; Peptides; Proteasome Inhibitors; Proteome; Pyrazines | 2013 |
Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Remission Induction; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Multiple myeloma: so much progress, but so many unsolved questions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Outcome Assessment, Health Care; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2013 |
NS-398 enhances the efficacy of bortezomib against RPMI8226 human multiple myeloma cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Down-Regulation; Drug Synergism; Humans; Multiple Myeloma; NF-kappa B; Nitrobenzenes; Pyrazines; Signal Transduction; Sulfonamides; Treatment Outcome | 2013 |
Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells.
Topics: Animals; Apoptosis; Autophagy; Azithromycin; Boronic Acids; Bortezomib; Cell Line, Tumor; Clarithromycin; Endoplasmic Reticulum Stress; Erythromycin; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Macrolides; Mice; Multiple Myeloma; Pyrazines; Transcription Factor CHOP | 2013 |
Inactivation of the mTORC1-eukaryotic translation initiation factor 4E pathway alters stress granule formation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Boronic Acids; Bortezomib; Cell Cycle Proteins; Chick Embryo; Cytoplasmic Granules; Eukaryotic Initiation Factor-4E; HeLa Cells; Humans; Indoles; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Phosphoproteins; Phosphorylation; Purines; Pyrazines; TOR Serine-Threonine Kinases | 2013 |
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Heterozygote; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Proteasome Endopeptidase Complex; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Sequence Analysis, DNA; Treatment Outcome; Young Adult | 2013 |
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide; Transplantation, Autologous | 2013 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cytarabine; Deoxycytidine; Doxorubicin; Fetal Blood; Flow Cytometry; Gemcitabine; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Interleukin Receptor Common gamma Subunit; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Podophyllotoxin; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Vorinostat; Xenograft Model Antitumor Assays | 2013 |
Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Calpain; Cell Line, Tumor; Cell Survival; Drug Synergism; HIV Protease Inhibitors; Humans; Mice; Mice, SCID; Multiple Myeloma; Nelfinavir; Pyrazines; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2013 |
The unfolded protein response selectively targets active smoothened mutants.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Benzoquinones; Boronic Acids; Bortezomib; Carcinoma, Basal Cell; Cell Line; DNA-Binding Proteins; Drosophila melanogaster; Drosophila Proteins; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Enzyme Inhibitors; Green Fluorescent Proteins; Hedgehog Proteins; Heterocyclic Compounds, 4 or More Rings; HSP90 Heat-Shock Proteins; Lactams, Macrocyclic; Medulloblastoma; Mice; Mutant Proteins; Pyrazines; Receptors, G-Protein-Coupled; RNA Interference; RNA, Small Interfering; Signal Transduction; Smoothened Receptor; Thapsigargin; Ubiquitin-Protein Ligases; Unfolded Protein Response | 2013 |
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Prognosis; Proportional Hazards Models; Pyrazines; Recurrence; Retrospective Studies; Risk Factors; Salvage Therapy; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs.
Topics: Animals; Boronic Acids; Bortezomib; Chymotrypsin; Collagen; Dogs; Dystroglycans; Dystrophin-Associated Protein Complex; Gene Expression; Immunohistochemistry; Inflammation; Muscle, Skeletal; Muscular Dystrophy, Animal; Muscular Dystrophy, Duchenne; Proteasome Endopeptidase Complex; Pyrazines | 2013 |
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Cellular Microenvironment; Coculture Techniques; Drug Resistance, Neoplasm; Fluorescent Dyes; Gene Expression Regulation; Humans; Multiple Myeloma; Pyrazines; Rhodamine 123; Stromal Cells | 2013 |
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
Topics: Aged; Antineoplastic Agents; Blood Component Removal; Boronic Acids; Bortezomib; Dexamethasone; Female; Filgrastim; Glucocorticoids; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recombinant Proteins; Retrospective Studies; Thalidomide; Transplantation, Autologous | 2013 |
Correction of cystathionine β-synthase deficiency in mice by treatment with proteasome inhibitors.
Topics: Animals; Boronic Acids; Bortezomib; Cystathionine beta-Synthase; Female; Homocystinuria; Humans; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation, Missense; Oligopeptides; Proteasome Inhibitors; Protein Folding; Pyrazines | 2013 |
Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Discovery; Humans; Immunoblotting; Neoplasms; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tetrazolium Salts; Thiazoles | 2013 |
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Leukemia; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Thalidomide; Young Adult | 2013 |
Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Risk Factors; Transplantation, Autologous; Treatment Outcome | 2013 |
Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.
Topics: Activating Transcription Factor 4; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Gene Expression Regulation; Humans; Immunosuppressive Agents; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Protein Biosynthesis; Proteins; Proto-Oncogene Proteins c-myc; Pyrazines; Rats; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transcription Factor CHOP; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Unfolded Protein Response | 2013 |
Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma.
Topics: Animals; Antiviral Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; CD27 Ligand; Cell Death; Cell Line, Tumor; Humans; Interferon-gamma; Kidney Neoplasms; Mice; Necrosis; Phosphorylation; Protein Binding; Pyrazines; Receptor-Interacting Protein Serine-Threonine Kinases; Recombinant Fusion Proteins; Signal Transduction; Species Specificity; STAT1 Transcription Factor | 2013 |
Focusing on boron in medicinal chemistry.
Topics: Antineoplastic Agents; Boron Compounds; Boron Neutron Capture Therapy; Boronic Acids; Bortezomib; Chemistry, Pharmaceutical; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines | 2013 |
Successful treatment of severe ABO antibody-mediated rejection using bortezomib: a case report.
Topics: ABO Blood-Group System; Boronic Acids; Bortezomib; Female; Graft Rejection; Humans; Infant; Kidney Transplantation; Pyrazines; Wilms Tumor | 2013 |
Proteasome inhibition profoundly affects activated human B cells.
Topics: Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Humans; Immunoglobulin G; Immunoglobulin M; In Vitro Techniques; Oligopeptides; Plasma Cells; Proteasome Endopeptidase Complex; Pyrazines | 2013 |
Mitochondrial dysfunction and therapeutic approaches in respiratory and limb muscles of cancer cachectic mice.
Topics: Acetylcysteine; Animals; Antioxidants; Boronic Acids; Bortezomib; Cachexia; Diaphragm; Electron Transport Chain Complex Proteins; Female; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mitochondria; Mitochondrial Diseases; Mitogen-Activated Protein Kinases; Muscle Strength; Muscle, Skeletal; NF-kappa B; Oxidative Stress; Pyrazines | 2013 |
Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; HEK293 Cells; Herpesviridae Infections; Herpesvirus 8, Human; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Lymphoma, Primary Effusion; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Proteasome Inhibitors; Proto-Oncogene Proteins c-myc; Pyrazines; Tumor Suppressor Protein p53; Virus Latency; Virus Replication; Vorinostat; Xenograft Model Antitumor Assays | 2013 |
Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Discovery; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Medical Records; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Retrospective Studies; Skin; Thalidomide | 2014 |
BAG3 induction is required to mitigate proteotoxicity via selective autophagy following inhibition of constitutive protein degradation pathways.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; HEK293 Cells; Humans; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Up-Regulation | 2014 |
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mitogen-Activated Protein Kinases; NF-kappa B; O(6)-Methylguanine-DNA Methyltransferase; Proto-Oncogene Proteins c-akt; Pyrazines; STAT3 Transcription Factor; Temozolomide; Tumor Suppressor Protein p53 | 2013 |
Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts.
Topics: Boronic Acids; Bortezomib; CD40 Ligand; Cell Adhesion; Cell Line, Tumor; Cell Survival; Down-Regulation; Enzyme Activation; Fibroblasts; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Humans; Interferon Regulatory Factors; NF-kappa B; Pyrazines | 2014 |
Vitamin D analogue TX 527 down-regulates the NF-κB pathway and controls the proliferation of endothelial cells transformed by Kaposi sarcoma herpesvirus.
Topics: Alkynes; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Transformed; Cell Proliferation; Cholecalciferol; Endothelial Cells; Gene Expression Regulation; Herpesvirus 8, Human; I-kappa B Proteins; Mice; NF-kappa B; Pyrazines; Sarcoma, Kaposi; Signal Transduction; Vitamin D | 2013 |
The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Forecasting; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Remission Induction; Retrospective Studies; Transplantation, Autologous; Treatment Outcome; Vincristine | 2013 |
MicroRNA-21 in scleroderma fibrosis and its function in TGF-β-regulated fibrosis-related genes expression.
Topics: Animals; Bleomycin; Boronic Acids; Bortezomib; Cells, Cultured; Female; Fibroblasts; Fibrosis; Gene Expression Regulation; Humans; Mice; Mice, Inbred DBA; MicroRNAs; Molecular Targeted Therapy; Pyrazines; RNA, Small Interfering; Scleroderma, Diffuse; Signal Transduction; Skin; Smad7 Protein; Transforming Growth Factor beta | 2013 |
NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Line, Tumor; Enzyme Activation; Humans; I-kappa B Kinase; Interferon-gamma; Kidney Neoplasms; Necrosis; NF-kappa B; Proteasome Inhibitors; Pyrazines; Receptor-Interacting Protein Serine-Threonine Kinases | 2013 |
Effect of bortezomib in combination with cisplatin and 5‑fluorouracil on 4T1 breast cancer cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Synergism; Female; Fluorouracil; Humans; Inhibitory Concentration 50; Pyrazines | 2013 |
The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Tolerance; Female; Humans; Lenalidomide; Logistic Models; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Oligopeptides; Outcome Assessment, Health Care; Prognosis; Pyrazines; Retrospective Studies; Risk Factors; Survival Analysis; Thalidomide | 2014 |
Combination of oxidative stress and FOXM1 inhibitors induces apoptosis in cancer cells and inhibits xenograft tumor growth.
Topics: 2-Methoxyestradiol; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Administration Schedule; Estradiol; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Humans; Isothiocyanates; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Oxidative Stress; Pyrazines; Random Allocation; Reactive Oxygen Species; RNA Interference; Transplantation, Heterologous; Treatment Outcome | 2013 |
[The appearance of t(9;22)(q34;q11.2) in BJP-λ type multiple myeloma during maintenance therapy including lenalidomide].
Topics: Bence Jones Protein; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Translocation, Genetic | 2013 |
[Clinical feature and efficacy of patients with multiple myeloma and renal impairment treated with bortezomib based chemotherapy].
Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Retrospective Studies; Treatment Outcome | 2013 |
[The efficacy and safety analysis of bortezomib retreatment in 76 patients with relapsed/refractory multiple myeloma].
Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Treatment Outcome | 2013 |
[Clinical significance of abnormal protein bands in multiple myeloma treated with bortezomib-based induction regimen and autologous stem cell transplantation].
Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prognosis; Pyrazines; Retrospective Studies; Transplantation, Autologous | 2013 |
[Curative effect observation of patients with primary systemic amyloidosis treated by the combination of bortezomib with dexamethasone and cyclophosphamide].
Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Pyrazines; Retrospective Studies; Treatment Outcome | 2013 |
XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Survival; Down-Regulation; Gene Expression Profiling; Gene Expression Regulation, Leukemic; HL-60 Cells; HSP72 Heat-Shock Proteins; Humans; I-kappa B Proteins; Leukemia, Myeloid, Acute; Leupeptins; Myeloid Cell Leukemia Sequence 1 Protein; NF-KappaB Inhibitor alpha; Oligonucleotides, Antisense; Oligopeptides; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunoglobulins, Intravenous; Kidney Transplantation; Liver Transplantation; Male; Plasmapheresis; Pyrazines; Rituximab; Splenectomy | 2013 |
Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Stress; Female; Humans; Insulin-Like Growth Factor I; Multiple Myeloma; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Biosynthesis; Pyrazines; Signal Transduction; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2013 |
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Diseases; Boronic Acids; Bortezomib; Carpal Tunnel Syndrome; Dexamethasone; Disease Progression; Doxorubicin; Duodenal Diseases; Female; Femur Head; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Jejunal Diseases; Lenalidomide; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Thalidomide; Vincristine | 2013 |
Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Membrane Proteins; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplastic Stem Cells; Polycomb Repressive Complex 1; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA Interference; Side-Population Cells; Up-Regulation | 2014 |
The protective effects of the proteasome inhibitor bortezomib (velcade) on ischemia-reperfusion injury in the rat retina.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers; Boronic Acids; Bortezomib; Cell Count; Chymotrypsin; Gene Expression Regulation; Inflammation Mediators; Male; NF-kappa B; Nitric Oxide Synthase Type II; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Retina; Retinal Ganglion Cells; RNA, Messenger | 2013 |
Very long-lasting remission of refractory T-large granular lymphocytes leukemia and myeloma by lenalidomide treatment.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Treatment Outcome | 2013 |
Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma.
Topics: Blood Coagulation; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Phosphatidylserines; Pyrazines; Thalidomide; Thromboplastin | 2013 |
Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Flow Cytometry; Humans; I-kappa B Proteins; Immunoblotting; Inhibitor of Apoptosis Proteins; Lymphoma, Large B-Cell, Diffuse; Mitochondria; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Proteasome Endopeptidase Complex; Proteolysis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Survivin; X-Linked Inhibitor of Apoptosis Protein | 2014 |
Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
Topics: Aminoglycosides; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Enediynes; Humans; JNK Mitogen-Activated Protein Kinases; Multiple Myeloma; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Pyrazines | 2013 |
Nuclear factor-erythroid 2-related factor 1 regulates expression of proteasome genes in hepatocytes and protects against endoplasmic reticulum stress and steatosis in mice.
Topics: Animals; Boronic Acids; Bortezomib; Endoplasmic Reticulum Stress; Fatty Liver; Gene Expression; Gene Expression Regulation, Enzymologic; Hepatocytes; Liver; Mice; Mice, Knockout; NF-E2-Related Factor 1; Proteasome Endopeptidase Complex; Pyrazines | 2013 |
The antidepressant amitriptyline shows potent therapeutic activity against multiple myeloma.
Topics: Administration, Oral; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib.
Topics: 3T3 Cells; Activating Transcription Factor 4; Animals; Antineoplastic Agents; Biomarkers; Bone Marrow Cells; Boronic Acids; Bortezomib; Calcification, Physiologic; Cells, Cultured; Endoplasmic Reticulum Stress; Gene Expression Regulation; Gene Silencing; Humans; Mice; Multiple Myeloma; Neoplasm Proteins; Osteoblasts; Osteocalcin; Osteogenesis; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Stromal Cells | 2013 |
Bortezomib-induced polyneuropathy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Humans; Multiple Myeloma; Polyneuropathies; Pyrazines; Retrospective Studies | 2013 |
Bortezomib induces apoptosis of endometrial cancer cells through microRNA-17-5p by targeting p21.
Topics: Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; MicroRNAs; Molecular Sequence Data; Proteasome Endopeptidase Complex; Protein Binding; Pyrazines; RNA, Small Interfering | 2013 |
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy | 2013 |
Changes in IgG subclasses of donor specific anti-HLA antibodies following bortezomib-based therapy for antibody mediated rejection.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Graft Rejection; HLA Antigens; Humans; Immunoglobulin G; Immunosuppressive Agents; Male; Middle Aged; Organ Transplantation; Plasmapheresis; Pyrazines; Steroids; Tissue Donors | 2012 |
Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Mice; Multiple Myeloma; Prognosis; Pyrazines; Receptors, CXCR4; Sarcoma, Myeloid; Survival Rate | 2013 |
Stabilization of activation induced cytidine deaminase by bortezomib does not confer increased drug target mutation frequency.
Topics: Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line, Tumor; Cytidine Deaminase; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Inhibitory Concentration 50; Mutation; Mutation Rate; Pyrazines | 2014 |
Effect of mycophenolic acid and bortezomib on purified human B cells: an in vitro study of long-term functionally stable MICA-sensitized renal recipients.
Topics: Aged; Antigens, CD19; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Case-Control Studies; Cell Differentiation; Cells, Cultured; Female; Histocompatibility Antigens Class I; Humans; Immunoglobulin M; In Vitro Techniques; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Proteasome Inhibitors; Pyrazines | 2013 |
BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.
Topics: Animals; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Embryo, Mammalian; Fibroblasts; Gene Expression Regulation, Neoplastic; Immunohistochemistry; Mesothelioma; Mice; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines; Transcription, Genetic | 2013 |
Identification of proteasome subunit beta type 6 (PSMB6) associated with deltamethrin resistance in mosquitoes by proteomic and bioassay analyses.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Cloning, Molecular; Culicidae; Cysteine Proteinase Inhibitors; Drug Resistance; Electrophoresis, Gel, Two-Dimensional; Gene Expression Regulation; Insect Proteins; Insecticides; Larva; Leupeptins; Nitriles; Phylogeny; Proteasome Endopeptidase Complex; Proteomics; Pyrazines; Pyrethrins; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2013 |
Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Topics: Adult; Aged; Anti-Bacterial Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Cohort Studies; Cyclams; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Health Care Costs; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Thalidomide; Time Factors; Transplantation Conditioning; Treatment Outcome | 2013 |
Proteasome inhibitor PS-341 attenuates flow-induced pulmonary arterial hypertension.
Topics: Animals; Blotting, Western; Boronic Acids; Bortezomib; Disease Models, Animal; Gene Expression Profiling; Hypertension, Pulmonary; Immunohistochemistry; Lung; Male; NF-kappa B; Proliferating Cell Nuclear Antigen; Proteasome Inhibitors; Pyrazines; Rats, Wistar; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Smad Proteins; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A; Vascular Remodeling | 2014 |
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nervous System; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Injections, Spinal; Kaplan-Meier Estimate; Lenalidomide; Male; Meninges; Middle Aged; Multiple Myeloma; Orbit; Proportional Hazards Models; Pyrazines; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Spine; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2013 |
Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis.
Topics: Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Immunoglobulin D; Male; Middle Aged; Pyrazines; Thalidomide; Treatment Outcome; Vincristine | 2013 |
Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
Topics: Adenocarcinoma, Follicular; Adult; Boronic Acids; Bortezomib; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazines; Sorafenib; Thyroid Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Preventing graft-versus-host disease: transplanters glimpse hope beyond immunosuppressants.
Topics: Acute Disease; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Cyclohexanes; Cyclophosphamide; Cyclosporine; Evidence-Based Medicine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Immunosuppressive Agents; Maraviroc; Methotrexate; Pentostatin; Peripheral Blood Stem Cell Transplantation; Pyrazines; Quality of Life; Tacrolimus; Triazoles; Vorinostat | 2013 |
Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Databases, Pharmaceutical; France; Heart Failure; Heart Function Tests; Humans; Male; Middle Aged; Multiple Myeloma; Pharmacovigilance; Pyrazines; Treatment Outcome | 2014 |
Inhibition of the human proteasome by imidazoline scaffolds.
Topics: Boronic Acids; Bortezomib; Cell Line; Humans; Imidazolines; NF-kappa B; Proteasome Inhibitors; Pyrazines | 2013 |
Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Clarithromycin; Drug Screening Assays, Antitumor; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Inclusion Bodies; Intracellular Space; Mice; Proteolysis; Pyrazines; Transcription Factor CHOP; Vorinostat | 2013 |
Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Flow Cytometry; Follow-Up Studies; Humans; Immunohistochemistry; Multiple Myeloma; Pyrazines; Rituximab; Waldenstrom Macroglobulinemia | 2013 |
Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
Topics: Adult; Aged; Antigens, CD34; Blood Component Removal; Boronic Acids; Bortezomib; Cyclophosphamide; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Male; Middle Aged; Multiple Myeloma; Plasmacytoma; Pyrazines; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2013 |
Targeted silencing of DNA-specific B cells combined with partial plasma cell depletion displays additive effects on delaying disease onset in lupus-prone mice.
Topics: Animals; Antibodies, Monoclonal; Autoantigens; B-Lymphocytes; Boronic Acids; Bortezomib; Cyclophosphamide; Disease Models, Animal; Disease Susceptibility; DNA; Female; Humans; Lupus Erythematosus, Systemic; Lymphocyte Depletion; Mice; Mice, Inbred MRL lpr; Peptide Fragments; Pyrazines; Receptors, IgG; Recombinant Fusion Proteins | 2013 |
Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Female; Follow-Up Studies; France; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2014 |
Sequence of novel agents in multiple myeloma: an instrumental variable analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide | 2013 |
Plasmacytoma-like post-transplant lymphoproliferative disorder seen in pediatric combined liver and intestinal transplant recipients.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Child; Dexamethasone; Female; Humans; Immunocompromised Host; Infant; Intestine, Small; Liver Transplantation; Lymphoproliferative Disorders; Pyrazines | 2013 |
PAX3-FOXO1 induces up-regulation of Noxa sensitizing alveolar rhabdomyosarcoma cells to apoptosis.
Topics: Animals; Apoptosis; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Mice; Myoblasts; Nitrophenols; Oligopeptides; Oncogene Proteins, Fusion; Paired Box Transcription Factors; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Rhabdomyosarcoma, Alveolar; Sulfonamides; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
[The combination of chronic myeloid leukemia and multiple myeloma in one patient].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Imatinib Mesylate; Induction Chemotherapy; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Piperazines; Polyneuropathies; Pyrazines; Pyrimidines; Recurrence; Watchful Waiting | 2013 |
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Republic of Korea; Singapore; Survival Rate; Tertiary Care Centers; Thalidomide | 2013 |
Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Genital Neoplasms, Male; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Orchiectomy; Proteasome Inhibitors; Pyrazines; Secondary Prevention; Spermatic Cord; Stem Cell Transplantation; Testicular Neoplasms; Thalidomide; Vincristine | 2014 |
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.
Topics: Acrylamides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Case-Control Studies; Caspases; Cell Proliferation; Drug Synergism; Female; Fluorescent Antibody Technique; Gene Expression Profiling; Humans; Male; Mice; Mice, SCID; Multiple Myeloma; NAD; Neoplasm Recurrence, Local; NF-kappa B; Nicotinamide Phosphoribosyltransferase; Oligonucleotide Array Sequence Analysis; Piperidines; Poly(ADP-ribose) Polymerases; Prognosis; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Down-regulation of 11β-hydroxysteroid dehydrogenase type 2 by bortezomib sensitizes Jurkat leukemia T cells against glucocorticoid-induced apoptosis.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Screening Assays, Antitumor; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Leukemic; Glucocorticoids; Humans; Hydrocortisone; Jurkat Cells; Leukemia; MAP Kinase Signaling System; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyrazines; Receptors, Glucocorticoid; RNA, Messenger | 2013 |
The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cell Cycle Checkpoints; Cytotoxicity, Immunologic; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Lymphoma, B-Cell; Neoplasm Proteins; Oligopeptides; Proteasome Inhibitors; Pyrazines; Rituximab; Tumor Cells, Cultured; Up-Regulation | 2013 |
Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred C57BL; Multiple Myeloma; Nitroimidazoles; Phosphoramide Mustards; Pyrazines; Signal Transduction | 2013 |
Failure of bortezomib to cure acute antibody-mediated rejection in a non-compliant renal transplant patient.
Topics: Adolescent; Adrenal Cortex Hormones; Antibodies; Biopsy; Boronic Acids; Bortezomib; Complement C4b; Graft Rejection; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Kidney Transplantation; Male; Patient Compliance; Peptide Fragments; Polycystic Kidney, Autosomal Recessive; Protease Inhibitors; Pyrazines; Renal Dialysis; Treatment Outcome | 2013 |
Pomalidomide in the treatment of relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2013 |
Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Multidrug Resistance-Associated Proteins; Pemetrexed; Pyrazines; Selenious Acid | 2013 |
A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosomal Instability; Clinical Trials as Topic; Comparative Genomic Hybridization; DNA Damage; DNA Repair; Humans; Multiple Myeloma; Multivariate Analysis; Prognosis; Proportional Hazards Models; Pyrazines; Risk; Transcriptome; Treatment Outcome | 2013 |
Bortezomib monotherapy in patients with multiple myeloma is associated with reactivation of hepatitis B.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Hepatitis B; Humans; Male; Multiple Myeloma; Pyrazines | 2013 |
Predictive biomarkers may help individualize treatment for patients with follicular lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Humans; Lymphoma, Follicular; Precision Medicine; Proteasome Endopeptidase Complex; Pyrazines; Rituximab | 2013 |
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide; Time Factors; Young Adult | 2013 |
CXCR4 is a good survival prognostic indicator in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Chemokine CXCL12; Chromosome Aberrations; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazines; Receptors, CXCR4; Survival Rate; Thalidomide | 2013 |
Improvement of mucocutaneous involvement of immunoglobulin light chain amyloidosis after chemotherapy and hematopoietic stem cell transplantation for multiple myeloma.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Male; Multiple Myeloma; Pyrazines | 2013 |
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Immunologic Factors; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Thrombocytopenia; Treatment Outcome | 2014 |
Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brefeldin A; Caspases, Initiator; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Endoplasmic Reticulum Stress; Epithelial Cells; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Orthoreovirus, Mammalian; Pancreas; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; ras Proteins; Reoviridae; Tunicamycin; Virus Replication; Xenograft Model Antitumor Assays | 2013 |
Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells.
Topics: Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Chromatin Immunoprecipitation; DNA Methylation; DNA Primers; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HSP72 Heat-Shock Proteins; Humans; Immunoblotting; Microarray Analysis; Protein Isoforms; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Urinary Bladder Neoplasms | 2013 |
Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cholangiocarcinoma; Endoplasmic Reticulum Stress; Humans; Janus Kinase 3; Luciferases; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Transcription Factor CHOP; Tumor Cells, Cultured; Unfolded Protein Response | 2013 |
Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Nucleolus; Cell Proliferation; Cysteine; Cytosol; Drug Resistance, Neoplasm; Flow Cytometry; Free Radical Scavengers; Humans; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins; Nucleophosmin; Oxides; Pyrazines; Reactive Oxygen Species; Tryptophan; Tumor Cells, Cultured | 2013 |
Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Axons; Boronic Acids; Bortezomib; Energy Metabolism; Hyperalgesia; Male; Mitochondria; Neoplasm Transplantation; Neuralgia; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nerves; Peroxynitrous Acid; Physical Stimulation; Protein Processing, Post-Translational; Pyrazines; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells; Superoxide Dismutase | 2013 |
Multiple myeloma: a descriptive study of 217 Egyptian patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Dexamethasone; Egypt; Female; Hospitals, Urban; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Retrospective Studies; Severity of Illness Index; Thalidomide; Vincristine | 2014 |
Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromatin Immunoprecipitation; Enzyme-Linked Immunosorbent Assay; Humans; I-kappa B Kinase; Interleukin-8; Male; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Transfection | 2013 |
Structures of an ATP-independent Lon-like protease and its complexes with covalent inhibitors.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Bacterial Proteins; Boronic Acids; Bortezomib; Catalytic Domain; Crystallography, X-Ray; Deinococcus; Lactones; Models, Molecular; Molecular Sequence Data; Protease Inhibitors; Protease La; Protein Conformation; Pyrazines | 2013 |
Acute antibody-mediated rejection in pediatric kidney transplants: a single center experience.
Topics: Adolescent; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Child; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Hypotension; Immunoglobulins, Intravenous; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Transplantation; Male; Methylprednisolone Hemisuccinate; Patient Compliance; Plasma Exchange; Pyrazines; Renal Insufficiency; Retrospective Studies; Rituximab; Treatment Outcome | 2013 |
Sweet-like syndrome induced by bortezomib.
Topics: Adrenal Cortex Hormones; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Male; Multiple Myeloma; Pyrazines; Sweet Syndrome; Treatment Outcome | 2013 |
Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Abscess; Female; Host-Pathogen Interactions; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Nocardia; Nocardia Infections; Pyrazines; Thalidomide | 2014 |
[Efficacy comparison between standard and reduced doses of bortezomib combined with adriamycin and dexamethasone in the treatment of patients with multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2013 |
Chaperone-mediated autophagy degrades mutant p53.
Topics: Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Leupeptins; Lysosomes; Molecular Chaperones; Mutation; Proteasome Endopeptidase Complex; Proteolysis; Pyrazines; Tumor Suppressor Protein p53; Ubiquitination | 2013 |
Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation.
Topics: Activating Transcription Factor 4; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; HIV Protease Inhibitors; Humans; Nelfinavir; Neoplasm Proteins; Neoplasms; Nuclear Proteins; Pyrazines; TOR Serine-Threonine Kinases; Up-Regulation | 2013 |
Anticancer agent ukrain and bortezomib combination is synergistic in 4T1 breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Berberine Alkaloids; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Female; Humans; Melanoma, Experimental; Phenanthridines; Pyrazines | 2014 |
Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Multiple Myeloma; Pancreatitis; Pyrazines; Tomography, X-Ray Computed | 2014 |
[Right cervical lymph node enlargement].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclin D1; Dexamethasone; Diagnosis, Differential; Follow-Up Studies; Histiocytic Necrotizing Lymphadenitis; Humans; Infectious Mononucleosis; Ki-67 Antigen; Lymph Nodes; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Middle Aged; Neck; Pyrazines; SOXC Transcription Factors | 2013 |
Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Melphalan; Middle Aged; Multimodal Imaging; Osteolysis; Positron-Emission Tomography; Pyrazines; Recurrence; Remission Induction; Rituximab; Tomography, X-Ray Computed; Waldenstrom Macroglobulinemia; Zoledronic Acid | 2013 |
Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; Basic-Leucine Zipper Transcription Factors; Blotting, Western; Boronic Acids; Bortezomib; Cell Nucleus; Cytoplasm; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Oxidative Stress; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Transport; Pyrazines; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Gold nanoparticle delivery-enhanced proteasome inhibitor effect in adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Synergism; Epithelial Cells; Gold; Humans; Nanoparticles; Pancreatic Ducts; Pancreatic Neoplasms; Polyethylene Glycols; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured | 2013 |
Meningeal myelomatosis developed after treatment with novel agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cerebrospinal Fluid; Dexamethasone; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Meningeal Neoplasms; Multiple Myeloma; Plasma Cells; Pyrazines; Thalidomide | 2013 |
Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus.
Topics: Aged; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lupus Erythematosus, Systemic; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2014 |
Transplants for the elderly in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2013 |
Light chain deposition.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light Chains; Kidney Diseases; Kidney Tubules; Male; Multiple Myeloma; Prognosis; Pyrazines | 2013 |
Bortezomib-induced neuropathy: axonal membrane depolarization precedes development of neuropathy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axons; Boronic Acids; Bortezomib; Female; Humans; Male; Membrane Potentials; Middle Aged; Multiple Myeloma; Neural Conduction; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Sodium-Potassium-Exchanging ATPase | 2014 |
Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Osteocytes; p38 Mitogen-Activated Protein Kinases; Pyrazines; Signal Transduction; Time Factors | 2013 |
A mental retardation-linked nonsense mutation in cereblon is rescued by proteasome inhibition.
Topics: Adaptor Proteins, Signal Transducing; Boronic Acids; Bortezomib; Codon, Nonsense; HEK293 Cells; Humans; Immunoblotting; Intellectual Disability; Lysine; Microscopy, Fluorescence; Mutant Proteins; Nuclear Proteins; Peptide Hydrolases; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Ubiquitin-Protein Ligases; Ubiquitination | 2013 |
Ex-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of Multiple Myeloma biology and response to therapy.
Topics: Adult; Aged; Angiopoietin-2; Animals; beta 2-Microglobulin; Bioreactors; Bone and Bones; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Cell Culture Techniques; Female; Genetic Markers; Humans; Immunohistochemistry; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Tibia; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2013 |
Durable remission of mantle cell lymphoma relapsing a third time after allogeneic hematopoietic stem cell transplantation treated with rituximab, bortezomib, donor lymphocytes, and pegylated interferon.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Boronic Acids; Bortezomib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Interferons; Lymph Nodes; Lymphoma, Mantle-Cell; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Retreatment; Rituximab; Transplantation, Homologous | 2013 |
Use of bortezomib to treat anti-HLA antibodies in renal transplant patients: a single-center experience.
Topics: Adult; Allografts; Antineoplastic Agents; Autoantibodies; Boronic Acids; Bortezomib; Female; Graft Rejection; Graft Survival; Humans; Immunoglobulins, Intravenous; Kidney Transplantation; Male; Middle Aged; Plasmapheresis; Pyrazines | 2013 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous | 2014 |
[Effect of bortezomib on reverse multidrug resistance and XIAP expression in imatinib-resistant primary cells of chronic myeloid leukemia in blastic crisis].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proteasome Inhibitors; Pyrazines; Pyrimidines; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein; Young Adult | 2013 |
[Effect of proteasome inhibitor bortezomib on proliferation, apoptosis and SHIP gene expression in K562 cells].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Humans; Inositol Polyphosphate 5-Phosphatases; K562 Cells; Phosphoric Monoester Hydrolases; Proteasome Inhibitors; Pyrazines | 2013 |
[Myeloma therapy(2) Treatment of transplant-ineligible patients].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Core-shell Fe3O4 polydopamine nanoparticles serve multipurpose as drug carrier, catalyst support and carbon adsorbent.
Topics: Adsorption; Boronic Acids; Bortezomib; Carbon; Catalysis; Drug Carriers; Ferrosoferric Oxide; Indoles; Magnetite Nanoparticles; Particle Size; Polymers; Pyrazines; Rhodamines; Water | 2013 |
Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress.
Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Gene Expression Profiling; Humans; Oxidative Stress; Piperidones; Polymerase Chain Reaction; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Reactive Oxygen Species; Transcription, Genetic; Ubiquitin-Specific Proteases | 2014 |
Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: a potential therapeutic target.
Topics: Animals; Boronic Acids; Bortezomib; Disease Models, Animal; Endoplasmic Reticulum Stress; Mice; Muscle Weakness; Muscle, Skeletal; Myositis; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin; Ubiquitination | 2013 |
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Korea; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.
Topics: Activating Transcription Factor 6; Boronic Acids; Bortezomib; Cell Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; eIF-2 Kinase; Endoplasmic Reticulum Stress; Endoribonucleases; Humans; Immunophenotyping; Membrane Proteins; Multiple Myeloma; Mutation; Plasma Cells; Precursor Cells, B-Lymphoid; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Regulatory Factor X Transcription Factors; Signal Transduction; Transcription Factors; X-Box Binding Protein 1 | 2013 |
Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Chronic Disease; Female; Glomerular Filtration Rate; Graft Rejection; HLA Antigens; Humans; Immunoglobulins, Intravenous; Isoantibodies; Kidney; Kidney Transplantation; Male; Middle Aged; Plasmapheresis; Pyrazines; Retrospective Studies; Rituximab | 2013 |
The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dog Diseases; Dogs; Melanoma; Melanoma, Cutaneous Malignant; NF-kappa B; Proteasome Inhibitors; Pyrazines; Signal Transduction; Skin Neoplasms | 2013 |
Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Axonal Transport; Boronic Acids; Bortezomib; Cell Death; Cells, Cultured; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Embryo, Mammalian; Ganglia, Spinal; Microscopy, Electron, Transmission; Microtubules; Neurons; Organ Culture Techniques; Pyrazines; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Time Factors | 2013 |
Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer.
Topics: Animals; Boronic Acids; Bortezomib; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; DNA Repair; Fanconi Anemia Complementation Group D2 Protein; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Rad51 Recombinase; Radiation-Sensitizing Agents; Radiation, Ionizing; Radiotherapy; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Xenograft Model Antitumor Assays | 2013 |
Bortezomib rescue therapy in a patient with recurrent antibody-mediated rejection after lung transplantation.
Topics: Aged; Antibodies; Biopsy; Boronic Acids; Bortezomib; Graft Rejection; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Transplantation; Male; Proteasome Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2013 |
VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Remodeling; Bone Resorption; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Serum Response Element; Thalidomide; Transplantation, Autologous | 2014 |
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies | 2013 |
The ubiquitin-proteasome-system.
Topics: Animals; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin; Ubiquitination | 2014 |
Induction of steroid sulfatase expression in PC-3 human prostate cancer cells by insulin-like growth factor II.
Topics: 17-Hydroxysteroid Dehydrogenases; Androstadienes; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromones; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Insulin-Like Growth Factor II; Leupeptins; Male; Morpholines; NF-kappa B; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Polymerase Chain Reaction; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; Sequence Analysis, DNA; Signal Transduction; Steryl-Sulfatase; Sulfones; Sulfotransferases; Wortmannin | 2013 |
Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.
Topics: Adolescent; Boronic Acids; Bortezomib; Child; Child, Preschool; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines | 2013 |
Proteasome inhibition induces DNA damage and reorganizes nuclear architecture and protein synthesis machinery in sensory ganglion neurons.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Nucleus; DNA Damage; DNA Repair; Ganglia, Sensory; Gene Expression; Male; Microscopy, Confocal; Nissl Bodies; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2014 |
Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Combined Modality Therapy; Cricetinae; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Mice; Multiple Myeloma; NF-kappa B; Oncolytic Virotherapy; Pyrazines; Real-Time Polymerase Chain Reaction; Vesicular Stomatitis; Vesicular stomatitis Indiana virus; Virus Replication | 2013 |
Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse.
Topics: Activating Transcription Factor 3; Animals; Boronic Acids; Bortezomib; Electrophysiology; Female; Mice; Mice, Inbred BALB C; Peripheral Nervous System Diseases; Pyrazines | 2013 |
BMP7 expression correlates with secondary drug resistance in mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bone Morphogenetic Protein 7; Boronic Acids; Bortezomib; Cell Line, Tumor; CpG Islands; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Molecular Sequence Data; Neoplasm Staging; Pyrazines; Recurrence; RNA Interference; Treatment Outcome | 2013 |
The role of mutant protein level in autosomal recessive catecholamine dependent polymorphic ventricular tachycardia (CPVT2).
Topics: Aging; Animals; Animals, Newborn; Boronic Acids; Bortezomib; Calcium; Calsequestrin; Cells, Cultured; Gene Expression; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Myocytes, Cardiac; Pyrazines; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Severity of Illness Index; Tachycardia, Ventricular | 2013 |
OTUB1 enhances TGFβ signalling by inhibiting the ubiquitylation and degradation of active SMAD2/3.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine Endopeptidases; Deubiquitinating Enzymes; Gene Expression Regulation; Genes, Reporter; Green Fluorescent Proteins; Humans; Mice; Phosphoproteins; Phosphorylation; Primary Cell Culture; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Stability; Pyrazines; Signal Transduction; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta; Ubiquitin; Ubiquitination | 2013 |
Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Topics: Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diarrhea; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thrombocytopenia | 2013 |
Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Injections, Subcutaneous; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide; Transplantation, Autologous; Treatment Failure | 2014 |
Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent manner.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Dipeptides; Gene Expression Regulation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; I-kappa B Kinase; I-kappa B Proteins; Interleukin-8; Ketones; Leupeptins; Lysosomes; Microtubule-Associated Proteins; Mutation, Missense; NF-kappa B; NF-KappaB Inhibitor alpha; Proteasome Inhibitors; Proteolysis; Pyrazines; Thiophenes; Time Factors | 2013 |
Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; DNA Methylation; Drug Carriers; fms-Like Tyrosine Kinase 3; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Experimental; Leukemia, Myeloid, Acute; Liposomes; Mice; Mice, Mutant Strains; MicroRNAs; Mutation; Myeloid-Lymphoid Leukemia Protein; Proteasome Inhibitors; Pyrazines; RNA, Neoplasm; Tandem Repeat Sequences | 2013 |
Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.
Topics: Adenosine Triphosphate; Analysis of Variance; Apoptosis; Base Sequence; Blotting, Western; Boronic Acids; Bortezomib; Casein Kinase II; Cell Line, Tumor; DNA Primers; Humans; Immunohistochemistry; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; Molecular Sequence Data; Multiple Myeloma; Naphthyridines; NF-kappa B; Phenazines; Pyrazines; Real-Time Polymerase Chain Reaction; RNA Interference; Signal Transduction; STAT3 Transcription Factor | 2013 |
JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells.
Topics: Autophagy; Blotting, Western; Boronic Acids; Bortezomib; Endoplasmic Reticulum Stress; Enzyme Activation; Gene Knockdown Techniques; Humans; Lymphoma, Primary Effusion; MAP Kinase Kinase 4; Microscopy, Electron; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bevacizumab; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Glioblastoma; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Temozolomide; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
Sustained reduction of alloantibody secreting plasma cells and donor specific antibody with proteasome inhibition in mice.
Topics: Allografts; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Heart Transplantation; Isoantibodies; Lymphocyte Depletion; Mice; Mice, Inbred BALB C; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2013 |
Effect of novel proteasome and immunoproteasome inhibitors on dendritic cell maturation, function, and expression of IκB and NFκB.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Coculture Techniques; Dendritic Cells; Gene Expression Regulation; Graft vs Host Disease; Humans; I-kappa B Kinase; NF-kappa B; Proteasome Inhibitors; Pyrazines | 2013 |
MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disease Progression; Extracellular Signal-Regulated MAP Kinases; Humans; Lymphoma, T-Cell, Peripheral; Mice; MicroRNAs; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Pyrazines | 2014 |
Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells.
Topics: Adenine; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Mitochondria; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Signal Transduction; Ubiquitin-Activating Enzymes | 2014 |
[Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement].
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Heart Neoplasms; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Melphalan; Middle Aged; Pyrazines; Remission Induction; Thalidomide; Treatment Outcome | 2013 |
Thermally targeted p21 peptide enhances bortezomib cytotoxicity in androgen-independent prostate cancer cell lines.
Topics: Androgens; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Hot Temperature; Humans; Male; Molecular Mimicry; Peptides; Prostatic Neoplasms, Castration-Resistant; Protein Engineering; Pyrazines; Recombinant Fusion Proteins; Tumor Cells, Cultured | 2014 |
Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib.
Topics: ADAM Proteins; ADAMTS13 Protein; Adolescent; Antibodies, Monoclonal; Boronic Acids; Bortezomib; Female; Humans; Immunosuppressive Agents; Plasma Exchange; Purpura, Thrombotic Thrombocytopenic; Pyrazines; Recurrence; Remission Induction; Treatment Outcome | 2014 |
Opposing effects on immune function and skin barrier regulation by the proteasome inhibitor bortezomib in an allergen-induced eczema model.
Topics: Animals; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dermatitis, Atopic; Disease Models, Animal; Eczema; Female; Immune System; Immunoglobulin E; Immunohistochemistry; Inflammation; Mice; Mice, Inbred BALB C; Organ Culture Techniques; Proteasome Inhibitors; Pyrazines; Skin | 2013 |
Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Boronic Acids; Bortezomib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Pathology, Molecular; Prognosis; Pyrazines | 2013 |
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Microscopy, Electron, Scanning; Nanospheres; Pyrazines; Silicon Dioxide; Spectrophotometry, Ultraviolet | 2014 |
Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.
Topics: Aldehyde Oxidoreductases; Antigens, CD20; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Hypoxia; Cell Line, Tumor; Down-Regulation; Humans; Intercellular Signaling Peptides and Proteins; Multiple Myeloma; Neoplastic Stem Cells; Oxygen; PAX5 Transcription Factor; Peptides; Pyrazines; Receptors, CXCR4; Syndecan-1; Tretinoin; Tumor Microenvironment | 2013 |
Bortezomib enhances fatty liver preservation in Institut George Lopez-1 solution through adenosine monophosphate activated protein kinase and Akt/mTOR pathways.
Topics: AMP-Activated Protein Kinases; Animals; Boronic Acids; Bortezomib; Fatty Liver; Liver; Organ Preservation; Organ Preservation Solutions; Proto-Oncogene Proteins c-akt; Pyrazines; Rats; Rats, Zucker; Reperfusion Injury; Solutions; TOR Serine-Threonine Kinases | 2014 |
Initial treatment of nontransplant patients with multiple myeloma.
Topics: Age Factors; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria.
Topics: Animals; Blotting, Western; Boronic Acids; Bortezomib; Circular Dichroism; DNA Primers; Erythroid Cells; Humans; Mice; Models, Molecular; Mutation, Missense; Porphyria, Erythropoietic; Porphyrins; Proteasome Inhibitors; Protein Folding; Pyrazines; Real-Time Polymerase Chain Reaction; Spectrometry, Fluorescence; Uroporphyrinogen III Synthetase | 2013 |
Authorising bortezomib treatment prior to reviewing haematology results: a step toward home administration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Monitoring; Home Care Services; Humans; Middle Aged; Multiple Myeloma; Platelet Count; Predictive Value of Tests; Prospective Studies; Proteasome Inhibitors; Pyrazines; Risk Assessment; Risk Factors; Scotland; Severity of Illness Index; Thrombocytopenia; Time Factors; Treatment Outcome | 2014 |
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.
Topics: Benzamides; Boronic Acids; Bortezomib; Caspases; Cell Death; Cell Line, Tumor; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Heterocyclic Compounds, 2-Ring; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Leukemia; Mitosis; Models, Biological; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pteridines; Pyrazines; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles | 2013 |
[Effect of PCI-32765 and bortezomib on proliferation and apoptosis of B-cell tumor cell lines and its mechanisms].
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Leukemic; Humans; Inhibitor of Apoptosis Proteins; NF-kappa B; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines | 2013 |
Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells.
Topics: 2-Methoxyestradiol; Acetylcysteine; Apoptosis; Boronic Acids; Bortezomib; Calcium; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Humans; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Pyrazines; Reactive Oxygen Species | 2013 |
Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Brain-Derived Neurotrophic Factor; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines | 2014 |
Successful treatment of POEMS syndrome with bortezomib and dexamethasone, combined with radiotherapy, and followed by autologous stem cell transplantation.
Topics: Adult; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; POEMS Syndrome; Positron-Emission Tomography; Pyrazines; Radiotherapy; Tomography Scanners, X-Ray Computed; Transplantation, Autologous; Treatment Outcome | 2013 |
Global cellular response to chemotherapy-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Genome, Human; Heat Shock Transcription Factors; Humans; Multiple Myeloma; Protease Inhibitors; Protein Biosynthesis; Proteolysis; Pyrazines; Ribosomes; Stress, Physiological; Transcription Factors; Transcription, Genetic | 2013 |
Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Ceramides; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinase 5; Morpholines; Pancreatic Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Pyrazines | 2014 |
Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma.
Topics: Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Biomarkers; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lectins, C-Type; Mice; Multiple Myeloma; Plasma Cells; Pyrazines | 2013 |
Bortezomib, a proteasome inhibitor, attenuates angiotensin II-induced hypertension and aortic remodeling in rats.
Topics: Angiotensin II; Animals; Aorta; Boronic Acids; Bortezomib; Cell Proliferation; Extracellular Matrix; Gene Expression Regulation; Hypertension; Male; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Vascular Cell Adhesion Molecule-1 | 2013 |
Bortezomib: a therapeutic resource for the veterinary oncologist?
Topics: Animals; Boronic Acids; Bortezomib; Dog Diseases; Melanoma; Melanoma, Cutaneous Malignant; NF-kappa B; Proteasome Inhibitors; Pyrazines; Signal Transduction; Skin Neoplasms | 2013 |
High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Cohort Studies; Cytomegalovirus Infections; Dexamethasone; Doxorubicin; Humans; Immunocompromised Host; Incidence; Induction Chemotherapy; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transplantation, Autologous; Vincristine | 2014 |
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; I-kappa B Kinase; Lapatinib; Mice, SCID; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Is bortezomib a rare cause of acute pancreatitis?
Topics: Abdominal Pain; Acute Disease; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Pancreatitis; Pyrazines | 2013 |
Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antibodies, Neoplasm; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoantigens; Boronic Acids; Bortezomib; Chaperonin 60; Combined Modality Therapy; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Female; Glucocorticoids; Hematopoietic Stem Cell Transplantation; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Male; Melphalan; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm Proteins; Oligoclonal Bands; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous | 2014 |
Synthetic lethality between CCNE1 amplification and loss of BRCA1.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; BRCA1 Protein; Cyclin E; Female; Gene Expression Regulation, Neoplastic; Homologous Recombination; Humans; Microarray Analysis; Oncogene Proteins; Ovarian Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; RNA, Small Interfering | 2013 |
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2014 |
Dissecting apoptosis the omics way.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Heat Shock Transcription Factors; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Transcription Factors | 2013 |
Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Disease Models, Animal; Flow Cytometry; Humans; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Pyrazines; Receptors, Interleukin-2 | 2013 |
An anti-leishmanial thiadiazine agent induces multiple myeloma cell apoptosis by suppressing the nuclear factor kappaB signalling pathway.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Growth Processes; Female; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; NF-kappa B; Pyrazines; Random Allocation; Signal Transduction; Thiadiazines; Xenograft Model Antitumor Assays | 2014 |
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Gossypol; Humans; Lenalidomide; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Thalidomide; Waldenstrom Macroglobulinemia | 2014 |
Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure.
Topics: Acute Kidney Injury; Adsorption; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Female; Hemodiafiltration; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Ion Exchange Resins; Male; Membranes, Artificial; Middle Aged; Multiple Myeloma; Myeloma Proteins; Polymers; Pyrazines; Serum Albumin; Thalidomide; Treatment Outcome | 2013 |
Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum.
Topics: Acute Kidney Injury; Anemia; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Drug Monitoring; Drug Substitution; Flank Pain; Humans; Immunoglobulin kappa-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Renal Dialysis; Thalidomide | 2013 |
High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Body Mass Index; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Pyrazines; Retrospective Studies; Risk Factors | 2013 |
Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Patient Preference; Pyrazines | 2013 |
Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation.
Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; G2 Phase; Humans; Immunoprecipitation; Microtubules; Pyrazines | 2013 |
Reactive nucleolar and Cajal body responses to proteasome inhibition in sensory ganglion neurons.
Topics: Animals; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Nucleolus; Cell Nucleus; Coiled Bodies; Cytoplasm; Ganglia, Sensory; Humans; Neurodegenerative Diseases; Proteasome Endopeptidase Complex; Pyrazines; Rats; Sensory Receptor Cells; Signal Transduction | 2014 |
The effect of PS-341 on pulmonary vascular remodeling in high blood flow-induced pulmonary hypertension.
Topics: Animals; Blood Flow Velocity; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Down-Regulation; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; I-kappa B Proteins; Lung; Male; NF-KappaB Inhibitor alpha; Pulmonary Artery; Pyrazines; Rats; Rats, Wistar; Signal Transduction; Transcription Factor RelA | 2014 |
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Disease-Free Survival; Drug Evaluation; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Nervous System Diseases; Prednisone; Prognosis; Proportional Hazards Models; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; NF-kappa B; Pyrazines; Signal Transduction; Syndecan-1; Thalidomide; Ubiquitination | 2014 |
PKC?-dependent activation of the ubiquitin proteasome system is responsible for high glucose-induced human breast cancer MCF-7 cell proliferation, migration and invasion.
Topics: Acetophenones; Apoptosis; Benzopyrans; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Glucose; Humans; MCF-7 Cells; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase C-delta; Pyrazines; Ubiquitin | 2013 |
The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endoplasmic Reticulum Stress; Enzyme Activation; Flow Cytometry; Humans; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Proteasome Endopeptidase Complex; Pyrazines; Xanthones; Xenograft Model Antitumor Assays | 2014 |
Hyperammonemic encephalopathy in multiple myeloma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Boronic Acids; Bortezomib; Brain; Brain Edema; Coma; Cyclophosphamide; Dexamethasone; Diphosphonates; Fatal Outcome; Humans; Hyperammonemia; Imidazoles; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteolysis; Pyrazines; Tomography, X-Ray Computed; Zoledronic Acid | 2014 |
The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cannabidiol; Cell Cycle; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; In Situ Hybridization, Fluorescence; Membrane Potential, Mitochondrial; Multiple Myeloma; NF-kappa B; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TRPV Cation Channels; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2014 |
[Sensitivity to bortezomib of RPIM8226 cells after co-cultured with down-regulated Cav-1 expression HUVECs].
Topics: Apoptosis; Boronic Acids; Bortezomib; Caveolin 1; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Down-Regulation; Human Umbilical Vein Endothelial Cells; Humans; Multiple Myeloma; Pyrazines | 2013 |
Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous | 2014 |
Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474).
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Proliferation; Drug Synergism; Glioblastoma; Humans; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases; Triazines; Tumor Cells, Cultured | 2014 |
TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells.
Topics: Anthracyclines; Antineoplastic Agents; Apoptosis; ATPases Associated with Diverse Cellular Activities; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; eIF-2 Kinase; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Phosphorylation; Proteasome Endopeptidase Complex; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2014 |
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Endothelial Cells; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Panobinostat; Proteome; Pyrazines; Reactive Oxygen Species; Thalidomide; Transcription, Genetic | 2014 |
Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Female; Heterografts; Humans; Immunotherapy; Interleukin-12; Killer Cells, Natural; Male; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Pyrazines | 2014 |
Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
Topics: Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Chromatin Immunoprecipitation; Core Binding Factor Alpha 3 Subunit; Drug Resistance, Neoplasm; Humans; Mice; Mice, Inbred NOD; Mice, SCID; NF-kappa B; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Real-Time Polymerase Chain Reaction; Receptor, Notch1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured | 2014 |
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
Topics: Adult; Age Distribution; Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Registries; Survival Analysis; Sweden; Thalidomide; Treatment Outcome | 2014 |
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Multiple Myeloma; Piperidones; Protease Inhibitors; Pyrazines; Ubiquitin Thiolesterase; Up-Regulation | 2014 |
Changes in proteasome chymotrypsin-like activity during the development of human mammary and thyroid carcinomas.
Topics: Boronic Acids; Bortezomib; Breast; Breast Neoplasms; Chymotrypsin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Neoplasm Staging; Proteasome Endopeptidase Complex; Pyrazines; Thyroid Gland; Thyroid Neoplasms | 2013 |
Bortezomib in multiple myeloma: a practice guideline.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines | 2014 |
Antibody against tumor necrosis factor-α reduces bortezomib-induced allodynia in a rat model.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Female; Hyperalgesia; Pyrazines; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2013 |
Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Thalidomide; Transplantation Conditioning | 2013 |
Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Interleukin-6; MAP Kinase Signaling System; Multiple Myeloma; NF-kappa B; Pyrazines; Signal Transduction; Transcriptome | 2014 |
Investigation of the diffusion abnormality index as a new imaging biomarker for early assessment of brain tumor response to radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Boronic Acids; Bortezomib; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Diffusion Magnetic Resonance Imaging; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazines; Radiation-Sensitizing Agents | 2014 |
Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Incidence; Japan; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk | 2014 |
A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Endoplasmic Reticulum Stress; Female; Genes, p53; Humans; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Piperidones; Proteasome Inhibitors; Pyrazines; Ubiquitination | 2013 |
Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Ganglia, Spinal; Neurons; Peripheral Nervous System Diseases; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats, Wistar; Sciatic Nerve; Tubulin | 2014 |
Bortezomib congeners induce apoptosis of hepatocellular carcinoma via CIP2A inhibition.
Topics: Antineoplastic Agents; Apoptosis; Autoantigens; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Membrane Proteins; Molecular Structure; Pyrazines; Structure-Activity Relationship | 2013 |
How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Multiple Myeloma; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazines; Survival Rate | 2014 |
Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus; Chemokine CCL2; Chemokine CXCL5; Early Growth Response Protein 1; Female; Gene Expression Regulation, Leukemic; Humans; I-kappa B Kinase; Interleukin-8; Multiple Myeloma; Ovarian Neoplasms; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Transcription Factor RelA | 2014 |
Bortezomib-induced Sweet's syndrome confirmed by rechallenge.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Pyrazines; Sweet Syndrome | 2014 |
The proteasome inhibitor bortezomib induces an inhibitory chromatin environment at a distal enhancer of the estrogen receptor-α gene.
Topics: Acetylation; Boronic Acids; Bortezomib; Chromatin; E1A-Associated p300 Protein; Enhancer Elements, Genetic; Estrogen Receptor alpha; Gene Expression Regulation, Neoplastic; Histones; Humans; MCF-7 Cells; Molecular Targeted Therapy; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; RNA, Messenger | 2013 |
Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura.
Topics: ADAM Proteins; ADAMTS13 Protein; Antineoplastic Agents; Autoantibodies; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Purpura, Thrombotic Thrombocytopenic; Pyrazines; Recurrence; Remission Induction | 2014 |
Romidepsin overcomes cell adhesion-mediated drug resistance in multiple myeloma cells.
Topics: Boronic Acids; Bortezomib; Cell Adhesion; Cell Line; Depsipeptides; Dexamethasone; Down-Regulation; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Integrin alpha4; Integrin beta1; Melphalan; Multiple Myeloma; Pyrazines; RNA, Messenger; RNA, Neoplasm; Syndecan-1 | 2014 |
Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Male; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Renal Insufficiency; Risk; Thalidomide; Treatment Outcome | 2014 |
IL-1β and TLR4 signaling are involved in the aggravated murine acute graft-versus-host disease caused by delayed bortezomib administration.
Topics: Acute Disease; Animals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Cell Transplantation; Cyclophosphamide; Cytokines; Dendritic Cells; Gene Expression Regulation; Graft vs Host Disease; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Protease Inhibitors; Pyrazines; Signal Transduction; Specific Pathogen-Free Organisms; Spleen; Toll-Like Receptor 4; Transplantation Conditioning; Whole-Body Irradiation | 2014 |
Increasing bone sclerosis during bortezomib therapy in multiple myeloma patients: results of a reduced-dose whole-body MDCT study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Radiation Dosage; Retrospective Studies; Risk Factors; Sclerosis; Tomography, X-Ray Computed; Whole Body Imaging | 2014 |
Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; G2 Phase Cell Cycle Checkpoints; Humans; Multiple Myeloma; Oxides; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2013 |
Magnetic fluid hyperthermia enhances cytotoxicity of bortezomib in sensitive and resistant cancer cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Caco-2 Cells; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Drug Resistance, Neoplasm; Drug Synergism; Humans; Hyperthermia, Induced; Magnetic Field Therapy; Magnetic Fields; Magnetite Nanoparticles; Neoplasms, Experimental; Pyrazines; Treatment Outcome | 2014 |
Protective role of bortezomib in steatotic liver ischemia/reperfusion injury through abrogation of MMP activation and YKL-40 expression.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Chitinase-3-Like Protein 1; Enzyme Activation; Extracellular Matrix Proteins; Fatty Liver; Gene Expression Regulation; Glycoproteins; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyrazines; Rats; Rats, Zucker; Reperfusion Injury | 2014 |
HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Heme Oxygenase-1; Humans; N-Myc Proto-Oncogene Protein; Neuroblastoma; NF-E2-Related Factor 2; Nuclear Proteins; Oncogene Proteins; Pyrazines; Risk; Up-Regulation | 2014 |
Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity.
Topics: Active Transport, Cell Nucleus; Adult; Aged; Animals; Bone Marrow Cells; Boronic Acids; Bortezomib; Disease Progression; Female; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Fluorescence; Middle Aged; NF-kappa B; Phenotype; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Time Factors; Tumor Necrosis Factor-alpha | 2014 |
Efficient induction of apoptosis by proteasome inhibitor: bortezomib in the human breast cancer cell line MDA-MB-231.
Topics: Antineoplastic Agents; Apoptosis; beta-Galactosidase; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Survival; Female; Fibroblasts; HSP70 Heat-Shock Proteins; Humans; Hypoxia; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2014 |
Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; Humans; Male; Mice; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Receptor, Parathyroid Hormone, Type 1 | 2014 |
Acupuncture for neuropathic pain due to bortezomib in a patient with multiple myeloma.
Topics: Acupuncture Therapy; Aged; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Neuralgia; Pyrazines | 2014 |
Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Models, Theoretical; Multiple Myeloma; Pyrazines; Renal Dialysis; Thalidomide | 2014 |
Bortezomib inhibits STAT5-dependent degradation of LEF-1, inducing granulocytic differentiation in congenital neutropenia CD34(+) cells.
Topics: Antigens, CD34; Boronic Acids; Bortezomib; Cell Differentiation; Cells, Cultured; Congenital Bone Marrow Failure Syndromes; Granulocytes; HEK293 Cells; Hematopoiesis; Hematopoietic Stem Cells; Humans; Lymphoid Enhancer-Binding Factor 1; Neutropenia; Proteolysis; Pyrazines; STAT5 Transcription Factor | 2014 |
Clinical analysis of 36 multiple myeloma patients with extramedullary plasmacytoma invasion of the spinal canal.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Combined Modality Therapy; Decompression, Surgical; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm Invasiveness; Prognosis; Pyrazines; Retrospective Studies; Spinal Canal; Spinal Cord Compression; Treatment Outcome | 2015 |
Systematic comparison of peptidic proteasome inhibitors highlights the α-ketoamide electrophile as an auspicious reversible lead motif.
Topics: Binding Sites; Boronic Acids; Bortezomib; Catalytic Domain; Crystallography, X-Ray; HeLa Cells; Humans; Leupeptins; Molecular Dynamics Simulation; Oligopeptides; Peptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Binding; Pyrazines | 2014 |
Characterization of and protection from neurotoxicity induced by oxaliplatin, bortezomib and epothilone-B.
Topics: Adrenal Gland Neoplasms; Amifostine; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cyclin B2; Epothilones; Microtubule-Associated Proteins; Neurites; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Pheochromocytoma; Pyrazines; Radiation-Protective Agents; Rats; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survivin; Tumor Cells, Cultured | 2014 |
Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model.
Topics: Action Potentials; Animals; Antibodies; Boronic Acids; Bortezomib; Cells, Cultured; Cytokines; Disease Models, Animal; Female; Ganglia, Spinal; Gene Expression Regulation; Mice; Motor Activity; Neural Conduction; Neurotoxicity Syndromes; Pain Measurement; Pain Threshold; Proteasome Inhibitors; Pyrazines; Sciatic Nerve; Sensory Receptor Cells; Time Factors; Tumor Necrosis Factor-alpha | 2014 |
Correcting the cystic fibrosis disease mutant, A455E CFTR.
Topics: Anilides; Animals; Boronic Acids; Bortezomib; Chlorocebus aethiops; COS Cells; Cycloheximide; Cystic Fibrosis Transmembrane Conductance Regulator; Gene Expression; Genetic Complementation Test; Half-Life; Humans; Hydroxamic Acids; Leupeptins; Mutation; Plasmids; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Small Molecule Libraries; Transfection | 2014 |
Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Histocompatibility Antigens Class I; HLA Antigens; Humans; Interferon-gamma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Up-Regulation | 2014 |
Kaposi sarcoma associated herpesvirus (KSHV) induces AKT hyperphosphorylation, bortezomib-resistance and GLUT-1 plasma membrane exposure in THP-1 monocytic cell line.
Topics: Boronic Acids; Bortezomib; Cell Line; Cell Membrane; Glucose Transporter Type 1; Herpesvirus 8, Human; Humans; Monocytes; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphorylation; Pyrazines; Sarcoma, Kaposi; Signal Transduction | 2013 |
Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Pyrazines; Renal Insufficiency | 2014 |
Acquired Fanconi syndrome with proximal tubular cytoplasmic fibrillary inclusions of λ light chain restriction.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cytoplasm; Dexamethasone; Fanconi Syndrome; Humans; Immunoglobulin Light Chains; Kidney Tubules, Proximal; Male; Microscopy, Fluorescence; Microscopy, Immunoelectron; Multiple Myeloma; Myeloma Proteins; Phagosomes; Proteinuria; Pyrazines; Thalidomide | 2014 |
Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy.
Topics: Boronic Acids; Bortezomib; Female; Glomerulonephritis, Membranous; Humans; Middle Aged; Nephrotic Syndrome; Proteasome Inhibitors; Pyrazines | 2014 |
Bortezomib-induced lung toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Substitution; Female; Humans; Lenalidomide; Lung Diseases; Multiple Myeloma; Pyrazines; Spirometry; Thalidomide | 2014 |
Comparative cost-effectiveness models for the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Models, Economic; Multiple Myeloma; Prednisolone; Pyrazines; Survival Analysis; Thalidomide; United Kingdom | 2014 |
A case of eosinophilic dermatosis of hematologic malignancy in a patient with multiple myeloma.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Eosinophilia; Herpes Simplex; Herpes Zoster; Humans; Insect Bites and Stings; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Paraneoplastic Syndromes; Pemphigoid, Bullous; Pyrazines; Skin Diseases | 2014 |
Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Prognosis; Pyrazines; Remission Induction; Salvage Therapy; Time Factors; Transplantation, Autologous; Treatment Outcome | 2014 |
Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling.
Topics: Benzylamines; Boronic Acids; Bortezomib; Chemokine CXCL12; Computer Simulation; Cyclams; Drug Delivery Systems; Drug Synergism; Heterocyclic Compounds; Humans; Markov Chains; Models, Biological; Monte Carlo Method; Multiple Myeloma; Neoplastic Stem Cells; Paracrine Communication; Pyrazines; Tumor Microenvironment | 2014 |
Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diffusion Magnetic Resonance Imaging; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Prospective Studies; Pyrazines; Reproducibility of Results; Thalidomide; Treatment Outcome; Whole Body Imaging | 2014 |
A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Dendritic Cells; Humans; Lenalidomide; Lymphocyte Activation; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Oligodeoxyribonucleotides; Pyrazines; T-Lymphocytes; Thalidomide; Toll-Like Receptor 9 | 2014 |
IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; I-kappa B Kinase; I-kappa B Proteins; Imidazoles; MCF-7 Cells; NF-KappaB Inhibitor alpha; Phosphorylation; Pyrazines; Quinoxalines; Transcription Factor RelA | 2014 |
Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Depsipeptides; Drug Synergism; Histone Deacetylases; Histones; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyrazines; Up-Regulation | 2014 |
Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; bcl-X Protein; Beclin-1; Boronic Acids; Bortezomib; Cell Death; Dose-Response Relationship, Drug; Drug Synergism; HCT116 Cells; Humans; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Xenograft Model Antitumor Assays | 2014 |
Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosomes, Human, Pair 8; Disease-Free Survival; Female; Follow-Up Studies; Gene Amplification; Gene Expression; Genes, myc; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Recurrence; Retrospective Studies | 2014 |
Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; NF-kappa B; Pyrazines; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
PTPN6 expression is epigenetically regulated and influences survival and response to chemotherapy in high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; Epigenesis, Genetic; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Grading; Prognosis; Promoter Regions, Genetic; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrazines | 2014 |
Nitric oxide (NO) releasing poly ADP-ribose polymerase 1 (PARP-1) inhibitors targeted to glutathione S-transferase P1-overexpressing cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Comet Assay; DNA Damage; Drug Design; Drug Synergism; Enzyme Inhibitors; Glutathione S-Transferase pi; Humans; Isoenzymes; Models, Molecular; Neoplasms; Nitric Oxide; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Prodrugs; Pyrazines; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2014 |
Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line; Cell Survival; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; G2 Phase Cell Cycle Checkpoints; M Phase Cell Cycle Checkpoints; Mice; Muscle Fibers, Skeletal; Proteasome Inhibitors; Pyrazines | 2014 |
Bendamustine: the remedy that came in from the cold.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines | 2014 |
CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pyrazines; Rituximab | 2014 |
TNF-α-mediated JNK activation in the dorsal root ganglion neurons contributes to Bortezomib-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Ganglia, Spinal; Hyperalgesia; JNK Mitogen-Activated Protein Kinases; Male; Mice, Inbred C57BL; Neurons; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha | 2014 |
Bortezomib-based antibody-mediated rejection therapy and simultaneous conversion to belatacept.
Topics: Abatacept; Adult; Azathioprine; Biopsy; Boronic Acids; Bortezomib; Calcineurin Inhibitors; Cyclosporine; Glomerulonephritis, IGA; Graft Rejection; Humans; Immunoconjugates; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Diseases; Kidney Failure, Chronic; Kidney Transplantation; Male; Prednisone; Pyrazines; Treatment Outcome | 2014 |
Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Diterpenes; Humans; Jatropha; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Ubiquitin-Specific Proteases | 2014 |
Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neurologic Examination; Peripheral Nervous System Diseases; Pyrazines; Risk Factors | 2014 |
Inhibition of autophagy by autophagic inhibitors enhances apoptosis induced by bortezomib in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Epithelial Cells; Humans; Pyrazines | 2014 |
SNS01-T modulation of eIF5A inhibits B-cell cancer progression and synergizes with bortezomib and lenalidomide.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Eukaryotic Translation Initiation Factor 5A; Humans; Lenalidomide; Lymphoproliferative Disorders; Mice; Nanoparticles; Neoplasm Transplantation; Peptide Initiation Factors; Polyethyleneimine; Pyrazines; RNA-Binding Proteins; RNA, Small Interfering; Thalidomide; Xenograft Model Antitumor Assays | 2014 |
Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity.
Topics: Acetamides; Animals; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Mice; Oxadiazoles; Proteasome Inhibitors; Pyrazines | 2014 |
Simple benchmark for complex dose finding studies.
Topics: Algorithms; Antineoplastic Agents; Bayes Theorem; Benchmarking; Biometry; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computer Simulation; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Lymphoma; Models, Statistical; Pyrazines; Stroke; Urinary Bladder Neoplasms | 2014 |
Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure.
Topics: Animals; Boronic Acids; Bortezomib; Dependovirus; Disease Models, Animal; Genetic Therapy; Genetic Vectors; Heart Failure; Humans; Myocardium; Myocytes, Cardiac; Pyrazines; Rats; Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2014 |
Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Proliferation; Cyclins; E2F Transcription Factors; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Phenotype; Proteasome Inhibitors; Pyrazines; RNA Interference; RNA, Messenger; Transfection | 2014 |
Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisolone; Prognosis; Pyrazines; Retreatment; Salvage Therapy; Thalidomide; Treatment Outcome | 2014 |
New role for the mitochondrial peptide humanin: protective agent against chemotherapy-induced side effects.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Development; Boronic Acids; Bortezomib; Humans; Intracellular Signaling Peptides and Proteins; Male; Medulloblastoma; Neuroblastoma; Proteasome Inhibitors; Pyrazines | 2014 |
Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Development; Boronic Acids; Bortezomib; Cell Line, Tumor; Chondrocytes; Dose-Response Relationship, Drug; Drug Administration Schedule; Femur; Growth Plate; Heterografts; Humans; Intracellular Signaling Peptides and Proteins; Male; Medulloblastoma; Metatarsal Bones; Mice; Mice, Nude; Neuroblastoma; Proteasome Inhibitors; Pyrazines; Time Factors | 2014 |
Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Checkpoint Kinase 1; Cytoprotection; Down-Regulation; Drug Resistance, Neoplasm; Humans; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Mesenchymal Stem Cells; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins; Pyrazines; Syndecan-1; Up-Regulation | 2014 |
Hypoxia enhances the senescence effect of bortezomib--the proteasome inhibitor--on human skin fibroblasts.
Topics: Apoptosis; beta-Galactosidase; Blotting, Western; Boronic Acids; Bortezomib; Cell Hypoxia; Cell Survival; Cellular Senescence; Fibroblasts; HSP70 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Proteasome Inhibitors; Pyrazines; Skin | 2014 |
Reversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Bone Marrow Cells; Boronic Acids; Bortezomib; Butadienes; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Flavonoids; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Nitriles; Nuclear Proteins; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines | 2014 |
Use of bortezomib in heavy-chain deposition disease: a report of 3 cases.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Glomerular Filtration Rate; Heavy Chain Disease; Humans; Immunoglobulin Heavy Chains; Kidney; Male; Middle Aged; Pyrazines; Treatment Outcome | 2014 |
Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness.
Topics: Animals; Autophagy; Boronic Acids; Bortezomib; Butadienes; Cachexia; Cell Line, Tumor; Inflammation; Lung Neoplasms; Mice; Mice, Inbred BALB C; Muscle Contraction; Muscle Proteins; Muscle Weakness; Muscle, Skeletal; NF-kappa B; Nitriles; Oxidation-Reduction; Proteolysis; Pyrazines; Signal Transduction; Sulfasalazine; Tyrosine; Weight Gain | 2014 |
Bortezomib for the treatment of multiple myeloma.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Half-Life; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Transplantation, Autologous | 2014 |
Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.
Topics: Acetylation; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Gene Expression; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Indoles; Inhibitory Concentration 50; Lactams, Macrocyclic; Middle Aged; Protein Processing, Post-Translational; Pyrazines; Urinary Bladder Neoplasms; Urothelium | 2014 |
The proteasome inhibitor bortezomib is a potent inducer of zinc finger AN1-type domain 2a gene expression: role of heat shock factor 1 (HSF1)-heat shock factor 2 (HSF2) heterocomplexes.
Topics: Blotting, Western; Boronic Acids; Bortezomib; Cells, Cultured; DNA-Binding Proteins; Gene Expression; Heat Shock Transcription Factors; Heat-Shock Proteins; Human Umbilical Vein Endothelial Cells; Humans; Kinetics; Microscopy, Confocal; Promoter Regions, Genetic; Proteasome Inhibitors; Protein Binding; Protein Multimerization; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA-Binding Proteins; Transcription Factors | 2014 |
Dissecting the first and the second meiotic divisions using a marker-less drug-hypersensitive fission yeast.
Topics: Antifungal Agents; Aurora Kinases; Boronic Acids; Bortezomib; Brefeldin A; Cycloheximide; Drug Resistance, Multiple, Fungal; M Phase Cell Cycle Checkpoints; Meiosis; Prometaphase; Protein Serine-Threonine Kinases; Pyrazines; Schizosaccharomyces; Schizosaccharomyces pombe Proteins | 2014 |
URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Case-Control Studies; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Neoplastic Stem Cells; Pyrazines; Repressor Proteins; RNA Interference; Side-Population Cells; Signal Transduction; STAT3 Transcription Factor; Time Factors; Transcription Factor RelA; Transcription, Genetic; Transfection; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Sequential treatment of HPV E6 and E7-expressing TC-1 cells with bortezomib and celecoxib promotes apoptosis through p-p38 MAPK-mediated downregulation of cyclin D1 and CDK2.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclooxygenase 2 Inhibitors; Down-Regulation; Endoplasmic Reticulum Stress; Female; G1 Phase Cell Cycle Checkpoints; Imidazoles; Mice; Mice, Inbred C57BL; Oncogene Proteins, Viral; p38 Mitogen-Activated Protein Kinases; Papillomavirus E7 Proteins; Pyrazines; Pyrazoles; Pyridines; Repressor Proteins; STAT3 Transcription Factor; Sulfonamides; Transcription Factor CHOP; Uterine Cervical Neoplasms | 2014 |
Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Epidermal Growth Factor; HEK293 Cells; HeLa Cells; Humans; Neoplasms; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; STAT3 Transcription Factor; Tyrosine; Up-Regulation | 2014 |
Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clone Cells; Disease Progression; Disease-Free Survival; Female; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Leukemia, Plasma Cell; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Myeloma Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Plasmacytoma; Prognosis; Proteasome Inhibitors; Pyrazines; Recurrence; Republic of Korea; Retrospective Studies; Salvage Therapy | 2014 |
Bortezomib partially improves laminin α2 chain-deficient muscular dystrophy.
Topics: Animals; Apoptosis; Body Weight; Boronic Acids; Bortezomib; Cells, Cultured; Disease Models, Animal; Fibrosis; Gene Expression Regulation; Laminin; Locomotion; Mice, Inbred C57BL; MicroRNAs; Muscle Cells; Muscles; Muscular Dystrophy, Animal; Organ Specificity; Proteasome Endopeptidase Complex; Pyrazines; Survival Analysis | 2014 |
Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Glutathione; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Mucin-1; Multiple Myeloma; Peptides; Phosphoric Monoester Hydrolases; Protein Subunits; Pyrazines; Reactive Oxygen Species | 2014 |
Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Topics: Adult; Aged; Amyloidogenic Proteins; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Diseases; Lenalidomide; Male; Melphalan; Middle Aged; Myeloablative Agonists; Proteasome Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report.
Topics: ADAM Proteins; ADAMTS13 Protein; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Cyclophosphamide; Drug Resistance; Female; Glucocorticoids; Humans; Immunocompromised Host; Immunosuppressive Agents; Middle Aged; Purpura, Thrombotic Thrombocytopenic; Pyrazines; Recurrence; Remission Induction; Rituximab; Staphylococcal Infections | 2014 |
Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Copy Number Variations; Doxorubicin; Heterografts; Humans; Immunophenotyping; Melphalan; Mice, SCID; Multiple Myeloma; Neoplastic Stem Cells; Phenotype; Plasma Cells; Precursor Cells, B-Lymphoid; Pyrazines; Syndecan-1 | 2014 |
Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Drugs, Investigational; Europe; Female; Humans; Japan; Kaplan-Meier Estimate; Lenalidomide; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrazines; Retrospective Studies; Salvage Therapy; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients.
Topics: Adult; Anemia; Antineoplastic Agents; Area Under Curve; beta 2-Microglobulin; Biomarkers; Boronic Acids; Bortezomib; Creatinine; Disease Progression; Female; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Pyrazines; Retrospective Studies; Risk Factors; ROC Curve; Serum Albumin; Tumor Lysis Syndrome | 2014 |
[Culture and regulation of osteoblasts in multiple myeloma patients].
Topics: Adult; Aged; Bone Marrow Cells; Bone Morphogenetic Protein 2; Boronic Acids; Bortezomib; Case-Control Studies; Cell Differentiation; Female; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteogenesis; Pyrazines; Serum; Tumor Cells, Cultured; Young Adult | 2014 |
[Bortezomib-based chemotherapy for patients with multiple myeloma: a single center experience].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Treatment Outcome | 2014 |
Proteasomal serine hydrolases are up-regulated by and required for influenza virus infection.
Topics: Animals; Aprotinin; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Dogs; Host-Pathogen Interactions; Humans; Influenza A Virus, H1N1 Subtype; Leupeptins; Madin Darby Canine Kidney Cells; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteome; Proteomics; Pyrazines; RNA Interference; Serine Proteases; Sulfones; Up-Regulation; Virus Replication | 2014 |
Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.
Topics: Age Factors; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Fasciitis, Necrotizing; Fatal Outcome; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Pyrazines; Rituximab; Waldenstrom Macroglobulinemia | 2014 |
Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Polyethylene Glycols; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2014 |
United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Clinical Trials as Topic; Consolidation Chemotherapy; Disease Management; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Remission Induction; Survival Analysis; Thalidomide; United Kingdom | 2014 |
Inhibition of the ubiquitin-proteasome pathway does not protect against ventilator-induced accelerated proteolysis or atrophy in the diaphragm.
Topics: Anesthesia; Animals; Antibiotics, Antineoplastic; Atrophy; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Diaphragm; DNA, Complementary; Female; Muscle Contraction; Muscle Proteins; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteolysis; Pyrazines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Respiration, Artificial; SKP Cullin F-Box Protein Ligases; Tripartite Motif Proteins; Ubiquitin; Ubiquitin-Protein Ligases; Ventilator-Induced Lung Injury | 2014 |
Gabapentin inhibits bortezomib-induced mechanical allodynia through supraspinal action in mice.
Topics: Adrenergic Neurons; Amines; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Hyperalgesia; Mice; Mice, Inbred C57BL; Norepinephrine; Pyrazines; Spinal Cord | 2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Paraffin Embedding; Peptide Hydrolases; Prednisolone; Pyrazines; Salvage Therapy; Survival Analysis; Syndecan-1; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases | 2014 |
A rare cause of severe hepatomegaly with an improving outcome.
Topics: Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Hepatomegaly; Humans; Male; Multiple Myeloma; Pyrazines | 2014 |
Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cells, Cultured; Coculture Techniques; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Fibronectins; Humans; Mesenchymal Stem Cells; Multiple Myeloma; Pyrazines; Tumor Microenvironment | 2014 |
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Humans; Multiple Myeloma; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrimidines; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Ubiquitin-Activating Enzymes; Up-Regulation | 2014 |
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Profiling; Humans; Interferon Regulatory Factors; Lenalidomide; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Neoplasm Transplantation; Proteasome Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-myc; Pyrazines; Signal Transduction; Thalidomide | 2014 |
The osteoblastogenesis potential of adipose mesenchymal stem cells in myeloma patients who had received intensive therapy.
Topics: Adipose Tissue; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cycloheximide; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; Osteoblasts; Osteogenesis; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous | 2014 |
Protective immunity and use of bortezomib for antibody-mediated rejection in a pediatric kidney transplant recipient.
Topics: Boronic Acids; Bortezomib; Child; Graft Rejection; Humans; Kidney Transplantation; Male; Proteasome Inhibitors; Pyrazines | 2014 |
Haematological complete remission by ponatinib and bortezomib in a patient with relapsed, Ph⁺ pre-B acute lymphoblastic leukaemia.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Imidazoles; Male; Philadelphia Chromosome; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Pyridazines; Recurrence; Remission Induction | 2014 |
Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Constipation; Cyclophosphamide; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Evaluation; Drug Substitution; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Sensation Disorders; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Enhancing proteasome-lnhibitor effect by functionalized gold nanoparticles.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gold; Humans; Male; Metal Nanoparticles; Prostatic Neoplasms; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2014 |
Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.
Topics: Adult; Animals; Apoptosis; Boronic Acids; Bortezomib; DNA-Binding Proteins; G2 Phase Cell Cycle Checkpoints; Histone-Lysine N-Methyltransferase; Humans; M Phase Cell Cycle Checkpoints; Mice; Myeloid-Lymphoid Leukemia Protein; Nuclear Proteins; Oncogene Proteins, Fusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Transcriptional Elongation Factors; Transfection; Translocation, Genetic | 2014 |
Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromosomes; Computational Biology; Core Binding Factor Alpha 2 Subunit; Cytogenetics; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Introns; Leukemia, Myeloid, Acute; Male; Melanoma; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplasm Proteins; NF-kappa B; Phenotype; Pyrazines; RNA, Messenger; Tumor Suppressor Protein p53 | 2014 |
Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
Topics: Actinobacteria; Boronic Acids; Bortezomib; Catalysis; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lactones; Leukemia; Mutation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Up-Regulation | 2014 |
[Bortezomib enhances the sensitivity of prostate cancer cells to natural killer cell-mediated cytotoxicity].
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytotoxicity, Immunologic; Humans; Killer Cells, Natural; Male; Prostatic Neoplasms; Pyrazines | 2014 |
Polyclonal serum IgM level identifies a subgroup of multiple myeloma patients with low-risk clinicobiological features and superior survival.
Topics: Antigens, CD19; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Immunoglobulin M; Male; Middle Aged; Multiple Myeloma; Proto-Oncogene Proteins c-kit; Pyrazines | 2014 |
Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues.
Topics: Adipogenesis; Alkaline Phosphatase; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; Female; Humans; Integrin-Binding Sialoprotein; Mesenchymal Stem Cells; Osteoblasts; Osteogenesis; Osteoporosis; Placenta; Pregnancy; Pyrazines; Sp7 Transcription Factor; Transcription Factors; Up-Regulation | 2014 |
Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma.
Topics: Animals; Bombesin; Boronic Acids; Bortezomib; Cisplatin; GTP-Binding Protein alpha Subunits, G12-G13; GTP-Binding Protein alpha Subunits, Gq-G11; Hedgehog Proteins; HEK293 Cells; Humans; Lung Neoplasms; Mice; NIH 3T3 Cells; Oncogene Proteins; Pyrazines; Receptors, Bombesin; Signal Transduction; Small Cell Lung Carcinoma; Trans-Activators; Zinc Finger Protein GLI1 | 2015 |
Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes.
Topics: Amides; Animals; Antineoplastic Agents; Blood Platelets; Bone Marrow; Boronic Acids; Bortezomib; Colony-Forming Units Assay; Disease Models, Animal; Male; Megakaryocyte Progenitor Cells; Megakaryocytes; Mice; Multiple Myeloma; Platelet Count; Pyrazines; Pyridines; rho-Associated Kinases; Thrombocytopenia; Thrombopoiesis; Thrombopoietin | 2014 |
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease Progression; Female; Greece; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Recurrence, Local; Plasmacytoma; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Effect of a proteasome inhibitor plus steroids on HLA antibodies in sensitized patients awaiting a renal transplant.
Topics: Adult; Aged; Antibodies; Boronic Acids; Bortezomib; Dexamethasone; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Kidney Transplantation; Male; Middle Aged; Neutrophils; Preoperative Period; Prospective Studies; Proteasome Inhibitors; Pyrazines; Renal Insufficiency; Steroids; Time Factors; Treatment Outcome | 2014 |
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
Bortezomib protects from varicose-like venous remodeling.
Topics: Animals; Animals, Outbred Strains; Boronic Acids; Bortezomib; Cell Division; Cell Movement; Cells, Cultured; Collagen; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Mice; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nuclear Proteins; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteolysis; Pyrazines; Spheroids, Cellular; Trans-Activators; Varicose Veins | 2014 |
Impact of dose modification on intravenous bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Patient Outcome Assessment; Peripheral Nervous System Diseases; Pyrazines | 2014 |
Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Proliferation; Depsipeptides; DNA Damage; Endoplasmic Reticulum Stress; Enzyme Activation; Female; Fluoresceins; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Peptides, Cyclic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyridines; Reactive Oxygen Species | 2014 |
The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2).
Topics: Animals; Boronic Acids; Bortezomib; Carotid Artery Thrombosis; Cells, Cultured; Coronary Occlusion; Cytoprotection; Human Umbilical Vein Endothelial Cells; Humans; Kruppel-Like Transcription Factors; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrazines; Whole Blood Coagulation Time | 2014 |
Efficient bioactive delivery of aerosolized drugs to human pulmonary epithelial cells cultured in air-liquid interface conditions.
Topics: Administration, Inhalation; Aerosols; Anti-Inflammatory Agents; Blood-Air Barrier; Boronic Acids; Bortezomib; Cell Culture Techniques; Cell Line, Tumor; Dose-Response Relationship, Drug; Epithelial Cells; Humans; Interleukin-8; Kinetics; Promoter Regions, Genetic; Proteasome Inhibitors; Pyrazines; Reproducibility of Results; Respiratory Mucosa; Transcriptional Activation; Tumor Necrosis Factor-alpha; Up-Regulation | 2014 |
Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry.
Topics: Boronic Acids; Bortezomib; Cell Survival; Chromatography, High Pressure Liquid; Humans; Liquid-Liquid Extraction; Proteasome Inhibitors; Pyrazines; Tandem Mass Spectrometry | 2014 |
Silencing of PKCη induces cycle arrest of EBV(+) B lymphoma cells by upregulating expression of p38-MAPK/TAp73/GADD45α and increases susceptibility to chemotherapeutic agents.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Drug Resistance, Neoplasm; Herpesvirus 4, Human; Humans; Membrane Potential, Mitochondrial; NF-kappa B; Niacinamide; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase C; Pyrazines; RNA Interference; RNA, Small Interfering; Sorafenib; Tumor Protein p73; Tumor Suppressor Proteins; Up-Regulation | 2014 |
Down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma.
Topics: Azacitidine; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Down-Regulation; Drug Interactions; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Pyrazines; Tetraspanin 29 | 2014 |
Role of CIP2A in the antitumor effect of bortezomib in colon cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Down-Regulation; HCT116 Cells; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Mice, Nude; Pyrazines; RNA Interference; RNA, Messenger; RNA, Small Interfering; Transcription, Genetic; Transplantation, Heterologous | 2014 |
Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Real-Time Polymerase Chain Reaction; Young Adult | 2014 |
Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Line, Tumor; Humans; Integrins; Lipopeptides; Multiple Myeloma; Pyrazines; Stromal Cells; Toll-Like Receptor 1; Toll-Like Receptor 2 | 2014 |
Differential effect of bortezomib on HLA class I and class II antibody.
Topics: Antibodies; Apoptosis; Boronic Acids; Bortezomib; Cell Membrane; Female; Graft Rejection; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Humans; Kidney Failure, Chronic; Kidney Transplantation; Lymphocytes; Male; Proteasome Inhibitors; Pyrazines; Retrospective Studies | 2014 |
Activation of the ubiquitin-proteasome system against arsenic trioxide cardiotoxicity involves ubiquitin ligase Parkin for mitochondrial homeostasis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Blotting, Western; Boronic Acids; Bortezomib; Heart Diseases; Homeostasis; Immunoprecipitation; Lysosomes; Membrane Potential, Mitochondrial; Mice; Microscopy, Fluorescence; Mitochondria, Heart; Myocytes, Cardiac; Oxides; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin; Ubiquitin-Protein Ligases; Voltage-Dependent Anion Channel 1 | 2014 |
Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation.
Topics: Antineoplastic Agents; Blood Group Incompatibility; Boronic Acids; Bortezomib; Humans; Injections, Subcutaneous; Male; Middle Aged; Pyrazines; Red-Cell Aplasia, Pure | 2014 |
Bortezomib resistance and MUC1 in myeloma.
Topics: Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Humans; Intracellular Signaling Peptides and Proteins; Mucin-1; Peptides; Phosphoric Monoester Hydrolases; Pyrazines; Reactive Oxygen Species | 2014 |
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.
Topics: Active Transport, Cell Nucleus; Adaptor Proteins, Signal Transducing; Analysis of Variance; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; DNA Damage; DNA Primers; Doxorubicin; Fluorescent Antibody Technique; Genetic Vectors; Genomic Instability; Hematologic Neoplasms; Humans; Immunohistochemistry; Immunoprecipitation; Intracellular Signaling Peptides and Proteins; Phosphoproteins; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-abl; Pyrazines; Real-Time Polymerase Chain Reaction; Transcription Factors; YAP-Signaling Proteins | 2014 |
Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen.
Topics: Adolescent; Antibodies; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Child; Child, Preschool; Female; Glomerular Filtration Rate; Graft Rejection; Humans; Immunoglobulins, Intravenous; Immunosuppression Therapy; Immunosuppressive Agents; Isoantibodies; Kidney Failure, Chronic; Kidney Transplantation; Male; Methylprednisolone; Plasmapheresis; Pyrazines; Retrospective Studies; Rituximab; Steroids; Tissue Donors; Treatment Outcome; Young Adult | 2014 |
Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Herpesvirus 1, Human; Humans; Mice, Nude; Necrosis; Oncolytic Virotherapy; Oncolytic Viruses; Pyrazines; Unfolded Protein Response; Virus Replication; Xenograft Model Antitumor Assays | 2014 |
Bortezomib induces apoptosis by interacting with JAK/STAT pathway in K562 leukemic cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Humans; Janus Kinases; K562 Cells; Pyrazines; RNA, Messenger; Signal Transduction; STAT Transcription Factors | 2014 |
Access to expensive cancer drugs in Dutch daily practice: should we be concerned?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Costs; Drug Prescriptions; Health Policy; Health Services Accessibility; Humans; Interviews as Topic; Netherlands; Practice Patterns, Physicians'; Pyrazines | 2014 |
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Imidazoles; Mutation; Pancreatic Neoplasms; Piperazines; Pyrazines; Quinazolines; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2014 |
Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells.
Topics: Adenine; AMP-Activated Protein Kinases; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Survival; Cells, Cultured; Chloroquine; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Neoplasm Proteins; Pancreatic Neoplasms; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering | 2014 |
Development of P22 viral capsid nanocomposites as anti-cancer drug, bortezomib (BTZ), delivery nanoplatforms.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Capsid Proteins; Carcinoma, Hepatocellular; Catechols; Drug Delivery Systems; Humans; Liver Neoplasms; Nanocomposites; Pyrazines | 2014 |
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Immunosuppressive Agents; Lenalidomide; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pyrazines; Retrospective Studies; Thalidomide; Time Factors | 2014 |
Complete remission achieved in a multiple myeloma patient with elevated serum KL-6 level by a combination regimen with bortezomib, cyclophosphamide, and dexamethasone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diplopia; Female; Humans; Mucin-1; Multiple Myeloma; Pyrazines; Remission Induction | 2014 |
USP15 targets ALK3/BMPR1A for deubiquitylation to enhance bone morphogenetic protein signalling.
Topics: Animals; Bone Morphogenetic Protein Receptors, Type I; Bone Morphogenetic Proteins; Boronic Acids; Bortezomib; Cell Line; Gene Expression Regulation, Developmental; HEK293 Cells; HeLa Cells; Humans; Mice; Phosphorylation; Pyrazines; Signal Transduction; Smad1 Protein; Ubiquitin-Specific Proteases; Ubiquitination; Xenopus laevis; Xenopus Proteins | 2014 |
Use of bortezomib as anti-humoral therapy in kidney transplantation.
Topics: Adult; Boronic Acids; Bortezomib; Desensitization, Immunologic; Female; Graft Rejection; HLA Antigens; Humans; Kidney; Kidney Transplantation; Male; Middle Aged; Pyrazines; Treatment Outcome | 2014 |
Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; NF-kappa B; Prostatic Neoplasms; Pyrazines | 2014 |
[Analysis of Bortezomib-containing combinations in newly-diagnosed multiple myeloma patients: a comparative study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines | 2014 |
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Protein Aggregates; Pyrazines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2014 |
Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2014 |
Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve.
Topics: Animals; Behavior, Animal; Boronic Acids; Bortezomib; Calcitonin Gene-Related Peptide; Disease Models, Animal; Female; Ganglia, Spinal; Gene Expression Regulation; Nerve Tissue Proteins; Nociception; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Wistar; Sciatic Nerve; Spinal Cord; Substance P; TRPV Cation Channels | 2014 |
Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Hypertension, Pulmonary; Induction Chemotherapy; Lenalidomide; Leukemia, Plasma Cell; Male; Pyrazines; Remission Induction; Renal Insufficiency; Thalidomide | 2014 |
Effective control of skin reaction by air sandwich technique in a patient with IgE-κ myeloma treated with subcutaneous bortezomib injection.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunoglobulin E; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Pyrazines; Skin Diseases; Treatment Outcome | 2014 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Leukemia, Plasma Cell; Neoplasms, Second Primary; Pyrazines; Thalidomide; Treatment Outcome | 2015 |
Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Biopsy; Bone Density Conservation Agents; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulin G; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Referral and Consultation; Thalidomide; Translocation, Genetic; Transplantation, Autologous; Zoledronic Acid | 2014 |
Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Esters; Humans; Liposomes; Mice, SCID; Multiple Myeloma; Nanoparticles; Neoplasm Transplantation; Prodrugs; Proteasome Endopeptidase Complex; Pyrazines | 2014 |
Molecular mechanisms of converting K562/DNR cellular drug-resistance by bortezomib.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Daunorubicin; Drug Resistance, Neoplasm; Humans; I-kappa B Proteins; K562 Cells; NF-kappa B; Pyrazines | 2014 |
Posterior reversible encephalopathy syndrome resulting from repeat bortezomib usage.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Multiple Myeloma; Neuroimaging; Posterior Leukoencephalopathy Syndrome; Pyrazines | 2014 |
Astrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the rat.
Topics: Animals; Antineoplastic Agents; Astrocytes; Boronic Acids; Bortezomib; Glial Fibrillary Acidic Protein; Hyperalgesia; Male; Microglia; Minocycline; Neuroprotective Agents; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Pyrazines; Rats, Sprague-Dawley; Spinal Cord; Spinal Nerves | 2014 |
Evaluating cytoplasmic and nuclear levels of inflammatory cytokines in cancer cells by western blotting.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Fractionation; Cell Line, Tumor; Cell Nucleus; Complex Mixtures; Cytoplasm; Electrophoresis, Polyacrylamide Gel; Female; Gene Expression; HMGB1 Protein; Humans; Interleukin-8; Male; Pyrazines | 2014 |
Quantitative analysis of bortezomib-induced IL-8 gene expression in ovarian cancer cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Female; Gene Expression; Humans; Interleukin-6; Interleukin-8; NF-kappa B; Pyrazines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha | 2014 |
Chromatin immunoprecipitation analysis of bortezomib-mediated inhibition of NFκB recruitment to IL-1β and TNFα gene promoters in human macrophages.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromatin Immunoprecipitation; Humans; Interleukin-1beta; Lipopolysaccharides; Macrophages; NF-kappa B; Promoter Regions, Genetic; Pyrazines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tetradecanoylphorbol Acetate; Transcription, Genetic; Tumor Necrosis Factor-alpha | 2014 |
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Survival; Drug Synergism; Female; Hepatocytes; Humans; Ovarian Neoplasms; Protein Binding; Pyrazines; Receptors, IgG; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins | 2015 |
A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; HEK293 Cells; Hep G2 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Organometallic Compounds; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Pyridines; Ubiquitin; Ubiquitin-Specific Proteases | 2014 |
ShRNA-mediated Bmi-1 silencing sensitizes multiple myeloma cells to bortezomib.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Mice; Mitogen-Activated Protein Kinase 7; Multiple Myeloma; Primary Cell Culture; Pyrazines | 2014 |
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Mitochondrial Proteins; Oligopeptides; Proteasome Inhibitors; Pyrazines; Vorinostat | 2014 |
The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Treatment Outcome | 2014 |
Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Dexamethasone; Drug Administration Schedule; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Cell Movement; Cell Proliferation; Cytokines; Doxorubicin; Drug Resistance, Neoplasm; Exosomes; Flow Cytometry; Humans; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Inbred C57BL; Multiple Myeloma; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Stromal Cells; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2014 |
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Agents; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Paraproteinemias; Pyrazines; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.
Topics: Aged; Antineoplastic Agents; Antineoplastic Protocols; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Immunosuppressive Agents; Kidney; Kidney Failure, Chronic; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; New Zealand; Pyrazines; Remission Induction; Renal Dialysis; Thalidomide; Treatment Outcome | 2014 |
Bortezomib use in a pediatric cardiac transplant center.
Topics: Adolescent; Adult; Antibodies; Biopsy; Boronic Acids; Bortezomib; Child; Child, Preschool; Drug Administration Schedule; Female; Follow-Up Studies; Graft Rejection; Heart Defects, Congenital; Heart Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Isoantibodies; Male; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Platelet Aggregation; Platelet Function Tests; Prospective Studies; Pyrazines; Thalidomide; Venous Thromboembolism | 2014 |
Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
Topics: Adult; Allografts; Antibodies, Monoclonal, Murine-Derived; Baltimore; Biomarkers; Boronic Acids; Bortezomib; Creatinine; Drug Substitution; Female; Graft Rejection; Graft Survival; Humans; Immunity, Humoral; Immunoglobulins, Intravenous; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Odds Ratio; Plasmapheresis; Pyrazines; Retrospective Studies; Risk Factors; Rituximab; Time Factors; Treatment Outcome | 2014 |
Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Poly(ADP-ribose) Polymerases; Pyrazines; Pyrimidines; Reactive Oxygen Species; RNA, Messenger | 2014 |
[Safety and efficacy of subcutaneous administration of bortezomib in the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Infusions, Intravenous; Injections, Subcutaneous; Multiple Myeloma; Pyrazines; Remission Induction; Retrospective Studies | 2014 |
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
Modified bortezomib, adriamycin and dexamethasone (PAD) regimen in advanced multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Salvage Therapy; Survival Rate | 2014 |
Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Cattle; Cell Line, Tumor; Cell Proliferation; Drug Design; Endopeptidases; Humans; Hydrolysis; Molecular Docking Simulation; Peptidomimetics; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Proteolysis; Pyrazines; Trypsin | 2014 |
Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathy.
Topics: Action Potentials; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperalgesia; Lumbar Vertebrae; Male; Motor Activity; Neurons; Pain Threshold; Peripheral Nervous System Diseases; Physical Stimulation; Pyrazines; Rats, Sprague-Dawley; Spinal Cord; Temperature; Touch | 2014 |
Bortezomib treatment causes long-term testicular dysfunction in young male mice.
Topics: Animals; Boronic Acids; Bortezomib; Follicle Stimulating Hormone; Humans; Male; Mice; Neoplasms; Proteasome Inhibitors; Pyrazines; Spermatogenesis; Testicular Diseases; Testis; Testosterone | 2014 |
Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells.
Topics: Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Endoribonucleases; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred NOD; Mice, SCID; Naphthalenes; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Pyrazines; Regulatory Factor X Transcription Factors; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA Splicing; Sulfonamides; Thiophenes; Toyocamycin; Transcription Factors; Unfolded Protein Response; X-Box Binding Protein 1; Xenograft Model Antitumor Assays | 2014 |
Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lactate Dehydrogenases; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
Autophagic-lysosomal inhibition compromises ubiquitin-proteasome system performance in a p62 dependent manner in cardiomyocytes.
Topics: Adenine; Animals; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Heat-Shock Proteins; Lysosomes; Mice; Mice, Transgenic; Myocytes, Cardiac; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Rats; Sequestosome-1 Protein; Ubiquitin | 2014 |
CSNK1α1 mediates malignant plasma cell survival.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Casein Kinase Ialpha; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Progression; Gene Expression Profiling; Humans; Interleukin-3; Lentivirus; Mice; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Plasma Cells; Plasmacytoma; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction | 2015 |
Isolated autonomic failure without evident somatic polyneuropathy in AL amyloidosis.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Neural Conduction; Pure Autonomic Failure; Pyrazines; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2014 |
Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significance.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Pyrazines; YY1 Transcription Factor | 2014 |
Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients.
Topics: Adolescent; Adult; Age of Onset; Antineoplastic Agents; Autoantibodies; Boronic Acids; Bortezomib; Cells, Cultured; Endoplasmic Reticulum Stress; Female; Humans; Male; Plasma Cells; Primary Cell Culture; Proteasome Endopeptidase Complex; Pyrazines; Thymus Gland; Young Adult | 2014 |
Chalazia associated with bortezomib therapy for multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chalazion; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2014 |
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Drug Evaluation; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Sensation Disorders; Thalidomide; Thromboembolism; Transplantation, Autologous | 2014 |
Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Papillary; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Endoplasmic Reticulum Stress; Gene Knockdown Techniques; Humans; Mucoproteins; Neoplasm Invasiveness; Oncogene Proteins; Oxidation-Reduction; Protein Disulfide-Isomerases; Proteins; Pyrazines; Thyroid Cancer, Papillary; Thyroid Neoplasms; Up-Regulation | 2014 |
Treatment-refractory multi-lineage autoimmune cytopenia after unrelated cord blood transplantation: remission after combined bortezomib and vincristine treatment.
Topics: Boronic Acids; Bortezomib; Cord Blood Stem Cell Transplantation; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Infant; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Purpura, Thrombocytopenic, Idiopathic; Pyrazines; Vincristine | 2014 |
Clinical analysis of six cases of multiple myeloma first presenting with coagulopathy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Sedimentation; Boronic Acids; Bortezomib; Coagulants; Coagulation Protein Disorders; Dexamethasone; Doxorubicin; Female; Hematoma; Hematuria; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide | 2014 |
Engineered nanomedicine for myeloma and bone microenvironment targeting.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Delivery Systems; Heterografts; Humans; Lactic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Nanoparticles; Neoplasm Transplantation; Neoplasms, Experimental; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |
New data on subcutaneous bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines | 2015 |
An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arm; Boronic Acids; Bortezomib; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Severity of Illness Index | 2015 |
The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines | 2014 |
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Dexamethasone; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Male; Mediastinal Neoplasms; Middle Aged; Multiple Myeloma; Mutation, Missense; Neoplasm Proteins; Neoplasms, Second Primary; Osteolysis; Palliative Care; Plasmacytoma; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; Remission Induction; Salvage Therapy; Sulfonamides; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vemurafenib | 2014 |
Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97.
Topics: Boronic Acids; Bortezomib; Cell Line; Endoplasmic Reticulum; HEK293 Cells; Humans; Leupeptins; Nuclear Proteins; Nuclear Respiratory Factor 1; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; RNA Interference; RNA, Small Interfering; Ubiquitin Thiolesterase; Ubiquitination; Unfolded Protein Response | 2014 |
Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.
Topics: Activating Transcription Factor 4; Amino Acid Transport System y+; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glutathione; Glycine; HEK293 Cells; HeLa Cells; Humans; Leupeptins; NF-E2-Related Factor 2; Oligopeptides; Proteasome Endopeptidase Complex; Pyrazines; RNA, Small Interfering; Sulfasalazine; Urinary Bladder Neoplasms | 2014 |
Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Cyclin T; Cyclin-Dependent Kinase 9; Cycloheximide; Flavonoids; Gene Expression Regulation; Heat-Shock Proteins; Humans; Indoles; Leupeptins; Membrane Proteins; Mice; Mice, Knockout; Mitochondrial Proteins; Piperidines; Protein Transport; Pyrazines; Pyrroles; RNA, Small Interfering; Sequestosome-1 Protein | 2014 |
EGFR inhibitors may induce tumor stemness.
Topics: Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Integrin beta3; Neoplastic Stem Cells; Pyrazines; Quinazolines | 2014 |
High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Mice; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured | 2014 |
Blood distribution of bortezomib and its kinetics in multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Erythrocyte Count; Female; Humans; Male; Middle Aged; Multiple Myeloma; Plasma; Pyrazines | 2014 |
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Clone Cells; Dexamethasone; Fatal Outcome; Female; Gene Deletion; Genes, p53; Humans; Incidental Findings; Lenalidomide; Liver; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Multiple Primary; Osteolysis; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Tumor Suppressor Protein p53; Uterine Neoplasms | 2014 |
[Gastrointestinal amyloidosis in a patient with multiple myeloma].
Topics: Abdominal Pain; Amyloidosis; Biopsy; Boronic Acids; Bortezomib; Colon, Sigmoid; Dexamethasone; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2014 |
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; B-Lymphocytes; Biomarkers; Biopsy; Boronic Acids; Bortezomib; Child; Female; France; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Plasmapheresis; Pyrazines; Retrospective Studies; Rituximab; Time Factors; Treatment Outcome; Young Adult | 2015 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide | 2014 |
POEMS syndrome: a challenging diagnosis of a rare disease.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diagnosis, Differential; Drug Therapy, Combination; Humans; Male; POEMS Syndrome; Pyrazines; Rare Diseases | 2014 |
Treatment strategies to treat antibody-mediated rejection and to reduce donor-specific antibodies.
Topics: Antibodies; Boronic Acids; Bortezomib; Female; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Pyrazines; Steroids | 2014 |
sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Female; Humans; Liposomes; Mice; Mice, Nude; Neuroblastoma; Pyrazines; TNF-Related Apoptosis-Inducing Ligand | 2014 |
Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Coculture Techniques; Endopeptidases; Gelatinases; Humans; Membrane Proteins; Mesenchymal Stem Cells; Multiple Myeloma; Pyrazines; Serine Endopeptidases; Signal Transduction | 2014 |
Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells.
Topics: Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Endocytosis; Humans; Lactic Acid; Nanoparticles; Pancreatic Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Proteasome Inhibitors; Pyrazines; Spectroscopy, Fourier Transform Infrared; Telomerase; Transferrin | 2015 |
The treatment outcome of multiple myeloma patients ineligible for hematopoietic transplantation--a single institutional experience in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Taiwan; Treatment Outcome | 2015 |
Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrazines; Ubiquitin-Protein Ligases | 2014 |
Amitriptyline-induced agranulocytosis with bone marrow confirmation.
Topics: Agranulocytosis; Amitriptyline; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diagnosis, Differential; Febrile Neutropenia; Female; Filgrastim; Fractures, Spontaneous; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Multiple Myeloma; Osteolysis; Peripheral Nervous System Diseases; Pyrazines; Recombinant Proteins; Urinary Tract Infections | 2014 |
Hepcidin and GDF15 in anemia of multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Dexamethasone; Female; Ferritins; Gene Expression Regulation, Neoplastic; Growth Differentiation Factor 15; Hemoglobins; Hepcidins; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; RNA, Messenger | 2014 |
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Dexamethasone; Humans; Immunoglobulin Light Chains; Melphalan; Middle Aged; Pyrazines; Treatment Outcome | 2014 |
Myeloma cell sensitivity to bortezomib is associated with Dicer1 expression.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DEAD-box RNA Helicases; Humans; Multiple Myeloma; Mutation; Pyrazines; Ribonuclease III; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2014 |
Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels.
Topics: Acute Disease; Animals; Antibodies, Neutralizing; Antineoplastic Agents; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Disease Models, Animal; Female; Graft vs Host Disease; Interleukin-6; Liver Diseases; Mice; Organ Specificity; Pyrazines; Skin Diseases | 2014 |
[Hyperammonemic encephalopathy in multiple myeloma].
Topics: Alkalosis, Respiratory; Ammonia; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Dyspnea; Fatal Outcome; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Rett Syndrome | 2014 |
Mitochondrial impairment triggers cytosolic oxidative stress and cell death following proteasome inhibition.
Topics: Animals; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; CHO Cells; Cricetinae; Cricetulus; Membrane Potential, Mitochondrial; Mitochondria; Neurodegenerative Diseases; Oxidative Stress; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Reactive Oxygen Species; Resveratrol; Stilbenes; Ubiquitination | 2014 |
Proteasome inhibitors alter levels of intracellular peptides in HEK293T and SH-SY5Y cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; HEK293 Cells; Humans; Inhibitory Concentration 50; Intracellular Space; Leupeptins; Oligopeptides; Peptides; Proteasome Inhibitors; Pyrazines | 2014 |
Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure.
Topics: Adult; Aged; Antineoplastic Agents; Autografts; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Kidney Failure, Chronic; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Dialysis; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning | 2014 |
Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody-mediated rejection after kidney transplant.
Topics: Adult; Biomarkers; Biopsy; Boronic Acids; Bortezomib; Creatinine; Female; Graft Rejection; Graft Survival; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Length of Stay; Male; Middle Aged; Plasmapheresis; Pyrazines; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients.
Topics: Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Asian People; Boronic Acids; Bortezomib; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents; Benzodiazepinones; beta 2-Microglobulin; Biomarkers, Tumor; Boronic Acids; Bortezomib; Depsipeptides; Disease Models, Animal; Drug Therapy, Combination; Gene Expression Regulation, Leukemic; Humans; Interleukin-2 Receptor alpha Subunit; Leukemia-Lymphoma, Adult T-Cell; Mice; Mice, Inbred NOD; Mice, SCID; NF-kappa B; Pyrazines; Receptor, Notch1; Signal Transduction; Tumor Burden | 2015 |
Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Retrospective Studies; Survivin; Thalidomide; Vincristine | 2014 |
Spinal administration of mGluR5 antagonist prevents the onset of bortezomib induced neuropathic pain in rat.
Topics: Analgesics; Animals; Boronic Acids; Bortezomib; Ceftriaxone; Cell Line, Tumor; Cell Survival; Central Nervous System Agents; Disease Models, Animal; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Hyperalgesia; Injections, Spinal; Male; Neural Conduction; Neuralgia; Peripheral Nervous System Diseases; Pyrazines; Pyridines; Random Allocation; Rats; Receptor, Metabotropic Glutamate 5 | 2014 |
Diffuse parenchymal pulmonary amyloidosis showing an objective response to bortezomib-based chemotherapy.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Boronic Acids; Bortezomib; Female; Humans; Lung Diseases; Multiple Myeloma; Pyrazines; Radiography; Treatment Outcome | 2014 |
Bortezomib-induced posterior reversible encephalopathy syndrome: clinical and imaging features.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Posterior Leukoencephalopathy Syndrome; Pyrazines; Syndrome | 2014 |
Bortezomib for effective treatment of a child with refractory autoimmune hemolytic anemia post allogeneic hematopoietic stem cell transplant.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Prognosis; Pyrazines; Severe Combined Immunodeficiency; Transplantation, Homologous | 2014 |
The proteasome inhibitor bortezomib reduced cholesterol accumulation in fibroblasts from Niemann-Pick type C patients carrying missense mutations.
Topics: Boronic Acids; Bortezomib; Carrier Proteins; Cells, Cultured; Cholesterol; Endosomes; Fibroblasts; Humans; Intracellular Signaling Peptides and Proteins; Leupeptins; Membrane Glycoproteins; Mutation, Missense; Niemann-Pick C1 Protein; Niemann-Pick Disease, Type C; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Stability; Protein Transport; Proteolysis; Pyrazines | 2014 |
Bortezomib/bendamustine/dexamethasone induced good PR in refractory relapse post auto-SCT with constitutive RAS activation due to V600E BRAF mutation.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunoglobulin G; Karyotyping; Male; Middle Aged; Multiple Myeloma; Mutation; Nitrogen Mustard Compounds; Proto-Oncogene Proteins B-raf; Pyrazines; ras Proteins; Recurrence; Signal Transduction; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2014 |
Bortezomib, lenalidomide and dexamethasone (VRD) combination as salvage therapy in refractory angioimmunoblastic T cell lymphoma.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunoblastic Lymphadenopathy; Lenalidomide; Lymphoma, T-Cell; Pyrazines; Salvage Therapy; Thalidomide; Tomography, Emission-Computed | 2014 |
Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes.
Topics: Boronic Acids; Bortezomib; Cells, Cultured; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucose; Glycogen; Humans; Insulin; Insulin Resistance; Lipid Metabolism; Male; Muscle, Skeletal; Oxidative Stress; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Carbonylation; Proteome; Pyrazines; RNA Interference; Signal Transduction | 2014 |
Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human; DNA Copy Number Variations; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Polymorphism, Single Nucleotide; Prednisone; Pyrazines | 2015 |
MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Binding Sites; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Early Growth Response Protein 1; Gene Expression Regulation, Neoplastic; Genes, p16; Genes, p53; Membrane Proteins; Mice; Promoter Regions, Genetic; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines; Transcription, Genetic | 2014 |
Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Endoplasmic Reticulum Stress; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Unfolded Protein Response | 2014 |
Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
Topics: Animals; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Burkitt Lymphoma; Caspase 3; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Epstein-Barr Virus Infections; Gene Expression Regulation, Neoplastic; Herpesvirus 4, Human; Histone Deacetylase Inhibitors; Humans; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyrazines; Up-Regulation; Viral Proteins; Xenograft Model Antitumor Assays | 2014 |
Subcutaneous bortezomib for treatment of TEMPI syndrome.
Topics: Boronic Acids; Bortezomib; Edema; Female; Humans; Middle Aged; Paraproteinemias; Polycythemia; Proteasome Inhibitors; Pyrazines; Skin; Telangiectasis; Treatment Outcome | 2014 |
Bortezomib prevents the expression of MMP-13 and the degradation of collagen type 2 in human chondrocytes.
Topics: Boronic Acids; Bortezomib; Chondrocytes; Collagen Type II; Gene Expression Regulation; Humans; Interferon Regulatory Factor-1; Janus Kinase 2; Matrix Metalloproteinase 13; Osteoarthritis; Primary Cell Culture; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Signal Transduction; STAT1 Transcription Factor; Tumor Necrosis Factor-alpha | 2014 |
Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Multiple Myeloma; Propiophenones; Proteasome Inhibitors; Pyrazines | 2014 |
HLA desensitization with bortezomib in a highly sensitized pediatric patient.
Topics: Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Cardiomyopathy, Dilated; Child; Combined Modality Therapy; Drug Therapy, Combination; Graft Rejection; Heart Transplantation; HLA Antigens; Humans; Immunologic Factors; Isoantibodies; Male; Plasmapheresis; Proteasome Inhibitors; Pyrazines; Rituximab; Transplantation Conditioning | 2014 |
Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Endoplasmic Reticulum Stress; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Kidney Neoplasms; Mice, Inbred BALB C; Panobinostat; Pyrazines; Ubiquitinated Proteins | 2014 |
Treating advanced cardiac damage in light chain amyloidosis: still an unmet need.
Topics: Amyloidosis; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Pyrazines | 2014 |
Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Mice; Multiple Myeloma; Myristoylated Alanine-Rich C Kinase Substrate; Neoplasm Transplantation; Phosphorylation; Primary Cell Culture; Pyrazines; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Signal Transduction; Survival Analysis | 2015 |
Effect of 13q deletion on IL-6 production in patients with multiple myeloma: a hypothesis may hold true.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Case-Control Studies; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 13; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Interleukin-6; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density; Bone Diseases; Boronic Acids; Bortezomib; Case-Control Studies; Female; Humans; Lenalidomide; Male; Middle Aged; Multidetector Computed Tomography; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Proteasome: target for acute and chronic GVHD?
Topics: Animals; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Pyrazines | 2014 |
Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biopsy; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diagnosis, Differential; Disease Progression; Doxorubicin; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Lactams, Macrocyclic; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous | 2014 |
A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Membrane Proteins; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Multiple Myeloma; Proto-Oncogene Proteins; Pyrazines; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Injections, Subcutaneous; Male; Multiple Myeloma; Pyrazines | 2015 |
Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Female; Humans; Incidence; Infections; Levofloxacin; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2014 |
Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Boronic Acids; Bortezomib; Bridged-Ring Compounds; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Hedgehog Proteins; Humans; Ovarian Neoplasms; Proteasome Inhibitors; Pyrazines; Pyridines; Signal Transduction; Taxoids | 2014 |
Chemo-sensitizing effects of EP4 receptor-induced inactivation of nuclear factor-κB.
Topics: Alprostadil; Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Burkitt Lymphoma; Caspases; Cell Line, Tumor; Doxorubicin; Humans; Jurkat Cells; Leukemia, B-Cell; Lymphoma, B-Cell; NF-kappa B; Pyrazines; Receptors, Prostaglandin E, EP4 Subtype; Signal Transduction; U937 Cells | 2014 |
Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Male; NF-kappa B; Nitriles; Prostatic Neoplasms, Castration-Resistant; Pyrazines; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Xenograft Model Antitumor Assays | 2015 |
Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis.
Topics: Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Gene Library; HEK293 Cells; Humans; Luminescent Proteins; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Array Analysis; Protein Interaction Maps; Proteolysis; Proto-Oncogene Proteins; Pyrazines; Transcriptome | 2014 |
Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice.
Topics: Action Potentials; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Behavior, Animal; Boronic Acids; Bortezomib; Cisplatin; Electrophysiology; Gait; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Paclitaxel; Polyneuropathies; Pyrazines; Vincristine | 2014 |
MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Lentivirus; Mice; Mice, Inbred NOD; MicroRNAs; Multiple Myeloma; Neoplasm Transplantation; Nuclear Proteins; Ornithine Decarboxylase; Phagosomes; Primary Cell Culture; Proteasome Endopeptidase Complex; Pyrazines; RNA, Small Interfering; Signal Transduction; Survival Analysis | 2015 |
[Modified bortezomib-based combination therapy for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines | 2014 |
Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Prednisolone; Pyrazines; Retrospective Studies | 2014 |
Bortezomib prevents acute doxorubicin ovarian insult and follicle demise, improving the fertility window and pup birth weight in mice.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Birth Weight; Boronic Acids; Bortezomib; DNA Damage; Doxorubicin; Female; Fertility; Humans; Litter Size; Mice; Ovarian Follicle; Ovarian Neoplasms; Ovary; Primary Ovarian Insufficiency; Pyrazines | 2014 |
Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their niche.
Topics: Adenosine; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Mice; Multiple Myeloma; Polycomb Repressive Complex 2; Pyrazines; Syndecan-1; Xenograft Model Antitumor Assays | 2014 |
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Matched-Pair Analysis; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Retrospective Studies; Survival Rate | 2015 |
SDF-1 inhibition targets the bone marrow niche for cancer therapy.
Topics: Animals; Bone Marrow; Bone Marrow Neoplasms; Boronic Acids; Bortezomib; Chemokine CXCL12; Female; Gene Knockdown Techniques; Humans; Male; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Metastasis; Oligonucleotides; Polyethylene Glycols; Pyrazines | 2014 |
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Edema; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Renal; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Podocytes; Proteasome Inhibitors; Proteinuria; Pyrazines; Recurrence; Shock, Septic; Teniposide; Thalidomide; Thrombotic Microangiopathies | 2014 |
Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia-Lymphoma, Adult T-Cell; Nitrophenols; Piperazines; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; Vorinostat | 2014 |
Omega-3 fatty acids, EPA and DHA induce apoptosis and enhance drug sensitivity in multiple myeloma cells but not in normal peripheral mononuclear cells.
Topics: Antineoplastic Agents; Apoptosis; Arachidonic Acid; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Gene Expression Regulation; Humans; Leukocytes, Mononuclear; Membrane Potential, Mitochondrial; Mitochondria; Multiple Myeloma; NF-kappa B; Pyrazines | 2014 |
Delayed flare reaction of draining vein due to subcutaneous bortezomib more likely to occur at the inner thigh.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Hypersensitivity; Erythema; Humans; Hypersensitivity, Delayed; Pyrazines; Skin; Thigh | 2015 |
Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient.
Topics: Aged; Anemia, Hemolytic; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Boronic Acids; Bortezomib; Comorbidity; Female; Humans; Lupus Erythematosus, Systemic; Proteasome Inhibitors; Pyrazines; Rituximab; Treatment Failure; Treatment Outcome | 2015 |
Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; HEK293 Cells; Humans; Meningioma; Mitochondrial Proteins; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured | 2014 |
A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; DNA Replication; DNA, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Energy Metabolism; Female; Humans; Proteasome Endopeptidase Complex; Protein Folding; Protein Processing, Post-Translational; Proteome; Proteomics; Pyrazines; Tumor Suppressor Protein p53 | 2015 |
Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, SCID; Monomeric GTP-Binding Proteins; Multiple Myeloma; Mutation; Neoplasm Transplantation; Pyrazines; Pyrazoles; Retinal Pigment Epithelium | 2015 |
"Multiplexed viability, cytotoxicity, and caspase activity assays".
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Culture Techniques; Enzyme Activation; Humans; K562 Cells; Molecular Biology; Pyrazines; Toxicity Tests | 2015 |
Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Boronic Acids; Bortezomib; Cell Extracts; Drug Synergism; Endocytosis; HCT116 Cells; Humans; Leucine; Lysosomes; Macrolides; Proteolysis; Pyrazines; Receptors, Death Domain; Signal Transduction; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53 | 2014 |
Inhibition of Nek2 by small molecules affects proteasome activity.
Topics: Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Line, Tumor; Cyclin B; Drug Resistance, Neoplasm; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Humans; Mitosis; NIMA-Related Kinases; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteolysis; Pyrazines; Small Molecule Libraries | 2014 |
Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspase 9; Cell Line, Tumor; Cloning, Molecular; Dimerization; Enzyme Activation; Gene Knockdown Techniques; Genes, Transgenic, Suicide; Genetic Vectors; Green Fluorescent Proteins; Humans; Immunoblotting; Luciferases, Firefly; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, SCID; Organic Chemicals; Pyrazines; X-Linked Inhibitor of Apoptosis Protein | 2014 |
The importance of screening for serum free light chains in suspected cases of multiple myeloma and their impact on the kidney.
Topics: Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Electrophoresis; Humans; Immunoglobulin Light Chains; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Paraproteinemias; Pyrazines; Thalidomide | 2014 |
Cell-type variation in stress responses as a consequence of manipulating GRP78 expression in neuroectodermal cells.
Topics: Biomarkers; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Shape; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Fenretinide; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Neural Plate; Pyrazines; RNA, Small Interfering; Stress, Physiological; Unfolded Protein Response | 2015 |
A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Examination; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Drug Substitution; Female; Humans; Immunohistochemistry; Lenalidomide; Leukemia, Plasma Cell; Leukocyte Common Antigens; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Pyrazines; Remission Induction; Thalidomide; Time Factors; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine | 2014 |
[Effects of bortezomib combined with 5-azacytidine on the apoptosis of K562 cells and expression of SHIP mRNA].
Topics: Apoptosis; Azacitidine; Boronic Acids; Bortezomib; Cell Proliferation; Humans; Inositol Polyphosphate 5-Phosphatases; K562 Cells; Phosphoric Monoester Hydrolases; Pyrazines; RNA, Messenger | 2014 |
Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Reactive Oxygen Species; Signal Transduction; src-Family Kinases | 2015 |
[Effect of PI3Kδ inhibitor CAL-101 on myeloma cell lines and preliminary study of synergistic effects with other new drugs].
Topics: Adenine; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Multiple Myeloma; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazines; Pyrazoles; Pyrimidines; Quinazolinones | 2014 |
Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
Topics: Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Caspase 8; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Head and Neck Neoplasms; HEK293 Cells; Humans; Oncogene Proteins, Viral; Papillomaviridae; Protein Stability; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Up-Regulation; X-Linked Inhibitor of Apoptosis Protein | 2014 |
Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis.
Topics: Animals; Benzylamines; Boronic Acids; Bortezomib; Cyclams; Drug Synergism; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Integrin alpha4beta1; Mice, Inbred BALB C; Mice, Knockout; Proteasome Inhibitors; Pyrazines; Time Factors; Vascular Cell Adhesion Molecule-1 | 2014 |
Refractory atypical hemolytic uremic syndrome with monoclonal gammopathy responsive to bortezomib-based therapy.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Atypical Hemolytic Uremic Syndrome; Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Paraproteinemias; Pyrazines | 2015 |
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Failure | 2015 |
Role of AMP-activated protein kinase in cross-talk between apoptosis and autophagy in human colon cancer.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Boronic Acids; Bortezomib; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Enzyme Activation; Humans; Kinetics; Melphalan; Membrane Proteins; Mice; Mitochondria; Phosphorylation; Phosphoserine; Pyrazines; Sirolimus | 2014 |
Differential impact of bortezomib on HL-60 and K562 cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Survival; Dose-Response Relationship, Drug; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation, Leukemic; Heat-Shock Proteins; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; K562 Cells; Leukemia; Proteasome Endopeptidase Complex; Pyrazines; Time Factors | 2015 |
Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytomegalovirus Infections; Dexamethasone; Doxorubicin; Female; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Vincristine | 2014 |
A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Cell Culture Techniques; Cell Movement; Cell Proliferation; Cell Survival; Human Umbilical Vein Endothelial Cells; Humans; Microfluidic Analytical Techniques; Neovascularization, Pathologic; Pyrazines; Vascular Endothelial Growth Factor A | 2015 |
Resolution of bilateral cystoid macular edema and subfoveal serous retinal detachments after treatment with bortezomib in a patient with "smoldering" multiple myeloma.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Macular Edema; Male; Multiple Myeloma; Pyrazines; Retinal Detachment; Treatment Outcome | 2014 |
Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.
Topics: Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cisplatin; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Leupeptins; MAP Kinase Kinase 4; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Phagosomes; Phosphorylation; Proteasome Inhibitors; Pyrazines; Signal Transduction | 2014 |
[Bortezomib-based therapy in patients with light chain deposition disease].
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Paraproteinemias; Pyrazines; Treatment Outcome | 2014 |
In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.
Topics: Aged; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Case-Control Studies; Cell Line, Tumor; Chemokine CXCL12; Chemotaxis; Coculture Techniques; Humans; I-kappa B Proteins; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; NF-KappaB Inhibitor alpha; Phosphorylation; Proteasome Inhibitors; Pyrazines; Serum; Signal Transduction; Tumor Necrosis Factor-alpha | 2014 |
Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress‑mediated cell death in multiple myeloma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Clarithromycin; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Histone Deacetylase 6; Histone Deacetylases; Humans; Hydroxamic Acids; Mice; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Vorinostat | 2015 |
Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells.
Topics: Aurovertins; Autophagy; Boronic Acids; Bortezomib; Breast Neoplasms; Calcium; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cyclin D3; eIF-2 Kinase; Electron Transport; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Female; Humans; Mitochondrial Proton-Translocating ATPases; Molecular Targeted Therapy; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptors, Purinergic; Tumor Stem Cell Assay; Ubiquitin; Unfolded Protein Response; Vacuoles | 2014 |
Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Japan; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Pyrazines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Inhibition of PGC-1α after chemotherapy-mediated insult confines multiple myeloma cell survival by affecting ROS accumulation.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Catalase; Cell Line, Tumor; Cell Survival; Dexamethasone; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Mitochondria; Multiple Myeloma; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pyrazines; Reactive Oxygen Species; RNA, Small Interfering; Superoxide Dismutase; Transcription Factors | 2015 |
Radiofrequency ablation-induced upregulation of hypoxia-inducible factor-1α can be suppressed with adjuvant bortezomib or liposomal chemotherapy.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Catheter Ablation; Chemotherapy, Adjuvant; Disease Models, Animal; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Liposomes; Liver; Pyrazines; Rats; Rats, Inbred F344; Up-Regulation | 2014 |
Proteasome inhibitors induce auditory hair cell death through peroxisome dysfunction.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Boronic Acids; Bortezomib; Catalase; Cell Line; Cell Survival; Hair Cells, Auditory; Hearing Loss; Humans; Lipids; Organ of Corti; Peroxisomes; Phenotype; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species | 2015 |
Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Pyrazines; RNA, Messenger | 2015 |
Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 5; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Knockout Techniques; Humans; Microtubule-Associated Proteins; Multiple Myeloma; Pyrazines; Transfection | 2014 |
Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour Registry Lymphatic Neoplasms (TLN).
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Germany; Glucocorticoids; Hematology; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Pyrazines; Registries | 2014 |
Expression of constitutively activated NF-κB/mTORC pathway proteins and response to CHOP with bortezomib in a patient with angioimmunoblastic peripheral T-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, T-Cell, Peripheral; NF-kappa B; Positron-Emission Tomography; Prednisone; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Burden; Vincristine | 2014 |
Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital.
Topics: Aged; Antineoplastic Agents; Australia; Boronic Acids; Bortezomib; Cost of Illness; Female; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Pyrazines; Respiratory Tract Infections; Risk Factors; Thalidomide | 2015 |
Still no certainty about the role of upfront bortezomib among patients with AL amyloidosis.
Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Pyrazines; Treatment Outcome | 2014 |
XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Mutation; Phosphatidylinositol 3-Kinases; Pyrazines; Receptors, Death Domain; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein | 2014 |
The effect of bortezomib on expression of inflammatory cytokines and survival in a murine sepsis model induced by cecal ligation and puncture.
Topics: Animals; Boronic Acids; Bortezomib; Cecum; Cell Adhesion Molecules; Cell Line; Cell Proliferation; Cell Survival; Chymotrypsin; Cytokines; Disease Models, Animal; Inflammation Mediators; Ligation; Lipopolysaccharides; Lung; Male; Mice, Inbred C57BL; Nitric Oxide; Proteasome Inhibitors; Punctures; Pyrazines; Sepsis | 2015 |
Suppression of BRCA1 sensitizes cells to proteasome inhibitors.
Topics: Animals; Boronic Acids; Bortezomib; BRCA1 Protein; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Down-Regulation; Female; Gene Silencing; Humans; Mice; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Retinoblastoma Protein; RNA, Small Interfering; Signal Transduction | 2014 |
Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Humans; Imidazoles; Indoles; Multiple Myeloma; Naphthoquinones; Necrosis; Proteasome Inhibitors; Purine Nucleosides; Pyrazines; Regulatory Factor X Transcription Factors; Transcription Factors; X-Box Binding Protein 1 | 2015 |
The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Death; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Prognosis; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Prospective iterative trial of proteasome inhibitor-based desensitization.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Desensitization, Immunologic; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerular Filtration Rate; Graft Rejection; Graft Survival; Histocompatibility Testing; HLA Antigens; Humans; Immunoglobulins, Intravenous; Kidney Diseases; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Plasmapheresis; Prognosis; Prospective Studies; Proteasome Inhibitors; Pyrazines; Risk Factors; Rituximab; Young Adult | 2015 |
Refractory primary Sjögren syndrome successfully treated with bortezomib.
Topics: Adrenal Cortex Hormones; Adult; Boronic Acids; Bortezomib; Drug Resistance; Fatigue; Female; Globulins; Humans; Incidence; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Sjogren's Syndrome; Treatment Outcome | 2015 |
[Clinical characteristics and therapeutic efficacy of immunoglobin D multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Immunoglobulins; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2014 |
Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Communication; Cell Growth Processes; Cytokines; Disease Progression; Female; HLA-DR Antigens; Humans; Lipopolysaccharide Receptors; Male; Middle Aged; Multiple Myeloma; Myeloid Cells; Pyrazines; T-Lymphocytes, Regulatory; Treatment Outcome | 2015 |
Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in mice.
Topics: ADP Ribose Transferases; Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Bacterial Toxins; Boronic Acids; Bortezomib; Enzyme-Linked Immunosorbent Assay; Exotoxins; Female; Immunotherapy; Mesothelin; Mice; Mice, Inbred BALB C; Proteasome Inhibitors; Pseudomonas aeruginosa Exotoxin A; Pyrazines; Recombinant Proteins; Virulence Factors | 2015 |
2,4,6-trinitrobenzene sulfonic acid-induced chronic colitis with fibrosis and modulation of TGF-β1 signaling.
Topics: Animals; Boronic Acids; Bortezomib; Chronic Disease; Colitis; Colon; Disease Models, Animal; Fibrosis; Male; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats, Sprague-Dawley; Signal Transduction; Tight Junction Proteins; Transforming Growth Factor beta1; Trinitrobenzenesulfonic Acid | 2014 |
A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow.
Topics: Antigens, CD19; Antilymphocyte Serum; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Differentiation; Cell Survival; Diphtheria-Tetanus Vaccine; Humans; Immunity, Humoral; Immunoglobulin G; Immunologic Memory; Inflammation; Lymphocyte Depletion; Models, Immunological; Mutation; Phenotype; Plasma Cells; Pyrazines; V(D)J Recombination | 2015 |
Preferential cytotoxicity of bortezomib toward highly malignant human liposarcoma cells via suppression of MDR1 expression and function.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cycloheximide; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Liposarcoma; MAP Kinase Kinase 4; Mice, Nude; Protein Kinase Inhibitors; Pyrazines; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Prospective Studies; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
RAS mutation status and bortezomib therapy for relapsed multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Genes, ras; Humans; Multiple Myeloma; Mutation; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2015 |
[Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Myeloma Proteins; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2014 |
How I treat relapsed myeloma.
Topics: Adult; Allografts; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Salvage Therapy; Stem Cell Transplantation | 2015 |
[Clinical features of peripheral neuropathy in paraproteinemic hemoblastosis].
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Neoplasms, Plasma Cell; Peripheral Nervous System Diseases; Polyneuropathies; Pyrazines | 2014 |
Persistent dizziness.
Topics: Aged; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Dizziness; Drug Therapy, Combination; Female; Humans; Pyrazines; Rituximab; Waldenstrom Macroglobulinemia | 2015 |
CyBorD induction therapy in clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Multiple Myeloma; Pyrazines; Remission Induction | 2015 |
Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914.
Topics: Boronic Acids; Bortezomib; Catalytic Domain; Crystallography, X-Ray; Drug Resistance, Neoplasm; Models, Molecular; Molecular Structure; Mutagenesis; Mutation; Oligopeptides; Proteasome Endopeptidase Complex; Protein Conformation; Pyrazines; X-Ray Diffraction; Yeasts | 2015 |
Bortezomib inhibits gastric carcinoma HGC-27 cells through the phospho-Jun N-terminal kinase (p-JNK) pathway in vitro.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Shape; Cell Survival; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Pyrazines; Stomach Neoplasms; Up-Regulation | 2015 |
Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Glycine; Hematologic Neoplasms; Humans; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin | 2015 |
Bortezomib, C1-inhibitor and plasma exchange do not prolong the survival of multi-transgenic GalT-KO pig kidney xenografts in baboons.
Topics: Animals; Animals, Genetically Modified; Autoimmune Diseases; Boronic Acids; Bortezomib; Complement C1 Inhibitor Protein; Cytomegalovirus; Galactosyltransferases; Gene Knockout Techniques; Graft Survival; Heterografts; Immunity, Innate; Immunosuppressive Agents; Kidney; Kidney Transplantation; Models, Animal; Papio anubis; Plasma Exchange; Pyrazines; Sus scrofa; Virus Replication | 2015 |
Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Positron-Emission Tomography; Prednisone; Pyrazines; Treatment Outcome; Vincristine | 2015 |
Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Hydroxamic Acids; Indoles; Lactones; Leukemia, Myeloid, Acute; Panobinostat; Proteasome Inhibitors; Pyrazines; Pyrroles; Tumor Cells, Cultured | 2015 |
TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzyl Alcohols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Humans; Janus Kinase 2; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Quantitative Structure-Activity Relationship; STAT3 Transcription Factor | 2015 |
[Multiple myeloma and renal impairment].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Kidney Diseases; Multiple Myeloma; Paraproteinemias; Prognosis; Pyrazines | 2015 |
[The mechanisms of drug resistance via the interaction of myeloma cells with stromal cells].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Pyrazines; Stromal Cells; Tumor Microenvironment | 2015 |
[Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2015 |
Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.
Topics: Aged; Bone Marrow Cells; Boronic Acids; Bortezomib; C-Reactive Protein; Creatinine; Disease Progression; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Metaphase; Middle Aged; Multiple Myeloma; Multivariate Analysis; Plasma Cells; Prognosis; Proportional Hazards Models; Pyrazines; Renal Insufficiency; Retrospective Studies; Treatment Outcome | 2015 |
Blocking NF-κB sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Depsipeptides; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; NF-kappa B; Pyrazines; Reactive Oxygen Species; Transcription, Genetic | 2015 |
Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Proteins; Interleukin-10; Interleukin-17; Interleukin-8; Lymphoma, T-Cell, Cutaneous; Models, Genetic; NF-kappa B; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Protein Binding; Pyrazines; Receptors, CXCR4; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Skin Neoplasms; Transforming Growth Factor beta1 | 2015 |
[Analysis of bortezomib treatment efficacy and adverse reactions for patients with follicular lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Epirubicin; Humans; Lymphoma, Follicular; Prednisolone; Pyrazines; Treatment Outcome; Vincristine | 2015 |
[Latest advances on the maintenance therapy of multiple myeloma].
Topics: Boronic Acids; Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2015 |
Farnesol inhibits tumor growth and enhances the anticancer effects of bortezomib in multiple myeloma xenograft mouse model through the modulation of STAT3 signaling pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Farnesol; Female; Humans; Mice; Multiple Myeloma; Pyrazines; Random Allocation; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2015 |
Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Pyrazines; Retrospective Studies; Waldenstrom Macroglobulinemia | 2015 |
Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cytarabine; Drug Resistance, Neoplasm; Female; G1 Phase Cell Cycle Checkpoints; Histone Deacetylase Inhibitors; Humans; Lymphoma, B-Cell; Male; Mice; Mice, SCID; Pyrazines; Pyridines; Rituximab; Xenograft Model Antitumor Assays | 2015 |
FOXP3-miR-146-NF-κB Axis and Therapy for Precancerous Lesions in Prostate.
Topics: Animals; Boronic Acids; Bortezomib; Cell Transformation, Neoplastic; Cells, Cultured; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Transgenic; MicroRNAs; Precancerous Conditions; Prostate; Prostatic Neoplasms; Pyrazines; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Optimized combinations of bortezomib, camptothecin, and doxorubicin show increased efficacy and reduced toxicity in treating oral cancer.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Humans; Mouth Neoplasms; Pyrazines | 2015 |
Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptotic Protease-Activating Factor 1; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Dasatinib; Drug Synergism; Fluorescent Antibody Technique; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Immunoprecipitation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Thiazoles; Tumor Cells, Cultured | 2015 |
[Bortezomib-associated acute congestive heart failure in a patient with multiple myeloma].
Topics: Acute Disease; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Electrocardiography; Female; Heart Failure; Humans; Multiple Myeloma; Pyrazines | 2015 |
Metabolic signature identifies novel targets for drug resistance in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Hypoxia; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Glycolysis; Hexokinase; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Mice, SCID; Multiple Myeloma; Pyrazines; Xenograft Model Antitumor Assays | 2015 |
Bortezomib treatment for patients with mantle-cell lymphoma.
Topics: Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Pyrazines | 2015 |
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; In Situ Hybridization, Fluorescence; Male; Middle Aged; Prognosis; Pyrazines; Retrospective Studies; Translocation, Genetic; Treatment Outcome | 2015 |
An in vitro and in vivo investigation of the cytotoxic effects of caffeic acid (3,4-dihydroxycinnamic acid) phenethyl ester and bortezomib in multiple myeloma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caffeic Acids; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Female; Humans; Interleukin-6; Mice; Mice, Inbred BALB C; Multiple Myeloma; NF-kappa B; Phenylethyl Alcohol; Pyrazines; Survival Analysis | 2015 |
Anticancer drug bortezomib increases interleukin-8 expression in human monocytes.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Interleukin-8; Macrophages; p38 Mitogen-Activated Protein Kinases; Pyrazines; Real-Time Polymerase Chain Reaction; U937 Cells | 2015 |
Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman's disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Castleman Disease; Humans; Male; Pyrazines; Thalidomide | 2015 |
A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy.
Topics: Acute Disease; Adult; Atrophy; Biomarkers; Biopsy; Boronic Acids; Bortezomib; Chi-Square Distribution; Chronic Disease; Complement C4b; Drug Monitoring; Female; Fibrosis; Graft Rejection; Humans; Immunity, Humoral; Immunosuppressive Agents; Kidney; Kidney Transplantation; Male; Middle Aged; Peptide Fragments; Predictive Value of Tests; Pyrazines; Time Factors; Treatment Outcome | 2015 |
NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib.
Topics: Boronic Acids; Bortezomib; Disease-Free Survival; Drug Approval; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2015 |
[Bortezomib-based triple combinations (VCD, PAD) for untreated patients with multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Humans; Multiple Myeloma; Pyrazines | 2015 |
[Complications and managements in treatment of melphalan, prednisone and new agents].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide | 2015 |
Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Humans; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Models, Biological; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Radiography; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide | 2015 |
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Creatinine; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Induction Chemotherapy; Kidney; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Dialysis; Renal Insufficiency, Chronic; Survival Analysis | 2015 |
[Carfilzomib in multiple myeloma relapses].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Heart; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide | 2015 |
[Improvement of hepatomegaly after treatment with autologous hematopoietic stem cell transplantation followed by bortezomib and dexamethasone in Bence-Jones protein κ-type of multiple myeloma with systemic amyloidosis].
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Multiple Myeloma; Pyrazines; Transplantation, Autologous | 2015 |
The proteasome inhibitor bortezomib induces testicular toxicity by upregulation of oxidative stress, AMP-activated protein kinase (AMPK) activation and deregulation of germ cell development in adult murine testis.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Enzyme Activation; Fertility; Germ Cells; Gonadal Steroid Hormones; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Proteasome Endopeptidase Complex; Pyrazines; Sertoli Cells; Spermatogenesis; Testicular Diseases; Testis; Up-Regulation | 2015 |
Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nervous System; Pyrazines; Vinblastine; Vinorelbine | 2015 |
Immunosurveillance and therapy of multiple myeloma are CD226 dependent.
Topics: Animals; Antibodies, Monoclonal; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Crosses, Genetic; CTLA-4 Antigen; Cyclophosphamide; Disease Progression; Genes, myc; Genetic Predisposition to Disease; Immunologic Surveillance; Immunotherapy; Interferon-gamma; Killer Cells, Natural; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Pore Forming Cytotoxic Proteins; Programmed Cell Death 1 Receptor; Pyrazines; Receptors, Virus; Tumor Burden; Tumor Necrosis Factor Receptor Superfamily, Member 9 | 2015 |
CCMCL1: a new model of aggressive mantle cell lymphoma.
Topics: Adenine; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Lymphoma, Mantle-Cell; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Transplantation; Neoplasms, Experimental; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Rituximab; Tumor Cells, Cultured | 2015 |
Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Protein Kinase Inhibitors; Pyrazines; Sarcoma, Myeloid; Survival Analysis | 2015 |
[Analysis of prognostic factors in transplant-eligeble newly diagnosed myeloma patients treated with bortezomib plus dexamethasone as induction therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Peripheral Blood Stem Cell Transplantation; Pyrazines; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2015 |
[Multiple myeloma recurring as small intestinal polyposis after autologous hematopoietic stem cell transplantation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Intestinal Polyposis; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2015 |
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.
Topics: Amyloid; Amyloidosis; Boronic Acids; Bortezomib; Cooperative Behavior; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Europe; Heart Diseases; Humans; Kidney Diseases; Pyrazines; Treatment Outcome | 2015 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |
Bortezomib Causes ER Stress-related Death of Acute Promyelocytic Leukemia Cells Through Excessive Accumulation of PML-RARA.
Topics: Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Endoplasmic Reticulum Stress; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Pyrazines; Transcriptional Activation; Ubiquitin-Conjugating Enzymes | 2015 |
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Male; Multiple Myeloma; Neoplasm Staging; Neoplasms, Second Primary; Plasmacytoma; Pyrazines; Remission Induction; Risk; Thalidomide; Treatment Outcome | 2015 |
FDA approves new agent for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Approval; Drug Resistance, Neoplasm; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Pyrazines; Treatment Outcome; United States; United States Food and Drug Administration | 2015 |
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Topics: Adenine; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; I-kappa B Proteins; Lymphoma, Mantle-Cell; Multiple Myeloma; Oligopeptides; Phosphorylation; Piperidines; Proteasome Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2015 |
Bortezomib-containing regimen for primary treatment of early antibody-mediated cardiac allograft rejection: a case report.
Topics: Adult; Allografts; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Graft Rejection; Heart Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Isoantibodies; Methylprednisolone; Prospective Studies; Pyrazines; Rituximab; Treatment Outcome | 2015 |
Safety of a second-generation tyrosine kinase inhibitor and novel targeted therapy for the treatment of a patient with chronic myeloid leukemia and multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multiple Myeloma; Protein-Tyrosine Kinases; Pyrazines; Pyrimidines | 2015 |
A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Gene Expression; Genetic Loci; Heavy Chain Disease; Humans; Immunoglobulin Heavy Chains; Kidney Diseases; Kidney Glomerulus; Mice; Mice, Transgenic; Molecular Sequence Data; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Aggregation, Pathological; Protein Structure, Tertiary; Pyrazines; Sequence Deletion; Unfolded Protein Response | 2015 |
Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Butanes; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Neovascularization, Pathologic; NF-kappa B; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Suppressor Protein p53; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
129-Derived Mouse Strains Express an Unstable but Catalytically Active DNA Polymerase Iota Variant.
Topics: Animals; Base Sequence; Boronic Acids; Bortezomib; Cell Line; DNA Damage; DNA Polymerase iota; DNA Repair; DNA Replication; DNA-Directed DNA Polymerase; HEK293 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Isoforms; Pyrazines; RNA, Messenger; Sequence Analysis, DNA; Ubiquitination; Xeroderma Pigmentosum | 2015 |
Bortezomib Inhibits Osteoclastogenesis and Porphyromonas gingivalis Lipopolysaccharide-induced Alveolar Bone Resorption.
Topics: Alveolar Process; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Osteoclasts; Porphyromonas gingivalis; Pyrazines | 2015 |
MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.
Topics: 3' Untranslated Regions; Animals; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor Proteins; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Knockdown Techniques; HCT116 Cells; Hep G2 Cells; Humans; MCF-7 Cells; Mice; MicroRNAs; Molecular Chaperones; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2015 |
Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.
Topics: Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Logic; Multiple Myeloma; NF-kappa B; Poly(ADP-ribose) Polymerases; Pyrazines; Signal Transduction | 2015 |
Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin B; Cyclin D1; Cyclin D3; Drug Synergism; Fenretinide; G2 Phase Cell Cycle Checkpoints; Humans; I-kappa B Proteins; Lymphoma, Mantle-Cell; NF-KappaB Inhibitor alpha; Pyrazines | 2015 |
Pseudo-Peritoneal Carcinomatosis Presentation of a Crystal-Storing Histiocytosis With an Unmutated Monoclonal κ Light Chain.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Crystallization; Histiocytosis; Humans; Immunoglobulin kappa-Chains; Kidney; Lymph Nodes; Macrophages; Male; Monoclonal Gammopathy of Undetermined Significance; Peritoneal Neoplasms; Pyrazines | 2015 |
The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Graft Rejection; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Isoantibodies; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Plasmapheresis; Pyrazines; Transplantation, Homologous | 2015 |
[Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Formazans; Humans; Lymphoma, Mantle-Cell; MAP Kinase Signaling System; Neoplasm Proteins; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Purines; Pyrazines; Quinazolinones; Signal Transduction; Software; Tetrazolium Salts | 2015 |
Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy.
Topics: Adult; Aged; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Pyrazines; Retrospective Studies; Transplantation, Autologous | 2016 |
Life beyond bortezomib: increasing treatment options in refractory myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines | 2016 |
[A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Disease-Free Survival; Epirubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Retrospective Studies; Treatment Outcome | 2016 |
Commentary on "Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents".
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Mice; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2016 |
[A clinical analysis of 69 newly diagnosed multiple myeloma patients with renal insufficiency].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Insufficiency; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2016 |
"The Second Time is Sweeter After All".
Topics: Boronic Acids; Bortezomib; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines | 2017 |
Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously Untreated Myeloma Patients Eligible for Transplants.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2017 |
Bortezomib Comes to the Rescue: Comment on the Article by Nachmias et al. Entitled "A Bortezomib-Based Protocol Induces a High Rate of CR with Minor Toxicity in Adult Patients with Relapsed/Refractory ALL".
Topics: Adult; Boronic Acids; Bortezomib; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Remission Induction | 2018 |
[Clinical Analysis of Maintenance Therapy with Thalidomine and Bortezomib for Multiple Myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2018 |
Inhibition of TRPA1 and IL-6 signal alleviates neuropathic pain following chemotherapeutic bortezomib.
Topics: Acetanilides; Analgesics; Animals; Bortezomib; Disease Models, Animal; Ganglia, Spinal; Interleukin-6; JNK Mitogen-Activated Protein Kinases; Male; Neuralgia; p38 Mitogen-Activated Protein Kinases; Pain Threshold; Phosphorylation; Proteasome Inhibitors; Purines; Pyrazines; Quinoxalines; Rats, Sprague-Dawley; Receptors, Interleukin-6; Sensory Receptor Cells; Signal Transduction; TRPA1 Cation Channel | 2019 |
Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Bortezomib; Cell Line, Tumor; Heat-Shock Response; Hot Temperature; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteostasis; Pyrazines; Signal Transduction; Ubiquitin; Ubiquitination | 2020 |
[Analysis of Risk Factors of Herpes Zoster in Patients with Multiple Myeloma Treated with Bortezomib].
Topics: Boronic Acids; Bortezomib; Herpes Zoster; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors | 2020 |
The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells.
Topics: Animals; Benzimidazoles; Bortezomib; Cell Cycle Checkpoints; Cell Proliferation; Drug Therapy, Combination; Endoplasmic Reticulum Stress; Humans; Mice; Microtubules; Multiple Myeloma; Polymerization; Proteasome Inhibitors; Pyrazines; Tubulin; Xenograft Model Antitumor Assays | 2021 |
Herpesviral encephalitis associated with bortezomib use in a patient with multiple myeloma and associated light-chain amyloidosis.
Topics: Acyclovir; Amyloidosis; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Dexamethasone; Encephalitis, Herpes Simplex; Herpesvirus 3, Human; Humans; Middle Aged; Multiple Myeloma; Pyrazines | 2022 |
Bortezomib inhibits the proteasome, leading to cell death via apoptosis in feline injection site sarcoma cells in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cat Diseases; Cats; Cell Line, Tumor; Proteasome Endopeptidase Complex; Pyrazines; Sarcoma | 2022 |
Dietary Flavonoids with Catechol Moiety Inhibit Anticancer Action of Bortezomib: What about the other Boronic Acid-based Drugs?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Catechols; Flavonoids; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2022 |
A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance; Drug Resistance, Neoplasm; Extracellular Matrix Proteins; Humans; Hyaluronic Acid; Matrix Metalloproteinase 2; Multiple Myeloma; NF-kappa B; Proteoglycans; Pyrazines; Signal Transduction; Tumor Microenvironment | 2022 |
Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib.
Topics: Adult; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Lymphoma, Mantle-Cell; Metformin; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2022 |
ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Exonucleases; Humans; Interferons; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2022 |
Effects of invivo CXCR4 blockade and proteasome inhibition on bone marrow plasma cells in HLA-sensitized kidney transplant candidates.
Topics: Animals; Bone Marrow; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Kidney Transplantation; Mice; Pilot Projects; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptors, CXCR4 | 2023 |
High-content microscopy reveals a morphological signature of bortezomib resistance.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Microscopy; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2023 |
A Landmark Paper That Introduced Proteasome Inhibition in Myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2023 |
Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians.
Topics: Bortezomib; Humans; Multiple Myeloma; Physicians; Pyrazines; Standard of Care | 2023 |